Bradycardia	O
-	O
induced	S-Positive_regulation
coronary	S-Multi-tissue_structure
angiogenesis	S-Blood_vessel_development
is	O
dependent	S-Positive_regulation
on	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
.	O

A	O
marked	O
coronary	S-Multi-tissue_structure
angiogenesis	S-Blood_vessel_development
is	O
known	O
to	O
occur	O
with	O
chronic	O
bradycardia	O
.	O

We	O
tested	O
the	O
hypothesis	O
that	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
(	O
VEGF	S-Gene_or_gene_product
)	O
,	O
an	O
endothelial	B-Cell
cell	E-Cell
mitogen	O
and	O
a	O
major	O
regulator	O
of	O
angiogenesis	S-Blood_vessel_development
,	O
is	O
upregulated	S-Positive_regulation
in	O
response	O
to	O
low	O
heart	S-Organ
rate	O
and	O
consequential	O
increased	O
stroke	O
volume	O
.	O

Bradycardia	O
was	O
induced	O
in	O
rats	S-Organism
by	O
administering	S-Planned_process
the	O
bradycardic	O
drug	O
alinidine	S-Drug_or_compound
(	O
3	O
mg	O
/	O
kg	O
body	O
weight	O
)	O
twice	O
daily	O
.	O

Heart	O
rate	O
decreased	O
by	O
32	O
%	O
for	O
20	O
to	O
40	O
minutes	O
after	O
injection	O
and	O
was	O
chronically	O
reduced	O
by	O
10	O
%	O
,	O
14	O
%	O
,	O
and	O
18	O
.	O
5	O
%	O
after	O
1	O
,	O
2	O
,	O
and	O
3	O
weeks	O
of	O
treatment	O
,	O
respectively	O
.	O

Arterial	S-Multi-tissue_structure
pressure	O
and	O
cardiac	O
output	O
were	O
unchanged	O
.	O

Left	B-Tissue
ventricular	I-Tissue
capillary	E-Tissue
length	O
density	O
(	O
mm	O
/	O
mm	O
(	O
3	O
)	O
)	O
increased	S-Positive_regulation
gradually	O
with	O
alinidine	S-Drug_or_compound
administration	S-Planned_process
;	O
a	O
15	O
%	O
increase	S-Positive_regulation
after	O
2	O
weeks	O
and	O
a	O
40	O
%	O
increase	S-Positive_regulation
after	O
3	O
weeks	O
of	O
alinidine	S-Drug_or_compound
treatment	S-Planned_process
were	O
documented	O
.	O

Left	B-Multi-tissue_structure
ventricular	E-Multi-tissue_structure
weight	O
,	O
body	O
weight	O
,	O
and	O
their	O
ratio	O
were	O
not	O
significantly	O
altered	O
by	O
alinidine	S-Drug_or_compound
treatment	S-Planned_process
.	O

After	O
1	O
week	O
of	O
treatment	O
,	O
before	O
an	O
increase	S-Positive_regulation
in	O
capillary	S-Tissue
length	O
density	O
,	O
VEGF	S-Gene_or_gene_product
mRNA	O
increased	S-Positive_regulation
greater	O
than	O
2	O
-	O
fold	O
and	O
then	O
declined	S-Negative_regulation
to	O
control	O
levels	O
after	O
3	O
weeks	O
of	O
treatment	O
.	O

VEGF	S-Gene_or_gene_product
protein	O
was	O
higher	O
in	O
alinidine	S-Drug_or_compound
-	O
treated	S-Planned_process
rats	S-Organism
than	O
in	O
controls	O
after	O
2	O
weeks	O
and	O
increased	S-Positive_regulation
further	O
after	O
3	O
weeks	O
of	O
treatment	O
.	O

Injection	S-Planned_process
of	O
VEGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
neutralizing	I-Gene_or_gene_product
antibodies	E-Gene_or_gene_product
over	O
a	O
2	O
-	O
week	O
period	O
completely	O
blocked	S-Negative_regulation
alinidine	S-Drug_or_compound
-	O
stimulated	S-Positive_regulation
angiogenesis	S-Blood_vessel_development
.	O

In	O
contrast	O
,	O
bFGF	S-Gene_or_gene_product
mRNA	O
was	O
not	O
altered	S-Regulation
by	O
alinidine	S-Drug_or_compound
treatment	S-Planned_process
.	O

These	O
data	O
suggest	O
that	O
VEGF	S-Gene_or_gene_product
plays	B-Regulation
a	I-Regulation
key	I-Regulation
role	E-Regulation
in	O
the	O
angiogenic	S-Blood_vessel_development
response	O
that	O
occurs	O
with	O
chronic	O
bradycardia	O
.	O

The	O
mechanism	O
underlying	O
this	O
VEGF	S-Gene_or_gene_product
-	O
associated	S-Regulation
angiogenesis	S-Blood_vessel_development
may	O
be	O
an	O
increase	O
in	O
stretch	O
due	O
to	O
enhanced	O
diastolic	O
filling	O
.	O

UFT	S-Drug_or_compound
and	O
its	O
metabolites	O
inhibit	S-Negative_regulation
the	O
angiogenesis	S-Blood_vessel_development
induced	S-Positive_regulation
by	O
murine	S-Organism
renal	B-Pathological_formation
cell	I-Pathological_formation
carcinoma	E-Pathological_formation
,	O
as	O
determined	O
by	O
a	O
dorsal	O
air	O
sac	O
assay	O
in	O
mice	S-Organism
.	O

UFT	S-Drug_or_compound
,	O
an	O
anticancer	O
agent	O
that	O
is	O
composed	O
of	O
tegafur	S-Drug_or_compound
(	O
FT	S-Drug_or_compound
)	O
and	O
uracil	S-Drug_or_compound
at	O
a	O
molar	O
ratio	O
of	O
1	O
:	O
4	O
,	O
is	O
widely	O
used	O
in	O
clinical	O
practice	O
in	O
Japan	O
to	O
treat	S-Planned_process
cancer	S-Pathological_formation
patients	S-Organism
requiring	O
a	O
long	O
-	O
term	O
chemotherapy	S-Planned_process
,	O
and	O
it	O
is	O
associated	O
with	O
few	O
side	O
effects	O
,	O
if	O
any	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
evaluated	O
the	O
inhibitory	B-Negative_regulation
effect	E-Negative_regulation
of	O
UFT	S-Drug_or_compound
against	O
RENCA	B-Cell
cell	E-Cell
-	O
induced	S-Positive_regulation
angiogenesis	S-Blood_vessel_development
by	O
a	O
dorsal	O
air	O
sac	O
assay	O
.	O

Marked	O
angiogenesis	S-Blood_vessel_development
is	O
induced	S-Positive_regulation
by	O
implantation	S-Planned_process
of	O
a	O
chamber	O
containing	O
RENCA	B-Cell
cells	E-Cell
into	O
mice	S-Organism
.	O

In	O
this	O
model	O
,	O
UFT	S-Drug_or_compound
showed	O
a	O
strong	O
angiogenesis	S-Blood_vessel_development
-	O
inhibitory	B-Negative_regulation
effect	E-Negative_regulation
,	O
whereas	O
5	B-Drug_or_compound
-	I-Drug_or_compound
fluorouracil	E-Drug_or_compound
(	O
5	B-Drug_or_compound
-	I-Drug_or_compound
FU	E-Drug_or_compound
)	O
and	O
doxifluridine	S-Drug_or_compound
were	O
less	O
effective	S-Negative_regulation
.	O

Additional	O
experiments	O
revealed	O
FT	S-Drug_or_compound
to	O
be	O
effective	O
component	O
of	O
UFT	S-Drug_or_compound
;	O
uracil	S-Drug_or_compound
remained	O
ineffective	S-Regulation
in	O
the	O
inhibition	S-Negative_regulation
of	O
angiogenesis	S-Blood_vessel_development
.	O

Moreover	O
,	O
we	O
have	O
found	O
that	O
gamma	B-Drug_or_compound
-	I-Drug_or_compound
hydroxybutyric	I-Drug_or_compound
acid	E-Drug_or_compound
and	O
gamma	B-Drug_or_compound
-	I-Drug_or_compound
butyrolactone	E-Drug_or_compound
,	O
the	O
metabolites	O
of	O
FT	S-Drug_or_compound
,	O
possess	O
a	O
potent	O
angiogenesis	S-Blood_vessel_development
inhibitory	B-Negative_regulation
effect	E-Negative_regulation
that	O
is	O
amplified	S-Positive_regulation
when	O
the	O
compounds	O
are	O
administered	S-Planned_process
by	O
a	O
continuous	O
infusion	O
.	O

This	O
may	O
reflect	O
a	O
transition	O
in	O
blood	S-Organism_substance
concentration	O
of	O
each	O
metabolite	O
resulting	O
from	O
the	O
administration	S-Planned_process
of	O
UFT	S-Drug_or_compound
.	O

Similar	O
results	O
were	O
also	O
obtained	O
with	O
respect	O
to	O
5	B-Drug_or_compound
-	I-Drug_or_compound
FU	E-Drug_or_compound
.	O

It	O
was	O
suggested	O
that	O
UFT	S-Drug_or_compound
has	O
a	O
stronger	O
angiogenesis	S-Blood_vessel_development
-	O
inhibitory	B-Negative_regulation
effect	E-Negative_regulation
than	O
did	O
other	O
fluorinated	B-Drug_or_compound
pyrimidines	E-Drug_or_compound
,	O
partly	O
due	O
to	O
its	O
pharmacokinetic	O
properties	O
characterized	O
by	O
maintaining	O
of	O
higher	O
and	O
long	O
-	O
lasting	O
blood	S-Organism_substance
levels	O
of	O
5	B-Drug_or_compound
-	I-Drug_or_compound
FU	E-Drug_or_compound
and	O
partly	O
due	O
the	O
inhibitory	O
effects	O
derived	O
from	O
gamma	B-Drug_or_compound
-	I-Drug_or_compound
hydroxybutyric	I-Drug_or_compound
acid	E-Drug_or_compound
and	O
gamma	B-Drug_or_compound
-	I-Drug_or_compound
butyrolactone	E-Drug_or_compound
,	O
UFT	S-Drug_or_compound
-	O
specific	O
metabolites	O
.	O

External	O
beam	O
radiotherapy	O
for	O
subretinal	O
neovascularization	S-Blood_vessel_development
in	O
age	O
-	O
related	O
macular	S-Tissue
degeneration	S-Breakdown
:	O
is	O
this	O
treatment	O
efficient	O
?	O

PURPOSE	O
:	O
Control	S-Regulation
of	O
the	O
natural	O
course	O
of	O
subretinal	O
neovascularization	S-Blood_vessel_development
(	O
SRNV	O
)	O
in	O
age	O
-	O
related	O
macular	S-Tissue
degeneration	S-Breakdown
(	O
AMD	O
)	O
is	O
difficult	O
.	O

Only	O
a	O
subset	O
of	O
patients	S-Organism
is	O
suitable	O
for	O
laser	O
coagulation	O
.	O

This	O
prospective	O
study	O
aimed	O
to	O
determine	O
the	O
efficacy	O
and	O
individual	O
benefit	O
of	O
external	O
beam	O
radiotherapy	O
(	O
EBRT	O
)	O
.	O

METHODS	O
AND	O
MATERIALS	O
:	O
The	O
prospective	O
trial	O
included	O
287	O
patients	S-Organism
with	O
subfoveal	O
neovascularization	S-Blood_vessel_development
due	O
to	O
AMD	O
which	O
was	O
verified	O
by	O
fluorescein	S-Drug_or_compound
angiography	O
.	O

Patients	S-Organism
have	O
been	O
treated	S-Planned_process
between	O
January	O
1996	O
and	O
October	O
1997	O
.	O

All	O
patients	S-Organism
received	S-Planned_process
a	O
total	O
dose	O
of	O
16	O
Gy	O
in	O
2	O
-	O
Gy	O
daily	O
fractions	O
with	O
5	O
-	O
6	O
MeV	O
photons	O
based	O
on	O
computerized	O
treatment	O
planning	O
in	O
individual	O
head	S-Organism_subdivision
mask	O
fixation	O
.	O

This	O
first	O
analysis	O
is	O
based	O
on	O
73	O
patients	S-Organism
(	O
50	O
women	S-Organism
,	O
23	O
men	S-Organism
,	O
median	O
age	O
74	O
.	O
3	O
years	O
)	O
,	O
with	O
a	O
median	O
follow	O
-	O
up	O
of	O
13	O
.	O
3	O
months	O
and	O
a	O
minimum	O
follow	O
-	O
up	O
of	O
11	O
months	O
.	O

RESULTS	O
:	O
All	O
patients	S-Organism
completed	O
therapy	S-Planned_process
and	O
tolerability	O
was	O
good	O
.	O

First	O
clinical	O
control	O
with	O
second	O
angiography	O
was	O
performed	O
6	O
weeks	O
after	O
irradiation	O
,	O
then	O
in	O
3	O
-	O
month	O
intervals	O
.	O

Eighteen	O
patients	S-Organism
with	O
SRNV	O
refusing	S-Negative_regulation
radiotherapy	S-Planned_process
served	O
as	O
a	O
control	O
group	O
and	O
were	O
matched	O
with	O
18	O
irradiated	S-Planned_process
patients	S-Organism
.	O

After	O
7	O
months	O
median	O
visual	O
acuity	O
(	O
VA	O
)	O
was	O
20	O
/	O
160	O
for	O
the	O
irradiated	S-Planned_process
and	O
20	O
/	O
400	O
for	O
the	O
untreated	S-Planned_process
patients	S-Organism
.	O

One	O
year	O
after	O
radiotherapy	O
final	O
median	O
VA	O
was	O
20	O
/	O
400	O
in	O
both	O
groups	O
.	O

CONCLUSION	O
:	O
These	O
results	O
suggest	O
that	O
16	O
Gy	O
of	O
conventionally	O
fractionated	O
external	O
beam	O
irradiation	O
slows	O
down	O
the	O
visual	O
loss	O
in	O
exudative	O
AMD	O
for	O
only	O
a	O
few	O
months	O
.	O

Patients	S-Organism
'	O
reading	O
vision	O
could	O
not	O
be	O
saved	O
for	O
a	O
long	O
-	O
term	O
run	O
.	O

Increased	S-Positive_regulation
serum	S-Organism_substance
levels	O
of	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
in	O
patients	S-Organism
with	O
renal	B-Pathological_formation
cell	I-Pathological_formation
carcinoma	E-Pathological_formation
.	O

Neovascularization	S-Blood_vessel_development
,	O
an	O
essential	S-Positive_regulation
event	O
for	O
the	O
growth	S-Growth
of	O
solid	B-Pathological_formation
tumors	E-Pathological_formation
,	O
is	O
regulated	S-Regulation
by	O
a	O
number	O
of	O
angiogenic	S-Blood_vessel_development
factors	O
.	O

One	O
such	O
factor	O
,	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
(	O
VEGF	S-Gene_or_gene_product
)	O
,	O
is	O
considered	O
to	O
exert	O
a	O
potent	O
angiogenic	S-Blood_vessel_development
activity	O
,	O
as	O
indicated	O
by	O
immunohistochemical	O
and	O
molecular	O
evidence	O
.	O

In	O
this	O
study	O
we	O
investigated	O
the	O
serum	S-Organism_substance
VEGF	S-Gene_or_gene_product
level	O
(	O
s	O
-	O
VEGF	S-Gene_or_gene_product
)	O
in	O
patients	S-Organism
with	O
renal	B-Pathological_formation
cell	I-Pathological_formation
carcinoma	E-Pathological_formation
(	O
RCC	S-Pathological_formation
)	O
.	O

s	O
-	O
VEGF	S-Gene_or_gene_product
in	O
peripheral	B-Organism_substance
blood	I-Organism_substance
samples	E-Organism_substance
was	O
analyzed	O
in	O
40	O
RCC	S-Pathological_formation
patients	S-Organism
and	O
40	O
patients	S-Organism
without	O
cancer	S-Pathological_formation
(	O
controls	O
)	O
using	O
a	O
sandwich	O
enzyme	O
-	O
linked	O
immunoassay	O
.	O

In	O
20	O
RCC	S-Pathological_formation
patients	S-Organism
,	O
serum	B-Organism_substance
samples	E-Organism_substance
were	O
obtained	O
separately	O
from	O
the	O
bilateral	B-Multi-tissue_structure
renal	I-Multi-tissue_structure
veins	E-Multi-tissue_structure
.	O

s	O
-	O
VEGF	S-Gene_or_gene_product
was	O
also	O
measured	O
before	O
,	O
4	O
and	O
8	O
weeks	O
after	O
nephrectomy	O
in	O
11	O
patients	S-Organism
.	O

There	O
were	O
significant	O
differences	O
in	O
s	O
-	O
VEGF	S-Gene_or_gene_product
between	O
the	O
RCC	S-Pathological_formation
patients	S-Organism
and	O
the	O
controls	O
(	O
207	O
.	O
3	O
+	O
/	O
-	O
32	O
.	O
9	O
vs	O
.	O
71	O
.	O
5	O
+	O
/	O
-	O
9	O
.	O
1	O
pg	O
/	O
ml	O
,	O
mean	O
+	O
/	O
-	O
SE	O
)	O
(	O
P	O
less	O
than	O
0	O
.	O
005	O
)	O
,	O
between	O
the	O
tumor	S-Pathological_formation
-	O
bearing	O
renal	B-Multi-tissue_structure
veins	E-Multi-tissue_structure
and	O
the	O
contralateral	O
ones	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
,	O
between	O
the	O
pre	O
-	O
and	O
post	O
-	O
nephrectomy	O
situations	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
and	O
among	O
the	O
various	O
parameters	O
of	O
tumor	S-Pathological_formation
status	O
such	O
as	O
tumor	S-Pathological_formation
extent	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
and	O
existence	O
of	O
metastasis	S-Pathological_formation
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O

s	O
-	O
VEGF	S-Gene_or_gene_product
significantly	O
correlated	O
with	O
the	O
tumor	S-Pathological_formation
volume	O
obtained	O
by	O
a	O
three	O
-	O
dimensional	O
measurement	O
(	O
r	O
=	O
0	O
.	O
802	O
,	O
P	O
less	O
than	O
0	O
.	O
0001	O
)	O
.	O

The	O
sensitivity	O
and	O
specificity	O
of	O
s	O
-	O
VEGF	S-Gene_or_gene_product
at	O
the	O
cut	O
-	O
off	O
level	O
of	O
100	O
pg	O
/	O
ml	O
,	O
as	O
determined	O
by	O
the	O
receiver	O
-	O
operating	O
-	O
characteristics	O
curve	O
,	O
were	O
80	O
.	O
0	O
%	O
and	O
72	O
.	O
5	O
%	O
,	O
respectively	O
.	O

The	O
results	O
indicate	O
that	O
tumor	B-Tissue
tissue	E-Tissue
of	O
RCC	S-Pathological_formation
liberates	S-Localization
VEGF	S-Gene_or_gene_product
into	O
the	O
systemic	O
blood	S-Organism_substance
flow	O
and	O
that	O
s	O
-	O
VEGF	S-Gene_or_gene_product
is	O
a	O
possible	O
marker	O
for	O
RCC	S-Pathological_formation
.	O

Insulin	S-Gene_or_gene_product
-	O
induced	S-Positive_regulation
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
expression	S-Gene_expression
in	O
retina	S-Multi-tissue_structure
.	O

PURPOSE	O
:	O
Clinical	O
studies	O
have	O
demonstrated	O
that	O
intensive	O
insulin	S-Gene_or_gene_product
therapy	S-Planned_process
causes	O
a	O
transient	O
worsening	O
of	O
retinopathy	O
.	O

The	O
mechanisms	O
underlying	O
the	O
initial	O
insulin	S-Gene_or_gene_product
-	O
induced	O
deterioration	O
of	O
retinal	O
status	O
in	O
patients	S-Organism
with	O
diabetes	O
remain	O
unknown	O
.	O

Vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
(	O
VEGF	S-Gene_or_gene_product
)	O
is	O
known	O
to	O
be	O
operative	O
in	O
the	O
pathogenesis	O
of	O
diabetic	O
retinopathy	O
.	O

The	O
current	O
study	O
was	O
conducted	O
to	O
characterize	O
the	O
effect	S-Regulation
of	O
insulin	S-Gene_or_gene_product
on	O
retinal	O
VEGF	S-Gene_or_gene_product
gene	O
expression	S-Gene_expression
in	O
vitro	O
and	O
in	O
vivo	O
.	O

METHODS	O
:	O
The	O
effect	S-Regulation
of	O
insulin	S-Gene_or_gene_product
on	O
VEGF	S-Gene_or_gene_product
expression	S-Gene_expression
in	O
vivo	O
was	O
examined	O
by	O
in	O
situ	O
hybridization	O
studies	O
of	O
rat	S-Organism
retinal	O
VEGF	S-Gene_or_gene_product
transcripts	O
.	O

To	O
examine	O
the	O
mechanisms	O
by	O
which	O
insulin	S-Gene_or_gene_product
regulates	S-Regulation
VEGF	S-Gene_or_gene_product
expression	S-Gene_expression
,	O
human	S-Organism
retinal	B-Cell
pigment	I-Cell
epithelial	I-Cell
(	I-Cell
RPE	I-Cell
)	I-Cell
cells	E-Cell
were	O
exposed	S-Planned_process
to	O
insulin	S-Gene_or_gene_product
,	O
and	O
VEGF	S-Gene_or_gene_product
mRNA	O
levels	O
were	O
quantified	O
with	O
RNase	S-Gene_or_gene_product
protection	O
assays	O
(	O
RPAs	O
)	O
.	O

Conditioned	O
media	O
from	O
insulin	S-Gene_or_gene_product
-	O
treated	S-Planned_process
RPE	B-Cell
cells	E-Cell
were	O
assayed	S-Planned_process
for	O
VEGF	S-Gene_or_gene_product
protein	O
and	O
capillary	B-Cell
endothelial	I-Cell
cell	E-Cell
proliferation	S-Cell_proliferation
.	O

The	O
capacity	O
of	O
insulin	S-Gene_or_gene_product
to	O
stimulate	S-Positive_regulation
the	O
VEGF	S-Gene_or_gene_product
promoter	S-DNA_domain_or_region
linked	S-Planned_process
to	O
a	O
luciferase	S-Gene_or_gene_product
reporter	O
gene	O
was	O
characterized	O
in	O
transient	O
transfection	O
assays	O
.	O

RESULTS	O
:	O
Insulin	S-Gene_or_gene_product
increased	S-Positive_regulation
VEGF	S-Gene_or_gene_product
mRNA	O
levels	O
in	O
the	O
ganglion	S-Tissue
,	O
inner	B-Tissue
nuclear	E-Tissue
,	O
and	O
RPE	B-Tissue
cell	I-Tissue
layers	E-Tissue
.	O

In	O
vitro	O
,	O
insulin	S-Gene_or_gene_product
increased	S-Positive_regulation
VEGF	S-Gene_or_gene_product
mRNA	O
levels	O
in	O
human	S-Organism
RPE	B-Cell
cells	E-Cell
and	O
enhanced	S-Positive_regulation
VEGF	S-Gene_or_gene_product
promoter	S-DNA_domain_or_region
activity	O
without	O
affecting	O
transcript	O
stability	O
.	O

Insulin	S-Gene_or_gene_product
treatment	S-Planned_process
also	O
increased	S-Positive_regulation
VEGF	S-Gene_or_gene_product
protein	O
levels	O
in	O
conditioned	O
RPE	B-Cell
cell	E-Cell
media	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
with	O
a	O
median	O
effective	O
concentration	O
of	O
5	O
nM	O
.	O

The	O
insulin	S-Gene_or_gene_product
-	O
conditioned	O
RPE	B-Cell
cell	E-Cell
media	O
stimulated	S-Positive_regulation
capillary	B-Cell
endothelial	I-Cell
cell	E-Cell
proliferation	S-Cell_proliferation
,	O
an	O
effect	O
that	O
was	O
completely	O
blocked	S-Negative_regulation
by	O
anti	B-Gene_or_gene_product
-	I-Gene_or_gene_product
VEGF	I-Gene_or_gene_product
neutralizing	I-Gene_or_gene_product
antibody	E-Gene_or_gene_product
.	O

CONCLUSIONS	O
:	O
Insulin	S-Gene_or_gene_product
increases	S-Positive_regulation
VEGF	S-Gene_or_gene_product
mRNA	O
and	O
secreted	O
protein	O
levels	O
in	O
RPE	B-Cell
cells	E-Cell
through	O
enhanced	S-Positive_regulation
transcription	S-Transcription
of	O
the	O
VEGF	S-Gene_or_gene_product
gene	O
.	O

Intensive	O
insulin	S-Gene_or_gene_product
therapy	S-Planned_process
may	O
cause	O
a	O
transient	O
worsening	O
of	O
retinopathy	O
in	O
patients	S-Organism
with	O
diabetes	O
through	O
increased	S-Positive_regulation
retinal	O
VEGF	S-Gene_or_gene_product
gene	O
expression	S-Gene_expression
.	O

The	O
antiangiogenic	S-Blood_vessel_development
agent	O
linomide	S-Drug_or_compound
inhibits	S-Negative_regulation
the	O
growth	S-Growth
rate	O
of	O
von	B-Pathological_formation
Hippel	I-Pathological_formation
-	I-Pathological_formation
Lindau	I-Pathological_formation
paraganglioma	I-Pathological_formation
xenografts	E-Pathological_formation
to	O
mice	S-Organism
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
ascertain	O
the	O
potential	O
usefulness	O
of	O
the	O
antiangiogenic	S-Blood_vessel_development
compound	O
linomide	S-Drug_or_compound
for	O
treatment	S-Planned_process
of	O
von	B-Pathological_formation
Hippel	I-Pathological_formation
-	I-Pathological_formation
Lindau	I-Pathological_formation
(	I-Pathological_formation
VHL	I-Pathological_formation
)	I-Pathological_formation
-	I-Pathological_formation
related	I-Pathological_formation
tumors	E-Pathological_formation
.	O

Paraganglioma	B-Tissue
tissue	I-Tissue
fragments	E-Tissue
obtained	S-Planned_process
at	O
surgery	O
from	O
a	O
VHL	O
type	O
2a	O
patient	S-Organism
were	O
transplanted	S-Planned_process
s	O
.	O
c	O
.	O
to	O
male	O
BALB	B-Organism
/	I-Organism
c	I-Organism
nu	I-Organism
/	I-Organism
nu	I-Organism
(	I-Organism
nude	I-Organism
)	I-Organism
mice	E-Organism
:	O
(	O
a	O
)	O
2	O
-	O
3	O
-	O
mm	O
fragments	O
for	O
"	O
prevention	O
"	O
experiments	O
;	O
and	O
(	O
b	O
)	O
2	O
-	O
3	O
-	O
mm	O
fragments	O
allowed	O
to	O
grow	O
to	O
1	O
cm	O
for	O
"	O
intervention	O
"	O
studies	O
.	O

Both	O
groups	O
received	S-Planned_process
either	O
0	O
.	O
5	O
mg	O
/	O
ml	O
linomide	S-Drug_or_compound
in	O
drinking	O
water	O
or	O
acidified	O
water	O
and	O
were	O
followed	O
until	O
tumor	S-Pathological_formation
diameter	O
reached	O
3	O
cm	O
or	O
for	O
4	O
weeks	O
.	O

In	O
both	O
the	O
prevention	O
and	O
intervention	O
experiments	O
,	O
a	O
significant	O
diminution	S-Negative_regulation
of	O
tumor	S-Pathological_formation
size	O
and	O
weight	O
was	O
observed	O
in	O
the	O
drug	O
-	O
treated	O
animals	O
.	O

In	O
vivo	O
nuclear	O
magnetic	O
resonance	O
analysis	O
of	O
tumor	S-Pathological_formation
blood	S-Organism_substance
flow	O
in	O
linomide	S-Drug_or_compound
-	O
treated	S-Planned_process
animals	O
showed	O
localization	S-Localization
of	O
blood	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
almost	O
exclusively	O
to	O
the	O
periphery	O
of	O
the	O
poorly	O
vascularized	O
tumors	S-Pathological_formation
with	O
a	O
significant	O
reduction	O
of	O
both	O
vascular	O
functionality	O
and	O
vasodilation	O
.	O

Histological	O
examination	O
of	O
tumors	S-Pathological_formation
from	O
linomide	S-Drug_or_compound
-	O
treated	S-Planned_process
animals	O
revealed	O
marked	O
avascularity	O
.	O

Treated	O
animals	O
also	O
displayed	O
a	O
2	O
.	O
4	O
-	O
fold	O
reduction	S-Negative_regulation
of	O
tumor	S-Pathological_formation
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
mRNA	O
levels	O
.	O

Taken	O
together	O
,	O
our	O
data	O
indicate	O
that	O
in	O
VHL	O
disease	O
,	O
therapy	O
directed	O
at	O
inhibition	S-Negative_regulation
of	O
constitutively	O
expressed	S-Gene_expression
VEGF	S-Gene_or_gene_product
induction	S-Positive_regulation
of	O
angiogenesis	S-Blood_vessel_development
by	O
VHL	B-Pathological_formation
tumors	E-Pathological_formation
may	O
constitute	O
an	O
effective	O
medical	O
treatment	O
.	O

Vascular	S-Multi-tissue_structure
proliferation	S-Development
and	O
enhanced	S-Positive_regulation
expression	S-Gene_expression
of	O
endothelial	B-Gene_or_gene_product
nitric	I-Gene_or_gene_product
oxide	I-Gene_or_gene_product
synthase	E-Gene_or_gene_product
in	O
human	S-Organism
peritoneum	S-Multi-tissue_structure
exposed	O
to	O
long	O
-	O
term	O
peritoneal	O
dialysis	O
.	O

Long	O
-	O
term	O
peritoneal	O
dialysis	O
(	O
PD	O
)	O
is	O
associated	O
with	O
alterations	O
in	O
peritoneal	O
permeability	O
and	O
loss	O
of	O
ultrafiltration	O
.	O

These	O
changes	O
originate	O
from	O
increased	S-Positive_regulation
peritoneal	B-Immaterial_anatomical_entity
surface	I-Immaterial_anatomical_entity
area	E-Immaterial_anatomical_entity
,	O
but	O
the	O
morphologic	O
and	O
molecular	O
mechanisms	O
involved	O
remain	O
unknown	O
.	O

The	O
hypothesis	O
that	O
modifications	O
of	O
activity	O
and	O
/	O
or	O
expression	S-Gene_expression
of	O
nitric	B-Gene_or_gene_product
oxide	I-Gene_or_gene_product
synthase	E-Gene_or_gene_product
(	O
NOS	S-Gene_or_gene_product
)	O
isozymes	O
might	O
play	B-Regulation
a	I-Regulation
role	E-Regulation
in	O
these	O
modifications	O
,	O
via	O
enhanced	S-Positive_regulation
local	O
production	S-Synthesis
of	O
nitric	B-Drug_or_compound
oxide	E-Drug_or_compound
,	O
was	O
tested	O
in	O
this	O
study	O
.	O

NOS	S-Gene_or_gene_product
activities	O
were	O
measured	O
by	O
the	O
L	O
-	O
citrulline	O
assay	O
in	O
peritoneal	O
biopsies	O
from	O
seven	O
control	O
subjects	O
,	O
eight	O
uremic	O
patients	S-Organism
immediately	O
before	O
the	O
onset	O
of	O
PD	O
,	O
and	O
13	O
uremic	O
patients	S-Organism
on	O
short	O
-	O
term	O
(	O
less	O
than	O
18	O
mo	O
,	O
n	O
=	O
6	O
)	O
or	O
long	O
-	O
term	O
(	O
greater	O
than	O
18	O
mo	O
,	O
n	O
=	O
7	O
)	O
PD	O
.	O

Peritoneal	O
NOS	S-Gene_or_gene_product
activity	O
is	O
increased	S-Positive_regulation
fivefold	O
in	O
long	O
-	O
term	O
PD	O
patients	S-Organism
compared	O
with	O
control	O
subjects	O
.	O

In	O
uremic	O
patients	S-Organism
,	O
NOS	S-Gene_or_gene_product
activity	O
is	O
positively	O
correlated	O
with	O
the	O
duration	O
of	O
PD	O
.	O

Increased	S-Positive_regulation
NOS	S-Gene_or_gene_product
activity	O
is	O
mediated	S-Regulation
solely	O
by	O
Ca	O
(	O
2	O
+	O
)	O
-	O
dependent	O
NOS	S-Gene_or_gene_product
and	O
,	O
as	O
shown	O
by	O
immunoblotting	O
,	O
an	O
upregulation	S-Positive_regulation
of	O
endothelial	B-Gene_or_gene_product
NOS	E-Gene_or_gene_product
.	O

The	O
biologic	O
relevance	O
of	O
increased	S-Positive_regulation
NOS	S-Gene_or_gene_product
in	O
long	O
-	O
term	O
PD	O
was	O
demonstrated	O
by	O
enhanced	S-Positive_regulation
nitrotyrosine	S-Drug_or_compound
immunoreactivity	O
and	O
a	O
significant	O
increase	S-Positive_regulation
in	O
vascular	S-Multi-tissue_structure
density	O
and	O
endothelial	B-Tissue
area	E-Tissue
in	O
the	O
peritoneum	S-Multi-tissue_structure
.	O

Immunoblotting	O
and	O
immunostaining	O
studies	O
demonstrated	O
an	O
upregulation	S-Positive_regulation
of	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
(	O
VEGF	S-Gene_or_gene_product
)	O
mostly	O
along	O
the	O
endothelium	S-Tissue
lining	O
peritoneal	B-Multi-tissue_structure
blood	I-Multi-tissue_structure
vessels	E-Multi-tissue_structure
in	O
long	O
-	O
term	O
PD	O
patients	S-Organism
.	O

In	O
the	O
latter	O
,	O
VEGF	S-Gene_or_gene_product
colocalized	S-Localization
with	O
the	O
advanced	O
glycation	O
end	O
product	O
pentosidine	S-Drug_or_compound
deposits	O
.	O

These	O
data	O
provide	O
a	O
morphologic	O
(	O
angiogenesis	S-Blood_vessel_development
and	O
increased	S-Positive_regulation
endothelial	B-Tissue
area	E-Tissue
)	O
and	O
molecular	O
(	O
enhanced	S-Positive_regulation
NOS	S-Gene_or_gene_product
activity	O
and	O
endothelial	B-Gene_or_gene_product
NOS	E-Gene_or_gene_product
upregulation	S-Positive_regulation
)	O
basis	O
for	O
explaining	O
the	O
permeability	O
changes	O
observed	O
in	O
long	O
-	O
term	O
PD	O
.	O

They	O
also	O
support	O
the	O
implication	O
of	O
local	O
advanced	O
glycation	O
end	O
product	O
deposits	O
and	O
liberation	S-Localization
of	O
VEGF	S-Gene_or_gene_product
in	O
that	O
process	O
.	O

Adenovirus	S-Organism
-	O
mediated	S-Positive_regulation
gene	B-Planned_process
transfer	E-Planned_process
of	O
endostatin	S-Gene_or_gene_product
in	O
vivo	O
results	S-Positive_regulation
in	O
high	O
level	O
of	O
transgene	O
expression	S-Gene_expression
and	O
inhibition	S-Negative_regulation
of	O
tumor	S-Pathological_formation
growth	S-Growth
and	O
metastases	S-Localization
.	O

Inhibition	S-Negative_regulation
of	O
angiogenesis	S-Blood_vessel_development
has	O
been	O
shown	O
to	O
be	O
an	O
effective	O
strategy	O
in	O
cancer	S-Pathological_formation
therapy	S-Planned_process
in	O
mice	S-Organism
.	O

However	O
,	O
its	O
widespread	O
application	O
has	O
been	O
hampered	O
by	O
difficulties	O
in	O
the	O
large	O
-	O
scale	O
production	O
of	O
the	O
antiangiogenic	S-Blood_vessel_development
proteins	O
.	O

This	O
limitation	O
may	O
be	O
resolved	O
by	O
in	O
vivo	O
delivery	O
and	O
expression	O
of	O
the	O
antiangiogenic	S-Blood_vessel_development
genes	O
.	O

We	O
have	O
constructed	S-Planned_process
a	O
recombinant	O
adenovirus	S-Organism
that	O
expresses	S-Gene_expression
murine	S-Organism
endostatin	S-Gene_or_gene_product
that	O
is	O
biologically	O
active	O
both	O
in	O
vitro	O
,	O
as	O
determined	O
in	O
endothelial	B-Cell
cell	E-Cell
proliferation	S-Cell_proliferation
assays	O
,	O
and	O
in	O
vivo	O
,	O
by	O
suppression	S-Negative_regulation
of	O
angiogenesis	S-Blood_vessel_development
induced	S-Positive_regulation
by	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
165	E-Gene_or_gene_product
.	O

Persistent	O
high	O
serum	S-Organism_substance
levels	O
of	O
endostatin	S-Gene_or_gene_product
(	O
605	O
-	O
1740	O
ng	O
/	O
ml	O
;	O
mean	O
,	O
936	O
ng	O
/	O
ml	O
)	O
were	O
achieved	O
after	O
systemic	O
administration	S-Planned_process
of	O
the	O
vector	O
to	O
nude	B-Organism
mice	E-Organism
,	O
which	O
resulted	S-Positive_regulation
in	O
significant	O
reduction	S-Negative_regulation
of	O
the	O
growth	S-Growth
rates	O
and	O
the	O
volumes	O
of	O
JC	B-Pathological_formation
breast	I-Pathological_formation
carcinoma	E-Pathological_formation
and	O
Lewis	B-Pathological_formation
lung	I-Pathological_formation
carcinoma	E-Pathological_formation
(	O
P	O
less	O
than	O
0	O
.	O
001	O
and	O
P	O
less	O
than	O
0	O
.	O
05	O
,	O
respectively	O
)	O
.	O

In	O
addition	O
,	O
the	O
endostatin	S-Gene_or_gene_product
vector	B-Planned_process
treatment	E-Planned_process
completely	O
prevented	S-Negative_regulation
the	O
formation	S-Development
of	O
pulmonary	B-Pathological_formation
micrometastases	E-Pathological_formation
in	O
Lewis	B-Pathological_formation
lung	I-Pathological_formation
carcinoma	E-Pathological_formation
(	O
P	O
=	O
0	O
.	O
0001	O
)	O
.	O

Immunohistochemical	O
staining	O
of	O
the	O
tumors	S-Pathological_formation
demonstrated	O
a	O
decreased	S-Negative_regulation
number	O
of	O
blood	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
in	O
the	O
treatment	O
group	O
versus	O
the	O
controls	O
.	O

In	O
conclusion	O
,	O
the	O
present	O
study	O
clearly	O
demonstrates	O
the	O
potential	O
of	O
vector	O
-	O
mediated	O
antiangiogenic	S-Blood_vessel_development
gene	O
therapy	O
as	O
a	O
component	O
in	O
cancer	S-Pathological_formation
therapy	S-Planned_process
.	O

Active	O
hair	S-Multi-tissue_structure
growth	S-Growth
(	O
anagen	O
)	O
is	O
associated	S-Regulation
with	O
angiogenesis	S-Blood_vessel_development
.	O

After	O
the	O
completion	O
of	O
skin	S-Organ
development	S-Development
,	O
angiogenesis	S-Blood_vessel_development
,	O
i	O
.	O
e	O
.	O
,	O
the	O
growth	S-Growth
of	O
new	O
capillaries	S-Tissue
from	O
pre	O
-	O
existing	O
blood	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
,	O
is	O
held	O
to	O
occur	O
in	O
the	O
skin	S-Organ
only	O
under	O
pathologic	O
conditions	O
.	O

It	O
has	O
long	O
been	O
noted	O
,	O
however	O
,	O
that	O
hair	B-Multi-tissue_structure
follicle	E-Multi-tissue_structure
cycling	S-Development
is	O
associated	S-Regulation
with	O
prominent	O
changes	O
in	O
skin	S-Organ
perfusion	O
,	O
that	O
the	O
epithelial	B-Tissue
hair	I-Tissue
bulbs	E-Tissue
of	O
anagen	B-Multi-tissue_structure
follicles	E-Multi-tissue_structure
display	O
angiogenic	S-Blood_vessel_development
properties	O
,	O
and	O
that	O
the	O
follicular	B-Tissue
dermal	I-Tissue
papilla	E-Tissue
can	O
produce	O
angiogenic	S-Blood_vessel_development
factors	O
.	O

Despite	O
these	O
suggestive	O
observations	O
,	O
no	O
formal	O
proof	O
is	O
as	O
yet	O
available	O
for	O
the	O
concept	O
that	O
angiogenesis	S-Blood_vessel_development
is	O
a	O
physiologic	O
event	O
that	O
occurs	O
all	O
over	O
the	O
mature	O
mammalian	O
integument	O
whenever	O
hair	B-Multi-tissue_structure
follicles	E-Multi-tissue_structure
switch	O
from	O
resting	S-Growth
(	O
telogen	O
)	O
to	O
active	O
growth	S-Growth
(	O
anagen	O
)	O
.	O

This	O
study	O
uses	O
quantitative	O
histomorphometry	O
and	O
double	O
-	O
immunohistologic	O
detection	O
techniques	O
for	O
the	O
demarcation	O
of	O
proliferating	S-Cell_proliferation
endothelial	B-Cell
cells	E-Cell
,	O
to	O
show	O
that	O
synchronized	O
hair	B-Multi-tissue_structure
follicle	E-Multi-tissue_structure
cycling	S-Development
in	O
adolescent	O
C57BL	B-Organism
/	I-Organism
6	I-Organism
mice	E-Organism
is	O
associated	S-Regulation
with	O
substantial	O
angiogenesis	S-Blood_vessel_development
,	O
and	O
that	O
inhibiting	S-Negative_regulation
angiogenesis	S-Blood_vessel_development
in	O
vivo	O
by	O
the	O
intraperitoneal	O
application	O
of	O
a	O
fumagillin	B-Drug_or_compound
derivative	E-Drug_or_compound
retards	O
experimentally	O
induced	O
anagen	O
development	O
in	O
these	O
mice	S-Organism
.	O

Thus	O
,	O
angiogenesis	S-Blood_vessel_development
is	O
a	O
physiologic	O
event	O
in	O
normal	O
postnatal	O
murine	S-Organism
skin	S-Organ
,	O
apparently	O
is	O
dictated	O
by	O
the	O
hair	B-Multi-tissue_structure
follicle	E-Multi-tissue_structure
,	O
and	O
appears	O
to	O
be	O
required	O
for	O
normal	O
anagen	O
development	O
.	O

Anagen	O
-	O
associated	S-Regulation
angiogenesis	S-Blood_vessel_development
offers	O
an	O
attractive	O
model	O
for	O
identifying	O
the	O
physiologic	O
controls	O
of	O
cutaneous	O
angiogenesis	S-Blood_vessel_development
,	O
and	O
an	O
interesting	O
system	O
for	O
screening	O
the	O
effects	O
of	O
potential	O
antiangiogenic	S-Blood_vessel_development
drugs	O
in	O
vivo	O
.	O

Alpha	B-Gene_or_gene_product
-	I-Gene_or_gene_product
melanocyte	I-Gene_or_gene_product
-	I-Gene_or_gene_product
stimulating	I-Gene_or_gene_product
hormone	E-Gene_or_gene_product
modulates	S-Regulation
activation	S-Positive_regulation
of	O
NF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
kappa	I-Gene_or_gene_product
B	E-Gene_or_gene_product
and	O
AP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
and	O
secretion	S-Localization
of	O
interleukin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	E-Gene_or_gene_product
in	O
human	S-Organism
dermal	B-Cell
fibroblasts	E-Cell
.	O

Alpha	B-Gene_or_gene_product
-	I-Gene_or_gene_product
melanocyte	I-Gene_or_gene_product
-	I-Gene_or_gene_product
stimulating	I-Gene_or_gene_product
hormone	E-Gene_or_gene_product
(	O
alpha	B-Gene_or_gene_product
-	I-Gene_or_gene_product
MSH	E-Gene_or_gene_product
)	O
has	O
evolved	O
as	O
a	O
mediator	S-Regulation
of	O
diverse	O
biological	O
activities	O
in	O
an	O
ever	O
-	O
growing	S-Cell_proliferation
number	O
of	O
non	B-Cell
-	I-Cell
melanocytic	I-Cell
cell	E-Cell
types	O
.	O

One	O
mechanism	O
by	O
which	O
alpha	B-Gene_or_gene_product
-	I-Gene_or_gene_product
MSH	E-Gene_or_gene_product
exerts	O
its	O
effects	O
is	O
modulation	S-Regulation
of	O
AP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
and	O
NF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
kappa	I-Gene_or_gene_product
B	E-Gene_or_gene_product
.	O

These	O
two	O
transcription	O
factors	O
also	O
play	B-Regulation
an	I-Regulation
important	I-Regulation
role	E-Regulation
in	O
fibroblasts	S-Cell
,	O
in	O
extracellular	B-Cellular_component
matrix	E-Cellular_component
composition	O
,	O
and	O
in	O
cytokine	O
expression	O
.	O

By	O
use	O
of	O
electric	O
mobility	O
shift	O
assays	O
,	O
we	O
demonstrate	O
that	O
alpha	B-Gene_or_gene_product
-	I-Gene_or_gene_product
MSH	E-Gene_or_gene_product
(	O
10	O
(	O
-	O
6	O
)	O
to	O
10	O
(	O
-	O
14	O
)	O
M	O
)	O
activates	S-Positive_regulation
AP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
in	O
human	S-Organism
dermal	B-Cell
fibroblasts	E-Cell
,	O
whereas	O
coincubation	S-Planned_process
with	O
interleukin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
beta	E-Gene_or_gene_product
(	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
beta	E-Gene_or_gene_product
)	O
results	O
in	O
suppression	S-Negative_regulation
of	O
its	O
activation	O
.	O

alpha	B-Gene_or_gene_product
-	I-Gene_or_gene_product
MSH	E-Gene_or_gene_product
also	O
induces	S-Positive_regulation
activation	S-Positive_regulation
of	O
NF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
kappa	I-Gene_or_gene_product
B	E-Gene_or_gene_product
but	O
does	O
not	O
modulate	S-Regulation
DNA	O
binding	S-Binding
on	O
costimulation	S-Positive_regulation
with	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
beta	E-Gene_or_gene_product
.	O

Since	O
AP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
and	O
NF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
kappa	I-Gene_or_gene_product
B	E-Gene_or_gene_product
are	O
key	O
elements	O
in	O
controlling	S-Regulation
interleukin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	E-Gene_or_gene_product
(	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	E-Gene_or_gene_product
)	O
transcription	S-Transcription
,	O
human	S-Organism
fibroblasts	S-Cell
were	O
treated	S-Planned_process
with	O
alpha	B-Gene_or_gene_product
-	I-Gene_or_gene_product
MSH	E-Gene_or_gene_product
and	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
beta	E-Gene_or_gene_product
for	O
24	O
hours	O
,	O
and	O
cytokine	O
levels	O
in	O
the	O
supernatants	O
were	O
measured	O
by	O
ELISA	O
.	O

alpha	B-Gene_or_gene_product
-	I-Gene_or_gene_product
MSH	E-Gene_or_gene_product
alone	O
had	O
little	O
effect	O
,	O
whereas	O
coincubation	S-Planned_process
with	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
beta	E-Gene_or_gene_product
led	S-Positive_regulation
to	O
marked	O
downregulation	S-Negative_regulation
of	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	E-Gene_or_gene_product
secretion	S-Localization
(	O
at	O
most	O
288	O
+	O
/	O
-	O
152	O
ng	O
/	O
mL	O
)	O
when	O
compared	O
to	O
treatment	S-Planned_process
with	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
beta	E-Gene_or_gene_product
alone	O
(	O
919	O
+	O
/	O
-	O
157	O
ng	O
/	O
mL	O
)	O
.	O

Our	O
results	O
indicate	O
that	O
alpha	B-Gene_or_gene_product
-	I-Gene_or_gene_product
MSH	E-Gene_or_gene_product
exerts	O
modulatory	O
effects	S-Regulation
on	O
the	O
activation	S-Positive_regulation
of	O
NF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
kappa	I-Gene_or_gene_product
B	E-Gene_or_gene_product
and	O
AP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
,	O
and	O
that	O
it	O
can	O
regulate	O
chemokine	O
secretion	O
in	O
human	S-Organism
dermal	B-Cell
fibroblasts	E-Cell
.	O

These	O
effects	O
of	O
alpha	B-Gene_or_gene_product
-	I-Gene_or_gene_product
MSH	E-Gene_or_gene_product
may	O
have	B-Regulation
important	I-Regulation
regulatory	I-Regulation
functions	E-Regulation
in	O
extracellular	B-Cellular_component
matrix	E-Cellular_component
composition	O
,	O
wound	S-Pathological_formation
healing	O
,	O
or	O
angiogenesis	S-Blood_vessel_development
.	O

Vasodilator	B-Gene_or_gene_product
-	I-Gene_or_gene_product
stimulated	I-Gene_or_gene_product
phosphoprotein	E-Gene_or_gene_product
is	O
involved	S-Regulation
in	O
stress	B-Cellular_component
-	I-Cellular_component
fiber	E-Cellular_component
and	O
membrane	B-Cellular_component
ruffle	E-Cellular_component
formation	S-Development
in	O
endothelial	B-Cell
cells	E-Cell
.	O

Vasodilator	B-Gene_or_gene_product
-	I-Gene_or_gene_product
stimulated	I-Gene_or_gene_product
phosphoprotein	E-Gene_or_gene_product
(	O
VASP	S-Gene_or_gene_product
)	O
is	O
highly	O
expressed	S-Gene_expression
in	O
vascular	B-Cell
endothelial	I-Cell
cells	E-Cell
,	O
where	O
it	O
has	O
been	O
implicated	O
in	O
cellular	O
reorganization	O
during	O
angiogenesis	S-Blood_vessel_development
,	O
as	O
well	O
as	O
in	O
endothelial	O
retraction	O
and	O
changes	S-Regulation
in	O
vessel	S-Multi-tissue_structure
permeability	O
.	O

However	O
,	O
the	O
cellular	O
functions	O
of	O
VASP	S-Gene_or_gene_product
are	O
not	O
known	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
expressed	S-Planned_process
wild	O
-	O
type	O
and	O
mutant	O
forms	O
of	O
VASP	S-Gene_or_gene_product
in	O
endothelial	B-Cell
cells	E-Cell
to	O
determine	O
in	O
what	O
aspects	O
of	O
cytoskeletal	O
behavior	O
this	O
protein	O
participates	O
.	O

Expression	S-Gene_expression
of	O
wild	O
-	O
type	O
VASP	S-Gene_or_gene_product
induces	S-Positive_regulation
marked	O
membrane	S-Cellular_component
ruffling	S-Regulation
and	O
formation	S-Development
of	O
prominent	O
stress	B-Cellular_component
fibers	E-Cellular_component
in	O
bovine	S-Organism
aortic	B-Cell
endothelial	I-Cell
cells	E-Cell
.	O

Deletion	O
of	O
the	O
proline	B-Protein_domain_or_region
-	I-Protein_domain_or_region
rich	I-Protein_domain_or_region
domain	E-Protein_domain_or_region
of	O
VASP	S-Gene_or_gene_product
abolishes	S-Negative_regulation
its	O
ability	O
to	O
bind	S-Binding
profilin	S-Gene_or_gene_product
but	O
does	O
not	O
affect	S-Regulation
ruffling	O
or	O
stress	B-Cellular_component
fiber	E-Cellular_component
formation	S-Development
.	O

Further	O
deletions	O
reveal	O
a	O
sequence	O
within	O
the	O
carboxy	O
-	O
terminal	O
domain	O
that	O
is	O
responsible	O
for	O
in	O
vivo	O
bundle	O
formation	O
.	O

Ruffling	O
occurs	O
only	O
on	O
the	O
expression	S-Gene_expression
of	O
forms	O
of	O
VASP	S-Gene_or_gene_product
that	O
possess	O
bundling	O
activity	O
and	O
the	O
capacity	O
to	O
bind	S-Binding
zyxin	S-Gene_or_gene_product
/	O
vinculin	S-Gene_or_gene_product
-	O
derived	O
peptide	O
.	O

The	O
ability	O
of	O
distinct	O
subdomains	S-Protein_domain_or_region
within	O
VASP	S-Gene_or_gene_product
to	O
bind	S-Binding
adhesion	O
proteins	O
and	O
induce	S-Positive_regulation
F	B-Gene_or_gene_product
-	I-Gene_or_gene_product
actin	E-Gene_or_gene_product
bundling	O
in	O
vivo	O
suggests	O
that	O
this	O
protein	O
could	O
function	O
in	O
the	O
aggregation	O
and	O
tethering	O
of	O
actin	S-Gene_or_gene_product
filaments	O
during	O
the	O
formation	S-Development
of	O
endothelial	B-Cellular_component
cell	I-Cellular_component
-	I-Cellular_component
substrate	E-Cellular_component
and	O
cell	B-Cellular_component
-	I-Cellular_component
cell	I-Cellular_component
contacts	E-Cellular_component
.	O

These	O
data	O
provide	O
a	O
mechanism	O
whereby	O
VASP	S-Gene_or_gene_product
can	O
influence	S-Negative_regulation
endothelial	S-Cell
migration	S-Localization
and	O
organization	S-Development
during	O
capillary	S-Tissue
formation	S-Development
and	O
modulate	S-Regulation
vascular	S-Multi-tissue_structure
permeability	O
via	O
effects	S-Regulation
on	O
endothelial	B-Cell
cell	E-Cell
contractility	O
.	O

Urokinase	B-Gene_or_gene_product
receptor	E-Gene_or_gene_product
:	O
a	O
molecular	O
organizer	O
in	O
cellular	O
communication	O
.	O

In	O
a	O
variety	O
of	O
cell	S-Cell
types	O
,	O
the	O
glycolipid	B-Gene_or_gene_product
-	I-Gene_or_gene_product
anchored	I-Gene_or_gene_product
urokinase	I-Gene_or_gene_product
receptor	E-Gene_or_gene_product
(	O
uPAR	S-Gene_or_gene_product
)	O
is	O
colocalized	S-Localization
pericellularly	O
with	O
components	O
of	O
the	O
plasminogen	S-Gene_or_gene_product
activation	O
system	O
and	O
endocytosis	O
receptors	O
.	O

uPAR	S-Gene_or_gene_product
is	O
also	O
coexpressed	S-Gene_expression
with	O
caveolin	S-Gene_or_gene_product
and	O
members	O
of	O
the	O
integrin	B-Gene_or_gene_product
adhesion	I-Gene_or_gene_product
receptor	E-Gene_or_gene_product
superfamily	O
.	O

The	O
formation	O
of	O
functional	O
units	O
with	O
these	O
various	O
proteins	O
allows	O
the	O
uPAR	S-Gene_or_gene_product
to	O
mediate	O
the	O
focused	O
proteolysis	O
required	S-Positive_regulation
for	O
cell	S-Cell
migration	S-Localization
and	O
invasion	S-Localization
and	O
to	O
contribute	S-Regulation
both	O
directly	O
and	O
indirectly	O
to	O
cell	S-Cell
adhesive	B-Binding
processes	E-Binding
in	O
a	O
non	O
-	O
proteolytic	O
fashion	O
.	O

This	O
dual	O
activity	O
,	O
together	O
with	O
the	O
initiation	S-Positive_regulation
of	O
signal	B-Pathway
transduction	I-Pathway
pathways	E-Pathway
by	O
uPAR	S-Gene_or_gene_product
,	O
is	O
believed	O
to	O
influence	S-Negative_regulation
cellular	O
behaviour	O
in	O
angiogenesis	S-Blood_vessel_development
,	O
inflammation	O
,	O
wound	S-Pathological_formation
repair	O
and	O
tumor	S-Pathological_formation
progression	S-Development
/	O
metastasis	S-Localization
and	O
open	O
up	O
the	O
way	O
for	O
uPAR	S-Gene_or_gene_product
-	O
based	O
therapeutic	O
approaches	O
.	O

Building	S-Development
the	O
vertebrate	O
vasculature	S-Anatomical_system
:	O
research	O
is	O
going	O
swimmingly	O
.	O

The	O
vertebrate	O
vasculature	S-Anatomical_system
develops	S-Development
in	O
remarkably	O
similar	O
fashion	O
in	O
all	O
vertebrates	O
.	O

A	O
cohort	O
of	O
unspecified	O
mesodermal	B-Cell
cells	E-Cell
differentiates	S-Development
into	O
primitive	O
endothelial	B-Cell
cells	E-Cell
,	O
which	O
migrate	S-Localization
to	O
and	O
occupy	O
positions	O
within	O
the	O
stereotypical	O
blueprint	O
of	O
the	O
primitive	O
vasculature	S-Anatomical_system
.	O

Once	O
in	O
position	O
,	O
these	O
cells	S-Cell
coalesce	S-Localization
and	O
form	S-Development
cords	S-Tissue
,	O
which	O
lumenize	S-Development
and	O
become	O
ensheathed	S-Localization
by	O
supporting	O
pericytes	S-Cell
and	O
smooth	B-Cell
muscle	I-Cell
cells	E-Cell
.	O

This	O
primitive	O
vascular	B-Anatomical_system
network	E-Anatomical_system
is	O
extensively	O
remodeled	S-Remodeling
in	O
some	O
places	O
,	O
and	O
expanded	O
by	O
sprouting	O
in	O
others	O
.	O

Various	O
studies	O
using	O
the	O
mouse	S-Organism
,	O
quail	S-Organism
/	O
chick	S-Organism
,	O
and	O
frog	S-Organism
have	O
uncovered	O
a	O
number	O
of	O
signals	O
that	O
guide	O
these	O
complex	O
processes	O
but	O
many	O
gaps	O
still	O
exist	O
in	O
our	O
understanding	O
of	O
the	O
mechanisms	O
by	O
which	O
the	O
embryonic	B-Anatomical_system
vasculature	E-Anatomical_system
is	O
built	S-Development
.	O

Because	O
many	O
questions	O
will	O
require	O
in	O
vivo	O
studies	O
to	O
be	O
properly	O
addressed	O
,	O
the	O
zebrafish	S-Organism
,	O
with	O
its	O
unique	O
accessibility	O
to	O
analysis	O
by	O
combined	O
embryological	O
,	O
molecular	O
,	O
and	O
genetic	O
methods	O
,	O
should	O
prove	O
invaluable	O
in	O
identifying	O
new	O
molecules	O
involved	O
in	O
blood	B-Multi-tissue_structure
vessel	E-Multi-tissue_structure
development	S-Development
and	O
integrating	O
pathways	O
that	O
influence	O
embryonic	O
blood	B-Multi-tissue_structure
vessel	E-Multi-tissue_structure
formation	S-Development
.	O

Nitric	B-Gene_or_gene_product
oxide	I-Gene_or_gene_product
synthase	E-Gene_or_gene_product
inhibition	S-Negative_regulation
results	S-Positive_regulation
in	O
synergistic	O
anti	O
-	O
tumour	S-Pathological_formation
activity	S-Negative_regulation
with	O
melphalan	S-Drug_or_compound
and	O
tumour	B-Gene_or_gene_product
necrosis	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
alpha	E-Gene_or_gene_product
-	O
based	O
isolated	O
limb	S-Organism_subdivision
perfusions	O
.	O

Nitric	B-Drug_or_compound
oxide	E-Drug_or_compound
(	O
NO	S-Drug_or_compound
)	O
is	O
an	O
important	O
molecule	O
in	O
regulating	O
tumour	S-Pathological_formation
blood	S-Organism_substance
flow	O
and	O
stimulating	S-Positive_regulation
tumour	S-Pathological_formation
angiogenesis	S-Blood_vessel_development
.	O

Inhibition	S-Negative_regulation
of	O
NO	B-Gene_or_gene_product
synthase	E-Gene_or_gene_product
by	O
L	B-Drug_or_compound
-	I-Drug_or_compound
NAME	E-Drug_or_compound
might	O
induce	S-Positive_regulation
an	O
anti	O
-	O
tumour	S-Pathological_formation
effect	S-Negative_regulation
by	O
limiting	S-Negative_regulation
nutrients	O
and	O
oxygen	S-Drug_or_compound
to	O
reach	S-Localization
tumour	B-Tissue
tissue	E-Tissue
or	O
affecting	S-Regulation
vascular	S-Multi-tissue_structure
growth	S-Growth
.	O

The	O
anti	O
-	O
tumour	S-Pathological_formation
effect	S-Negative_regulation
of	O
L	B-Drug_or_compound
-	I-Drug_or_compound
NAME	E-Drug_or_compound
after	O
systemic	O
administration	S-Planned_process
was	O
studied	O
in	O
a	O
renal	B-Pathological_formation
subcapsular	I-Pathological_formation
CC531	I-Pathological_formation
adenocarcinoma	E-Pathological_formation
model	O
in	O
rats	S-Organism
.	O

Moreover	O
,	O
regional	O
administration	S-Planned_process
of	O
L	B-Drug_or_compound
-	I-Drug_or_compound
NAME	E-Drug_or_compound
,	O
in	O
combination	O
with	O
TNF	S-Gene_or_gene_product
and	O
melphalan	S-Drug_or_compound
,	O
was	O
studied	O
in	O
an	O
isolated	O
limb	S-Organism_subdivision
perfusion	O
(	O
ILP	O
)	O
model	O
using	O
BN175	B-Pathological_formation
soft	I-Pathological_formation
-	I-Pathological_formation
tissue	I-Pathological_formation
sarcomas	E-Pathological_formation
.	O

Systemic	O
treatment	S-Planned_process
with	O
L	B-Drug_or_compound
-	I-Drug_or_compound
NAME	E-Drug_or_compound
inhibited	S-Negative_regulation
growth	S-Growth
of	O
adenocarcinoma	S-Pathological_formation
significantly	O
but	O
was	O
accompanied	O
by	O
impaired	S-Negative_regulation
renal	S-Organ
function	O
.	O

In	O
ILP	O
,	O
reduced	S-Negative_regulation
tumour	S-Pathological_formation
growth	S-Growth
was	O
observed	O
when	O
L	B-Drug_or_compound
-	I-Drug_or_compound
NAME	E-Drug_or_compound
was	O
used	O
alone	O
.	O

In	O
combination	O
with	O
TNF	S-Gene_or_gene_product
or	O
melphalan	S-Drug_or_compound
,	O
L	B-Drug_or_compound
-	I-Drug_or_compound
NAME	E-Drug_or_compound
increased	O
response	O
rates	O
significantly	O
compared	O
to	O
perfusions	O
without	O
L	B-Drug_or_compound
-	I-Drug_or_compound
NAME	E-Drug_or_compound
(	O
0	O
-	O
64	O
%	O
and	O
0	O
-	O
63	O
%	O
respectively	O
)	O
.	O

An	O
additional	O
anti	O
-	O
tumour	S-Pathological_formation
effect	S-Negative_regulation
was	O
demonstrated	O
when	O
L	B-Drug_or_compound
-	I-Drug_or_compound
NAME	E-Drug_or_compound
was	O
added	S-Planned_process
to	O
the	O
synergistic	O
combination	O
of	O
melphalan	S-Drug_or_compound
and	O
TNF	S-Gene_or_gene_product
(	O
responses	O
increased	O
from	O
70	O
to	O
100	O
%	O
)	O
.	O

Inhibition	S-Negative_regulation
of	O
NO	B-Gene_or_gene_product
synthase	E-Gene_or_gene_product
reduces	S-Negative_regulation
tumour	S-Pathological_formation
growth	S-Growth
both	O
after	O
systemic	O
and	O
regional	O
(	O
ILP	O
)	O
treatment	O
.	O

A	O
synergistic	O
anti	O
-	O
tumour	S-Pathological_formation
effect	S-Negative_regulation
of	O
L	B-Drug_or_compound
-	I-Drug_or_compound
NAME	E-Drug_or_compound
is	O
observed	O
in	O
combination	O
with	O
melphalan	S-Drug_or_compound
and	O
/	O
or	O
TNF	S-Gene_or_gene_product
using	O
ILP	O
.	O

These	O
results	O
indicate	O
a	O
possible	O
role	S-Regulation
of	O
L	B-Drug_or_compound
-	I-Drug_or_compound
NAME	E-Drug_or_compound
for	O
the	O
treatment	S-Planned_process
of	O
solid	O
tumours	S-Pathological_formation
in	O
a	O
systemic	O
or	O
regional	O
setting	O
.	O

RNA	O
damage	O
and	O
inhibition	S-Negative_regulation
of	O
neoplastic	O
endothelial	B-Cell
cell	E-Cell
growth	S-Cell_proliferation
:	O
effects	O
of	O
human	S-Organism
and	O
amphibian	O
ribonucleases	S-Gene_or_gene_product
.	O

Angiogenesis	S-Blood_vessel_development
defines	O
the	O
many	O
steps	O
involved	O
in	O
the	O
growth	S-Growth
and	O
migration	S-Localization
of	O
endothelial	B-Cell
cell	E-Cell
-	O
derived	S-Development
blood	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
.	O

This	O
process	O
is	O
necessary	O
for	O
the	O
growth	S-Growth
and	O
metastasis	S-Localization
of	O
tumors	S-Pathological_formation
,	O
and	O
considerable	O
effort	O
is	O
being	O
expended	O
to	O
find	O
inhibitors	O
of	O
tumor	S-Pathological_formation
angiogenesis	S-Blood_vessel_development
.	O

This	O
usually	O
involves	O
screening	O
of	O
potential	O
anti	O
-	O
angiogenic	S-Blood_vessel_development
compounds	O
on	O
endothelial	B-Cell
cells	E-Cell
.	O

To	O
this	O
end	O
,	O
two	O
candidate	O
anti	O
-	O
angiogenic	S-Blood_vessel_development
RNA	O
-	O
damaging	O
agents	O
,	O
onconase	S-Drug_or_compound
and	O
(	B-Drug_or_compound
-	I-Drug_or_compound
4	I-Drug_or_compound
)	I-Drug_or_compound
rhEDN	E-Drug_or_compound
,	O
were	O
screened	O
for	O
their	O
effects	S-Regulation
on	O
endothelial	B-Cell
cell	E-Cell
proliferation	S-Cell_proliferation
using	O
three	O
distinct	O
types	O
of	O
endothelial	B-Cell
cells	E-Cell
in	O
culture	O
:	O
HPV	B-Organism
-	I-Organism
16	I-Organism
E6	E-Organism
/	O
E7	S-Organism
-	O
immortalized	S-Planned_process
human	B-Cell
umbilical	I-Cell
vein	I-Cell
endothelial	I-Cell
cells	E-Cell
(	O
HUVECs	S-Cell
)	O
,	O
a	O
Kras	S-Gene_or_gene_product
-	O
transformed	S-Planned_process
HPV	B-Organism
-	I-Organism
16	I-Organism
E6	E-Organism
/	O
E7	S-Organism
HUVEC	S-Cell
(	O
Rhim	O
et	O
al	O
.	O
,	O
Carcinogenesis	O
4	O
,	O
673	O
-	O
681	O
,	O
1998	O
)	O
,	O
and	O
primary	O
HUVECs	S-Cell
.	O

Onconase	S-Drug_or_compound
similarly	O
inhibited	S-Negative_regulation
proliferation	S-Cell_proliferation
in	O
all	O
three	O
cell	B-Cell
lines	E-Cell
(	O
IC	O
(	O
50	O
)	O
=	O
0	O
.	O
3	O
-	O
1	O
.	O
0	O
microM	O
)	O
while	O
(	B-Drug_or_compound
-	I-Drug_or_compound
4	I-Drug_or_compound
)	I-Drug_or_compound
rhEDN	E-Drug_or_compound
was	O
more	O
effective	S-Positive_regulation
on	O
immortalized	S-Planned_process
HUVEC	B-Cell
cell	I-Cell
lines	E-Cell
(	O
IC	O
(	O
50	O
)	O
=	O
0	O
.	O
02	O
-	O
0	O
.	O
06	O
microM	O
)	O
than	O
on	O
primary	O
HUVECs	S-Cell
(	O
IC	O
(	O
50	O
)	O
>	O
0	O
.	O
1	O
microM	O
)	O
.	O

Differential	O
sensitivity	O
to	O
these	O
agents	O
implies	O
that	O
more	O
than	O
one	O
endothelial	B-Cell
cell	I-Cell
type	E-Cell
must	O
be	O
used	O
in	O
proliferation	S-Cell_proliferation
assays	O
to	O
screen	O
for	O
novel	O
anti	O
-	O
angiogenic	S-Blood_vessel_development
compounds	O
.	O

IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
12	E-Gene_or_gene_product
inhibition	S-Negative_regulation
of	O
endothelial	B-Cell
cell	E-Cell
functions	O
and	O
angiogenesis	S-Blood_vessel_development
depends	O
on	O
lymphocyte	S-Cell
-	O
endothelial	B-Cell
cell	E-Cell
cross	O
-	O
talk	O
.	O

In	O
vivo	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
12	E-Gene_or_gene_product
-	O
dependent	S-Positive_regulation
tumor	S-Pathological_formation
inhibition	S-Negative_regulation
rests	O
on	O
the	O
ability	O
of	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
12	E-Gene_or_gene_product
to	O
activate	O
a	O
CD8	S-Gene_or_gene_product
-	O
mediated	O
cytotoxicity	O
,	O
inhibit	S-Negative_regulation
angiogenesis	S-Blood_vessel_development
,	O
and	O
cause	O
vascular	O
injury	O
.	O

Although	O
in	O
vivo	O
studies	O
have	O
shown	O
that	O
such	O
inhibition	O
stems	O
from	O
complex	O
interactions	O
of	O
immune	B-Cell
cells	E-Cell
and	O
the	O
production	S-Gene_expression
of	O
IFN	B-Gene_or_gene_product
-	I-Gene_or_gene_product
gamma	E-Gene_or_gene_product
and	O
other	O
downstream	O
angiostatic	O
chemokines	O
,	O
the	O
mechanisms	O
involved	O
are	O
still	O
poorly	O
defined	O
.	O

Here	O
we	O
show	O
that	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
12	E-Gene_or_gene_product
activates	S-Positive_regulation
an	O
anti	O
-	O
angiogenic	S-Blood_vessel_development
program	S-Negative_regulation
in	O
Con	B-Drug_or_compound
A	E-Drug_or_compound
-	O
activated	S-Positive_regulation
mouse	S-Organism
spleen	B-Cell
cells	E-Cell
(	O
activated	S-Positive_regulation
spc	S-Cell
)	O
or	O
human	S-Organism
PBMC	S-Cell
(	O
activated	S-Positive_regulation
PBMC	S-Cell
)	O
.	O

The	O
soluble	O
factors	O
they	O
release	O
in	O
its	O
presence	O
arrest	S-Negative_regulation
the	O
cycle	O
of	O
endothelial	B-Cell
cells	E-Cell
(	O
EC	S-Cell
)	O
,	O
inhibit	S-Negative_regulation
in	O
vitro	O
angiogenesis	S-Blood_vessel_development
,	O
negatively	B-Negative_regulation
modulate	E-Negative_regulation
the	O
production	S-Gene_expression
of	O
matrix	B-Gene_or_gene_product
metalloproteinase	I-Gene_or_gene_product
-	I-Gene_or_gene_product
9	E-Gene_or_gene_product
,	O
and	O
the	O
ability	O
of	O
EC	S-Cell
to	O
adhere	S-Binding
to	O
vitronectin	S-Gene_or_gene_product
and	O
up	B-Positive_regulation
-	I-Positive_regulation
regulate	E-Positive_regulation
ICAM	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
and	O
VCAM	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
expression	S-Gene_expression
.	O

These	O
effects	O
do	O
not	O
require	S-Regulation
direct	O
cell	S-Cell
-	O
cell	S-Cell
contact	S-Binding
,	O
yet	O
result	O
from	O
continuous	O
interaction	S-Binding
between	O
activated	S-Positive_regulation
lymphoid	B-Cell
cells	E-Cell
and	O
EC	S-Cell
.	O

We	O
used	O
neutralizing	O
Abs	O
to	O
show	O
that	O
the	O
IFN	B-Gene_or_gene_product
-	I-Gene_or_gene_product
inducible	I-Gene_or_gene_product
protein	I-Gene_or_gene_product
-	I-Gene_or_gene_product
10	E-Gene_or_gene_product
and	O
monokine	O
-	O
induced	O
by	O
IFN	O
-	O
gamma	O
chemokines	O
are	O
pivotal	O
in	O
inducing	O
these	O
effects	O
.	O

Experiments	O
with	O
nu	B-Organism
/	I-Organism
nu	I-Organism
mice	E-Organism
,	O
nonobese	B-Organism
diabetic	I-Organism
-	I-Organism
SCID	I-Organism
mice	E-Organism
,	O
or	O
activated	S-Positive_regulation
spc	S-Cell
enriched	O
in	O
specific	O
cell	S-Cell
subpopulations	O
demonstrated	O
that	O
CD4	B-Cell
(	I-Cell
+	I-Cell
)	E-Cell
,	O
CD8	B-Cell
(	I-Cell
+	I-Cell
)	E-Cell
,	O
and	O
NK	B-Cell
cells	E-Cell
are	O
all	O
needed	O
to	O
mediate	S-Regulation
the	O
full	O
anti	O
-	O
angiogenetic	S-Blood_vessel_development
effect	S-Regulation
of	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
12	E-Gene_or_gene_product
.	O

Vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
-	I-Gene_or_gene_product
B	E-Gene_or_gene_product
and	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
-	I-Gene_or_gene_product
C	E-Gene_or_gene_product
expression	S-Gene_expression
in	O
renal	B-Pathological_formation
cell	I-Pathological_formation
carcinomas	E-Pathological_formation
:	O
regulation	O
by	O
the	O
von	B-Gene_or_gene_product
Hippel	I-Gene_or_gene_product
-	I-Gene_or_gene_product
Lindau	E-Gene_or_gene_product
gene	O
and	O
hypoxia	O
.	O

Angiogenesis	S-Blood_vessel_development
is	O
essential	S-Positive_regulation
for	O
tumor	S-Pathological_formation
growth	S-Growth
and	O
metastasis	S-Localization
.	O

It	O
is	O
regulated	O
by	O
numerous	O
angiogenic	S-Blood_vessel_development
factors	O
,	O
one	O
of	O
the	O
most	O
important	O
being	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
(	O
VEGF	S-Gene_or_gene_product
)	O
.	O

Recently	O
VEGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
B	E-Gene_or_gene_product
and	O
VEGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
C	E-Gene_or_gene_product
,	O
two	O
new	O
VEGF	S-Gene_or_gene_product
family	O
members	O
,	O
have	O
been	O
identified	O
that	O
bind	S-Binding
to	O
the	O
tyrosine	O
kinase	O
receptors	O
flt	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
(	O
VEGFR1	S-Gene_or_gene_product
)	O
,	O
KDR	S-Gene_or_gene_product
(	O
VEGFR2	S-Gene_or_gene_product
)	O
,	O
and	O
flt	B-Gene_or_gene_product
-	I-Gene_or_gene_product
4	E-Gene_or_gene_product
(	O
VEGFR3	S-Gene_or_gene_product
)	O
.	O

Although	O
the	O
importance	O
of	O
VEGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
A	E-Gene_or_gene_product
has	O
been	O
shown	O
in	O
renal	B-Pathological_formation
carcinomas	E-Pathological_formation
,	O
the	O
contribution	O
of	O
these	O
new	O
ligands	O
in	O
kidney	B-Pathological_formation
tumors	E-Pathological_formation
is	O
not	O
clear	O
.	O

We	O
have	O
,	O
therefore	O
,	O
measured	O
the	O
mRNA	O
level	O
of	O
VEGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
B	E-Gene_or_gene_product
and	O
VEGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
C	E-Gene_or_gene_product
together	O
with	O
their	O
receptors	O
by	O
RNase	S-Gene_or_gene_product
protection	O
assay	O
(	O
RPA	O
)	O
in	O
26	O
normal	B-Multi-tissue_structure
kidney	I-Multi-tissue_structure
samples	E-Multi-tissue_structure
and	O
45	O
renal	B-Pathological_formation
cell	I-Pathological_formation
cancers	E-Pathological_formation
.	O

We	O
observed	O
a	O
significant	O
up	B-Positive_regulation
-	I-Positive_regulation
regulation	E-Positive_regulation
of	O
VEGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
B	E-Gene_or_gene_product
(	O
P	O
=	O
0	O
.	O
002	O
)	O
but	O
not	O
VEGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
C	E-Gene_or_gene_product
(	O
P	O
=	O
0	O
.	O
3	O
)	O
in	O
neoplastic	B-Organ
kidney	E-Organ
compared	O
with	O
normal	B-Tissue
tissues	E-Tissue
.	O

In	O
addition	O
,	O
although	O
VEGF	B-Gene_or_gene_product
receptors	E-Gene_or_gene_product
were	O
higher	O
in	O
tumors	S-Pathological_formation
than	O
normal	O
kidney	S-Organ
,	O
there	O
was	O
a	O
significant	O
up	B-Positive_regulation
-	I-Positive_regulation
regulation	E-Positive_regulation
of	O
only	O
flt	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
(	O
P	O
=	O
0	O
.	O
003	O
)	O
but	O
not	O
KDR	S-Gene_or_gene_product
(	O
P	O
=	O
0	O
.	O
12	O
)	O
or	O
flt	B-Gene_or_gene_product
-	I-Gene_or_gene_product
4	E-Gene_or_gene_product
(	O
P	O
=	O
0	O
.	O
09	O
)	O
.	O

There	O
was	O
also	O
a	O
significant	O
correlation	O
between	O
VEGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
C	E-Gene_or_gene_product
and	O
both	O
of	O
its	O
receptors	O
flt	B-Gene_or_gene_product
-	I-Gene_or_gene_product
4	E-Gene_or_gene_product
(	O
P	O
=	O
0	O
.	O
006	O
)	O
and	O
KDR	S-Gene_or_gene_product
(	O
P	O
=	O
0	O
.	O
03	O
)	O
but	O
no	O
association	O
between	O
VEGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
B	E-Gene_or_gene_product
and	O
its	O
receptor	O
flt	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
(	O
P	O
=	O
0	O
.	O
23	O
)	O
.	O

A	O
significant	O
increase	S-Positive_regulation
was	O
observed	O
in	O
flt	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
KDR	S-Gene_or_gene_product
(	O
P	O
=	O
0	O
.	O
02	O
)	O
,	O
and	O
flt	B-Gene_or_gene_product
-	I-Gene_or_gene_product
4	E-Gene_or_gene_product
(	O
P	O
=	O
0	O
.	O
01	O
)	O
but	O
not	O
VEGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
B	E-Gene_or_gene_product
(	O
P	O
=	O
0	O
.	O
82	O
)	O
or	O
VEGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
C	E-Gene_or_gene_product
(	O
P	O
=	O
0	O
.	O
52	O
)	O
expression	S-Gene_expression
in	O
clear	B-Cell
cell	E-Cell
compared	O
with	O
chromophil	B-Pathological_formation
(	I-Pathological_formation
papillary	I-Pathological_formation
)	I-Pathological_formation
carcinomas	E-Pathological_formation
.	O

No	O
significant	O
association	O
was	O
demonstrated	O
between	O
VEGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
B	E-Gene_or_gene_product
,	O
VEGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
C	E-Gene_or_gene_product
,	O
flt	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
,	O
KDR	S-Gene_or_gene_product
,	O
and	O
flt	B-Gene_or_gene_product
-	I-Gene_or_gene_product
4	E-Gene_or_gene_product
with	O
patient	S-Organism
sex	O
,	O
patient	S-Organism
age	O
,	O
or	O
tumor	S-Pathological_formation
size	O
(	O
P	O
greater	O
than	O
0	O
.	O
05	O
)	O
.	O

The	O
effect	S-Regulation
of	O
von	B-Gene_or_gene_product
Hippel	I-Gene_or_gene_product
-	I-Gene_or_gene_product
Lindau	E-Gene_or_gene_product
(	O
VHL	S-Gene_or_gene_product
)	O
gene	O
and	O
hypoxia	O
on	O
VEGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
B	E-Gene_or_gene_product
and	O
VEGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
C	E-Gene_or_gene_product
expression	S-Gene_expression
in	O
the	O
renal	B-Pathological_formation
carcinoma	E-Pathological_formation
cell	O
line	O
786	B-Cell
-	I-Cell
0	E-Cell
transfected	S-Planned_process
with	O
wild	O
-	O
type	O
and	O
mutant	O
VHL	S-Gene_or_gene_product
was	O
determined	O
by	O
growing	S-Cell_proliferation
cells	S-Cell
under	O
21	O
%	O
O2	O
-	O
and	O
0	O
.	O
1	O
%	O
O2	O
.	O

In	O
wild	B-Cell
-	I-Cell
type	I-Cell
VHL	I-Cell
cells	E-Cell
,	O
whereas	O
VEGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
A	E-Gene_or_gene_product
was	O
significantly	O
up	B-Positive_regulation
-	I-Positive_regulation
regulated	E-Positive_regulation
under	O
hypoxic	O
compared	O
with	O
normoxic	O
conditions	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
expression	S-Gene_expression
of	O
VEGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
C	E-Gene_or_gene_product
was	O
reduced	S-Negative_regulation
(	O
P	O
less	O
than	O
0	O
.	O
002	O
)	O
.	O

Nevertheless	O
,	O
the	O
repression	S-Negative_regulation
of	O
VEGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
C	E-Gene_or_gene_product
was	O
lost	O
in	O
mutant	B-Cell
VHL	I-Cell
cell	I-Cell
lines	E-Cell
under	O
hypoxia	O
.	O

In	O
contrast	O
VEGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
B	E-Gene_or_gene_product
was	O
not	O
regulated	S-Regulation
by	O
VHL	S-Gene_or_gene_product
despite	O
clear	O
up	B-Positive_regulation
-	I-Positive_regulation
regulation	E-Positive_regulation
in	O
vivo	O
.	O

These	O
findings	O
strongly	O
support	O
an	O
enhanced	O
role	O
for	O
this	O
pathway	O
in	O
clear	B-Pathological_formation
cell	I-Pathological_formation
carcinomas	E-Pathological_formation
by	O
regulating	S-Regulation
angiogenesis	S-Blood_vessel_development
and	O
/	O
or	O
lymphangiogenesis	S-Blood_vessel_development
.	O

The	O
study	O
shows	O
that	O
clear	B-Pathological_formation
cell	I-Pathological_formation
tumors	E-Pathological_formation
are	O
able	O
to	O
up	O
-	O
regulate	O
angiogenic	S-Blood_vessel_development
growth	O
factor	O
receptors	O
more	O
efficiently	O
than	O
chromophil	S-Pathological_formation
(	O
papillary	S-Pathological_formation
)	O
,	O
that	O
clear	B-Pathological_formation
cell	I-Pathological_formation
tumors	E-Pathological_formation
can	O
use	O
pathways	O
independent	O
of	O
VHL	S-Gene_or_gene_product
to	O
regulate	S-Regulation
angiogenesis	S-Blood_vessel_development
,	O
and	O
that	O
this	O
combined	O
regulation	O
may	O
account	O
for	O
their	O
more	O
aggressive	O
phenotype	O
,	O
which	O
suggests	O
that	O
targeting	O
VEGFR1	S-Gene_or_gene_product
(	O
flt	B-Gene_or_gene_product
-	I-Gene_or_gene_product
l	E-Gene_or_gene_product
)	O
may	O
be	O
particularly	O
effective	O
in	O
these	O
tumor	S-Pathological_formation
types	O
.	O

A	O
small	O
peptide	O
derived	O
from	O
Flt	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
(	O
VEGFR	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
)	O
functions	O
as	O
an	O
angiogenic	S-Blood_vessel_development
inhibitor	S-Negative_regulation
.	O

Vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
(	O
VEGF	S-Gene_or_gene_product
)	O
is	O
an	O
angiogenic	S-Blood_vessel_development
stimulator	S-Positive_regulation
which	O
functions	S-Regulation
through	O
two	O
endothelial	O
specific	O
tyrosine	O
kinase	O
receptors	O
,	O
Flt	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
and	O
Flk	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
.	O

In	O
this	O
work	O
,	O
we	O
show	O
that	O
an	O
11	O
-	O
amino	O
acid	O
peptide	O
derived	O
from	O
the	O
second	O
immunoglobulin	O
-	O
like	O
domain	O
of	O
Flt	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
functions	O
as	O
an	O
angiogenic	S-Blood_vessel_development
inhibitor	S-Negative_regulation
in	O
chick	S-Organism
chorioallantoic	B-Multi-tissue_structure
membrane	E-Multi-tissue_structure
and	O
inhibited	O
VEGF	S-Gene_or_gene_product
-	O
induced	O
vascular	O
permeability	O
in	O
Miles	O
'	O
assay	O
without	O
binding	S-Binding
to	O
VEGF	S-Gene_or_gene_product
directly	O
.	O

Circular	O
dichroism	O
and	O
nuclear	O
magnetic	O
resonance	O
analyses	O
indicate	O
that	O
this	O
peptide	O
forms	O
a	O
stable	O
extended	O
structure	O
in	O
solution	O
,	O
presumably	O
beta	O
-	O
sheet	O
structure	O
and	O
is	O
most	O
likely	O
existing	O
as	O
a	O
dimer	O
.	O

Our	O
results	O
suggest	O
that	O
this	O
small	O
peptide	O
functions	O
as	O
an	O
angiogenic	S-Blood_vessel_development
inhibitor	O
by	O
inhibiting	S-Negative_regulation
VEGF	S-Gene_or_gene_product
function	O
through	O
a	O
non	O
-	O
VEGF	S-Gene_or_gene_product
binding	S-Binding
mechanism	O
.	O

Effects	S-Regulation
of	O
morphological	O
patterning	O
on	O
endothelial	B-Cell
cell	E-Cell
migration	S-Localization
.	O

The	O
migration	S-Localization
of	O
vascular	B-Cell
endothelial	I-Cell
cells	E-Cell
(	O
ECs	S-Cell
)	O
plays	B-Regulation
an	I-Regulation
important	I-Regulation
role	E-Regulation
in	O
vascular	S-Multi-tissue_structure
remodeling	S-Remodeling
.	O

Here	O
we	O
studied	O
the	O
effects	O
of	O
cell	S-Cell
morphology	O
on	O
the	O
migration	S-Localization
of	O
bovine	S-Organism
aortic	B-Cell
ECs	E-Cell
by	O
culturing	S-Planned_process
cells	S-Cell
on	O
micropatterned	O
strips	O
of	O
collagen	S-Gene_or_gene_product
matrix	S-Cellular_component
(	O
60	O
-	O
,	O
30	O
-	O
,	O
and	O
15	O
-	O
microm	O
wide	O
)	O
.	O

The	O
spreading	O
areas	O
of	O
the	O
cells	S-Cell
on	O
15	O
-	O
and	O
30	O
-	O
microm	O
wide	O
strips	O
were	O
30	O
%	O
lower	O
than	O
those	O
on	O
60	O
-	O
microm	O
wide	O
strips	O
and	O
unpatterned	O
collagen	S-Gene_or_gene_product
.	O

The	O
cells	S-Cell
on	O
15	O
-	O
microm	O
wide	O
strips	O
completely	O
aligned	O
in	O
the	O
direction	O
of	O
the	O
strip	O
,	O
and	O
had	O
significantly	O
lower	O
shape	O
index	O
than	O
those	O
in	O
all	O
other	O
groups	O
.	O

On	O
strips	O
of	O
all	O
widths	O
,	O
ECs	S-Cell
tended	O
to	O
migrate	S-Localization
in	O
the	O
direction	O
of	O
strips	O
.	O

ECs	S-Cell
on	O
15	O
-	O
microm	O
wide	O
strips	O
had	O
highest	O
speed	O
,	O
particularly	O
in	O
the	O
direction	O
of	O
the	O
strip	O
.	O

Vinculin	S-Gene_or_gene_product
staining	O
showed	O
that	O
the	O
leading	O
edge	O
of	O
ECs	S-Cell
on	O
15	O
-	O
microm	O
wide	O
strips	O
had	O
focal	O
adhesions	O
that	O
were	O
oriented	O
with	O
their	O
lamellipodial	O
protrusion	O
and	O
the	O
direction	O
of	O
cell	S-Cell
migration	S-Localization
;	O
this	O
arrangement	O
of	O
the	O
focal	O
adhesions	O
may	O
promote	S-Positive_regulation
EC	S-Cell
migration	S-Localization
.	O

The	O
present	O
study	O
provides	O
direct	O
evidence	O
on	O
the	O
role	S-Regulation
of	O
cell	S-Cell
morphology	O
in	O
EC	S-Cell
migration	S-Localization
,	O
and	O
will	O
help	O
us	O
to	O
understand	O
the	O
mechanisms	O
of	O
EC	S-Cell
migration	S-Localization
during	O
angiogenesis	S-Blood_vessel_development
and	O
wound	S-Pathological_formation
healing	O
.	O

Thrombospondin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
plays	O
a	O
protective	O
role	O
in	O
multistep	O
carcinogenesis	O
:	O
a	O
novel	O
host	O
anti	O
-	O
tumor	S-Pathological_formation
defense	S-Negative_regulation
mechanism	O
.	O

The	O
angiogenic	S-Blood_vessel_development
switch	O
during	O
tumorigenesis	O
is	O
thought	O
to	O
be	O
induced	S-Positive_regulation
by	O
a	O
change	O
in	O
the	O
balance	O
of	O
pro	O
-	O
angiogenic	S-Blood_vessel_development
and	O
anti	O
-	O
angiogenic	S-Blood_vessel_development
factors	O
.	O

To	O
elucidate	O
the	O
biological	O
role	O
of	O
the	O
endogenous	O
angiogenesis	S-Blood_vessel_development
inhibitor	S-Negative_regulation
thrombospondin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
(	O
TSP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
)	O
during	O
multistep	O
carcinogenesis	O
,	O
we	O
subjected	S-Planned_process
TSP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
-	O
deficient	S-Gene_expression
and	O
wild	O
-	O
type	O
mice	S-Organism
to	O
a	O
chemical	O
skin	S-Organ
carcinogenesis	O
regimen	O
.	O

Surprisingly	O
,	O
TSP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
expression	S-Gene_expression
was	O
strongly	O
upregulated	S-Positive_regulation
in	O
the	O
mesenchymal	B-Tissue
stroma	E-Tissue
of	O
wild	O
-	O
type	O
mice	S-Organism
throughout	O
the	O
consecutive	O
stages	O
of	O
tumorigenesis	O
whereas	O
the	O
angiogenesis	S-Blood_vessel_development
factor	O
,	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
,	O
was	O
induced	S-Positive_regulation
predominantly	O
in	O
tumor	B-Cell
cells	E-Cell
.	O

TSP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
deficiency	S-Gene_expression
dramatically	O
enhanced	O
susceptibility	O
to	O
skin	S-Organ
carcinogenesis	O
and	O
resulted	O
in	O
accelerated	O
and	O
increased	S-Positive_regulation
tumor	S-Pathological_formation
formation	S-Development
.	O

The	O
angiogenic	S-Blood_vessel_development
switch	O
occurred	O
in	O
early	O
stages	O
of	O
pre	O
-	O
malignant	O
tumor	S-Pathological_formation
formation	S-Development
,	O
and	O
tumor	S-Pathological_formation
angiogenesis	S-Blood_vessel_development
was	O
significantly	O
enhanced	S-Positive_regulation
in	O
TSP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
-	O
deficient	S-Gene_expression
mice	S-Organism
.	O

While	O
TSP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
deficiency	S-Gene_expression
did	O
not	O
affect	S-Regulation
tumor	S-Pathological_formation
differentiation	S-Development
or	O
proliferation	S-Growth
,	O
tumor	B-Cell
cell	E-Cell
apoptosis	S-Death
was	O
significantly	O
reduced	S-Negative_regulation
.	O

These	O
results	O
reveal	O
upregulation	O
of	O
an	O
endogenous	O
angiogenesis	S-Blood_vessel_development
inhibitor	O
during	O
multi	O
step	O
tumorigenesis	O
and	O
identify	O
enhanced	S-Positive_regulation
stromal	O
TSP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
expression	S-Gene_expression
as	O
a	O
novel	O
host	O
anti	O
-	O
tumor	S-Pathological_formation
defense	S-Negative_regulation
mechanism	O
.	O

Coexpression	S-Gene_expression
of	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
and	O
p53	S-Gene_or_gene_product
protein	O
in	O
squamous	B-Pathological_formation
cell	I-Pathological_formation
carcinoma	E-Pathological_formation
of	O
the	O
esophagus	S-Organ
.	O

OBJECTIVE	O
:	O
p53	S-Gene_or_gene_product
plays	B-Regulation
a	I-Regulation
role	E-Regulation
in	O
tumor	S-Pathological_formation
angiogenesis	S-Blood_vessel_development
,	O
and	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
(	O
VEGF	S-Gene_or_gene_product
)	O
plays	B-Regulation
a	I-Regulation
key	I-Regulation
role	E-Regulation
in	O
tumor	S-Pathological_formation
angiogenesis	S-Blood_vessel_development
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
clarify	O
how	O
expression	S-Gene_expression
of	O
p53	S-Gene_or_gene_product
protein	O
participates	S-Regulation
in	O
angiogenesis	S-Blood_vessel_development
,	O
and	O
whether	O
the	O
coexpression	S-Gene_expression
of	O
VEGF	S-Gene_or_gene_product
and	O
p53	S-Gene_or_gene_product
protein	O
has	O
a	O
significance	S-Regulation
for	O
angiogenesis	S-Blood_vessel_development
and	O
the	O
clinicopathological	O
features	O
in	O
esophageal	B-Pathological_formation
squamous	I-Pathological_formation
cell	I-Pathological_formation
carcinoma	E-Pathological_formation
(	O
SCC	S-Pathological_formation
)	O
.	O

METHODS	O
:	O
Tissues	B-Tissue
samples	E-Tissue
were	O
taken	S-Planned_process
from	O
60	O
patients	S-Organism
with	O
esophageal	B-Pathological_formation
SCC	E-Pathological_formation
after	O
surgery	S-Planned_process
.	O

The	O
expression	S-Gene_expression
of	O
VEGF	S-Gene_or_gene_product
and	O
p53	S-Gene_or_gene_product
protein	O
in	O
these	O
SCC	S-Pathological_formation
was	O
examined	O
immunohistochemically	O
.	O

Microvessel	S-Tissue
density	O
(	O
MVD	O
)	O
was	O
determined	O
by	O
counting	O
microvessels	S-Tissue
in	O
tumor	S-Pathological_formation
sections	O
stained	O
for	O
Factor	B-Gene_or_gene_product
VIII	I-Gene_or_gene_product
-	I-Gene_or_gene_product
related	I-Gene_or_gene_product
antigen	E-Gene_or_gene_product
.	O

Ki	B-Gene_or_gene_product
-	I-Gene_or_gene_product
67	E-Gene_or_gene_product
labeling	O
index	O
(	O
LI	O
)	O
was	O
calculated	O
,	O
based	O
on	O
Ki	B-Gene_or_gene_product
-	I-Gene_or_gene_product
67	E-Gene_or_gene_product
antigen	O
immunostaining	O
,	O
as	O
a	O
proliferative	O
marker	O
.	O

Apoptotic	O
index	O
(	O
AI	O
)	O
was	O
calculated	O
,	O
based	O
on	O
the	O
terminal	B-Gene_or_gene_product
deoxynucleotidyl	I-Gene_or_gene_product
transferase	E-Gene_or_gene_product
-	O
mediated	O
deoxyuridine	B-Drug_or_compound
triphosphate	I-Drug_or_compound
biotin	E-Drug_or_compound
nick	O
end	O
labeling	O
,	O
to	O
evaluate	O
apoptosis	O
.	O

RESULTS	O
:	O
VEGF	S-Gene_or_gene_product
expression	S-Gene_expression
was	O
observed	O
in	O
58	O
.	O
3	O
%	O
,	O
and	O
p53	S-Gene_or_gene_product
protein	O
expression	S-Gene_expression
was	O
observed	O
in	O
61	O
.	O
7	O
%	O
of	O
the	O
60	O
patients	S-Organism
.	O

VEGF	S-Gene_or_gene_product
and	O
p53	S-Gene_or_gene_product
protein	O
were	O
significantly	O
coexpressed	S-Gene_expression
in	O
26	O
(	O
43	O
.	O
4	O
%	O
)	O
.	O

Histological	O
venous	S-Multi-tissue_structure
invasion	S-Localization
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
and	O
distant	O
metastasis	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
were	O
significantly	O
correlated	O
with	O
p53	S-Gene_or_gene_product
protein	O
expression	S-Gene_expression
.	O

The	O
two	O
parameters	O
were	O
more	O
frequently	O
observed	O
in	O
the	O
SCC	S-Pathological_formation
with	O
VEGF	S-Gene_or_gene_product
/	O
p53	S-Gene_or_gene_product
coexpression	S-Gene_expression
than	O
in	O
those	O
without	O
the	O
coexpression	S-Gene_expression
.	O

The	O
MVD	O
and	O
Ki	B-Gene_or_gene_product
-	I-Gene_or_gene_product
67	E-Gene_or_gene_product
LI	O
were	O
significantly	O
higher	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
and	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
and	O
the	O
AI	O
was	O
significantly	O
lower	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
in	O
the	O
SCC	S-Pathological_formation
with	O
p53	S-Gene_or_gene_product
protein	O
expression	S-Gene_expression
than	O
in	O
the	O
SCC	S-Pathological_formation
without	O
it	O
.	O

The	O
MVD	O
and	O
Ki	B-Gene_or_gene_product
-	I-Gene_or_gene_product
67	E-Gene_or_gene_product
LI	O
were	O
higher	O
,	O
and	O
the	O
AI	O
was	O
lower	O
in	O
the	O
SCC	S-Pathological_formation
with	O
VEGF	S-Gene_or_gene_product
/	O
p53	S-Gene_or_gene_product
coexpression	S-Gene_expression
than	O
in	O
those	O
without	O
the	O
coexpression	S-Gene_expression
.	O

The	O
5	O
-	O
yr	O
survival	O
rate	O
in	O
patients	S-Organism
with	O
the	O
coexpression	S-Gene_expression
was	O
poorer	O
than	O
in	O
the	O
other	O
patients	S-Organism
.	O

CONCLUSION	O
:	O
These	O
results	O
suggest	O
that	O
mutant	O
p53	S-Gene_or_gene_product
expression	S-Gene_expression
is	O
associated	O
with	O
angiogenesis	S-Blood_vessel_development
and	O
distant	O
metastasis	S-Pathological_formation
in	O
esophageal	B-Pathological_formation
SCC	E-Pathological_formation
,	O
and	O
that	O
the	O
coexpression	S-Gene_expression
of	O
p53	S-Gene_or_gene_product
and	O
VEGF	S-Gene_or_gene_product
may	O
play	B-Regulation
an	I-Regulation
important	I-Regulation
role	E-Regulation
in	O
angiogenesis	S-Blood_vessel_development
,	O
and	O
have	O
important	O
clinical	O
significance	O
.	O

Current	O
prospects	O
for	O
controlling	S-Regulation
cancer	S-Pathological_formation
growth	S-Growth
with	O
non	O
-	O
cytotoxic	O
agents	O
-	O
-	O
nutrients	O
,	O
phytochemicals	O
,	O
herbal	O
extracts	O
,	O
and	O
available	O
drugs	O
.	O

In	O
animal	O
or	O
cell	S-Cell
culture	S-Planned_process
studies	O
,	O
the	O
growth	S-Growth
and	O
spread	S-Localization
of	O
cancer	S-Pathological_formation
can	O
be	O
slowed	S-Negative_regulation
by	O
many	O
nutrients	O
,	O
food	O
factors	O
,	O
herbal	O
extracts	O
,	O
and	O
well	O
-	O
tolerated	O
,	O
available	O
drugs	O
that	O
are	O
still	O
rarely	O
used	O
in	O
the	O
clinical	O
management	O
of	O
cancer	S-Pathological_formation
,	O
in	O
part	O
because	O
they	O
seem	O
unlikely	O
to	O
constitute	O
definitive	O
therapies	O
in	O
themselves	O
.	O

However	O
,	O
it	O
is	O
reasonable	O
to	O
expect	O
that	O
mechanistically	O
complementary	O
combinations	O
of	O
these	O
measures	O
could	O
have	O
a	O
worthwhile	O
impact	O
on	O
survival	O
times	O
and	O
,	O
when	O
used	O
as	O
adjuvants	O
,	O
could	O
improve	O
the	O
cure	O
rates	O
achievable	O
with	O
standard	O
therapies	O
.	O

The	O
therapeutic	O
options	O
available	O
in	O
this	O
regard	O
include	O
measures	O
that	O
:	O
down	B-Negative_regulation
-	I-Negative_regulation
regulate	E-Negative_regulation
serum	O
free	O
IGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
I	E-Gene_or_gene_product
;	O
suppress	S-Negative_regulation
the	O
synthesis	S-Synthesis
of	O
mevalonic	B-Drug_or_compound
acid	E-Drug_or_compound
and	O
/	O
or	O
certain	O
derivatives	O
thereof	O
;	O
modulate	S-Regulation
arachidonate	S-Drug_or_compound
metabolism	S-Metabolism
by	O
inhibiting	S-Negative_regulation
5	B-Gene_or_gene_product
-	I-Gene_or_gene_product
lipoxygenase	E-Gene_or_gene_product
,	O
12	B-Gene_or_gene_product
-	I-Gene_or_gene_product
lipoxygenase	E-Gene_or_gene_product
,	O
or	O
COX	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
;	O
antagonize	S-Negative_regulation
the	O
activation	S-Positive_regulation
of	O
AP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
transcription	O
factors	O
;	O
promote	S-Positive_regulation
the	O
activation	S-Positive_regulation
of	O
PPAR	B-Gene_or_gene_product
-	I-Gene_or_gene_product
gamma	E-Gene_or_gene_product
transcription	O
factors	O
;	O
and	O
that	O
suppress	S-Negative_regulation
angiogenesis	S-Blood_vessel_development
by	O
additional	O
mechanisms	O
.	O

Many	O
of	O
these	O
measures	O
appear	O
suitable	O
for	O
use	O
in	O
cancer	S-Pathological_formation
prevention	S-Negative_regulation
.	O

Troponin	B-Gene_or_gene_product
I	E-Gene_or_gene_product
inhibits	S-Negative_regulation
capillary	B-Cell
endothelial	I-Cell
cell	E-Cell
proliferation	S-Cell_proliferation
by	O
interaction	S-Binding
with	O
the	O
cell	S-Cell
'	O
s	O
bFGF	B-Gene_or_gene_product
receptor	E-Gene_or_gene_product
.	O

Troponin	B-Gene_or_gene_product
I	E-Gene_or_gene_product
(	O
TnI	S-Gene_or_gene_product
)	O
is	O
a	O
novel	O
cartilage	O
-	O
derived	O
angiogenesis	S-Blood_vessel_development
inhibitor	O
,	O
first	O
demonstrated	O
by	O
Moses	O
et	O
al	O
.	O

(	O
1999	O
,	O
Proc	O
.	O
Natl	O
.	O
Acad	O
.	O
Sci	O
.	O
USA	O
2645	O
-	O
2650	O
)	O
to	O
inhibit	S-Negative_regulation
endothelial	B-Cell
cell	E-Cell
proliferation	S-Cell_proliferation
and	O
angiogenesis	S-Blood_vessel_development
,	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
,	O
and	O
to	O
inhibit	S-Negative_regulation
metastasis	S-Localization
of	O
a	O
wide	O
variety	O
of	O
tumors	S-Pathological_formation
in	O
vivo	O
.	O

Despite	O
convincing	O
evidence	O
of	O
its	O
efficacy	O
,	O
little	O
is	O
known	O
about	O
the	O
mechanism	O
of	O
action	O
of	O
TnI	S-Gene_or_gene_product
as	O
an	O
anti	O
-	O
proliferative	O
and	O
anti	O
-	O
angiogenic	S-Blood_vessel_development
agent	O
.	O

In	O
the	O
current	O
article	O
we	O
demonstrate	O
that	O
TnI	S-Gene_or_gene_product
inhibits	S-Negative_regulation
both	O
bFGF	S-Gene_or_gene_product
-	O
stimulated	S-Positive_regulation
and	O
basal	O
levels	O
of	O
endothelial	B-Cell
cell	E-Cell
proliferation	S-Cell_proliferation
,	O
and	O
we	O
hypothesize	O
that	O
this	O
inhibition	S-Negative_regulation
is	O
occurring	O
,	O
at	O
least	O
in	O
part	O
,	O
via	O
an	O
interaction	S-Binding
of	O
TnI	S-Gene_or_gene_product
with	O
the	O
cell	S-Cell
-	O
surface	O
bFGF	B-Gene_or_gene_product
receptor	E-Gene_or_gene_product
on	O
capillary	B-Cell
endothelial	I-Cell
cells	E-Cell
.	O

We	O
further	O
support	O
this	O
hypothesis	O
by	O
providing	O
the	O
first	O
evidence	O
that	O
TnI	S-Gene_or_gene_product
can	O
act	S-Regulation
on	O
nonendothelial	S-Cell
as	O
well	O
as	O
endothelial	B-Cell
cells	E-Cell
and	O
by	O
demonstrating	O
that	O
this	O
inhibitory	B-Negative_regulation
action	E-Negative_regulation
is	O
specific	O
for	O
the	O
bFGF	B-Gene_or_gene_product
receptor	E-Gene_or_gene_product
on	O
the	O
target	O
cells	S-Cell
.	O

Preliminary	O
data	O
suggest	O
that	O
TnI	S-Gene_or_gene_product
may	O
be	O
competing	S-Negative_regulation
with	O
bFGF	S-Gene_or_gene_product
for	O
interaction	S-Binding
with	O
the	O
bFGF	B-Gene_or_gene_product
receptor	E-Gene_or_gene_product
on	O
responsive	O
cells	S-Cell
.	O

Clinical	O
significance	O
of	O
plasma	B-Gene_or_gene_product
endostatin	E-Gene_or_gene_product
in	O
acute	O
myeloid	O
leukemia	O
/	O
myelodysplastic	O
syndrome	O
.	O

BACKGROUND	O
:	O
Endostatin	S-Gene_or_gene_product
,	O
a	O
C	O
-	O
terminal	O
fragment	O
of	O
collagen	B-Gene_or_gene_product
XVIII	E-Gene_or_gene_product
,	O
is	O
an	O
endogenous	O
angiogenesis	S-Blood_vessel_development
inhibitor	O
.	O

While	O
endostatin	S-Gene_or_gene_product
is	O
being	O
investigated	O
for	O
its	O
usefulness	O
in	O
treating	S-Planned_process
solid	B-Pathological_formation
tumors	E-Pathological_formation
,	O
its	O
significance	O
in	O
hematologic	O
malignancies	O
is	O
unknown	O
.	O

METHODS	O
:	O
The	O
authors	O
evaluated	O
plasma	B-Gene_or_gene_product
endostatin	E-Gene_or_gene_product
(	O
PE	S-Gene_or_gene_product
)	O
levels	O
using	O
an	O
enzyme	B-Planned_process
linked	I-Planned_process
immunoassay	E-Planned_process
in	O
71	O
patients	S-Organism
with	O
acute	O
myeloid	O
leukemia	O
(	O
AML	O
)	O
and	O
43	O
patients	S-Organism
with	O
myelodysplastic	O
syndrome	O
(	O
MDS	O
)	O
,	O
and	O
correlated	O
PE	S-Gene_or_gene_product
with	O
various	O
clinical	O
parameters	O
.	O

RESULTS	O
:	O
There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
median	O
PE	S-Gene_or_gene_product
level	O
between	O
AML	O
/	O
MDS	O
patients	S-Organism
and	O
the	O
normal	O
controls	O
.	O

Nevertheless	O
,	O
patients	S-Organism
who	O
achieved	O
complete	O
remission	O
(	O
CR	O
)	O
had	O
a	O
significantly	O
lower	O
median	O
PE	S-Gene_or_gene_product
level	O
compared	O
to	O
those	O
who	O
did	O
not	O
.	O

In	O
multivariate	O
analysis	O
,	O
PE	S-Gene_or_gene_product
was	O
found	O
to	O
be	O
a	O
significant	O
(	O
P	O
=	O
0	O
.	O
03	O
)	O
predictor	O
of	O
overall	O
survival	O
(	O
OS	O
)	O
with	O
adjustment	O
of	O
the	O
other	O
baseline	O
covariates	O
,	O
including	O
patient	S-Organism
age	O
,	O
history	O
of	O
antecedent	O
hematologic	O
disorders	O
,	O
and	O
the	O
use	O
of	O
protective	O
environments	O
.	O

The	O
prognostic	O
value	O
of	O
PE	S-Gene_or_gene_product
was	O
also	O
evaluated	O
by	O
dividing	O
MDS	O
/	O
AML	O
patients	S-Organism
into	O
high	O
and	O
low	O
PE	S-Gene_or_gene_product
groups	O
using	O
the	O
median	O
PE	S-Gene_or_gene_product
level	O
of	O
normal	O
controls	O
as	O
the	O
cut	O
-	O
off	O
.	O

The	O
authors	O
found	O
that	O
patients	S-Organism
in	O
the	O
high	O
PE	S-Gene_or_gene_product
group	O
survived	S-Death
for	O
a	O
significantly	O
shorter	O
time	O
than	O
those	O
patients	S-Organism
in	O
the	O
low	O
PE	S-Gene_or_gene_product
group	O
.	O

CONCLUSIONS	O
:	O
PE	S-Gene_or_gene_product
is	O
a	O
useful	O
prognostic	O
predictor	O
of	O
CR	O
and	O
OS	O
for	O
AML	O
/	O
MDS	O
patients	S-Organism
.	O

The	O
mechanism	O
underlying	O
the	O
association	O
between	O
high	O
PE	S-Gene_or_gene_product
and	O
poor	O
clinical	O
outcome	O
is	O
unclear	O
,	O
although	O
it	O
may	O
be	O
related	O
to	O
the	O
possible	O
PE	S-Gene_or_gene_product
reflection	O
of	O
tumor	S-Pathological_formation
burden	O
.	O

Modulation	S-Regulation
of	O
angiogenesis	S-Blood_vessel_development
and	O
progelatinase	B-Gene_or_gene_product
a	E-Gene_or_gene_product
by	O
thrombin	B-Gene_or_gene_product
receptor	E-Gene_or_gene_product
mimetics	O
and	O
antagonists	O
.	O

The	O
angiogenic	S-Blood_vessel_development
action	O
of	O
thrombin	S-Gene_or_gene_product
has	O
been	O
shown	O
to	O
be	O
mediated	S-Regulation
by	O
activation	S-Positive_regulation
of	O
the	O
thrombin	B-Gene_or_gene_product
receptor	E-Gene_or_gene_product
.	O

In	O
this	O
report	O
we	O
studied	O
the	O
effects	S-Regulation
of	O
SFLLR	S-Gene_or_gene_product
,	O
an	O
agonist	O
of	O
the	O
activated	S-Positive_regulation
thrombin	B-Gene_or_gene_product
receptor	E-Gene_or_gene_product
and	O
thrombin	B-Gene_or_gene_product
receptor	E-Gene_or_gene_product
peptide	O
and	O
non	O
peptide	O
antagonists	O
on	O
angiogenesis	S-Blood_vessel_development
in	O
the	O
chick	S-Organism
chorioallantoic	B-Multi-tissue_structure
membrane	E-Multi-tissue_structure
(	O
CAM	S-Multi-tissue_structure
)	O
system	O
.	O

As	O
antagonists	O
were	O
used	O
the	O
tripeptide	B-Gene_or_gene_product
FPR	E-Gene_or_gene_product
and	O
non	O
-	O
peptide	O
1	B-Drug_or_compound
,	I-Drug_or_compound
4	I-Drug_or_compound
-	I-Drug_or_compound
disubstituted	I-Drug_or_compound
piperazine	I-Drug_or_compound
derivatives	E-Drug_or_compound
.	O

The	O
pentapeptide	B-Gene_or_gene_product
SFLLR	E-Gene_or_gene_product
,	O
like	O
thrombin	S-Gene_or_gene_product
,	O
caused	O
a	O
marked	O
stimulation	S-Positive_regulation
of	O
angiogenesis	S-Blood_vessel_development
in	O
the	O
CAM	S-Multi-tissue_structure
.	O

FPR	S-Gene_or_gene_product
and	O
the	O
piperazine	B-Drug_or_compound
derivatives	E-Drug_or_compound
caused	O
suppression	S-Negative_regulation
of	O
angiogenesis	S-Blood_vessel_development
and	O
in	O
combination	O
with	O
thrombin	S-Gene_or_gene_product
antagonized	S-Negative_regulation
its	O
angiogenic	S-Blood_vessel_development
effect	O
.	O

Thrombin	S-Gene_or_gene_product
and	O
SFLLR	S-Gene_or_gene_product
activated	S-Positive_regulation
progelatinase	B-Gene_or_gene_product
A	E-Gene_or_gene_product
(	O
MMP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
)	O
in	O
the	O
culture	O
medium	O
of	O
human	B-Cell
umbilical	I-Cell
cord	I-Cell
endothelial	I-Cell
cells	E-Cell
(	O
HUVECs	S-Cell
)	O
.	O

MMP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
is	O
involved	O
in	O
the	O
early	O
steps	O
of	O
angiogenesis	S-Blood_vessel_development
leading	S-Positive_regulation
to	O
local	O
dissolution	S-Catabolism
of	O
basement	B-Gene_or_gene_product
membrane	I-Gene_or_gene_product
collagen	E-Gene_or_gene_product
and	O
migration	S-Localization
of	O
the	O
activated	S-Positive_regulation
endothelial	B-Cell
cells	E-Cell
.	O

FPR	S-Gene_or_gene_product
and	O
the	O
piperazine	B-Drug_or_compound
derivatives	E-Drug_or_compound
inhibited	S-Negative_regulation
the	O
activation	S-Positive_regulation
of	O
this	O
enzyme	O
.	O

They	O
also	O
antagonised	S-Negative_regulation
the	O
effects	S-Regulation
of	O
both	O
thrombin	S-Gene_or_gene_product
and	O
SFLLR	S-Gene_or_gene_product
on	O
MMP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
activation	S-Positive_regulation
.	O

These	O
results	O
suggest	O
that	O
non	O
-	O
thrombogenic	O
agonists	O
or	O
antagonists	O
of	O
the	O
activated	S-Positive_regulation
thrombin	B-Gene_or_gene_product
receptor	E-Gene_or_gene_product
can	O
be	O
used	O
as	O
modulators	S-Regulation
of	O
angiogenesis	S-Blood_vessel_development
.	O

Inhibition	S-Negative_regulation
of	O
PDGF	S-Gene_or_gene_product
-	O
stimulated	S-Positive_regulation
and	O
matrix	S-Cellular_component
-	O
mediated	S-Positive_regulation
proliferation	S-Cell_proliferation
of	O
human	S-Organism
vascular	B-Cell
smooth	I-Cell
muscle	I-Cell
cells	E-Cell
by	O
SPARC	S-Gene_or_gene_product
is	O
independent	S-Regulation
of	O
changes	S-Development
in	O
cell	S-Cell
shape	O
or	O
cyclin	B-Drug_or_compound
-	I-Drug_or_compound
dependent	I-Drug_or_compound
kinase	I-Drug_or_compound
inhibitors	E-Drug_or_compound
.	O

Interactions	S-Binding
among	O
growth	O
factors	O
,	O
cells	S-Cell
,	O
and	O
extracellular	B-Cellular_component
matrix	E-Cellular_component
regulate	S-Regulation
proliferation	S-Cell_proliferation
during	O
normal	O
development	O
and	O
in	O
pathologies	O
such	O
as	O
atherosclerosis	O
.	O

SPARC	S-Gene_or_gene_product
(	O
secreted	B-Gene_or_gene_product
protein	I-Gene_or_gene_product
,	I-Gene_or_gene_product
acidic	I-Gene_or_gene_product
,	I-Gene_or_gene_product
and	I-Gene_or_gene_product
rich	I-Gene_or_gene_product
in	I-Gene_or_gene_product
cysteine	E-Gene_or_gene_product
)	O
is	O
a	O
matrix	S-Cellular_component
-	O
associated	S-Binding
glycoprotein	O
that	O
modulates	S-Regulation
the	O
adhesion	S-Binding
and	O
proliferation	S-Cell_proliferation
of	O
vascular	B-Cell
cells	E-Cell
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
SPARC	S-Gene_or_gene_product
inhibits	S-Negative_regulation
human	S-Organism
arterial	B-Cell
smooth	I-Cell
muscle	I-Cell
cell	E-Cell
proliferation	S-Cell_proliferation
stimulated	S-Positive_regulation
by	O
platelet	B-Gene_or_gene_product
-	I-Gene_or_gene_product
derived	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
or	O
by	O
adhesion	S-Binding
to	O
monomeric	B-Gene_or_gene_product
type	I-Gene_or_gene_product
I	I-Gene_or_gene_product
collagen	E-Gene_or_gene_product
.	O

Binding	S-Binding
studies	O
with	O
SPARC	S-Gene_or_gene_product
and	O
SPARC	B-Gene_or_gene_product
peptides	E-Gene_or_gene_product
indicate	O
specific	O
and	O
saturable	O
interaction	S-Binding
with	O
smooth	B-Cell
muscle	I-Cell
cells	E-Cell
that	O
involves	O
the	O
C	B-Protein_domain_or_region
-	I-Protein_domain_or_region
terminal	I-Protein_domain_or_region
Ca2	I-Protein_domain_or_region
+	I-Protein_domain_or_region
-	I-Protein_domain_or_region
binding	I-Protein_domain_or_region
region	E-Protein_domain_or_region
of	O
the	O
protein	O
.	O

We	O
also	O
report	O
that	O
SPARC	S-Gene_or_gene_product
arrests	S-Negative_regulation
monomeric	O
collagen	S-Gene_or_gene_product
-	O
supported	S-Positive_regulation
smooth	B-Cell
muscle	I-Cell
cell	E-Cell
proliferation	S-Cell_proliferation
in	O
the	O
late	O
G1	O
-	O
phase	O
of	O
the	O
cell	S-Cell
cycle	O
in	O
the	O
absence	O
of	O
an	O
effect	S-Regulation
on	O
cell	S-Cell
shape	O
or	O
on	O
levels	O
of	O
cyclin	B-Drug_or_compound
-	I-Drug_or_compound
dependent	I-Drug_or_compound
kinase	I-Drug_or_compound
inhibitors	E-Drug_or_compound
.	O

Cyclin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
dependent	I-Gene_or_gene_product
kinase	I-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
activity	O
,	O
p107	S-Gene_or_gene_product
and	O
cyclin	B-Gene_or_gene_product
A	E-Gene_or_gene_product
levels	O
,	O
and	O
retinoblastoma	B-Gene_or_gene_product
protein	E-Gene_or_gene_product
phosphorylation	S-Phosphorylation
are	O
markedly	O
reduced	S-Negative_regulation
in	O
response	S-Positive_regulation
to	O
the	O
addition	S-Planned_process
of	O
exogenous	O
SPARC	S-Gene_or_gene_product
and	O
/	O
or	O
peptides	O
derived	O
from	O
specific	O
domains	O
of	O
SPARC	S-Gene_or_gene_product
.	O

Thus	O
,	O
SPARC	S-Gene_or_gene_product
,	O
previously	O
characterized	O
as	O
an	O
inhibitor	O
of	O
platelet	B-Gene_or_gene_product
-	I-Gene_or_gene_product
derived	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
binding	S-Binding
to	O
its	O
receptor	O
,	O
also	O
antagonizes	S-Negative_regulation
smooth	B-Cell
muscle	I-Cell
cell	E-Cell
proliferation	S-Cell_proliferation
mediated	S-Regulation
by	O
monomeric	O
collagen	S-Gene_or_gene_product
at	O
the	O
level	O
of	O
cyclin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
dependent	I-Gene_or_gene_product
kinase	I-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
activity	O
.	O

Upregulation	S-Positive_regulation
of	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
receptors	E-Gene_or_gene_product
is	O
associated	O
with	O
advanced	O
neuroblastoma	O
.	O

BACKGROUND	O
:	O
Angiogenesis	S-Blood_vessel_development
is	O
essential	S-Positive_regulation
for	O
tumor	S-Pathological_formation
growth	S-Growth
and	O
relies	O
on	O
the	O
production	O
of	O
angiogenic	S-Blood_vessel_development
factors	O
.	O

Vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
(	O
VEGF	S-Gene_or_gene_product
)	O
is	O
a	O
major	O
regulator	O
of	O
angiogenesis	S-Blood_vessel_development
that	O
binds	S-Binding
to	O
tyrosine	O
kinase	O
receptors	O
Flt	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
and	O
KDR	S-Gene_or_gene_product
.	O

The	O
interaction	S-Binding
of	O
VEGF	S-Gene_or_gene_product
and	O
its	O
receptors	O
at	O
gene	O
and	O
protein	O
levels	O
in	O
neuroblastoma	S-Pathological_formation
remains	O
widely	O
unknown	O
.	O

METHODS	O
:	O
Tumor	B-Multi-tissue_structure
biopsy	I-Multi-tissue_structure
specimens	E-Multi-tissue_structure
and	O
serum	S-Organism_substance
were	O
obtained	O
from	O
37	O
neuroblastoma	S-Pathological_formation
patients	S-Organism
;	O
adrenal	B-Multi-tissue_structure
biopsy	I-Multi-tissue_structure
sections	E-Multi-tissue_structure
and	O
sera	S-Organism_substance
of	O
7	O
normal	O
children	S-Organism
served	O
as	O
controls	O
.	O

Biopsy	B-Multi-tissue_structure
specimens	E-Multi-tissue_structure
were	O
examined	O
by	O
real	O
-	O
time	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
Western	O
blotting	O
;	O
serum	S-Organism_substance
was	O
analyzed	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
.	O

VEGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
A	I-Gene_or_gene_product
(	I-Gene_or_gene_product
165	I-Gene_or_gene_product
)	E-Gene_or_gene_product
,	O
B	S-Gene_or_gene_product
,	O
C	S-Gene_or_gene_product
,	O
Flt	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
,	O
and	O
KDR	S-Gene_or_gene_product
were	O
analyzed	O
.	O

RESULTS	O
:	O
VEGF	S-Gene_or_gene_product
isoforms	O
and	O
its	O
receptors	O
'	O
mRNA	O
were	O
expressed	S-Transcription
in	O
neuroblastoma	S-Pathological_formation
and	O
control	O
tissues	S-Tissue
.	O

Whereas	O
the	O
ligands	O
were	O
increased	O
in	O
stages	O
III	O
and	O
IV	O
,	O
the	O
receptors	O
were	O
upregulated	O
in	O
stage	O
III	O
only	O
.	O

At	O
protein	O
level	O
,	O
VEGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
B	E-Gene_or_gene_product
and	O
C	S-Gene_or_gene_product
,	O
Flt	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
,	O
and	O
KDR	S-Gene_or_gene_product
were	O
not	O
detectable	S-Gene_expression
in	O
tissue	B-Organism_substance
lysates	E-Organism_substance
,	O
whereas	O
VEGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
A	E-Gene_or_gene_product
was	O
increased	S-Positive_regulation
in	O
stages	O
III	O
and	O
IV	O
.	O

Serum	S-Organism_substance
VEGF	S-Gene_or_gene_product
protein	B-Gene_expression
levels	E-Gene_expression
were	O
upregulated	S-Positive_regulation
in	O
stage	O
III	O
.	O

CONCLUSIONS	O
:	O
VEGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
A	I-Gene_or_gene_product
(	I-Gene_or_gene_product
165	I-Gene_or_gene_product
)	E-Gene_or_gene_product
is	O
one	O
of	O
the	O
major	O
angiogenesis	S-Blood_vessel_development
regulators	O
among	O
the	O
ligands	O
'	O
family	O
of	O
VEGF	S-Gene_or_gene_product
,	O
whereas	O
its	O
receptors	O
KDR	S-Gene_or_gene_product
,	O
and	O
most	O
probably	O
Flt	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
,	O
may	O
contribute	O
to	O
a	O
poor	O
prognosis	O
(	O
angiogenic	S-Blood_vessel_development
)	O
phenotype	O
,	O
as	O
indicated	O
by	O
their	O
upregulated	O
MRNA	O
levels	O
in	O
stage	B-Pathological_formation
III	I-Pathological_formation
neuroblastoma	E-Pathological_formation
.	O

VEGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
A	I-Gene_or_gene_product
(	I-Gene_or_gene_product
165	I-Gene_or_gene_product
)	E-Gene_or_gene_product
mainly	O
contributes	S-Regulation
to	O
increased	S-Positive_regulation
serum	S-Organism_substance
VEGF	S-Gene_or_gene_product
levels	O
and	O
may	O
serve	O
as	O
a	O
diagnostic	O
tool	O
in	O
advanced	O
-	O
stage	O
neuroblastoma	O
.	O

VEGF165	S-Gene_or_gene_product
mediates	S-Regulation
formation	S-Binding
of	O
complexes	O
containing	O
VEGFR	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
and	O
neuropilin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
that	O
enhance	S-Positive_regulation
VEGF165	S-Gene_or_gene_product
-	O
receptor	O
binding	S-Binding
.	O

Co	B-Gene_expression
-	I-Gene_expression
expression	E-Gene_expression
of	O
NRP1	S-Gene_or_gene_product
and	O
(	O
VEGFR	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
)	O
KDR	S-Gene_or_gene_product
on	O
the	O
surface	O
of	O
endothelial	B-Cell
cells	E-Cell
(	O
EC	S-Cell
)	O
enhances	S-Positive_regulation
VEGF165	S-Gene_or_gene_product
binding	S-Binding
to	O
KDR	S-Gene_or_gene_product
and	O
EC	S-Cell
chemotaxis	S-Localization
in	O
response	S-Positive_regulation
to	O
VEGF165	S-Gene_or_gene_product
.	O

Overexpression	S-Gene_expression
of	O
NRP1	S-Gene_or_gene_product
by	O
prostate	B-Cell
tumor	I-Cell
cells	E-Cell
in	O
vivo	O
results	O
in	O
increased	S-Positive_regulation
tumor	S-Pathological_formation
angiogenesis	S-Blood_vessel_development
and	O
growth	S-Growth
.	O

We	O
investigated	O
the	O
molecular	O
mechanisms	O
underlying	O
NRP1	S-Gene_or_gene_product
-	O
mediated	S-Positive_regulation
angiogenesis	S-Blood_vessel_development
by	O
analyzing	O
the	O
association	S-Binding
of	O
NRP1	S-Gene_or_gene_product
and	O
KDR	S-Gene_or_gene_product
.	O

An	O
intracellular	O
complex	O
containing	O
NRP1	S-Gene_or_gene_product
and	O
KDR	S-Gene_or_gene_product
was	O
immunoprecipitated	O
from	O
EC	S-Cell
by	O
anti	B-Gene_or_gene_product
-	I-Gene_or_gene_product
NRP1	I-Gene_or_gene_product
antibodies	E-Gene_or_gene_product
only	O
in	O
the	O
presence	O
of	O
VEGF165	S-Gene_or_gene_product
.	O

In	O
contrast	O
,	O
VEGF121	S-Gene_or_gene_product
,	O
which	O
does	O
not	O
bind	S-Binding
to	O
NRP1	S-Gene_or_gene_product
,	O
did	O
not	O
support	S-Positive_regulation
complex	B-Binding
formation	E-Binding
.	O

Complexes	O
containing	O
VEGF165	S-Gene_or_gene_product
,	O
NRP1	S-Gene_or_gene_product
,	O
and	O
KDR	S-Gene_or_gene_product
were	O
also	O
formed	S-Binding
in	O
an	O
intercellular	O
fashion	O
by	O
co	B-Planned_process
-	I-Planned_process
culture	E-Planned_process
of	O
EC	S-Cell
expressing	S-Gene_expression
KDR	S-Gene_or_gene_product
only	O
,	O
with	O
cells	S-Cell
expressing	S-Gene_expression
NRP1	S-Gene_or_gene_product
only	O
,	O
for	O
example	O
,	O
breast	B-Cell
carcinoma	I-Cell
cells	E-Cell
.	O

VEGF165	S-Gene_or_gene_product
also	O
mediated	S-Regulation
the	O
binding	S-Binding
of	O
a	O
soluble	O
NRP1	S-Gene_or_gene_product
dimer	O
to	O
cells	S-Cell
expressing	S-Gene_expression
KDR	S-Gene_or_gene_product
only	O
,	O
confirming	O
the	O
formation	O
of	O
such	O
complexes	O
.	O

Furthermore	O
,	O
the	O
formation	S-Binding
of	O
complexes	O
containing	O
KDR	S-Gene_or_gene_product
and	O
NRP1	S-Gene_or_gene_product
markedly	O
increased	S-Positive_regulation
125I	B-Gene_or_gene_product
-	I-Gene_or_gene_product
VEGF165	E-Gene_or_gene_product
binding	S-Binding
to	O
KDR	S-Gene_or_gene_product
.	O

Our	O
results	O
suggest	O
that	O
formation	S-Binding
of	O
a	O
ternary	O
complex	O
of	O
VEGF165	S-Gene_or_gene_product
,	O
KDR	S-Gene_or_gene_product
,	O
and	O
NRP1	S-Gene_or_gene_product
potentiates	S-Positive_regulation
VEGF165	S-Gene_or_gene_product
binding	S-Binding
to	O
KDR	S-Gene_or_gene_product
.	O

These	O
complexes	O
are	O
formed	S-Binding
on	O
the	O
surface	O
of	O
EC	S-Cell
and	O
in	O
a	O
juxtacrine	O
manner	O
via	O
association	S-Binding
of	O
tumor	B-Cell
cell	E-Cell
NRP1	S-Gene_or_gene_product
and	O
EC	S-Cell
KDR	S-Gene_or_gene_product
.	O

Hypoxic	O
induction	S-Positive_regulation
of	O
HIF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1alpha	E-Gene_or_gene_product
and	O
VEGF	S-Gene_or_gene_product
expression	S-Gene_expression
in	O
head	B-Cell
and	I-Cell
neck	I-Cell
squamous	I-Cell
cell	I-Cell
carcinoma	I-Cell
lines	E-Cell
is	O
mediated	S-Regulation
by	O
stress	O
activated	O
protein	O
kinases	O
.	O

Solid	B-Pathological_formation
tumors	E-Pathological_formation
must	O
establish	O
a	O
blood	S-Organism_substance
supply	O
in	O
order	O
to	O
proliferate	S-Growth
and	O
grow	S-Growth
.	O

Cancer	B-Cell
cells	E-Cell
secrete	O
soluble	O
factors	O
which	O
can	O
induce	S-Positive_regulation
proliferation	S-Cell_proliferation
and	O
migration	S-Localization
of	O
capillary	B-Cell
endothelial	I-Cell
cells	E-Cell
.	O

Among	O
the	O
most	O
potent	O
of	O
the	O
angiogenic	S-Blood_vessel_development
factors	O
is	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
(	O
VEGF	S-Gene_or_gene_product
)	O
.	O

Increased	S-Positive_regulation
VEGF	S-Gene_or_gene_product
expression	S-Gene_expression
by	O
malignant	O
tumors	S-Pathological_formation
has	O
been	O
associated	S-Regulation
with	O
high	O
vascularity	O
,	O
increased	S-Positive_regulation
cancer	B-Cell
cell	E-Cell
growth	S-Cell_proliferation
,	O
and	O
lymph	B-Multi-tissue_structure
node	E-Multi-tissue_structure
metastasis	S-Localization
.	O

Reduced	S-Negative_regulation
oxygen	S-Drug_or_compound
tension	O
has	O
been	O
shown	O
to	O
increase	S-Positive_regulation
VEGF	S-Gene_or_gene_product
production	S-Gene_expression
by	O
induction	S-Positive_regulation
of	O
the	O
transcription	O
factor	O
hypoxia	B-Gene_or_gene_product
inducible	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
1	I-Gene_or_gene_product
alpha	E-Gene_or_gene_product
(	O
HIF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1alpha	E-Gene_or_gene_product
)	O
.	O

The	O
mechanisms	O
by	O
which	O
hypoxic	O
tumor	S-Pathological_formation
environments	O
induce	S-Positive_regulation
HIF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1alpha	E-Gene_or_gene_product
and	O
VEGF	S-Gene_or_gene_product
expression	S-Gene_expression
are	O
largely	O
unknown	O
.	O

Jun	B-Gene_or_gene_product
N	I-Gene_or_gene_product
terminal	I-Gene_or_gene_product
kinase	E-Gene_or_gene_product
(	O
JNK1	S-Gene_or_gene_product
)	O
and	O
p38	B-Gene_or_gene_product
kinase	E-Gene_or_gene_product
are	O
activated	S-Positive_regulation
by	O
a	O
variety	O
of	O
stress	O
stimuli	O
.	O

To	O
determine	O
if	O
hypoxic	O
activation	O
of	O
these	O
stress	O
activated	O
protein	O
kinases	O
regulated	S-Regulation
HIF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1alpha	E-Gene_or_gene_product
and	O
VEGF	S-Gene_or_gene_product
expression	S-Gene_expression
,	O
we	O
assayed	O
JNK1	S-Gene_or_gene_product
and	O
p38	S-Gene_or_gene_product
activity	O
in	O
squamous	B-Cell
cell	I-Cell
carcinoma	I-Cell
(	I-Cell
SCC	I-Cell
)	I-Cell
lines	E-Cell
grown	O
under	O
normoxic	O
or	O
hypoxic	O
conditions	O
.	O

Hypoxia	O
rapidly	O
induced	S-Positive_regulation
both	O
JNK1	S-Gene_or_gene_product
and	O
p38	S-Gene_or_gene_product
activity	O
in	O
these	O
cells	S-Cell
.	O

This	O
activation	S-Positive_regulation
correlated	O
with	O
induction	S-Positive_regulation
of	O
HIF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1alpha	E-Gene_or_gene_product
expression	S-Gene_expression
and	O
DNA	O
binding	S-Binding
activity	O
which	O
was	O
blocked	S-Negative_regulation
by	O
the	O
p38	S-Gene_or_gene_product
inhibitor	O
SB203580	S-Drug_or_compound
.	O

Hypoxia	O
also	O
increased	S-Positive_regulation
VEGF	S-Gene_or_gene_product
production	S-Gene_expression
by	O
SCC	B-Cell
lines	E-Cell
,	O
which	O
was	O
inhibited	O
by	O
treatment	S-Planned_process
with	O
SB203580	S-Drug_or_compound
.	O

Overexpression	S-Gene_expression
of	O
JNK1	S-Gene_or_gene_product
or	O
p38	S-Gene_or_gene_product
was	O
sufficient	O
to	O
induce	S-Positive_regulation
HIF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1alpha	E-Gene_or_gene_product
and	O
VEGF	S-Gene_or_gene_product
expression	S-Gene_expression
.	O

These	O
results	O
indicate	O
that	O
induction	S-Positive_regulation
of	O
SAPKs	S-Gene_or_gene_product
by	O
hypoxia	O
regulates	S-Regulation
HIF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1alpha	E-Gene_or_gene_product
and	O
VEGF	S-Gene_or_gene_product
expression	S-Gene_expression
in	O
head	B-Cell
and	I-Cell
neck	I-Cell
carcinoma	I-Cell
cell	I-Cell
lines	E-Cell
.	O

[	O
Radiologic	O
-	O
pathologic	O
correlations	O
in	O
breast	S-Organism_subdivision
diseases	O
]	O

The	O
objective	O
of	O
this	O
article	O
is	O
to	O
explain	O
radiologic	O
patterns	O
of	O
benign	O
and	O
malignant	O
breast	B-Pathological_formation
lesions	E-Pathological_formation
(	O
masses	O
,	O
microcalcifications	O
)	O
based	O
on	O
histological	O
correlations	O
.	O

The	O
stromal	O
fibrous	O
reaction	O
associated	O
to	O
infiltrating	S-Localization
carcinomas	S-Pathological_formation
is	O
responsible	O
of	O
focal	O
increased	O
density	O
,	O
and	O
architectural	O
distorsion	O
,	O
ultrasound	O
acoustic	O
shadowing	O
;	O
abnormal	O
neoangiogenesis	S-Blood_vessel_development
can	O
be	O
detected	O
by	O
Doppler	O
,	O
CT	O
or	O
MR	O
imaging	O
.	O

Invasive	S-Localization
carcinomas	S-Pathological_formation
without	O
spiculated	O
margins	O
are	O
poorly	O
differentiated	S-Development
tumors	S-Pathological_formation
.	O

Mammographic	O
patterns	O
of	O
microcalcifications	O
depend	O
on	O
their	O
physiopathological	O
process	O
(	O
necrosis	O
,	O
secretion	O
)	O
,	O
and	O
the	O
shape	O
of	O
clusters	O
(	O
round	O
,	O
triangular	O
)	O
typifies	O
their	O
anatomical	O
site	O
of	O
origin	O
(	O
lobular	O
,	O
ductal	O
)	O
.	O

Less	O
frequent	O
lesions	S-Pathological_formation
(	O
invasive	O
lobular	O
,	O
mucinous	O
,	O
and	O
medullary	O
carcinomas	S-Pathological_formation
,	O
radial	O
scar	S-Pathological_formation
)	O
will	O
be	O
also	O
explained	O
based	O
on	O
radiopathological	O
correlations	O
.	O

Knowledge	O
of	O
radiopathological	O
correlations	O
in	O
breast	S-Organism_subdivision
diseases	O
helps	O
the	O
radiologists	O
to	O
analyze	O
and	O
characterize	O
breast	B-Pathological_formation
lesions	E-Pathological_formation
.	O

Pten	S-Gene_or_gene_product
signaling	S-Pathway
in	O
gliomas	S-Pathological_formation
.	O

In	O
1997	O
,	O
the	O
PTEN	S-Gene_or_gene_product
gene	O
(	O
phosphatase	B-Gene_or_gene_product
and	I-Gene_or_gene_product
tensin	I-Gene_or_gene_product
homolog	I-Gene_or_gene_product
deleted	I-Gene_or_gene_product
on	I-Gene_or_gene_product
chromosome	I-Gene_or_gene_product
10	E-Gene_or_gene_product
)	O
was	O
identified	O
as	O
a	O
tumor	S-Pathological_formation
suppressor	S-Negative_regulation
gene	O
on	O
the	O
long	O
arm	O
of	O
chromosome	O
10	O
.	O

Since	O
then	O
,	O
important	O
progress	O
has	O
been	O
made	O
with	O
respect	O
to	O
the	O
understanding	O
of	O
the	O
role	S-Regulation
of	O
the	O
Pten	S-Gene_or_gene_product
protein	O
in	O
the	O
normal	O
development	S-Development
of	O
the	O
brain	S-Organ
as	O
well	O
as	O
in	O
the	O
molecular	O
pathogenesis	O
of	O
human	S-Organism
gliomas	S-Pathological_formation
.	O

This	O
review	O
summarizes	O
the	O
current	O
state	O
of	O
the	O
art	O
concerning	O
the	O
involvement	O
of	O
aberrant	S-Regulation
Pten	S-Gene_or_gene_product
function	O
in	O
the	O
development	S-Development
of	O
different	O
biologic	O
features	O
of	O
malignant	B-Pathological_formation
gliomas	E-Pathological_formation
,	O
such	O
as	O
loss	O
of	O
cell	S-Cell
-	O
cycle	O
control	O
and	O
uncontrolled	S-Regulation
cell	S-Cell
proliferation	S-Cell_proliferation
,	O
escape	S-Negative_regulation
from	O
apoptosis	S-Death
,	O
brain	S-Organ
invasion	S-Localization
,	O
and	O
aberrant	S-Regulation
neoangiogenesis	S-Blood_vessel_development
.	O

Most	O
of	O
the	O
tumor	S-Pathological_formation
-	O
suppressive	O
properties	O
of	O
Pten	S-Gene_or_gene_product
are	O
dependent	S-Regulation
on	O
its	O
lipid	S-Drug_or_compound
phosphatase	O
activity	O
,	O
which	O
inhibits	S-Negative_regulation
the	O
phosphatidylinositol	B-Gene_or_gene_product
-	I-Gene_or_gene_product
3	I-Gene_or_gene_product
'	I-Gene_or_gene_product
-	I-Gene_or_gene_product
kinase	E-Gene_or_gene_product
(	O
PI3K	S-Gene_or_gene_product
)	O
/	O
Akt	S-Gene_or_gene_product
signaling	B-Pathway
pathway	E-Pathway
through	O
dephosphorylation	S-Dephosphorylation
of	O
phosphatidylinositol	B-Drug_or_compound
-	I-Drug_or_compound
(	I-Drug_or_compound
3	I-Drug_or_compound
,	I-Drug_or_compound
4	I-Drug_or_compound
,	I-Drug_or_compound
5	I-Drug_or_compound
)	I-Drug_or_compound
-	I-Drug_or_compound
triphosphate	E-Drug_or_compound
.	O

The	O
additional	O
function	O
of	O
Pten	S-Gene_or_gene_product
as	O
a	O
dual	O
-	O
specificity	O
protein	O
phosphatase	O
may	O
also	O
play	B-Regulation
a	I-Regulation
role	E-Regulation
in	O
glioma	S-Pathological_formation
pathogenesis	O
.	O

Besides	O
the	O
wealth	O
of	O
data	O
elucidating	O
the	O
functional	O
roles	O
of	O
Pten	S-Gene_or_gene_product
,	O
recent	O
studies	O
suggest	O
a	O
diagnostic	O
significance	O
of	O
PTEN	S-Gene_or_gene_product
gene	O
alterations	S-Regulation
as	O
a	O
molecular	O
marker	O
for	O
poor	O
prognosis	O
in	O
anaplastic	O
astrocytomas	O
and	O
anaplastic	O
oligodendrogliomas	O
.	O

Furthermore	O
,	O
the	O
possibility	O
of	O
selective	B-Planned_process
targeting	E-Planned_process
of	O
PTEN	B-Cell
mutant	I-Cell
tumor	I-Cell
cells	E-Cell
by	O
specific	O
pharmacologic	O
inhibitors	O
of	O
members	O
of	O
the	O
Pten	S-Gene_or_gene_product
/	O
PI3K	S-Gene_or_gene_product
/	O
Akt	S-Gene_or_gene_product
pathway	S-Pathway
opens	O
up	O
new	O
perspectives	O
for	O
a	O
targeted	O
molecular	O
therapy	S-Planned_process
of	O
malignant	O
gliomas	S-Pathological_formation
.	O

Systemic	O
regulation	O
of	O
distraction	O
osteogenesis	O
:	O
a	O
cascade	O
of	O
biochemical	O
factors	O
.	O

This	O
study	O
investigates	O
the	O
systemic	O
biochemical	O
regulation	O
of	O
fracture	O
healing	O
in	O
distraction	O
osteogenesis	O
compared	O
with	O
rigid	O
osteotomy	O
in	O
a	O
prospective	O
in	O
vivo	O
study	O
in	O
humans	S-Organism
.	O

To	O
further	O
clarify	O
the	O
influence	O
of	O
mechanical	O
strain	O
on	O
the	O
regulation	S-Regulation
of	O
bone	S-Organ
formation	S-Development
,	O
bone	S-Organ
growth	O
factors	O
(	O
insulin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
like	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
[	I-Gene_or_gene_product
IGF	I-Gene_or_gene_product
]	I-Gene_or_gene_product
I	E-Gene_or_gene_product
,	O
IGF	B-Gene_or_gene_product
binding	I-Gene_or_gene_product
protein	I-Gene_or_gene_product
[	I-Gene_or_gene_product
IGFBP	I-Gene_or_gene_product
]	I-Gene_or_gene_product
3	E-Gene_or_gene_product
,	O
transforming	B-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
[	I-Gene_or_gene_product
TGF	I-Gene_or_gene_product
]	I-Gene_or_gene_product
beta1	E-Gene_or_gene_product
,	O
and	O
basic	B-Gene_or_gene_product
FGF	E-Gene_or_gene_product
[	O
bFGF	S-Gene_or_gene_product
]	O
)	O
,	O
bone	B-Cellular_component
matrix	E-Cellular_component
degrading	O
enzymes	O
(	O
matrix	B-Gene_or_gene_product
-	I-Gene_or_gene_product
metalloproteinases	I-Gene_or_gene_product
[	I-Gene_or_gene_product
MMPs	I-Gene_or_gene_product
]	I-Gene_or_gene_product
1	E-Gene_or_gene_product
,	O
2	S-Gene_or_gene_product
,	O
and	O
3	S-Gene_or_gene_product
)	O
,	O
human	B-Gene_or_gene_product
growth	I-Gene_or_gene_product
hormone	E-Gene_or_gene_product
(	O
hGH	S-Gene_or_gene_product
)	O
,	O
and	O
bone	S-Organ
formation	O
markers	O
(	O
ALP	S-Gene_or_gene_product
,	O
bone	B-Gene_or_gene_product
-	I-Gene_or_gene_product
specific	I-Gene_or_gene_product
ALP	E-Gene_or_gene_product
[	O
BAP	S-Gene_or_gene_product
]	O
,	O
and	O
osteocalcin	S-Gene_or_gene_product
[	O
OC	S-Gene_or_gene_product
]	O
)	O
have	O
been	O
analyzed	O
in	O
serum	B-Organism_substance
samples	E-Organism_substance
from	O
10	O
patients	S-Organism
in	O
each	O
group	O
pre	O
-	O
and	O
postoperatively	O
.	O

In	O
the	O
distraction	O
group	O
,	O
a	O
significant	O
postoperative	O
increase	S-Positive_regulation
in	O
MMP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
,	O
bFGF	S-Gene_or_gene_product
,	O
ALP	S-Gene_or_gene_product
,	O
and	O
BAP	S-Gene_or_gene_product
could	O
be	O
observed	O
during	O
the	O
lengthening	O
and	O
the	O
consolidation	O
period	O
when	O
compared	O
with	O
the	O
baseline	O
levels	O
.	O

Osteotomy	O
fracture	O
healing	O
without	O
the	O
traction	O
stimulus	O
failed	O
to	O
induce	O
a	O
corresponding	O
increase	O
in	O
these	O
factors	O
.	O

In	O
addition	O
,	O
comparison	O
of	O
both	O
groups	O
revealed	O
a	O
significantly	O
higher	O
increase	S-Positive_regulation
in	O
TGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
beta1	E-Gene_or_gene_product
,	O
IGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
I	E-Gene_or_gene_product
,	O
IGFBP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
3	E-Gene_or_gene_product
,	O
and	O
hGH	S-Gene_or_gene_product
in	O
the	O
lengthening	O
group	O
during	O
the	O
distraction	O
period	O
,	O
indicating	O
key	O
regulatory	O
functions	O
in	O
mechanotransduction	O
.	O

The	O
time	O
courses	O
of	O
changes	S-Regulation
in	O
MMP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
,	O
bone	S-Organ
growth	O
factors	O
(	O
TGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
beta1	E-Gene_or_gene_product
and	O
bFGF	S-Gene_or_gene_product
)	O
,	O
and	O
hGH	S-Gene_or_gene_product
,	O
respectively	O
,	O
correlated	O
significantly	O
during	O
the	O
lengthening	O
phase	O
,	O
indicating	O
common	O
regulatory	O
pathways	O
for	O
these	O
factors	O
in	O
distraction	O
osteogenesis	O
.	O

Significant	O
correlation	O
between	O
the	O
osteoblastic	O
marker	O
BAP	S-Gene_or_gene_product
,	O
TGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
beta1	E-Gene_or_gene_product
,	O
and	O
bFGF	S-Gene_or_gene_product
suggests	O
strain	O
-	O
activated	S-Positive_regulation
osteoblastic	B-Cell
cells	E-Cell
as	O
a	O
major	O
source	O
of	O
systemically	O
increased	O
bone	S-Organ
growth	O
factors	O
during	O
callus	O
distraction	O
.	O

The	O
systemic	O
increase	S-Positive_regulation
in	O
bFGF	S-Gene_or_gene_product
and	O
MMP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
might	O
reflect	O
an	O
increased	S-Positive_regulation
local	O
stimulation	S-Positive_regulation
of	O
angiogenesis	S-Blood_vessel_development
during	O
distraction	O
osteogenesis	O
.	O

Optimizing	O
treatment	S-Planned_process
of	O
choroidal	O
neovascularization	S-Blood_vessel_development
feeder	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
associated	S-Regulation
with	O
age	O
-	O
related	O
macular	S-Tissue
degeneration	S-Breakdown
.	O

PURPOSE	O
:	O
To	O
optimize	O
the	O
method	O
of	O
treating	S-Planned_process
choroidal	O
neovascularization	S-Blood_vessel_development
(	O
CNV	S-Blood_vessel_development
)	O
associated	S-Regulation
with	O
age	O
-	O
related	O
macular	S-Tissue
degeneration	S-Breakdown
(	O
AMD	O
)	O
.	O

DESIGN	O
:	O
Experimental	O
study	O
and	O
interventional	O
case	O
series	O
.	O

METHODS	O
:	O
The	O
parameters	O
associated	O
with	O
locating	O
and	O
then	O
photocoagulating	S-Planned_process
CNV	S-Blood_vessel_development
feeder	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
were	O
identified	O
and	O
optimized	O
using	O
published	O
data	O
and	O
data	O
derived	O
from	O
modeling	O
the	O
choroidal	B-Multi-tissue_structure
vasculature	E-Multi-tissue_structure
.	O

Based	O
on	O
these	O
optimized	O
parameters	O
,	O
a	O
prototype	O
diagnostic	O
/	O
treatment	O
system	O
was	O
designed	O
that	O
captures	O
high	O
-	O
speed	O
indocyanine	B-Drug_or_compound
green	E-Drug_or_compound
(	O
ICG	S-Drug_or_compound
)	O
angiogram	O
images	O
and	O
facilitates	O
analysis	O
of	O
the	O
images	O
by	O
enhancing	O
visualization	O
of	O
dye	O
movement	O
through	O
CNV	S-Blood_vessel_development
feeder	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
(	O
FVs	S-Multi-tissue_structure
)	O
.	O

The	O
system	O
also	O
permits	O
precise	O
aiming	O
and	O
delivery	O
of	O
810	O
-	O
nm	O
wavelength	O
photocoagulation	O
laser	O
energy	O
to	O
target	O
FVs	S-Multi-tissue_structure
on	O
a	O
real	O
-	O
time	O
ICG	S-Drug_or_compound
angiogram	O
image	O
of	O
the	O
choroidal	B-Multi-tissue_structure
vasculature	E-Multi-tissue_structure
.	O

Target	O
FVs	S-Multi-tissue_structure
are	O
tracked	O
by	O
a	O
joy	O
-	O
stick	O
controlled	O
laser	O
aiming	O
beam	O
until	O
an	O
intravenously	B-Planned_process
-	I-Planned_process
injected	E-Planned_process
high	O
-	O
concentration	O
ICG	B-Drug_or_compound
dye	E-Drug_or_compound
bolus	O
is	O
observed	S-Localization
to	O
enter	O
the	O
target	O
vessel	S-Multi-tissue_structure
,	O
at	O
which	O
time	O
the	O
laser	O
is	O
fired	O
.	O

Proof	O
of	O
principle	O
of	O
the	O
combined	O
diagnosis	O
/	O
treatment	O
system	O
design	O
for	O
performing	O
dye	O
-	O
enhanced	O
photocoagulation	O
(	O
DEP	O
)	O
in	O
the	O
clinical	O
setting	O
and	O
determination	O
of	O
the	O
minimum	O
DEP	O
laser	O
energy	O
needed	O
to	O
close	O
CNV	S-Blood_vessel_development
FVs	S-Multi-tissue_structure
was	O
made	O
in	O
11	O
AMD	O
patients	S-Organism
requiring	S-Positive_regulation
treatment	S-Planned_process
of	O
CNV	S-Blood_vessel_development
,	O
but	O
for	O
whom	O
other	O
treatment	O
was	O
not	O
appropriate	O
.	O

RESULTS	O
:	O
Using	O
ICG	S-Drug_or_compound
-	O
DEP	O
,	O
CNV	S-Blood_vessel_development
feeder	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
were	O
closed	S-Planned_process
with	O
single	O
pulse	O
laser	O
energy	O
,	O
delivering	O
as	O
little	O
as	O
0	O
.	O
6	O
to	O
1	O
.	O
8	O
J	O
of	O
energy	O
to	O
the	O
fundus	S-Multi-tissue_structure
,	O
producing	O
no	O
visible	O
change	O
in	O
the	O
fundus	S-Multi-tissue_structure
.	O

Successful	O
FV	S-Multi-tissue_structure
closure	S-Planned_process
was	O
usually	O
indicated	O
immediately	O
by	O
presence	O
of	O
incarcerated	O
ICG	B-Drug_or_compound
dye	E-Drug_or_compound
in	O
the	O
vessel	S-Multi-tissue_structure
adjacent	O
to	O
the	O
burn	O
site	O
.	O

The	O
prototype	O
system	O
proved	O
relatively	O
easy	O
to	O
operate	O
.	O

After	O
acquiring	O
and	O
interpreting	O
diagnostic	O
angiograms	O
and	O
repositioning	O
a	O
patient	S-Organism
in	O
front	O
of	O
the	O
device	O
,	O
feeder	B-Multi-tissue_structure
vessel	E-Multi-tissue_structure
DEP	O
and	O
treatment	O
evaluation	O
required	O
15	O
to	O
20	O
minutes	O
.	O

CONCLUSIONS	O
:	O
Indocyanine	B-Drug_or_compound
green	I-Drug_or_compound
dye	E-Drug_or_compound
-	O
enhanced	S-Positive_regulation
photocoagulation	S-Planned_process
of	O
CNV	S-Blood_vessel_development
feeder	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
,	O
facilitated	O
by	O
use	O
of	O
a	O
device	O
that	O
permits	O
real	O
-	O
time	O
visualization	O
of	O
the	O
choroidal	O
circulation	O
while	O
aiming	O
the	O
treatment	O
laser	O
beam	O
,	O
appears	O
to	O
minimize	O
the	O
amount	O
of	O
energy	O
applied	O
to	O
the	O
fundus	S-Multi-tissue_structure
and	O
the	O
volume	O
of	O
fundus	B-Tissue
tissue	E-Tissue
affected	O
by	O
treatment	O
,	O
compared	O
with	O
other	O
treatment	O
modalities	O
.	O

The	O
combination	O
diagnosis	O
/	O
treatment	O
device	O
should	O
be	O
useful	O
in	O
optimizing	O
FV	S-Multi-tissue_structure
treatment	S-Planned_process
and	O
in	O
refining	O
and	O
evaluating	O
the	O
efficacy	O
of	O
DEP	O
in	O
future	O
clinical	O
trials	O
.	O

Inhibition	S-Negative_regulation
of	O
angiogenesis	S-Blood_vessel_development
by	O
the	O
cancer	S-Pathological_formation
chemopreventive	O
agent	O
conjugated	B-Drug_or_compound
linoleic	I-Drug_or_compound
acid	E-Drug_or_compound
.	O

Dietary	O
conjugated	B-Drug_or_compound
linoleic	I-Drug_or_compound
acid	E-Drug_or_compound
(	O
CLA	S-Drug_or_compound
)	O
has	O
been	O
shown	O
previously	O
to	O
inhibit	O
rat	S-Organism
mammary	S-Organ
carcinogenesis	O
.	O

In	O
addition	O
to	O
direct	O
effects	S-Regulation
on	O
mammary	B-Cell
epithelial	I-Cell
cells	E-Cell
,	O
including	O
decreased	S-Negative_regulation
proliferation	S-Cell_proliferation
and	O
induction	S-Positive_regulation
of	O
apoptosis	S-Death
,	O
CLA	S-Drug_or_compound
may	O
exert	O
its	O
effects	S-Regulation
indirectly	O
by	O
inhibiting	S-Negative_regulation
the	O
differentiation	S-Development
of	O
mammary	B-Cell
stromal	I-Cell
cells	E-Cell
to	O
an	O
endothelial	B-Cell
cell	E-Cell
type	O
.	O

Specifically	O
,	O
CLA	S-Drug_or_compound
was	O
found	O
to	O
decrease	S-Negative_regulation
the	O
ability	O
of	O
mammary	B-Cell
stromal	I-Cell
cells	E-Cell
to	O
form	S-Development
complex	O
anastomosing	O
microcapillary	B-Multi-tissue_structure
networks	E-Multi-tissue_structure
in	O
vitro	O
on	O
Engelbreth	O
-	O
Holm	O
-	O
Swarm	O
-	O
derived	O
reconstituted	O
basement	B-Cellular_component
membrane	E-Cellular_component
.	O

This	O
suggested	O
that	O
CLA	S-Drug_or_compound
might	O
inhibit	S-Negative_regulation
angiogenesis	S-Blood_vessel_development
in	O
vivo	O
.	O

To	O
test	O
this	O
possibility	O
,	O
CD2	O
/	O
F	O
(	O
1	O
)	O
mice	S-Organism
were	O
placed	S-Planned_process
on	O
synthetic	O
diets	O
containing	O
0	O
,	O
1	O
,	O
or	O
2	O
%	O
CLA	S-Drug_or_compound
for	O
6	O
weeks	O
,	O
before	O
angiogenic	S-Blood_vessel_development
challenge	O
by	O
s	B-Planned_process
.	I-Planned_process
c	I-Planned_process
.	I-Planned_process
injection	E-Planned_process
with	O
an	O
angiogenic	S-Blood_vessel_development
gel	O
substrate	O
(	O
Matrigel	O
pellet	O
assay	O
)	O
.	O

After	O
7	O
days	O
,	O
the	O
pellets	O
from	O
animals	O
fed	O
the	O
control	O
diet	O
were	O
infiltrated	O
by	O
abundant	S-Positive_regulation
branching	S-Development
networks	B-Multi-tissue_structure
of	I-Multi-tissue_structure
blood	I-Multi-tissue_structure
vessels	E-Multi-tissue_structure
with	O
patent	O
lumen	S-Immaterial_anatomical_entity
-	O
containing	O
RBCs	S-Cell
.	O

In	O
contrast	O
,	O
pellets	O
from	O
the	O
CLA	S-Drug_or_compound
-	O
fed	S-Planned_process
animals	O
contained	O
fewer	O
infiltrating	S-Localization
cells	S-Cell
,	O
which	O
formed	S-Development
limited	O
branching	O
cellular	B-Multi-tissue_structure
networks	E-Multi-tissue_structure
,	O
the	O
majority	O
of	O
which	O
had	O
collapsed	S-Breakdown
lumen	S-Immaterial_anatomical_entity
and	O
no	O
RBCs	S-Cell
.	O

Both	O
levels	O
of	O
dietary	O
CLA	S-Drug_or_compound
showed	O
similar	O
effects	O
,	O
with	O
the	O
number	O
of	O
RBC	S-Cell
-	O
containing	O
vessels	S-Multi-tissue_structure
per	O
20x	O
field	O
decreased	O
to	O
a	O
third	O
of	O
that	O
seen	O
in	O
control	O
.	O

Dietary	O
CLA	S-Drug_or_compound
decreased	S-Negative_regulation
serum	S-Organism_substance
levels	O
of	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
(	O
VEGF	S-Gene_or_gene_product
)	O
and	O
whole	O
mammary	B-Organ
gland	E-Organ
levels	O
of	O
VEGF	S-Gene_or_gene_product
and	O
its	O
receptor	O
Flk	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
.	O

Both	O
cis	B-Drug_or_compound
-	I-Drug_or_compound
9	E-Drug_or_compound
,	O
trans	B-Drug_or_compound
-	I-Drug_or_compound
11	E-Drug_or_compound
and	O
trans	B-Drug_or_compound
-	I-Drug_or_compound
10	E-Drug_or_compound
,	O
cis	B-Drug_or_compound
-	I-Drug_or_compound
12	I-Drug_or_compound
CLA	I-Drug_or_compound
isomers	E-Drug_or_compound
were	O
effective	S-Regulation
in	O
inhibiting	S-Negative_regulation
angiogenesis	S-Blood_vessel_development
in	O
vitro	O
in	O
a	O
dose	O
-	O
dependent	O
fashion	O
.	O

The	O
ability	O
of	O
CLA	S-Drug_or_compound
to	O
inhibit	S-Negative_regulation
angiogenesis	S-Blood_vessel_development
may	O
contribute	O
to	O
its	O
efficacy	O
as	O
a	O
chemopreventive	O
agent	O
.	O

Molecular	O
characterization	O
of	O
angiogenic	S-Blood_vessel_development
properties	O
of	O
human	S-Organism
oral	B-Cell
squamous	I-Cell
cell	I-Cell
carcinoma	I-Cell
cells	E-Cell
.	O

Little	O
is	O
known	O
about	O
the	O
specificity	O
of	O
angiogenic	S-Blood_vessel_development
properties	O
of	O
oral	B-Cell
cancer	I-Cell
cells	E-Cell
and	O
the	O
possible	O
mechanisms	O
.	O

Stimulatory	B-Positive_regulation
effects	E-Positive_regulation
on	O
proliferation	S-Cell_proliferation
and	O
migration	S-Localization
of	O
human	B-Cell
umbilical	I-Cell
vein	I-Cell
endothelial	I-Cell
cells	E-Cell
(	O
HUVEC	S-Cell
)	O
characterized	O
the	O
angiogenic	S-Blood_vessel_development
properties	O
of	O
oral	B-Cell
cancer	I-Cell
cells	E-Cell
but	O
not	O
normal	B-Cell
oral	I-Cell
keratinocytes	E-Cell
(	O
NOK	S-Cell
)	O
.	O

ELISA	O
found	O
the	O
presence	O
of	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factors	E-Gene_or_gene_product
(	O
VEGF	S-Gene_or_gene_product
)	O
both	O
in	O
the	O
tested	O
oral	B-Cell
cancer	I-Cell
cells	E-Cell
and	O
NOK	S-Cell
.	O

Attenuation	S-Negative_regulation
of	O
the	O
proangiogenic	S-Blood_vessel_development
effects	O
by	O
neutralizing	B-Gene_or_gene_product
VEGF	I-Gene_or_gene_product
antibodies	E-Gene_or_gene_product
suggests	O
VEGF	S-Gene_or_gene_product
play	B-Regulation
a	I-Regulation
key	I-Regulation
role	E-Regulation
in	O
the	O
acquisition	O
of	O
the	O
angiogenic	S-Blood_vessel_development
phenotype	O
in	O
oral	B-Cell
cancer	I-Cell
cells	E-Cell
.	O

Western	O
blotting	O
of	O
p53	S-Gene_or_gene_product
and	O
murine	B-Gene_or_gene_product
double	I-Gene_or_gene_product
mutant	I-Gene_or_gene_product
2	E-Gene_or_gene_product
(	O
Mdm2	S-Gene_or_gene_product
)	O
together	O
with	O
p53	S-Gene_or_gene_product
DNA	O
sequencing	O
analysis	O
indicate	O
that	O
p53	S-Gene_or_gene_product
function	B-Negative_regulation
loss	E-Negative_regulation
by	O
mutation	O
or	O
overexpression	S-Gene_expression
of	O
Mdm2	S-Gene_or_gene_product
occurred	O
in	O
all	O
tested	O
oral	B-Cell
cancer	I-Cell
cells	E-Cell
regardless	O
of	O
their	O
etiology	O
.	O

In	O
summary	O
,	O
the	O
angiogenic	S-Blood_vessel_development
property	O
of	O
oral	B-Cell
cancer	I-Cell
cells	E-Cell
is	O
mediated	S-Regulation
by	O
many	O
factors	O
in	O
addition	O
to	O
VEGF	S-Gene_or_gene_product
and	O
the	O
functional	O
status	O
of	O
p53	S-Gene_or_gene_product
.	O

Retinal	O
microangiopathies	O
overlying	O
pigment	B-Tissue
epithelial	E-Tissue
detachment	S-Breakdown
in	O
age	O
-	O
related	O
macular	S-Tissue
degeneration	S-Breakdown
.	O

PURPOSE	O
:	O
To	O
evaluate	O
alterations	S-Remodeling
in	O
the	O
retinal	B-Multi-tissue_structure
vasculature	E-Multi-tissue_structure
overlying	O
pigment	B-Tissue
epithelial	E-Tissue
detachments	S-Breakdown
(	O
PED	O
)	O
in	O
exudative	O
age	O
-	O
related	O
macular	S-Tissue
degeneration	S-Breakdown
(	O
ARMD	O
)	O
using	O
indocyanine	B-Drug_or_compound
green	E-Drug_or_compound
and	O
fluorescein	S-Drug_or_compound
angiography	O
.	O

METHODS	O
:	O
Forty	O
-	O
one	O
patients	S-Organism
(	O
41	O
eyes	S-Organ
)	O
with	O
a	O
clinical	O
diagnosis	O
of	O
exudative	O
ARMD	O
with	O
PED	O
underwent	O
simultaneous	O
fluorescein	S-Drug_or_compound
and	O
indocyanine	B-Drug_or_compound
green	E-Drug_or_compound
angiography	S-Planned_process
,	O
also	O
under	O
high	O
(	O
10	O
degrees	O
)	O
magnification	O
.	O

Vascular	S-Multi-tissue_structure
abnormalities	O
in	O
the	O
retina	S-Multi-tissue_structure
were	O
compared	O
between	O
patients	S-Organism
with	O
vascularized	O
(	O
n	O
=	O
34	O
,	O
group	O
1	O
)	O
and	O
nonvascularized	O
(	O
n	O
=	O
7	O
,	O
group	O
2	O
)	O
PED	O
on	O
indocyanine	B-Drug_or_compound
green	E-Drug_or_compound
angiography	O
and	O
correlated	O
with	O
the	O
size	O
of	O
the	O
PED	O
and	O
the	O
presence	O
of	O
serous	B-Multi-tissue_structure
retinal	E-Multi-tissue_structure
detachment	S-Breakdown
.	O

RESULTS	O
:	O
In	O
all	O
,	O
67	O
vascular	O
abnormalities	O
were	O
found	O
by	O
indocyanine	O
green	O
angiography	O
and	O
only	O
22	O
by	O
fluorescein	O
angiography	O
;	O
this	O
finding	O
was	O
statistically	O
significant	O
(	O
P	O
less	O
than	O
0	O
.	O
0001	O
)	O
.	O

The	O
finding	O
of	O
retinal	O
vasculopathy	O
(	O
32	O
patients	S-Organism
in	O
group	O
1	O
and	O
two	O
patients	S-Organism
in	O
group	O
2	O
)	O
was	O
directly	O
correlated	O
with	O
the	O
presence	O
of	O
choroidal	O
neovascularizations	S-Blood_vessel_development
(	O
P	O
=	O
0	O
.	O
002	O
)	O
.	O

There	O
was	O
also	O
a	O
direct	O
correlation	O
between	O
the	O
presence	O
of	O
choroidal	O
neovascularization	S-Blood_vessel_development
and	O
size	O
of	O
the	O
PED	O
(	O
P	O
=	O
0	O
.	O
03	O
)	O
.	O

The	O
number	O
of	O
retinal	B-Multi-tissue_structure
vascular	E-Multi-tissue_structure
findings	O
was	O
not	O
significantly	O
correlated	O
with	O
serous	O
elevation	S-Positive_regulation
of	O
the	O
retina	S-Multi-tissue_structure
.	O

CONCLUSIONS	O
:	O
Retinal	O
vasculopathies	O
may	O
be	O
observed	O
in	O
eyes	S-Organ
with	O
PED	O
and	O
are	O
detectable	O
by	O
indocyanine	B-Drug_or_compound
green	E-Drug_or_compound
and	O
fluorescein	S-Drug_or_compound
angiography	S-Planned_process
.	O

Antiangiogenic	S-Blood_vessel_development
and	O
antitumor	S-Pathological_formation
effects	S-Negative_regulation
of	O
a	O
protein	B-Gene_or_gene_product
kinase	I-Gene_or_gene_product
Cbeta	E-Gene_or_gene_product
inhibitor	O
in	O
human	S-Organism
breast	B-Pathological_formation
cancer	E-Pathological_formation
and	O
ovarian	B-Pathological_formation
cancer	I-Pathological_formation
xenografts	E-Pathological_formation
.	O

In	O
cell	S-Cell
culture	S-Planned_process
,	O
the	O
compound	O
317615	B-Drug_or_compound
2HCl	E-Drug_or_compound
,	O
a	O
potent	O
inhibitor	S-Negative_regulation
of	O
VEGF	S-Gene_or_gene_product
-	O
stimulated	S-Positive_regulation
HUVEC	S-Cell
proliferation	S-Cell_proliferation
,	O
was	O
not	O
very	O
effective	B-Negative_regulation
against	E-Negative_regulation
MX	B-Cell
-	I-Cell
1	I-Cell
breast	I-Cell
cancer	I-Cell
cells	E-Cell
(	O
IC50	O
=	O
8	O
.	O
1	O
microM	O
)	O
or	O
SKOV	B-Cell
-	I-Cell
3	I-Cell
ovarian	I-Cell
carcinoma	I-Cell
cells	E-Cell
(	O
IC50	O
=	O
9	O
.	O
5	O
microM	O
)	O
.	O

Exposure	S-Planned_process
to	O
combinations	O
of	O
paclitaxel	S-Drug_or_compound
or	O
carboplatin	S-Drug_or_compound
and	O
317615	B-Drug_or_compound
x	I-Drug_or_compound
2HCl	E-Drug_or_compound
with	O
MX	B-Cell
-	I-Cell
1	I-Cell
cells	E-Cell
in	O
culture	O
resulted	S-Positive_regulation
in	O
cell	S-Cell
survival	S-Death
that	O
reflected	O
primarily	O
additivity	O
of	O
the	O
two	O
agents	O
.	O

Exposure	S-Planned_process
of	O
SKOV	B-Cell
-	I-Cell
3	I-Cell
cells	E-Cell
to	O
paclitaxel	S-Drug_or_compound
or	O
carboplatin	S-Drug_or_compound
along	O
with	O
317615	B-Drug_or_compound
2HCl	E-Drug_or_compound
resulted	S-Positive_regulation
in	O
cell	S-Cell
survivals	S-Death
that	O
reflected	O
additivity	O
of	O
317615	B-Drug_or_compound
x	I-Drug_or_compound
2HCl	E-Drug_or_compound
with	O
paclitaxel	S-Drug_or_compound
and	O
greater	O
-	O
than	O
-	O
additive	O
cytotoxicity	O
with	O
carboplatin	S-Drug_or_compound
.	O

Administration	S-Planned_process
of	O
317615	B-Drug_or_compound
x	I-Drug_or_compound
2HCI	E-Drug_or_compound
orally	O
twice	O
daily	O
to	O
nude	B-Organism
mice	E-Organism
bearing	O
subcutaneous	O
MX	B-Pathological_formation
-	I-Pathological_formation
1	I-Pathological_formation
tumors	E-Pathological_formation
or	O
SKOV	B-Pathological_formation
-	I-Pathological_formation
3	I-Pathological_formation
tumors	E-Pathological_formation
resulted	S-Positive_regulation
in	O
a	O
decreased	S-Negative_regulation
number	O
of	O
intratumoral	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
as	O
determined	O
by	O
CD31	S-Gene_or_gene_product
and	O
CD105	S-Gene_or_gene_product
staining	O
with	O
decreases	O
of	O
35	O
%	O
and	O
43	O
%	O
in	O
MX	B-Pathological_formation
-	I-Pathological_formation
1	I-Pathological_formation
tumors	E-Pathological_formation
and	O
60	O
%	O
and	O
75	O
%	O
in	O
SKOV	B-Pathological_formation
-	I-Pathological_formation
3	I-Pathological_formation
tumors	E-Pathological_formation
,	O
respectively	O
.	O

317615	B-Drug_or_compound
x	I-Drug_or_compound
2HCl	E-Drug_or_compound
was	O
an	O
active	O
antitumor	S-Pathological_formation
agent	O
against	S-Negative_regulation
the	O
MX	B-Pathological_formation
-	I-Pathological_formation
1	I-Pathological_formation
xenograft	E-Pathological_formation
and	O
increased	S-Positive_regulation
the	O
tumor	S-Pathological_formation
growth	S-Growth
delay	S-Negative_regulation
produced	O
by	O
paclitaxel	S-Drug_or_compound
by	O
1	O
.	O
7	O
-	O
fold	O
and	O
the	O
tumor	S-Pathological_formation
growth	S-Growth
delay	S-Negative_regulation
produced	O
by	O
carboplatin	S-Drug_or_compound
by	O
3	O
.	O
8	O
-	O
fold	O
.	O

Administration	S-Planned_process
of	O
317615	B-Drug_or_compound
x	I-Drug_or_compound
2HCl	E-Drug_or_compound
also	O
increased	S-Positive_regulation
the	O
tumor	S-Pathological_formation
growth	S-Growth
delay	S-Negative_regulation
produced	O
by	O
fractionated	O
radiation	O
therapy	O
in	O
the	O
MX	B-Pathological_formation
-	I-Pathological_formation
1	I-Pathological_formation
tumor	E-Pathological_formation
.	O

Treatment	S-Planned_process
with	O
317615	B-Drug_or_compound
x	I-Drug_or_compound
2HCl	E-Drug_or_compound
alone	O
increased	O
the	O
lifespan	O
of	O
animals	O
bearing	O
intraperitoneal	O
SKOV	B-Pathological_formation
-	I-Pathological_formation
3	I-Pathological_formation
xenografts	E-Pathological_formation
by	O
1	O
.	O
9	O
fold	O
compared	O
with	O
untreated	O
control	O
animals	O
.	O

The	O
combination	O
of	O
paclitaxel	S-Drug_or_compound
and	O
317615	B-Drug_or_compound
x	I-Drug_or_compound
2HCl	E-Drug_or_compound
resulted	O
in	O
100	O
%	O
120	O
-	O
day	O
survival	O
of	O
SKOV	B-Pathological_formation
-	I-Pathological_formation
3	E-Pathological_formation
bearing	O
animals	O
.	O

Administration	S-Planned_process
of	O
317615	B-Drug_or_compound
x	I-Drug_or_compound
2HCl	E-Drug_or_compound
along	O
with	O
carboplatin	S-Drug_or_compound
to	O
animals	O
bearing	O
the	O
SKOV	B-Pathological_formation
-	I-Pathological_formation
3	I-Pathological_formation
tumor	E-Pathological_formation
produced	O
a	O
1	O
.	O
8	O
-	O
fold	O
increase	O
in	O
lifespan	O
compared	O
with	O
carboplatin	S-Drug_or_compound
alone	O
.	O

317615	B-Drug_or_compound
x	I-Drug_or_compound
2HCl	E-Drug_or_compound
is	O
a	O
promising	O
new	O
antiangiogenic	S-Blood_vessel_development
agent	O
that	O
is	O
in	O
early	O
phase	O
clinical	O
testing	O
.	O

Enforced	S-Positive_regulation
expression	S-Gene_expression
of	O
tissue	B-Gene_or_gene_product
inhibitor	I-Gene_or_gene_product
of	I-Gene_or_gene_product
matrix	I-Gene_or_gene_product
metalloproteinase	I-Gene_or_gene_product
-	I-Gene_or_gene_product
3	E-Gene_or_gene_product
affects	S-Regulation
functional	O
capillary	S-Tissue
morphogenesis	S-Development
and	O
inhibits	S-Negative_regulation
tumor	S-Pathological_formation
growth	S-Growth
in	O
a	O
murine	S-Organism
tumor	S-Pathological_formation
model	O
.	O

Homeostasis	O
of	O
the	O
extracellular	B-Cellular_component
matrix	E-Cellular_component
is	O
a	O
delicate	O
balance	O
between	O
degradation	S-Breakdown
and	O
remodeling	S-Remodeling
,	O
the	O
balance	O
being	O
maintained	S-Regulation
by	O
the	O
interaction	S-Binding
of	O
activated	S-Positive_regulation
matrix	B-Gene_or_gene_product
metalloproteinases	E-Gene_or_gene_product
(	O
MMPs	S-Gene_or_gene_product
)	O
and	O
specific	O
tissue	B-Gene_or_gene_product
inhibitors	I-Gene_or_gene_product
of	I-Gene_or_gene_product
matrix	I-Gene_or_gene_product
metalloproteinases	E-Gene_or_gene_product
(	O
TIMPs	S-Gene_or_gene_product
)	O
.	O

Up	B-Positive_regulation
-	I-Positive_regulation
regulation	E-Positive_regulation
of	O
MMP	S-Gene_or_gene_product
activity	O
,	O
favoring	O
proteolytic	O
degradation	S-Breakdown
of	O
the	O
basement	B-Cellular_component
membrane	E-Cellular_component
and	O
extracellular	B-Cellular_component
matrix	E-Cellular_component
,	O
has	O
been	O
linked	O
to	O
tumor	S-Pathological_formation
growth	S-Growth
and	O
metastasis	S-Localization
,	O
as	O
well	O
as	O
tumor	S-Pathological_formation
-	O
associated	O
angiogenesis	S-Blood_vessel_development
,	O
whereas	O
inhibition	S-Negative_regulation
of	O
MMP	S-Gene_or_gene_product
activity	O
appears	O
to	O
restrict	S-Negative_regulation
these	O
processes	O
.	O

We	O
have	O
used	O
retroviral	O
-	O
mediated	O
gene	O
delivery	O
to	O
effect	S-Positive_regulation
sustained	O
autocrine	O
expression	S-Gene_expression
of	O
TIMP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
3	E-Gene_or_gene_product
in	O
murine	S-Organism
neuroblastoma	S-Cell
and	O
melanoma	B-Cell
tumor	I-Cell
cells	E-Cell
in	O
order	O
to	O
further	O
examine	O
the	O
ability	O
of	O
TIMPs	S-Gene_or_gene_product
to	O
inhibit	S-Negative_regulation
angiogenesis	S-Blood_vessel_development
in	O
vivo	O
.	O

Growth	S-Growth
of	O
both	O
histologic	O
types	O
of	O
gene	O
-	O
modified	O
tumor	B-Cell
cells	E-Cell
in	O
severe	O
combined	O
immunodeficiency	O
(	O
SCID	O
)	O
mice	S-Organism
was	O
significantly	O
restricted	S-Negative_regulation
when	O
compared	O
with	O
controls	O
.	O

Grossly	O
,	O
these	O
tumors	S-Pathological_formation
were	O
small	O
and	O
had	O
few	O
feeding	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
.	O

Histologic	O
evaluation	O
revealed	O
that	O
although	O
tumors	S-Pathological_formation
overexpressing	S-Gene_expression
TIMP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
3	E-Gene_or_gene_product
had	O
an	O
increased	O
number	O
of	O
CD31	B-Cell
(	I-Cell
+	I-Cell
)	I-Cell
endothelial	I-Cell
cells	E-Cell
,	O
these	O
endothelial	B-Cell
cells	E-Cell
had	O
not	O
formed	S-Development
functional	O
tubules	S-Tissue
,	O
as	O
evidenced	O
by	O
decreased	S-Negative_regulation
vessel	S-Multi-tissue_structure
continuity	O
and	O
minimal	O
pericyte	S-Cell
recruitment	S-Localization
.	O

This	O
effect	O
appears	O
to	O
be	O
mediated	O
,	O
in	O
part	O
,	O
by	O
decreased	S-Negative_regulation
expression	S-Gene_expression
of	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
(	I-Gene_or_gene_product
VE	I-Gene_or_gene_product
)	I-Gene_or_gene_product
-	I-Gene_or_gene_product
cadherin	E-Gene_or_gene_product
by	O
endothelial	B-Cell
cells	E-Cell
in	O
the	O
presence	O
of	O
TIMP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
3	E-Gene_or_gene_product
as	O
seen	O
both	O
in	O
an	O
in	O
vitro	O
assay	O
and	O
in	O
TIMP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
3	E-Gene_or_gene_product
-	O
overexpressing	S-Gene_expression
tumors	S-Pathological_formation
.	O

Taken	O
together	O
,	O
these	O
results	O
demonstrate	O
that	O
overexpression	S-Gene_expression
of	O
TIMP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
3	E-Gene_or_gene_product
can	O
inhibit	S-Negative_regulation
angiogenesis	S-Blood_vessel_development
and	O
associated	O
tumor	S-Pathological_formation
growth	S-Growth
,	O
and	O
that	O
the	O
antiangiogenic	S-Blood_vessel_development
effects	S-Negative_regulation
of	O
TIMP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
3	E-Gene_or_gene_product
appear	O
to	O
be	O
mediated	S-Regulation
through	O
the	O
inhibition	S-Negative_regulation
of	O
functional	O
capillary	S-Tissue
morphogenesis	S-Development
.	O

Fibroblast	B-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
2	E-Gene_or_gene_product
promotes	S-Positive_regulation
microvessel	S-Tissue
formation	S-Development
from	O
mouse	S-Organism
embryonic	B-Multi-tissue_structure
aorta	E-Multi-tissue_structure
.	O

To	O
delineate	O
the	O
roles	O
that	O
oxygen	S-Drug_or_compound
and	O
fibroblast	B-Gene_or_gene_product
growth	I-Gene_or_gene_product
factors	E-Gene_or_gene_product
(	O
FGFs	S-Gene_or_gene_product
)	O
play	S-Regulation
in	O
the	O
process	O
of	O
angiogenesis	S-Blood_vessel_development
from	O
the	O
embryonic	B-Multi-tissue_structure
aorta	E-Multi-tissue_structure
,	O
we	O
cultured	S-Planned_process
mouse	S-Organism
embryonic	B-Multi-tissue_structure
aorta	E-Multi-tissue_structure
explants	O
(	O
thoracic	S-Organism_subdivision
level	O
to	O
lateral	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
supplying	O
the	O
mesonephros	S-Organ
and	O
metanephros	S-Organ
)	O
in	O
a	O
three	O
-	O
dimensional	O
type	B-Gene_or_gene_product
I	I-Gene_or_gene_product
collagen	E-Gene_or_gene_product
gel	O
matrix	O
.	O

During	O
8	O
days	O
of	O
culture	O
under	O
5	O
%	O
O	B-Drug_or_compound
(	I-Drug_or_compound
2	I-Drug_or_compound
)	E-Drug_or_compound
,	O
but	O
not	O
room	O
air	O
,	O
the	O
addition	S-Planned_process
of	O
FGF2	S-Gene_or_gene_product
to	O
explants	O
stimulated	S-Positive_regulation
the	O
formation	S-Development
of	O
Gs	B-Tissue
-	I-Tissue
IB	I-Tissue
(	I-Tissue
4	I-Tissue
-	I-Tissue
)	I-Tissue
positive	E-Tissue
,	O
CD31	B-Tissue
-	I-Tissue
positive	E-Tissue
,	O
and	O
Flk	B-Tissue
-	I-Tissue
1	I-Tissue
-	I-Tissue
positive	I-Tissue
microvessels	E-Tissue
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
.	O

FGF2	S-Gene_or_gene_product
-	O
stimulated	S-Positive_regulation
microvessel	S-Tissue
formation	S-Development
was	O
inhibited	S-Negative_regulation
by	O
sequestration	S-Negative_regulation
of	O
FGF2	S-Gene_or_gene_product
via	O
addition	S-Planned_process
of	O
soluble	O
FGF	B-Gene_or_gene_product
receptor	E-Gene_or_gene_product
(	O
FGFR	S-Gene_or_gene_product
)	O
chimera	O
protein	O
or	O
anti	B-Gene_or_gene_product
-	I-Gene_or_gene_product
FGF2	I-Gene_or_gene_product
antibodies	E-Gene_or_gene_product
.	O

FGFR1	S-Gene_or_gene_product
and	O
FGFR2	S-Gene_or_gene_product
were	O
present	O
on	O
explants	O
.	O

Levels	O
of	O
FGFR1	S-Gene_or_gene_product
,	O
but	O
not	O
FGFR2	S-Gene_or_gene_product
,	O
were	O
increased	S-Positive_regulation
in	O
embryonic	B-Multi-tissue_structure
aorta	E-Multi-tissue_structure
cultured	S-Planned_process
under	O
5	O
%	O
O	B-Drug_or_compound
(	I-Drug_or_compound
2	I-Drug_or_compound
)	E-Drug_or_compound
relative	O
to	O
room	O
air	O
.	O

Our	O
data	O
suggest	O
that	O
low	O
oxygen	S-Drug_or_compound
upregulates	S-Positive_regulation
FGFR1	S-Gene_or_gene_product
expression	S-Gene_expression
in	O
embryonic	B-Multi-tissue_structure
aorta	E-Multi-tissue_structure
in	O
vitro	O
and	O
renders	O
it	O
more	O
responsive	S-Regulation
to	O
FGF2	S-Gene_or_gene_product
.	O

Brn	B-Gene_or_gene_product
-	I-Gene_or_gene_product
3a	E-Gene_or_gene_product
,	O
a	O
neuronal	O
transcription	O
factor	O
of	O
the	O
POU	O
gene	O
family	O
:	O
indications	O
for	O
its	O
involvement	O
in	O
cancer	S-Pathological_formation
and	O
angiogenesis	S-Blood_vessel_development
.	O

Brn	B-Gene_or_gene_product
-	I-Gene_or_gene_product
3a	E-Gene_or_gene_product
,	O
a	O
member	O
of	O
the	O
POU	O
gene	O
family	O
(	O
so	O
-	O
called	O
because	O
of	O
the	O
similarity	O
with	O
the	O
group	O
of	O
transcription	O
factors	O
Pit	S-Gene_or_gene_product
,	O
Oct	S-Gene_or_gene_product
,	O
and	O
Unc	S-Gene_or_gene_product
)	O
,	O
was	O
found	O
in	O
neuronal	B-Cell
cells	E-Cell
engaged	S-Regulation
in	O
the	O
transcription	S-Transcription
activity	O
of	O
the	O
p1	S-DNA_domain_or_region
and	O
p2	B-DNA_domain_or_region
promoters	E-DNA_domain_or_region
of	O
the	O
most	O
powerful	O
antiapoptotic	O
gene	O
,	O
namely	O
,	O
Bcl	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
.	O

The	O
alternative	O
splicing	O
of	O
Brn	B-Gene_or_gene_product
-	I-Gene_or_gene_product
3a	E-Gene_or_gene_product
mRNA	O
produces	S-Gene_expression
two	O
molecular	O
forms	O
:	O
a	O
longer	O
,	O
Bcl	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
transactivating	O
form	O
,	O
and	O
a	O
shorter	O
inactive	O
form	O
,	O
lacking	O
84	O
AA	O
in	O
the	O
aminoterminus	O
.	O

In	O
neuronal	B-Cell
cells	E-Cell
,	O
following	O
Brn	B-Gene_or_gene_product
-	I-Gene_or_gene_product
3a	E-Gene_or_gene_product
gene	O
transfection	S-Planned_process
and	O
superexpression	S-Gene_expression
,	O
an	O
increase	S-Positive_regulation
of	O
30	O
fold	O
of	O
the	O
Bcl	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
protein	O
occurs	O
,	O
leading	S-Positive_regulation
to	O
apoptosis	S-Death
protection	S-Negative_regulation
.	O

However	O
,	O
recent	O
works	O
demonstrate	O
that	O
Brn	B-Gene_or_gene_product
-	I-Gene_or_gene_product
3a	E-Gene_or_gene_product
expression	S-Gene_expression
is	O
not	O
restricted	S-Negative_regulation
to	O
neuronal	B-Cell
cells	E-Cell
,	O
as	O
its	O
activity	O
was	O
detected	O
also	O
in	O
cancer	B-Cell
cells	E-Cell
of	O
non	O
-	O
neuronal	O
nature	O
.	O

Looking	O
for	O
mechanisms	O
linking	O
Brn	B-Gene_or_gene_product
-	I-Gene_or_gene_product
3a	E-Gene_or_gene_product
to	O
carcinogenesis	O
,	O
we	O
discuss	O
the	O
role	S-Regulation
of	O
this	O
transcription	O
factor	O
in	O
influencing	S-Negative_regulation
Bcl	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
/	O
p53	S-Gene_or_gene_product
antagonism	S-Negative_regulation
and	O
Bcl	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
/	O
VEGF	S-Gene_or_gene_product
induction	S-Positive_regulation
of	O
tumor	S-Pathological_formation
angiogenesis	S-Blood_vessel_development
,	O
concluding	O
this	O
review	O
with	O
a	O
proposal	O
for	O
the	O
oncogenic	O
nature	O
of	O
Brn	B-Gene_or_gene_product
-	I-Gene_or_gene_product
3a	E-Gene_or_gene_product
.	O

Roles	O
of	O
cell	O
adhesion	O
molecules	O
in	O
tumor	S-Pathological_formation
angiogenesis	S-Blood_vessel_development
induced	S-Positive_regulation
by	O
cotransplantation	S-Planned_process
of	O
cancer	S-Cell
and	O
endothelial	B-Cell
cells	E-Cell
to	O
nude	B-Organism
rats	E-Organism
.	O

Roles	O
of	O
cell	O
adhesion	O
molecules	O
mediating	S-Positive_regulation
the	O
interaction	S-Binding
of	O
cancer	S-Cell
and	O
endothelial	B-Cell
cells	E-Cell
in	O
tumor	S-Pathological_formation
angiogenesis	S-Blood_vessel_development
were	O
investigated	O
using	O
new	O
in	O
vitro	O
and	O
in	O
vivo	O
model	O
systems	O
with	O
a	O
cultured	S-Planned_process
murine	S-Organism
endothelial	B-Cell
cell	I-Cell
line	E-Cell
(	O
F	B-Cell
-	I-Cell
2	E-Cell
)	O
and	O
human	S-Organism
cultured	S-Planned_process
epidermoid	B-Cell
cancer	I-Cell
cells	E-Cell
(	O
A431	S-Cell
)	O
.	O

The	O
A431	B-Cell
cells	E-Cell
exhibited	O
typical	O
in	O
vitro	O
cell	S-Cell
adhesion	S-Binding
to	O
the	O
endothelial	B-Cell
F	I-Cell
-	I-Cell
2	I-Cell
cells	E-Cell
.	O

The	O
initial	O
step	O
of	O
adhesion	S-Binding
was	O
mediated	S-Positive_regulation
by	O
sialyl	B-Drug_or_compound
Lewis	I-Drug_or_compound
(	I-Drug_or_compound
x	I-Drug_or_compound
)	E-Drug_or_compound
(	O
Le	B-Drug_or_compound
(	I-Drug_or_compound
x	I-Drug_or_compound
)	E-Drug_or_compound
)	O
and	O
sialyl	B-Drug_or_compound
Le	I-Drug_or_compound
(	I-Drug_or_compound
a	I-Drug_or_compound
)	E-Drug_or_compound
,	O
the	O
carbohydrate	O
determinants	O
expressed	O
on	O
the	O
cancer	B-Cell
cells	E-Cell
,	O
and	O
E	B-Gene_or_gene_product
-	I-Gene_or_gene_product
selectin	E-Gene_or_gene_product
expressed	S-Gene_expression
constitutively	O
on	O
F	B-Cell
-	I-Cell
2	I-Cell
cells	E-Cell
.	O

Prolonged	O
culture	O
led	O
to	O
the	O
implantation	S-Planned_process
of	O
cancer	B-Cell
cells	E-Cell
into	O
the	O
monolayer	O
of	O
the	O
F	B-Cell
-	I-Cell
2	I-Cell
cells	E-Cell
,	O
which	O
was	O
mediated	S-Regulation
mainly	O
by	O
alpha	B-Gene_or_gene_product
(	I-Gene_or_gene_product
3	I-Gene_or_gene_product
)	I-Gene_or_gene_product
beta	I-Gene_or_gene_product
(	I-Gene_or_gene_product
1	I-Gene_or_gene_product
)	I-Gene_or_gene_product
-	I-Gene_or_gene_product
integrin	E-Gene_or_gene_product
.	O

F	B-Cell
-	I-Cell
2	I-Cell
cells	E-Cell
cultured	S-Planned_process
on	O
Matrigel	O
showed	O
evident	O
tube	S-Tissue
formation	S-Development
,	O
and	O
coculture	S-Planned_process
of	O
F	B-Cell
-	I-Cell
2	I-Cell
cells	E-Cell
with	O
A431	B-Cell
cells	E-Cell
led	O
to	O
the	O
formation	O
of	O
A431	B-Cell
cell	E-Cell
nests	O
constantly	O
surrounded	O
by	O
tube	O
-	O
like	O
networks	O
consisting	O
of	O
F	B-Cell
-	I-Cell
2	I-Cell
cells	E-Cell
.	O

This	O
in	O
vitro	O
morphogenesis	O
was	O
inhibited	O
by	O
the	O
addition	O
of	O
anti	B-Gene_or_gene_product
-	I-Gene_or_gene_product
sialyl	I-Gene_or_gene_product
Le	I-Gene_or_gene_product
(	I-Gene_or_gene_product
x	I-Gene_or_gene_product
)	I-Gene_or_gene_product
/	I-Gene_or_gene_product
Le	I-Gene_or_gene_product
(	I-Gene_or_gene_product
a	I-Gene_or_gene_product
)	E-Gene_or_gene_product
or	O
anti	B-Gene_or_gene_product
-	I-Gene_or_gene_product
beta	I-Gene_or_gene_product
(	I-Gene_or_gene_product
1	I-Gene_or_gene_product
)	I-Gene_or_gene_product
-	I-Gene_or_gene_product
integrin	I-Gene_or_gene_product
antibodies	E-Gene_or_gene_product
,	O
which	O
led	O
to	O
the	O
formation	S-Positive_regulation
of	O
cancer	B-Cell
cell	E-Cell
aggregates	S-Binding
that	O
were	O
independent	S-Regulation
from	O
the	O
F	B-Cell
-	I-Cell
2	I-Cell
cell	E-Cell
networks	O
.	O

This	O
in	O
vitro	O
morphological	O
appearance	O
was	O
exactly	O
reproduced	O
in	O
the	O
in	O
vivo	O
tumors	S-Pathological_formation
,	O
which	O
were	O
formed	S-Development
when	O
the	O
mixture	O
of	O
A431	S-Cell
and	O
F	B-Cell
-	I-Cell
2	I-Cell
cells	E-Cell
at	O
the	O
ratio	O
of	O
10	O
:	O
1	O
were	O
cotransplanted	S-Planned_process
s	O
.	O
c	O
.	O
into	O
the	O
back	S-Organism_subdivision
of	O
nude	B-Organism
rats	E-Organism
.	O

The	O
tumors	S-Pathological_formation
of	O
A431	S-Cell
supplemented	S-Planned_process
with	O
F	B-Cell
-	I-Cell
2	I-Cell
cells	E-Cell
were	O
profoundly	O
vascularized	O
throughout	O
by	O
the	O
tubular	B-Tissue
structures	E-Tissue
formed	S-Development
by	O
F	B-Cell
-	I-Cell
2	I-Cell
cells	E-Cell
,	O
the	O
lumen	S-Immaterial_anatomical_entity
of	O
which	O
contained	O
the	O
host	O
rat	S-Organism
blood	B-Cell
cells	E-Cell
.	O

The	O
tumor	S-Pathological_formation
mass	O
thus	O
formed	S-Development
was	O
an	O
average	O
5	O
.	O
8	O
-	O
fold	O
as	O
large	O
as	O
control	O
A431	B-Pathological_formation
tumors	E-Pathological_formation
that	O
were	O
grown	S-Growth
without	O
F	B-Cell
-	I-Cell
2	I-Cell
cells	E-Cell
.	O

The	O
co	B-Planned_process
-	I-Planned_process
injection	E-Planned_process
of	O
anti	B-Gene_or_gene_product
-	I-Gene_or_gene_product
Le	I-Gene_or_gene_product
(	I-Gene_or_gene_product
x	I-Gene_or_gene_product
)	I-Gene_or_gene_product
/	I-Gene_or_gene_product
Le	I-Gene_or_gene_product
(	I-Gene_or_gene_product
a	I-Gene_or_gene_product
)	E-Gene_or_gene_product
or	O
anti	B-Gene_or_gene_product
-	I-Gene_or_gene_product
beta	I-Gene_or_gene_product
(	I-Gene_or_gene_product
1	I-Gene_or_gene_product
)	I-Gene_or_gene_product
-	I-Gene_or_gene_product
integrin	I-Gene_or_gene_product
antibodies	E-Gene_or_gene_product
produced	S-Positive_regulation
a	O
marked	O
reduction	S-Negative_regulation
in	O
the	O
size	O
of	O
A431	B-Pathological_formation
tumors	E-Pathological_formation
,	O
which	O
were	O
not	O
vascularized	O
and	O
accompanied	O
an	O
independent	O
tiny	O
remnant	O
clump	O
of	O
F	B-Cell
-	I-Cell
2	I-Cell
cells	E-Cell
.	O

The	O
size	O
of	O
these	O
A431	B-Pathological_formation
tumors	E-Pathological_formation
did	O
not	O
differ	O
significantly	O
from	O
those	O
of	O
control	O
A431	B-Pathological_formation
tumors	E-Pathological_formation
raised	S-Growth
without	O
F	B-Cell
-	I-Cell
2	I-Cell
cells	E-Cell
.	O

These	O
results	O
indicate	O
that	O
the	O
interaction	S-Binding
of	O
tumor	B-Cell
cells	E-Cell
and	O
endothelial	B-Cell
cells	E-Cell
in	O
orderly	O
tumor	S-Pathological_formation
angiomorphogenesis	S-Blood_vessel_development
is	O
highly	O
dependent	S-Positive_regulation
on	O
the	O
action	O
of	O
cell	O
adhesion	O
molecules	O
mediating	S-Regulation
the	O
adhesion	S-Binding
of	O
cancer	B-Cell
cells	E-Cell
to	O
endothelial	B-Cell
cells	E-Cell
,	O
inhibition	S-Negative_regulation
of	O
which	O
remarkably	O
retards	S-Negative_regulation
tumor	S-Pathological_formation
growth	S-Growth
and	O
angiogenesis	S-Blood_vessel_development
.	O

Adaptor	O
protein	O
Crk	S-Gene_or_gene_product
is	O
required	S-Positive_regulation
for	O
ephrin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
B1	E-Gene_or_gene_product
-	O
induced	S-Positive_regulation
membrane	S-Cellular_component
ruffling	S-Localization
and	O
focal	B-Cellular_component
complex	E-Cellular_component
assembly	S-Binding
of	O
human	S-Organism
aortic	B-Cell
endothelial	I-Cell
cells	E-Cell
.	O

Endothelial	B-Cell
cell	E-Cell
migration	S-Localization
is	O
an	O
essential	S-Positive_regulation
step	O
in	O
vasculogenesis	S-Blood_vessel_development
and	O
angiogenesis	S-Blood_vessel_development
,	O
in	O
which	O
receptor	B-Gene_or_gene_product
tyrosine	I-Gene_or_gene_product
kinases	E-Gene_or_gene_product
play	B-Regulation
a	I-Regulation
pivotal	I-Regulation
role	E-Regulation
.	O

We	O
investigated	O
the	O
mechanism	O
by	O
which	O
ephrin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
B1	E-Gene_or_gene_product
promotes	S-Positive_regulation
membrane	S-Cellular_component
ruffling	S-Localization
in	O
human	S-Organism
aortic	B-Cell
endothelial	I-Cell
cells	E-Cell
,	O
because	O
membrane	S-Cellular_component
ruffling	S-Localization
heralds	O
cell	B-Cell
body	E-Cell
migration	S-Localization
.	O

We	O
especially	O
focused	O
on	O
the	O
role	S-Regulation
of	O
Crk	S-Gene_or_gene_product
adaptor	O
protein	O
in	O
EphB	S-Gene_or_gene_product
-	O
mediated	S-Positive_regulation
signaling	S-Pathway
.	O

Using	O
DsRed	S-Drug_or_compound
-	O
tagged	S-Planned_process
Crk	S-Gene_or_gene_product
and	O
a	O
fluorescent	O
time	O
-	O
lapse	O
microscope	O
,	O
we	O
showed	O
that	O
Crk	S-Gene_or_gene_product
was	O
recruited	S-Localization
to	O
the	O
nascent	B-Cellular_component
focal	I-Cellular_component
complex	E-Cellular_component
after	O
ephrin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
B1	E-Gene_or_gene_product
stimulation	S-Positive_regulation
.	O

Furthermore	O
,	O
we	O
found	O
that	O
p130	B-Gene_or_gene_product
(	I-Gene_or_gene_product
Cas	I-Gene_or_gene_product
)	E-Gene_or_gene_product
,	O
but	O
not	O
paxillin	S-Gene_or_gene_product
,	O
recruited	S-Localization
Crk	S-Gene_or_gene_product
to	O
the	O
nascent	B-Cellular_component
focal	I-Cellular_component
complex	E-Cellular_component
.	O

The	O
necessity	S-Positive_regulation
of	O
Crk	S-Gene_or_gene_product
in	O
ephrin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
B1	E-Gene_or_gene_product
-	O
induced	S-Positive_regulation
membrane	S-Cellular_component
ruffling	S-Localization
was	O
shown	O
both	O
by	O
the	O
overexpression	O
of	O
dominant	O
negative	O
Crk	S-Gene_or_gene_product
mutants	O
and	O
by	O
the	O
depletion	S-Negative_regulation
of	O
Crk	S-Gene_or_gene_product
by	O
using	O
RNA	O
interference	O
.	O

Then	O
,	O
we	O
examined	O
the	O
role	O
of	O
two	O
major	O
downstream	O
molecules	O
of	O
Crk	S-Gene_or_gene_product
,	O
Rac1	S-Gene_or_gene_product
and	O
Rap1	S-Gene_or_gene_product
.	O

The	O
dominant	O
negative	O
mutant	O
of	O
Rac1	S-Gene_or_gene_product
completely	O
inhibited	S-Negative_regulation
ephrin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
B1	E-Gene_or_gene_product
-	O
induced	S-Positive_regulation
membrane	S-Cellular_component
ruffling	S-Localization
and	O
focal	B-Cellular_component
complex	E-Cellular_component
assembly	S-Binding
.	O

In	O
contrast	O
,	O
rap1GAPII	S-Gene_or_gene_product
,	O
a	O
negative	O
regulator	O
of	O
Rap1	S-Gene_or_gene_product
,	O
did	O
not	O
inhibit	S-Negative_regulation
ephrin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
B1	E-Gene_or_gene_product
-	O
induced	S-Positive_regulation
membrane	S-Cellular_component
ruffling	S-Localization
.	O

However	O
,	O
in	O
rap1GAPII	B-Cell
-	I-Cell
expressing	I-Cell
cells	E-Cell
,	O
ephrin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
B1	E-Gene_or_gene_product
did	O
not	O
induce	S-Positive_regulation
membrane	S-Cellular_component
spreading	S-Localization
,	O
probably	O
due	O
to	O
instability	O
of	O
the	O
focal	B-Cellular_component
complex	E-Cellular_component
.	O

These	O
results	O
indicated	O
that	O
Crk	S-Gene_or_gene_product
plays	B-Regulation
a	I-Regulation
critical	I-Regulation
role	E-Regulation
in	O
Rac1	S-Gene_or_gene_product
-	O
induced	S-Positive_regulation
membrane	S-Cellular_component
ruffling	S-Localization
and	O
Rap1	S-Gene_or_gene_product
-	O
mediated	S-Regulation
nascent	B-Cellular_component
focal	I-Cellular_component
complex	E-Cellular_component
stabilization	S-Planned_process
contributing	S-Regulation
to	O
ephrin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
B1	E-Gene_or_gene_product
-	O
induced	S-Positive_regulation
human	S-Organism
aortic	B-Cell
endothelial	I-Cell
cells	E-Cell
migration	S-Localization
.	O

Regulation	S-Regulation
of	O
transforming	B-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
-	I-Gene_or_gene_product
beta	E-Gene_or_gene_product
signaling	S-Pathway
and	O
vascular	O
diseases	O
.	O

PURPOSE	O
:	O
Members	O
of	O
the	O
transforming	B-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
(	I-Gene_or_gene_product
TGF	I-Gene_or_gene_product
)	I-Gene_or_gene_product
-	I-Gene_or_gene_product
beta	E-Gene_or_gene_product
superfamily	O
play	O
critical	O
roles	O
in	O
regulation	O
of	O
various	O
cellular	O
functions	O
.	O

Dysregulation	S-Regulation
of	O
the	O
signaling	O
mechanisms	O
of	O
the	O
TGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
beta	E-Gene_or_gene_product
superfamily	O
proteins	O
is	O
associated	O
with	O
clinical	O
diseases	O
such	O
as	O
cancer	O
,	O
fibrotic	O
diseases	O
,	O
and	O
vascular	O
disorders	O
.	O

Therefore	O
,	O
understanding	O
these	O
signaling	O
mechanisms	O
may	O
provide	O
us	O
with	O
novel	O
ways	O
to	O
develop	O
strategies	O
for	O
treating	O
clinical	O
diseases	O
induced	O
by	O
these	O
cytokines	O
.	O

METHODS	O
:	O
This	O
review	O
discusses	O
our	O
current	O
understanding	O
of	O
the	O
mechanisms	O
of	O
TGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
beta	E-Gene_or_gene_product
signaling	S-Pathway
,	O
focusing	O
on	O
the	O
roles	S-Regulation
of	O
TGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
beta	E-Gene_or_gene_product
in	O
regulation	S-Regulation
of	O
vascular	B-Cell
wall	I-Cell
cells	E-Cell
and	O
on	O
the	O
regulation	S-Regulation
of	O
TGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
beta	E-Gene_or_gene_product
superfamily	O
signals	O
by	O
inhibitory	S-Negative_regulation
Smads	S-Gene_or_gene_product
.	O

Insulin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
like	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
-	I-Gene_or_gene_product
I	I-Gene_or_gene_product
receptor	E-Gene_or_gene_product
-	O
mediated	S-Regulation
vasculogenesis	S-Blood_vessel_development
/	O
angiogenesis	S-Blood_vessel_development
in	O
human	S-Organism
lung	S-Organ
development	S-Development
.	O

The	O
structural	O
and	O
functional	O
development	S-Development
of	O
the	O
pulmonary	B-Anatomical_system
system	E-Anatomical_system
is	O
dependent	S-Positive_regulation
upon	O
appropriate	O
early	O
vascularization	S-Blood_vessel_development
of	O
the	O
embryonic	B-Organ
lung	E-Organ
.	O

Our	O
previous	O
in	O
vitro	O
studies	O
in	O
a	O
rat	S-Organism
model	O
indicated	O
that	O
insulin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
like	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
-	I-Gene_or_gene_product
I	E-Gene_or_gene_product
(	O
IGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
I	E-Gene_or_gene_product
)	O
is	O
a	O
potent	O
angiogenic	S-Blood_vessel_development
agent	O
for	O
fetal	B-Cell
lung	I-Cell
endothelial	I-Cell
cells	E-Cell
.	O

To	O
assess	O
its	O
role	O
on	O
human	S-Organism
vascular	O
lung	S-Organ
development	S-Development
,	O
we	O
first	O
examined	O
the	O
expression	S-Gene_expression
of	O
IGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
I	E-Gene_or_gene_product
/	O
II	S-Gene_or_gene_product
and	O
IGF	B-Gene_or_gene_product
receptor	I-Gene_or_gene_product
type	I-Gene_or_gene_product
I	E-Gene_or_gene_product
(	O
IGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
IR	E-Gene_or_gene_product
)	O
in	O
human	S-Organism
embryonic	S-Tissue
and	O
fetal	B-Tissue
lung	I-Tissue
tissues	E-Tissue
at	O
4	O
-	O
12	O
wk	O
of	O
gestation	O
.	O

Immunohistochemical	O
and	O
in	O
situ	O
hybridization	O
studies	O
revealed	O
the	O
presence	S-Gene_expression
of	O
IGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
I	E-Gene_or_gene_product
/	O
II	S-Gene_or_gene_product
-	O
IGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
IR	E-Gene_or_gene_product
ligands	O
and	O
mRNA	O
transcripts	O
in	O
embryonic	B-Organ
lungs	E-Organ
as	O
early	O
as	O
4	O
wk	O
gestation	O
.	O

Immunotargeting	S-Planned_process
using	O
an	O
anti	B-Gene_or_gene_product
-	I-Gene_or_gene_product
IGF	I-Gene_or_gene_product
-	I-Gene_or_gene_product
IR	I-Gene_or_gene_product
neutralizing	I-Gene_or_gene_product
antibody	E-Gene_or_gene_product
on	O
human	S-Organism
fetal	B-Organ
lung	I-Organ
explants	E-Organ
demonstrated	O
a	O
significant	O
blockade	S-Negative_regulation
of	O
IGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
IR	E-Gene_or_gene_product
signaling	S-Pathway
.	O

Inactivation	S-Negative_regulation
of	O
IGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
IR	E-Gene_or_gene_product
resulted	S-Positive_regulation
in	O
a	O
loss	S-Negative_regulation
of	O
endothelial	B-Cell
cells	E-Cell
,	O
accompanied	O
by	O
dramatic	O
changes	S-Regulation
in	O
fetal	B-Organ
lung	E-Organ
explant	O
morphology	O
.	O

Terminal	O
transferase	O
dUTP	O
end	O
-	O
labeling	O
assay	O
and	O
TEM	O
studies	O
of	O
anti	B-Gene_or_gene_product
-	I-Gene_or_gene_product
IGF	I-Gene_or_gene_product
-	I-Gene_or_gene_product
IR	E-Gene_or_gene_product
-	O
treated	S-Planned_process
lungs	S-Organ
demonstrated	O
numerous	O
apoptotic	S-Death
mesenchymal	B-Cell
cells	E-Cell
.	O

Rat	S-Organism
embryonic	O
lung	S-Organ
explant	O
studies	O
further	O
validated	O
the	O
importance	S-Positive_regulation
of	O
the	O
IGF	S-Gene_or_gene_product
-	O
IGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
IR	E-Gene_or_gene_product
system	S-Pathway
for	O
lung	B-Multi-tissue_structure
vascular	E-Multi-tissue_structure
development	S-Development
.	O

These	O
data	O
provide	O
the	O
first	O
demonstration	O
of	O
IGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
I	E-Gene_or_gene_product
/	O
II	S-Gene_or_gene_product
expression	S-Gene_expression
in	O
the	O
human	S-Organism
lung	S-Organ
in	O
early	O
gestation	O
and	O
indicate	O
that	O
the	O
IGF	S-Gene_or_gene_product
family	O
of	O
growth	O
factors	O
,	O
acting	S-Regulation
through	O
the	O
IGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
IR	E-Gene_or_gene_product
,	O
is	O
required	S-Positive_regulation
as	O
a	O
survival	O
factor	O
during	O
normal	O
human	S-Organism
lung	S-Organ
vascularization	S-Blood_vessel_development
.	O

Enhanced	S-Positive_regulation
expression	S-Gene_expression
of	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
by	O
periodontal	S-Organism_subdivision
pathogens	O
in	O
gingival	B-Cell
fibroblasts	E-Cell
.	O

Vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
(	O
VEGF	S-Gene_or_gene_product
)	O
has	O
recently	O
attracted	O
attention	O
as	O
a	O
potent	O
inducer	S-Positive_regulation
of	O
vascular	S-Multi-tissue_structure
permeability	O
and	O
angiogenesis	S-Blood_vessel_development
.	O

Aberrant	S-Regulation
angiogenesis	S-Blood_vessel_development
is	O
often	O
associated	S-Regulation
with	O
lesion	S-Pathological_formation
formation	S-Development
in	O
chronic	O
periodontitis	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
properties	O
of	O
VEGF	S-Gene_or_gene_product
expression	S-Gene_expression
in	O
human	S-Organism
gingival	B-Cell
fibroblasts	E-Cell
(	O
HGF	S-Cell
)	O
culture	O
.	O

HGF	S-Cell
were	O
stimulated	S-Positive_regulation
with	O
lipopolysaccharide	S-Drug_or_compound
(	O
LPS	S-Drug_or_compound
)	O
,	O
vesicle	S-Cellular_component
(	O
Ve	S-Cellular_component
)	O
and	O
outer	B-Gene_or_gene_product
membrane	I-Gene_or_gene_product
protein	E-Gene_or_gene_product
(	O
OMP	S-Gene_or_gene_product
)	O
from	O
Actinobacillus	B-Organism
actinomycetemcomitans	E-Organism
and	O
Porphyromonas	B-Organism
gingivalis	E-Organism
.	O

HGF	S-Cell
constitutively	O
produced	S-Gene_expression
VEGF	S-Gene_or_gene_product
and	O
levels	O
were	O
significantly	O
enhanced	S-Positive_regulation
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
by	O
stimulation	S-Positive_regulation
with	O
Ve	S-Cellular_component
and	O
OMP	S-Gene_or_gene_product
from	O
A	B-Organism
.	I-Organism
actinomycetemcomitans	E-Organism
and	O
P	B-Organism
.	I-Organism
gingivalis	E-Organism
at	O
concentrations	O
of	O
10	O
microg	O
/	O
ml	O
or	O
higher	O
.	O

On	O
the	O
other	O
hand	O
,	O
VEGF	S-Gene_or_gene_product
levels	O
were	O
not	O
increased	S-Positive_regulation
by	O
LPS	S-Drug_or_compound
stimulation	O
.	O

VEGF	S-Gene_or_gene_product
mRNA	O
expression	S-Transcription
was	O
also	O
observed	O
in	O
Ve	S-Cellular_component
-	O
and	O
OMP	S-Gene_or_gene_product
-	O
stimulated	S-Positive_regulation
HGF	S-Cell
.	O

A	O
vascular	S-Multi-tissue_structure
permeability	O
enhancement	S-Positive_regulation
(	O
VPE	O
)	O
assay	O
was	O
performed	O
using	O
guinea	B-Organism
pigs	E-Organism
to	O
ascertain	O
whether	O
supernatant	O
from	O
cultures	O
of	O
Ve	S-Cellular_component
-	O
and	O
OMP	S-Gene_or_gene_product
-	O
stimulated	S-Positive_regulation
HGF	S-Cell
enhance	S-Positive_regulation
vascular	S-Multi-tissue_structure
permeability	O
in	O
vivo	O
.	O

Supernatant	O
from	O
cultures	O
of	O
Ve	S-Cellular_component
-	O
and	O
OMP	S-Gene_or_gene_product
-	O
stimulated	S-Positive_regulation
HGF	S-Cell
strongly	O
induced	O
VPE	O
.	O

This	O
was	O
markedly	O
suppressed	O
upon	O
simultaneous	O
injection	S-Planned_process
of	O
anti	B-Gene_or_gene_product
-	I-Gene_or_gene_product
VEGF	I-Gene_or_gene_product
polyclonal	I-Gene_or_gene_product
antibodies	E-Gene_or_gene_product
with	O
the	O
supernatant	O
.	O

Heating	O
and	O
protease	O
treatment	O
of	O
the	O
stimulants	O
reduced	S-Negative_regulation
the	O
VEGF	S-Gene_or_gene_product
enhancing	S-Positive_regulation
levels	O
in	O
Ve	S-Cellular_component
and	O
OMP	S-Gene_or_gene_product
in	O
vitro	O
.	O

These	O
results	O
suggest	O
that	O
Ve	S-Cellular_component
and	O
OMP	S-Gene_or_gene_product
may	O
be	O
crucial	O
heat	O
-	O
labile	O
and	O
protease	O
-	O
sensitive	O
components	O
of	O
periodontal	S-Organism_subdivision
pathogens	O
that	O
enhance	S-Positive_regulation
VEGF	S-Gene_or_gene_product
expression	S-Gene_expression
.	O

In	O
addition	O
,	O
VEGF	S-Gene_or_gene_product
might	O
be	O
associated	O
with	O
the	O
etiology	O
of	O
periodontitis	O
in	O
its	O
early	O
stages	O
according	O
to	O
neovascularization	S-Blood_vessel_development
stimulated	S-Positive_regulation
by	O
periodontal	S-Organism_subdivision
pathogens	O
causing	O
swelling	O
and	O
edema	S-Pathological_formation
.	O

Postoperative	O
progression	S-Positive_regulation
of	O
pulmonary	S-Organ
metastasis	S-Localization
in	O
osteosarcoma	S-Pathological_formation
.	O

Early	O
relapse	O
with	O
distant	O
metastasis	S-Localization
often	O
is	O
observed	O
in	O
patients	S-Organism
with	O
cancer	S-Pathological_formation
after	O
resection	S-Planned_process
of	O
the	O
primary	O
tumor	S-Pathological_formation
.	O

It	O
is	O
considered	O
that	O
resection	S-Planned_process
of	O
the	O
primary	O
tumor	S-Pathological_formation
induces	S-Positive_regulation
activation	S-Positive_regulation
of	O
systemic	O
angiogenesis	S-Blood_vessel_development
and	O
enhances	S-Positive_regulation
progression	S-Positive_regulation
of	O
remote	O
metastasis	S-Localization
.	O

The	O
authors	O
show	O
that	O
resection	S-Planned_process
of	O
the	O
primary	O
osteosarcoma	B-Pathological_formation
tumor	E-Pathological_formation
enhances	S-Positive_regulation
progression	S-Positive_regulation
of	O
pulmonary	S-Organ
metastasis	S-Localization
in	O
animal	O
osteosarcoma	S-Pathological_formation
models	O
.	O

Matrigel	O
plug	O
neovascularization	S-Blood_vessel_development
assay	O
revealed	O
that	O
systemic	O
angiogenic	S-Blood_vessel_development
activity	O
was	O
elevated	S-Positive_regulation
after	O
primary	O
tumor	S-Pathological_formation
removal	S-Planned_process
(	O
tumor	S-Pathological_formation
intact	O
group	O
,	O
1	O
.	O
61	O
+	O
/	O
-	O
0	O
.	O
21	O
g	O
/	O
dL	O
;	O
tumor	S-Pathological_formation
removed	O
group	O
,	O
4	O
.	O
92	O
+	O
/	O
-	O
0	O
.	O
35	O
g	O
/	O
dL	O
)	O
.	O

In	O
addition	O
,	O
serum	S-Organism_substance
concentration	O
of	O
the	O
angiogenesis	S-Blood_vessel_development
inhibitor	O
,	O
endostatin	S-Gene_or_gene_product
,	O
decreased	S-Negative_regulation
significantly	O
after	O
primary	O
tumor	S-Pathological_formation
removal	S-Planned_process
.	O

Treatment	S-Planned_process
with	O
the	O
antiangiogenic	S-Blood_vessel_development
reagent	O
TNP	B-Drug_or_compound
-	I-Drug_or_compound
470	E-Drug_or_compound
suppressed	S-Negative_regulation
postoperative	O
progression	S-Positive_regulation
of	O
pulmonary	S-Organ
metastasis	S-Localization
.	O

These	O
results	O
indicate	O
the	O
possibility	O
that	O
activation	S-Positive_regulation
of	O
angiogenic	S-Blood_vessel_development
activity	O
after	O
resection	S-Planned_process
of	O
osteosarcoma	B-Pathological_formation
tumors	E-Pathological_formation
enhances	S-Positive_regulation
progression	S-Positive_regulation
of	O
pulmonary	S-Organ
metastasis	S-Localization
.	O

The	O
current	O
data	O
also	O
suggest	O
that	O
administration	S-Planned_process
of	O
antiangiogenic	S-Blood_vessel_development
reagents	O
can	O
prevent	S-Negative_regulation
progression	S-Positive_regulation
of	O
pulmonary	S-Organ
metastasis	S-Localization
in	O
osteosarcoma	S-Pathological_formation
postoperatively	O
.	O

Arteriogenesis	S-Blood_vessel_development
:	O
the	O
development	S-Development
and	O
growth	S-Growth
of	O
collateral	B-Multi-tissue_structure
arteries	E-Multi-tissue_structure
.	O

In	O
patients	S-Organism
with	O
atherosclerotic	O
vascular	O
diseases	O
,	O
collateral	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
bypassing	O
major	O
arterial	B-Pathological_formation
obstructions	E-Pathological_formation
have	O
frequently	O
been	O
observed	O
.	O

This	O
may	O
explain	O
why	O
some	O
patients	S-Organism
remain	O
without	O
symptoms	O
or	O
signs	O
of	O
ischemia	O
.	O

The	O
term	O
"	O
arteriogenesis	S-Blood_vessel_development
"	O
was	O
introduced	O
to	O
differentiate	O
the	O
formation	S-Development
of	O
collateral	B-Multi-tissue_structure
arteries	E-Multi-tissue_structure
from	O
angiogenesis	S-Blood_vessel_development
,	O
which	O
mainly	O
occurs	O
in	O
the	O
ischemic	O
,	O
collateral	O
flow	O
-	O
dependent	S-Positive_regulation
tissue	S-Tissue
.	O

Many	O
observations	O
in	O
various	O
animal	O
models	O
and	O
humans	S-Organism
support	O
that	O
the	O
remodeling	S-Remodeling
of	O
preexisting	O
collateral	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
is	O
the	O
mechanism	O
of	O
collateral	B-Multi-tissue_structure
artery	E-Multi-tissue_structure
formation	S-Development
.	O

This	O
remodeling	S-Remodeling
process	O
seems	O
to	O
be	O
mainly	O
flow	O
-	O
mediated	O
.	O

It	O
involves	S-Regulation
endothelial	B-Cell
cell	E-Cell
activation	S-Positive_regulation
,	O
basal	B-Cellular_component
membrane	E-Cellular_component
degradation	S-Breakdown
,	O
leukocyte	S-Cell
invasion	S-Localization
,	O
proliferation	S-Cell_proliferation
of	O
vascular	B-Cell
cells	E-Cell
,	O
neointima	S-Tissue
formation	S-Development
(	O
in	O
most	O
species	O
studied	O
)	O
,	O
and	O
changes	S-Regulation
of	O
the	O
extracellular	B-Cellular_component
matrix	E-Cellular_component
.	O

The	O
contribution	O
of	O
ischemia	O
to	O
arteriogenesis	S-Blood_vessel_development
is	O
still	O
unclear	O
,	O
but	O
arteriogenesis	S-Blood_vessel_development
clearly	O
can	O
occur	O
in	O
the	O
absence	O
of	O
any	O
significant	O
ischemia	O
.	O

It	O
is	O
questionable	O
,	O
whether	O
collateral	B-Multi-tissue_structure
arteries	E-Multi-tissue_structure
also	O
form	S-Development
de	O
novo	O
in	O
ischemic	O
vascular	O
diseases	O
.	O

A	O
better	O
understanding	O
of	O
the	O
mechanisms	O
of	O
arteriogenesis	S-Blood_vessel_development
will	O
be	O
important	O
for	O
the	O
design	O
of	O
more	O
effective	O
strategies	O
for	O
the	O
treatment	O
of	O
patients	S-Organism
with	O
ischemic	O
vascular	O
diseases	O
.	O

Possible	O
role	O
of	O
cyclooxygenase	B-Gene_or_gene_product
II	E-Gene_or_gene_product
in	O
the	O
acquisition	O
of	O
ovarian	B-Multi-tissue_structure
luteal	E-Multi-tissue_structure
function	O
in	O
rodents	O
.	O

The	O
development	S-Development
of	O
the	O
corpus	B-Multi-tissue_structure
luteum	E-Multi-tissue_structure
(	O
CL	S-Multi-tissue_structure
)	O
,	O
which	O
involves	O
angiogenesis	S-Blood_vessel_development
,	O
is	O
essential	O
for	O
the	O
establishment	O
of	O
early	O
pregnancy	O
.	O

We	O
investigated	O
the	O
roles	S-Regulation
of	O
the	O
prostaglandin	S-Drug_or_compound
synthases	O
cyclooxygenase	B-Gene_or_gene_product
(	I-Gene_or_gene_product
COX	I-Gene_or_gene_product
)	I-Gene_or_gene_product
I	E-Gene_or_gene_product
and	O
COX	B-Gene_or_gene_product
-	I-Gene_or_gene_product
II	E-Gene_or_gene_product
in	O
angiogenesis	S-Blood_vessel_development
and	O
progesterone	S-Drug_or_compound
production	S-Synthesis
in	O
the	O
newly	O
formed	S-Development
CL	S-Multi-tissue_structure
,	O
using	O
inhibitors	O
of	O
the	O
COX	B-Gene_or_gene_product
enzymes	E-Gene_or_gene_product
and	O
the	O
gonadotropin	S-Gene_or_gene_product
-	O
induced	S-Positive_regulation
pseudopregnant	S-Planned_process
rat	S-Organism
as	O
a	O
model	O
.	O

Injection	S-Planned_process
of	O
indomethacin	S-Drug_or_compound
,	O
a	O
nonselective	O
COX	S-Gene_or_gene_product
inhibitor	O
,	O
on	O
the	O
day	O
of	O
ovulation	O
and	O
the	O
following	O
day	O
decreased	S-Negative_regulation
serum	S-Organism_substance
levels	O
of	O
progesterone	S-Drug_or_compound
,	O
as	O
did	O
injection	S-Planned_process
of	O
the	O
selective	O
COX	B-Gene_or_gene_product
-	I-Gene_or_gene_product
II	E-Gene_or_gene_product
inhibitor	O
NS	B-Drug_or_compound
-	I-Drug_or_compound
398	E-Drug_or_compound
.	O

In	O
contrast	O
,	O
a	O
selective	O
COX	B-Gene_or_gene_product
-	I-Gene_or_gene_product
I	E-Gene_or_gene_product
inhibitor	O
,	O
SC	B-Drug_or_compound
-	I-Drug_or_compound
560	E-Drug_or_compound
,	O
had	O
no	O
effect	S-Regulation
on	O
serum	S-Organism_substance
progesterone	S-Drug_or_compound
concentrations	O
.	O

None	O
of	O
the	O
inhibitors	O
had	O
any	O
effect	S-Regulation
on	O
the	O
weight	O
of	O
the	O
superovulated	B-Organ
ovaries	E-Organ
or	O
on	O
the	O
synthesis	S-Synthesis
of	O
progesterone	S-Drug_or_compound
by	O
cultured	B-Cell
luteal	I-Cell
cells	E-Cell
.	O

To	O
determine	O
whether	O
changes	S-Regulation
in	O
angiogenesis	S-Blood_vessel_development
are	O
responsible	S-Regulation
for	O
the	O
decrease	S-Negative_regulation
in	O
progesterone	S-Drug_or_compound
synthesis	S-Synthesis
,	O
we	O
measured	O
hemoglobin	S-Gene_or_gene_product
and	O
CD34	S-Gene_or_gene_product
levels	O
in	O
luteinized	S-Development
ovaries	S-Organ
following	O
injection	O
of	O
COX	S-Gene_or_gene_product
inhibitors	O
and	O
measured	O
the	O
relative	O
frequency	O
of	O
cells	S-Cell
positive	O
for	O
platelet	B-Gene_or_gene_product
-	I-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
cell	I-Gene_or_gene_product
adhesion	I-Gene_or_gene_product
molecule	E-Gene_or_gene_product
as	O
a	O
specific	O
marker	O
for	O
endothelial	B-Cell
cells	E-Cell
.	O

All	O
of	O
these	O
parameters	O
were	O
reduced	O
by	O
the	O
COX	B-Gene_or_gene_product
-	I-Gene_or_gene_product
II	E-Gene_or_gene_product
inhibitors	O
,	O
suggesting	O
that	O
changes	S-Regulation
in	O
the	O
vasculature	S-Multi-tissue_structure
are	O
responsible	S-Regulation
for	O
the	O
decrease	S-Negative_regulation
in	O
serum	S-Organism_substance
progesterone	S-Drug_or_compound
.	O

Histological	O
examination	O
of	O
ovarian	S-Organ
corrosion	O
casts	O
indicated	O
that	O
NS	B-Drug_or_compound
-	I-Drug_or_compound
398	E-Drug_or_compound
inhibited	S-Negative_regulation
the	O
establishment	S-Development
of	O
luteal	B-Multi-tissue_structure
capillary	I-Multi-tissue_structure
vessels	E-Multi-tissue_structure
following	O
the	O
injection	S-Planned_process
of	O
hCG	S-Gene_or_gene_product
.	O

The	O
results	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
the	O
activity	O
of	O
COX	B-Gene_or_gene_product
-	I-Gene_or_gene_product
II	E-Gene_or_gene_product
is	O
associated	S-Regulation
with	O
the	O
formation	S-Development
of	O
functional	O
CL	S-Multi-tissue_structure
via	O
its	O
stimulation	S-Positive_regulation
of	O
angiogenesis	S-Blood_vessel_development
.	O

Tumor	S-Pathological_formation
angiogenesis	S-Blood_vessel_development
modulates	S-Regulation
leukocyte	S-Cell
-	O
vessel	B-Multi-tissue_structure
wall	E-Multi-tissue_structure
interactions	S-Binding
in	O
vivo	O
by	O
reducing	S-Negative_regulation
endothelial	B-Gene_or_gene_product
adhesion	I-Gene_or_gene_product
molecule	E-Gene_or_gene_product
expression	S-Gene_expression
.	O

The	O
expression	S-Gene_expression
of	O
endothelial	B-Gene_or_gene_product
cell	I-Gene_or_gene_product
(	I-Gene_or_gene_product
EC	I-Gene_or_gene_product
)	I-Gene_or_gene_product
adhesion	I-Gene_or_gene_product
molecules	E-Gene_or_gene_product
involved	S-Regulation
in	O
leukocyte	S-Cell
-	O
vessel	B-Multi-tissue_structure
wall	E-Multi-tissue_structure
interactions	S-Binding
is	O
suppressed	O
in	O
malignancies	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
in	O
vivo	O
the	O
regulation	S-Regulation
of	O
leukocyte	S-Cell
-	O
vessel	B-Multi-tissue_structure
wall	E-Multi-tissue_structure
interactions	S-Binding
by	O
the	O
presence	O
of	O
a	O
tumor	S-Pathological_formation
.	O

By	O
means	O
of	O
intravital	O
microscopy	O
,	O
tumor	B-Gene_or_gene_product
necrosis	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
alpha	E-Gene_or_gene_product
-	O
stimulated	S-Positive_regulation
leukocyte	S-Cell
-	O
vessel	B-Multi-tissue_structure
wall	E-Multi-tissue_structure
interactions	S-Binding
were	O
studied	O
in	O
ear	B-Tissue
skin	I-Tissue
microvessels	E-Tissue
of	O
nude	B-Organism
mice	E-Organism
bearing	O
small	O
human	S-Organism
LS174T	B-Pathological_formation
colon	I-Pathological_formation
carcinomas	E-Pathological_formation
and	O
in	O
C57Bl	B-Organism
/	I-Organism
6	I-Organism
mice	E-Organism
bearing	O
murine	S-Organism
B16F10	B-Pathological_formation
melanomas	E-Pathological_formation
.	O

Leukocyte	S-Cell
-	O
vessel	B-Multi-tissue_structure
wall	E-Multi-tissue_structure
interactions	S-Binding
were	O
studied	O
both	O
within	O
and	O
outside	O
small	O
tumors	S-Pathological_formation
growing	S-Growth
in	O
the	O
ear	S-Organ
,	O
and	O
in	O
ear	B-Tissue
microvessels	E-Tissue
of	O
mice	S-Organism
with	O
a	O
large	O
tumor	S-Pathological_formation
growing	S-Growth
on	O
their	O
flank	S-Organism_subdivision
.	O

Tumor	S-Pathological_formation
-	O
free	O
mice	S-Organism
were	O
used	O
as	O
controls	O
.	O

Compared	O
with	O
values	O
measured	O
at	O
the	O
edge	O
of	O
the	O
ear	S-Organ
and	O
in	O
the	O
contralateral	O
ear	S-Organ
,	O
leukocyte	S-Cell
adhesion	S-Binding
was	O
found	O
to	O
be	O
diminished	S-Negative_regulation
significantly	O
in	O
vessels	S-Tissue
inside	O
the	O
ear	B-Pathological_formation
tumor	E-Pathological_formation
in	O
both	O
mouse	S-Organism
models	O
.	O

This	O
reduction	S-Negative_regulation
disappeared	O
with	O
increasing	O
distance	O
from	O
the	O
tumor	S-Pathological_formation
.	O

Surprisingly	O
,	O
the	O
level	O
of	O
leukocyte	S-Cell
adhesion	S-Binding
in	O
ear	B-Multi-tissue_structure
venules	E-Multi-tissue_structure
of	O
mice	S-Organism
with	O
a	O
large	O
flank	B-Pathological_formation
tumor	E-Pathological_formation
was	O
also	O
reduced	S-Negative_regulation
significantly	O
.	O

Leukocyte	S-Cell
rolling	O
,	O
i	O
.	O
e	O
.	O
,	O
the	O
step	O
preceding	O
adhesion	O
,	O
was	O
not	O
influenced	O
by	O
the	O
presence	O
of	O
a	O
tumor	S-Pathological_formation
in	O
nude	B-Organism
mice	E-Organism
,	O
but	O
was	O
down	O
-	O
regulated	O
in	O
immune	O
-	O
competent	O
C57Bl	B-Organism
/	I-Organism
6	I-Organism
mice	E-Organism
.	O

Treatment	S-Planned_process
of	O
mice	S-Organism
bearing	O
a	O
small	O
ear	B-Pathological_formation
tumor	E-Pathological_formation
with	O
a	O
humanized	B-Gene_or_gene_product
antivascular	I-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
antibody	E-Gene_or_gene_product
prevented	S-Negative_regulation
the	O
down	B-Negative_regulation
-	I-Negative_regulation
regulation	E-Negative_regulation
of	O
leukocyte	S-Cell
-	O
vessel	B-Multi-tissue_structure
wall	E-Multi-tissue_structure
interactions	S-Binding
inside	O
the	O
tumor	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
compared	O
with	O
the	O
nontreated	S-Planned_process
group	O
.	O

Fluorescence	O
-	O
activated	S-Positive_regulation
cell	S-Cell
sorter	O
analysis	O
showed	O
that	O
isolated	O
tumor	B-Cell
ECs	E-Cell
have	O
suppressed	S-Negative_regulation
levels	O
of	O
intercellular	B-Gene_or_gene_product
adhesion	I-Gene_or_gene_product
molecule	I-Gene_or_gene_product
1	E-Gene_or_gene_product
as	O
compared	O
with	O
ECs	S-Cell
from	O
normal	O
mouse	S-Organism
tissues	S-Tissue
.	O

In	O
cultured	O
b	B-Cell
.	I-Cell
END5	I-Cell
cells	E-Cell
the	O
tumor	B-Gene_or_gene_product
necrosis	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
alpha	E-Gene_or_gene_product
-	O
induced	S-Positive_regulation
up	B-Positive_regulation
-	I-Positive_regulation
regulation	E-Positive_regulation
of	O
intercellular	B-Gene_or_gene_product
adhesion	I-Gene_or_gene_product
molecule	I-Gene_or_gene_product
1	E-Gene_or_gene_product
and	O
vascular	B-Gene_or_gene_product
cell	I-Gene_or_gene_product
adhesion	I-Gene_or_gene_product
molecule	I-Gene_or_gene_product
1	E-Gene_or_gene_product
was	O
reduced	S-Negative_regulation
in	O
ECs	S-Cell
that	O
were	O
preincubated	S-Planned_process
with	O
basic	B-Gene_or_gene_product
fibroblast	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
or	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
.	O

The	O
current	O
results	O
may	O
have	O
an	O
impact	O
on	O
the	O
effectiveness	O
of	O
clinical	O
immunotherapeutic	O
treatment	O
protocols	O
,	O
because	O
immune	B-Cell
effector	I-Cell
cells	E-Cell
may	O
not	O
be	O
able	O
to	O
enter	S-Localization
tumor	B-Pathological_formation
tissue	E-Pathological_formation
.	O

Antiapoptotic	O
effect	O
of	O
coagulation	B-Gene_or_gene_product
factor	I-Gene_or_gene_product
VIIa	E-Gene_or_gene_product
.	O

Binding	S-Binding
of	O
factor	B-Gene_or_gene_product
VIIa	E-Gene_or_gene_product
(	O
FVIIa	S-Gene_or_gene_product
)	O
to	O
its	O
cellular	O
receptor	O
tissue	B-Gene_or_gene_product
factor	E-Gene_or_gene_product
(	O
TF	S-Gene_or_gene_product
)	O
was	O
previously	O
shown	O
to	O
induce	S-Positive_regulation
various	O
intracellular	O
signaling	O
events	O
,	O
which	O
were	O
thought	O
to	O
be	O
responsible	O
for	O
TF	S-Gene_or_gene_product
-	O
mediated	S-Positive_regulation
biologic	O
effects	O
,	O
including	O
angiogenesis	S-Blood_vessel_development
,	O
tumor	S-Pathological_formation
metastasis	S-Localization
,	O
and	O
restenosis	O
.	O

To	O
understand	O
the	O
mechanisms	O
behind	O
these	O
processes	O
,	O
we	O
have	O
examined	O
the	O
effect	O
of	O
FVIIa	S-Gene_or_gene_product
on	O
apoptosis	O
.	O

Serum	S-Organism_substance
deprivation	O
-	O
induced	S-Positive_regulation
apoptosis	S-Death
of	O
BHK	B-Cell
(	I-Cell
+	I-Cell
TF	I-Cell
)	I-Cell
cells	E-Cell
was	O
characterized	O
by	O
apoptotic	O
blebs	O
,	O
nuclei	S-Cellular_component
with	O
chromatin	S-Cellular_component
-	O
condensed	O
bodies	O
,	O
DNA	O
degradation	O
,	O
and	O
activation	S-Positive_regulation
of	O
caspase	B-Gene_or_gene_product
3	E-Gene_or_gene_product
.	O

FVIIa	S-Gene_or_gene_product
markedly	O
decreased	O
the	O
number	O
of	O
cells	S-Cell
with	O
apoptotic	O
morphology	O
and	O
prevented	O
the	O
DNA	O
degradation	O
as	O
measured	O
by	O
means	O
of	O
TdT	S-Gene_or_gene_product
-	O
mediated	O
dUTP	S-Drug_or_compound
nick	O
end	O
labeling	O
(	O
TUNEL	O
)	O
.	O

The	O
antiapoptotic	O
effect	O
of	O
FVIIa	S-Gene_or_gene_product
was	O
confirmed	O
by	O
the	O
observation	O
that	O
FVIIa	S-Gene_or_gene_product
attenuated	S-Negative_regulation
caspase	B-Gene_or_gene_product
3	E-Gene_or_gene_product
activation	S-Positive_regulation
.	O

FVIIa	S-Gene_or_gene_product
-	O
induced	O
antiapoptotic	O
effect	O
was	O
dependent	O
on	O
its	O
proteolytic	O
activity	O
and	O
TF	S-Gene_or_gene_product
but	O
independent	O
of	O
factor	B-Gene_or_gene_product
Xa	E-Gene_or_gene_product
and	O
thrombin	S-Gene_or_gene_product
.	O

FVIIa	S-Gene_or_gene_product
-	O
induced	S-Positive_regulation
cell	S-Cell
survival	S-Death
correlated	O
with	O
the	O
activation	S-Positive_regulation
of	O
Akt	S-Gene_or_gene_product
and	O
was	O
inhibited	O
markedly	O
by	O
the	O
specific	O
PI3	B-Gene_or_gene_product
-	I-Gene_or_gene_product
kinase	E-Gene_or_gene_product
inhibitor	O
,	O
LY294002	S-Drug_or_compound
.	O

Blocking	S-Negative_regulation
the	O
activation	S-Positive_regulation
of	O
p44	B-Gene_or_gene_product
/	I-Gene_or_gene_product
42	I-Gene_or_gene_product
mitogen	I-Gene_or_gene_product
-	I-Gene_or_gene_product
activated	I-Gene_or_gene_product
protein	I-Gene_or_gene_product
kinase	E-Gene_or_gene_product
(	O
MAPK	S-Gene_or_gene_product
)	O
by	O
the	O
specific	O
mitogen	B-Gene_or_gene_product
-	I-Gene_or_gene_product
induced	I-Gene_or_gene_product
extracellular	I-Gene_or_gene_product
kinase	E-Gene_or_gene_product
(	O
MEK	S-Gene_or_gene_product
)	O
inhibitor	O
,	O
U0126	S-Drug_or_compound
,	O
impaired	S-Negative_regulation
modestly	O
the	O
ability	O
of	O
FVIIa	S-Gene_or_gene_product
to	O
promote	S-Positive_regulation
cell	S-Cell
survival	S-Death
.	O

In	O
conclusion	O
,	O
FVIIa	S-Gene_or_gene_product
binding	S-Binding
to	O
TF	S-Gene_or_gene_product
provided	O
protection	O
against	O
apoptosis	O
induced	O
by	O
growth	O
factor	O
deprivation	O
,	O
primarily	O
through	O
activation	S-Positive_regulation
of	O
PI3	B-Gene_or_gene_product
-	I-Gene_or_gene_product
kinase	E-Gene_or_gene_product
/	O
Akt	S-Gene_or_gene_product
pathway	S-Pathway
,	O
and	O
to	O
a	O
lesser	O
extent	O
,	O
p44	B-Gene_or_gene_product
/	I-Gene_or_gene_product
42	I-Gene_or_gene_product
MAPK	E-Gene_or_gene_product
pathway	S-Pathway
.	O

Combined	O
topical	O
fluconazole	S-Drug_or_compound
and	O
corticosteroid	S-Drug_or_compound
treatment	S-Planned_process
for	O
experimental	O
Candida	B-Organism
albicans	E-Organism
keratomycosis	O
.	O

PURPOSE	O
:	O
To	O
determine	O
the	O
most	O
efficient	O
time	O
point	O
and	O
concentration	O
of	O
topical	O
corticosteroids	S-Drug_or_compound
in	O
Candida	B-Organism
albicans	E-Organism
keratitis	O
treated	S-Planned_process
with	O
fluconazole	S-Drug_or_compound
.	O

METHODS	O
:	O
Corneas	S-Multi-tissue_structure
of	O
105	O
rabbits	S-Organism
were	O
infected	O
with	O
viable	O
yeast	S-Organism
cells	S-Cell
of	O
C	B-Organism
.	I-Organism
albicans	E-Organism
(	O
2	O
.	O
5	O
x	O
10	O
(	O
5	O
)	O
)	O
.	O

After	O
a	O
48	O
-	O
hour	O
incubation	O
period	O
,	O
seven	O
groups	O
of	O
animals	O
were	O
treated	S-Planned_process
for	O
21	O
days	O
with	O
fluconazole	S-Drug_or_compound
,	O
with	O
group	O
I	O
acting	O
as	O
a	O
control	O
,	O
and	O
groups	O
II	O
to	O
VII	O
receiving	O
adjunct	O
therapy	S-Planned_process
with	O
the	O
corticosteroid	S-Drug_or_compound
prednisolone	S-Drug_or_compound
(	O
5	O
or	O
10	O
times	O
daily	O
;	O
3	O
,	O
9	O
,	O
or	O
15	O
days	O
after	O
infection	O
)	O
.	O

The	O
degree	O
of	O
corneal	S-Multi-tissue_structure
infiltration	S-Localization
,	O
ulceration	O
,	O
corneal	S-Multi-tissue_structure
clouding	O
,	O
hypopyon	O
,	O
conjunctivitis	O
,	O
neovascularization	S-Blood_vessel_development
,	O
and	O
corneal	S-Multi-tissue_structure
perforation	O
was	O
monitored	O
over	O
a	O
24	O
-	O
day	O
period	O
,	O
as	O
well	O
as	O
recultivation	O
and	O
resistance	O
to	O
fluconazole	S-Drug_or_compound
of	O
the	O
C	B-Organism
.	I-Organism
albicans	E-Organism
pathogen	O
.	O

RESULTS	O
:	O
The	O
control	O
group	O
showed	O
the	O
highest	O
level	O
of	O
corneal	S-Multi-tissue_structure
clouding	O
and	O
neovascularization	S-Blood_vessel_development
.	O

In	O
comparison	O
,	O
by	O
day	O
24	O
,	O
the	O
majority	O
of	O
groups	O
also	O
treated	S-Planned_process
with	O
prednisolone	S-Drug_or_compound
displayed	O
significantly	O
less	O
corneal	S-Multi-tissue_structure
clouding	O
and	O
neovascularization	S-Blood_vessel_development
.	O

An	O
immediate	O
decrease	O
in	O
corneal	S-Multi-tissue_structure
clouding	O
was	O
observed	O
in	O
groups	O
treated	S-Planned_process
with	O
additional	O
low	O
-	O
or	O
high	O
-	O
dose	O
prednisolone	S-Drug_or_compound
from	O
day	O
9	O
after	O
inoculation	O
.	O

After	O
additional	O
prednisolone	S-Drug_or_compound
treatment	S-Planned_process
from	O
day	O
9	O
or	O
15	O
after	O
inoculation	O
,	O
no	O
significant	O
difference	O
was	O
detected	O
in	O
the	O
recultivation	S-Reproduction
rate	O
of	O
C	B-Organism
.	I-Organism
albicans	E-Organism
compared	O
with	O
the	O
control	O
.	O

Early	O
administration	S-Planned_process
of	O
prednisolone	S-Drug_or_compound
(	O
day	O
3	O
,	O
low	O
and	O
high	O
dose	O
)	O
resulted	O
in	O
the	O
recultivation	S-Reproduction
of	O
significantly	O
more	O
C	B-Organism
.	I-Organism
albicans	E-Organism
.	O

CONCLUSIONS	O
:	O
Fluconazole	S-Drug_or_compound
plus	O
adjunct	O
high	O
-	O
dose	O
prednisolone	S-Drug_or_compound
treatment	S-Planned_process
was	O
most	O
effective	O
when	O
administered	O
9	O
days	O
after	O
infection	O
.	O

The	O
delayed	O
application	S-Planned_process
of	O
corticosteroids	S-Drug_or_compound
after	O
treatment	S-Planned_process
with	O
antimycotic	B-Drug_or_compound
drugs	E-Drug_or_compound
in	O
cases	O
of	O
fungal	O
keratitis	O
is	O
therefore	O
not	O
contraindicated	O
and	O
may	O
be	O
beneficial	O
in	O
patients	S-Organism
.	O

Solid	B-Pathological_formation
tumor	E-Pathological_formation
therapy	S-Planned_process
:	O
manipulation	S-Regulation
of	O
the	O
vasculature	S-Multi-tissue_structure
with	O
TNF	S-Gene_or_gene_product
.	O

Drug	O
delivery	O
to	O
solid	B-Pathological_formation
tumors	E-Pathological_formation
is	O
one	O
of	O
the	O
most	O
challenging	O
aspects	O
in	O
cancer	O
therapy	O
.	O

Whereas	O
agents	O
seem	O
promising	O
in	O
the	O
test	O
tube	O
,	O
clinical	O
trials	O
often	O
fail	O
due	O
to	O
unfavorable	O
pharmacokinetics	O
,	O
poor	O
delivery	O
,	O
low	O
local	O
concentrations	O
,	O
and	O
limited	O
accumulation	O
in	O
the	O
target	O
cell	S-Cell
.	O

A	O
major	O
step	O
forwards	O
in	O
the	O
treatment	S-Planned_process
of	O
solid	B-Pathological_formation
tumors	E-Pathological_formation
is	O
the	O
recognition	O
of	O
the	O
tumor	S-Pathological_formation
-	O
associated	O
vasculature	S-Multi-tissue_structure
as	O
an	O
important	O
target	O
for	O
therapy	O
.	O

Inhibition	S-Negative_regulation
of	O
tumor	B-Multi-tissue_structure
vascular	E-Multi-tissue_structure
development	S-Development
has	O
a	O
direct	O
effect	S-Regulation
on	O
the	O
growth	S-Growth
and	O
progression	S-Development
of	O
the	O
tumor	S-Pathological_formation
.	O

Destruction	S-Breakdown
of	O
an	O
existing	O
vasculature	S-Multi-tissue_structure
also	O
directly	O
inflicts	S-Positive_regulation
serious	O
damage	S-Breakdown
to	O
the	O
tumor	B-Cell
cell	E-Cell
.	O

Moreover	O
,	O
the	O
tumor	B-Multi-tissue_structure
vascular	I-Multi-tissue_structure
bed	E-Multi-tissue_structure
can	O
be	O
manipulated	S-Regulation
facilitating	O
enhanced	O
permissiveness	O
of	O
the	O
tumor	S-Pathological_formation
for	O
administered	S-Planned_process
chemotherapeutics	O
.	O

In	O
this	O
review	O
,	O
we	O
focus	O
on	O
the	O
use	O
of	O
tumor	B-Gene_or_gene_product
necrosis	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
alpha	E-Gene_or_gene_product
(	O
TNF	S-Gene_or_gene_product
)	O
in	O
local	O
and	O
systemic	O
therapy	S-Planned_process
in	O
conjunction	O
with	O
chemotherapy	O
.	O

In	O
these	O
settings	O
TNF	S-Gene_or_gene_product
demonstrates	O
potent	O
and	O
selective	O
activity	O
on	O
the	O
tumor	B-Multi-tissue_structure
vascular	I-Multi-tissue_structure
bed	E-Multi-tissue_structure
,	O
which	O
strongly	O
improves	S-Positive_regulation
tumor	S-Pathological_formation
response	O
.	O

Prognostic	O
value	O
of	O
p53	S-Gene_or_gene_product
protein	O
expression	S-Gene_expression
and	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
expression	S-Gene_expression
in	O
resected	S-Planned_process
squamous	B-Pathological_formation
cell	I-Pathological_formation
carcinoma	E-Pathological_formation
of	O
the	O
esophagus	S-Organ
.	O

The	O
most	O
common	O
genetic	O
alterations	O
found	O
in	O
a	O
wide	O
variety	O
of	O
cancers	S-Pathological_formation
are	O
p53	S-Gene_or_gene_product
tumor	O
suppressor	O
gene	O
mutations	O
.	O

p53	S-Gene_or_gene_product
appears	O
to	O
be	O
a	O
nuclear	O
transcription	O
factor	O
that	O
plays	O
a	O
role	O
in	O
the	O
control	S-Regulation
of	O
cell	S-Cell
proliferation	S-Cell_proliferation
,	O
apoptosis	S-Death
,	O
and	O
the	O
maintenance	O
of	O
genetic	O
stability	O
.	O

Angiogenesis	S-Blood_vessel_development
is	O
a	O
critical	S-Regulation
process	O
in	O
solid	B-Pathological_formation
tumor	E-Pathological_formation
growth	S-Growth
and	O
metastasis	S-Localization
.	O

Vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
(	O
VEGF	S-Gene_or_gene_product
)	O
,	O
a	O
recently	O
identified	O
growth	O
factor	O
with	O
significant	O
angiogenic	S-Blood_vessel_development
properties	O
,	O
may	O
be	O
a	O
major	O
tumor	S-Pathological_formation
angiogenesis	S-Blood_vessel_development
regulator	S-Regulation
.	O

Few	O
studies	O
have	O
investigated	O
the	O
association	O
between	O
p53	S-Gene_or_gene_product
and	O
VEGF	S-Gene_or_gene_product
expressions	S-Gene_expression
and	O
prognosis	O
in	O
esophageal	B-Pathological_formation
carcinoma	E-Pathological_formation
.	O

Forty	O
-	O
seven	O
specimens	O
resected	S-Planned_process
from	O
patients	S-Organism
with	O
stage	O
II	O
and	O
III	O
squamous	B-Pathological_formation
cell	I-Pathological_formation
carcinoma	E-Pathological_formation
(	O
SCC	S-Pathological_formation
)	O
of	O
the	O
esophagus	S-Organ
were	O
studied	O
using	O
immunohistochemical	O
staining	O
.	O

VEGF	S-Gene_or_gene_product
and	O
p53	S-Gene_or_gene_product
expressions	S-Gene_expression
were	O
observed	O
in	O
40	O
%	O
and	O
53	O
%	O
of	O
the	O
tumors	S-Pathological_formation
,	O
respectively	O
.	O

The	O
p53	S-Gene_or_gene_product
and	O
VEGF	S-Gene_or_gene_product
staining	O
statuses	O
were	O
coincident	O
in	O
only	O
21	O
%	O
of	O
the	O
tumors	S-Pathological_formation
,	O
and	O
no	O
significant	O
correlation	O
was	O
found	O
between	O
p53	S-Gene_or_gene_product
and	O
VEGF	S-Gene_or_gene_product
statuses	O
.	O

No	O
clinicopathologic	O
factors	O
were	O
significantly	O
correlated	O
with	O
p53	S-Gene_or_gene_product
or	O
VEGF	S-Gene_or_gene_product
expression	S-Gene_expression
.	O

No	O
significant	O
association	O
between	O
p53	S-Gene_or_gene_product
and	O
VEGF	S-Gene_or_gene_product
expressions	S-Gene_expression
and	O
poor	O
prognosis	O
was	O
found	O
.	O

In	O
conclusion	O
,	O
p53	S-Gene_or_gene_product
and	O
VEGF	S-Gene_or_gene_product
were	O
not	O
correlated	O
with	O
prognosis	O
in	O
patients	S-Organism
with	O
stage	O
II	O
and	O
III	O
SCC	S-Pathological_formation
of	O
the	O
esophagus	S-Organ
.	O

Comparison	O
of	O
tissue	S-Tissue
integration	O
between	O
polyester	S-Drug_or_compound
and	O
polypropylene	S-Drug_or_compound
prostheses	O
in	O
the	O
preperitoneal	B-Immaterial_anatomical_entity
space	E-Immaterial_anatomical_entity
.	O

Tissue	S-Tissue
integration	O
and	O
implant	O
characteristics	O
of	O
various	O
biomaterials	O
commonly	O
used	O
for	O
inguinal	O
hernia	O
repair	O
have	O
not	O
been	O
studied	O
extensively	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
compare	O
behavior	O
and	O
tissue	S-Tissue
response	O
between	O
two	O
new	O
polyester	S-Drug_or_compound
prostheses	O
and	O
a	O
commonly	O
used	O
polypropylene	S-Drug_or_compound
(	O
PP	S-Drug_or_compound
)	O
mesh	O
.	O

The	O
polyester	S-Drug_or_compound
prostheses	O
utilized	O
were	O
polyester	S-Drug_or_compound
flat	O
(	O
PF	O
)	O
and	O
polyester	S-Drug_or_compound
soft	O
three	O
-	O
dimensional	O
(	O
PS	O
)	O
;	O
the	O
PP	O
mesh	O
utilized	O
was	O
Marlex	O
.	O

Eight	O
randomly	O
assigned	O
4	O
x	O
4	O
-	O
cm2	O
pieces	O
of	O
two	O
different	O
meshes	O
were	O
fixed	O
in	O
the	O
preperitoneal	B-Immaterial_anatomical_entity
space	E-Immaterial_anatomical_entity
with	O
a	O
centrally	O
placed	O
single	O
suture	O
.	O

Gross	O
evaluation	O
included	O
shrinkage	O
and	O
stiffness	O
.	O

Histological	O
evaluation	O
included	O
amount	O
of	O
fibrous	S-Tissue
and	O
fat	S-Tissue
encapsulation	S-Localization
,	O
connective	B-Tissue
tissue	E-Tissue
,	O
foreign	O
-	O
body	O
reaction	O
,	O
neovascularization	S-Blood_vessel_development
,	O
hemorrhage	O
,	O
necrosis	S-Death
,	O
and	O
exudate	S-Organism_substance
.	O

Evaluations	O
were	O
graded	O
on	O
a	O
zero	O
to	O
four	O
scale	O
.	O

The	O
area	O
and	O
the	O
area	O
ratio	O
were	O
measured	O
using	O
a	O
calibrated	O
micrometer	O
.	O

PP	S-Drug_or_compound
mesh	O
resulted	S-Positive_regulation
in	O
more	O
fibrous	S-Tissue
encapsulation	S-Localization
and	O
stiffness	O
than	O
PF	O
and	O
PS	O
prostheses	O
.	O

PP	S-Drug_or_compound
also	O
resulted	S-Positive_regulation
in	O
less	O
connective	B-Tissue
tissue	E-Tissue
formation	S-Development
and	O
foreign	O
-	O
body	O
reaction	O
than	O
PF	O
and	O
PS	O
prostheses	O
.	O

There	O
was	O
no	O
difference	O
in	O
fat	S-Tissue
encapsulation	S-Localization
,	O
necrosis	S-Death
,	O
hemorrhage	O
,	O
or	O
exudate	S-Organism_substance
between	O
prostheses	O
.	O

Both	O
polyester	S-Drug_or_compound
prostheses	O
(	O
PF	O
and	O
PS	O
)	O
have	O
better	O
tissue	S-Tissue
integration	O
than	O
the	O
PP	S-Drug_or_compound
mesh	O
,	O
as	O
evidenced	O
by	O
the	O
higher	O
amount	O
of	O
connective	B-Tissue
tissue	E-Tissue
and	O
lower	O
extent	O
of	O
fibrous	S-Tissue
encapsulation	S-Localization
.	O

Therapeutic	O
targeting	S-Regulation
of	O
the	O
survivin	S-Gene_or_gene_product
pathway	S-Pathway
in	O
cancer	O
:	O
initiation	O
of	O
mitochondrial	O
apoptosis	O
and	O
suppression	S-Negative_regulation
of	O
tumor	S-Pathological_formation
-	O
associated	O
angiogenesis	S-Blood_vessel_development
.	O

PURPOSE	O
:	O
Molecular	O
antagonists	O
of	O
the	O
inhibitor	O
of	O
apoptosis	O
protein	O
survivin	S-Gene_or_gene_product
have	O
shown	O
promise	O
as	O
novel	O
anticancer	O
strategies	O
for	O
triggering	S-Positive_regulation
tumor	B-Cell
cell	E-Cell
apoptosis	S-Death
,	O
dysregulating	O
mitotic	O
progression	O
,	O
and	O
inhibiting	S-Negative_regulation
tumor	S-Pathological_formation
growth	S-Growth
in	O
preclinical	O
models	O
.	O

However	O
,	O
how	O
survivin	S-Gene_or_gene_product
couples	O
to	O
the	O
cell	S-Cell
death	S-Death
machinery	O
has	O
remained	O
elusive	O
,	O
and	O
the	O
relevant	O
cellular	O
targets	O
of	O
survivin	S-Gene_or_gene_product
antagonists	O
have	O
not	O
been	O
completely	O
elucidated	O
.	O

Experimental	O
Design	O
:	O
Human	S-Organism
umbilical	B-Cell
vein	E-Cell
and	O
dermal	B-Cell
microvascular	I-Cell
endothelial	I-Cell
cells	E-Cell
were	O
infected	S-Planned_process
with	O
replication	O
-	O
deficient	O
adenoviruses	S-Organism
encoding	O
survivin	S-Gene_or_gene_product
(	O
pAd	B-Gene_or_gene_product
-	I-Gene_or_gene_product
Survivin	E-Gene_or_gene_product
)	O
,	O
green	B-Gene_or_gene_product
fluorescent	I-Gene_or_gene_product
protein	E-Gene_or_gene_product
(	O
pAd	B-Gene_or_gene_product
-	I-Gene_or_gene_product
GFP	E-Gene_or_gene_product
)	O
,	O
or	O
a	O
phosphorylation	O
-	O
defective	O
survivin	S-Gene_or_gene_product
Thr	O
(	O
34	O
)	O
-	O
-	O
>	O
Ala	O
(	O
pAd	B-Gene_or_gene_product
-	I-Gene_or_gene_product
T34A	E-Gene_or_gene_product
)	O
dominant	O
negative	O
mutant	O
.	O

The	O
effect	S-Regulation
of	O
wild	O
-	O
type	O
or	O
mutant	O
survivin	S-Gene_or_gene_product
was	O
investigated	O
on	O
capillary	B-Multi-tissue_structure
network	E-Multi-tissue_structure
stability	O
,	O
endothelial	B-Cell
cell	E-Cell
viability	O
,	O
and	O
caspase	S-Gene_or_gene_product
activation	S-Positive_regulation
in	O
vitro	O
and	O
on	O
kinetics	O
of	O
tumor	S-Pathological_formation
growth	S-Growth
and	O
development	O
of	O
angiogenesis	S-Blood_vessel_development
in	O
a	O
breast	B-Pathological_formation
cancer	I-Pathological_formation
xenograft	E-Pathological_formation
model	O
in	O
vivo	O
.	O

The	O
cell	S-Cell
death	S-Death
pathway	O
initiated	S-Positive_regulation
by	O
survivin	S-Gene_or_gene_product
targeting	S-Planned_process
was	O
mapped	O
with	O
respect	O
to	O
cytochrome	B-Gene_or_gene_product
c	E-Gene_or_gene_product
release	S-Localization
,	O
changes	O
in	O
mitochondrial	O
transmembrane	O
potential	O
,	O
and	O
apoptosome	O
requirements	O
using	O
mouse	S-Organism
embryonic	B-Cell
fibroblasts	E-Cell
deficient	S-Gene_expression
in	O
Apaf	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
or	O
caspase	B-Gene_or_gene_product
-	I-Gene_or_gene_product
9	E-Gene_or_gene_product
.	O

RESULTS	O
:	O
Adenoviral	S-Organism
transduction	S-Planned_process
of	O
endothelial	B-Cell
cells	E-Cell
with	O
pAd	B-Gene_or_gene_product
-	I-Gene_or_gene_product
Survivin	E-Gene_or_gene_product
inhibited	O
growth	O
factor	O
deprivation	O
-	O
or	O
ceramide	S-Drug_or_compound
-	O
induced	O
apoptosis	O
,	O
reduced	S-Negative_regulation
caspase	B-Gene_or_gene_product
-	I-Gene_or_gene_product
3	E-Gene_or_gene_product
and	O
-	B-Gene_or_gene_product
7	E-Gene_or_gene_product
generation	S-Gene_expression
,	O
and	O
stabilized	O
three	O
-	O
dimensional	O
capillary	B-Multi-tissue_structure
networks	E-Multi-tissue_structure
in	O
vitro	O
.	O

Conversely	O
,	O
expression	S-Gene_expression
of	O
pAd	B-Gene_or_gene_product
-	I-Gene_or_gene_product
T34A	E-Gene_or_gene_product
caused	S-Positive_regulation
apoptosis	S-Death
in	O
umbilical	B-Cell
vein	E-Cell
and	O
dermal	B-Cell
microvascular	I-Cell
endothelial	I-Cell
cells	E-Cell
and	O
resulted	S-Positive_regulation
in	O
caspase	B-Gene_or_gene_product
-	I-Gene_or_gene_product
3	E-Gene_or_gene_product
activity	O
.	O

Cell	S-Cell
death	S-Death
induced	S-Positive_regulation
by	O
survivin	S-Gene_or_gene_product
targeting	S-Planned_process
exhibited	O
the	O
hallmarks	O
of	O
mitochondrial	O
-	O
dependent	O
apoptosis	O
with	O
release	S-Localization
of	O
cytochrome	B-Gene_or_gene_product
c	E-Gene_or_gene_product
and	O
loss	O
of	O
mitochondrial	O
transmembrane	O
potential	O
and	O
was	O
suppressed	O
in	O
Apaf	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
or	O
caspase	B-Gene_or_gene_product
-	I-Gene_or_gene_product
9	E-Gene_or_gene_product
knockout	S-Planned_process
mouse	S-Organism
embryonic	B-Cell
fibroblasts	E-Cell
.	O

When	O
injected	S-Planned_process
in	O
human	S-Organism
breast	B-Pathological_formation
cancer	I-Pathological_formation
xenografts	E-Pathological_formation
,	O
pAd	B-Gene_or_gene_product
-	I-Gene_or_gene_product
T34A	E-Gene_or_gene_product
inhibited	S-Negative_regulation
growth	S-Growth
of	O
established	O
tumors	S-Pathological_formation
and	O
triggered	S-Positive_regulation
tumor	B-Cell
cell	E-Cell
apoptosis	S-Death
in	O
vivo	O
.	O

This	O
was	O
associated	O
with	O
a	O
approximately	O
60	O
%	O
reduction	S-Negative_regulation
in	O
tumor	S-Pathological_formation
-	O
derived	O
blood	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
by	O
quantitative	O
morphometry	O
of	O
CD31	S-Gene_or_gene_product
-	O
stained	O
tumor	S-Pathological_formation
areas	O
,	O
and	O
appearance	O
of	O
endothelial	B-Cell
cell	E-Cell
apoptosis	S-Death
by	O
internucleosomal	O
DNA	O
fragmentation	O
in	O
vivo	O
.	O

CONCLUSIONS	O
:	O
Survivin	S-Gene_or_gene_product
functions	O
as	O
a	O
novel	O
upstream	O
regulator	O
of	O
mitochondrial	O
-	O
dependent	O
apoptosis	O
,	O
and	O
molecular	O
targeting	O
of	O
this	O
pathway	O
results	O
in	O
anticancer	O
activity	O
via	O
a	O
dual	O
mechanism	O
of	O
induction	S-Positive_regulation
of	O
tumor	B-Cell
cell	E-Cell
apoptosis	S-Death
and	O
suppression	S-Negative_regulation
of	O
angiogenesis	S-Blood_vessel_development
.	O

The	O
role	O
of	O
organ	S-Organ
vascularization	S-Blood_vessel_development
and	O
lipoplex	S-Drug_or_compound
-	O
serum	S-Organism_substance
initial	O
contact	O
in	O
intravenous	O
murine	S-Organism
lipofection	S-Planned_process
.	O

Following	O
intravenous	O
administration	S-Planned_process
of	O
cationic	O
lipid	O
-	O
DNA	O
complexes	O
(	O
lipoplexes	S-Drug_or_compound
)	O
into	O
mice	S-Organism
,	O
transfection	O
(	O
lipofection	O
)	O
occurs	O
predominantly	O
in	O
the	O
lungs	S-Organ
.	O

This	O
was	O
attributed	O
to	O
high	O
entrapment	S-Localization
of	O
lipoplexes	S-Drug_or_compound
in	O
the	O
extended	O
lung	B-Multi-tissue_structure
vascular	I-Multi-tissue_structure
tree	E-Multi-tissue_structure
.	O

To	O
determine	O
whether	O
lipofection	S-Planned_process
in	O
other	O
organs	S-Organ
could	O
be	O
enhanced	S-Positive_regulation
by	O
increasing	S-Positive_regulation
the	O
degree	O
of	O
vascularization	S-Blood_vessel_development
,	O
we	O
used	O
a	O
transgenic	O
mouse	S-Organism
model	O
with	O
tissue	S-Tissue
-	O
specific	O
angiogenesis	S-Blood_vessel_development
in	O
liver	S-Organ
.	O

Tail	B-Multi-tissue_structure
vein	E-Multi-tissue_structure
injection	S-Planned_process
of	O
N	B-Drug_or_compound
-	I-Drug_or_compound
(	I-Drug_or_compound
1	I-Drug_or_compound
-	I-Drug_or_compound
(	I-Drug_or_compound
2	I-Drug_or_compound
,	I-Drug_or_compound
3	I-Drug_or_compound
-	I-Drug_or_compound
dioleoyloxy	I-Drug_or_compound
)	I-Drug_or_compound
propyl	I-Drug_or_compound
)	I-Drug_or_compound
-	I-Drug_or_compound
N	I-Drug_or_compound
,	I-Drug_or_compound
N	I-Drug_or_compound
,	I-Drug_or_compound
N	I-Drug_or_compound
-	I-Drug_or_compound
trimethylammonium	I-Drug_or_compound
chloride	I-Drug_or_compound
(	I-Drug_or_compound
DOTAP	I-Drug_or_compound
)	I-Drug_or_compound
/	I-Drug_or_compound
cholesterol	I-Drug_or_compound
lipoplexes	E-Drug_or_compound
resulted	S-Positive_regulation
in	O
increased	S-Positive_regulation
lipoplex	S-Drug_or_compound
entrapment	S-Localization
in	O
hypervascularized	O
liver	S-Organ
but	O
did	O
not	O
boost	S-Positive_regulation
luciferase	S-Gene_or_gene_product
expression	S-Gene_expression
,	O
suggesting	O
that	O
lipoplex	S-Drug_or_compound
delivery	S-Localization
is	O
not	O
a	O
sufficient	S-Positive_regulation
condition	O
for	O
efficient	O
organ	S-Organ
lipofection	S-Planned_process
.	O

Because	O
the	O
intravenously	O
injected	S-Planned_process
lipoplexes	S-Drug_or_compound
migrated	S-Localization
within	O
seconds	O
to	O
lungs	S-Organ
,	O
we	O
checked	O
whether	O
the	O
effects	O
of	O
immediate	O
contact	O
with	O
serum	S-Organism_substance
correlate	O
with	O
lung	S-Organ
lipofection	S-Planned_process
efficiency	O
of	O
different	O
DOTAP	S-Drug_or_compound
-	O
based	O
formulations	O
.	O

Under	O
conditions	O
mimicking	O
the	O
injection	O
environment	O
,	O
the	O
lipoplex	S-Drug_or_compound
-	O
serum	S-Organism_substance
interaction	O
was	O
strongly	O
dependent	O
on	O
helper	O
lipid	S-Drug_or_compound
and	O
ionic	O
strength	O
:	O
lipoplexes	S-Drug_or_compound
prepared	O
in	O
150	O
mM	O
NaCl	O
or	O
lipoplexes	S-Drug_or_compound
with	O
high	O
(	O
greater	O
than	O
33	O
mol	O
%	O
)	O
cholesterol	S-Drug_or_compound
were	O
found	O
to	O
aggregate	S-Binding
immediately	O
.	O

This	O
aggregation	S-Binding
process	O
was	O
irreversible	O
and	O
was	O
inversely	O
correlated	O
with	O
the	O
percentage	O
of	O
lung	B-Cell
cells	E-Cell
that	O
took	O
up	O
lipoplexes	S-Drug_or_compound
and	O
with	O
the	O
efficiency	O
of	O
lipofection	S-Planned_process
.	O

No	O
other	O
structural	O
changes	O
in	O
serum	S-Organism_substance
were	O
observed	O
for	O
cholesterol	B-Drug_or_compound
-	I-Drug_or_compound
based	I-Drug_or_compound
lipoplexes	E-Drug_or_compound
.	O

Dioleoyl	B-Drug_or_compound
phosphatidylethanolamine	I-Drug_or_compound
-	I-Drug_or_compound
based	I-Drug_or_compound
lipoplexes	E-Drug_or_compound
were	O
found	O
to	O
give	O
low	O
expression	O
,	O
apparently	O
because	O
of	O
an	O
immediate	O
loss	O
of	O
integrity	O
in	O
serum	S-Organism_substance
,	O
without	O
lipid	O
-	O
DNA	O
dissociation	O
.	O

Our	O
study	O
suggests	O
that	O
efficient	O
in	O
vivo	O
lipofection	O
is	O
the	O
result	O
of	O
cross	O
-	O
talk	O
between	O
lipoplex	S-Drug_or_compound
composition	O
,	O
interaction	O
with	O
serum	S-Organism_substance
,	O
hemodynamics	O
,	O
and	O
target	O
tissue	S-Tissue
"	O
susceptibility	O
"	O
to	O
transfection	O
.	O

Proliferative	O
diabetic	O
retinopathy	O
is	O
associated	O
with	O
a	O
low	O
level	O
of	O
the	O
natural	O
ocular	S-Organ
anti	O
-	O
angiogenic	S-Blood_vessel_development
agent	O
pigment	B-Gene_or_gene_product
epithelium	I-Gene_or_gene_product
-	I-Gene_or_gene_product
derived	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
(	O
PEDF	S-Gene_or_gene_product
)	O
in	O
aqueous	B-Organism_substance
humor	E-Organism_substance
.	O

a	O
pilot	O
study	O
.	O

Retinopathy	O
is	O
the	O
most	O
common	O
microvascular	S-Tissue
diabetes	O
complication	O
and	O
represents	O
a	O
major	O
threat	O
to	O
the	O
eyesight	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
address	O
the	O
role	O
of	O
pro	O
-	O
and	O
anti	O
-	O
angiogenic	S-Blood_vessel_development
molecules	O
in	O
diabetic	O
retinopathy	O
in	O
the	O
aqueous	B-Organism_substance
humor	E-Organism_substance
of	O
the	O
eye	S-Organ
.	O

Aqueous	B-Organism_substance
humor	E-Organism_substance
was	O
collected	S-Planned_process
at	O
cataract	O
surgery	O
from	O
19	O
diabetic	O
patients	S-Organism
and	O
from	O
13	O
age	O
-	O
and	O
sex	O
-	O
matched	O
normoglycemic	O
controls	S-Organism
.	O

Levels	O
of	O
pro	O
-	O
angiogenic	S-Blood_vessel_development
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
(	O
VEGF	S-Gene_or_gene_product
)	O
and	O
angiogenic	S-Blood_vessel_development
inhibitor	O
pigment	B-Gene_or_gene_product
epithelium	I-Gene_or_gene_product
-	I-Gene_or_gene_product
derived	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
(	O
PEDF	S-Gene_or_gene_product
)	O
were	O
determined	O
.	O

Angiogenic	S-Blood_vessel_development
activity	O
of	O
the	O
aqueous	B-Organism_substance
humor	E-Organism_substance
was	O
quantified	O
by	O
measuring	O
its	O
effect	S-Regulation
on	O
the	O
migration	S-Localization
of	O
capillary	B-Cell
endothelial	I-Cell
cells	E-Cell
.	O

In	O
the	O
aqueous	B-Organism_substance
fluid	E-Organism_substance
,	O
VEGF	S-Gene_or_gene_product
levels	O
were	O
increased	S-Positive_regulation
in	O
diabetics	O
(	O
mean	O
values	O
:	O
501	O
vs	O
.	O
367	O
pg	O
/	O
ml	O
;	O
p	O
=	O
0	O
.	O
05	O
)	O
,	O
compared	O
to	O
controls	O
.	O

PEDF	S-Gene_or_gene_product
was	O
found	O
to	O
be	O
decreased	S-Negative_regulation
in	O
diabetics	O
(	O
mean	O
values	O
:	O
2080	O
vs	O
.	O
5780	O
ng	O
/	O
ml	O
;	O
p	O
=	O
0	O
.	O
04	O
)	O
compared	O
to	O
controls	O
.	O

In	O
seven	O
diabetic	O
patients	S-Organism
with	O
proliferative	O
retinopathy	O
,	O
the	O
most	O
profound	O
finding	O
was	O
a	O
significant	O
decrease	S-Negative_regulation
of	O
the	O
PEDF	S-Gene_or_gene_product
level	O
(	O
mean	O
value	O
:	O
237	O
ng	O
/	O
ml	O
)	O
,	O
whereas	O
VEGF	S-Gene_or_gene_product
levels	O
were	O
comparable	O
to	O
diabetic	O
patients	S-Organism
without	O
proliferation	O
(	O
mean	O
value	O
:	O
3153	O
;	O
p	O
=	O
0	O
.	O
003	O
)	O
.	O

Angiogenic	S-Blood_vessel_development
activity	O
in	O
samples	O
of	O
patients	S-Organism
from	O
the	O
control	O
group	O
was	O
generally	O
inhibitory	S-Negative_regulation
due	O
to	O
PEDF	S-Gene_or_gene_product
,	O
and	O
inhibition	S-Negative_regulation
was	O
blocked	S-Negative_regulation
by	O
neutralizing	B-Gene_or_gene_product
antibodies	I-Gene_or_gene_product
to	I-Gene_or_gene_product
PEDF	E-Gene_or_gene_product
.	O

Likewise	O
,	O
in	O
diabetics	O
without	O
proliferation	O
,	O
angiogenic	S-Blood_vessel_development
activity	O
was	O
also	O
blocked	S-Negative_regulation
by	O
antibodies	B-Gene_or_gene_product
to	I-Gene_or_gene_product
PEDF	E-Gene_or_gene_product
.	O

We	O
will	O
demonstrate	O
here	O
that	O
the	O
level	O
of	O
the	O
natural	O
ocular	O
anti	O
-	O
angiogenic	S-Blood_vessel_development
agent	O
PEDF	S-Gene_or_gene_product
is	O
inversely	O
associated	O
with	O
proliferative	O
retinopathy	O
.	O

PEDF	S-Gene_or_gene_product
is	O
an	O
important	O
negative	B-Negative_regulation
regulator	E-Negative_regulation
of	O
angiogenic	S-Blood_vessel_development
activity	O
of	O
aqueous	B-Organism_substance
humor	E-Organism_substance
.	O

Our	O
data	O
may	O
have	O
implications	O
for	O
the	O
development	O
of	O
novel	O
regimens	O
for	O
diabetic	O
retinopathy	O
.	O

CCL16	S-Gene_or_gene_product
activates	S-Positive_regulation
an	O
angiogenic	S-Blood_vessel_development
program	O
in	O
vascular	B-Cell
endothelial	I-Cell
cells	E-Cell
.	O

Besides	O
regulating	S-Regulation
leukocyte	S-Cell
trafficking	S-Localization
in	O
normal	O
and	O
injured	S-Breakdown
tissues	S-Tissue
,	O
several	O
chemokines	O
may	O
positively	S-Positive_regulation
or	O
negatively	B-Negative_regulation
regulate	E-Negative_regulation
angiogenesis	S-Blood_vessel_development
.	O

Here	O
we	O
report	O
that	O
CCL16	S-Gene_or_gene_product
activates	S-Positive_regulation
an	O
angiogenic	S-Blood_vessel_development
program	O
in	O
vascular	B-Cell
endothelial	I-Cell
cells	E-Cell
by	O
activating	S-Positive_regulation
CCR1	S-Gene_or_gene_product
.	O

CCL16	S-Gene_or_gene_product
induces	S-Positive_regulation
dose	O
-	O
dependent	O
random	O
and	O
directional	O
migration	S-Localization
of	O
endothelial	B-Cell
cells	E-Cell
isolated	O
from	O
large	O
vessels	S-Multi-tissue_structure
and	O
liver	B-Tissue
capillaries	E-Tissue
without	O
inducing	S-Positive_regulation
their	O
proliferation	S-Cell_proliferation
.	O

It	O
also	O
promotes	S-Positive_regulation
endothelial	S-Cell
differentiation	S-Development
into	O
capillary	B-Tissue
-	I-Tissue
like	I-Tissue
structures	E-Tissue
in	O
an	O
in	O
vitro	O
assay	O
and	O
is	O
angiogenic	S-Blood_vessel_development
in	O
the	O
chick	S-Organism
chorionallantoic	B-Multi-tissue_structure
membrane	E-Multi-tissue_structure
.	O

These	O
angiogenic	S-Blood_vessel_development
activities	O
are	O
neutralized	S-Negative_regulation
by	O
a	O
specific	O
antibody	O
against	O
CCL16	S-Gene_or_gene_product
.	O

The	O
direct	O
angiogenic	S-Blood_vessel_development
activity	O
of	O
CCL16	S-Gene_or_gene_product
is	O
further	O
amplified	O
by	O
its	O
ability	O
to	O
prime	O
endothelium	S-Tissue
to	O
a	O
mitogen	O
signal	O
induced	O
by	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
A	E-Gene_or_gene_product
and	O
to	O
raise	S-Positive_regulation
their	O
basal	O
production	S-Gene_expression
of	O
CXCL8	S-Gene_or_gene_product
and	O
CCL2	S-Gene_or_gene_product
,	O
2	O
other	O
angiogenic	S-Blood_vessel_development
chemokines	O
.	O

BX471	S-Drug_or_compound
(	O
R	B-Drug_or_compound
-	I-Drug_or_compound
N	I-Drug_or_compound
-	I-Drug_or_compound
[	I-Drug_or_compound
5	I-Drug_or_compound
-	I-Drug_or_compound
chloro	I-Drug_or_compound
-	I-Drug_or_compound
2	I-Drug_or_compound
-	I-Drug_or_compound
[	I-Drug_or_compound
2	I-Drug_or_compound
-	I-Drug_or_compound
[	I-Drug_or_compound
4	I-Drug_or_compound
(	I-Drug_or_compound
4	I-Drug_or_compound
-	I-Drug_or_compound
fluorophenyl	I-Drug_or_compound
)	I-Drug_or_compound
methyl	I-Drug_or_compound
]	I-Drug_or_compound
-	I-Drug_or_compound
2	I-Drug_or_compound
-	I-Drug_or_compound
methyl	I-Drug_or_compound
-	I-Drug_or_compound
1	I-Drug_or_compound
-	I-Drug_or_compound
piperazinyl	I-Drug_or_compound
]	I-Drug_or_compound
-	I-Drug_or_compound
2	I-Drug_or_compound
-	I-Drug_or_compound
oxoethoxy	I-Drug_or_compound
]	I-Drug_or_compound
phenyl	I-Drug_or_compound
]	I-Drug_or_compound
urea	I-Drug_or_compound
hydrochloric	I-Drug_or_compound
acid	I-Drug_or_compound
salt	E-Drug_or_compound
)	O
,	O
a	O
CCR1	S-Gene_or_gene_product
antagonist	O
,	O
inhibits	S-Negative_regulation
angiogenic	S-Blood_vessel_development
properties	O
of	O
CCL16	S-Gene_or_gene_product
,	O
whereas	O
blocking	S-Negative_regulation
of	O
CCR8	S-Gene_or_gene_product
or	O
desensitizing	S-Negative_regulation
CCR2	S-Gene_or_gene_product
,	O
which	O
are	O
both	O
well	O
known	O
receptors	O
for	O
CCL16	S-Gene_or_gene_product
,	O
did	O
not	O
abolish	S-Negative_regulation
endothelial	S-Cell
activation	S-Positive_regulation
.	O

CCL16	S-Gene_or_gene_product
may	O
be	O
specifically	O
cross	O
-	O
linked	O
to	O
CCR1	S-Gene_or_gene_product
expressed	S-Gene_expression
on	O
endothelial	B-Cell
cells	E-Cell
.	O

The	O
largely	O
restricted	S-Negative_regulation
CCL16	S-Gene_or_gene_product
expression	S-Gene_expression
in	O
the	O
liver	S-Organ
suggests	O
that	O
this	O
chemokine	O
may	B-Regulation
play	I-Regulation
a	I-Regulation
role	E-Regulation
in	O
hepatic	O
vascular	S-Multi-tissue_structure
formation	S-Development
during	O
development	O
and	O
in	O
angiogenesis	S-Blood_vessel_development
associated	O
to	O
hepatic	O
diseases	O
.	O

Autocrine	O
angiotensin	S-Gene_or_gene_product
system	S-Pathway
regulation	S-Regulation
of	O
bovine	S-Organism
aortic	B-Cell
endothelial	I-Cell
cell	E-Cell
migration	S-Localization
and	O
plasminogen	B-Gene_or_gene_product
activator	E-Gene_or_gene_product
involves	O
modulation	S-Regulation
of	O
proto	O
-	O
oncogene	O
pp60c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
src	E-Gene_or_gene_product
expression	S-Gene_expression
.	O

Rapid	O
endothelial	B-Cell
cell	E-Cell
migration	S-Localization
and	O
inhibition	O
of	O
thrombosis	O
are	O
critical	O
for	O
the	O
resolution	O
of	O
denudation	O
injuries	O
to	O
the	O
vessel	B-Multi-tissue_structure
wall	E-Multi-tissue_structure
.	O

Inhibition	S-Negative_regulation
of	O
the	O
endothelial	B-Cell
cell	E-Cell
autocrine	O
angiotensin	S-Gene_or_gene_product
system	S-Pathway
,	O
with	O
either	O
the	O
angiotensin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
converting	I-Gene_or_gene_product
enzyme	E-Gene_or_gene_product
inhibitor	O
lisinopril	S-Drug_or_compound
or	O
the	O
angiotensin	B-Gene_or_gene_product
II	I-Gene_or_gene_product
receptor	E-Gene_or_gene_product
antagonist	O
sar1	S-Gene_or_gene_product
,	O
ile8	B-Drug_or_compound
-	I-Drug_or_compound
angiotensin	I-Drug_or_compound
II	I-Drug_or_compound
,	E-Drug_or_compound
leads	O
to	O
increased	S-Positive_regulation
endothelial	B-Cell
cell	E-Cell
migration	S-Localization
and	O
urokinase	B-Gene_or_gene_product
-	I-Gene_or_gene_product
like	I-Gene_or_gene_product
plasminogen	I-Gene_or_gene_product
activator	E-Gene_or_gene_product
(	O
u	B-Gene_or_gene_product
-	I-Gene_or_gene_product
PA	E-Gene_or_gene_product
)	O
activity	O
(	O
Bell	O
,	O
L	O
.	O
,	O
and	O
J	O
.	O
A	O
.	O
Madri	O
.	O
1990	O
.	O
Am	O
.	O
J	O
.	O
Pathol	O
.	O
137	O
:	O
7	O
-	O
12	O
)	O
.	O

Inhibition	S-Negative_regulation
of	O
the	O
autocrine	O
angiotensin	S-Gene_or_gene_product
system	S-Pathway
with	O
the	O
converting	O
-	O
enzyme	O
inhibitor	O
or	O
the	O
receptor	O
antagonist	O
also	O
leads	O
to	O
increased	S-Positive_regulation
expression	S-Gene_expression
of	O
the	O
proto	O
-	O
oncogene	O
c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
src	E-Gene_or_gene_product
:	O
pp60c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
src	E-Gene_or_gene_product
mRNA	O
increased	S-Positive_regulation
7	O
-	O
11	O
-	O
fold	O
,	O
c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
src	E-Gene_or_gene_product
protein	O
3	O
-	O
fold	O
,	O
and	O
c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
src	E-Gene_or_gene_product
kinase	O
activity	O
2	O
-	O
3	O
-	O
fold	O
.	O

Endothelial	B-Cell
cell	E-Cell
expression	S-Gene_expression
of	O
c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
src	E-Gene_or_gene_product
was	O
constitutively	O
elevated	S-Positive_regulation
after	O
stable	O
infection	O
with	O
a	O
retroviral	O
vector	O
containing	O
the	O
c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
src	E-Gene_or_gene_product
coding	O
sequence	O
.	O

Constitutively	O
increased	S-Positive_regulation
c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
src	E-Gene_or_gene_product
kinase	O
activity	O
reconstituted	O
the	O
increases	S-Positive_regulation
in	O
migration	O
and	O
u	B-Gene_or_gene_product
-	I-Gene_or_gene_product
PA	E-Gene_or_gene_product
observed	O
with	O
angiotensin	S-Gene_or_gene_product
system	S-Pathway
interruption	S-Negative_regulation
.	O

Antisera	O
to	O
bovine	S-Organism
u	B-Gene_or_gene_product
-	I-Gene_or_gene_product
PA	E-Gene_or_gene_product
blocked	O
the	O
increase	O
in	O
migration	O
associated	O
with	O
increased	S-Positive_regulation
c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
src	E-Gene_or_gene_product
expression	S-Gene_expression
.	O

These	O
data	O
suggest	O
that	O
increases	S-Positive_regulation
in	O
endothelial	B-Cell
cell	E-Cell
migration	S-Localization
and	O
plasminogen	B-Gene_or_gene_product
activator	E-Gene_or_gene_product
after	O
angiotensin	S-Gene_or_gene_product
system	S-Pathway
inhibition	S-Negative_regulation
are	O
at	O
least	O
partially	O
pp60c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
src	E-Gene_or_gene_product
mediated	S-Regulation
.	O

Elevated	S-Positive_regulation
c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
src	E-Gene_or_gene_product
expression	S-Gene_expression
with	O
angiotensin	S-Gene_or_gene_product
system	S-Pathway
inhibition	S-Negative_regulation
may	O
act	O
to	O
enhance	O
intimal	O
wound	O
closure	O
and	O
to	O
reduce	O
luminal	O
thrombogenicity	O
in	O
vivo	O
.	O

Angiogenesis	S-Blood_vessel_development
-	O
-	O
biomedical	O
technology	O
.	O

All	O
of	O
these	O
studies	O
show	O
that	O
angiogenesis	S-Blood_vessel_development
research	O
can	O
benefit	O
from	O
new	O
biomedical	O
technology	O
tools	O
currently	O
being	O
developed	O
,	O
as	O
well	O
as	O
contribute	O
by	O
providing	O
new	O
technologies	O
that	O
can	O
be	O
used	O
in	O
other	O
areas	O
of	O
medicine	O
.	O

It	O
is	O
hoped	O
that	O
the	O
chapters	O
in	O
this	O
book	O
in	O
this	O
area	O
will	O
provide	O
the	O
reader	O
with	O
an	O
up	O
-	O
to	O
-	O
date	O
appreciation	O
of	O
some	O
of	O
the	O
exciting	O
research	O
that	O
is	O
currently	O
being	O
pursued	O
.	O

Interleukin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
receptor	I-Gene_or_gene_product
antagonist	E-Gene_or_gene_product
inhibits	S-Negative_regulation
ischaemic	O
and	O
excitotoxic	O
neuronal	S-Cell
damage	S-Breakdown
in	O
the	O
rat	S-Organism
.	O

Interleukin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
(	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
)	O
synthesis	S-Gene_expression
in	O
the	O
brain	S-Organ
is	O
stimulated	S-Positive_regulation
by	O
mechanical	O
injury	O
and	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
mimics	O
some	O
effects	O
of	O
injury	O
,	O
such	O
as	O
gliosis	O
and	O
neovascularization	S-Blood_vessel_development
.	O

We	O
report	O
that	O
neuronal	S-Cell
death	S-Death
resulting	O
from	O
focal	O
cerebral	O
ischaemia	O
(	O
middle	O
cerebral	B-Multi-tissue_structure
artery	E-Multi-tissue_structure
occlusion	O
,	O
24	O
h	O
)	O
is	O
significantly	O
inhibited	S-Negative_regulation
(	O
by	O
50	O
%	O
)	O
in	O
rats	S-Organism
injected	S-Planned_process
with	O
a	O
recombinant	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
receptor	I-Gene_or_gene_product
antagonist	E-Gene_or_gene_product
(	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1ra	E-Gene_or_gene_product
,	O
10	O
micrograms	O
,	O
icv	O
30	O
min	O
before	O
and	O
10	O
min	O
after	O
ischaemia	O
)	O
.	O

Excitotoxic	O
damage	O
due	O
to	O
striatal	O
infusion	S-Planned_process
of	O
an	O
NMDA	S-Drug_or_compound
-	O
receptor	O
agonist	O
(	O
cis	B-Drug_or_compound
-	I-Drug_or_compound
2	I-Drug_or_compound
,	I-Drug_or_compound
4	I-Drug_or_compound
-	I-Drug_or_compound
methanoglutamate	E-Drug_or_compound
)	O
was	O
also	O
markedly	O
inhibited	O
(	O
71	O
%	O
)	O
by	O
injection	S-Planned_process
of	O
the	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1ra	E-Gene_or_gene_product
.	O

These	O
data	O
indicate	O
that	O
endogenous	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
is	O
a	O
mediator	S-Positive_regulation
of	O
ischaemic	O
and	O
excitotoxic	O
brain	S-Organ
damage	S-Breakdown
,	O
and	O
that	O
inhibitors	O
of	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
action	O
may	O
be	O
of	O
therapeutic	O
value	O
in	O
the	O
treatment	O
of	O
acute	O
or	O
chronic	O
neuronal	S-Cell
death	S-Death
.	O

Laser	O
treatment	O
of	O
eccentric	O
leaks	O
in	O
central	O
serous	O
chorioretinopathy	O
resulting	O
in	O
disappearance	O
of	O
untreated	O
juxtafoveal	O
leaks	O
.	O

In	O
central	O
serous	O
chorioretinopathy	O
(	O
CSCR	O
)	O
laser	O
treatment	O
of	O
leaking	O
points	O
close	O
to	O
the	O
macular	B-Tissue
center	E-Tissue
should	O
be	O
avoided	O
because	O
of	O
the	O
possibility	O
of	O
producing	O
juxtafoveal	O
scotoma	O
and	O
stimulating	S-Positive_regulation
choroidal	O
neovascularization	S-Blood_vessel_development
.	O

Nine	O
eyes	S-Organ
of	O
nine	O
consecutive	O
patients	S-Organism
with	O
CSCR	O
had	O
two	O
or	O
more	O
leaking	O
points	O
within	O
a	O
macular	S-Tissue
detachment	S-Breakdown
,	O
one	O
of	O
which	O
was	O
foveal	S-Tissue
or	O
near	O
to	O
the	O
fovea	S-Tissue
.	O

Photocoagulation	O
with	O
green	O
argon	O
laser	O
was	O
performed	O
in	O
all	O
eyes	S-Organ
,	O
treating	O
all	O
the	O
leaking	O
points	O
except	O
for	O
the	O
central	O
one	O
.	O

Visual	O
symptoms	O
regressed	O
after	O
treatment	O
,	O
and	O
the	O
serous	S-Organism_substance
detachment	O
was	O
resolved	O
10	O
days	O
to	O
4	O
weeks	O
after	O
photocoagulation	O
in	O
all	O
cases	O
.	O

Fluorescein	S-Drug_or_compound
angiography	O
showed	O
no	O
leakage	O
at	O
either	O
the	O
central	O
leakage	O
point	O
or	O
the	O
leakage	O
point	O
that	O
had	O
been	O
treated	O
.	O

These	O
results	O
led	O
us	O
to	O
believe	O
that	O
the	O
central	O
or	O
dependent	O
leak	O
in	O
our	O
cases	O
was	O
not	O
sufficient	O
to	O
maintain	O
the	O
serous	S-Organism_substance
detachment	O
by	O
itself	O
.	O

An	O
alternative	O
hypothesis	O
is	O
that	O
the	O
untreated	O
leak	O
did	O
not	O
represent	O
real	O
fluid	O
movement	O
but	O
only	O
diffusion	O
of	O
fluorescein	S-Drug_or_compound
molecules	O
,	O
or	O
a	O
false	O
leak	O
.	O

In	O
cases	O
of	O
CSCR	O
with	O
multiple	O
leaks	O
within	O
a	O
single	O
macular	S-Tissue
detachment	S-Breakdown
,	O
we	O
believe	O
that	O
a	O
foveal	S-Tissue
leak	O
may	O
be	O
a	O
dependent	O
or	O
false	O
leak	O
and	O
that	O
direct	O
treatment	O
is	O
not	O
necessary	O
.	O

Transcriptional	S-Transcription
and	O
post	B-Protein_processing
-	I-Protein_processing
translation	E-Protein_processing
regulation	S-Regulation
of	O
the	O
Tie1	B-Gene_or_gene_product
receptor	E-Gene_or_gene_product
by	O
fluid	O
shear	O
stress	O
changes	O
in	O
vascular	B-Cell
endothelial	I-Cell
cells	E-Cell
.	O

The	O
interaction	O
between	O
the	O
vascular	B-Tissue
endothelium	E-Tissue
and	O
hemodynamic	O
forces	O
(	O
and	O
more	O
specifically	O
,	O
fluid	O
shear	O
stress	O
)	O
,	O
induced	O
by	O
the	O
flow	O
of	O
blood	S-Organism_substance
,	O
plays	B-Regulation
a	I-Regulation
major	I-Regulation
role	E-Regulation
in	O
vascular	S-Multi-tissue_structure
remodeling	S-Remodeling
and	O
in	O
new	O
blood	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
formation	S-Development
via	S-Regulation
a	O
process	O
termed	O
arteriogenesis	S-Blood_vessel_development
.	O

Tie1	S-Gene_or_gene_product
is	O
an	O
orphan	O
tyrosine	O
kinase	O
receptor	O
expressed	S-Gene_expression
almost	O
exclusively	O
in	O
endothelial	B-Cell
cells	E-Cell
and	O
is	O
required	S-Positive_regulation
for	O
normal	O
vascular	S-Multi-tissue_structure
development	S-Development
and	O
maintenance	S-Regulation
.	O

The	O
present	O
study	O
demonstrates	O
that	O
Tie1	S-Gene_or_gene_product
expression	S-Gene_expression
is	O
rapidly	O
down	B-Negative_regulation
-	I-Negative_regulation
regulated	E-Negative_regulation
in	O
endothelial	B-Cell
cells	E-Cell
exposed	S-Planned_process
to	O
shear	O
stress	O
,	O
and	O
more	O
so	O
to	O
shear	O
stress	O
changes	O
.	O

This	O
down	B-Negative_regulation
-	I-Negative_regulation
regulation	E-Negative_regulation
is	O
accompanied	O
by	O
a	O
rapid	O
cleavage	S-Catabolism
of	O
Tie1	S-Gene_or_gene_product
and	O
binding	S-Binding
of	O
the	O
cleaved	S-Catabolism
Tie1	S-Gene_or_gene_product
45	B-Protein_domain_or_region
kDa	I-Protein_domain_or_region
endodomain	E-Protein_domain_or_region
to	O
Tie2	S-Gene_or_gene_product
.	O

The	O
rapid	O
cleavage	S-Catabolism
of	O
Tie1	S-Gene_or_gene_product
is	O
followed	O
by	O
a	O
transcriptional	S-Transcription
down	B-Negative_regulation
-	I-Negative_regulation
regulation	E-Negative_regulation
in	O
response	O
to	O
shear	O
stress	O
.	O

The	O
activity	O
of	O
the	O
Tie1	S-Gene_or_gene_product
promoter	S-DNA_domain_or_region
is	O
suppressed	S-Negative_regulation
by	O
shear	O
stress	O
and	O
by	O
tumor	B-Gene_or_gene_product
necrosis	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
alpha	E-Gene_or_gene_product
.	O

Shear	O
stress	O
-	O
induced	S-Positive_regulation
transcriptional	S-Transcription
suppression	S-Negative_regulation
of	O
Tie1	S-Gene_or_gene_product
is	O
mediated	S-Regulation
by	O
a	O
negative	B-DNA_domain_or_region
shear	I-DNA_domain_or_region
stress	I-DNA_domain_or_region
response	I-DNA_domain_or_region
element	E-DNA_domain_or_region
,	O
localized	O
in	O
a	O
region	O
of	O
250	O
bp	O
within	O
the	O
promoter	O
.	O

The	O
rapid	O
down	B-Negative_regulation
-	I-Negative_regulation
regulation	E-Negative_regulation
of	O
Tie1	S-Gene_or_gene_product
by	O
shear	O
stress	O
changes	O
and	O
its	O
rapid	O
binding	S-Binding
to	O
Tie2	S-Gene_or_gene_product
may	O
be	O
required	S-Positive_regulation
for	O
destabilization	S-Negative_regulation
of	O
endothelial	B-Cell
cells	E-Cell
in	O
order	O
to	O
initiate	S-Positive_regulation
the	O
process	O
of	O
vascular	S-Multi-tissue_structure
restructuring	S-Remodeling
.	O

Therapeutic	O
angiogenesis	S-Blood_vessel_development
:	O
a	O
complex	O
problem	O
requiring	O
a	O
sophisticated	O
approach	O
.	O

Blood	S-Organism_substance
and	O
vascular	S-Multi-tissue_structure
disorders	O
underlie	O
a	O
plethora	O
of	O
pathologic	O
conditions	O
and	O
are	O
the	O
single	O
most	O
frequent	O
cause	O
of	O
human	S-Organism
disease	O
.	O

Ischemia	O
,	O
involving	O
restricted	O
blood	S-Organism_substance
flow	O
to	O
tissues	S-Tissue
is	O
the	O
most	O
common	O
consequence	O
of	O
vessel	S-Multi-tissue_structure
dysfunction	S-Breakdown
resulting	O
in	O
the	O
disruption	S-Catabolism
of	O
oxygen	S-Drug_or_compound
and	O
nutrient	O
delivery	O
and	O
the	O
accumulation	O
of	O
waste	O
metabolites	O
.	O

Cells	S-Cell
cannot	O
survive	S-Death
extended	O
severe	O
ischemia	O
but	O
may	O
be	O
able	O
to	O
adapt	O
to	O
a	O
moderate	O
condition	O
where	O
diffusion	O
to	O
and	O
from	O
bordering	O
nonischemic	O
regions	O
sustains	O
vital	O
functions	O
.	O

Under	O
this	O
condition	O
,	O
the	O
secondary	O
functions	O
of	O
effected	S-Regulation
cells	S-Cell
are	O
likely	O
to	O
be	O
impaired	O
,	O
and	O
a	O
new	O
metabolic	O
equilibrium	O
is	O
established	O
,	O
determined	O
by	O
the	O
level	O
of	O
cross	O
-	O
diffusion	O
and	O
degree	O
of	O
hypoxia	O
.	O

In	O
tissues	S-Tissue
with	O
a	O
normally	O
high	O
metabolic	O
turnover	O
such	O
as	O
skeletal	S-Tissue
and	O
cardiac	B-Tissue
muscle	E-Tissue
,	O
even	O
mild	O
ischemia	O
causes	O
hypoxia	O
,	O
acidosis	O
,	O
and	O
depressed	O
function	O
(	O
contractility	O
)	O
and	O
eventually	O
threatens	O
myocyte	S-Cell
viability	O
and	O
organ	S-Organ
function	O
.	O

Ischemic	O
cardiac	B-Tissue
muscle	E-Tissue
is	O
additionally	O
vulnerable	O
because	O
reperfusion	O
is	O
essential	O
for	O
survival	O
but	O
reperfusion	O
itself	O
poses	O
additional	O
stress	O
principally	O
from	O
increased	O
production	O
of	O
free	O
radicals	O
during	O
reoxygenation	O
.	O

The	O
latter	O
effect	O
is	O
called	O
reperfusion	O
injury	O
and	O
can	O
cause	O
as	O
much	O
damage	O
as	O
the	O
ischemia	O
.	O

The	O
treatment	O
possibilities	O
for	O
ischemia	O
-	O
related	O
vascular	O
disease	O
are	O
limited	O
.	O

Lipid	S-Drug_or_compound
/	O
cholesterol	S-Drug_or_compound
-	O
lowering	O
agents	O
,	O
diet	O
and	O
antiplatelet	O
adherence	O
(	O
aspirin	S-Drug_or_compound
)	O
therapy	S-Planned_process
may	O
help	O
slow	O
the	O
progression	O
of	O
vessel	S-Multi-tissue_structure
disease	O
in	O
some	O
instances	O
;	O
but	O
surgical	O
reconstruction	O
may	O
be	O
the	O
only	O
option	O
in	O
advanced	O
stages	O
,	O
and	O
even	O
this	O
is	O
not	O
always	O
an	O
option	O
.	O

An	O
alternative	O
and	O
rather	O
obvious	O
strategy	O
to	O
treat	O
ischemia	O
is	O
to	O
activate	S-Positive_regulation
endogenous	O
angiogenic	S-Blood_vessel_development
or	O
arteriogenic	B-Blood_vessel_development
pathways	E-Blood_vessel_development
to	O
stimulate	S-Positive_regulation
revascularization	S-Blood_vessel_development
of	O
the	O
tissue	S-Tissue
.	O

The	O
feasibility	O
of	O
such	O
a	O
strategy	O
has	O
now	O
been	O
established	O
through	O
the	O
results	O
of	O
studies	O
over	O
the	O
past	O
decade	O
,	O
and	O
a	O
new	O
discipline	O
called	O
therapeutic	O
angiogenesis	S-Blood_vessel_development
has	O
emerged	O
.	O

This	O
review	O
focuses	O
on	O
the	O
application	O
of	O
therapeutic	O
angiogenesis	S-Blood_vessel_development
for	O
treating	O
ischemic	O
muscle	S-Organ
disease	O
and	O
includes	O
a	O
critical	O
evaluation	O
of	O
the	O
parameters	O
and	O
limitations	O
of	O
current	O
procedures	O
.	O

The	O
development	O
of	O
this	O
technology	O
has	O
benefited	O
from	O
its	O
application	O
to	O
both	O
peripheral	S-Multi-tissue_structure
and	O
coronary	B-Multi-tissue_structure
artery	E-Multi-tissue_structure
disease	O
and	O
results	O
from	O
both	O
are	O
reviewed	O
here	O
.	O

Cell	S-Cell
type	O
-	O
specific	O
regulation	O
of	O
angiogenic	S-Blood_vessel_development
growth	O
factor	O
gene	O
expression	O
and	O
induction	S-Positive_regulation
of	O
angiogenesis	S-Blood_vessel_development
in	O
nonischemic	B-Tissue
tissue	E-Tissue
by	O
a	O
constitutively	O
active	O
form	O
of	O
hypoxia	B-Gene_or_gene_product
-	I-Gene_or_gene_product
inducible	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
1	E-Gene_or_gene_product
.	O

Understanding	O
molecular	O
mechanisms	O
regulating	S-Regulation
angiogenesis	S-Blood_vessel_development
may	O
lead	O
to	O
novel	O
therapies	O
for	O
ischemic	O
disorders	O
.	O

Hypoxia	B-Gene_or_gene_product
-	I-Gene_or_gene_product
inducible	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
1	E-Gene_or_gene_product
(	O
HIF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
)	O
activates	S-Positive_regulation
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
(	O
VEGF	S-Gene_or_gene_product
)	O
gene	O
expression	S-Gene_expression
in	O
hypoxic	S-Tissue
/	O
ischemic	B-Tissue
tissue	E-Tissue
.	O

In	O
this	O
study	O
we	O
demonstrate	O
that	O
exposure	S-Planned_process
of	O
primary	O
cultures	O
of	O
cardiac	S-Cell
and	O
vascular	B-Cell
cells	E-Cell
to	O
hypoxia	O
or	O
AdCA5	S-Organism
,	O
an	O
adenovirus	O
encoding	O
a	O
constitutively	O
active	O
form	O
of	O
HIF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1alpha	E-Gene_or_gene_product
,	O
modulates	S-Regulation
the	O
expression	S-Gene_expression
of	O
genes	O
encoding	O
the	O
angiogenic	S-Blood_vessel_development
factors	O
angiopoietin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
(	O
ANGPT1	S-Gene_or_gene_product
)	O
,	O
ANGPT2	S-Gene_or_gene_product
,	O
placental	B-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
,	O
and	O
platelet	B-Gene_or_gene_product
-	I-Gene_or_gene_product
derived	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
-	I-Gene_or_gene_product
B	E-Gene_or_gene_product
.	O

Loss	O
-	O
of	O
-	O
function	O
effects	O
were	O
also	O
observed	O
in	O
HIF	B-Cell
-	I-Cell
1alpha	I-Cell
-	I-Cell
null	I-Cell
embryonic	I-Cell
stem	I-Cell
cells	E-Cell
.	O

Depending	O
on	O
the	O
cell	S-Cell
type	O
,	O
expression	S-Gene_expression
of	O
ANGPT1	S-Gene_or_gene_product
and	O
ANGPT2	S-Gene_or_gene_product
was	O
either	O
activated	S-Positive_regulation
or	O
repressed	S-Negative_regulation
in	O
response	O
to	O
hypoxia	O
or	O
AdCA5	S-Organism
.	O

In	O
all	O
cases	O
,	O
there	O
was	O
complete	O
concordance	O
between	O
the	O
effects	O
of	O
hypoxia	O
and	O
AdCA5	S-Organism
.	O

Injection	S-Planned_process
of	O
AdCA5	S-Organism
into	O
mouse	S-Organism
eyes	S-Organ
induced	S-Positive_regulation
neovascularization	S-Blood_vessel_development
in	O
multiple	O
capillary	B-Multi-tissue_structure
beds	E-Multi-tissue_structure
,	O
including	O
those	O
not	O
responsive	O
to	O
VEGF	S-Gene_or_gene_product
alone	O
.	O

Analysis	O
of	O
gene	O
expression	O
revealed	O
increased	S-Positive_regulation
expression	S-Transcription
of	O
ANGPT1	S-Gene_or_gene_product
,	O
ANGPT2	S-Gene_or_gene_product
,	O
platelet	B-Gene_or_gene_product
-	I-Gene_or_gene_product
derived	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
-	I-Gene_or_gene_product
B	E-Gene_or_gene_product
,	O
placental	B-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
,	O
and	O
VEGF	S-Gene_or_gene_product
mRNA	O
in	O
AdCA5	S-Organism
-	O
injected	S-Planned_process
eyes	S-Organ
.	O

These	O
results	O
indicate	O
that	O
HIF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
functions	O
as	O
a	O
master	O
regulator	S-Regulation
of	O
angiogenesis	S-Blood_vessel_development
by	O
controlling	S-Regulation
the	O
expression	O
of	O
multiple	O
angiogenic	S-Blood_vessel_development
growth	O
factors	O
and	O
that	O
adenovirus	O
-	O
mediated	O
expression	S-Gene_expression
of	O
a	O
constitutively	O
active	O
form	O
of	O
HIF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1alpha	E-Gene_or_gene_product
is	O
sufficient	O
to	O
induce	S-Positive_regulation
angiogenesis	S-Blood_vessel_development
in	O
nonischemic	B-Tissue
tissue	E-Tissue
of	O
an	O
adult	O
animal	O
.	O

Differential	O
regulation	S-Regulation
of	O
in	O
vivo	O
angiogenesis	S-Blood_vessel_development
by	O
angiotensin	B-Gene_or_gene_product
II	I-Gene_or_gene_product
receptors	E-Gene_or_gene_product
.	O

Angiotensin	B-Gene_or_gene_product
II	E-Gene_or_gene_product
(	O
ANG	B-Gene_or_gene_product
II	E-Gene_or_gene_product
)	O
,	O
a	O
key	O
regulator	O
of	O
blood	S-Organism_substance
pressure	O
and	O
body	O
fluid	O
homeostasis	O
,	O
exerts	B-Regulation
mitogenic	I-Regulation
effects	E-Regulation
on	O
endothelial	B-Cell
cells	E-Cell
.	O

We	O
therefore	O
hypothesized	O
that	O
ANG	B-Gene_or_gene_product
II	E-Gene_or_gene_product
could	O
be	O
a	O
mediator	S-Regulation
between	O
homeostatic	O
changes	S-Regulation
within	O
the	O
vascular	B-Multi-tissue_structure
perfusion	I-Multi-tissue_structure
bed	E-Multi-tissue_structure
and	O
growth	O
factor	O
-	O
driven	O
angiogenesis	S-Blood_vessel_development
.	O

In	O
the	O
present	O
study	O
,	O
we	O
applied	O
the	O
alginate	S-Drug_or_compound
implant	S-Planned_process
angiogenesis	S-Blood_vessel_development
model	O
in	O
mice	S-Organism
with	O
normal	O
ANG	B-Gene_or_gene_product
II	E-Gene_or_gene_product
levels	O
,	O
elevated	S-Positive_regulation
ANG	B-Gene_or_gene_product
II	E-Gene_or_gene_product
levels	O
by	O
transgenic	O
overexpression	S-Gene_expression
of	O
angiotensinogen	S-Gene_or_gene_product
(	O
AOGEN	S-Gene_or_gene_product
)	O
,	O
or	O
in	O
AT2	B-Gene_or_gene_product
receptor	E-Gene_or_gene_product
-	O
deficient	S-Gene_expression
mice	S-Organism
.	O

We	O
demonstrate	O
that	O
a	O
decrease	S-Negative_regulation
in	O
the	O
amount	O
of	O
circulating	O
ANG	B-Gene_or_gene_product
II	E-Gene_or_gene_product
by	O
the	O
angiotensin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
converting	I-Gene_or_gene_product
enzyme	E-Gene_or_gene_product
(	O
ACE	S-Gene_or_gene_product
)	O
inhibitor	O
enalapril	S-Drug_or_compound
or	O
the	O
AT1	B-Gene_or_gene_product
receptor	E-Gene_or_gene_product
antagonist	O
losartan	S-Drug_or_compound
induced	S-Positive_regulation
a	O
stimulation	S-Positive_regulation
of	O
in	O
vivo	O
angiogenesis	S-Blood_vessel_development
implying	O
an	O
inhibitory	O
function	O
of	O
ANG	B-Gene_or_gene_product
II	E-Gene_or_gene_product
through	O
the	O
AT1	B-Gene_or_gene_product
receptor	E-Gene_or_gene_product
.	O

However	O
,	O
the	O
strong	O
increase	S-Positive_regulation
of	O
angiogenesis	S-Blood_vessel_development
in	O
AOGEN	S-Gene_or_gene_product
-	O
transgenic	O
mice	S-Organism
compared	O
with	O
mice	S-Organism
with	O
normal	O
ANG	B-Gene_or_gene_product
II	E-Gene_or_gene_product
levels	O
suggests	O
additional	O
stimulatory	O
activity	O
.	O

We	O
showed	O
that	O
the	O
ANG	B-Gene_or_gene_product
II	E-Gene_or_gene_product
-	O
induced	S-Positive_regulation
stimulation	S-Positive_regulation
of	O
angiogenesis	S-Blood_vessel_development
is	O
linked	O
to	O
the	O
AT2	B-Gene_or_gene_product
receptor	E-Gene_or_gene_product
as	O
an	O
impaired	S-Negative_regulation
induction	S-Positive_regulation
of	O
angiogenesis	S-Blood_vessel_development
was	O
obtained	O
in	O
AT2	B-Organism
receptor	I-Organism
knockout	I-Organism
mice	E-Organism
.	O

These	O
findings	O
provide	O
the	O
first	O
evidence	O
that	O
the	O
AT2	B-Gene_or_gene_product
receptor	E-Gene_or_gene_product
mediates	S-Regulation
a	O
stimulation	S-Positive_regulation
of	O
in	O
vivo	O
angiogenesis	S-Blood_vessel_development
and	O
indicate	O
that	O
ANG	B-Gene_or_gene_product
II	E-Gene_or_gene_product
is	O
a	O
humoral	O
regulator	O
of	O
peripheral	O
angiogenesis	S-Blood_vessel_development
involving	O
two	O
receptor	O
subtypes	O
with	O
opposing	O
actions	O
.	O

Expression	S-Gene_expression
,	O
regulation	S-Regulation
,	O
and	O
function	O
of	O
IGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
,	O
IGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1R	E-Gene_or_gene_product
,	O
and	O
IGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
binding	I-Gene_or_gene_product
proteins	E-Gene_or_gene_product
in	O
blood	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
.	O

The	O
vascular	O
insulin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
like	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
(	I-Gene_or_gene_product
IGF	I-Gene_or_gene_product
)	I-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
system	S-Pathway
includes	O
the	O
IGFs	S-Gene_or_gene_product
,	O
the	O
IGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
receptor	E-Gene_or_gene_product
(	O
IGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1R	E-Gene_or_gene_product
)	O
,	O
and	O
multiple	O
binding	O
proteins	O
.	O

This	O
growth	O
factor	O
system	O
exerts	O
multiple	O
physiologic	O
effects	O
on	O
the	O
vasculature	S-Anatomical_system
through	O
both	O
endocrine	O
and	O
autocrine	O
/	O
paracrine	O
mechanisms	O
.	O

The	O
effects	O
of	O
IGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
are	O
mediated	S-Regulation
principally	O
through	O
the	O
IGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1R	E-Gene_or_gene_product
but	O
are	O
modulated	O
by	O
complex	O
interactions	S-Binding
with	O
multiple	O
IGF	B-Gene_or_gene_product
binding	I-Gene_or_gene_product
proteins	E-Gene_or_gene_product
that	O
themselves	O
are	O
regulated	S-Regulation
by	O
phosphorylation	S-Phosphorylation
,	O
proteolysis	S-Catabolism
,	O
polymerization	S-Binding
,	O
and	O
cell	S-Cell
or	O
matrix	S-Cellular_component
association	S-Binding
.	O

During	O
the	O
last	O
decade	O
,	O
a	O
significant	O
body	O
of	O
evidence	O
has	O
accumulated	O
,	O
indicating	O
that	O
expression	O
of	O
the	O
components	O
of	O
the	O
IGF	S-Gene_or_gene_product
system	S-Pathway
are	O
regulated	O
by	O
multiple	O
factors	O
,	O
including	O
growth	O
factors	O
,	O
cytokines	O
,	O
lipoproteins	O
,	O
reactive	O
oxygen	S-Drug_or_compound
species	O
,	O
and	O
hemodynamic	O
forces	O
.	O

In	O
addition	O
,	O
cross	O
-	O
talk	O
between	O
the	O
IGF	S-Gene_or_gene_product
system	S-Pathway
and	O
other	O
growth	O
factors	O
and	O
integrin	S-Gene_or_gene_product
receptors	O
has	O
been	O
demonstrated	O
.	O

There	O
is	O
accumulating	O
evidence	O
of	O
a	O
role	S-Regulation
for	O
IGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
in	O
multiple	O
vascular	O
pathologies	O
,	O
including	O
atherosclerosis	O
,	O
hypertension	O
,	O
restenosis	O
,	O
angiogenesis	S-Blood_vessel_development
,	O
and	O
diabetic	O
vascular	O
disease	O
.	O

This	O
review	O
will	O
discuss	O
the	O
regulation	S-Regulation
of	O
expression	S-Gene_expression
of	O
IGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
,	O
IGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1R	E-Gene_or_gene_product
,	O
and	O
IGF	B-Gene_or_gene_product
binding	I-Gene_or_gene_product
proteins	E-Gene_or_gene_product
in	O
the	O
vasculature	S-Anatomical_system
and	O
summarize	O
evidence	O
implicating	O
involvement	O
of	O
this	O
system	O
in	O
vascular	O
diseases	O
.	O

Angiopoietin	S-Gene_or_gene_product
/	O
tie	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
as	O
mediators	O
of	O
angiogenesis	S-Blood_vessel_development
:	O
a	O
role	O
in	O
congestive	O
heart	S-Organ
failure	O
?	O

Angiogenic	S-Blood_vessel_development
factors	O
,	O
in	O
particular	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
(	O
VEGF	S-Gene_or_gene_product
)	O
and	O
the	O
angiopoietins	S-Gene_or_gene_product
,	O
Ang	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
and	O
-	B-Gene_or_gene_product
2	E-Gene_or_gene_product
,	O
have	O
recently	O
generated	O
significant	O
interest	O
,	O
especially	O
in	O
oncology	O
.	O

The	O
process	O
of	O
angiogenesis	S-Blood_vessel_development
is	O
also	O
thought	O
to	O
occur	O
in	O
response	O
to	O
ischaemic	O
conditions	O
,	O
which	O
lie	O
at	O
the	O
core	O
of	O
cardiovascular	O
disease	O
states	O
such	O
as	O
coronary	B-Multi-tissue_structure
artery	E-Multi-tissue_structure
disease	O
and	O
congestive	O
heart	S-Organ
failure	O
.	O

However	O
,	O
current	O
data	O
do	O
not	O
conclusively	O
show	O
evidence	O
of	O
angiogenesis	S-Blood_vessel_development
per	O
se	O
in	O
these	O
conditions	O
,	O
despite	O
(	O
for	O
example	O
)	O
the	O
presence	S-Localization
of	O
high	O
levels	O
of	O
VEGF	S-Gene_or_gene_product
and	O
Ang	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
.	O

High	O
levels	O
of	O
these	O
angiogenic	S-Blood_vessel_development
factors	O
in	O
heart	S-Organ
disease	O
also	O
have	O
not	O
translated	O
into	O
clinically	O
significant	O
new	O
vessel	S-Multi-tissue_structure
formation	S-Development
,	O
as	O
in	O
accelerated	S-Positive_regulation
cancer	S-Pathological_formation
growth	S-Growth
or	O
proliferative	O
retinopathy	O
.	O

Indeed	O
,	O
we	O
would	O
hypothesize	O
that	O
these	O
angiogenic	S-Blood_vessel_development
markers	O
-	O
-	O
especially	O
the	O
angiopoietins	S-Gene_or_gene_product
-	O
-	O
do	O
not	O
necessarily	O
translate	S-Regulation
into	O
new	O
vessel	S-Multi-tissue_structure
formation	S-Development
in	O
congestive	O
heart	S-Organ
failure	O
(	O
CHF	O
)	O
,	O
but	O
may	O
well	O
reflect	S-Regulation
disturbances	S-Breakdown
of	O
endothelial	S-Tissue
integrity	O
in	O
CHF	O
.	O

Morphogenesis	S-Development
of	O
embryonic	B-Multi-tissue_structure
CNS	I-Multi-tissue_structure
vessels	E-Multi-tissue_structure
.	O

This	O
chapter	O
focuses	O
on	O
the	O
morphology	O
of	O
blood	B-Multi-tissue_structure
vessel	E-Multi-tissue_structure
formation	S-Development
in	O
and	O
around	O
the	O
early	O
central	B-Anatomical_system
nervous	I-Anatomical_system
system	E-Anatomical_system
(	O
CNS	S-Anatomical_system
,	O
i	O
.	O
e	O
.	O
,	O
brain	S-Organ
and	O
spinal	B-Organ
cord	E-Organ
)	O
of	O
avian	S-Organism
embryos	S-Developing_anatomical_structure
.	O

We	O
discuss	O
cell	S-Cell
lineages	O
,	O
proliferation	S-Cell_proliferation
and	O
interactions	S-Binding
of	O
endothelial	B-Cell
cells	E-Cell
,	O
pericytes	S-Cell
and	O
smooth	B-Cell
muscle	I-Cell
cells	E-Cell
,	O
and	O
macrophages	S-Cell
.	O

Due	O
to	O
space	O
limitations	O
,	O
we	O
can	O
not	O
review	O
the	O
molecular	O
control	S-Regulation
of	O
CNS	S-Anatomical_system
angiogenesis	S-Blood_vessel_development
,	O
but	O
refer	O
the	O
reader	O
to	O
other	O
chapters	O
in	O
this	O
book	O
and	O
to	O
recent	O
publications	O
on	O
the	O
assembly	S-Development
of	O
the	O
vasculature	S-Multi-tissue_structure
(	O
1	O
,	O
2	O
)	O
.	O

The	O
candidate	O
tumour	S-Pathological_formation
suppressor	S-Negative_regulation
protein	O
ING4	S-Gene_or_gene_product
regulates	S-Regulation
brain	B-Pathological_formation
tumour	E-Pathological_formation
growth	S-Growth
and	O
angiogenesis	S-Blood_vessel_development
.	O

Gliomas	S-Pathological_formation
are	O
the	O
most	O
common	O
primary	O
tumours	S-Pathological_formation
of	O
the	O
central	B-Anatomical_system
nervous	I-Anatomical_system
system	E-Anatomical_system
,	O
with	O
nearly	O
15	O
,	O
000	O
diagnosed	O
annually	O
in	O
the	O
United	O
States	O
and	O
a	O
lethality	O
approaching	O
80	O
%	O
within	O
the	O
first	O
year	O
of	O
glioblastoma	S-Pathological_formation
diagnosis	O
.	O

The	O
marked	O
induction	S-Positive_regulation
of	O
angiogenesis	S-Blood_vessel_development
in	O
glioblastomas	S-Pathological_formation
suggests	O
that	O
it	O
is	O
a	O
necessary	O
part	O
of	O
malignant	B-Development
progression	E-Development
;	O
however	O
,	O
the	O
precise	O
molecular	O
mechanisms	O
underlying	O
the	O
regulation	S-Regulation
of	O
brain	B-Pathological_formation
tumour	E-Pathological_formation
growth	S-Growth
and	O
angiogenesis	S-Blood_vessel_development
remain	O
unresolved	O
.	O

Here	O
we	O
report	O
that	O
a	O
candidate	O
tumour	S-Pathological_formation
suppressor	O
gene	O
,	O
ING4	S-Gene_or_gene_product
,	O
is	O
involved	O
in	O
regulating	S-Regulation
brain	B-Pathological_formation
tumour	E-Pathological_formation
growth	S-Growth
and	O
angiogenesis	S-Blood_vessel_development
.	O

Expression	S-Gene_expression
of	O
ING4	S-Gene_or_gene_product
is	O
significantly	O
reduced	S-Negative_regulation
in	O
gliomas	S-Pathological_formation
as	O
compared	O
with	O
normal	O
human	S-Organism
brain	B-Tissue
tissue	E-Tissue
,	O
and	O
the	O
extent	O
of	O
reduction	S-Negative_regulation
correlates	O
with	O
the	O
progression	S-Development
from	O
lower	O
to	O
higher	O
grades	O
of	O
tumours	S-Pathological_formation
.	O

In	O
mice	S-Organism
,	O
xenografts	O
of	O
human	S-Organism
glioblastoma	B-Pathological_formation
U87MG	E-Pathological_formation
,	O
which	O
has	O
decreased	S-Negative_regulation
expression	S-Gene_expression
of	O
ING4	S-Gene_or_gene_product
,	O
grow	S-Growth
significantly	O
faster	O
and	O
have	O
higher	O
vascular	S-Multi-tissue_structure
volume	O
fractions	O
than	O
control	O
tumours	S-Pathological_formation
.	O

We	O
show	O
that	O
ING4	S-Gene_or_gene_product
physically	O
interacts	S-Binding
with	O
p65	S-Gene_or_gene_product
(	O
RelA	S-Gene_or_gene_product
)	O
subunit	O
of	O
nuclear	O
factor	O
NF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
kappaB	E-Gene_or_gene_product
,	O
and	O
that	O
ING4	S-Gene_or_gene_product
regulates	S-Regulation
brain	B-Pathological_formation
tumour	E-Pathological_formation
angiogenesis	S-Blood_vessel_development
through	O
transcriptional	O
repression	O
of	O
NF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
kappaB	E-Gene_or_gene_product
-	O
responsive	O
genes	O
.	O

These	O
results	O
indicate	O
that	O
ING4	S-Gene_or_gene_product
has	B-Regulation
an	I-Regulation
important	I-Regulation
role	E-Regulation
in	O
brain	B-Pathological_formation
tumour	E-Pathological_formation
pathogenesis	S-Development
.	O

TGFbeta1	S-Gene_or_gene_product
,	O
back	O
to	O
the	O
future	O
:	O
revisiting	O
its	O
role	O
as	O
a	O
transforming	O
growth	O
factor	O
.	O

TGFbeta1	S-Gene_or_gene_product
was	O
initially	O
identified	O
in	O
culture	O
media	O
from	O
transformed	B-Cell
cells	E-Cell
as	O
part	O
of	O
a	O
factor	O
that	O
could	O
produce	O
a	O
transformed	O
phenotype	O
in	O
a	O
nontransformed	B-Cell
cell	E-Cell
line	O
.	O

Subsequently	O
this	O
activity	O
was	O
separated	O
into	O
TGFbeta	S-Gene_or_gene_product
and	O
TGFalpha	S-Gene_or_gene_product
an	O
EGF	S-Gene_or_gene_product
receptor	O
ligand	O
.	O

With	O
the	O
discovery	O
that	O
TGFbeta1	S-Gene_or_gene_product
was	O
a	O
potent	O
growth	S-Growth
inhibitor	O
of	O
epithelial	B-Cell
cells	E-Cell
,	O
and	O
the	O
identification	O
of	O
inactivating	S-Negative_regulation
mutations	O
within	O
the	O
TGFbeta1	S-Gene_or_gene_product
signaling	B-Pathway
pathway	E-Pathway
in	O
cancers	S-Pathological_formation
it	O
became	O
clear	O
that	O
TGFbeta1	S-Gene_or_gene_product
signaling	S-Pathway
is	O
a	O
tumor	S-Pathological_formation
suppressor	O
pathway	O
for	O
early	O
stages	O
of	O
cancer	S-Pathological_formation
.	O

However	O
many	O
human	S-Organism
carcinomas	S-Pathological_formation
overexpress	S-Gene_expression
TGFbeta1	S-Gene_or_gene_product
and	O
this	O
is	O
associated	O
with	O
poor	O
patient	S-Organism
prognosis	O
and	O
increased	S-Positive_regulation
frequency	O
of	O
metastasis	S-Localization
.	O

Similar	O
results	O
have	O
been	O
obtained	O
with	O
tumor	B-Cell
cell	I-Cell
lines	E-Cell
and	O
experimental	O
animal	O
models	O
.	O

Thus	O
stage	O
specific	O
duality	O
of	O
function	O
is	O
the	O
emerging	O
paradigm	O
for	O
the	O
role	S-Regulation
of	O
TGFbeta1	S-Gene_or_gene_product
in	O
cancer	S-Pathological_formation
.	O

This	O
review	O
will	O
focus	O
on	O
the	O
evidence	O
for	O
TGFbeta1	S-Gene_or_gene_product
as	O
a	O
tumor	S-Pathological_formation
promoting	S-Positive_regulation
and	O
metastasis	S-Localization
factor	O
and	O
examine	O
the	O
biological	O
and	O
molecular	O
basis	O
for	O
these	O
effects	O
.	O

It	O
is	O
proposed	O
that	O
the	O
switch	O
from	O
tumor	S-Pathological_formation
suppressor	O
to	O
oncogene	O
reflects	O
genetic	O
or	O
epigenetic	O
alterations	O
in	O
signaling	O
pathways	O
in	O
tumor	B-Cell
cells	E-Cell
that	O
alter	S-Regulation
the	O
readout	O
from	O
the	O
TGFbeta1	S-Gene_or_gene_product
pathway	S-Pathway
.	O

Role	S-Regulation
of	O
thrombin	S-Gene_or_gene_product
in	O
angiogenesis	S-Blood_vessel_development
and	O
tumor	S-Pathological_formation
progression	S-Development
.	O

Clinical	O
,	O
laboratory	O
,	O
histopathological	O
,	O
and	O
pharmacological	O
evidence	O
support	O
the	O
notion	O
that	O
the	O
coagulation	B-Pathway
system	E-Pathway
,	O
which	O
is	O
activated	S-Positive_regulation
in	O
most	O
cancer	S-Pathological_formation
patients	S-Organism
,	O
plays	B-Regulation
an	I-Regulation
important	I-Regulation
role	E-Regulation
in	O
tumor	S-Pathological_formation
biology	O
.	O

Our	O
laboratory	O
has	O
provided	O
evidence	O
that	O
thrombin	S-Gene_or_gene_product
activates	S-Positive_regulation
angiogenesis	S-Blood_vessel_development
,	O
a	O
process	O
which	O
is	O
essential	S-Positive_regulation
in	O
tumor	S-Pathological_formation
growth	S-Growth
and	O
metastasis	S-Localization
.	O

This	O
event	O
is	O
independent	O
of	O
fibrin	S-Gene_or_gene_product
formation	S-Metabolism
.	O

At	O
the	O
cellular	O
level	O
many	O
actions	O
of	O
thrombin	S-Gene_or_gene_product
can	O
contribute	O
to	O
activation	S-Positive_regulation
of	O
angiogenesis	S-Blood_vessel_development
:	O
(	O
1	O
)	O
.	O

Thrombin	S-Gene_or_gene_product
decreases	S-Negative_regulation
the	O
ability	O
of	O
endothelial	B-Cell
cells	E-Cell
to	O
attach	S-Binding
to	O
basement	B-Cellular_component
membrane	E-Cellular_component
proteins	O
.	O

(	O
2	O
)	O
.	O

Thrombin	S-Gene_or_gene_product
greatly	O
potentiates	S-Regulation
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
-	O
(	O
VEGF	S-Gene_or_gene_product
-	O
)	O
induced	S-Positive_regulation
endothelial	B-Cell
cell	E-Cell
proliferation	S-Cell_proliferation
.	O

This	O
potentiation	O
is	O
accompanied	O
by	O
up	B-Positive_regulation
-	I-Positive_regulation
regulation	E-Positive_regulation
of	O
the	O
expression	S-Gene_expression
of	O
VEGF	S-Gene_or_gene_product
receptors	O
(	O
kinase	B-Gene_or_gene_product
insert	I-Gene_or_gene_product
domain	I-Gene_or_gene_product
-	I-Gene_or_gene_product
containing	I-Gene_or_gene_product
receptor	E-Gene_or_gene_product
[	O
KDR	S-Gene_or_gene_product
]	O
and	O
fms	B-Gene_or_gene_product
-	I-Gene_or_gene_product
like	I-Gene_or_gene_product
tyrosine	I-Gene_or_gene_product
kinase	E-Gene_or_gene_product
[	O
Flt	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
]	O
)	O
.	O

(	O
3	O
)	O
.	O

Thrombin	S-Gene_or_gene_product
increases	S-Positive_regulation
the	O
mRNA	S-Transcription
and	O
protein	B-Gene_expression
levels	E-Gene_expression
of	O
alpha	B-Gene_or_gene_product
(	I-Gene_or_gene_product
v	I-Gene_or_gene_product
)	I-Gene_or_gene_product
beta	I-Gene_or_gene_product
(	I-Gene_or_gene_product
3	I-Gene_or_gene_product
)	I-Gene_or_gene_product
integrin	E-Gene_or_gene_product
and	O
serves	O
as	O
a	O
ligand	O
to	O
this	O
receptor	O
.	O

Furthermore	O
,	O
thrombin	S-Gene_or_gene_product
increases	S-Positive_regulation
the	O
secretion	S-Localization
of	O
VEGF	S-Gene_or_gene_product
and	O
enhances	S-Positive_regulation
the	O
expression	S-Gene_expression
and	O
protein	B-Translation
synthesis	E-Translation
of	O
matrix	B-Gene_or_gene_product
metalloprotease	I-Gene_or_gene_product
-	I-Gene_or_gene_product
9	E-Gene_or_gene_product
and	O
alpha	B-Gene_or_gene_product
(	I-Gene_or_gene_product
v	I-Gene_or_gene_product
)	I-Gene_or_gene_product
beta	I-Gene_or_gene_product
(	I-Gene_or_gene_product
3	I-Gene_or_gene_product
)	I-Gene_or_gene_product
integrin	E-Gene_or_gene_product
in	O
human	S-Organism
prostate	B-Cell
cancer	I-Cell
PC	I-Cell
-	I-Cell
3	I-Cell
cells	E-Cell
.	O

These	O
results	O
could	O
explain	O
the	O
angiogenic	S-Blood_vessel_development
and	O
tumor	S-Pathological_formation
-	O
promoting	S-Positive_regulation
effect	O
of	O
thrombin	S-Gene_or_gene_product
and	O
provide	O
the	O
basis	O
for	O
development	O
of	O
thrombin	B-Gene_or_gene_product
receptor	E-Gene_or_gene_product
mimetics	O
or	O
antagonists	O
for	O
therapeutic	O
application	O
.	O

Levels	O
of	O
expression	S-Gene_expression
of	O
CYR61	S-Gene_or_gene_product
and	O
CTGF	S-Gene_or_gene_product
are	O
prognostic	O
for	O
tumor	S-Pathological_formation
progression	S-Development
and	O
survival	S-Death
of	O
individuals	S-Organism
with	O
gliomas	S-Pathological_formation
.	O

The	O
biological	O
properties	O
of	O
CCN	S-Gene_or_gene_product
proteins	O
include	O
stimulation	S-Positive_regulation
of	O
cell	S-Cell
proliferation	S-Cell_proliferation
,	O
migration	S-Localization
,	O
and	O
adhesion	S-Binding
,	O
as	O
well	O
as	O
angiogenesis	S-Blood_vessel_development
and	O
tumorigenesis	O
.	O

We	O
quantified	O
CYR61	S-Gene_or_gene_product
,	O
CTGF	S-Gene_or_gene_product
,	O
WISP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
,	O
and	O
NOV	S-Gene_or_gene_product
mRNA	O
expression	S-Transcription
levels	O
in	O
samples	O
from	O
sixty	O
-	O
six	O
primary	O
gliomas	S-Pathological_formation
and	O
five	O
normal	O
brain	B-Multi-tissue_structure
samples	E-Multi-tissue_structure
using	O
quantitative	O
real	O
-	O
time	O
PCR	O
assay	O
.	O

Statistical	O
analysis	O
was	O
performed	O
to	O
explore	O
the	O
links	O
between	O
expression	S-Gene_expression
of	O
the	O
CCN	S-Gene_or_gene_product
genes	O
and	O
clinical	O
and	O
pathological	O
parameters	O
.	O

Overexpression	S-Gene_expression
of	O
CYR61	S-Gene_or_gene_product
,	O
CTGF	S-Gene_or_gene_product
,	O
WISP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
,	O
and	O
NOV	S-Gene_or_gene_product
occurred	O
in	O
48	O
%	O
(	O
32	O
of	O
66	O
)	O
,	O
58	O
%	O
(	O
38	O
of	O
66	O
)	O
,	O
36	O
%	O
(	O
24	O
of	O
66	O
)	O
,	O
and	O
15	O
%	O
(	O
10	O
of	O
66	O
)	O
of	O
primary	O
gliomas	S-Pathological_formation
,	O
respectively	O
.	O

Interestingly	O
,	O
significant	O
associations	O
were	O
found	O
between	O
CYR61	S-Gene_or_gene_product
expression	S-Gene_expression
versus	O
tumor	S-Pathological_formation
grade	O
,	O
pathology	O
,	O
gender	O
,	O
and	O
age	O
at	O
diagnosis	O
.	O

Also	O
,	O
a	O
significant	O
correlation	O
existed	O
between	O
CTGF	S-Gene_or_gene_product
mRNA	O
levels	O
versus	O
tumor	S-Pathological_formation
grade	O
,	O
gender	O
,	O
and	O
pathology	O
.	O

In	O
contrast	O
to	O
CYR61	S-Gene_or_gene_product
and	O
CTGF	S-Gene_or_gene_product
,	O
no	O
significant	O
association	O
was	O
found	O
between	O
expression	S-Gene_expression
of	O
either	O
WISP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
or	O
NOV	S-Gene_or_gene_product
versus	O
any	O
of	O
the	O
pathological	O
features	O
.	O

Furthermore	O
,	O
Cox	O
regression	O
analysis	O
showed	O
that	O
CYR61	S-Gene_or_gene_product
and	O
CTGF	S-Gene_or_gene_product
expression	S-Gene_expression
had	O
a	O
significant	O
correlation	O
with	O
patient	S-Organism
survival	S-Death
.	O

These	O
results	O
suggest	O
that	O
CYR61	S-Gene_or_gene_product
and	O
CTGF	S-Gene_or_gene_product
may	O
play	B-Regulation
a	I-Regulation
role	E-Regulation
in	O
the	O
progression	S-Development
of	O
gliomas	S-Pathological_formation
;	O
their	O
levels	O
at	O
diagnosis	O
may	O
have	O
prognostic	O
significance	O
;	O
and	O
these	O
proteins	O
might	O
serve	O
as	O
valuable	O
targets	O
for	O
therapeutic	O
intervention	O
.	O

Hypothesis	O
:	O
Induced	S-Positive_regulation
angiogenesis	S-Blood_vessel_development
after	O
surgery	S-Planned_process
in	O
premenopausal	O
node	O
-	O
positive	O
breast	B-Pathological_formation
cancer	E-Pathological_formation
patients	S-Organism
is	O
a	O
major	O
underlying	O
reason	O
why	O
adjuvant	O
chemotherapy	S-Planned_process
works	O
particularly	O
well	O
for	O
those	O
patients	S-Organism
.	O

BACKGROUND	O
:	O
We	O
suggest	O
that	O
surgical	B-Planned_process
extirpation	E-Planned_process
of	O
primary	O
breast	B-Pathological_formation
cancer	E-Pathological_formation
among	O
other	O
effects	O
accelerates	O
relapse	O
for	O
some	O
premenopausal	O
node	O
-	O
positive	O
patients	S-Organism
.	O

These	O
accelerated	O
relapses	O
occur	O
within	O
10	O
months	O
of	O
surgery	S-Planned_process
for	O
untreated	S-Planned_process
patients	S-Organism
.	O

The	O
mechanism	O
proposed	O
is	O
a	O
stimulation	S-Positive_regulation
of	O
angiogenesis	S-Blood_vessel_development
for	O
distant	B-Pathological_formation
dormant	I-Pathological_formation
micrometastases	E-Pathological_formation
.	O

This	O
has	O
been	O
suggested	O
as	O
one	O
of	O
the	O
mechanisms	O
to	O
explain	O
the	O
mammography	O
paradox	O
for	O
women	S-Organism
aged	O
40	O
-	O
49	O
years	O
.	O

We	O
could	O
imagine	O
that	O
it	O
also	O
plays	O
a	O
role	O
in	O
adjuvant	O
chemotherapy	S-Planned_process
effectiveness	O
since	O
,	O
perhaps	O
not	O
coincidentally	O
,	O
this	O
is	O
most	O
beneficial	O
for	O
premenopausal	O
node	O
-	O
positive	O
patients	S-Organism
.	O

HYPOTHESIS	O
:	O
We	O
speculate	O
that	O
there	O
is	O
a	O
burst	S-Positive_regulation
of	O
angiogenesis	S-Blood_vessel_development
of	O
distant	B-Pathological_formation
dormant	I-Pathological_formation
micrometastases	E-Pathological_formation
after	O
surgery	S-Planned_process
in	O
approximately	O
20	O
%	O
of	O
premenopausal	O
node	O
-	O
positive	O
patients	S-Organism
.	O

We	O
also	O
speculate	O
that	O
this	O
synchronizes	O
them	O
into	O
a	O
temporal	O
highly	O
chemosensitive	O
state	O
and	O
is	O
the	O
underlying	O
reason	O
why	O
adjuvant	O
chemotherapy	S-Planned_process
works	O
particularly	O
well	O
for	O
that	O
patient	S-Organism
category	O
.	O

Furthermore	O
,	O
this	O
may	O
explain	O
why	O
cancer	O
in	O
younger	O
patients	S-Organism
is	O
more	O
often	O
'	O
aggressive	O
'	O
.	O

TESTING	O
THE	O
HYPOTHESIS	O
:	O
Stimulation	S-Positive_regulation
of	O
dormant	B-Pathological_formation
micrometastases	E-Pathological_formation
by	O
primary	O
tumor	S-Pathological_formation
removal	S-Planned_process
is	O
known	O
to	O
occur	O
in	O
animal	O
models	O
.	O

However	O
,	O
we	O
need	O
to	O
determine	O
whether	O
it	O
happens	O
in	O
breast	B-Pathological_formation
cancer	E-Pathological_formation
.	O

Transient	O
circulating	O
levels	O
of	O
angioactive	S-Blood_vessel_development
molecules	O
and	O
serial	O
high	O
-	O
resolution	O
imaging	O
studies	O
of	O
focal	O
angiogenesis	S-Blood_vessel_development
might	O
help	O
.	O

IMPLICATIONS	O
:	O
Short	O
-	O
course	O
cytotoxic	O
chemotherapy	O
after	O
surgery	O
has	O
probably	O
reached	O
its	O
zenith	O
,	O
and	O
other	O
strategies	O
,	O
perhaps	O
antiangiogenic	S-Blood_vessel_development
methods	O
,	O
are	O
needed	O
to	O
successfully	O
treat	S-Planned_process
more	O
patients	S-Organism
.	O

In	O
addition	O
,	O
the	O
hypothesis	O
predicts	O
that	O
early	O
detection	O
,	O
which	O
is	O
designed	O
to	O
find	O
more	O
patients	S-Organism
without	O
involved	O
lymph	B-Multi-tissue_structure
nodes	E-Multi-tissue_structure
,	O
may	O
not	O
be	O
a	O
synergistic	O
strategy	O
with	O
adjuvant	O
chemotherapy	S-Planned_process
,	O
which	O
works	O
best	O
with	O
positive	O
lymph	B-Multi-tissue_structure
node	E-Multi-tissue_structure
patients	S-Organism
.	O

Matrix	B-Gene_or_gene_product
metalloproteinase	E-Gene_or_gene_product
activity	O
and	O
immunohistochemical	O
profile	O
of	O
matrix	B-Gene_or_gene_product
metalloproteinase	I-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
and	O
-	B-Gene_or_gene_product
9	E-Gene_or_gene_product
and	O
tissue	B-Gene_or_gene_product
inhibitor	I-Gene_or_gene_product
of	I-Gene_or_gene_product
metalloproteinase	I-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
during	O
human	S-Organism
dermal	S-Multi-tissue_structure
wound	O
healing	O
.	O

Proteolytic	O
activity	O
is	O
required	O
for	O
the	O
turnover	S-Remodeling
of	O
the	O
extracellular	B-Cellular_component
matrix	E-Cellular_component
during	O
wound	O
healing	O
.	O

Matrix	B-Gene_or_gene_product
metalloproteinases	E-Gene_or_gene_product
can	O
collectively	O
cleave	S-Breakdown
all	O
components	O
of	O
the	O
extracellular	B-Cellular_component
matrix	E-Cellular_component
,	O
with	O
the	O
endogenous	O
tissue	B-Gene_or_gene_product
inhibitor	I-Gene_or_gene_product
of	I-Gene_or_gene_product
metalloproteinase	I-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
regulating	S-Regulation
their	O
activity	O
.	O

Breast	B-Tissue
tissue	E-Tissue
taken	O
at	O
varying	O
postoperative	O
times	O
(	O
n	O
=	O
92	O
)	O
or	O
during	O
surgery	O
(	O
controls	O
,	O
n	O
=	O
17	O
)	O
,	O
was	O
used	O
to	O
investigate	O
the	O
temporal	O
and	O
spatial	O
activity	O
of	O
matrix	B-Gene_or_gene_product
metalloproteinase	I-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
and	O
-	B-Gene_or_gene_product
9	E-Gene_or_gene_product
and	O
tissue	B-Gene_or_gene_product
inhibitor	I-Gene_or_gene_product
of	I-Gene_or_gene_product
metalloproteinase	I-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
during	O
human	S-Organism
wound	O
healing	O
.	O

Matrix	B-Gene_or_gene_product
metalloproteinase	E-Gene_or_gene_product
activity	O
,	O
determined	O
using	O
a	O
quenched	O
fluorescence	O
substrate	O
assay	O
,	O
increased	S-Positive_regulation
during	O
early	O
healing	O
(	O
3	O
-	O
8	O
weeks	O
)	O
compared	O
to	O
controls	O
,	O
and	O
then	O
decreased	S-Negative_regulation
between	O
24	O
and	O
36	O
weeks	O
after	O
surgery	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
until	O
24	O
weeks	O
,	O
Mann	O
-	O
Whitney	O
U	O
-	O
test	O
)	O
.	O

Immunohistochemistry	O
scores	O
for	O
matrix	B-Gene_or_gene_product
metalloproteinase	I-Gene_or_gene_product
-	I-Gene_or_gene_product
9	E-Gene_or_gene_product
expression	S-Gene_expression
were	O
significantly	O
elevated	S-Positive_regulation
compared	O
to	O
controls	O
in	O
scar	O
endothelial	B-Cell
cells	E-Cell
and	O
fibroblasts	S-Cell
from	O
2	O
until	O
12	O
and	O
20	O
weeks	O
,	O
respectively	O
.	O

Matrix	B-Gene_or_gene_product
metalloproteinase	I-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
staining	O
was	O
observed	O
exclusively	O
in	O
fibroblasts	S-Cell
,	O
reaching	O
maximum	O
levels	O
8	O
-	O
12	O
weeks	O
after	O
surgery	O
,	O
decreasing	S-Negative_regulation
by	O
1	O
.	O
5	O
years	O
but	O
remaining	O
significantly	O
increased	S-Positive_regulation
.	O

Tissue	B-Gene_or_gene_product
inhibitor	I-Gene_or_gene_product
of	I-Gene_or_gene_product
metalloproteinase	I-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
staining	O
was	O
relatively	O
sparse	O
but	O
was	O
significantly	O
increased	S-Positive_regulation
until	O
8	O
weeks	O
after	O
surgery	O
.	O

These	O
results	O
show	O
that	O
matrix	B-Gene_or_gene_product
metalloproteinases	E-Gene_or_gene_product
are	O
present	S-Gene_expression
at	O
elevated	S-Positive_regulation
levels	O
during	O
early	O
wound	S-Pathological_formation
healing	O
,	O
when	O
angiogenesis	S-Blood_vessel_development
occurs	O
,	O
and	O
suggest	O
that	O
matrix	B-Gene_or_gene_product
metalloproteinase	I-Gene_or_gene_product
-	I-Gene_or_gene_product
9	E-Gene_or_gene_product
may	O
play	B-Regulation
a	I-Regulation
significant	I-Regulation
role	E-Regulation
.	O

The	O
later	O
expression	S-Gene_expression
of	O
matrix	B-Gene_or_gene_product
metalloproteinase	I-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
and	O
-	B-Gene_or_gene_product
9	E-Gene_or_gene_product
in	O
fibroblasts	S-Cell
suggests	O
a	O
role	S-Regulation
in	O
extracellular	B-Cellular_component
matrix	E-Cellular_component
remodeling	S-Remodeling
.	O

Vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
(	O
VEGF	S-Gene_or_gene_product
)	O
in	O
seizures	O
:	O
a	O
double	O
-	O
edged	O
sword	O
.	O

Vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
(	O
VEGF	S-Gene_or_gene_product
)	O
is	O
a	O
vascular	O
growth	O
factor	O
which	O
induces	S-Positive_regulation
angiogenesis	S-Blood_vessel_development
(	O
the	O
development	S-Development
of	O
new	O
blood	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
)	O
,	O
vascular	O
permeability	O
,	O
and	O
inflammation	O
.	O

In	O
brain	S-Organ
,	O
receptors	O
for	O
VEGF	S-Gene_or_gene_product
have	O
been	O
localized	O
to	O
vascular	B-Tissue
endothelium	E-Tissue
,	O
neurons	S-Cell
,	O
and	O
glia	S-Cell
.	O

VEGF	S-Gene_or_gene_product
is	O
upregulated	S-Positive_regulation
after	O
hypoxic	O
injury	O
to	O
the	O
brain	S-Organ
,	O
which	O
can	O
occur	O
during	O
cerebral	O
ischemia	O
or	O
high	O
-	O
altitude	O
edema	S-Pathological_formation
,	O
and	O
has	O
been	O
implicated	O
in	O
the	O
blood	B-Multi-tissue_structure
-	I-Multi-tissue_structure
brain	I-Multi-tissue_structure
barrier	E-Multi-tissue_structure
breakdown	S-Breakdown
associated	O
with	O
these	O
conditions	O
.	O

Given	O
its	O
recently	O
-	O
described	O
role	O
as	O
an	O
inflammatory	O
mediator	O
,	O
VEGF	S-Gene_or_gene_product
could	O
also	O
contribute	O
to	O
the	O
inflammatory	O
responses	O
observed	O
in	O
cerebral	O
ischemia	O
.	O

After	O
seizures	O
,	O
blood	B-Multi-tissue_structure
-	I-Multi-tissue_structure
brain	I-Multi-tissue_structure
barrier	E-Multi-tissue_structure
breakdown	S-Breakdown
and	O
inflammation	O
is	O
also	O
observed	O
in	O
brain	S-Organ
,	O
albeit	O
on	O
a	O
lower	O
scale	O
than	O
that	O
observed	O
after	O
stroke	O
.	O

Recent	O
evidence	O
has	O
suggested	O
a	O
role	O
for	O
inflammation	O
in	O
seizure	O
disorders	O
.	O

We	O
have	O
described	O
striking	O
increases	S-Positive_regulation
in	O
VEGF	S-Gene_or_gene_product
protein	O
in	O
both	O
neurons	S-Cell
and	O
glia	S-Cell
after	O
pilocarpine	S-Drug_or_compound
-	O
induced	O
status	O
epilepticus	O
in	O
the	O
brain	S-Organ
.	O

Increases	S-Positive_regulation
in	O
VEGF	S-Gene_or_gene_product
could	O
contribute	S-Positive_regulation
to	O
the	O
blood	B-Multi-tissue_structure
-	I-Multi-tissue_structure
brain	I-Multi-tissue_structure
barrier	E-Multi-tissue_structure
breakdown	S-Breakdown
and	O
inflammation	O
observed	O
after	O
seizures	O
.	O

However	O
,	O
VEGF	S-Gene_or_gene_product
has	O
also	O
been	O
shown	O
to	O
be	O
neuroprotective	O
across	O
several	O
experimental	O
paradigms	O
,	O
and	O
hence	O
could	O
potentially	O
protect	S-Negative_regulation
vulnerable	O
cells	S-Cell
from	O
damage	S-Breakdown
associated	O
with	O
seizures	O
.	O

Therefore	O
,	O
the	O
role	O
of	O
VEGF	S-Gene_or_gene_product
after	O
seizures	O
could	O
be	O
either	O
protective	O
or	O
destructive	O
.	O

Although	O
only	O
further	O
research	O
will	O
determine	O
the	O
exact	O
nature	O
of	O
VEGF	S-Gene_or_gene_product
'	O
s	O
role	O
after	O
seizures	O
,	O
preliminary	O
data	O
indicate	O
that	O
VEGF	S-Gene_or_gene_product
plays	O
a	O
protective	O
role	O
after	O
seizures	O
.	O

Safety	O
of	O
verteporfin	S-Drug_or_compound
for	O
treatment	S-Planned_process
of	O
subfoveal	B-Multi-tissue_structure
choroidal	I-Multi-tissue_structure
neovascular	I-Multi-tissue_structure
membranes	E-Multi-tissue_structure
associated	O
with	O
age	O
-	O
related	O
macular	S-Tissue
degeneration	S-Breakdown
.	O

Photodynamic	O
therapy	O
(	O
PDT	O
)	O
is	O
a	O
novel	O
treatment	O
entity	O
that	O
exploits	O
the	O
photophysical	O
properties	O
of	O
various	O
photosensitive	O
chemical	O
entities	O
which	O
,	O
upon	O
light	O
activation	O
,	O
results	O
in	O
targeted	O
photooxidation	O
and	O
subsequent	O
tissue	S-Tissue
destruction	S-Breakdown
.	O

The	O
antiangiogenic	S-Blood_vessel_development
properties	S-Negative_regulation
of	O
PDT	O
have	O
been	O
adapted	O
for	O
treatment	S-Planned_process
of	O
subfoveal	B-Multi-tissue_structure
choroidal	I-Multi-tissue_structure
neovascular	I-Multi-tissue_structure
membranes	E-Multi-tissue_structure
due	O
to	O
disease	O
states	O
such	O
as	O
age	O
-	O
related	O
macular	S-Tissue
degeneration	S-Breakdown
(	O
AMD	O
)	O
.	O

Historically	O
,	O
PDT	O
has	O
been	O
limited	O
by	O
a	O
lack	O
of	O
suitable	O
photosensitive	O
dyes	O
.	O

However	O
,	O
agents	O
such	O
as	O
verteporfin	S-Drug_or_compound
,	O
a	O
second	O
-	O
generation	O
benzoporphyrin	S-Drug_or_compound
derivative	O
,	O
appear	O
to	O
be	O
free	O
from	O
the	O
extensive	O
phototoxicity	O
that	O
limited	O
the	O
success	O
of	O
previous	O
agents	O
.	O

Verteporfin	S-Drug_or_compound
has	O
a	O
high	O
affinity	S-Binding
for	O
choroidal	B-Multi-tissue_structure
neovascular	I-Multi-tissue_structure
membranes	E-Multi-tissue_structure
,	O
typically	O
found	O
with	O
exudative	O
AMD	O
,	O
and	O
upon	O
photoactivation	O
results	S-Positive_regulation
in	O
targeted	O
microvascular	S-Tissue
damage	S-Breakdown
and	O
thrombus	S-Pathological_formation
formation	S-Development
with	O
resultant	O
vessel	S-Multi-tissue_structure
occlusion	O
.	O

Scrutiny	O
of	O
diagnostic	O
indicators	O
for	O
verteporfin	S-Drug_or_compound
administration	S-Planned_process
,	O
including	O
critical	O
angiographic	O
evaluation	O
of	O
lesion	S-Pathological_formation
size	O
and	O
visual	O
acuity	O
,	O
is	O
essential	O
to	O
treatment	O
success	O
.	O

Large	O
lesions	S-Pathological_formation
with	O
relatively	O
good	O
visual	O
acuity	O
(	O
20	O
/	O
50	O
or	O
better	O
)	O
may	O
be	O
at	O
particular	O
risk	O
for	O
marked	O
vision	O
loss	O
following	O
verteporfin	S-Drug_or_compound
administration	S-Planned_process
.	O

Lesion	S-Pathological_formation
composition	O
also	O
appears	O
to	O
influence	O
visual	O
outcome	O
with	O
verteporfin	S-Drug_or_compound
use	S-Planned_process
.	O

The	O
safety	O
of	O
verteporfin	S-Drug_or_compound
is	O
directly	O
dependent	O
upon	O
the	O
appropriate	O
integration	O
of	O
dosage	O
,	O
infusion	O
and	O
light	O
activation	O
required	O
for	O
a	O
suitable	O
pharmacotherapeutic	O
outcome	O
.	O

When	O
used	O
appropriately	O
,	O
and	O
with	O
adequate	O
patient	S-Organism
education	O
regarding	O
photosensitivity	O
,	O
the	O
risk	O
-	O
benefit	O
of	O
verteporfin	S-Drug_or_compound
for	O
the	O
medical	O
treatment	S-Planned_process
of	O
neovascular	O
AMD	O
is	O
favourable	O
.	O

Retrospective	O
case	O
series	O
of	O
juxtafoveal	O
choroidal	O
neovascularization	S-Blood_vessel_development
treated	S-Planned_process
with	O
photodynamic	O
therapy	O
with	O
verteporfin	S-Drug_or_compound
.	O

PURPOSE	O
:	O
To	O
describe	O
visual	O
acuity	O
and	O
angiographic	O
outcomes	O
of	O
juxtafoveal	O
choroidal	O
neovascularization	S-Blood_vessel_development
(	O
CNV	S-Blood_vessel_development
)	O
treated	S-Planned_process
with	O
photodynamic	O
therapy	O
and	O
verteporfin	S-Drug_or_compound
(	O
PDT	O
)	O
.	O

METHODS	O
:	O
Four	O
hundred	O
eighty	O
-	O
four	O
consecutive	O
eyes	S-Organ
of	O
446	O
patients	S-Organism
treated	S-Planned_process
with	O
PDT	O
from	O
January	O
1	O
,	O
2001	O
,	O
to	O
June	O
30	O
,	O
2002	O
,	O
were	O
identified	O
from	O
billing	O
records	O
.	O

Fluorescein	S-Drug_or_compound
angiograms	O
were	O
reviewed	O
retrospectively	O
to	O
identify	O
juxtafoveal	O
CNV	S-Blood_vessel_development
.	O

Eligible	O
patients	S-Organism
had	O
CNV	S-Blood_vessel_development
in	O
which	O
the	O
central	O
boundary	O
of	O
the	O
lesion	S-Pathological_formation
was	O
between	O
1	O
and	O
199	O
microm	O
from	O
the	O
geometric	O
center	O
of	O
the	O
foveal	B-Tissue
avascular	I-Tissue
zone	E-Tissue
(	O
FAZ	S-Tissue
)	O
.	O

Patient	S-Organism
charts	O
were	O
reviewed	O
for	O
visual	O
acuity	O
of	O
the	O
treated	S-Planned_process
eye	S-Organ
before	O
PDT	O
and	O
at	O
6	O
-	O
and	O
12	O
-	O
month	O
follow	O
-	O
up	O
examinations	O
.	O

Presence	O
of	O
subfoveal	O
CNV	S-Blood_vessel_development
at	O
6	O
and	O
12	O
months	O
of	O
follow	O
-	O
up	O
was	O
determined	O
by	O
review	O
of	O
fluorescein	S-Drug_or_compound
angiograms	O
.	O

A	O
lesion	S-Pathological_formation
was	O
considered	O
subfoveal	O
if	O
it	O
extended	O
underneath	O
the	O
geometric	O
center	O
of	O
the	O
FAZ	S-Tissue
.	O

RESULTS	O
:	O
Twenty	O
-	O
one	O
eyes	S-Organ
had	O
juxtafoveal	O
CNV	S-Blood_vessel_development
.	O

Median	O
change	O
in	O
visual	O
acuity	O
both	O
6	O
and	O
12	O
months	O
after	O
the	O
initial	O
PDT	O
was	O
0	O
lines	O
(	O
n	O
=	O
18	O
at	O
6	O
months	O
,	O
range	O
-	O
14	O
to	O
+	O
8	O
lines	O
;	O
n	O
=	O
17	O
at	O
12	O
months	O
,	O
range	O
-	O
18	O
to	O
+	O
7	O
lines	O
)	O
.	O

Eleven	O
lesions	S-Pathological_formation
progressed	S-Development
to	O
a	O
subfoveal	O
location	O
by	O
12	O
months	O
.	O

Visual	O
acuity	O
in	O
eyes	S-Organ
with	O
progressive	O
lesions	S-Pathological_formation
decreased	O
a	O
median	O
of	O
4	O
lines	O
of	O
vision	O
.	O

CONCLUSIONS	O
:	O
Despite	O
a	O
small	O
sample	O
size	O
and	O
limited	O
length	O
of	O
follow	O
-	O
up	O
,	O
this	O
study	O
shows	O
that	O
visual	O
acuity	O
on	O
average	O
can	O
remain	O
stable	O
for	O
at	O
least	O
12	O
months	O
after	O
PDT	O
of	O
juxtafoveal	O
lesions	S-Pathological_formation
.	O

Growth	O
through	O
the	O
foveal	B-Tissue
center	E-Tissue
still	O
can	O
occur	O
,	O
however	O
,	O
and	O
this	O
can	O
be	O
associated	O
with	O
substantial	O
visual	O
loss	O
.	O

Enhanced	S-Positive_regulation
IGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
expression	S-Gene_expression
improves	S-Positive_regulation
smooth	B-Cell
muscle	I-Cell
cell	E-Cell
engraftment	S-Development
after	O
cell	S-Cell
transplantation	S-Planned_process
.	O

The	O
functional	O
benefit	O
of	O
cell	S-Cell
transplantation	S-Planned_process
after	O
a	O
myocardial	O
infarction	O
is	O
diminished	O
by	O
early	O
cell	S-Cell
losses	S-Death
.	O

IGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
enhances	S-Positive_regulation
cell	S-Cell
proliferation	S-Cell_proliferation
and	O
survival	S-Death
.	O

We	O
hypothesized	O
that	O
IGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
-	O
transfected	S-Planned_process
smooth	B-Cell
muscle	I-Cell
cells	E-Cell
(	O
SMCs	S-Cell
)	O
would	O
enhance	S-Positive_regulation
cell	S-Cell
survival	S-Death
and	O
improve	S-Positive_regulation
engraftment	S-Development
after	O
cell	S-Cell
transplantation	S-Planned_process
.	O

The	O
IGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
gene	O
was	O
transfected	S-Planned_process
into	O
male	O
SMCs	S-Cell
and	O
compared	O
with	O
SMCs	S-Cell
transfected	S-Planned_process
with	O
a	O
plasmid	O
vector	O
(	O
vector	O
control	O
)	O
and	O
nontransfected	S-Planned_process
SMCs	S-Cell
(	O
cell	S-Cell
control	O
)	O
.	O

IGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
mRNA	O
(	O
n	O
=	O
10	O
/	O
group	O
)	O
and	O
protein	O
levels	O
(	O
n	O
=	O
6	O
/	O
group	O
)	O
were	O
higher	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
for	O
all	O
groups	O
)	O
at	O
3	O
,	O
7	O
,	O
and	O
14	O
days	O
compared	O
with	O
controls	O
.	O

VEGF	S-Gene_or_gene_product
was	O
also	O
increased	S-Positive_regulation
in	O
parallel	O
to	O
enhanced	S-Positive_regulation
IGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
expression	S-Gene_expression
.	O

IGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
-	O
transfected	S-Planned_process
cells	S-Cell
demonstrated	O
greater	O
cell	S-Cell
proliferation	S-Cell_proliferation
,	O
stimulated	S-Positive_regulation
angiogenesis	S-Blood_vessel_development
,	O
and	O
decreased	S-Negative_regulation
caspase	B-Gene_or_gene_product
-	I-Gene_or_gene_product
3	E-Gene_or_gene_product
activity	O
after	O
simulated	O
ischemia	O
and	O
reperfusion	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
for	O
all	O
groups	O
compared	O
with	O
vector	O
or	O
cell	S-Cell
controls	O
)	O
.	O

A	O
uniform	O
left	O
ventricular	O
injury	O
was	O
produced	O
in	O
female	O
rats	S-Organism
using	O
a	O
cryoprobe	O
.	O

Three	O
weeks	O
later	O
,	O
2	O
x	O
10	O
(	O
6	O
)	O
cells	S-Cell
from	O
three	O
groups	O
were	O
implanted	S-Planned_process
into	O
the	O
scar	O
.	O

One	O
week	O
later	O
,	O
IGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
-	O
transfected	S-Planned_process
SMCs	S-Cell
had	O
increased	S-Positive_regulation
myocardial	O
IGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
and	O
VEGF	S-Gene_or_gene_product
levels	O
,	O
increased	S-Positive_regulation
Bcl2	S-Gene_or_gene_product
expression	S-Gene_expression
,	O
limited	S-Negative_regulation
cell	S-Cell
apoptosis	S-Death
,	O
and	O
enhanced	S-Positive_regulation
vessel	S-Multi-tissue_structure
formation	S-Development
in	O
the	O
myocardial	O
scar	O
compared	O
with	O
the	O
two	O
control	O
groups	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
for	O
all	O
groups	O
)	O
.	O

The	O
proportion	O
of	O
SMCs	S-Cell
surviving	S-Death
in	O
the	O
implanted	S-Planned_process
region	O
was	O
greater	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
in	O
the	O
IGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
-	O
transfected	S-Planned_process
group	O
than	O
in	O
the	O
vector	O
or	O
cell	S-Cell
controls	O
.	O

Gene	O
enhancement	S-Positive_regulation
with	O
IGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
improved	S-Positive_regulation
donor	B-Cell
cell	E-Cell
proliferation	S-Cell_proliferation
,	O
survival	S-Death
,	O
and	O
engraftment	S-Development
after	O
cell	S-Cell
transplantation	S-Planned_process
,	O
perhaps	O
mediated	O
by	O
enhanced	S-Positive_regulation
angiogenesis	S-Blood_vessel_development
and	O
reduced	O
apoptosis	O
.	O

[	O
Glaucoma	O
and	O
ocular	O
ischemic	O
syndrome	O
-	O
-	O
case	O
report	O
]	O

PURPOSE	O
:	O
Ocular	S-Organ
ischemic	O
syndrome	O
(	O
OIS	O
)	O
is	O
often	O
poorly	O
diagnosed	O
and	O
treated	O
as	O
primary	O
open	O
angle	O
glaucoma	O
or	O
later	O
on	O
,	O
as	O
neovascular	O
glaucoma	O
.	O

We	O
present	O
a	O
54	O
year	O
old	O
male	S-Organism
,	O
treated	S-Planned_process
topical	O
since	O
23	O
years	O
for	O
glaucoma	O
and	O
sent	O
to	O
our	O
clinic	O
for	O
trabeculectomy	O
because	O
of	O
rapid	O
worsening	O
of	O
vision	O
on	O
right	O
eye	S-Organ
with	O
bilateral	O
total	O
excavation	O
of	O
optic	O
disc	O
.	O

MATERIAL	O
AND	O
METHODS	O
:	O
Observational	O
case	O
report	O
.	O

RESULTS	O
:	O
Because	O
of	O
typical	O
signs	O
of	O
IOS	O
(	O
iris	S-Multi-tissue_structure
neovascularization	S-Blood_vessel_development
,	O
mid	O
-	O
peripheral	O
dot	O
and	O
blot	O
hemorrhages	O
in	O
both	O
eyes	S-Organ
,	O
narrowed	O
arterioles	S-Multi-tissue_structure
in	O
right	O
eye	S-Organ
,	O
following	O
examinations	O
were	O
performed	O
:	O
Doppler	O
ultrasonography	O
of	O
carotid	B-Multi-tissue_structure
arteries	E-Multi-tissue_structure
,	O
digital	O
subtractional	O
angiography	O
of	O
the	O
carotid	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
and	O
magnetic	O
resonance	O
angiography	O
.	O

The	O
examinations	O
showed	O
occlusion	O
of	O
the	O
right	B-Multi-tissue_structure
common	I-Multi-tissue_structure
carotid	I-Multi-tissue_structure
artery	E-Multi-tissue_structure
and	O
with	O
80	O
%	O
stenosis	O
of	O
the	O
left	B-Multi-tissue_structure
common	I-Multi-tissue_structure
carotid	I-Multi-tissue_structure
artery	E-Multi-tissue_structure
,	O
occlusion	O
of	O
abdominal	B-Multi-tissue_structure
aorta	E-Multi-tissue_structure
.	O

After	O
phacoemulsification	O
with	O
implantation	S-Planned_process
of	O
intraocular	O
lens	S-Multi-tissue_structure
because	O
of	O
rapid	O
intumescence	O
cataract	O
in	O
the	O
right	O
eye	S-Organ
,	O
and	O
endarterectomy	O
of	O
left	B-Multi-tissue_structure
external	I-Multi-tissue_structure
carotid	I-Multi-tissue_structure
artery	E-Multi-tissue_structure
,	O
the	O
neovascularization	S-Blood_vessel_development
of	O
the	O
iris	S-Multi-tissue_structure
regressed	S-Negative_regulation
in	O
both	O
eyes	S-Organ
.	O

CONCLUSION	O
:	O
In	O
case	O
of	O
iris	S-Multi-tissue_structure
neovascularization	S-Blood_vessel_development
or	O
mid	O
-	O
peripheral	O
hemorrhages	O
the	O
Doppler	O
sonography	O
of	O
carotid	B-Multi-tissue_structure
arteries	E-Multi-tissue_structure
should	O
be	O
performed	O
.	O

Quick	O
cooperation	O
between	O
ophthalmologist	O
,	O
radiologist	O
and	O
vascular	O
surgeon	O
following	O
endarterectomy	O
seems	O
to	O
stop	O
progressing	O
changes	O
of	O
ocular	O
ischemic	O
syndrome	O
.	O

Oxidation	O
in	O
rheumatoid	O
arthritis	O
.	O

Oxygen	S-Drug_or_compound
metabolism	S-Metabolism
has	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
rheumatoid	O
arthritis	O
.	O

Reactive	B-Drug_or_compound
oxygen	I-Drug_or_compound
species	E-Drug_or_compound
(	O
ROS	S-Drug_or_compound
)	O
produced	S-Synthesis
in	O
the	O
course	O
of	O
cellular	O
oxidative	O
phosphorylation	O
,	O
and	O
by	O
activated	S-Positive_regulation
phagocytic	B-Cell
cells	E-Cell
during	O
oxidative	O
bursts	O
,	O
exceed	O
the	O
physiological	O
buffering	O
capacity	O
and	O
result	O
in	O
oxidative	O
stress	O
.	O

The	O
excessive	S-Positive_regulation
production	S-Synthesis
of	O
ROS	S-Drug_or_compound
can	O
damage	S-Catabolism
protein	O
,	O
lipids	S-Drug_or_compound
,	O
nucleic	B-Drug_or_compound
acids	E-Drug_or_compound
,	O
and	O
matrix	B-Cellular_component
components	E-Cellular_component
.	O

They	O
also	O
serve	O
as	O
important	O
intracellular	O
signaling	O
molecules	O
that	O
amplify	O
the	O
synovial	S-Multi-tissue_structure
inflammatory	O
-	O
proliferative	O
response	O
.	O

Repetitive	O
cycles	O
of	O
hypoxia	O
and	O
reoxygenation	O
associated	O
with	O
changes	O
in	O
synovial	S-Multi-tissue_structure
perfusion	S-Planned_process
are	O
postulated	O
to	O
activate	S-Positive_regulation
hypoxia	B-Gene_or_gene_product
-	I-Gene_or_gene_product
inducible	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
-	I-Gene_or_gene_product
1alpha	E-Gene_or_gene_product
and	O
nuclear	B-Gene_or_gene_product
factor	I-Gene_or_gene_product
-	I-Gene_or_gene_product
kappaB	E-Gene_or_gene_product
,	O
two	O
key	O
transcription	O
factors	O
that	O
are	O
regulated	S-Regulation
by	O
changes	O
in	O
cellular	O
oxygenation	O
and	O
cytokine	O
stimulation	O
,	O
and	O
that	O
in	O
turn	O
orchestrate	O
the	O
expression	O
of	O
a	O
spectrum	O
of	O
genes	O
critical	O
to	O
the	O
persistence	O
of	O
synovitis	O
.	O

An	O
understanding	O
of	O
the	O
complex	O
interactions	O
involved	O
in	O
these	O
pathways	O
might	O
allow	O
the	O
development	O
of	O
novel	O
therapeutic	O
strategies	O
for	O
rheumatoid	O
arthritis	O
.	O

Hypoxia	B-DNA_domain_or_region
-	I-DNA_domain_or_region
responsive	I-DNA_domain_or_region
element	E-DNA_domain_or_region
-	O
mediated	S-Regulation
soluble	O
Tie2	S-Gene_or_gene_product
vector	O
exhibits	O
an	O
anti	O
-	O
angiogenic	S-Blood_vessel_development
activity	S-Negative_regulation
in	O
vitro	O
under	O
hypoxic	O
condition	O
.	O

Hypoxia	B-Gene_or_gene_product
-	I-Gene_or_gene_product
inducible	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
(	O
HIF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
)	O
is	O
one	O
of	O
the	O
key	O
mammalian	O
transcription	O
factors	O
and	O
shows	O
increased	O
levels	O
in	O
both	O
protein	O
stability	O
and	O
intrinsic	O
transcriptional	O
activity	O
during	O
low	O
oxygen	S-Drug_or_compound
tension	O
.	O

Hypoxia	O
-	O
activated	O
functional	O
HIF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
protein	O
binds	S-Binding
to	O
hypoxia	B-DNA_domain_or_region
-	I-DNA_domain_or_region
responsive	I-DNA_domain_or_region
elements	E-DNA_domain_or_region
(	O
HRE	S-DNA_domain_or_region
)	O
in	O
the	O
enhancers	O
of	O
several	O
genes	O
including	O
VEGF	S-Gene_or_gene_product
,	O
the	O
major	O
player	O
in	O
angiogenesis	S-Blood_vessel_development
,	O
and	O
initiates	S-Positive_regulation
their	O
mRNA	O
expression	S-Transcription
.	O

The	O
molecular	O
mechanisms	O
regulating	O
the	O
gene	O
expression	O
under	O
hypoxic	O
conditions	O
could	O
increase	O
the	O
therapeutic	O
window	O
of	O
tumor	S-Pathological_formation
-	O
specific	O
delivery	O
systems	O
.	O

In	O
this	O
study	O
,	O
to	O
examine	O
hypoxia	O
-	O
specific	O
production	O
of	O
anti	O
-	O
angiogenic	S-Blood_vessel_development
therapeutic	O
gene	O
,	O
we	O
constructed	S-Planned_process
5	O
copies	O
of	O
HRE	S-DNA_domain_or_region
(	O
5xHRE	S-DNA_domain_or_region
)	O
of	O
human	S-Organism
VEGF	S-Gene_or_gene_product
linked	S-Planned_process
to	O
soluble	O
Tie2	S-Gene_or_gene_product
(	O
sTie2	S-Gene_or_gene_product
)	O
driven	O
by	O
minimal	O
SV40	S-Gene_or_gene_product
promoter	S-DNA_domain_or_region
(	O
5xHRE	S-DNA_domain_or_region
/	O
SV40	S-Gene_or_gene_product
/	O
sTie2	S-Gene_or_gene_product
)	O
.	O

Our	O
data	O
showed	O
that	O
under	O
hypoxia	O
the	O
secreted	S-Localization
sTie2	S-Gene_or_gene_product
selectively	O
inhibited	S-Negative_regulation
tube	S-Tissue
formation	S-Development
and	O
migration	S-Localization
capacities	O
of	O
endothelial	B-Cell
cells	E-Cell
in	O
vitro	O
.	O

Hence	O
,	O
we	O
propose	O
that	O
the	O
vector	O
system	O
,	O
5xHRE	S-DNA_domain_or_region
/	O
SV40	S-Gene_or_gene_product
/	O
sTie2	S-Gene_or_gene_product
,	O
might	O
be	O
a	O
useful	O
tool	O
for	O
down	B-Negative_regulation
-	I-Negative_regulation
regulating	E-Negative_regulation
tumor	S-Pathological_formation
angiogenesis	S-Blood_vessel_development
under	O
hypoxic	O
condition	O
.	O

2	B-Drug_or_compound
-	I-Drug_or_compound
methoxyestradiol	E-Drug_or_compound
inhibits	S-Negative_regulation
hypoxia	B-Gene_or_gene_product
-	I-Gene_or_gene_product
inducible	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
1alpha	E-Gene_or_gene_product
,	O
tumor	S-Pathological_formation
growth	S-Growth
,	O
and	O
angiogenesis	S-Blood_vessel_development
and	O
augments	O
paclitaxel	S-Drug_or_compound
efficacy	O
in	O
head	B-Pathological_formation
and	I-Pathological_formation
neck	I-Pathological_formation
squamous	I-Pathological_formation
cell	I-Pathological_formation
carcinoma	E-Pathological_formation
.	O

PURPOSE	O
:	O
Head	B-Pathological_formation
and	I-Pathological_formation
neck	I-Pathological_formation
squamous	I-Pathological_formation
cell	I-Pathological_formation
carcinomas	E-Pathological_formation
have	O
been	O
reported	O
to	O
overexpress	S-Gene_expression
hypoxia	B-Gene_or_gene_product
-	I-Gene_or_gene_product
inducible	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
(	I-Gene_or_gene_product
HIF	I-Gene_or_gene_product
)	I-Gene_or_gene_product
-	I-Gene_or_gene_product
1alpha	E-Gene_or_gene_product
,	O
a	O
transcription	O
factor	O
that	O
promotes	O
expression	O
of	O
angiogenesis	S-Blood_vessel_development
factors	O
and	O
resistance	O
to	O
programmed	O
and	O
therapy	O
-	O
induced	S-Positive_regulation
cell	S-Cell
death	S-Death
.	O

2	B-Drug_or_compound
-	I-Drug_or_compound
Methoxyestradiol	E-Drug_or_compound
(	O
2ME2	S-Drug_or_compound
)	O
is	O
a	O
natural	O
compound	O
with	O
HIF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1alpha	E-Gene_or_gene_product
inhibitory	S-Negative_regulation
activity	O
that	O
is	O
currently	O
being	O
evaluated	O
in	O
phase	O
1	O
and	O
2	O
clinical	B-Planned_process
trials	E-Planned_process
for	O
advanced	O
solid	B-Pathological_formation
tumors	E-Pathological_formation
and	O
multiple	O
myeloma	S-Pathological_formation
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
study	O
to	O
evaluate	O
the	O
effects	S-Regulation
of	O
2ME2	S-Drug_or_compound
in	O
head	B-Pathological_formation
and	I-Pathological_formation
neck	I-Pathological_formation
squamous	I-Pathological_formation
cell	I-Pathological_formation
carcinoma	E-Pathological_formation
.	O

EXPERIMENTAL	O
DESIGN	O
:	O
In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
effects	S-Regulation
of	O
2ME2	S-Drug_or_compound
alone	O
and	O
in	O
combination	O
with	O
paclitaxel	S-Drug_or_compound
,	O
an	O
active	O
agent	O
in	O
recurrent	O
or	O
advanced	O
head	B-Pathological_formation
and	I-Pathological_formation
neck	I-Pathological_formation
squamous	I-Pathological_formation
cell	I-Pathological_formation
carcinoma	E-Pathological_formation
.	O

RESULTS	O
:	O
2ME2	S-Drug_or_compound
exhibited	S-Regulation
antiproliferative	O
and	O
cytotoxic	O
effects	O
in	O
a	O
panel	O
of	O
five	O
head	B-Cell
and	I-Cell
neck	I-Cell
squamous	I-Cell
cell	I-Cell
carcinoma	I-Cell
cell	I-Cell
lines	E-Cell
in	O
the	O
0	O
.	O
5	O
to	O
10	O
micromol	O
/	O
L	O
range	O
,	O
including	O
induction	S-Positive_regulation
of	O
G2	O
-	O
M	O
blockade	O
,	O
caspase	B-Gene_or_gene_product
-	I-Gene_or_gene_product
3	E-Gene_or_gene_product
/	O
7	S-Gene_or_gene_product
activation	S-Positive_regulation
,	O
and	O
apoptosis	S-Death
at	O
48	O
hours	O
.	O

2ME2	S-Drug_or_compound
resulted	O
in	O
decreased	S-Negative_regulation
nuclear	O
HIF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1alpha	E-Gene_or_gene_product
-	O
binding	S-Binding
activity	O
and	O
affected	S-Regulation
the	O
expression	S-Gene_expression
of	O
downstream	O
genes	O
,	O
such	O
as	O
bid	S-Gene_or_gene_product
,	O
a	O
proapoptotic	O
bcl	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
family	E-Gene_or_gene_product
member	O
,	O
and	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
,	O
a	O
proangiogenic	S-Blood_vessel_development
cytokine	O
.	O

The	O
up	B-Positive_regulation
-	I-Positive_regulation
regulation	E-Positive_regulation
of	O
Bid	S-Gene_or_gene_product
(	O
57	O
.	O
5	O
%	O
at	O
12	O
hours	O
,	O
P	O
less	O
than	O
0	O
.	O
0006	O
)	O
and	O
inhibition	S-Negative_regulation
of	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
secretion	S-Localization
(	O
57	O
.	O
7	O
%	O
at	O
24	O
hours	O
,	O
P	O
less	O
than	O
0	O
.	O
015	O
;	O
and	O
50	O
.	O
3	O
%	O
at	O
48	O
hours	O
,	O
P	O
less	O
than	O
0	O
.	O
0006	O
)	O
could	O
be	O
partially	O
attributed	O
to	O
the	O
effects	S-Regulation
on	O
HIF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1alpha	E-Gene_or_gene_product
,	O
because	O
HIF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1alpha	E-Gene_or_gene_product
small	O
interfering	O
RNAs	O
produced	O
similar	O
effects	O
.	O

Finally	O
,	O
in	O
vivo	O
,	O
in	O
a	O
xenograft	O
model	O
of	O
head	B-Pathological_formation
and	I-Pathological_formation
neck	I-Pathological_formation
squamous	I-Pathological_formation
cell	I-Pathological_formation
carcinoma	E-Pathological_formation
using	O
UM	B-Cell
-	I-Cell
SCC	I-Cell
-	I-Cell
11A	I-Cell
cells	E-Cell
,	O
2ME2	S-Drug_or_compound
exhibited	O
antitumor	S-Pathological_formation
and	O
antiangiogenic	S-Blood_vessel_development
activity	S-Negative_regulation
,	O
as	O
measured	O
by	O
CD31	S-Gene_or_gene_product
immunostaining	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
provide	O
support	O
for	O
the	O
use	O
of	O
2ME2	S-Drug_or_compound
in	O
combination	O
with	O
paclitaxel	S-Drug_or_compound
for	O
the	O
treatment	S-Planned_process
of	O
recurrent	O
or	O
advanced	O
head	B-Pathological_formation
and	I-Pathological_formation
neck	I-Pathological_formation
squamous	I-Pathological_formation
cell	I-Pathological_formation
carcinoma	E-Pathological_formation
.	O

Expression	S-Gene_expression
and	O
purification	O
of	O
the	O
catalytic	O
domain	O
of	O
human	S-Organism
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
receptor	I-Gene_or_gene_product
2	E-Gene_or_gene_product
for	O
inhibitor	O
screening	O
.	O

Vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
(	O
VEGF	S-Gene_or_gene_product
)	O
,	O
an	O
endothelial	B-Cell
cell	E-Cell
-	O
specific	O
mitogen	O
,	O
can	O
act	S-Regulation
in	O
tumor	S-Pathological_formation
-	O
induced	S-Positive_regulation
angiogenesis	S-Blood_vessel_development
by	O
binding	S-Binding
to	O
specific	O
receptors	O
on	O
the	O
surface	O
of	O
endothelial	B-Cell
cells	E-Cell
.	O

One	O
such	O
receptor	O
,	O
VEGFR	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
/	O
KDR	S-Gene_or_gene_product
,	O
plays	B-Regulation
a	I-Regulation
key	I-Regulation
role	E-Regulation
in	O
VEGF	S-Gene_or_gene_product
-	O
induced	S-Positive_regulation
angiogenesis	S-Blood_vessel_development
.	O

Here	O
,	O
we	O
expressed	S-Gene_expression
the	O
catalytic	O
domain	O
of	O
VEGFR	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
as	O
a	O
soluble	O
active	O
kinase	O
using	O
Bac	O
-	O
to	O
-	O
Bac	O
expression	O
system	O
,	O
and	O
investigated	O
correlations	O
between	O
VEGFR	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
activity	O
and	O
enzyme	O
concentration	O
,	O
ATP	S-Drug_or_compound
concentration	O
,	O
substrate	O
concentration	O
and	O
divalent	O
cation	O
type	O
.	O

We	O
used	O
these	O
data	O
to	O
establish	O
a	O
convenient	O
,	O
effective	O
and	O
non	O
-	O
radioactive	O
ELISA	O
screening	O
technique	O
for	O
the	O
identification	O
and	O
evaluation	O
of	O
potential	O
inhibitors	O
for	O
VEGFR	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
kinase	O
.	O

We	O
screened	O
200	O
RTK	O
target	O
-	O
based	O
compounds	O
and	O
identified	O
one	O
(	O
TKI	B-Drug_or_compound
-	I-Drug_or_compound
31	E-Drug_or_compound
)	O
that	O
potently	O
inhibited	S-Negative_regulation
VEGFR	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
kinase	O
activity	O
(	O
IC50	O
=	O
0	O
.	O
596	O
microM	O
)	O
.	O

Treatment	S-Planned_process
of	O
NIH3T3	B-Cell
/	I-Cell
KDR	I-Cell
cells	E-Cell
with	O
TKI	B-Drug_or_compound
-	I-Drug_or_compound
31	E-Drug_or_compound
blocked	S-Negative_regulation
VEGF	S-Gene_or_gene_product
-	O
induced	S-Positive_regulation
phosphorylation	S-Phosphorylation
of	O
KDR	S-Gene_or_gene_product
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

Moreover	O
,	O
TKI	B-Drug_or_compound
-	I-Drug_or_compound
31	E-Drug_or_compound
dose	O
-	O
dependently	O
suppressed	S-Negative_regulation
HUVEC	B-Tissue
tube	E-Tissue
formation	S-Development
.	O

Thus	O
,	O
we	O
herein	O
report	O
a	O
novel	O
,	O
efficient	O
method	O
for	O
identifying	O
VEGFR	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
kinase	O
inhibitors	O
and	O
introduce	O
one	O
,	O
TKI	B-Drug_or_compound
-	I-Drug_or_compound
31	E-Drug_or_compound
,	O
that	O
may	O
prove	O
to	O
be	O
a	O
useful	O
new	O
angiogenesis	S-Blood_vessel_development
inhibitor	O
.	O

An	O
evaluation	O
of	O
low	B-Drug_or_compound
molecular	I-Drug_or_compound
weight	I-Drug_or_compound
heparin	E-Drug_or_compound
and	O
hyperbaric	B-Drug_or_compound
oxygen	E-Drug_or_compound
treatment	S-Planned_process
in	O
the	O
prevention	O
of	O
intra	O
-	O
abdominal	O
adhesions	O
and	O
wound	O
healing	O
.	O

BACKGROUND	O
:	O
Abdominal	O
surgery	O
can	O
lead	O
to	O
intra	O
-	O
abdominal	O
adhesions	O
with	O
significant	O
morbidity	O
and	O
mortality	O
.	O

To	O
prevent	O
adhesions	O
,	O
an	O
experimental	O
study	O
was	O
planned	O
to	O
designate	O
the	O
effects	O
of	O
low	B-Drug_or_compound
molecular	I-Drug_or_compound
weight	I-Drug_or_compound
(	I-Drug_or_compound
LMW	I-Drug_or_compound
)	I-Drug_or_compound
heparins	E-Drug_or_compound
and	O
hyperbaric	B-Drug_or_compound
oxygen	E-Drug_or_compound
(	O
HBO	S-Drug_or_compound
)	O
therapy	S-Planned_process
both	O
on	O
the	O
formation	O
of	O
adhesions	O
and	O
wound	O
healing	O
.	O

METHODS	O
:	O
Thirty	O
-	O
eight	O
Wistar	B-Organism
albino	I-Organism
rats	E-Organism
underwent	S-Planned_process
laparotomy	O
to	O
cause	O
intra	O
-	O
abdominal	O
adhesions	O
by	O
mechanical	O
abrasion	S-Planned_process
of	O
the	O
cecum	S-Multi-tissue_structure
and	O
ethanol	S-Drug_or_compound
application	S-Planned_process
.	O

The	O
rats	S-Organism
were	O
divided	O
into	O
4	O
groups	O
.	O

In	O
the	O
control	O
group	O
(	O
group	O
1	O
)	O
no	O
further	O
management	O
was	O
undertaken	O
.	O

Group	O
2	O
was	O
treated	S-Planned_process
by	O
Enoxaparine	B-Drug_or_compound
Na	E-Drug_or_compound
,	O
group	O
3	O
received	O
HBO	S-Drug_or_compound
therapy	S-Planned_process
,	O
and	O
group	O
4	O
was	O
given	O
both	O
enoxaparine	B-Drug_or_compound
Na	E-Drug_or_compound
and	O
HBO	S-Drug_or_compound
treatment	S-Planned_process
.	O

RESULTS	O
:	O
There	O
was	O
a	O
statistically	O
significant	O
difference	O
between	O
the	O
control	O
and	O
enoxaparine	B-Drug_or_compound
Na	E-Drug_or_compound
groups	O
regarding	O
adhesions	O
.	O

Statistically	O
significant	O
differences	O
were	O
observed	O
between	O
groups	O
1	O
and	O
4	O
and	O
between	O
groups	O
1	O
and	O
3	O
regarding	O
the	O
hydroxyproline	O
content	O
of	O
the	O
abdominal	O
wounds	O
.	O

In	O
the	O
pathologic	O
analysis	O
of	O
the	O
abdominal	O
wounds	O
,	O
there	O
was	O
no	O
statistically	O
significant	O
difference	O
between	O
any	O
of	O
the	O
groups	O
,	O
including	O
the	O
control	O
group	O
,	O
regarding	O
inflammation	O
.	O

Statistically	O
significant	O
differences	O
were	O
observed	O
regarding	O
angiogenesis	S-Blood_vessel_development
between	O
the	O
control	O
group	O
and	O
groups	O
3	O
and	O
4	O
.	O

There	O
was	O
also	O
a	O
statistically	O
significant	O
difference	O
regarding	O
fibrosis	O
between	O
groups	O
1	O
and	O
4	O
.	O

CONCLUSIONS	O
:	O
Enoxaparine	B-Drug_or_compound
Na	E-Drug_or_compound
decreased	O
intra	O
-	O
abdominal	O
adhesions	O
,	O
and	O
HBO	S-Drug_or_compound
therapy	S-Planned_process
had	O
no	O
beneficial	O
effect	O
on	O
adhesions	O
.	O

Enoxaparine	B-Drug_or_compound
Na	E-Drug_or_compound
had	O
no	O
harmful	O
effects	O
on	O
wound	O
healing	O
,	O
and	O
HBO	S-Drug_or_compound
therapy	S-Planned_process
increased	O
the	O
process	O
of	O
wound	O
healing	O
.	O

Novel	O
biological	O
agents	O
for	O
the	O
treatment	S-Planned_process
of	O
hormone	B-Pathological_formation
-	I-Pathological_formation
refractory	I-Pathological_formation
prostate	I-Pathological_formation
cancer	E-Pathological_formation
(	O
HRPC	S-Pathological_formation
)	O
.	O

Hormone	B-Pathological_formation
-	I-Pathological_formation
refractory	I-Pathological_formation
prostate	I-Pathological_formation
cancer	E-Pathological_formation
(	O
HRPC	S-Pathological_formation
)	O
is	O
an	O
inevitable	O
evolution	O
of	O
prostate	S-Organ
carcinogenesis	S-Development
,	O
through	O
which	O
the	O
normal	O
dependence	O
on	O
hormones	O
for	O
growth	O
and	O
survival	O
is	O
bypassed	O
.	O

Although	O
advances	O
in	O
terms	O
of	O
symptoms	O
palliation	O
and	O
quality	O
of	O
life	O
improvement	O
have	O
been	O
addressed	O
with	O
current	O
treatment	O
options	O
,	O
innovative	O
approaches	O
are	O
needed	O
to	O
improve	O
survival	O
rates	O
.	O

A	O
thorough	O
understanding	O
of	O
HRPC	S-Pathological_formation
-	O
associated	O
molecular	O
pathways	O
and	O
mechanisms	O
of	O
resistance	O
are	O
a	O
prerequisite	O
for	O
novel	O
potential	O
therapeutic	O
interventions	O
.	O

Preclinical	O
and	O
early	O
clinical	O
studies	O
are	O
ongoing	O
to	O
evaluate	O
new	O
therapies	O
that	O
target	O
specific	O
molecular	O
entities	O
.	O

Agents	O
under	O
development	O
include	O
growth	O
factor	O
receptor	O
inhibitors	O
,	O
small	O
molecules	O
targeting	O
signal	O
transduction	O
pathways	O
,	O
apoptosis	O
and	O
cell	S-Cell
-	O
cycle	O
regulators	O
,	O
angiogenesis	S-Blood_vessel_development
and	O
metastasis	O
inhibitors	O
,	O
differentiation	O
agents	O
,	O
telomerase	S-Gene_or_gene_product
inactivators	O
,	O
and	O
epigenetic	O
therapeutics	O
.	O

Incorporation	O
of	O
these	O
agents	O
into	O
existing	O
treatment	O
regimens	O
will	O
guide	O
us	O
in	O
the	O
development	O
of	O
a	O
multidisciplinary	O
treatment	O
strategy	O
of	O
HRPC	S-Pathological_formation
.	O

This	O
article	O
critically	O
reviews	O
published	O
data	O
on	O
new	O
biological	O
agents	O
that	O
are	O
being	O
tested	O
in	O
HRPC	S-Pathological_formation
clinical	O
trials	O
,	O
highlights	O
ongoing	O
research	O
and	O
considers	O
the	O
future	O
perspectives	O
of	O
this	O
new	O
class	O
of	O
agents	O
.	O

Role	O
of	O
thrombogenic	B-Gene_or_gene_product
factors	E-Gene_or_gene_product
in	O
the	O
development	O
of	O
atherosclerosis	O
.	O

Hemostatic	B-Gene_or_gene_product
factors	E-Gene_or_gene_product
play	B-Positive_regulation
a	I-Positive_regulation
crucial	I-Positive_regulation
role	E-Positive_regulation
in	O
generating	S-Development
thrombotic	B-Pathological_formation
plugs	E-Pathological_formation
at	O
sites	O
of	O
vascular	S-Multi-tissue_structure
damage	S-Breakdown
(	O
atherothrombosis	O
)	O
.	O

However	O
,	O
whether	O
hemostatic	B-Gene_or_gene_product
factors	E-Gene_or_gene_product
contribute	O
directly	O
or	O
indirectly	O
to	O
the	O
pathogenesis	O
of	O
atherosclerosis	O
remains	O
uncertain	O
.	O

Autopsy	O
studies	O
have	O
revealed	O
that	O
intimal	S-Tissue
thickening	S-Growth
represents	O
the	O
first	O
stage	O
of	O
atherosclerosis	O
and	O
that	O
lipid	B-Pathological_formation
-	I-Pathological_formation
rich	I-Pathological_formation
plaque	E-Pathological_formation
arises	O
from	O
such	O
lesions	S-Pathological_formation
.	O

Several	O
factors	O
contribute	S-Positive_regulation
to	O
the	O
start	O
of	O
intimal	S-Tissue
thickening	S-Growth
.	O

Platelets	S-Cell
release	O
several	O
growth	O
factors	O
and	O
bioactive	O
agents	O
that	O
play	B-Positive_regulation
a	I-Positive_regulation
central	I-Positive_regulation
role	E-Positive_regulation
in	O
development	S-Development
of	O
not	O
only	O
thrombus	S-Pathological_formation
but	O
also	O
of	O
intimal	S-Tissue
thickening	S-Growth
.	O

We	O
have	O
been	O
investigating	O
which	O
coagulation	O
factors	O
simultaneously	O
,	O
or	O
subsequently	O
with	O
platelet	S-Cell
aggregation	S-Binding
,	O
participate	S-Positive_regulation
in	O
thrombus	S-Pathological_formation
formation	S-Development
.	O

Tissue	B-Gene_or_gene_product
factor	E-Gene_or_gene_product
(	O
TF	S-Gene_or_gene_product
)	O
is	O
an	O
essential	O
initiator	O
of	O
blood	S-Organism_substance
coagulation	O
that	O
is	O
expressed	S-Gene_expression
in	O
various	O
stages	O
of	O
atherosclerotic	B-Pathological_formation
lesions	E-Pathological_formation
in	O
humans	S-Organism
and	O
other	O
animals	O
.	O

Factors	O
including	O
thrombin	S-Gene_or_gene_product
and	O
fibrin	S-Gene_or_gene_product
,	O
which	O
are	O
downstream	S-Regulation
of	O
the	O
coagulation	B-Pathway
cascade	E-Pathway
activated	S-Positive_regulation
by	O
TF	S-Gene_or_gene_product
,	O
also	O
contribute	O
to	O
atherosclerosis	O
.	O

TF	S-Gene_or_gene_product
is	O
involved	S-Positive_regulation
in	O
cell	S-Cell
migration	S-Localization
,	O
embryogenesis	O
and	O
angiogenesis	S-Blood_vessel_development
.	O

Thus	O
TF	S-Gene_or_gene_product
,	O
in	O
addition	O
to	O
factors	O
downstream	O
of	O
the	O
coagulation	B-Pathway
cascade	E-Pathway
and	O
the	O
protease	B-Gene_or_gene_product
-	I-Gene_or_gene_product
activated	I-Gene_or_gene_product
receptor	I-Gene_or_gene_product
2	E-Gene_or_gene_product
activation	B-Pathway
system	E-Pathway
,	O
would	O
be	O
a	O
multifactorial	O
regulator	O
of	O
atherogenesis	O
.	O

Investigating	O
the	O
causes	O
of	O
low	O
birth	O
weight	O
in	O
contrasting	O
ovine	O
paradigms	O
.	O

Intrauterine	O
growth	O
restriction	O
(	O
IUGR	O
)	O
still	O
accounts	O
for	O
a	O
large	O
incidence	O
of	O
infant	S-Organism
mortality	O
and	O
morbidity	O
worldwide	O
.	O

Many	O
of	O
the	O
circulatory	O
and	O
transport	O
properties	O
of	O
the	O
sheep	S-Organism
placenta	S-Organ
are	O
similar	O
to	O
those	O
of	O
the	O
human	S-Organism
placenta	S-Organ
and	O
as	O
such	O
,	O
the	O
pregnant	O
sheep	S-Organism
offers	O
an	O
excellent	O
model	O
in	O
which	O
to	O
study	O
the	O
development	O
of	O
IUGR	O
.	O

Two	O
natural	O
models	O
of	O
ovine	O
IUGR	O
are	O
those	O
of	O
hyperthermic	O
exposure	O
during	O
pregnancy	O
,	O
and	O
adolescent	O
overfeeding	O
,	O
also	O
during	O
pregnancy	O
.	O

Both	O
models	O
yield	O
significantly	O
reduced	S-Negative_regulation
placental	S-Organ
weights	O
and	O
an	O
asymmetrically	O
growth	S-Growth
-	O
restricted	S-Negative_regulation
fetus	S-Developing_anatomical_structure
,	O
and	O
display	O
altered	O
maternal	O
hormone	O
concentrations	O
,	O
indicative	O
of	O
an	O
impaired	S-Negative_regulation
trophoblast	S-Cell
capacity	O
.	O

Additionally	O
,	O
impaired	S-Negative_regulation
placental	S-Organ
angiogenesis	S-Blood_vessel_development
and	O
uteroplacental	B-Organism_substance
blood	E-Organism_substance
flow	O
appears	O
to	O
be	O
an	O
early	O
defect	O
in	O
both	O
the	O
hyperthermic	O
and	O
adolescent	O
paradigms	O
.	O

The	O
effects	S-Regulation
of	O
these	O
alterations	S-Regulation
in	O
placental	S-Organ
functional	O
development	S-Development
appear	O
to	O
be	O
irreversible	O
.	O

IUGR	O
fetuses	S-Developing_anatomical_structure
are	O
both	O
hypoxic	O
and	O
hypoglycaemic	O
,	O
and	O
have	O
reduced	S-Negative_regulation
insulin	S-Gene_or_gene_product
and	O
insulin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
like	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
(	O
IGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
)	O
,	O
and	O
elevated	S-Positive_regulation
concentrations	O
of	O
lactate	S-Drug_or_compound
.	O

However	O
,	O
fetal	O
utilization	O
of	O
oxygen	S-Drug_or_compound
and	O
glucose	S-Drug_or_compound
,	O
on	O
a	O
weight	O
basis	O
,	O
remain	O
constant	O
compared	O
with	O
control	O
pregnancies	O
.	O

Maintained	O
utilization	O
of	O
these	O
substrates	O
,	O
in	O
a	O
substrate	O
-	O
deficient	O
environment	O
,	O
suggests	O
increased	O
sensitivities	O
to	O
metabolic	O
signals	O
,	O
which	O
may	O
play	O
a	O
role	O
in	O
the	O
development	O
of	O
metabolic	O
diseases	O
in	O
later	O
adult	O
life	O
.	O

Rofecoxib	S-Drug_or_compound
as	O
adjunctive	O
therapy	O
for	O
haemophilic	O
arthropathy	O
.	O

Joint	S-Multi-tissue_structure
haemorrhage	O
and	O
subsequent	O
haemophilic	O
arthropathy	O
are	O
significant	O
complications	O
in	O
haemophilia	O
.	O

The	O
pathophysiology	O
involves	O
inflammation	O
and	O
angiogenesis	S-Blood_vessel_development
.	O

Cyclooxygenase	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
(	O
COX	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
)	O
inhibitors	O
are	O
anti	O
-	O
inflammatory	O
agents	O
,	O
which	O
have	O
potent	O
anti	O
-	O
inflammatory	O
,	O
anti	O
-	O
angiogenic	S-Blood_vessel_development
and	O
analgesic	O
properties	S-Negative_regulation
yet	O
do	O
not	O
affect	S-Regulation
platelet	S-Cell
function	O
in	O
the	O
manner	O
of	O
traditional	O
non	B-Drug_or_compound
-	I-Drug_or_compound
steroidal	I-Drug_or_compound
anti	I-Drug_or_compound
-	I-Drug_or_compound
inflammatory	I-Drug_or_compound
drugs	E-Drug_or_compound
.	O

These	O
properties	O
make	O
such	O
agents	O
potentially	O
useful	O
as	O
adjunctive	O
therapy	O
in	O
haemophilia	O
.	O

There	O
is	O
only	O
one	O
prior	O
report	O
describing	O
rofecoxib	S-Drug_or_compound
treatment	S-Planned_process
in	O
a	O
single	O
haemophilia	O
patient	S-Organism
.	O

Our	O
objectives	O
were	O
to	O
determine	O
the	O
safety	O
and	O
efficacy	O
of	O
rofecoxib	S-Drug_or_compound
in	O
treating	S-Planned_process
acute	O
haemarthrosis	O
,	O
chronic	O
synovitis	O
,	O
target	O
joints	S-Multi-tissue_structure
and	O
pain	O
.	O

We	O
conducted	O
a	O
retrospective	O
medical	O
record	O
review	O
of	O
patients	S-Organism
treated	S-Planned_process
with	O
rofecoxib	S-Drug_or_compound
for	O
acute	O
haemarthrosis	O
,	O
chronic	O
synovitis	O
,	O
target	O
joint	S-Multi-tissue_structure
or	O
pain	O
.	O

The	O
safety	O
and	O
efficacy	O
of	O
rofecoxib	S-Drug_or_compound
treatment	S-Planned_process
were	O
determined	O
based	O
on	O
subjective	O
patient	S-Organism
reports	O
and	O
physical	O
examinations	O
during	O
follow	O
-	O
up	O
clinic	O
visits	O
.	O

A	O
total	O
of	O
28	O
patients	S-Organism
between	O
3	O
and	O
37	O
years	O
of	O
age	O
were	O
treated	S-Planned_process
for	O
a	O
total	O
of	O
42	O
courses	O
of	O
rofecoxib	S-Drug_or_compound
treatment	S-Planned_process
.	O

All	O
courses	O
were	O
evaluated	O
for	O
safety	O
and	O
31	O
for	O
efficacy	O
.	O

Rofecoxib	S-Drug_or_compound
was	O
used	S-Planned_process
for	O
eight	O
acute	O
haemarthrosis	O
,	O
four	O
target	O
joints	S-Multi-tissue_structure
,	O
seven	O
cases	O
of	O
synovitis	O
and	O
12	O
episodes	O
of	O
pain	O
.	O

Efficacy	O
was	O
demonstrated	O
particularly	O
for	O
chronic	O
synovitis	O
and	O
pain	O
and	O
no	O
serious	O
adverse	O
events	O
occurred	O
.	O

This	O
is	O
the	O
largest	O
study	O
to	O
date	O
evaluating	O
COX	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
inhibitors	O
as	O
adjunctive	O
therapy	O
in	O
haemophilia	O
and	O
suggests	O
that	O
these	O
agents	O
may	O
be	O
an	O
important	O
adjunctive	O
therapy	O
in	O
the	O
management	O
of	O
haemophilia	O
.	O

Randomized	O
,	O
open	O
label	O
,	O
prospective	O
study	O
on	O
the	O
effect	S-Regulation
of	O
zoledronic	B-Drug_or_compound
acid	E-Drug_or_compound
on	O
the	O
prevention	S-Negative_regulation
of	O
bone	B-Pathological_formation
metastases	E-Pathological_formation
in	O
patients	S-Organism
with	O
recurrent	O
solid	B-Pathological_formation
tumors	E-Pathological_formation
that	O
did	O
not	O
present	O
with	O
bone	B-Pathological_formation
metastases	E-Pathological_formation
at	O
baseline	O
.	O

OBJECTIVES	O
:	O
Bisphosphonates	S-Drug_or_compound
have	O
been	O
used	O
successfully	O
in	O
the	O
treatment	S-Planned_process
of	O
hypercalcemia	O
and	O
to	O
reduce	O
skeletal	S-Anatomical_system
-	O
related	O
complications	O
of	O
bone	B-Pathological_formation
metastases	E-Pathological_formation
.	O

Recent	O
in	O
vitro	O
and	O
in	O
vivo	O
evidence	O
suggest	O
that	O
they	O
may	O
also	O
have	O
direct	O
antitumor	O
effects	O
via	O
induction	O
of	O
apoptosis	O
,	O
inhibition	S-Negative_regulation
of	O
the	O
invasive	S-Localization
potential	O
of	O
tumor	B-Cell
cell	I-Cell
lines	E-Cell
in	O
vitro	O
,	O
inhibition	S-Negative_regulation
of	O
angiogenesis	S-Blood_vessel_development
,	O
and	O
reduction	S-Negative_regulation
in	O
tumor	S-Pathological_formation
growth	S-Growth
indirectly	O
via	O
effects	O
on	O
accessory	B-Cell
cells	E-Cell
.	O

This	O
is	O
a	O
randomized	O
,	O
open	O
label	O
,	O
prospective	O
study	O
that	O
examined	O
the	O
effect	S-Regulation
of	O
preventive	O
zoledronic	B-Drug_or_compound
acid	E-Drug_or_compound
treatment	S-Planned_process
on	O
the	O
development	S-Development
of	O
bone	B-Pathological_formation
metastases	E-Pathological_formation
in	O
patients	S-Organism
with	O
recurrent	O
solid	B-Pathological_formation
tumors	E-Pathological_formation
,	O
without	O
bone	B-Pathological_formation
metastases	E-Pathological_formation
at	O
the	O
time	O
of	O
randomization	O
.	O

METHODS	O
:	O
Forty	O
patients	S-Organism
with	O
recurrent	O
or	O
metastatic	O
advanced	O
cancer	O
,	O
without	O
bone	B-Pathological_formation
metastases	E-Pathological_formation
,	O
were	O
randomized	O
into	O
the	O
trial	O
to	O
either	O
receive	S-Planned_process
zoledronic	B-Drug_or_compound
acid	E-Drug_or_compound
or	O
no	O
treatment	S-Planned_process
.	O

Patients	S-Organism
were	O
followed	O
up	O
until	O
bone	B-Pathological_formation
metastases	E-Pathological_formation
were	O
established	O
.	O

RESULTS	O
:	O
The	O
percentage	O
of	O
patients	S-Organism
being	O
bone	B-Pathological_formation
metastases	E-Pathological_formation
free	O
at	O
12	O
mo	O
was	O
60	O
%	O
in	O
the	O
zoledronic	B-Drug_or_compound
acid	E-Drug_or_compound
and	O
10	O
%	O
in	O
the	O
control	O
group	O
(	O
p	O
less	O
than	O
0	O
.	O
0005	O
)	O
,	O
while	O
the	O
percentages	O
at	O
18	O
mo	O
were	O
20	O
%	O
and	O
5	O
%	O
respectively	O
(	O
p	O
=	O
0	O
.	O
0002	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
results	O
have	O
shown	O
that	O
bisphosphonates	S-Drug_or_compound
as	O
adjuvant	B-Planned_process
treatment	E-Planned_process
might	O
be	O
useful	O
for	O
the	O
prevention	S-Negative_regulation
of	O
bone	B-Pathological_formation
metastases	E-Pathological_formation
;	O
however	O
,	O
there	O
is	O
need	O
for	O
blinded	O
randomized	O
data	O
before	O
such	O
an	O
approach	O
would	O
be	O
confirmed	O
.	O

In	O
the	O
meantime	O
preventive	B-Planned_process
use	E-Planned_process
of	O
bisphosphonates	S-Drug_or_compound
in	O
patients	S-Organism
without	O
any	O
bone	B-Pathological_formation
metastases	E-Pathological_formation
should	O
not	O
be	O
used	O
outside	O
the	O
scope	O
of	O
a	O
clinical	O
trial	O
.	O

VEGF	S-Gene_or_gene_product
-	O
targeted	O
therapy	O
:	O
therapeutic	O
potential	O
and	O
recent	O
advances	O
.	O

After	O
over	O
30	O
years	O
of	O
theorizing	O
,	O
the	O
use	O
of	O
angiogenesis	S-Blood_vessel_development
inhibitors	O
as	O
anticancer	O
therapy	O
has	O
finally	O
moved	O
from	O
the	O
realm	O
of	O
research	O
to	O
reality	O
.	O

Normal	O
adult	O
vasculature	S-Anatomical_system
is	O
generally	O
quiescent	O
in	O
nature	O
,	O
with	O
endothelial	B-Cell
cells	E-Cell
dividing	S-Cell_division
approximately	O
every	O
10	O
years	O
.	O

In	O
contrast	O
,	O
the	O
growth	S-Growth
of	O
tumors	S-Pathological_formation
requires	S-Positive_regulation
constant	O
vascular	S-Multi-tissue_structure
growth	S-Growth
and	O
remodeling	S-Remodeling
in	O
order	O
for	O
solid	B-Pathological_formation
tumors	E-Pathological_formation
to	O
grow	S-Growth
beyond	O
1	O
-	O
2	O
mm	O
(	O
3	O
)	O
in	O
size	O
.	O

Vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
(	O
VEGF	S-Gene_or_gene_product
)	O
and	O
its	O
receptors	O
are	O
key	O
regulators	O
of	O
the	O
process	O
of	O
angiogenesis	S-Blood_vessel_development
,	O
which	O
makes	O
them	O
attractive	O
therapeutic	O
targets	O
.	O

A	O
multitude	O
of	O
VEGF	S-Gene_or_gene_product
-	O
targeted	O
inhibitory	O
agents	O
are	O
currently	O
being	O
investigated	O
for	O
the	O
treatment	O
of	O
cancer	O
.	O

This	O
review	O
article	O
focuses	O
on	O
recent	O
developments	O
in	O
the	O
use	O
of	O
angiogenesis	S-Blood_vessel_development
inhibitors	O
for	O
the	O
treatment	S-Planned_process
of	O
breast	S-Pathological_formation
,	O
lung	S-Pathological_formation
,	O
and	O
colorectal	B-Pathological_formation
cancers	E-Pathological_formation
.	O

Thalidomide	S-Drug_or_compound
and	O
angiostatin	S-Gene_or_gene_product
inhibit	S-Negative_regulation
tumor	S-Pathological_formation
growth	S-Growth
in	O
a	O
murine	S-Organism
xenograft	O
model	O
of	O
human	S-Organism
cervical	B-Pathological_formation
cancer	E-Pathological_formation
.	O

OBJECTIVE	O
:	O
To	O
determine	O
the	O
impact	O
of	O
thalidomide	S-Drug_or_compound
and	O
angiostatin	S-Gene_or_gene_product
on	O
tumor	S-Pathological_formation
growth	S-Growth
,	O
angiogenesis	S-Blood_vessel_development
,	O
and	O
apoptosis	S-Death
in	O
a	O
xenograft	O
model	O
of	O
cervical	B-Pathological_formation
cancer	E-Pathological_formation
.	O

METHODS	O
:	O
Human	S-Organism
umbilical	O
endothelial	B-Cell
cells	E-Cell
were	O
treated	S-Planned_process
with	O
angiostatin	S-Gene_or_gene_product
or	O
thalidomide	S-Drug_or_compound
and	O
bFGF	S-Gene_or_gene_product
-	O
induced	O
proliferation	O
was	O
assessed	O
with	O
the	O
MTT	O
assay	O
.	O

Human	S-Organism
cervical	B-Cell
cancer	I-Cell
cells	E-Cell
(	O
CaSki	S-Cell
and	O
SiHa	S-Cell
)	O
were	O
injected	S-Planned_process
into	O
the	O
flanks	S-Organism_subdivision
of	O
nude	B-Organism
mice	E-Organism
.	O

After	O
tumors	S-Pathological_formation
developed	S-Development
,	O
mice	S-Organism
were	O
treated	S-Planned_process
with	O
angiostatin	S-Gene_or_gene_product
20	O
mg	O
/	O
kg	O
/	O
day	O
or	O
thalidomide	S-Drug_or_compound
200	O
mg	O
/	O
kg	O
/	O
day	O
for	O
30	O
days	O
.	O

Fractional	O
tumor	S-Pathological_formation
growth	S-Growth
was	O
determined	O
and	O
immunohistochemical	O
analysis	O
of	O
tumors	S-Pathological_formation
was	O
used	O
to	O
determine	O
degree	O
of	O
angiogenesis	S-Blood_vessel_development
.	O

TUNEL	O
assay	O
was	O
used	O
to	O
assess	O
apoptosis	O
.	O

RESULTS	O
:	O
Angiostatin	S-Gene_or_gene_product
inhibited	S-Negative_regulation
endothelial	B-Cell
cell	E-Cell
proliferation	S-Cell_proliferation
by	O
50	O
-	O
60	O
%	O
.	O

Thalidomide	S-Drug_or_compound
had	O
no	B-Regulation
direct	I-Regulation
effect	E-Regulation
on	O
endothelial	B-Cell
cells	E-Cell
.	O

Angiostatin	S-Gene_or_gene_product
and	O
thalidomide	S-Drug_or_compound
both	O
inhibited	S-Negative_regulation
tumor	S-Pathological_formation
growth	S-Growth
by	O
about	O
55	O
%	O
.	O

We	O
found	O
no	O
additive	O
or	O
synergistic	O
effect	O
when	O
the	O
two	O
agents	O
were	O
combined	O
.	O

Both	O
agents	O
inhibited	S-Negative_regulation
angiogenesis	S-Blood_vessel_development
and	O
induced	O
apoptosis	O
when	O
compared	O
to	O
tumors	S-Pathological_formation
from	O
control	O
animals	O
.	O

CONCLUSIONS	O
:	O
Angiostatin	S-Gene_or_gene_product
and	O
thalidomide	S-Drug_or_compound
inhibit	S-Negative_regulation
tumor	S-Pathological_formation
growth	S-Growth
,	O
angiogenesis	S-Blood_vessel_development
,	O
and	O
induce	S-Positive_regulation
apoptosis	S-Death
in	O
this	O
xenograft	O
model	O
of	O
cervical	B-Pathological_formation
cancer	E-Pathological_formation
.	O

Therapeutic	O
Electromagnetic	O
Field	O
(	O
TEMF	O
)	O
and	O
gamma	O
irradiation	O
on	O
human	S-Organism
breast	B-Pathological_formation
cancer	I-Pathological_formation
xenograft	E-Pathological_formation
growth	S-Growth
,	O
angiogenesis	S-Blood_vessel_development
and	O
metastasis	O
.	O

BACKGROUND	O
:	O
The	O
effects	O
of	O
a	O
rectified	O
semi	O
-	O
sinewave	O
signal	O
(	O
15	O
mT	O
amplitude	O
,	O
120	O
pulses	O
per	O
second	O
,	O
EMF	O
Therapeutics	O
,	O
Inc	O
.	O
)	O
(	O
TEMF	O
)	O
alone	O
and	O
in	O
combination	O
with	O
gamma	O
irradiation	O
(	O
IR	O
)	O
therapy	O
in	O
nude	B-Organism
mice	E-Organism
bearing	O
a	O
human	S-Organism
MDA	B-Pathological_formation
MB231	I-Pathological_formation
breast	I-Pathological_formation
cancer	I-Pathological_formation
xenograft	E-Pathological_formation
were	O
tested	O
.	O

Green	B-Gene_or_gene_product
fluorescence	I-Gene_or_gene_product
protein	E-Gene_or_gene_product
transfected	S-Planned_process
cancer	B-Cell
cells	E-Cell
were	O
injected	S-Planned_process
into	O
the	O
mammary	B-Tissue
fat	I-Tissue
pad	E-Tissue
of	O
young	O
female	O
mice	S-Organism
.	O

Six	O
weeks	O
later	O
,	O
mice	S-Organism
were	O
randomly	O
divided	O
into	O
four	O
treatment	O
groups	O
:	O
untreated	O
controls	O
;	O
10	O
minute	O
daily	O
TEMF	O
;	O
200	O
cGy	O
of	O
IR	O
every	O
other	O
day	O
(	O
total	O
800	O
cGy	O
)	O
;	O
IR	O
plus	O
daily	O
TEMF	O
.	O

Some	O
mice	S-Organism
in	O
each	O
group	O
were	O
euthanized	S-Planned_process
24	O
hours	O
after	O
the	O
end	O
of	O
IR	O
.	O

TEMF	O
treatment	O
continued	O
for	O
3	O
additional	O
weeks	O
.	O

Tumor	B-Pathological_formation
sections	E-Pathological_formation
were	O
stained	O
for	O
:	O
endothelial	B-Cell
cells	E-Cell
with	O
CD31	S-Gene_or_gene_product
and	O
PAS	S-Drug_or_compound
or	O
hypoxia	B-Gene_or_gene_product
inducible	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
1alpha	E-Gene_or_gene_product
(	O
HIF	S-Gene_or_gene_product
)	O
.	O

RESULTS	O
:	O
Most	O
tumors	S-Pathological_formation
less	O
than	O
35	O
mm3	O
were	O
white	O
but	O
tumors	S-Pathological_formation
greater	O
than	O
35	O
mm3	O
were	O
pink	O
and	O
had	O
a	O
vascularized	B-Pathological_formation
capsule	E-Pathological_formation
.	O

The	O
cortex	S-Pathological_formation
within	O
100	O
microns	O
of	O
the	O
capsule	S-Pathological_formation
had	O
little	O
vascularization	S-Blood_vessel_development
.	O

Blood	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
,	O
capillaries	S-Tissue
,	O
and	O
endothelial	B-Cellular_component
pseudopods	E-Cellular_component
were	O
found	O
at	O
greater	O
than	O
100	O
microns	O
from	O
the	O
capsule	S-Pathological_formation
(	O
subcortex	S-Pathological_formation
)	O
.	O

Tumors	S-Pathological_formation
greater	O
than	O
35	O
mm3	O
treated	S-Planned_process
with	O
IR	O
24	O
hours	O
previously	O
or	O
with	O
TEMF	O
had	O
decreased	S-Negative_regulation
blood	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
in	O
the	O
subcortex	S-Pathological_formation
and	O
more	O
endothelial	B-Cellular_component
pseudopods	E-Cellular_component
projecting	O
into	O
hypoxic	O
,	O
HIF	S-Gene_or_gene_product
positive	O
areas	O
than	O
tumors	S-Pathological_formation
from	O
the	O
control	O
group	O
.	O

Mice	S-Organism
that	O
received	S-Planned_process
either	O
IR	O
or	O
TEMF	O
had	O
significantly	O
fewer	O
lung	S-Organ
metastatic	O
sites	O
and	O
slower	O
tumor	S-Pathological_formation
growth	S-Growth
than	O
did	O
untreated	S-Planned_process
mice	S-Organism
.	O

No	O
harmful	O
side	O
effects	O
were	O
attributed	O
to	O
TEMF	O
.	O

CONCLUSION	O
:	O
TEMF	O
therapy	O
provided	O
a	O
safe	O
means	O
for	O
retarding	S-Negative_regulation
tumor	S-Pathological_formation
vascularization	S-Blood_vessel_development
,	O
growth	S-Growth
and	O
metastasis	S-Localization
.	O

Thrombospondins	S-Gene_or_gene_product
,	O
metallo	B-Gene_or_gene_product
proteases	E-Gene_or_gene_product
and	O
thrombospondin	B-Gene_or_gene_product
receptors	E-Gene_or_gene_product
messenger	O
RNA	O
and	O
protein	O
expression	S-Gene_expression
in	O
different	O
tumour	B-Pathological_formation
sublines	E-Pathological_formation
of	O
the	O
Dunning	B-Pathological_formation
prostate	I-Pathological_formation
cancer	I-Pathological_formation
model	E-Pathological_formation
.	O

Thrombospondin	S-Gene_or_gene_product
is	O
a	O
potent	O
inhibitor	O
of	O
angiogenesis	S-Blood_vessel_development
and	O
might	O
therefore	O
be	O
important	O
in	O
controlling	S-Regulation
tumour	S-Pathological_formation
growth	S-Growth
.	O

TSP	S-Gene_or_gene_product
interacts	S-Binding
with	O
a	O
number	O
of	O
proteases	O
and	O
receptors	O
and	O
in	O
this	O
way	O
inhibits	S-Negative_regulation
stimulation	S-Positive_regulation
of	O
angiogenesis	S-Blood_vessel_development
.	O

An	O
earlier	O
study	O
showed	O
that	O
thrombospondin	S-Gene_or_gene_product
is	O
expressed	S-Gene_expression
in	O
benign	O
prostatic	O
hyperplasia	O
(	O
BPH	O
)	O
and	O
high	O
-	O
grade	O
prostatic	O
intraepithelial	O
neoplasia	O
(	O
PIN	O
)	O
but	O
is	O
absent	S-Gene_expression
in	O
prostate	B-Pathological_formation
cancer	E-Pathological_formation
.	O

The	O
present	O
study	O
was	O
therefore	O
designed	O
to	O
evaluate	O
the	O
expression	S-Gene_expression
of	O
thrombospondin	B-Gene_or_gene_product
1	E-Gene_or_gene_product
and	O
2	S-Gene_or_gene_product
(	O
TSP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
,	O
TSP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
)	O
,	O
TSP	S-Gene_or_gene_product
receptors	O
CD36	S-Gene_or_gene_product
and	O
CD47	S-Gene_or_gene_product
,	O
and	O
matrix	B-Gene_or_gene_product
-	I-Gene_or_gene_product
metalloproteases	I-Gene_or_gene_product
2	E-Gene_or_gene_product
and	O
9	S-Gene_or_gene_product
(	O
MMP	S-Gene_or_gene_product
-	O
,	O
MMP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
9	E-Gene_or_gene_product
)	O
in	O
a	O
rat	S-Organism
prostate	B-Pathological_formation
cancer	E-Pathological_formation
model	O
.	O

By	O
using	O
immunohistochemistry	O
,	O
Western	O
blot	O
,	O
and	O
real	O
-	O
time	O
PCR	O
the	O
expression	S-Gene_expression
patterns	O
of	O
TSP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
,	O
TSP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
,	O
CD36	S-Gene_or_gene_product
,	O
CD47	S-Gene_or_gene_product
,	O
MMP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
,	O
and	O
MMP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
9	E-Gene_or_gene_product
were	O
investigated	O
in	O
normal	O
rat	S-Organism
prostate	B-Tissue
tissue	E-Tissue
and	O
five	O
malignant	B-Tissue
Dunning	I-Tissue
sublines	I-Tissue
tissue	E-Tissue
.	O

TSP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
mRNA	O
levels	O
were	O
decreased	S-Negative_regulation
in	O
all	O
tumours	S-Pathological_formation
compared	O
with	O
normal	O
prostate	S-Organ
.	O

However	O
,	O
there	O
was	O
no	O
difference	O
in	O
expression	S-Transcription
of	O
TSP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
and	O
CD36	S-Gene_or_gene_product
mRNA	O
in	O
these	O
samples	O
.	O

MMP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
was	O
increased	S-Positive_regulation
with	O
malignancy	O
,	O
but	O
no	O
expression	S-Gene_expression
of	O
MMP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
9	E-Gene_or_gene_product
was	O
seen	O
.	O

The	O
CD47	B-Gene_or_gene_product
receptor	E-Gene_or_gene_product
did	O
slightly	O
increase	S-Positive_regulation
with	O
malignancy	O
except	O
for	O
H3327	S-Pathological_formation
.	O

The	O
results	O
showed	O
that	O
thrombospondin	S-Gene_or_gene_product
is	O
expressed	S-Gene_expression
in	O
normal	O
prostate	S-Organ
but	O
not	O
in	O
prostate	B-Pathological_formation
tumours	E-Pathological_formation
in	O
a	O
rat	S-Organism
model	O
.	O

Simultaneously	O
,	O
MMP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
expression	S-Gene_expression
increases	S-Positive_regulation
with	O
malignancy	O
.	O

Minimal	O
contribution	S-Regulation
of	O
marrow	B-Cell
-	I-Cell
derived	I-Cell
endothelial	I-Cell
precursors	E-Cell
to	O
tumor	B-Multi-tissue_structure
vasculature	E-Multi-tissue_structure
.	O

During	O
embryogenesis	O
,	O
vascular	S-Cell
and	O
hemopoietic	B-Cell
cells	E-Cell
originate	S-Development
from	O
a	O
common	O
precursor	O
,	O
the	O
hemangioblast	S-Cell
.	O

Recent	O
evidence	O
suggests	O
the	O
existence	S-Localization
of	O
endothelial	B-Cell
precursors	E-Cell
in	O
adult	O
bone	B-Cell
marrow	I-Cell
cells	E-Cell
,	O
but	O
it	O
is	O
unclear	O
whether	O
those	O
precursors	O
have	B-Regulation
a	I-Regulation
role	E-Regulation
in	O
tumor	S-Pathological_formation
neovascularization	S-Blood_vessel_development
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
murine	S-Organism
bone	B-Multi-tissue_structure
marrow	E-Multi-tissue_structure
contains	O
endothelial	B-Cell
progenitors	E-Cell
,	O
which	O
arise	O
from	O
a	O
cell	S-Cell
with	O
self	O
-	O
renewing	O
capacity	O
,	O
and	O
can	O
integrate	O
into	O
tumor	B-Tissue
microvasculature	E-Tissue
,	O
albeit	O
at	O
a	O
very	O
low	O
frequency	O
.	O

A	O
transgenic	O
double	O
-	O
reporter	O
strategy	O
allowed	O
us	O
to	O
demonstrate	O
definitively	O
that	O
tumor	B-Cell
bone	I-Cell
marrow	I-Cell
-	I-Cell
derived	I-Cell
endothelial	I-Cell
cells	E-Cell
arise	O
by	O
transdifferentiation	S-Development
of	O
marrow	B-Cell
progenitors	E-Cell
rather	O
than	O
by	O
cell	S-Cell
fusion	S-Development
.	O

Single	O
cell	S-Cell
transplants	S-Planned_process
showed	O
that	O
a	O
common	O
precursor	O
contributes	S-Regulation
to	O
both	O
the	O
hemopoietic	S-Cell
and	O
endothelial	B-Cell
lineages	E-Cell
,	O
thus	O
demonstrating	O
the	O
presence	O
of	O
an	O
adult	O
hemangioblast	S-Cell
.	O

Furthermore	O
,	O
we	O
demonstrate	O
that	O
increased	S-Positive_regulation
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
(	I-Gene_or_gene_product
VEGF	I-Gene_or_gene_product
)	I-Gene_or_gene_product
-	I-Gene_or_gene_product
A	E-Gene_or_gene_product
secretion	S-Localization
by	O
tumor	B-Cell
cells	E-Cell
,	O
as	O
well	O
as	O
activation	S-Positive_regulation
of	O
VEGF	B-Gene_or_gene_product
receptor	I-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
in	O
bone	B-Cell
marrow	I-Cell
cells	E-Cell
does	O
not	O
alter	O
the	O
mobilization	O
and	O
incorporation	S-Localization
of	O
marrow	B-Cell
-	I-Cell
derived	I-Cell
endothelial	I-Cell
progenitors	E-Cell
into	O
tumor	B-Tissue
vasculature	E-Tissue
.	O

Finally	O
,	O
in	O
human	S-Organism
umbilical	B-Cell
cord	I-Cell
blood	I-Cell
cells	E-Cell
,	O
we	O
show	O
that	O
endothelial	B-Cell
precursors	E-Cell
make	O
up	O
only	O
approximately	O
1	O
in	O
10	O
(	O
7	O
)	O
mononuclear	B-Cell
cells	E-Cell
but	O
are	O
highly	O
enriched	O
in	O
the	O
CD133	B-Cell
+	I-Cell
cell	E-Cell
population	O
.	O

By	O
ruling	O
out	O
cell	S-Cell
fusion	S-Development
,	O
we	O
clearly	O
demonstrate	O
the	O
existence	S-Localization
of	O
an	O
adult	O
hemangioblast	S-Cell
,	O
but	O
the	O
differentiation	S-Development
of	O
marrow	B-Cell
stem	I-Cell
cells	E-Cell
toward	O
the	O
endothelial	B-Cell
lineage	E-Cell
is	O
an	O
extremely	O
rare	O
event	O
.	O

Furthermore	O
,	O
we	O
show	O
that	O
VEGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
A	E-Gene_or_gene_product
stimulation	S-Positive_regulation
of	O
hemopoietic	B-Cell
cells	E-Cell
does	O
not	O
significantly	O
alter	O
this	O
process	O
.	O

Impaired	O
coronary	B-Multi-tissue_structure
collateral	I-Multi-tissue_structure
vessel	E-Multi-tissue_structure
development	S-Development
in	O
patients	S-Organism
with	O
proliferative	O
diabetic	O
retinopathy	O
.	O

BACKGROUND	O
:	O
Diabetic	O
patients	S-Organism
have	O
been	O
reported	O
to	O
have	O
impaired	O
coronary	B-Multi-tissue_structure
collateral	I-Multi-tissue_structure
vessel	E-Multi-tissue_structure
growth	S-Growth
,	O
although	O
they	O
have	O
excessive	O
neovascularization	S-Blood_vessel_development
in	O
the	O
retina	S-Multi-tissue_structure
.	O

HYPOTHESIS	O
:	O
This	O
study	O
was	O
designed	O
to	O
compare	O
coronary	O
collateral	O
circulation	O
(	O
CCC	O
)	O
in	O
patients	S-Organism
with	O
proliferative	O
diabetic	O
retinopathy	O
(	O
PDR	O
)	O
with	O
that	O
in	O
patients	S-Organism
without	O
DR	O
.	O

METHODS	O
:	O
Ninety	O
diabetic	O
patients	S-Organism
with	O
chronic	O
total	O
occlusion	O
in	O
at	O
least	O
one	O
major	O
epicardial	B-Multi-tissue_structure
coronary	I-Multi-tissue_structure
artery	E-Multi-tissue_structure
were	O
enrolled	O
in	O
the	O
study	O
.	O

Groups	O
1	O
and	O
2	O
consisted	O
of	O
48	O
patients	S-Organism
without	O
DR	O
and	O
42	O
patients	S-Organism
with	O
PDR	O
,	O
respectively	O
.	O

Coronary	O
collateral	O
circulation	O
(	O
CCC	O
)	O
was	O
analyzed	O
according	O
to	O
the	O
Rentrop	O
system	O
.	O

Each	O
group	O
was	O
also	O
divided	O
into	O
two	O
subgroups	O
according	O
to	O
poor	O
and	O
good	O
CCC	O
.	O

Serum	S-Organism_substance
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
(	O
VEGF	S-Gene_or_gene_product
)	O
levels	O
were	O
measured	O
using	O
the	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
kit	O
.	O

RESULTS	O
:	O
The	O
mean	O
Rentrop	O
collateral	O
score	O
was	O
higher	O
in	O
Group	O
1	O
than	O
in	O
Group	O
2	O
(	O
2	O
.	O
39	O
+	O
/	O
-	O
1	O
.	O
07	O
vs	O
.	O
1	O
.	O
76	O
+	O
/	O
-	O
0	O
.	O
76	O
,	O
respectively	O
,	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O

When	O
the	O
two	O
groups	O
were	O
compared	O
with	O
respect	O
to	O
poor	O
and	O
good	O
CCC	O
,	O
poor	O
CCC	O
was	O
higher	O
in	O
patients	S-Organism
with	O
PDR	O
(	O
64	O
vs	O
.	O
36	O
%	O
,	O
respectively	O
,	O
p	O
=	O
0	O
.	O
01	O
)	O
.	O

Serum	S-Organism_substance
VEGF	S-Gene_or_gene_product
levels	O
were	O
higher	O
in	O
patients	S-Organism
with	O
PDR	O
than	O
in	O
those	O
without	O
DR	O
(	O
219	O
+	O
/	O
-	O
99	O
vs	O
.	O
139	O
+	O
/	O
-	O
98	O
pg	O
/	O
ml	O
,	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
;	O
however	O
,	O
patients	S-Organism
with	O
poor	O
and	O
good	O
CCC	O
had	O
similar	O
VEGF	S-Gene_or_gene_product
levels	O
.	O

CONCLUSIONS	O
:	O
We	O
have	O
shown	O
that	O
patients	S-Organism
with	O
PDR	O
have	O
a	O
lower	O
coronary	O
collateral	O
score	O
than	O
patients	S-Organism
without	O
DR	O
.	O

Also	O
,	O
serum	S-Organism_substance
VEGF	S-Gene_or_gene_product
was	O
significantly	O
higher	O
in	O
patients	S-Organism
with	O
PDR	O
than	O
in	O
those	O
without	O
DR	O
.	O

These	O
findings	O
have	O
suggested	O
that	O
diabetes	O
mellitus	O
may	O
have	O
a	O
different	O
action	O
on	O
retinal	S-Multi-tissue_structure
and	O
coronary	S-Multi-tissue_structure
circulation	O
.	O

The	O
merits	O
of	O
vascular	O
targeting	O
for	O
gynecologic	O
malignancies	O
.	O

Neovascularization	S-Blood_vessel_development
is	O
an	O
early	O
and	O
critical	O
step	O
in	O
tumor	S-Pathological_formation
development	S-Development
and	O
progression	S-Development
.	O

Tumor	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
are	O
distinct	O
from	O
their	O
normal	O
counterparts	O
morphologically	O
as	O
well	O
as	O
at	O
a	O
molecular	O
level	O
.	O

Recent	O
studies	O
on	O
factors	O
involved	O
in	O
tumor	B-Multi-tissue_structure
vascular	E-Multi-tissue_structure
development	S-Development
have	O
identified	O
new	O
therapeutic	O
targets	O
for	O
inhibiting	S-Negative_regulation
tumor	S-Pathological_formation
neovascularization	S-Blood_vessel_development
and	O
thus	O
tumor	S-Pathological_formation
progression	S-Development
.	O

However	O
,	O
the	O
process	O
of	O
tumor	B-Multi-tissue_structure
blood	I-Multi-tissue_structure
vessel	E-Multi-tissue_structure
formation	S-Development
is	O
complex	O
,	O
and	O
each	O
tumor	S-Pathological_formation
exhibits	O
unique	O
features	O
in	O
its	O
vasculature	S-Multi-tissue_structure
.	O

An	O
understanding	O
of	O
the	O
relative	O
contribution	O
of	O
various	O
pathways	O
in	O
the	O
development	S-Development
of	O
tumor	B-Multi-tissue_structure
vasculature	E-Multi-tissue_structure
is	O
critical	O
for	O
developing	O
effective	O
and	O
selective	O
therapeutic	O
approaches	O
.	O

Several	O
such	O
agents	O
are	O
currently	O
in	O
clinical	O
trials	O
,	O
and	O
many	O
others	O
are	O
under	O
development	O
.	O

In	O
this	O
review	O
,	O
the	O
mechanisms	O
and	O
factors	O
involved	O
in	O
tumor	B-Multi-tissue_structure
blood	I-Multi-tissue_structure
vessel	E-Multi-tissue_structure
formation	S-Development
are	O
discussed	O
.	O

In	O
addition	O
,	O
selected	O
novel	O
classes	O
of	O
antivascular	O
therapies	O
,	O
including	O
those	O
targeting	S-Planned_process
tumor	B-Cell
endothelial	I-Cell
cells	E-Cell
and	O
other	O
components	O
of	O
the	O
tumor	B-Multi-tissue_structure
vasculature	E-Multi-tissue_structure
,	O
are	O
summarized	O
.	O

Domain	B-Protein_domain_or_region
5	E-Protein_domain_or_region
of	O
cleaved	S-Protein_processing
high	B-Gene_or_gene_product
molecular	I-Gene_or_gene_product
weight	I-Gene_or_gene_product
kininogen	E-Gene_or_gene_product
inhibits	S-Negative_regulation
endothelial	B-Cell
cell	E-Cell
migration	S-Localization
through	O
Akt	S-Gene_or_gene_product
.	O

Domain	B-Protein_domain_or_region
5	E-Protein_domain_or_region
(	O
D5	S-Protein_domain_or_region
)	O
of	O
cleaved	S-Protein_processing
high	B-Gene_or_gene_product
molecular	I-Gene_or_gene_product
weight	I-Gene_or_gene_product
kininogen	E-Gene_or_gene_product
(	O
HKa	S-Gene_or_gene_product
)	O
inhibits	S-Negative_regulation
angiogenesis	S-Blood_vessel_development
in	O
vivo	O
and	O
endothelial	B-Cell
cell	E-Cell
migration	S-Localization
in	O
vitro	O
,	O
but	O
the	O
cell	S-Cell
signaling	B-Pathway
pathways	E-Pathway
involved	S-Regulation
in	O
HKa	S-Gene_or_gene_product
and	O
D5	S-Protein_domain_or_region
inhibition	S-Negative_regulation
of	O
endothelial	B-Cell
cell	E-Cell
migration	S-Localization
are	O
incompletely	O
delineated	O
.	O

This	O
study	O
examines	O
the	O
mechanism	O
of	O
HKa	S-Gene_or_gene_product
and	O
D5	S-Protein_domain_or_region
inhibition	S-Negative_regulation
of	O
two	O
potent	O
stimulators	O
of	O
endothelial	B-Cell
cell	E-Cell
migration	S-Localization
,	O
sphingosine	B-Gene_or_gene_product
1	I-Gene_or_gene_product
-	I-Gene_or_gene_product
phosphate	E-Gene_or_gene_product
(	O
S1P	S-Gene_or_gene_product
)	O
and	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
(	O
VEGF	S-Gene_or_gene_product
)	O
,	O
that	O
act	S-Regulation
through	O
the	O
P13	B-Gene_or_gene_product
-	I-Gene_or_gene_product
kinase	E-Gene_or_gene_product
-	O
Akt	S-Gene_or_gene_product
signaling	B-Pathway
pathway	E-Pathway
.	O

HKa	S-Gene_or_gene_product
and	O
D5	S-Protein_domain_or_region
inhibit	S-Negative_regulation
bovine	S-Organism
pulmonary	B-Cell
artery	I-Cell
endothelial	I-Cell
cell	E-Cell
(	O
BPAE	S-Cell
)	O
or	O
human	S-Organism
umbilical	B-Cell
vein	I-Cell
endothelial	I-Cell
cell	E-Cell
chemotaxis	S-Localization
in	O
the	O
modified	O
-	O
Boyden	O
chamber	O
in	O
response	S-Positive_regulation
toVEGF	S-Gene_or_gene_product
or	O
S1P	S-Gene_or_gene_product
.	O

The	O
inhibition	S-Negative_regulation
of	O
migration	S-Localization
by	O
HKa	S-Gene_or_gene_product
is	O
reversed	S-Negative_regulation
by	O
antibodies	B-Gene_or_gene_product
to	I-Gene_or_gene_product
urokinase	I-Gene_or_gene_product
-	I-Gene_or_gene_product
type	I-Gene_or_gene_product
plasminogen	I-Gene_or_gene_product
activator	I-Gene_or_gene_product
receptor	E-Gene_or_gene_product
.	O

Both	O
HKa	S-Gene_or_gene_product
and	O
D5	S-Protein_domain_or_region
decrease	S-Negative_regulation
the	O
speed	O
of	O
BPAE	B-Cell
cell	E-Cell
migration	S-Localization
and	O
alter	O
the	O
morphology	O
in	O
live	O
,	O
time	O
-	O
lapse	O
microscopy	O
after	O
stimulation	S-Positive_regulation
with	O
S1P	S-Gene_or_gene_product
or	O
VEGF	S-Gene_or_gene_product
.	O

HKa	S-Gene_or_gene_product
and	O
D5	S-Protein_domain_or_region
reduce	S-Negative_regulation
the	O
localization	S-Localization
of	O
paxillin	S-Gene_or_gene_product
to	O
the	O
focal	B-Cellular_component
adhesions	E-Cellular_component
after	O
S1P	S-Gene_or_gene_product
and	O
VEGF	S-Gene_or_gene_product
stimulation	S-Positive_regulation
.	O

To	O
better	O
understand	O
the	O
intracellular	O
signaling	O
pathways	O
,	O
we	O
examined	O
the	O
effect	S-Regulation
of	O
HKa	S-Gene_or_gene_product
on	O
the	O
phosphorylation	S-Phosphorylation
of	O
Akt	S-Gene_or_gene_product
and	O
its	O
downstream	O
effector	O
,	O
GSK	B-Gene_or_gene_product
-	I-Gene_or_gene_product
3alpha	E-Gene_or_gene_product
HKa	S-Gene_or_gene_product
and	O
D5	S-Protein_domain_or_region
inhibit	S-Negative_regulation
phosphorylation	S-Phosphorylation
of	O
Akt	S-Gene_or_gene_product
and	O
GSK	B-Gene_or_gene_product
-	I-Gene_or_gene_product
3alpha	E-Gene_or_gene_product
after	O
stimulation	S-Positive_regulation
withVEGF	S-Gene_or_gene_product
and	O
S1P	S-Gene_or_gene_product
.	O

Inhibitors	O
of	O
Akt	S-Gene_or_gene_product
and	O
P13	B-Gene_or_gene_product
-	I-Gene_or_gene_product
kinase	E-Gene_or_gene_product
,	O
the	O
upstream	O
activator	O
of	O
Akt	S-Gene_or_gene_product
,	O
block	S-Negative_regulation
endothelial	B-Cell
cell	E-Cell
migration	S-Localization
and	O
disrupt	S-Negative_regulation
paxillin	S-Gene_or_gene_product
localization	S-Localization
to	O
the	O
focal	B-Cellular_component
adhesions	E-Cellular_component
after	O
stimulation	S-Positive_regulation
with	O
VEGF	S-Gene_or_gene_product
and	O
S1P	S-Gene_or_gene_product
.	O

Therefore	O
we	O
suggest	O
that	O
HKa	S-Gene_or_gene_product
through	O
its	O
D5	S-Protein_domain_or_region
domain	O
alters	S-Regulation
P13	B-Gene_or_gene_product
-	I-Gene_or_gene_product
kinase	E-Gene_or_gene_product
-	O
Akt	S-Gene_or_gene_product
signaling	S-Pathway
to	O
inhibit	S-Negative_regulation
endothelial	B-Cell
cell	E-Cell
migration	S-Localization
through	O
alterations	S-Regulation
in	O
the	O
focal	B-Cellular_component
adhesions	E-Cellular_component
.	O

Effect	O
of	O
thalidomide	S-Drug_or_compound
affecting	S-Regulation
VEGF	S-Gene_or_gene_product
secretion	S-Localization
,	O
cell	B-Localization
migration	E-Localization
,	O
adhesion	S-Binding
and	O
capillary	B-Tissue
tube	E-Tissue
formation	S-Development
of	O
human	S-Organism
endothelial	B-Cell
EA	I-Cell
.	I-Cell
hy	I-Cell
926	I-Cell
cells	E-Cell
.	O

Angiogenesis	S-Blood_vessel_development
,	O
new	O
blood	B-Multi-tissue_structure
vessel	E-Multi-tissue_structure
formation	S-Development
,	O
is	O
a	O
multistep	O
process	O
,	O
precisely	O
regulated	S-Regulation
by	O
pro	O
-	O
angiogenic	S-Blood_vessel_development
cytokines	O
,	O
which	O
stimulate	S-Positive_regulation
endothelial	B-Cell
cells	E-Cell
to	O
migrate	S-Localization
,	O
proliferate	S-Cell_proliferation
and	O
differentiate	S-Development
to	O
form	S-Development
new	O
capillary	B-Tissue
microvessels	E-Tissue
.	O

Excessive	O
vascular	S-Multi-tissue_structure
development	S-Development
and	O
blood	B-Multi-tissue_structure
vessel	E-Multi-tissue_structure
remodeling	S-Remodeling
appears	O
in	O
psoriasis	O
,	O
rheumatoid	O
arthritis	O
,	O
diabetic	O
retinopathy	O
and	O
solid	B-Pathological_formation
tumors	E-Pathological_formation
formation	S-Development
.	O

Thalidomide	S-Drug_or_compound
[	O
alpha	B-Drug_or_compound
-	I-Drug_or_compound
(	I-Drug_or_compound
N	I-Drug_or_compound
-	I-Drug_or_compound
phthalimido	I-Drug_or_compound
)	I-Drug_or_compound
-	I-Drug_or_compound
glutarimide	E-Drug_or_compound
]	O
is	O
known	O
to	O
be	O
a	O
potent	O
inhibitor	O
of	O
angiogenesis	S-Blood_vessel_development
,	O
but	O
the	O
mechanism	O
of	O
its	O
inhibitory	B-Negative_regulation
action	E-Negative_regulation
remains	O
unclear	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
investigate	O
the	O
potential	O
influence	S-Regulation
of	O
thalidomide	S-Drug_or_compound
on	O
the	O
several	O
steps	O
of	O
angiogenesis	S-Blood_vessel_development
,	O
using	O
in	O
vitro	O
models	O
.	O

We	O
have	O
evaluated	O
the	O
effect	S-Regulation
of	O
thalidomide	S-Drug_or_compound
on	O
VEGF	S-Gene_or_gene_product
secretion	S-Localization
,	O
cell	B-Localization
migration	E-Localization
,	O
adhesion	S-Binding
as	O
well	O
as	O
in	O
capillary	S-Tissue
formation	S-Development
of	O
human	S-Organism
endothelial	B-Cell
cell	I-Cell
line	I-Cell
EA	I-Cell
.	I-Cell
hy	I-Cell
926	E-Cell
.	O

Thalidomide	S-Drug_or_compound
at	O
the	O
concentrations	O
of	O
0	O
.	O
01	O
microM	O
and	O
10	O
microM	O
inhibited	S-Negative_regulation
VEGF	S-Gene_or_gene_product
secretion	S-Localization
into	O
supernatants	O
,	O
decreased	S-Negative_regulation
the	O
number	O
of	O
formed	S-Development
capillary	B-Tissue
tubes	E-Tissue
and	O
increased	S-Positive_regulation
cell	S-Cell
adhesion	S-Binding
to	O
collagen	S-Gene_or_gene_product
.	O

Administration	S-Planned_process
of	O
thalidomide	S-Drug_or_compound
at	O
the	O
concentration	O
of	O
0	O
.	O
01	O
microM	O
increased	S-Positive_regulation
cell	S-Cell
migration	S-Localization
,	O
while	O
at	O
10	O
microM	O
,	O
it	O
decreased	S-Negative_regulation
cell	S-Cell
migration	S-Localization
.	O

Thalidomide	S-Drug_or_compound
in	O
concentrations	O
from	O
0	O
.	O
1	O
microM	O
to	O
10	O
microM	O
did	O
not	O
change	S-Regulation
cell	S-Cell
proliferation	S-Cell_proliferation
of	O
72	O
-	O
h	O
cell	B-Cell
cultures	E-Cell
.	O

We	O
conclude	O
that	O
anti	O
-	O
angiogenic	S-Blood_vessel_development
action	S-Negative_regulation
of	O
thalidomide	S-Drug_or_compound
is	O
due	S-Positive_regulation
to	O
direct	O
inhibitory	B-Negative_regulation
action	E-Negative_regulation
on	O
VEGF	S-Gene_or_gene_product
secretion	S-Localization
and	O
capillary	B-Tissue
microvessel	E-Tissue
formation	S-Development
as	O
well	O
as	O
immunomodulatory	O
influence	S-Regulation
on	O
EA	B-Cell
.	I-Cell
hy	I-Cell
926	I-Cell
cells	E-Cell
migration	S-Localization
and	O
adhesion	S-Binding
.	O

Regulation	S-Regulation
of	O
skin	B-Tissue
microvasculature	E-Tissue
angiogenesis	S-Blood_vessel_development
,	O
cell	S-Cell
migration	S-Localization
,	O
and	O
permeability	O
by	O
a	O
specific	O
inhibitor	O
of	O
PKCalpha	S-Gene_or_gene_product
.	O

Activation	S-Positive_regulation
of	O
protein	B-Gene_or_gene_product
kinase	I-Gene_or_gene_product
C	E-Gene_or_gene_product
(	O
PKC	S-Gene_or_gene_product
)	O
induces	S-Positive_regulation
phenotypic	O
changes	S-Regulation
in	O
the	O
morphology	O
of	O
microvascular	B-Cell
endothelial	I-Cell
cells	E-Cell
that	O
affect	S-Regulation
major	O
functions	O
of	O
the	O
microvasculature	S-Tissue
.	O

These	O
functions	O
include	O
the	O
first	O
stages	O
of	O
sprouting	O
in	O
angiogenesis	S-Blood_vessel_development
,	O
cell	S-Cell
migration	S-Localization
following	O
wounding	O
,	O
and	O
vascular	S-Multi-tissue_structure
permeability	O
.	O

The	O
specific	O
isoform	O
(	O
s	O
)	O
of	O
PKC	S-Gene_or_gene_product
responsible	S-Regulation
for	O
each	O
of	O
these	O
changes	O
has	O
not	O
been	O
previously	O
identified	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
two	O
inflammatory	O
agents	O
,	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1beta	E-Gene_or_gene_product
and	O
phorbol	B-Drug_or_compound
myristic	I-Drug_or_compound
acetate	E-Drug_or_compound
,	O
to	O
activate	S-Positive_regulation
PKC	S-Gene_or_gene_product
isozymes	O
and	O
specific	O
inhibitors	O
of	O
PKCalpha	S-Gene_or_gene_product
(	O
Go6976	S-Drug_or_compound
)	O
and	O
PKCbeta	S-Gene_or_gene_product
(	O
hispidin	S-Drug_or_compound
)	O
to	O
distinguish	O
how	O
each	O
of	O
these	O
isoform	O
(	O
s	O
)	O
controls	S-Regulation
angiogenesis	S-Blood_vessel_development
,	O
wound	O
healing	O
,	O
and	O
permeability	O
.	O

In	O
all	O
cases	O
,	O
only	O
inhibition	S-Negative_regulation
of	O
PKCalpha	S-Gene_or_gene_product
inhibited	O
each	O
of	O
these	O
functions	O
when	O
compared	O
to	O
the	O
inhibition	S-Negative_regulation
of	O
PKCbeta	S-Gene_or_gene_product
.	O

Additional	O
analysis	O
of	O
the	O
mechanism	O
of	O
action	O
of	O
Go6976	S-Drug_or_compound
(	O
RT	O
-	O
PCR	O
,	O
Western	O
blots	O
,	O
and	O
immunohistochemistry	O
)	O
of	O
the	O
changes	S-Regulation
in	O
the	O
phosphorylated	S-Phosphorylation
and	O
nonphosphorylated	S-Phosphorylation
forms	O
of	O
PKCalpha	S-Gene_or_gene_product
in	O
the	O
cell	B-Cellular_component
membrane	E-Cellular_component
and	O
cytoplasm	S-Cellular_component
confirmed	O
the	O
specificity	O
of	O
PKCalpha	S-Gene_or_gene_product
inhibition	S-Negative_regulation
by	O
Go6976	S-Drug_or_compound
.	O

These	O
studies	O
therefore	O
indicate	O
a	O
specific	O
and	O
a	O
regulatory	O
role	O
of	O
the	O
PKCalpha	S-Gene_or_gene_product
isoform	O
in	O
three	O
major	O
endothelial	B-Cell
cell	E-Cell
functions	O
that	O
are	O
important	O
in	O
the	O
maintenance	O
of	O
microvascular	S-Tissue
homeostasis	O
.	O

The	O
differential	O
regulation	S-Regulation
of	O
human	S-Organism
telomerase	B-Gene_or_gene_product
reverse	I-Gene_or_gene_product
transcriptase	E-Gene_or_gene_product
and	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
may	O
contribute	O
to	O
the	O
clinically	O
more	O
aggressive	O
behavior	O
of	O
p63	B-Pathological_formation
-	I-Pathological_formation
positive	I-Pathological_formation
breast	I-Pathological_formation
carcinomas	E-Pathological_formation
.	O

p63	S-Gene_or_gene_product
,	O
a	O
p53	S-Gene_or_gene_product
homologue	O
,	O
is	O
a	O
myoepithelial	B-Cell
cell	E-Cell
marker	O
in	O
the	O
normal	O
mammary	B-Organ
gland	E-Organ
but	O
p63	B-Cell
-	I-Cell
positive	I-Cell
neoplastic	I-Cell
cells	E-Cell
may	O
be	O
found	O
in	O
up	O
to	O
11	O
%	O
of	O
invasive	B-Pathological_formation
breast	I-Pathological_formation
carcinomas	E-Pathological_formation
.	O

This	O
study	O
aims	O
to	O
verify	O
the	O
relationship	O
between	O
p63	S-Gene_or_gene_product
expression	S-Gene_expression
and	O
several	O
clinicopathological	O
features	O
and	O
tumor	S-Pathological_formation
markers	O
of	O
clinical	O
significance	O
in	O
breast	S-Organism_subdivision
pathology	O
including	O
key	O
regulators	O
of	O
the	O
cell	S-Cell
cycle	O
,	O
oncogenes	O
,	O
apoptosis	O
-	O
related	O
proteins	O
,	O
metalloproteinases	S-Gene_or_gene_product
and	O
their	O
inhibitors	O
.	O

Immunohistochemistry	O
with	O
27	O
primary	O
antibodies	O
was	O
performed	O
in	O
100	O
formalin	O
-	O
fixed	O
paraffin	O
-	O
embedded	O
samples	O
of	O
invasive	B-Pathological_formation
ductal	I-Pathological_formation
carcinomas	E-Pathological_formation
.	O

p63	B-Cell
-	I-Cell
positive	I-Cell
cells	E-Cell
were	O
found	S-Localization
in	O
16	O
%	O
of	O
carcinomas	S-Pathological_formation
.	O

p63	B-Cell
-	I-Cell
positive	I-Cell
carcinomas	E-Cell
were	O
poorly	O
differentiated	S-Development
,	O
hormone	O
receptor	O
-	O
negative	O
neoplasms	S-Pathological_formation
with	O
a	O
high	O
proliferation	S-Growth
rate	O
.	O

p63	S-Gene_or_gene_product
also	O
correlated	O
with	O
advanced	O
pathological	O
stage	O
,	O
tumor	S-Pathological_formation
size	O
,	O
and	O
the	O
expression	S-Gene_expression
of	O
human	S-Organism
telomerase	B-Gene_or_gene_product
reverse	I-Gene_or_gene_product
transcriptase	E-Gene_or_gene_product
(	O
hTERT	S-Gene_or_gene_product
)	O
,	O
tissue	B-Gene_or_gene_product
inhibitor	I-Gene_or_gene_product
of	I-Gene_or_gene_product
matrix	I-Gene_or_gene_product
metalloproteinase	I-Gene_or_gene_product
1	E-Gene_or_gene_product
(	O
TIMP1	S-Gene_or_gene_product
)	O
and	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
(	O
VEGF	S-Gene_or_gene_product
)	O
.	O

The	O
expression	S-Gene_expression
of	O
TIMP1	S-Gene_or_gene_product
suggests	O
that	O
the	O
anti	O
-	O
proteolytic	O
stimuli	O
may	O
be	O
preponderant	O
in	O
p63	B-Pathological_formation
-	I-Pathological_formation
positive	I-Pathological_formation
carcinomas	E-Pathological_formation
.	O

hTERT	S-Gene_or_gene_product
activity	O
is	O
associated	O
with	O
nodal	O
metastases	O
and	O
cellular	O
proliferation	O
.	O

VEGF	S-Gene_or_gene_product
regulates	S-Regulation
angiogenesis	S-Blood_vessel_development
,	O
which	O
is	O
also	O
a	O
fundamental	O
event	O
in	O
the	O
process	O
of	O
tumor	S-Pathological_formation
growth	S-Growth
and	O
metastatic	B-Localization
dissemination	E-Localization
.	O

Thus	O
,	O
the	O
differential	O
regulation	S-Regulation
of	O
hTERT	S-Gene_or_gene_product
and	O
VEGF	S-Gene_or_gene_product
in	O
p63	B-Pathological_formation
-	I-Pathological_formation
positive	I-Pathological_formation
breast	I-Pathological_formation
carcinomas	E-Pathological_formation
may	O
contribute	O
to	O
the	O
clinically	O
more	O
aggressive	O
behavior	O
of	O
these	O
neoplasms	S-Pathological_formation
.	O

Mechanisms	O
of	O
pericyte	S-Cell
recruitment	S-Localization
in	O
tumour	S-Pathological_formation
angiogenesis	S-Blood_vessel_development
:	O
a	O
new	O
role	O
for	O
metalloproteinases	S-Gene_or_gene_product
.	O

Pericytes	S-Cell
occur	O
in	O
tumour	B-Multi-tissue_structure
blood	I-Multi-tissue_structure
vessels	E-Multi-tissue_structure
and	O
are	O
critical	S-Positive_regulation
for	O
the	O
development	S-Development
of	O
a	O
functional	O
vascular	B-Multi-tissue_structure
network	E-Multi-tissue_structure
.	O

Targeting	S-Planned_process
tumour	B-Cell
pericytes	E-Cell
is	O
a	O
promising	O
anti	O
-	O
angiogenic	S-Blood_vessel_development
therapy	S-Negative_regulation
but	O
requires	O
identifying	O
the	O
mechanisms	O
of	O
their	O
recruitment	S-Localization
in	O
tumour	S-Pathological_formation
and	O
addressing	O
whether	O
these	O
mechanisms	O
can	O
be	O
selectively	O
harnessed	O
.	O

Among	O
the	O
pathways	O
involved	O
in	O
pericyte	S-Cell
recruitment	S-Localization
during	O
embryonic	O
development	O
,	O
the	O
contribution	S-Regulation
of	O
platelet	B-Gene_or_gene_product
-	I-Gene_or_gene_product
derived	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
B	E-Gene_or_gene_product
and	O
sphingosine	B-Gene_or_gene_product
1	I-Gene_or_gene_product
-	I-Gene_or_gene_product
phosphate	E-Gene_or_gene_product
is	O
confirmed	O
in	O
tumour	S-Pathological_formation
angiogenesis	S-Blood_vessel_development
.	O

The	O
effect	O
of	O
angiopoietin	B-Gene_or_gene_product
1	E-Gene_or_gene_product
depends	O
on	O
the	O
tumour	S-Pathological_formation
model	O
.	O

Transforming	B-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
-	I-Gene_or_gene_product
beta1	E-Gene_or_gene_product
enhances	S-Positive_regulation
tumour	S-Pathological_formation
vascularization	S-Blood_vessel_development
and	O
microvessel	S-Tissue
maturation	S-Development
.	O

Recent	O
reports	O
suggest	O
a	O
participation	S-Regulation
of	O
matrix	B-Gene_or_gene_product
metalloproteinases	E-Gene_or_gene_product
(	O
MMP	S-Gene_or_gene_product
)	O
in	O
tumour	B-Cell
pericyte	E-Cell
recruitment	S-Localization
that	O
is	O
consistent	O
with	O
the	O
effect	S-Regulation
of	O
certain	O
MMPs	S-Gene_or_gene_product
in	O
the	O
development	S-Development
of	O
microvasculature	S-Multi-tissue_structure
in	O
embryonic	O
development	O
and	O
in	O
in	O
vitro	O
models	O
of	O
vascular	S-Multi-tissue_structure
remodelling	S-Remodeling
.	O

Here	O
,	O
we	O
discuss	O
the	O
possibility	O
for	O
MMPs	S-Gene_or_gene_product
to	O
contribute	S-Positive_regulation
to	O
pericyte	S-Cell
recruitment	S-Localization
at	O
six	O
levels	O
:	O
(	O
1	O
)	O
direct	O
promotion	S-Positive_regulation
of	O
pericyte	S-Cell
invasion	S-Localization
by	O
extracellular	B-Cellular_component
matrix	E-Cellular_component
degradation	S-Breakdown
;	O
(	O
2	O
)	O
stimulation	S-Positive_regulation
of	O
pericyte	S-Cell
proliferation	S-Cell_proliferation
and	O
protection	O
against	O
apoptosis	O
by	O
modification	O
of	O
the	O
ECM	S-Cellular_component
;	O
(	O
3	O
)	O
activation	S-Positive_regulation
of	O
pericytes	S-Cell
through	O
the	O
release	O
of	O
growth	O
factor	O
bound	S-Binding
to	O
the	O
ECM	S-Cellular_component
;	O
(	O
4	O
)	O
transactivation	O
of	O
angiogenic	S-Blood_vessel_development
cell	O
surface	O
receptor	O
;	O
(	O
5	O
)	O
propagation	O
of	O
angiogenic	S-Blood_vessel_development
signalling	O
as	O
cofactor	O
;	O
and	O
(	O
6	O
)	O
recruitment	S-Localization
of	O
bone	B-Cell
marrow	I-Cell
-	I-Cell
derived	I-Cell
stem	I-Cell
cells	E-Cell
.	O

Regulation	S-Regulation
of	O
tumor	S-Pathological_formation
angiogenesis	S-Blood_vessel_development
by	O
thrombospondin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
.	O

Angiogenesis	S-Blood_vessel_development
plays	B-Regulation
a	I-Regulation
critical	I-Regulation
role	E-Regulation
in	O
the	O
growth	S-Growth
and	O
metastasis	S-Localization
of	O
tumors	S-Pathological_formation
.	O

Thrombospondin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
(	O
TSP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
)	O
is	O
a	O
potent	O
angiogenesis	S-Blood_vessel_development
inhibitor	O
,	O
and	O
down	B-Negative_regulation
-	I-Negative_regulation
regulation	E-Negative_regulation
of	O
TSP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
has	O
been	O
suggested	O
to	O
alter	S-Regulation
tumor	S-Pathological_formation
growth	S-Growth
by	O
modulating	S-Regulation
angiogenesis	S-Blood_vessel_development
in	O
a	O
variety	O
of	O
tumor	S-Pathological_formation
types	O
.	O

Expression	S-Gene_expression
of	O
TSP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
is	O
up	B-Positive_regulation
-	I-Positive_regulation
regulated	E-Positive_regulation
by	O
the	O
tumor	S-Pathological_formation
suppressor	O
gene	O
,	O
p53	S-Gene_or_gene_product
,	O
and	O
down	B-Negative_regulation
-	I-Negative_regulation
regulated	E-Negative_regulation
by	O
oncogenes	O
such	O
as	O
Myc	S-Gene_or_gene_product
and	O
Ras	S-Gene_or_gene_product
.	O

TSP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
inhibits	S-Negative_regulation
angiogenesis	S-Blood_vessel_development
by	O
inhibiting	S-Negative_regulation
endothelial	B-Cell
cell	E-Cell
migration	S-Localization
and	O
proliferation	S-Cell_proliferation
and	O
by	O
inducing	O
apoptosis	O
.	O

In	O
addition	O
,	O
activation	S-Positive_regulation
of	O
transforming	B-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
beta	E-Gene_or_gene_product
(	O
TGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
beta	E-Gene_or_gene_product
)	O
by	O
TSP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
plays	B-Regulation
a	I-Regulation
crucial	I-Regulation
role	E-Regulation
in	O
the	O
regulation	S-Regulation
of	O
tumor	S-Pathological_formation
progression	S-Development
.	O

An	O
understanding	O
of	O
the	O
molecular	O
basis	O
of	O
TSP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
-	O
mediated	O
inhibition	S-Negative_regulation
of	O
angiogenesis	S-Blood_vessel_development
and	O
tumor	S-Pathological_formation
progression	S-Development
will	O
aid	O
in	O
the	O
development	O
of	O
novel	O
therapeutics	O
for	O
the	O
treatment	O
of	O
cancer	O
.	O

Regulation	S-Regulation
of	O
the	O
composition	O
of	O
the	O
extracellular	B-Cellular_component
matrix	E-Cellular_component
by	O
low	B-Gene_or_gene_product
density	I-Gene_or_gene_product
lipoprotein	I-Gene_or_gene_product
receptor	I-Gene_or_gene_product
-	I-Gene_or_gene_product
related	I-Gene_or_gene_product
protein	I-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
:	O
activities	O
based	O
on	O
regulation	O
of	O
mRNA	O
expression	O
.	O

Low	B-Gene_or_gene_product
density	I-Gene_or_gene_product
lipoprotein	I-Gene_or_gene_product
receptor	I-Gene_or_gene_product
-	I-Gene_or_gene_product
related	I-Gene_or_gene_product
protein	I-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
(	O
LRP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
)	O
is	O
a	O
catabolic	O
receptor	O
for	O
extracellular	B-Cellular_component
matrix	E-Cellular_component
(	O
ECM	S-Cellular_component
)	O
structural	O
proteins	O
and	O
for	O
proteins	O
that	O
bind	S-Binding
to	O
ECM	S-Cellular_component
.	O

LRP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
also	O
is	O
implicated	S-Regulation
in	O
integrin	S-Gene_or_gene_product
maturation	S-Protein_processing
.	O

In	O
this	O
study	O
,	O
we	O
applied	O
a	O
proteomics	O
strategy	O
to	O
identify	O
novel	O
proteins	O
involved	O
in	O
ECM	S-Cellular_component
modeling	S-Development
that	O
are	O
regulated	S-Regulation
by	O
LRP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
.	O

We	O
show	O
that	O
LRP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
deficiency	S-Gene_expression
in	O
murine	S-Organism
embryonic	B-Cell
fibroblasts	E-Cell
(	O
MEFs	S-Cell
)	O
is	O
associated	O
with	O
increased	S-Positive_regulation
levels	O
of	O
type	B-Gene_or_gene_product
III	I-Gene_or_gene_product
collagen	E-Gene_or_gene_product
and	O
pigment	B-Gene_or_gene_product
epithelium	I-Gene_or_gene_product
-	I-Gene_or_gene_product
derived	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
,	O
which	O
accumulate	O
in	O
the	O
substratum	S-Cellular_component
surrounding	O
cells	S-Cell
.	O

The	O
collagen	S-Gene_or_gene_product
receptor	O
,	O
uPAR	B-Gene_or_gene_product
-	I-Gene_or_gene_product
AP	E-Gene_or_gene_product
/	O
Endo	B-Gene_or_gene_product
-	I-Gene_or_gene_product
180	E-Gene_or_gene_product
,	O
is	O
also	O
increased	S-Positive_regulation
in	O
LRP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
-	O
deficient	S-Gene_expression
MEFs	S-Cell
.	O

Human	S-Organism
LRP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
reversed	O
the	O
changes	O
in	O
protein	O
expression	O
associated	O
with	O
LRP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
deficiency	S-Gene_expression
;	O
however	O
,	O
the	O
endocytic	O
activity	O
of	O
LRP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
was	O
not	O
involved	O
.	O

Instead	O
,	O
regulation	O
occurred	O
at	O
the	O
mRNA	O
level	O
.	O

Inhibition	S-Negative_regulation
of	O
c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
Jun	I-Gene_or_gene_product
amino	I-Gene_or_gene_product
-	I-Gene_or_gene_product
terminal	I-Gene_or_gene_product
kinase	E-Gene_or_gene_product
(	O
JNK	S-Gene_or_gene_product
)	O
blocked	S-Negative_regulation
type	B-Gene_or_gene_product
III	I-Gene_or_gene_product
collagen	E-Gene_or_gene_product
expression	S-Gene_expression
in	O
LRP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
-	O
deficient	S-Gene_expression
MEFs	S-Cell
,	O
suggesting	O
regulation	S-Regulation
of	O
JNK	S-Gene_or_gene_product
activity	O
as	O
a	O
mechanism	O
by	O
which	O
LRP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
controls	O
mRNA	O
expression	O
.	O

The	O
ability	O
of	O
LRP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
to	O
regulate	O
expression	O
of	O
the	O
factors	O
identified	O
here	O
suggests	O
a	O
role	S-Regulation
for	O
LRP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
in	O
determining	O
blood	B-Multi-tissue_structure
vessel	E-Multi-tissue_structure
structure	O
and	O
in	O
angiogenesis	S-Blood_vessel_development
.	O

Pericytes	S-Cell
limit	S-Negative_regulation
tumor	B-Cell
cell	E-Cell
metastasis	S-Localization
.	O

Previously	O
we	O
observed	O
that	O
neural	B-Gene_or_gene_product
cell	I-Gene_or_gene_product
adhesion	I-Gene_or_gene_product
molecule	E-Gene_or_gene_product
(	O
NCAM	S-Gene_or_gene_product
)	O
deficiency	S-Gene_expression
in	O
beta	B-Cell
tumor	I-Cell
cells	E-Cell
facilitates	S-Positive_regulation
metastasis	S-Localization
into	O
distant	O
organs	S-Organ
and	O
local	O
lymph	B-Multi-tissue_structure
nodes	E-Multi-tissue_structure
.	O

Here	O
,	O
we	O
show	O
that	O
NCAM	B-Pathological_formation
-	I-Pathological_formation
deficient	I-Pathological_formation
beta	I-Pathological_formation
cell	I-Pathological_formation
tumors	E-Pathological_formation
grew	S-Development
leaky	O
blood	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
with	O
perturbed	O
pericyte	S-Cell
-	O
endothelial	S-Cell
cell	B-Binding
-	I-Binding
cell	I-Binding
interactions	E-Binding
and	O
deficient	O
perivascular	S-Immaterial_anatomical_entity
deposition	S-Localization
of	O
ECM	B-Cellular_component
components	E-Cellular_component
.	O

Conversely	O
,	O
tumor	B-Cell
cell	E-Cell
expression	S-Gene_expression
of	O
NCAM	S-Gene_or_gene_product
in	O
a	O
fibrosarcoma	B-Pathological_formation
model	E-Pathological_formation
(	O
T241	S-Pathological_formation
)	O
improved	S-Positive_regulation
pericyte	S-Cell
recruitment	S-Localization
and	O
increased	S-Positive_regulation
perivascular	S-Immaterial_anatomical_entity
deposition	S-Localization
of	O
ECM	B-Cellular_component
molecules	E-Cellular_component
.	O

Together	O
,	O
these	O
findings	O
suggest	O
that	O
NCAM	S-Gene_or_gene_product
may	O
limit	S-Negative_regulation
tumor	B-Cell
cell	E-Cell
metastasis	S-Localization
by	O
stabilizing	S-Positive_regulation
the	O
microvessel	B-Tissue
wall	E-Tissue
.	O

To	O
directly	O
address	O
whether	O
pericyte	S-Cell
dysfunction	S-Death
increases	S-Positive_regulation
the	O
metastatic	S-Localization
potential	O
of	O
solid	B-Pathological_formation
tumors	E-Pathological_formation
,	O
we	O
studied	O
beta	B-Cell
cell	E-Cell
tumorigenesis	O
in	O
primary	O
pericyte	S-Cell
-	O
deficient	O
Pdgfb	B-Organism
(	I-Organism
ret	I-Organism
/	I-Organism
ret	I-Organism
)	I-Organism
mice	E-Organism
.	O

This	O
resulted	O
in	O
beta	B-Cell
tumor	I-Cell
cell	E-Cell
metastases	S-Localization
in	O
distant	O
organs	S-Organ
and	O
local	O
lymph	B-Multi-tissue_structure
nodes	E-Multi-tissue_structure
,	O
demonstrating	O
a	O
role	S-Regulation
for	O
pericytes	S-Cell
in	O
limiting	S-Negative_regulation
tumor	B-Cell
cell	E-Cell
metastasis	S-Localization
.	O

These	O
data	O
support	O
a	O
new	O
model	O
for	O
how	O
tumor	B-Cell
cells	E-Cell
trigger	S-Positive_regulation
metastasis	S-Localization
by	O
perturbing	S-Regulation
pericyte	S-Cell
-	O
endothelial	S-Cell
cell	B-Binding
-	I-Binding
cell	I-Binding
interactions	E-Binding
.	O

NF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
kappaB	E-Gene_or_gene_product
and	O
IKK	S-Gene_or_gene_product
as	O
therapeutic	O
targets	O
in	O
cancer	S-Pathological_formation
.	O

The	O
transcription	O
factor	O
NF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
kappaB	E-Gene_or_gene_product
and	O
associated	S-Binding
regulatory	O
factors	O
(	O
including	O
IkappaB	S-Gene_or_gene_product
kinase	O
subunits	O
and	O
the	O
IkappaB	S-Gene_or_gene_product
family	O
member	O
Bcl	B-Gene_or_gene_product
-	I-Gene_or_gene_product
3	E-Gene_or_gene_product
)	O
are	O
strongly	O
implicated	O
in	O
a	O
variety	O
of	O
hematologic	O
and	O
solid	B-Pathological_formation
tumor	E-Pathological_formation
malignancies	O
.	O

A	O
role	O
for	O
NF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
kappaB	E-Gene_or_gene_product
in	O
cancer	B-Cell
cells	E-Cell
appears	O
to	O
involve	O
regulation	S-Regulation
of	O
cell	B-Cell_proliferation
proliferation	E-Cell_proliferation
,	O
control	S-Regulation
of	O
apoptosis	S-Death
,	O
promotion	S-Positive_regulation
of	O
angiogenesis	S-Blood_vessel_development
,	O
and	O
stimulation	S-Positive_regulation
of	O
invasion	S-Localization
/	O
metastasis	S-Localization
.	O

Consistent	O
with	O
a	O
role	O
for	O
NF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
kappaB	E-Gene_or_gene_product
in	O
oncogenesis	O
are	O
observations	O
that	O
inhibition	S-Negative_regulation
of	O
NF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
kappaB	E-Gene_or_gene_product
alone	O
or	O
in	O
combination	O
with	O
cancer	S-Pathological_formation
therapies	S-Planned_process
leads	S-Positive_regulation
to	O
tumor	B-Cell
cell	E-Cell
death	S-Death
or	O
growth	S-Growth
inhibition	S-Negative_regulation
.	O

However	O
,	O
other	O
experimental	O
data	O
indicate	O
that	O
NF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
kappaB	E-Gene_or_gene_product
can	O
play	S-Negative_regulation
a	O
tumor	S-Pathological_formation
suppressor	O
role	O
in	O
certain	O
settings	O
and	O
that	O
it	O
can	O
be	O
important	O
in	O
promoting	O
an	O
apoptotic	O
signal	O
downstream	O
of	O
certain	O
cancer	O
therapy	O
regimens	O
.	O

In	O
order	O
to	O
appropriately	O
move	O
NF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
kappaB	E-Gene_or_gene_product
inhibitors	O
in	O
the	O
clinic	O
,	O
thorough	O
approaches	O
must	O
be	O
initiated	O
to	O
determine	O
the	O
molecular	O
mechanisms	O
that	O
dictate	O
the	O
complexity	O
of	O
oncologic	O
and	O
therapeutic	O
outcomes	O
that	O
are	O
controlled	O
by	O
NF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
kappaB	E-Gene_or_gene_product
.	O

Circulating	O
endothelial	B-Cell
cells	E-Cell
in	O
malignant	O
disease	O
.	O

Cancer	S-Pathological_formation
is	O
a	O
disease	O
largely	O
dependent	S-Positive_regulation
on	O
neoangiogenesis	S-Blood_vessel_development
.	O

Cancer	S-Pathological_formation
neoangiogenesis	S-Blood_vessel_development
is	O
often	O
disordered	O
and	O
abnormal	O
,	O
with	O
evidence	O
of	O
coexisting	O
vascular	B-Tissue
endothelial	E-Tissue
dysfunction	S-Breakdown
.	O

A	O
novel	O
method	O
of	O
assessing	O
vascular	B-Tissue
endothelial	E-Tissue
function	O
in	O
cancer	S-Pathological_formation
is	O
via	O
the	O
quantification	O
of	O
circulating	B-Cell
endothelial	I-Cell
cells	E-Cell
(	O
CEC	S-Cell
)	O
.	O

Unusual	O
in	O
healthy	O
individuals	O
,	O
their	O
presence	O
in	O
elevated	O
numbers	O
often	O
indicates	O
substantial	O
vascular	B-Tissue
endothelial	E-Tissue
perturbation	O
.	O

Another	O
interesting	O
cell	S-Cell
type	O
is	O
the	O
endothelial	B-Cell
progenitor	I-Cell
cell	E-Cell
(	O
EPC	S-Cell
)	O
,	O
whose	O
numbers	O
increase	S-Positive_regulation
in	O
the	O
presence	O
of	O
vascular	S-Tissue
damage	S-Breakdown
.	O

Recent	O
research	O
suggests	O
that	O
EPCs	S-Cell
have	B-Regulation
an	I-Regulation
important	I-Regulation
role	E-Regulation
in	O
tumor	S-Pathological_formation
vasculogenesis	S-Blood_vessel_development
.	O

Another	O
marker	O
being	O
investigated	O
in	O
the	O
context	O
of	O
vascular	S-Tissue
dysfunction	S-Breakdown
and	O
coagulopathy	O
is	O
the	O
endothelial	B-Cellular_component
microparticle	E-Cellular_component
(	O
EMP	S-Cellular_component
)	O
.	O

Thus	O
,	O
CECs	S-Cell
,	O
EPCs	S-Cell
and	O
EMPs	S-Cellular_component
may	O
represent	O
potentially	O
novel	O
methods	O
for	O
evaluating	O
the	O
vascular	O
status	O
of	O
cancer	S-Pathological_formation
patients	S-Organism
.	O

This	O
review	O
will	O
summarize	O
the	O
current	O
position	O
of	O
CECs	S-Cell
,	O
EPCs	S-Cell
and	O
EMPs	S-Cellular_component
in	O
cell	S-Cell
biology	O
terms	O
,	O
with	O
particular	O
emphasis	O
on	O
their	O
relationship	O
to	O
malignant	O
disease	O
.	O

Ectopic	O
localization	S-Localization
of	O
mitochondrial	B-Gene_or_gene_product
ATP	I-Gene_or_gene_product
synthase	E-Gene_or_gene_product
:	O
a	O
target	S-Regulation
for	O
anti	O
-	O
angiogenesis	S-Blood_vessel_development
intervention	S-Negative_regulation
?	O

A	O
receptor	O
for	O
angiostatin	S-Gene_or_gene_product
was	O
identified	S-Localization
on	O
the	O
surface	O
of	O
endothelial	B-Cell
cells	E-Cell
as	O
F	B-Gene_or_gene_product
(	I-Gene_or_gene_product
1	I-Gene_or_gene_product
)	I-Gene_or_gene_product
-	I-Gene_or_gene_product
F	I-Gene_or_gene_product
(	I-Gene_or_gene_product
0	I-Gene_or_gene_product
)	I-Gene_or_gene_product
ATP	I-Gene_or_gene_product
synthase	E-Gene_or_gene_product
(	O
Moser	O
et	O
al	O
.	O
,	O
1999	O
)	O
.	O

Proc	O
.	O

Natl	O
.	O

Acad	O
.	O

Sci	O
.	O

U	O
.	O
S	O
.	O
A	O
.	O

96	O
,	O
2811	O
-	O
2816	O
.	O

This	O
ectopic	O
ATP	B-Gene_or_gene_product
synthase	E-Gene_or_gene_product
catalyzes	S-Positive_regulation
ATP	S-Drug_or_compound
synthesis	S-Synthesis
and	O
is	O
inhibited	S-Negative_regulation
by	O
angiostatin	S-Gene_or_gene_product
over	O
a	O
wide	O
pH	O
range	O
.	O

Endothelial	B-Cell
cells	E-Cell
grown	S-Cell_proliferation
at	O
normal	O
pH	O
suffer	O
no	O
ill	O
effects	O
from	O
this	O
angiostatin	S-Gene_or_gene_product
-	O
mediated	O
inhibition	S-Negative_regulation
of	O
ATP	B-Gene_or_gene_product
synthase	E-Gene_or_gene_product
,	O
whereas	O
endothelial	B-Cell
cells	E-Cell
grown	S-Cell_proliferation
at	O
low	O
,	O
tumor	S-Pathological_formation
-	O
like	O
extracellular	O
pH	O
cannot	O
maintain	O
a	O
normal	O
intracellular	O
pH	O
and	O
die	O
.	O

Angiostatin	S-Gene_or_gene_product
inhibits	S-Negative_regulation
both	O
ATP	S-Drug_or_compound
synthesis	S-Synthesis
and	O
ATP	S-Drug_or_compound
hydrolysis	S-Catabolism
(	O
Moser	O
et	O
al	O
.	O
,	O
2001	O
)	O
and	O
interferes	O
with	O
intracellular	O
pH	O
regulation	O
(	O
Wahl	O
and	O
Grant	O
,	O
2002	O
;	O
Wahl	O
et	O
al	O
.	O
,	O
2002	O
)	O
.	O

Although	O
angiostatin	S-Gene_or_gene_product
administered	S-Planned_process
intravenously	O
is	O
cleared	O
from	O
the	O
circulation	O
in	O
a	O
matter	O
of	O
minutes	O
,	O
angiostatin	B-Drug_or_compound
-	I-Drug_or_compound
mimetics	E-Drug_or_compound
that	O
are	O
more	O
stable	O
have	O
potential	O
for	O
clinical	O
application	O
.	O

An	O
angiostatin	B-Drug_or_compound
-	I-Drug_or_compound
mimetic	E-Drug_or_compound
activity	O
has	O
recently	O
been	O
observed	O
using	O
a	O
polyclonal	B-Gene_or_gene_product
antibody	I-Gene_or_gene_product
against	I-Gene_or_gene_product
the	I-Gene_or_gene_product
beta	I-Gene_or_gene_product
catalytic	I-Gene_or_gene_product
subunit	I-Gene_or_gene_product
of	I-Gene_or_gene_product
ATP	I-Gene_or_gene_product
synthase	E-Gene_or_gene_product
.	O

In	O
order	O
to	O
explore	O
the	O
mechanism	O
of	O
action	O
of	O
angiostatin	S-Gene_or_gene_product
and	O
its	O
mimetics	O
,	O
further	O
work	O
needs	O
to	O
be	O
done	O
to	O
evaluate	O
clinical	O
applicability	O
,	O
specificity	O
,	O
and	O
contraindications	O
for	O
this	O
class	O
of	O
therapeutics	O
.	O

GDP	S-Drug_or_compound
and	O
AGE	S-Drug_or_compound
receptors	O
:	O
mechanisms	O
of	O
peritoneal	S-Multi-tissue_structure
damage	S-Breakdown
.	O

Long	O
-	O
term	O
peritoneal	O
dialysis	O
(	O
PD	O
)	O
is	O
limited	O
by	O
morphological	B-Remodeling
changes	E-Remodeling
of	O
the	O
peritoneal	B-Multi-tissue_structure
membrane	E-Multi-tissue_structure
.	O

Structural	O
changes	O
were	O
promoted	S-Positive_regulation
by	O
toxicity	O
of	O
glucose	B-Drug_or_compound
degradation	I-Drug_or_compound
products	E-Drug_or_compound
(	O
GDPs	S-Drug_or_compound
)	O
which	O
are	O
generated	O
during	O
heat	O
sterilization	O
in	O
peritoneal	O
dialysis	O
fluids	O
(	O
PDFs	O
)	O
.	O

Besides	O
their	O
direct	O
toxicity	O
GDPs	S-Drug_or_compound
promote	S-Positive_regulation
formation	S-Synthesis
of	O
advanced	B-Drug_or_compound
glycation	I-Drug_or_compound
endproducts	E-Drug_or_compound
(	O
AGEs	S-Drug_or_compound
)	O
.	O

RAGE	S-Gene_or_gene_product
(	O
receptor	B-Gene_or_gene_product
for	I-Gene_or_gene_product
AGE	E-Gene_or_gene_product
)	O
is	O
the	O
best	O
characterized	O
signal	O
transduction	O
receptor	O
for	O
AGEs	S-Drug_or_compound
and	O
is	O
expressed	S-Gene_expression
on	O
mesothelial	B-Cell
cells	E-Cell
.	O

The	O
effects	O
of	O
PDFs	O
with	O
different	O
amounts	O
of	O
GDPs	S-Drug_or_compound
were	O
compared	O
on	O
morphological	B-Remodeling
changes	E-Remodeling
in	O
the	O
peritoneal	B-Multi-tissue_structure
membrane	E-Multi-tissue_structure
in	O
a	O
RAGE	B-Organism
-	I-Organism
/	I-Organism
-	I-Organism
mouse	E-Organism
model	O
.	O

It	O
could	O
be	O
demonstrated	O
that	O
RAGE	S-Gene_or_gene_product
plays	B-Regulation
a	I-Regulation
pivotal	I-Regulation
role	E-Regulation
in	O
structural	B-Breakdown
damage	E-Breakdown
(	O
e	O
.	O
g	O
.	O
inflammation	O
,	O
neoangiogenesis	S-Blood_vessel_development
and	O
fibrosis	O
)	O
of	O
the	O
peritoneal	B-Multi-tissue_structure
membrane	E-Multi-tissue_structure
.	O

Further	O
investigations	O
of	O
this	O
pathway	O
with	O
regard	O
to	O
preventing	O
peritoneal	S-Multi-tissue_structure
fibrosis	O
should	O
be	O
performed	O
to	O
maintain	O
the	O
integrity	O
of	O
the	O
peritoneal	B-Multi-tissue_structure
membrane	E-Multi-tissue_structure
in	O
peritoneal	S-Multi-tissue_structure
dialysis	O
patients	S-Organism
.	O

Prostate	B-Gene_or_gene_product
-	I-Gene_or_gene_product
specific	I-Gene_or_gene_product
membrane	I-Gene_or_gene_product
antigen	E-Gene_or_gene_product
regulates	S-Regulation
angiogenesis	S-Blood_vessel_development
by	O
modulating	S-Regulation
integrin	S-Gene_or_gene_product
signal	O
transduction	O
.	O

The	O
transmembrane	O
peptidase	O
prostate	B-Gene_or_gene_product
-	I-Gene_or_gene_product
specific	I-Gene_or_gene_product
membrane	I-Gene_or_gene_product
antigen	E-Gene_or_gene_product
(	O
PSMA	S-Gene_or_gene_product
)	O
is	O
universally	O
upregulated	S-Positive_regulation
in	O
the	O
vasculature	S-Multi-tissue_structure
of	O
solid	B-Pathological_formation
tumors	E-Pathological_formation
,	O
but	O
its	O
functional	O
role	S-Regulation
in	O
tumor	S-Pathological_formation
angiogenesis	S-Blood_vessel_development
has	O
not	O
been	O
investigated	O
.	O

Here	O
we	O
show	O
that	O
angiogenesis	S-Blood_vessel_development
is	O
severely	O
impaired	S-Negative_regulation
in	O
PSMA	S-Gene_or_gene_product
-	O
null	O
animals	O
and	O
that	O
this	O
angiogenic	S-Blood_vessel_development
defect	S-Negative_regulation
occurs	O
at	O
the	O
level	O
of	O
endothelial	B-Cell
cell	E-Cell
invasion	S-Localization
through	O
the	O
extracellular	B-Cellular_component
matrix	I-Cellular_component
barrier	E-Cellular_component
.	O

Because	O
proteolytic	O
degradation	S-Breakdown
of	O
the	O
extracellular	B-Cellular_component
matrix	E-Cellular_component
is	O
a	O
critical	O
component	O
of	O
endothelial	S-Cell
invasion	S-Localization
in	O
angiogenesis	S-Blood_vessel_development
,	O
it	O
is	O
logical	O
to	O
assume	O
that	O
PSMA	S-Gene_or_gene_product
participates	S-Regulation
in	O
matrix	S-Cellular_component
degradation	S-Breakdown
.	O

However	O
,	O
we	O
demonstrate	O
a	O
novel	O
and	O
more	O
complex	O
role	S-Regulation
for	O
PSMA	S-Gene_or_gene_product
in	O
angiogenesis	S-Blood_vessel_development
,	O
where	O
it	O
is	O
a	O
principal	O
component	O
of	O
a	O
regulatory	O
loop	O
that	O
is	O
tightly	O
modulating	S-Regulation
laminin	S-Gene_or_gene_product
-	O
specific	O
integrin	S-Gene_or_gene_product
signaling	S-Pathway
and	O
GTPase	O
-	O
dependent	O
,	O
p21	B-Gene_or_gene_product
-	I-Gene_or_gene_product
activated	I-Gene_or_gene_product
kinase	I-Gene_or_gene_product
1	E-Gene_or_gene_product
(	O
PAK	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
)	O
activity	O
.	O

We	O
show	O
that	O
PSMA	S-Gene_or_gene_product
inhibition	S-Negative_regulation
,	O
knockdown	S-Planned_process
,	O
or	O
deficiency	S-Gene_expression
decreases	S-Negative_regulation
endothelial	B-Cell
cell	E-Cell
invasion	S-Localization
in	O
vitro	O
via	O
integrin	S-Gene_or_gene_product
and	O
PAK	S-Gene_or_gene_product
,	O
thus	O
abrogating	S-Negative_regulation
angiogenesis	S-Blood_vessel_development
.	O

Interestingly	O
,	O
the	O
neutralization	S-Negative_regulation
of	O
beta	B-Gene_or_gene_product
(	I-Gene_or_gene_product
1	I-Gene_or_gene_product
)	E-Gene_or_gene_product
or	O
the	O
inactivation	S-Negative_regulation
of	O
PAK	S-Gene_or_gene_product
increases	S-Positive_regulation
PSMA	S-Gene_or_gene_product
activity	O
,	O
suggesting	O
that	O
they	O
negatively	B-Negative_regulation
regulate	E-Negative_regulation
PSMA	S-Gene_or_gene_product
.	O

This	O
negative	B-Negative_regulation
regulation	E-Negative_regulation
is	O
mediated	S-Regulation
by	O
the	O
cytoskeleton	O
as	O
the	O
disruption	S-Negative_regulation
of	O
interactions	S-Binding
between	O
the	O
PSMA	S-Gene_or_gene_product
cytoplasmic	O
tail	O
and	O
the	O
anchor	O
protein	O
filamin	B-Gene_or_gene_product
A	E-Gene_or_gene_product
decreases	S-Negative_regulation
PSMA	S-Gene_or_gene_product
activity	O
,	O
integrin	S-Gene_or_gene_product
function	O
,	O
and	O
PAK	S-Gene_or_gene_product
activation	S-Positive_regulation
.	O

Finally	O
,	O
the	O
inhibition	S-Negative_regulation
of	O
PAK	S-Gene_or_gene_product
activation	S-Positive_regulation
enhances	S-Positive_regulation
the	O
PSMA	S-Gene_or_gene_product
/	O
filamin	B-Gene_or_gene_product
A	E-Gene_or_gene_product
interaction	S-Binding
and	O
,	O
thus	O
,	O
boosts	S-Positive_regulation
PSMA	S-Gene_or_gene_product
activity	O
.	O

These	O
data	O
imply	O
that	O
PSMA	S-Gene_or_gene_product
participates	S-Regulation
in	O
an	O
autoregulatory	O
loop	O
,	O
wherein	O
active	O
PSMA	S-Gene_or_gene_product
facilitates	S-Positive_regulation
integrin	S-Gene_or_gene_product
signaling	S-Pathway
and	O
PAK	S-Gene_or_gene_product
activation	S-Positive_regulation
,	O
leading	S-Positive_regulation
to	O
both	O
productive	O
invasion	O
and	O
downregulation	S-Negative_regulation
of	O
integrin	B-Gene_or_gene_product
beta	I-Gene_or_gene_product
(	I-Gene_or_gene_product
1	I-Gene_or_gene_product
)	E-Gene_or_gene_product
signaling	S-Pathway
via	O
reduced	S-Negative_regulation
PSMA	S-Gene_or_gene_product
activity	O
.	O

Therefore	O
,	O
we	O
have	O
identified	O
a	O
novel	O
role	O
for	O
PSMA	S-Gene_or_gene_product
as	O
a	O
true	O
molecular	O
interface	O
,	O
integrating	O
both	O
extracellular	O
and	O
intracellular	O
signals	O
during	O
angiogenesis	S-Blood_vessel_development
.	O

Heparin	S-Drug_or_compound
immobilized	O
porous	O
PLGA	S-Drug_or_compound
microspheres	O
for	O
angiogenic	S-Blood_vessel_development
growth	O
factor	O
delivery	O
.	O

PURPOSE	O
:	O
Heparin	S-Drug_or_compound
immobilized	O
porous	O
poly	B-Drug_or_compound
(	I-Drug_or_compound
D	I-Drug_or_compound
,	I-Drug_or_compound
L	I-Drug_or_compound
-	I-Drug_or_compound
lactic	I-Drug_or_compound
-	I-Drug_or_compound
co	I-Drug_or_compound
-	I-Drug_or_compound
glycolic	I-Drug_or_compound
acid	I-Drug_or_compound
)	E-Drug_or_compound
(	O
PLGA	S-Drug_or_compound
)	O
microspheres	O
were	O
prepared	O
for	O
sustained	O
release	S-Localization
of	O
basic	B-Gene_or_gene_product
fibroblast	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
(	O
bFGF	S-Gene_or_gene_product
)	O
to	O
induce	S-Positive_regulation
angiogenesis	S-Blood_vessel_development
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Porous	O
PLGA	S-Drug_or_compound
microspheres	O
having	O
primary	O
amine	O
groups	O
on	O
the	O
surface	O
were	O
prepared	O
using	O
an	O
oil	O
-	O
in	O
-	O
water	O
(	O
O	O
/	O
W	O
)	O
single	O
emulsion	O
method	O
using	O
Pluronic	O
F	O
-	O
127	O
as	O
an	O
extractable	O
porogen	O
.	O

Heparin	S-Drug_or_compound
was	O
surface	O
immobilized	O
via	O
covalent	O
conjugation	O
.	O

bFGF	S-Gene_or_gene_product
was	O
loaded	S-Planned_process
into	O
the	O
heparin	S-Drug_or_compound
functionalized	O
(	O
PLGA	S-Drug_or_compound
-	O
heparin	S-Drug_or_compound
)	O
microspheres	O
by	O
a	O
simple	O
dipping	O
method	O
.	O

The	O
bFGF	S-Gene_or_gene_product
loaded	S-Planned_process
PLGA	S-Drug_or_compound
-	O
heparin	S-Drug_or_compound
microspheres	O
were	O
tested	O
for	O
in	O
vitro	O
release	S-Localization
and	O
in	O
vivo	O
angiogenic	S-Blood_vessel_development
activity	O
.	O

RESULTS	O
:	O
PLGA	S-Drug_or_compound
microspheres	O
with	O
an	O
open	O
-	O
porous	O
structure	O
were	O
formed	O
.	O

The	O
amount	O
of	O
conjugated	O
amine	O
group	O
onto	O
the	O
microspheres	O
was	O
1	O
.	O
93	O
+	O
/	O
-	O
0	O
.	O
01	O
nmol	O
/	O
mg	O
-	O
microspheres	O
,	O
while	O
the	O
amount	O
of	O
heparin	S-Drug_or_compound
was	O
95	O
.	O
8	O
pmol	O
/	O
mg	O
-	O
microspheres	O
.	O

PLGA	S-Drug_or_compound
-	O
heparin	S-Drug_or_compound
microspheres	O
released	S-Localization
out	O
bFGF	S-Gene_or_gene_product
in	O
a	O
more	O
sustained	O
manner	O
with	O
a	O
smaller	O
extent	O
of	O
initial	O
burst	O
than	O
PLGA	S-Drug_or_compound
microspheres	O
,	O
indicating	O
that	O
surface	O
immobilized	O
heparin	S-Drug_or_compound
controlled	S-Regulation
the	O
release	S-Localization
rate	O
of	O
bFGF	S-Gene_or_gene_product
.	O

Subcutaneous	O
implantation	S-Planned_process
of	O
bFGF	S-Gene_or_gene_product
loaded	S-Planned_process
PLGA	S-Drug_or_compound
-	O
heparin	S-Drug_or_compound
microspheres	O
in	O
mice	S-Organism
significantly	O
induced	S-Positive_regulation
the	O
formation	S-Development
of	O
new	O
vascular	B-Tissue
microvessels	E-Tissue
.	O

CONCLUSIONS	O
:	O
PLGA	S-Drug_or_compound
microspheres	O
with	O
an	O
open	O
porous	O
structure	O
allowed	O
significant	O
amount	O
of	O
heparin	S-Drug_or_compound
immobilization	S-Planned_process
and	O
bFGF	S-Gene_or_gene_product
loading	S-Planned_process
.	O

bFGF	S-Gene_or_gene_product
loaded	S-Planned_process
PLGA	S-Drug_or_compound
-	O
HP	S-Drug_or_compound
microspheres	O
showed	O
sustained	O
release	S-Localization
profiles	O
of	O
bFGF	S-Gene_or_gene_product
in	O
vitro	O
,	O
demonstrating	O
reversible	O
and	O
specific	O
binding	S-Binding
of	O
bFGF	S-Gene_or_gene_product
to	O
immobilized	O
heparin	S-Drug_or_compound
.	O

They	O
also	O
induced	S-Positive_regulation
local	O
angiogenesis	S-Blood_vessel_development
in	O
vivo	O
in	O
an	O
animal	O
model	O
.	O

[	O
Autologous	O
bone	B-Cell
marrow	I-Cell
stem	I-Cell
cell	E-Cell
or	O
peripheral	B-Cell
blood	I-Cell
endothelial	I-Cell
progenitor	I-Cell
cell	E-Cell
therapy	S-Planned_process
in	O
patients	S-Organism
with	O
peripheral	O
limb	S-Organism_subdivision
ischaemia	O
]	O

No	O
effective	O
medical	O
therapies	O
have	O
been	O
developed	O
sofar	O
to	O
enhance	O
blood	S-Organism_substance
flow	O
in	O
the	O
legs	S-Organism_subdivision
of	O
patients	S-Organism
with	O
peripheral	O
arterial	O
disease	O
(	O
PAD	O
)	O
.	O

For	O
patients	S-Organism
with	O
limb	S-Organism_subdivision
threatening	O
ischaemia	O
the	O
only	O
option	O
for	O
relief	O
of	O
rest	O
pain	O
or	O
gangraena	O
is	O
amputation	O
.	O

There	O
is	O
evidence	O
in	O
experimental	O
and	O
clinical	O
studies	O
that	O
adult	O
bone	B-Cell
marrow	I-Cell
-	I-Cell
derived	I-Cell
stem	I-Cell
cells	E-Cell
and	O
endothelial	B-Cell
progenitor	I-Cell
cells	E-Cell
participate	O
in	O
the	O
development	S-Development
of	O
new	O
blood	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
,	O
called	O
neoangiogenesis	S-Blood_vessel_development
or	O
neovascularization	S-Blood_vessel_development
.	O

Clinical	O
results	O
induced	O
by	O
autologous	O
bone	B-Cell
marrow	I-Cell
stem	I-Cell
cells	E-Cell
or	O
angiogenic	S-Blood_vessel_development
growth	O
/	O
differentiation	O
factors	O
in	O
end	O
-	O
stage	O
patients	S-Organism
with	O
PAD	O
are	O
summarized	O
.	O

Considering	O
the	O
relatively	O
few	O
number	O
of	O
patients	S-Organism
treated	S-Planned_process
by	O
angiogenic	S-Blood_vessel_development
therapy	O
,	O
the	O
interpretation	O
of	O
clinical	O
results	O
needs	O
cautiousness	O
.	O

Formation	S-Development
of	O
new	O
bone	S-Tissue
during	O
vertical	B-Planned_process
distraction	I-Planned_process
osteogenesis	E-Planned_process
of	O
the	O
human	S-Organism
mandible	S-Organ
is	O
related	O
to	O
the	O
presence	O
of	O
blood	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
.	O

We	O
examined	O
the	O
effect	O
of	O
distraction	O
rate	O
on	O
blood	B-Multi-tissue_structure
vessel	E-Multi-tissue_structure
growth	S-Growth
in	O
intramembraneous	O
ossification	O
after	O
vertical	B-Planned_process
distraction	I-Planned_process
osteogenesis	E-Planned_process
in	O
the	O
human	S-Organism
mandible	S-Organ
.	O

Six	O
edentulous	O
patients	S-Organism
(	O
aged	O
60	O
+	O
/	O
-	O
9	O
years	O
)	O
with	O
a	O
severely	O
atrophic	O
mandible	S-Organ
underwent	O
bone	S-Tissue
augmentation	O
with	O
distraction	O
osteogenesis	O
.	O

Two	O
distraction	O
rates	O
(	O
0	O
.	O
5	O
and	O
1	O
mm	O
/	O
day	O
)	O
were	O
compared	O
and	O
for	O
each	O
group	O
three	O
patients	S-Organism
were	O
analyzed	O
.	O

Vascular	O
histomorphometry	O
was	O
carried	O
out	O
in	O
two	O
different	O
areas	O
in	O
the	O
distraction	O
gap	O
:	O
(	O
1	O
)	O
in	O
the	O
first	O
and	O
(	O
2	O
)	O
in	O
the	O
second	O
1	O
mm	O
area	O
from	O
the	O
osteotomy	O
line	O
,	O
representing	O
the	O
oldest	O
and	O
younger	O
new	O
-	O
bone	S-Tissue
area	O
,	O
respectively	O
.	O

Correlation	O
analysis	O
was	O
performed	O
between	O
blood	B-Multi-tissue_structure
vessel	E-Multi-tissue_structure
parameters	O
and	O
the	O
amount	O
of	O
new	O
bone	S-Tissue
formed	S-Development
during	O
distraction	O
.	O

Histological	O
analysis	O
demonstrated	O
the	O
presence	O
of	O
blood	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
throughout	O
the	O
soft	B-Tissue
connective	I-Tissue
tissue	E-Tissue
in	O
the	O
distraction	O
gap	O
.	O

The	O
volume	O
density	O
of	O
blood	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
between	O
the	O
two	O
investigated	O
areas	O
was	O
significantly	O
lower	O
in	O
the	O
1	O
mm	O
/	O
day	O
groups	O
,	O
suggesting	O
a	O
delay	S-Negative_regulation
in	O
angiogenesis	S-Blood_vessel_development
in	O
this	O
group	O
of	O
patients	S-Organism
.	O

A	O
positive	O
correlation	O
between	O
blood	B-Multi-tissue_structure
vessel	E-Multi-tissue_structure
volume	O
and	O
bone	S-Tissue
volume	O
density	O
was	O
found	O
in	O
the	O
younger	O
new	O
-	O
bone	S-Tissue
area	O
but	O
not	O
in	O
the	O
oldest	O
new	O
-	O
bone	S-Tissue
area	O
.	O

This	O
correlation	O
was	O
due	O
to	O
a	O
higher	O
number	O
of	O
blood	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
rather	O
than	O
to	O
a	O
larger	O
size	O
of	O
the	O
blood	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
.	O

Our	O
data	O
suggest	O
that	O
the	O
lower	O
blood	B-Multi-tissue_structure
vessel	E-Multi-tissue_structure
density	O
found	O
in	O
the	O
patients	S-Organism
with	O
1	O
mm	O
/	O
day	O
distraction	O
rate	O
may	O
be	O
related	O
to	O
disruption	S-Negative_regulation
of	O
angiogenesis	S-Blood_vessel_development
in	O
the	O
soft	B-Tissue
connective	I-Tissue
tissue	E-Tissue
of	O
the	O
gap	O
or	O
to	O
a	O
less	O
optimal	O
mechanical	O
stimulation	S-Positive_regulation
of	O
cells	S-Cell
involved	O
in	O
angiogenesis	S-Blood_vessel_development
.	O

This	O
probably	O
results	O
in	O
the	O
slower	O
rate	O
of	O
osteogenesis	O
seen	O
at	O
the	O
1	O
mm	O
/	O
day	O
distraction	O
rate	O
compared	O
with	O
the	O
0	O
.	O
5	O
mm	O
/	O
day	O
distraction	O
rate	O
.	O

The	O
data	O
support	O
the	O
concept	O
that	O
a	O
positive	O
relationship	O
exists	O
between	O
the	O
density	O
of	O
blood	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
and	O
the	O
formation	S-Development
of	O
bone	S-Tissue
.	O

For	O
distraction	S-Planned_process
of	O
the	O
human	S-Organism
mandible	S-Organ
in	O
elderly	O
patients	S-Organism
,	O
a	O
distraction	O
rate	O
of	O
0	O
.	O
5	O
mm	O
/	O
day	O
seems	O
beneficial	O
.	O

The	O
role	O
of	O
syndecans	S-Gene_or_gene_product
in	O
disease	O
and	O
wound	O
healing	O
.	O

Syndecans	S-Gene_or_gene_product
are	O
a	O
family	O
of	O
transmembrane	O
heparan	O
sulfate	O
proteoglycans	O
widely	O
expressed	S-Gene_expression
in	O
both	O
developing	S-Tissue
and	O
adult	B-Tissue
tissues	E-Tissue
.	O

Until	O
recently	O
,	O
their	O
role	O
in	O
pathogenesis	O
was	O
largely	O
unexplored	O
.	O

In	O
this	O
review	O
,	O
we	O
discuss	O
the	O
reported	O
involvement	O
of	O
syndecans	S-Gene_or_gene_product
in	O
human	S-Organism
cancers	S-Pathological_formation
,	O
infectious	O
diseases	O
,	O
obesity	O
,	O
wound	S-Pathological_formation
healing	O
and	O
angiogenesis	S-Blood_vessel_development
.	O

In	O
some	O
cancers	S-Pathological_formation
,	O
syndecan	S-Gene_or_gene_product
expression	S-Gene_expression
has	O
been	O
shown	O
to	O
regulate	S-Regulation
tumor	B-Cell
cell	E-Cell
function	O
(	O
e	O
.	O
g	O
.	O
proliferation	S-Cell_proliferation
,	O
adhesion	S-Binding
,	O
and	O
motility	S-Localization
)	O
and	O
serve	O
as	O
a	O
prognostic	O
marker	O
for	O
tumor	S-Pathological_formation
progression	S-Development
and	O
patient	S-Organism
survival	S-Death
.	O

The	O
ectodomains	O
and	O
heparan	B-Drug_or_compound
sulfate	I-Drug_or_compound
glycosaminoglycan	E-Drug_or_compound
chains	O
of	O
syndecans	S-Gene_or_gene_product
can	O
also	O
act	O
as	O
receptors	O
/	O
co	O
-	O
receptors	O
for	O
some	O
bacterial	O
and	O
viral	O
pathogens	O
,	O
mediating	O
infection	O
.	O

In	O
addition	O
,	O
syndecans	S-Gene_or_gene_product
bind	S-Binding
to	O
obesity	O
-	O
related	O
factors	O
and	O
regulate	O
their	O
signaling	O
,	O
in	O
turn	O
modulating	O
food	O
consumption	O
and	O
weight	O
balance	O
.	O

In	O
vivo	O
animal	O
models	O
of	O
tissue	S-Tissue
injury	S-Breakdown
and	O
in	O
vitro	O
data	O
also	O
implicate	O
syndecans	S-Gene_or_gene_product
in	O
processes	O
necessary	S-Positive_regulation
for	O
wound	O
healing	O
,	O
including	O
fibroblast	S-Cell
and	O
endothelial	S-Cell
proliferation	S-Cell_proliferation
,	O
cell	S-Cell
motility	S-Localization
,	O
angiogenesis	S-Blood_vessel_development
,	O
and	O
extracellular	B-Cellular_component
matrix	E-Cellular_component
organization	S-Development
.	O

These	O
new	O
insights	O
into	O
the	O
involvement	O
of	O
syndecans	S-Gene_or_gene_product
in	O
disease	O
and	O
tissue	S-Tissue
repair	S-Remodeling
coupled	O
with	O
the	O
emergence	O
of	O
syndecan	S-Gene_or_gene_product
-	O
specific	O
molecular	O
tools	O
may	O
lead	O
to	O
novel	O
therapies	O
for	O
a	O
variety	O
of	O
human	S-Organism
diseases	O
.	O

High	O
-	O
Dose	O
celecoxib	S-Drug_or_compound
and	O
metronomic	O
"	O
low	O
-	O
dose	O
"	O
cyclophosphamide	S-Drug_or_compound
is	O
an	O
effective	O
and	O
safe	O
therapy	S-Planned_process
in	O
patients	S-Organism
with	O
relapsed	O
and	O
refractory	O
aggressive	O
histology	O
non	B-Pathological_formation
-	I-Pathological_formation
Hodgkin	I-Pathological_formation
'	I-Pathological_formation
s	I-Pathological_formation
lymphoma	E-Pathological_formation
.	O

PURPOSE	O
:	O
Angiogenesis	S-Blood_vessel_development
is	O
increased	S-Positive_regulation
in	O
aggressive	O
histology	O
non	B-Pathological_formation
-	I-Pathological_formation
Hodgkin	I-Pathological_formation
'	I-Pathological_formation
s	I-Pathological_formation
lymphoma	E-Pathological_formation
and	O
may	O
be	O
a	O
target	O
with	O
selective	O
cyclooxygenase	B-Drug_or_compound
-	I-Drug_or_compound
2	E-Drug_or_compound
inhibition	S-Negative_regulation
and	O
metronomic	O
chemotherapy	S-Planned_process
.	O

EXPERIMENTAL	O
DESIGN	O
:	O
We	O
assessed	O
response	O
,	O
toxicity	O
,	O
and	O
biomarkers	O
of	O
angiogenesis	S-Blood_vessel_development
to	O
low	O
-	O
dose	O
cyclophosphamide	S-Drug_or_compound
(	O
50	O
mg	O
p	O
.	O
o	O
.	O
o	O
.	O
d	O
.	O
)	O
and	O
high	O
-	O
dose	O
celecoxib	S-Drug_or_compound
(	O
400	O
mg	O
p	O
.	O
o	O
.	O
b	O
.	O
i	O
.	O
d	O
.	O
)	O
in	O
adult	O
patients	S-Organism
with	O
relapsed	O
or	O
refractory	O
aggressive	O
non	B-Pathological_formation
-	I-Pathological_formation
Hodgkin	I-Pathological_formation
'	I-Pathological_formation
s	I-Pathological_formation
lymphoma	E-Pathological_formation
in	O
a	O
multicenter	O
phase	O
II	O
prospective	O
study	O
.	O

RESULTS	O
:	O
Thirty	O
-	O
two	O
of	O
35	O
patients	S-Organism
(	O
median	O
age	O
,	O
62	O
years	O
)	O
are	O
evaluable	O
for	O
response	O
.	O

Patients	S-Organism
had	O
primarily	O
relapsed	O
diffuse	O
large	O
B	B-Pathological_formation
-	I-Pathological_formation
cell	I-Pathological_formation
lymphoma	E-Pathological_formation
(	O
63	O
%	O
)	O
were	O
heavily	O
pretreated	S-Planned_process
(	O
median	O
of	O
three	O
regimens	O
)	O
and	O
high	O
risk	O
(	O
79	O
%	O
international	O
prognostic	O
index	O
,	O
greater	O
than	O
or	O
=	O
2	O
)	O
and	O
34	O
%	O
were	O
relapsed	O
after	O
autologous	O
stem	B-Cell
cell	E-Cell
transplant	S-Planned_process
.	O

With	O
a	O
median	O
follow	O
-	O
up	O
of	O
8	O
.	O
4	O
months	O
,	O
the	O
overall	O
best	O
response	O
rate	O
is	O
37	O
%	O
(	O
2	O
complete	O
clinical	O
response	O
/	O
complete	O
clinical	O
response	O
unconfirmed	O
and	O
9	O
partial	O
response	O
)	O
,	O
with	O
22	O
%	O
achieving	O
stable	O
disease	O
.	O

Median	O
overall	O
and	O
progression	O
-	O
free	O
survivals	O
are	O
14	O
.	O
4	O
and	O
4	O
.	O
7	O
months	O
,	O
respectively	O
.	O

The	O
median	O
response	O
duration	O
was	O
8	O
.	O
2	O
months	O
.	O

The	O
most	O
common	O
toxicity	O
was	O
skin	S-Organ
rash	O
(	O
40	O
%	O
)	O
;	O
myelosuppression	O
and	O
gastrointestinal	S-Organism_subdivision
side	O
effects	O
were	O
uncommon	O
.	O

Three	O
patients	S-Organism
developed	O
deep	B-Pathological_formation
vein	I-Pathological_formation
thromboses	E-Pathological_formation
and	O
two	O
heavily	O
pretreated	S-Planned_process
patients	S-Organism
developed	O
treatment	S-Planned_process
-	O
related	O
acute	O
myelogenous	O
leukemia	O
or	O
myelodysplasia	O
after	O
3	O
.	O
7	O
and	O
12	O
months	O
of	O
therapy	S-Planned_process
.	O

Circulating	O
endothelial	B-Cell
cells	E-Cell
and	O
their	O
precursors	O
declined	O
and	O
remained	O
low	O
in	O
responders	O
,	O
whereas	O
plasma	S-Organism_substance
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
trended	O
to	O
decline	S-Negative_regulation
in	O
responding	O
patients	S-Organism
but	O
increase	S-Positive_regulation
in	O
nonresponders	O
.	O

Trough	O
celecoxib	S-Drug_or_compound
levels	O
achieved	O
targeted	S-Negative_regulation
"	O
antiangiogenic	S-Blood_vessel_development
"	O
levels	O
.	O

CONCLUSIONS	O
:	O
Low	O
-	O
dose	O
cyclophosphamide	S-Drug_or_compound
and	O
high	O
-	O
dose	O
celecoxib	S-Drug_or_compound
is	O
well	O
tolerated	O
and	O
active	O
in	O
pretreated	S-Planned_process
aggressive	O
non	B-Pathological_formation
-	I-Pathological_formation
Hodgkin	I-Pathological_formation
'	I-Pathological_formation
s	I-Pathological_formation
lymphoma	E-Pathological_formation
.	O

Close	O
surveillance	O
for	O
arterial	O
and	O
venous	O
thrombotic	O
events	O
is	O
recommended	O
.	O

The	O
decline	S-Negative_regulation
in	O
circulating	O
endothelial	B-Cell
cells	E-Cell
and	O
their	O
precursors	O
suggests	O
that	O
this	O
combination	O
may	O
be	O
working	O
by	O
inhibiting	S-Negative_regulation
angiogenesis	S-Blood_vessel_development
but	O
should	O
be	O
validated	O
in	O
a	O
larger	O
patient	S-Organism
sample	O
.	O

Photodynamic	B-Planned_process
therapy	E-Planned_process
with	O
verteporfin	S-Drug_or_compound
for	O
subfoveal	O
choroidal	O
neovascularization	S-Blood_vessel_development
secondary	O
to	O
pathologic	O
myopia	O
:	O
long	O
-	O
term	O
study	O
.	O

PURPOSE	O
:	O
To	O
assess	O
the	O
safety	O
and	O
effectiveness	O
of	O
photodynamic	B-Planned_process
therapy	E-Planned_process
(	O
PDT	O
)	O
with	O
verteporfin	S-Drug_or_compound
for	O
subfoveal	O
choroidal	O
neovascularization	S-Blood_vessel_development
(	O
CNV	S-Blood_vessel_development
)	O
secondary	O
to	O
pathologic	O
myopia	O
(	O
PM	O
)	O
.	O

METHODS	O
:	O
Sixty	O
-	O
two	O
patients	S-Organism
(	O
62	O
eyes	S-Organ
)	O
with	O
PM	O
underwent	O
PDT	S-Planned_process
according	O
to	O
the	O
guidelines	O
of	O
the	O
Verteporfin	S-Drug_or_compound
in	O
Photodynamic	B-Planned_process
Therapy	E-Planned_process
Study	O
.	O

Clinical	O
evaluations	O
performed	O
at	O
all	O
study	O
visits	O
included	O
measurement	O
of	O
best	O
-	O
corrected	O
Snellen	O
visual	O
acuity	O
,	O
slit	O
-	O
lamp	O
biomicroscopy	O
,	O
and	O
fundus	S-Multi-tissue_structure
fluorescein	S-Drug_or_compound
angiography	S-Planned_process
.	O

Patients	S-Organism
were	O
followed	O
up	O
at	O
1	O
month	O
and	O
3	O
months	O
after	O
treatment	S-Planned_process
and	O
thereafter	O
at	O
3	O
-	O
month	O
intervals	O
.	O

RESULTS	O
:	O
The	O
final	O
visual	O
acuity	O
of	O
the	O
study	O
patients	S-Organism
,	O
after	O
a	O
median	O
follow	O
-	O
up	O
of	O
31	O
months	O
,	O
improved	O
by	O
greater	O
than	O
or	O
=	O
1	O
Snellen	O
lines	O
in	O
8	O
patients	S-Organism
(	O
13	O
%	O
)	O
,	O
deteriorated	O
in	O
20	O
(	O
32	O
%	O
)	O
,	O
and	O
remained	O
stable	O
in	O
34	O
(	O
55	O
%	O
)	O
.	O

The	O
baseline	O
visual	O
acuity	O
was	O
similar	O
in	O
the	O
various	O
study	O
groups	O
.	O

The	O
final	O
mean	O
visual	O
acuity	O
in	O
group	O
A	O
(	O
55	O
years	O
of	O
age	O
or	O
younger	O
)	O
was	O
20	O
/	O
80	O
and	O
significantly	O
(	O
P	O
=	O
0	O
.	O
006	O
)	O
better	O
than	O
that	O
(	O
20	O
/	O
138	O
)	O
in	O
group	O
B	O
(	O
older	O
than	O
55	O
years	O
of	O
age	O
)	O
.	O

The	O
mean	O
final	O
visual	O
acuity	O
in	O
eyes	S-Organ
with	O
higher	O
refractive	O
error	O
at	O
baseline	O
(	O
greater	O
than	O
-	O
17	O
diopters	O
)	O
was	O
significantly	O
better	O
(	O
P	O
=	O
0	O
.	O
014	O
)	O
than	O
that	O
in	O
eyes	S-Organ
with	O
lower	O
refractive	O
error	O
(	O
-	O
6	O
to	O
-	O
10	O
diopters	O
)	O
.	O

CNV	S-Blood_vessel_development
size	O
did	O
not	O
affect	O
visual	O
outcomes	O
.	O

CONCLUSION	O
:	O
PDT	S-Planned_process
preserves	O
vision	O
in	O
patients	S-Organism
with	O
CNV	S-Blood_vessel_development
associated	O
with	O
PM	O
.	O

Younger	O
patients	S-Organism
and	O
eyes	S-Organ
with	O
higher	O
refractive	O
error	O
appear	O
more	O
likely	O
to	O
benefit	O
from	O
PDT	S-Planned_process
with	O
verteporfin	S-Drug_or_compound
.	O

Imaging	O
tumor	S-Pathological_formation
angiogenesis	S-Blood_vessel_development
.	O

Since	O
the	O
discovery	O
of	O
vascular	B-Gene_or_gene_product
-	I-Gene_or_gene_product
specific	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factors	E-Gene_or_gene_product
with	O
angiogenic	O
activity	O
,	O
there	O
has	O
been	O
a	O
significant	O
effort	O
to	O
develop	O
cancer	S-Pathological_formation
drugs	O
that	O
restrict	O
tumorigenesis	O
by	O
targeting	O
the	O
blood	S-Organism_substance
supply	O
.	O

In	O
this	O
issue	O
of	O
the	O
JCI	O
,	O
Mancuso	O
et	O
al	O
.	O
use	O
mouse	S-Organism
models	O
to	O
better	O
understand	O
the	O
plasticity	O
of	O
the	O
tumor	B-Multi-tissue_structure
vasculature	E-Multi-tissue_structure
in	O
the	O
face	O
of	O
antiangiogenic	S-Blood_vessel_development
therapy	O
(	O
see	O
the	O
related	O
article	O
beginning	O
on	O
page	O
2610	O
)	O
.	O

They	O
describe	O
a	O
rapid	O
regrowth	S-Growth
of	O
the	O
tumor	B-Multi-tissue_structure
vasculature	E-Multi-tissue_structure
following	O
withdrawal	O
of	O
VEGFR	S-Gene_or_gene_product
inhibitors	O
,	O
emphasizing	O
the	O
importance	O
of	O
fully	O
understanding	O
the	O
function	O
of	O
these	O
and	O
similar	O
treatments	O
used	O
in	O
the	O
clinic	O
at	O
the	O
cellular	O
and	O
molecular	O
level	O
.	O

Collagen	S-Gene_or_gene_product
-	O
poly	B-Drug_or_compound
glycolic	I-Drug_or_compound
acid	E-Drug_or_compound
hybrid	O
matrix	O
with	O
basic	B-Gene_or_gene_product
fibroblast	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
accelerated	S-Positive_regulation
angiogenesis	S-Blood_vessel_development
and	O
granulation	B-Tissue
tissue	E-Tissue
formation	S-Development
in	O
diabetic	O
mice	S-Organism
.	O

Because	O
poor	O
skin	S-Organ
wound	O
healing	O
associated	O
with	O
diabetes	O
is	O
thought	O
to	O
be	O
partly	O
a	O
result	O
from	O
impaired	S-Negative_regulation
angiogenesis	S-Blood_vessel_development
,	O
treatments	O
that	O
improve	S-Positive_regulation
angiogenesis	S-Blood_vessel_development
could	O
have	O
important	O
clinical	O
applications	O
.	O

We	O
herein	O
report	O
the	O
effects	O
of	O
novel	O
developed	O
material	O
,	O
collagen	S-Gene_or_gene_product
-	O
poly	B-Drug_or_compound
glycolic	I-Drug_or_compound
acid	E-Drug_or_compound
fiber	O
hybrid	O
matrix	O
,	O
being	O
used	O
together	O
with	O
basic	B-Gene_or_gene_product
fibroblast	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
to	O
promote	O
wound	O
healing	O
of	O
full	O
-	O
thickness	O
skin	S-Organ
defects	O
on	O
the	O
back	O
of	O
type	O
2	O
diabetic	O
Lepr	B-Organism
(	I-Organism
db	I-Organism
)	I-Organism
mice	E-Organism
.	O

Our	O
data	O
indicates	O
that	O
this	O
therapeutic	O
approach	O
markedly	O
promotes	S-Positive_regulation
angiogenesis	S-Blood_vessel_development
and	O
granulation	B-Tissue
tissue	E-Tissue
formation	S-Development
in	O
comparison	O
with	O
other	O
conditions	O
14	O
days	O
after	O
wounding	O
.	O

Punica	B-Organism
granatum	E-Organism
(	O
pomegranate	O
)	O
and	O
its	O
potential	O
for	O
prevention	O
and	O
treatment	O
of	O
inflammation	O
and	O
cancer	S-Pathological_formation
.	O

The	O
last	O
7	O
years	O
have	O
seen	O
over	O
seven	O
times	O
as	O
many	O
publications	O
indexed	O
by	O
Medline	O
dealing	O
with	O
pomegranate	O
and	O
Punica	B-Organism
granatum	E-Organism
than	O
in	O
all	O
the	O
years	O
preceding	O
them	O
.	O

Because	O
of	O
this	O
,	O
and	O
the	O
virtual	O
explosion	O
of	O
interest	O
in	O
pomegranate	O
as	O
a	O
medicinal	O
and	O
nutritional	O
product	O
that	O
has	O
followed	O
,	O
this	O
review	O
is	O
accordingly	O
launched	O
.	O

The	O
pomegranate	O
tree	O
,	O
Punica	B-Organism
granatum	E-Organism
,	O
especially	O
its	O
fruit	O
,	O
possesses	O
a	O
vast	O
ethnomedical	O
history	O
and	O
represents	O
a	O
phytochemical	O
reservoir	O
of	O
heuristic	O
medicinal	O
value	O
.	O

The	O
tree	O
/	O
fruit	O
can	O
be	O
divided	O
into	O
several	O
anatomical	O
compartments	O
:	O
(	O
1	O
)	O
seed	S-Developing_anatomical_structure
,	O
(	O
2	O
)	O
juice	S-Organism_substance
,	O
(	O
3	O
)	O
peel	S-Tissue
,	O
(	O
4	O
)	O
leaf	S-Organ
,	O
(	O
5	O
)	O
flower	S-Organism_subdivision
,	O
(	O
6	O
)	O
bark	S-Tissue
,	O
and	O
(	O
7	O
)	O
roots	S-Organ
,	O
each	O
of	O
which	O
has	O
interesting	O
pharmacologic	O
activity	O
.	O

Juice	S-Organism_substance
and	O
peels	S-Tissue
,	O
for	O
example	O
,	O
possess	O
potent	O
antioxidant	O
properties	O
,	O
while	O
juice	S-Organism_substance
,	O
peel	S-Tissue
and	O
oil	S-Organism_substance
are	O
all	O
weakly	O
estrogenic	O
and	O
heuristically	O
of	O
interest	O
for	O
the	O
treatment	O
of	O
menopausal	O
symptoms	O
and	O
sequellae	O
.	O

The	O
use	O
of	O
juice	S-Organism_substance
,	O
peel	S-Tissue
and	O
oil	S-Organism_substance
have	O
also	O
been	O
shown	O
to	O
possess	O
anticancer	O
activities	O
,	O
including	O
interference	O
with	O
tumor	B-Cell
cell	E-Cell
proliferation	S-Cell_proliferation
,	O
cell	S-Cell
cycle	O
,	O
invasion	S-Localization
and	O
angiogenesis	S-Blood_vessel_development
.	O

These	O
may	O
be	O
associated	O
with	O
plant	O
based	O
anti	O
-	O
inflammatory	O
effects	O
,	O
The	O
phytochemistry	O
and	O
pharmacological	O
actions	O
of	O
all	O
Punica	B-Organism
granatum	E-Organism
components	O
suggest	O
a	O
wide	O
range	O
of	O
clinical	O
applications	O
for	O
the	O
treatment	O
and	O
prevention	O
of	O
cancer	O
,	O
as	O
well	O
as	O
other	O
diseases	O
where	O
chronic	O
inflammation	O
is	O
believed	O
to	O
play	O
an	O
essential	O
etiologic	O
role	O
.	O

Angiotensin	B-Gene_or_gene_product
II	E-Gene_or_gene_product
induces	S-Positive_regulation
soluble	O
fms	B-Gene_or_gene_product
-	I-Gene_or_gene_product
Like	I-Gene_or_gene_product
tyrosine	I-Gene_or_gene_product
kinase	I-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
release	S-Localization
via	O
calcineurin	B-Pathway
signaling	I-Pathway
pathway	E-Pathway
in	O
pregnancy	O
.	O

Maternal	O
endothelial	S-Tissue
dysfunction	S-Breakdown
in	O
preeclampsia	O
is	O
associated	O
with	O
increased	S-Positive_regulation
soluble	O
fms	B-Gene_or_gene_product
-	I-Gene_or_gene_product
like	I-Gene_or_gene_product
tyrosine	I-Gene_or_gene_product
kinase	I-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
(	O
sFlt	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
)	O
,	O
a	O
circulating	S-Localization
antagonist	O
of	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
and	O
placental	B-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
.	O

Angiotensin	B-Gene_or_gene_product
II	E-Gene_or_gene_product
(	O
Ang	B-Gene_or_gene_product
II	E-Gene_or_gene_product
)	O
is	O
a	O
potent	O
vasoconstrictor	O
that	O
increases	S-Positive_regulation
concomitant	O
with	O
sFlt	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
during	O
pregnancy	O
.	O

Therefore	O
,	O
we	O
speculated	O
that	O
Ang	B-Gene_or_gene_product
II	E-Gene_or_gene_product
may	O
promote	S-Positive_regulation
the	O
expression	S-Gene_expression
of	O
sFlt	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
in	O
pregnancy	O
.	O

Here	O
we	O
report	O
that	O
infusion	S-Planned_process
of	O
Ang	B-Gene_or_gene_product
II	E-Gene_or_gene_product
significantly	O
increases	S-Positive_regulation
circulating	S-Localization
levels	O
of	O
sFlt	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
in	O
pregnant	O
mice	S-Organism
,	O
thereby	O
demonstrating	O
that	O
Ang	B-Gene_or_gene_product
II	E-Gene_or_gene_product
is	O
a	O
regulator	O
of	O
sFlt	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
secretion	S-Localization
in	O
vivo	O
.	O

Furthermore	O
,	O
Ang	B-Gene_or_gene_product
II	E-Gene_or_gene_product
stimulated	S-Positive_regulation
sFlt	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
production	S-Gene_expression
in	O
a	O
dose	O
-	O
and	O
time	O
-	O
dependent	O
manner	O
from	O
human	S-Organism
villous	O
explants	O
and	O
cultured	O
trophoblasts	S-Cell
but	O
not	O
from	O
endothelial	B-Cell
cells	E-Cell
,	O
suggesting	O
that	O
trophoblasts	S-Cell
are	O
the	O
primary	O
source	O
of	O
sFlt	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
during	O
pregnancy	O
.	O

As	O
expected	O
,	O
Ang	B-Gene_or_gene_product
II	E-Gene_or_gene_product
-	O
induced	S-Positive_regulation
sFlt	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
secretion	S-Localization
resulted	O
in	O
the	O
inhibition	S-Positive_regulation
of	O
endothelial	B-Cell
cell	E-Cell
migration	S-Localization
and	O
in	O
vitro	O
tube	S-Tissue
formation	S-Development
.	O

In	O
vitro	O
and	O
in	O
vivo	O
studies	O
with	O
losartan	S-Drug_or_compound
,	O
small	O
interfering	O
RNA	O
specific	O
for	O
calcineurin	S-Gene_or_gene_product
and	O
FK506	S-Drug_or_compound
demonstrated	O
that	O
Ang	B-Gene_or_gene_product
II	E-Gene_or_gene_product
-	O
mediated	S-Positive_regulation
sFlt	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
release	S-Localization
was	O
via	O
Ang	B-Gene_or_gene_product
II	I-Gene_or_gene_product
type	I-Gene_or_gene_product
1	I-Gene_or_gene_product
receptor	E-Gene_or_gene_product
activation	S-Positive_regulation
and	O
calcineurin	B-Pathway
signaling	E-Pathway
,	O
respectively	O
.	O

These	O
findings	O
reveal	O
a	O
previously	O
unrecognized	O
regulatory	B-Regulation
role	E-Regulation
for	O
Ang	B-Gene_or_gene_product
II	E-Gene_or_gene_product
on	O
sFlt	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
expression	S-Gene_expression
in	O
murine	S-Organism
and	O
human	S-Organism
pregnancy	O
and	O
suggest	O
that	O
elevated	S-Positive_regulation
sFlt	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
levels	O
in	O
preeclampsia	O
may	O
be	O
caused	S-Positive_regulation
by	O
a	O
dysregulation	S-Negative_regulation
of	O
the	O
local	O
renin	S-Gene_or_gene_product
/	O
angiotensin	S-Gene_or_gene_product
system	S-Pathway
.	O

Role	S-Regulation
of	O
the	O
fibrinolytic	S-Pathway
and	O
matrix	B-Gene_or_gene_product
metalloproteinase	E-Gene_or_gene_product
systems	S-Pathway
in	O
development	S-Development
of	O
adipose	B-Tissue
tissue	E-Tissue
.	O

Obesity	O
is	O
a	O
common	O
disorder	O
and	O
related	O
diseases	O
such	O
as	O
diabetes	O
,	O
atherosclerosis	O
,	O
hypertension	O
,	O
cardiovascular	O
disease	O
and	O
cancer	S-Pathological_formation
are	O
a	O
major	O
cause	O
of	O
mortality	O
and	O
morbidity	O
in	O
Western	O
-	O
type	O
societies	O
.	O

Development	O
of	O
obesity	O
is	O
associated	O
with	O
extensive	O
modifications	S-Remodeling
in	O
adipose	B-Tissue
tissue	E-Tissue
involving	O
adipogenesis	O
,	O
angiogenesis	S-Blood_vessel_development
and	O
extracellular	B-Cellular_component
matrix	E-Cellular_component
proteolysis	S-Breakdown
.	O

The	O
fibrinolytic	S-Pathway
(	O
plasminogen	S-Gene_or_gene_product
/	O
plasmin	S-Gene_or_gene_product
)	O
and	O
matrix	B-Gene_or_gene_product
metalloproteinase	E-Gene_or_gene_product
(	O
MMP	S-Gene_or_gene_product
)	O
systems	S-Pathway
cooperate	O
in	O
these	O
processes	O
.	O

A	O
nutritionally	O
induced	O
obesity	O
model	O
in	O
transgenic	S-Planned_process
mice	S-Organism
has	O
been	O
used	O
extensively	O
to	O
study	O
the	O
role	O
of	O
the	O
fibrinolytic	S-Pathway
and	O
MMP	S-Gene_or_gene_product
systems	S-Pathway
in	O
the	O
development	O
of	O
obesity	O
.	O

These	O
studies	O
support	O
a	O
role	O
of	O
both	O
systems	O
in	O
adipogenesis	O
and	O
obesity	O
;	O
the	O
role	O
of	O
specific	O
members	O
of	O
these	O
families	O
,	O
however	O
,	O
remains	O
to	O
be	O
determined	O
.	O

Recombinant	O
human	S-Organism
prothrombin	B-Gene_or_gene_product
kringle	I-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
inhibits	S-Negative_regulation
B16F10	B-Pathological_formation
melanoma	E-Pathological_formation
metastasis	S-Localization
through	O
inhibition	S-Negative_regulation
of	O
neovascularization	S-Blood_vessel_development
and	O
reduction	S-Negative_regulation
of	O
matrix	B-Gene_or_gene_product
metalloproteinase	E-Gene_or_gene_product
expression	S-Gene_expression
.	O

Angiogenesis	S-Blood_vessel_development
,	O
a	O
multi	O
-	O
step	O
process	O
which	O
involves	O
endothelial	B-Cell
cell	E-Cell
proliferation	S-Cell_proliferation
,	O
adhesion	S-Binding
,	O
migration	S-Localization
,	O
and	O
basement	B-Cellular_component
membrane	E-Cellular_component
(	O
BM	S-Cellular_component
)	O
degradation	S-Breakdown
,	O
is	O
essential	S-Positive_regulation
for	O
tumor	S-Pathological_formation
metastasis	S-Localization
.	O

Here	O
we	O
show	O
that	O
recombinant	O
human	S-Organism
prothrombin	B-Gene_or_gene_product
kringle	I-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
(	O
rk	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
)	O
inhibited	S-Negative_regulation
bovine	S-Organism
capillary	B-Cell
endothelial	I-Cell
cell	E-Cell
migration	S-Localization
with	O
an	O
IC	O
(	O
50	O
)	O
(	O
concentration	O
for	O
half	O
maximal	O
inhibition	O
)	O
of	O
38	O
nM	O
and	O
inhibited	O
adhesion	O
to	O
extracellular	B-Cellular_component
matrix	E-Cellular_component
(	O
ECM	S-Cellular_component
)	O
proteins	O
.	O

Because	O
tumor	S-Pathological_formation
metastasis	S-Localization
requires	S-Positive_regulation
angiogenesis	S-Blood_vessel_development
,	O
we	O
examined	O
whether	O
rk	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
could	O
inhibit	S-Negative_regulation
metastases	S-Pathological_formation
induced	S-Positive_regulation
by	O
injection	S-Planned_process
of	O
B16F10	B-Cell
melanoma	I-Cell
cells	E-Cell
into	O
mice	S-Organism
.	O

The	O
results	O
revealed	O
that	O
the	O
metastatic	S-Localization
tumors	S-Pathological_formation
in	O
mouse	S-Organism
lung	S-Organ
were	O
markedly	O
decreased	S-Negative_regulation
in	O
a	O
dose	O
-	O
dependent	O
manner	O
and	O
acute	O
lung	S-Organ
injury	O
induced	O
by	O
B16F10	B-Pathological_formation
melanoma	E-Pathological_formation
metastasis	S-Localization
was	O
diminished	O
by	O
systemic	O
rk	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
treatment	S-Planned_process
.	O

In	O
immunohistochemical	O
analysis	O
,	O
rk	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
reduced	S-Negative_regulation
expression	S-Gene_expression
of	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
,	O
which	O
is	O
a	O
potent	O
angiogenic	S-Blood_vessel_development
activator	O
and	O
neovascularization	S-Blood_vessel_development
in	O
the	O
mouse	S-Organism
lung	S-Organ
.	O

Also	O
,	O
rk	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
diminished	S-Negative_regulation
the	O
expression	S-Gene_expression
of	O
matrix	B-Gene_or_gene_product
metalloproteinase	I-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
and	O
-	B-Gene_or_gene_product
9	E-Gene_or_gene_product
in	O
the	O
mouse	S-Organism
lung	S-Organ
which	O
induces	S-Positive_regulation
tumor	S-Pathological_formation
metastasis	S-Localization
and	O
angiogenesis	S-Blood_vessel_development
.	O

These	O
data	O
suggest	O
that	O
inhibition	S-Negative_regulation
of	O
B16F10	B-Pathological_formation
melanoma	E-Pathological_formation
metastasis	S-Localization
by	O
rk	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
was	O
caused	S-Positive_regulation
by	O
inhibition	S-Negative_regulation
of	O
neovascularization	S-Blood_vessel_development
and	O
reduction	S-Negative_regulation
of	O
matrix	B-Gene_or_gene_product
metalloproteinase	E-Gene_or_gene_product
expression	S-Gene_expression
.	O

Extracellular	B-Cellular_component
matrix	E-Cellular_component
as	O
a	O
bioactive	O
material	O
for	O
soft	B-Tissue
tissue	E-Tissue
reconstruction	S-Remodeling
.	O

The	O
extracellular	B-Cellular_component
matrix	E-Cellular_component
(	O
ECM	S-Cellular_component
)	O
directs	O
all	O
phases	O
of	O
healing	O
following	O
trauma	O
or	O
disease	O
and	O
is	O
therefore	O
a	O
natural	O
source	O
of	O
prosthetic	O
mesh	O
material	O
that	O
can	O
be	O
used	O
strategically	O
to	O
induce	S-Positive_regulation
the	O
repair	S-Development
and	O
restoration	S-Development
of	O
soft	B-Tissue
tissues	E-Tissue
following	O
surgery	S-Planned_process
.	O

Biomaterials	O
such	O
as	O
Surgisis	O
(	O
Cook	O
Biotech	O
Incorporated	O
,	O
West	O
Lafayette	O
,	O
IN	O
,	O
USA	O
)	O
,	O
which	O
are	O
derived	O
from	O
natural	O
ECM	S-Cellular_component
,	O
provide	O
the	O
extracellular	O
components	O
necessary	O
to	O
direct	O
the	O
healing	O
response	O
,	O
allow	O
for	O
the	O
proliferation	S-Growth
of	O
new	O
,	O
healthy	O
tissue	S-Tissue
and	O
restore	O
tissue	S-Tissue
integrity	O
to	O
the	O
damaged	O
site	O
.	O

The	O
3	O
-	O
D	O
organization	O
of	O
these	O
extracellular	O
components	O
distinguishes	O
the	O
Surgisis	O
mesh	O
from	O
synthetic	O
materials	O
and	O
is	O
associated	O
with	O
constructive	O
tissue	S-Tissue
remodelling	S-Remodeling
instead	O
of	O
scar	O
tissue	S-Tissue
.	O

Common	O
features	O
of	O
this	O
ECM	S-Cellular_component
-	O
assisted	S-Positive_regulation
tissue	S-Tissue
remodelling	S-Remodeling
include	O
angiogenesis	S-Blood_vessel_development
,	O
recruitment	S-Localization
of	O
circulating	O
progenitor	B-Cell
cells	E-Cell
and	O
constructive	O
remodelling	S-Remodeling
of	O
damaged	O
tissue	S-Tissue
structures	O
.	O

The	O
tissue	S-Tissue
response	O
to	O
this	O
biologic	O
mesh	O
is	O
discussed	O
in	O
the	O
context	O
of	O
recent	O
reports	O
on	O
clinical	O
hernia	O
repair	O
.	O

Activation	S-Positive_regulation
of	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
through	O
reactive	O
oxygen	S-Drug_or_compound
species	O
mediates	S-Regulation
20	B-Drug_or_compound
-	I-Drug_or_compound
hydroxyeicosatetraenoic	I-Drug_or_compound
acid	E-Drug_or_compound
-	O
induced	S-Positive_regulation
endothelial	B-Cell
cell	E-Cell
proliferation	S-Cell_proliferation
.	O

20	B-Drug_or_compound
-	I-Drug_or_compound
Hydroxyeicosatetraenoic	I-Drug_or_compound
acid	E-Drug_or_compound
(	O
20	B-Drug_or_compound
-	I-Drug_or_compound
HETE	E-Drug_or_compound
)	O
is	O
formed	S-Synthesis
by	O
the	O
omega	O
-	O
hydroxylation	O
of	O
arachidonic	B-Drug_or_compound
acid	E-Drug_or_compound
by	O
cytochrome	B-Gene_or_gene_product
P450	I-Gene_or_gene_product
4A	E-Gene_or_gene_product
and	O
4F	S-Gene_or_gene_product
enzymes	O
,	O
and	O
it	O
induces	S-Positive_regulation
angiogenic	S-Blood_vessel_development
responses	O
in	O
vivo	O
.	O

To	O
test	O
the	O
hypothesis	O
that	O
20	B-Drug_or_compound
-	I-Drug_or_compound
HETE	E-Drug_or_compound
increases	S-Positive_regulation
endothelial	B-Cell
cell	E-Cell
(	O
EC	S-Cell
)	O
proliferation	S-Cell_proliferation
via	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
(	O
VEGF	S-Gene_or_gene_product
)	O
,	O
we	O
studied	O
the	O
effects	S-Regulation
of	O
WIT003	S-Drug_or_compound
[	O
20	B-Drug_or_compound
-	I-Drug_or_compound
hydroxyeicosa	I-Drug_or_compound
-	I-Drug_or_compound
5	I-Drug_or_compound
(	I-Drug_or_compound
Z	I-Drug_or_compound
)	I-Drug_or_compound
,	I-Drug_or_compound
14	I-Drug_or_compound
(	I-Drug_or_compound
Z	I-Drug_or_compound
)	I-Drug_or_compound
-	I-Drug_or_compound
dienoic	I-Drug_or_compound
acid	E-Drug_or_compound
]	O
,	O
a	O
20	B-Drug_or_compound
-	I-Drug_or_compound
HETE	E-Drug_or_compound
analog	O
on	O
human	S-Organism
macrovascular	S-Cell
or	O
microvascular	B-Cell
EC	E-Cell
.	O

WIT003	S-Drug_or_compound
,	O
as	O
well	O
as	O
pure	O
20	B-Drug_or_compound
-	I-Drug_or_compound
HETE	E-Drug_or_compound
,	O
stimulated	S-Positive_regulation
EC	S-Cell
proliferation	S-Cell_proliferation
by	O
approximately	O
40	O
%	O
.	O

These	O
proliferative	O
effects	O
were	O
accompanied	O
by	O
increased	S-Positive_regulation
VEGF	S-Gene_or_gene_product
expression	S-Gene_expression
and	O
release	S-Localization
that	O
were	O
observed	O
as	O
early	O
as	O
4	O
h	O
after	O
20	B-Drug_or_compound
-	I-Drug_or_compound
HETE	E-Drug_or_compound
agonist	O
addition	O
.	O

This	O
was	O
accompanied	O
by	O
increased	S-Positive_regulation
phosphorylation	S-Phosphorylation
of	O
the	O
VEGF	B-Gene_or_gene_product
receptor	I-Gene_or_gene_product
2	E-Gene_or_gene_product
.	O

The	O
proliferative	O
effects	O
of	O
20	B-Drug_or_compound
-	I-Drug_or_compound
HETE	E-Drug_or_compound
were	O
markedly	O
inhibited	S-Negative_regulation
by	O
a	O
VEGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
neutralizing	I-Gene_or_gene_product
antibody	E-Gene_or_gene_product
.	O

Polyethylene	B-Drug_or_compound
glycol	I-Drug_or_compound
-	I-Drug_or_compound
superoxide	I-Drug_or_compound
dismutase	E-Drug_or_compound
(	O
PEG	B-Drug_or_compound
-	I-Drug_or_compound
SOD	E-Drug_or_compound
)	O
markedly	O
inhibited	S-Negative_regulation
both	O
the	O
increases	S-Positive_regulation
in	O
VEGF	S-Gene_or_gene_product
expression	S-Gene_expression
and	O
the	O
proliferative	O
effects	O
of	O
20	B-Drug_or_compound
-	I-Drug_or_compound
HETE	E-Drug_or_compound
.	O

In	O
contrast	O
,	O
administration	S-Planned_process
of	O
the	O
NAD	B-Gene_or_gene_product
(	I-Gene_or_gene_product
P	I-Gene_or_gene_product
)	I-Gene_or_gene_product
H	I-Gene_or_gene_product
oxidase	E-Gene_or_gene_product
inhibitor	O
apocynin	S-Drug_or_compound
had	O
no	O
effect	S-Regulation
to	O
the	O
proliferative	O
response	O
to	O
20	B-Drug_or_compound
-	I-Drug_or_compound
HETE	E-Drug_or_compound
.	O

The	O
20	B-Drug_or_compound
-	I-Drug_or_compound
HETE	E-Drug_or_compound
agonist	O
markedly	O
increased	S-Positive_regulation
superoxide	S-Drug_or_compound
formation	S-Synthesis
as	O
reflected	O
by	O
an	O
increase	O
in	O
dihydroethidium	S-Drug_or_compound
staining	S-Planned_process
of	O
EC	S-Cell
,	O
and	O
this	O
increase	O
was	O
inhibited	S-Negative_regulation
by	O
PEG	B-Drug_or_compound
-	I-Drug_or_compound
SOD	E-Drug_or_compound
but	O
not	O
by	O
apocynin	S-Drug_or_compound
.	O

20	B-Drug_or_compound
-	I-Drug_or_compound
HETE	E-Drug_or_compound
also	O
increased	S-Positive_regulation
the	O
phosphorylation	S-Phosphorylation
of	O
p42	B-Gene_or_gene_product
/	I-Gene_or_gene_product
p44	I-Gene_or_gene_product
mitogen	I-Gene_or_gene_product
-	I-Gene_or_gene_product
activated	I-Gene_or_gene_product
protein	I-Gene_or_gene_product
kinase	E-Gene_or_gene_product
(	O
MAPK	S-Gene_or_gene_product
)	O
in	O
EC	S-Cell
,	O
whereas	O
an	O
inhibitor	O
of	O
MAPK	S-Gene_or_gene_product
[	O
U0126	S-Drug_or_compound
,	O
1	B-Drug_or_compound
,	I-Drug_or_compound
4	I-Drug_or_compound
-	I-Drug_or_compound
diamino	I-Drug_or_compound
-	I-Drug_or_compound
2	I-Drug_or_compound
,	I-Drug_or_compound
3	I-Drug_or_compound
-	I-Drug_or_compound
dicyano	I-Drug_or_compound
-	I-Drug_or_compound
1	I-Drug_or_compound
,	I-Drug_or_compound
4	I-Drug_or_compound
-	I-Drug_or_compound
bis	I-Drug_or_compound
(	I-Drug_or_compound
2	I-Drug_or_compound
-	I-Drug_or_compound
aminophenylthio	I-Drug_or_compound
)	I-Drug_or_compound
butadiene	E-Drug_or_compound
]	O
suppressed	S-Negative_regulation
the	O
proliferative	O
and	O
the	O
VEGF	S-Gene_or_gene_product
changes	S-Regulation
but	O
not	O
the	O
pro	O
-	O
oxidant	O
effects	O
of	O
20	B-Drug_or_compound
-	I-Drug_or_compound
HETE	E-Drug_or_compound
.	O

These	O
data	O
suggest	O
that	O
20	B-Drug_or_compound
-	I-Drug_or_compound
HETE	E-Drug_or_compound
stimulates	S-Positive_regulation
superoxide	S-Drug_or_compound
formation	S-Synthesis
by	O
pathways	O
other	O
than	O
apocynin	S-Drug_or_compound
-	O
sensitive	O
NAD	B-Gene_or_gene_product
(	I-Gene_or_gene_product
P	I-Gene_or_gene_product
)	I-Gene_or_gene_product
H	I-Gene_or_gene_product
oxidase	E-Gene_or_gene_product
,	O
thereby	O
activating	S-Positive_regulation
MAPK	S-Gene_or_gene_product
and	O
then	O
enhancing	S-Positive_regulation
VEGF	S-Gene_or_gene_product
synthesis	S-Gene_expression
that	O
drives	S-Regulation
EC	S-Cell
proliferation	S-Cell_proliferation
.	O

Thus	O
,	O
20	B-Drug_or_compound
-	I-Drug_or_compound
HETE	E-Drug_or_compound
may	O
be	O
involved	S-Regulation
in	O
the	O
regulation	S-Regulation
of	O
EC	S-Cell
functions	O
,	O
such	O
as	O
angiogenesis	S-Blood_vessel_development
.	O

[	O
Study	O
on	O
the	O
expression	O
of	O
angiogenesis	S-Blood_vessel_development
and	O
spontaneous	O
apoptosis	O
and	O
their	O
relevance	O
in	O
laryngeal	B-Pathological_formation
squamous	I-Pathological_formation
cell	I-Pathological_formation
carcinoma	E-Pathological_formation
]	O

OBJECTIVE	O
:	O
To	O
investigate	O
the	O
relationship	O
among	O
angiogenesis	S-Blood_vessel_development
,	O
spontaneous	O
apoptosis	O
and	O
clinicopathological	O
parameters	O
in	O
laryngeal	B-Pathological_formation
squamous	I-Pathological_formation
cell	I-Pathological_formation
carcinoma	E-Pathological_formation
(	O
LSCC	S-Pathological_formation
)	O
.	O

METHOD	O
:	O
The	O
intratumor	O
microvessel	S-Tissue
density	O
(	O
IMVD	O
)	O
,	O
apoptotic	O
index	O
(	O
AI	O
)	O
and	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
(	O
VEGF	S-Gene_or_gene_product
)	O
expression	S-Gene_expression
were	O
detected	O
by	O
immunohistochemistry	O
SABC	O
and	O
terminal	O
uridine	O
deoxynucleotidyl	O
transferase	O
mediated	O
nick	O
end	O
labeling	O
(	O
TUNEL	O
)	O
methods	O
in34	O
LSCC	S-Pathological_formation
patients	S-Organism
.	O

RESULT	O
:	O
The	O
average	O
IMVD	O
was	O
(	O
21	O
.	O
50	O
+	O
/	O
-	O
8	O
.	O
87	O
)	O
,	O
and	O
median	O
of	O
AI	O
was	O
1	O
.	O
15	O
%	O
.	O

The	O
average	O
IMVD	O
in	O
positive	O
and	O
negative	O
cervical	B-Pathological_formation
lymphatic	I-Pathological_formation
metastasis	E-Pathological_formation
was	O
(	O
26	O
.	O
33	O
+	O
/	O
-	O
9	O
.	O
70	O
)	O
and	O
(	O
17	O
.	O
68	O
+	O
/	O
-	O
6	O
.	O
06	O
)	O
respectively	O
,	O
and	O
the	O
IMVD	O
with	O
positive	O
lymphatic	B-Pathological_formation
metastasis	I-Pathological_formation
tumors	E-Pathological_formation
was	O
statistical	O
significantly	O
higher	O
than	O
those	O
with	O
negative	O
cervical	B-Pathological_formation
lymphatic	I-Pathological_formation
metastasis	I-Pathological_formation
tumors	E-Pathological_formation
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

The	O
average	O
IMVD	O
had	O
statistical	O
difference	O
in	O
histological	O
grading	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
,	O
and	O
analysis	O
by	O
one	O
to	O
one	O
,	O
the	O
average	O
IMVD	O
had	O
statistical	O
difference	O
between	O
high	O
and	O
median	O
grading	O
.	O

Expression	S-Gene_expression
of	O
VEGF	S-Gene_or_gene_product
had	O
a	O
significantly	O
positive	O
correlation	O
with	O
IMVD	O
(	O
r	O
=	O
0	O
.	O
51	O
,	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

Statistical	O
analysis	O
revealed	O
a	O
significantly	O
inverse	O
correlation	O
between	O
AI	O
and	O
IMVD	O
(	O
r	O
=	O
-	O
0	O
.	O
53	O
,	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

We	O
failed	O
to	O
find	O
the	O
statistical	O
difference	O
between	O
IMVD	O
and	O
tumor	S-Pathological_formation
T	O
-	O
stage	O
in	O
LSCC	S-Pathological_formation
.	O

CONCLUSION	O
:	O
IMVD	O
may	O
be	O
an	O
important	O
indicator	O
to	O
predict	O
cervical	B-Pathological_formation
lymphatic	I-Pathological_formation
metastasis	E-Pathological_formation
in	O
LSCC	S-Pathological_formation
.	O

VEGF	S-Gene_or_gene_product
might	O
be	O
an	O
important	O
angiogenic	S-Blood_vessel_development
factor	O
,	O
and	O
could	O
promote	S-Positive_regulation
tumor	S-Pathological_formation
angiogenesis	S-Blood_vessel_development
in	O
LSCC	S-Pathological_formation
.	O

Tumor	S-Pathological_formation
angiogenesis	S-Blood_vessel_development
might	O
contribute	S-Regulation
to	O
tumor	S-Pathological_formation
malignant	O
progression	S-Development
by	O
inhibiting	S-Negative_regulation
spontaneous	O
apoptosis	S-Death
in	O
LSCC	S-Pathological_formation
.	O

Hyperforin	S-Drug_or_compound
blocks	S-Negative_regulation
neutrophil	S-Cell
activation	S-Positive_regulation
of	O
matrix	B-Gene_or_gene_product
metalloproteinase	I-Gene_or_gene_product
-	I-Gene_or_gene_product
9	E-Gene_or_gene_product
,	O
motility	S-Localization
and	O
recruitment	S-Localization
,	O
and	O
restrains	O
inflammation	O
-	O
triggered	S-Positive_regulation
angiogenesis	S-Blood_vessel_development
and	O
lung	S-Organ
fibrosis	O
.	O

Hyperforin	S-Drug_or_compound
(	O
Hyp	S-Drug_or_compound
)	O
,	O
a	O
polyphenol	O
-	O
derivative	O
of	O
St	O
.	O

John	B-Organism
'	I-Organism
s	I-Organism
wort	E-Organism
(	O
Hypericum	B-Organism
perforatum	E-Organism
)	O
,	O
has	O
emerged	O
as	O
key	O
player	O
not	O
only	O
in	O
the	O
antidepressant	O
activity	O
of	O
the	O
plant	O
but	O
also	O
as	O
an	O
inhibitor	O
of	O
bacteria	O
lymphocyte	S-Cell
and	O
tumor	B-Cell
cell	E-Cell
proliferation	S-Cell_proliferation
,	O
and	O
matrix	B-Gene_or_gene_product
proteinases	E-Gene_or_gene_product
.	O

We	O
tested	O
whether	O
as	O
well	O
as	O
inhibiting	S-Negative_regulation
leukocyte	B-Gene_or_gene_product
elastase	E-Gene_or_gene_product
(	O
LE	S-Gene_or_gene_product
)	O
activity	O
,	O
Hyp	S-Drug_or_compound
might	O
be	O
effective	S-Regulation
in	O
containing	O
both	O
polymorphonuclear	B-Cell
neutrophil	I-Cell
(	I-Cell
PMN	I-Cell
)	I-Cell
leukocyte	E-Cell
recruitment	S-Localization
and	O
unfavorable	O
eventual	O
tissue	S-Tissue
responses	O
.	O

The	O
results	O
show	O
that	O
,	O
without	O
affecting	O
in	O
vitro	O
human	S-Organism
PMN	S-Cell
viability	O
and	O
chemokine	O
-	O
receptor	O
expression	O
,	O
Hyp	S-Drug_or_compound
(	O
as	O
stable	O
dicyclohexylammonium	B-Drug_or_compound
salt	E-Drug_or_compound
)	O
was	O
able	O
to	O
inhibit	S-Negative_regulation
in	O
a	O
dose	O
-	O
dependent	O
manner	O
their	O
chemotaxis	S-Localization
and	O
chemoinvasion	S-Localization
(	O
IC50	O
=	O
1	O
microM	O
for	O
both	O
)	O
;	O
this	O
effect	O
was	O
associated	O
with	O
a	O
reduced	S-Negative_regulation
expression	S-Gene_expression
of	O
the	O
adhesion	O
molecule	O
CD11b	S-Gene_or_gene_product
by	O
formyl	B-Drug_or_compound
-	I-Drug_or_compound
Met	I-Drug_or_compound
-	I-Drug_or_compound
Leu	I-Drug_or_compound
-	I-Drug_or_compound
Phe	E-Drug_or_compound
-	O
stimulated	S-Positive_regulation
neutrophils	S-Cell
and	O
block	S-Negative_regulation
of	O
LE	S-Gene_or_gene_product
-	O
triggered	S-Positive_regulation
activation	S-Positive_regulation
of	O
the	O
gelatinase	B-Gene_or_gene_product
matrix	I-Gene_or_gene_product
metalloproteinase	I-Gene_or_gene_product
-	I-Gene_or_gene_product
9	E-Gene_or_gene_product
.	O

PMN	S-Cell
-	O
triggered	S-Positive_regulation
angiogenesis	S-Blood_vessel_development
is	O
also	O
blocked	S-Negative_regulation
by	O
both	O
local	O
injection	S-Planned_process
and	O
daily	O
i	O
.	O
p	O
.	O
administration	S-Planned_process
of	O
the	O
Hyp	S-Drug_or_compound
salt	O
in	O
an	O
interleukin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	E-Gene_or_gene_product
-	O
induced	S-Positive_regulation
murine	S-Organism
model	O
.	O

Furthermore	O
,	O
i	O
.	O
p	O
.	O
treatment	S-Planned_process
with	O
Hyp	S-Drug_or_compound
reduces	S-Negative_regulation
acute	O
PMN	S-Cell
recruitment	S-Localization
and	O
enhances	O
resolution	O
in	O
a	O
pulmonary	O
bleomycin	S-Drug_or_compound
-	O
induced	O
inflammation	O
model	O
,	O
significantly	O
reducing	O
consequent	O
fibrosis	O
.	O

These	O
results	O
indicate	O
that	O
Hyp	S-Drug_or_compound
is	O
a	O
powerful	O
anti	O
-	O
inflammatory	O
compound	O
with	O
therapeutic	O
potential	O
,	O
and	O
they	O
elucidate	O
mechanistic	O
keys	O
.	O

New	O
vectors	O
and	O
strategies	O
for	O
cardiovascular	O
gene	O
therapy	O
.	O

Cardiovascular	O
diseases	O
are	O
the	O
major	O
cause	O
of	O
morbidity	O
and	O
mortality	O
in	O
both	O
men	S-Organism
and	O
women	S-Organism
in	O
industrially	O
developed	O
countries	O
.	O

These	O
disorders	O
may	O
result	O
from	O
impaired	S-Negative_regulation
angiogenesis	S-Blood_vessel_development
,	O
particularly	O
in	O
response	O
to	O
hypoxia	O
.	O

Despite	O
many	O
limitations	O
,	O
gene	O
therapy	O
is	O
still	O
emerging	O
as	O
a	O
potential	O
alternative	O
for	O
patients	S-Organism
who	O
are	O
not	O
candidates	O
for	O
traditional	O
revascularization	S-Blood_vessel_development
procedures	O
,	O
like	O
angioplasty	O
or	O
vein	B-Multi-tissue_structure
grafts	E-Multi-tissue_structure
.	O

This	O
review	O
focuses	O
on	O
recent	O
approaches	O
in	O
the	O
development	O
of	O
new	O
gene	O
delivery	O
vectors	O
,	O
with	O
great	O
respect	O
to	O
newly	O
discovered	O
AAV	B-Drug_or_compound
serotypes	E-Drug_or_compound
and	O
their	O
modified	O
forms	O
.	O

Moreover	O
,	O
some	O
new	O
cardiovascular	O
gene	O
therapy	O
strategies	O
have	O
been	O
highlighted	O
,	O
such	O
as	O
combination	O
of	O
different	O
angiogenic	S-Blood_vessel_development
growth	O
factors	O
or	O
simultaneous	O
application	O
of	O
genes	O
and	O
progenitor	B-Cell
cells	E-Cell
in	O
order	O
to	O
obtain	S-Development
stable	O
and	O
functional	O
blood	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
in	O
ischemic	B-Tissue
tissue	E-Tissue
.	O

Impaired	O
apoptosis	S-Death
of	O
pulmonary	B-Cell
endothelial	I-Cell
cells	E-Cell
is	O
associated	O
with	O
intimal	S-Tissue
proliferation	S-Growth
and	O
irreversibility	O
of	O
pulmonary	O
hypertension	O
in	O
congenital	O
heart	S-Organ
disease	O
.	O

OBJECTIVES	O
:	O
This	O
study	O
sought	O
to	O
assess	O
the	O
cellular	O
and	O
histologic	O
basis	O
of	O
irreversible	O
pulmonary	O
hypertension	O
(	O
PHT	O
)	O
in	O
the	O
clinical	O
setting	O
of	O
congenital	O
heart	S-Organ
disease	O
(	O
CHD	O
)	O
.	O

BACKGROUND	O
:	O
Although	O
many	O
children	S-Organism
with	O
CHD	O
develop	O
pulmonary	O
vascular	O
disease	O
,	O
it	O
is	O
unclear	O
why	O
this	O
complication	O
is	O
reversible	O
after	O
complete	O
repair	O
in	O
some	O
cases	O
but	O
irreversible	O
in	O
others	O
.	O

Because	O
failure	O
of	O
endothelial	B-Cell
cell	E-Cell
apoptosis	S-Death
might	O
lead	O
to	O
intimal	S-Tissue
proliferation	S-Growth
and	O
lack	O
of	O
reversibility	O
of	O
PHT	O
,	O
we	O
investigated	O
this	O
and	O
other	O
key	O
markers	O
of	O
vasoactivity	O
and	O
angiogenesis	S-Blood_vessel_development
in	O
subjects	O
with	O
PHT	O
and	O
CHD	O
.	O

METHODS	O
:	O
We	O
assessed	O
antiapoptotic	O
and	O
proapoptotic	O
markers	O
in	O
vascular	S-Cell
and	O
perivascular	B-Cell
cells	E-Cell
in	O
lung	B-Multi-tissue_structure
biopsy	I-Multi-tissue_structure
samples	E-Multi-tissue_structure
from	O
18	O
patients	S-Organism
with	O
CHD	O
,	O
7	O
with	O
reversible	O
and	O
11	O
with	O
irreversible	O
PHT	O
,	O
and	O
6	O
control	O
patients	S-Organism
.	O

Immunostaining	O
for	O
endothelial	B-Gene_or_gene_product
nitric	I-Gene_or_gene_product
oxide	I-Gene_or_gene_product
synthase	E-Gene_or_gene_product
,	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
,	O
and	O
CD34	S-Gene_or_gene_product
(	O
markers	O
of	O
vasoactivity	O
and	O
neoangiogenesis	S-Blood_vessel_development
)	O
was	O
also	O
performed	O
.	O

RESULTS	O
:	O
The	O
antiapoptotic	O
protein	O
Bcl	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
was	O
highly	O
expressed	S-Gene_expression
by	O
pulmonary	B-Cell
endothelial	I-Cell
cells	E-Cell
in	O
all	O
cases	O
of	O
irreversible	O
PHT	O
but	O
in	O
no	O
cases	O
of	O
reversible	O
PHT	O
,	O
nor	O
in	O
control	O
patients	S-Organism
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O

Intimal	S-Tissue
proliferation	S-Growth
was	O
present	O
in	O
10	O
of	O
11	O
irreversible	O
PHT	O
cases	O
,	O
but	O
never	O
observed	O
in	O
reversible	O
PHT	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O

Similarly	O
,	O
perivascular	B-Cell
inflammatory	I-Cell
T	I-Cell
-	I-Cell
cells	E-Cell
expressed	O
more	O
antiapoptotic	O
proteins	O
in	O
irreversible	O
PHT	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

Irreversible	O
PHT	O
cases	O
were	O
also	O
more	O
likely	O
to	O
show	O
compensatory	O
upregulation	S-Positive_regulation
of	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
and	O
new	O
small	O
vessel	S-Multi-tissue_structure
formation	S-Development
at	O
the	O
sites	O
of	O
native	O
vessel	S-Multi-tissue_structure
stenosis	O
or	O
occlusion	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O

CONCLUSIONS	O
:	O
Irreversible	O
PHT	O
is	O
strongly	O
associated	O
with	O
impaired	S-Negative_regulation
endothelial	B-Cell
cell	E-Cell
apoptosis	S-Death
and	O
antiapoptotic	B-Pathway
signaling	E-Pathway
from	O
perivascular	B-Cell
inflammatory	I-Cell
cells	E-Cell
.	O

These	O
changes	O
are	O
associated	O
with	O
intimal	S-Tissue
proliferation	S-Growth
and	O
vessel	S-Multi-tissue_structure
narrowing	O
,	O
and	O
thereby	O
may	O
contribute	O
to	O
clinical	O
outcomes	O
associated	O
with	O
pulmonary	O
hypertension	O
.	O

Inhibition	S-Negative_regulation
of	O
Dll4	S-Gene_or_gene_product
-	O
mediated	S-Positive_regulation
signaling	S-Pathway
induces	S-Positive_regulation
proliferation	S-Growth
of	O
immature	O
vessels	S-Multi-tissue_structure
and	O
results	O
in	O
poor	O
tissue	S-Tissue
perfusion	O
.	O

Vascular	S-Multi-tissue_structure
development	S-Development
is	O
dependent	S-Positive_regulation
on	O
various	O
growth	O
factors	O
and	O
certain	O
modifiers	O
critical	O
for	O
providing	O
arterial	O
or	O
venous	O
identity	O
,	O
interaction	S-Binding
with	O
the	O
surrounding	O
stroma	S-Tissue
and	O
tissues	S-Tissue
,	O
hierarchic	B-Tissue
network	E-Tissue
formation	S-Development
,	O
and	O
recruitment	S-Localization
of	O
pericytes	S-Cell
.	O

Notch	S-Gene_or_gene_product
receptors	O
and	O
ligands	O
(	O
Jagged	S-Gene_or_gene_product
and	O
Delta	S-Gene_or_gene_product
-	O
like	O
)	O
play	B-Regulation
a	I-Regulation
critical	I-Regulation
role	E-Regulation
in	O
this	O
process	O
in	O
addition	O
to	O
VEGF	S-Gene_or_gene_product
.	O

Dll4	S-Gene_or_gene_product
is	O
one	O
of	O
the	O
Notch	S-Gene_or_gene_product
ligands	O
that	O
regulates	S-Regulation
arterial	S-Multi-tissue_structure
specification	S-Development
and	O
maturation	S-Development
events	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
have	O
shown	O
that	O
loss	O
of	O
function	O
by	O
either	O
targeted	O
allele	O
deletion	O
or	O
use	O
of	O
a	O
soluble	O
form	O
of	O
Dll4	B-Gene_or_gene_product
extracellular	I-Gene_or_gene_product
domain	E-Gene_or_gene_product
leads	S-Positive_regulation
to	O
inhibition	S-Negative_regulation
of	O
Notch	S-Gene_or_gene_product
signaling	S-Pathway
,	O
resulting	O
in	O
increased	S-Positive_regulation
vascular	S-Multi-tissue_structure
proliferation	S-Growth
but	O
defective	S-Negative_regulation
maturation	S-Development
.	O

Newly	O
forming	S-Development
vessels	S-Multi-tissue_structure
have	O
thin	O
caliber	O
,	O
a	O
markedly	O
reduced	S-Negative_regulation
vessel	B-Immaterial_anatomical_entity
lumen	E-Immaterial_anatomical_entity
,	O
markedly	O
reduced	S-Negative_regulation
pericyte	S-Cell
recruitment	S-Localization
,	O
and	O
deficient	O
vascular	S-Multi-tissue_structure
perfusion	O
.	O

sDll4	S-Gene_or_gene_product
similarly	O
induced	S-Positive_regulation
defective	S-Negative_regulation
vascular	S-Multi-tissue_structure
response	S-Development
in	O
tumor	S-Pathological_formation
implants	O
leading	S-Positive_regulation
to	O
reduced	S-Negative_regulation
tumor	S-Pathological_formation
growth	S-Growth
.	O

Interference	O
with	O
Dll4	S-Gene_or_gene_product
-	O
Notch	S-Gene_or_gene_product
signaling	S-Pathway
may	O
be	O
particularly	O
desirable	O
in	O
tumors	S-Pathological_formation
that	O
have	O
highly	O
induced	S-Positive_regulation
Dll4	S-Gene_or_gene_product
-	O
Notch	S-Gene_or_gene_product
pathway	S-Pathway
.	O

Pathological	O
animal	O
models	O
in	O
the	O
experimental	O
evaluation	O
of	O
tumour	B-Tissue
microvasculature	E-Tissue
with	O
magnetic	O
resonance	O
imaging	O
.	O

PURPOSE	O
:	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
applications	O
of	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
,	O
and	O
in	O
particular	O
,	O
dynamic	O
contrast	O
-	O
enhanced	O
MRI	O
(	O
DCE	O
-	O
MRI	O
)	O
,	O
in	O
the	O
assessment	O
of	O
tumour	B-Tissue
microvasculature	E-Tissue
by	O
means	O
of	O
animal	O
tumour	S-Pathological_formation
models	O
evaluated	O
before	O
and	O
after	O
antiangiogenic	S-Blood_vessel_development
treatment	S-Planned_process
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Forty	O
-	O
two	O
MRI	O
exams	O
were	O
performed	O
with	O
intravascular	O
contrast	O
media	O
in	O
21	O
rats	S-Organism
:	O
tumours	S-Pathological_formation
were	O
induced	S-Positive_regulation
by	O
subcutaneous	B-Planned_process
injection	E-Planned_process
of	O
colon	B-Cell
carcinoma	I-Cell
cells	E-Cell
in	O
7	O
rats	S-Organism
and	O
mammary	B-Cell
adenocarcinoma	I-Cell
cells	E-Cell
in	O
14	O
rats	S-Organism
.	O

Perfusion	O
and	O
permeability	O
parameters	O
of	O
the	O
implanted	S-Planned_process
tumours	S-Pathological_formation
were	O
evaluated	O
by	O
using	O
two	O
contrast	O
media	O
(	O
B22956	B-Drug_or_compound
/	I-Drug_or_compound
1	E-Drug_or_compound
and	O
Gd	B-Drug_or_compound
-	I-Drug_or_compound
DTPA37	I-Drug_or_compound
-	I-Drug_or_compound
albumin	E-Drug_or_compound
)	O
to	O
establish	O
response	O
to	O
treatment	S-Planned_process
with	O
two	O
different	O
antiangiogenic	S-Blood_vessel_development
drugs	O
(	O
tamoxifen	S-Drug_or_compound
and	O
SU6668	S-Drug_or_compound
)	O
.	O

These	O
parameters	O
were	O
correlated	O
with	O
histology	O
to	O
obtain	O
a	O
radiological	O
-	O
histological	O
map	O
of	O
tumour	B-Tissue
microvasculature	E-Tissue
.	O

RESULTS	O
:	O
DCE	O
-	O
MRI	O
revealed	O
greater	O
enhancement	O
in	O
the	O
peripheral	O
area	O
than	O
in	O
the	O
central	O
area	O
in	O
all	O
the	O
examined	O
animal	O
models	O
.	O

In	O
the	O
mammary	B-Pathological_formation
carcinoma	E-Pathological_formation
experiment	O
,	O
vascular	S-Multi-tissue_structure
permeability	O
measured	O
by	O
means	O
of	O
B22956	B-Drug_or_compound
/	I-Drug_or_compound
1	E-Drug_or_compound
in	O
the	O
animals	O
treated	O
with	O
the	O
antiangiogenic	S-Blood_vessel_development
drug	O
(	O
0	O
.	O
0043317	O
+	O
/	O
-	O
0	O
.	O
0040418	O
ml	O
/	O
min	O
(	O
-	O
1	O
)	O
/	O
ml	O
(	O
-	O
1	O
)	O
)	O
was	O
significantly	O
less	O
than	O
in	O
untreated	O
animals	O
(	O
0	O
.	O
0090460	O
+	O
/	O
-	O
0	O
.	O
0043680	O
ml	O
/	O
min	O
(	O
-	O
1	O
)	O
/	O
ml	O
(	O
-	O
1	O
)	O
)	O
,	O
whereas	O
no	O
significant	O
difference	O
was	O
observed	O
with	O
Gd	B-Drug_or_compound
-	I-Drug_or_compound
DTPA	I-Drug_or_compound
-	I-Drug_or_compound
albumin	E-Drug_or_compound
(	O
13	O
.	O
14	O
+	O
/	O
-	O
13	O
.	O
94	O
ml	O
/	O
min	O
(	O
-	O
1	O
)	O
/	O
ml	O
(	O
-	O
1	O
)	O
in	O
treated	S-Planned_process
animals	O
and	O
18	O
.	O
07	O
+	O
/	O
-	O
11	O
.	O
92	O
ml	O
/	O
min	O
(	O
-	O
1	O
)	O
/	O
ml	O
(	O
-	O
1	O
)	O
in	O
untreated	O
animals	O
)	O
.	O

In	O
the	O
colon	B-Pathological_formation
carcinoma	E-Pathological_formation
experiment	O
,	O
mean	O
permeability	O
and	O
perfusion	O
decreased	O
by	O
51	O
%	O
(	O
from	O
5	O
.	O
2	O
+	O
/	O
-	O
1	O
.	O
1	O
to	O
2	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
8	O
ml	O
/	O
100	O
ml	O
)	O
and	O
59	O
%	O
(	O
from	O
0	O
.	O
00165	O
+	O
/	O
-	O
5	O
.	O
1	O
to	O
0	O
.	O
0067	O
+	O
/	O
-	O
4	O
.	O
8	O
ml	O
/	O
min	O
(	O
-	O
1	O
)	O
/	O
ml	O
(	O
-	O
1	O
)	O
of	O
tissue	S-Tissue
)	O
,	O
respectively	O
,	O
in	O
all	O
animals	O
after	O
antiangiogenic	S-Blood_vessel_development
drug	O
administration	O
.	O

CONCLUSIONS	O
:	O
DCE	O
-	O
MRI	O
permits	O
a	O
noninvasive	O
evaluation	O
of	O
tumour	S-Pathological_formation
microcirculation	O
and	O
in	O
particular	O
of	O
its	O
dynamic	O
characteristics	O
and	O
vascularity	O
before	O
and	O
after	O
antiangiogenic	S-Blood_vessel_development
treatment	O
.	O

An	O
antibody	O
directed	O
against	O
PDGF	B-Gene_or_gene_product
receptor	I-Gene_or_gene_product
beta	E-Gene_or_gene_product
enhances	S-Positive_regulation
the	O
antitumor	S-Pathological_formation
and	O
the	O
anti	O
-	O
angiogenic	S-Blood_vessel_development
activities	S-Negative_regulation
of	O
an	O
anti	B-Gene_or_gene_product
-	I-Gene_or_gene_product
VEGF	I-Gene_or_gene_product
receptor	I-Gene_or_gene_product
2	I-Gene_or_gene_product
antibody	E-Gene_or_gene_product
.	O

Platelet	B-Gene_or_gene_product
-	I-Gene_or_gene_product
derived	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
(	O
PDGF	S-Gene_or_gene_product
)	O
and	O
its	O
receptors	O
(	O
PDGFR	S-Gene_or_gene_product
)	O
play	O
important	O
roles	O
in	O
tumorigenesis	O
through	O
stimulating	S-Positive_regulation
tumor	S-Pathological_formation
growth	S-Growth
and	O
promoting	S-Positive_regulation
angiogenesis	S-Blood_vessel_development
via	O
enhancing	S-Positive_regulation
pericyte	S-Cell
recruitment	S-Localization
and	O
vessel	S-Multi-tissue_structure
maturation	S-Development
.	O

Here	O
we	O
produced	O
a	O
neutralizing	O
antibody	O
,	O
1B3	S-Drug_or_compound
,	O
directed	O
against	O
mouse	S-Organism
PDGFRbeta	S-Gene_or_gene_product
.	O

1B3	S-Drug_or_compound
binds	S-Binding
to	O
PDGFRbeta	S-Gene_or_gene_product
with	O
high	O
affinity	O
(	O
9x10	O
(	O
-	O
11	O
)	O
M	O
)	O
and	O
blocks	S-Negative_regulation
PDGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
BB	E-Gene_or_gene_product
from	O
binding	S-Binding
to	O
the	O
receptor	O
with	O
an	O
IC	O
(	O
50	O
)	O
of	O
approximately	O
1	O
.	O
2	O
nM	O
.	O

The	O
antibody	O
also	O
blocks	S-Negative_regulation
ligand	O
-	O
stimulated	O
activation	S-Positive_regulation
of	O
PDGFRbeta	S-Gene_or_gene_product
and	O
downstream	O
signaling	O
molecules	O
,	O
including	O
Akt	S-Gene_or_gene_product
and	O
MAPK	B-Gene_or_gene_product
p42	I-Gene_or_gene_product
/	I-Gene_or_gene_product
44	E-Gene_or_gene_product
,	O
in	O
tumor	B-Cell
cells	E-Cell
.	O

In	O
animal	O
studies	O
,	O
1B3	S-Drug_or_compound
significantly	O
enhanced	S-Positive_regulation
the	O
antitumor	S-Pathological_formation
and	O
the	O
anti	O
-	O
angiogenic	S-Blood_vessel_development
activities	S-Negative_regulation
of	O
DC101	S-Drug_or_compound
,	O
an	O
antibody	O
directed	O
against	O
mouse	S-Organism
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
receptor	I-Gene_or_gene_product
2	E-Gene_or_gene_product
,	O
in	O
a	O
pancreatic	S-Pathological_formation
(	O
BxPC	B-Pathological_formation
-	I-Pathological_formation
3	E-Pathological_formation
)	O
and	O
a	O
non	B-Pathological_formation
-	I-Pathological_formation
small	I-Pathological_formation
cell	I-Pathological_formation
lung	I-Pathological_formation
(	I-Pathological_formation
NCI	I-Pathological_formation
-	I-Pathological_formation
H460	I-Pathological_formation
)	I-Pathological_formation
tumor	I-Pathological_formation
xenograft	E-Pathological_formation
models	O
.	O

Treatment	S-Planned_process
with	O
the	O
combination	O
of	O
1B3	S-Drug_or_compound
and	O
DC101	S-Drug_or_compound
in	O
BxPC	B-Pathological_formation
-	I-Pathological_formation
3	I-Pathological_formation
xenograft	E-Pathological_formation
-	O
bearing	O
mice	S-Organism
resulted	S-Positive_regulation
in	O
tumor	S-Pathological_formation
regression	S-Negative_regulation
in	O
58	O
%	O
of	O
mice	S-Organism
compared	O
to	O
that	O
in	O
18	O
%	O
of	O
mice	S-Organism
treated	S-Planned_process
with	O
DC101	S-Drug_or_compound
alone	O
.	O

Taken	O
together	O
,	O
these	O
results	O
lend	O
great	O
support	O
to	O
use	O
PDGFRbeta	S-Gene_or_gene_product
antagonists	O
in	O
combinations	O
with	O
other	O
antitumor	S-Pathological_formation
and	O
/	O
or	O
anti	O
-	O
angiogenic	S-Blood_vessel_development
agents	O
in	O
the	O
treatment	S-Planned_process
of	O
a	O
variety	O
of	O
cancers	S-Pathological_formation
.	O

Caffeine	S-Drug_or_compound
inhibits	S-Negative_regulation
adenosine	S-Drug_or_compound
-	O
induced	O
accumulation	S-Positive_regulation
of	O
hypoxia	B-Gene_or_gene_product
-	I-Gene_or_gene_product
inducible	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
-	I-Gene_or_gene_product
1alpha	E-Gene_or_gene_product
,	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
,	O
and	O
interleukin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	E-Gene_or_gene_product
expression	S-Gene_expression
in	O
hypoxic	O
human	S-Organism
colon	B-Cell
cancer	I-Cell
cells	E-Cell
.	O

Frequent	O
coffee	O
consumption	O
has	O
been	O
associated	O
with	O
a	O
reduced	O
risk	O
of	O
colorectal	B-Pathological_formation
cancer	E-Pathological_formation
in	O
a	O
number	O
of	O
case	O
-	O
control	O
studies	O
.	O

Coffee	O
is	O
a	O
leading	O
source	O
of	O
methylxanthines	S-Drug_or_compound
,	O
such	O
as	O
caffeine	S-Drug_or_compound
.	O

The	O
induction	S-Positive_regulation
of	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
(	O
VEGF	S-Gene_or_gene_product
)	O
and	O
interleukin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	E-Gene_or_gene_product
(	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	E-Gene_or_gene_product
)	O
is	O
an	O
essential	S-Positive_regulation
feature	O
of	O
tumor	S-Pathological_formation
angiogenesis	S-Blood_vessel_development
,	O
and	O
the	O
hypoxia	B-Gene_or_gene_product
-	I-Gene_or_gene_product
inducible	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
(	O
HIF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
)	O
transcription	O
factor	O
is	O
known	O
to	O
be	O
a	O
key	O
regulator	O
of	O
this	O
process	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effects	S-Regulation
of	O
caffeine	S-Drug_or_compound
on	O
HIF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
protein	O
accumulation	S-Positive_regulation
and	O
on	O
VEGF	S-Gene_or_gene_product
and	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	E-Gene_or_gene_product
expression	S-Gene_expression
in	O
the	O
human	S-Organism
colon	B-Cell
cancer	I-Cell
cell	I-Cell
line	I-Cell
HT29	E-Cell
under	O
hypoxic	O
conditions	O
.	O

Our	O
results	O
show	O
that	O
caffeine	S-Drug_or_compound
significantly	O
inhibits	S-Negative_regulation
adenosine	S-Drug_or_compound
-	O
induced	S-Positive_regulation
HIF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1alpha	E-Gene_or_gene_product
protein	O
accumulation	S-Positive_regulation
in	O
cancer	B-Cell
cells	E-Cell
.	O

We	O
show	O
that	O
HIF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1alpha	E-Gene_or_gene_product
and	O
VEGF	S-Gene_or_gene_product
are	O
increased	S-Positive_regulation
through	O
A3	B-Gene_or_gene_product
adenosine	I-Gene_or_gene_product
receptor	E-Gene_or_gene_product
stimulation	S-Positive_regulation
,	O
whereas	O
the	O
effects	S-Regulation
on	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	E-Gene_or_gene_product
are	O
mediated	S-Regulation
via	O
the	O
A2B	S-Gene_or_gene_product
subtype	O
.	O

Pretreatment	S-Planned_process
of	O
cells	S-Cell
with	O
caffeine	S-Drug_or_compound
significantly	O
reduces	S-Negative_regulation
adenosine	S-Drug_or_compound
-	O
induced	S-Positive_regulation
VEGF	S-Gene_or_gene_product
promoter	S-DNA_domain_or_region
activity	O
and	O
VEGF	S-Gene_or_gene_product
and	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	E-Gene_or_gene_product
expression	S-Gene_expression
.	O

The	O
mechanism	O
of	O
caffeine	S-Drug_or_compound
seems	O
to	O
involve	S-Regulation
the	O
inhibition	S-Negative_regulation
of	O
the	O
extracellular	B-Gene_or_gene_product
signal	I-Gene_or_gene_product
-	I-Gene_or_gene_product
regulated	I-Gene_or_gene_product
kinase	I-Gene_or_gene_product
1	E-Gene_or_gene_product
/	O
2	S-Gene_or_gene_product
(	O
ERK1	S-Gene_or_gene_product
/	O
2	S-Gene_or_gene_product
)	O
,	O
p38	S-Gene_or_gene_product
,	O
and	O
Akt	S-Gene_or_gene_product
,	O
leading	S-Positive_regulation
to	O
a	O
marked	O
decrease	S-Negative_regulation
in	O
adenosine	S-Drug_or_compound
-	O
induced	S-Positive_regulation
HIF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1alpha	E-Gene_or_gene_product
accumulation	S-Positive_regulation
,	O
VEGF	S-Gene_or_gene_product
transcriptional	S-Transcription
activation	S-Positive_regulation
,	O
and	O
VEGF	S-Gene_or_gene_product
and	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	E-Gene_or_gene_product
protein	O
accumulation	S-Positive_regulation
.	O

From	O
a	O
functional	O
perspective	O
,	O
we	O
observe	O
that	O
caffeine	S-Drug_or_compound
also	O
significantly	O
inhibits	S-Negative_regulation
the	O
A3	B-Gene_or_gene_product
receptor	E-Gene_or_gene_product
-	O
stimulated	S-Positive_regulation
cell	S-Cell
migration	S-Localization
of	O
colon	B-Cell
cancer	I-Cell
cells	E-Cell
.	O

Conditioned	O
media	O
prepared	O
from	O
colon	B-Cell
cells	E-Cell
treated	S-Planned_process
with	O
an	O
adenosine	S-Drug_or_compound
analog	O
increased	S-Positive_regulation
human	B-Cell
umbilical	I-Cell
vein	I-Cell
endothelial	I-Cell
cell	E-Cell
migration	S-Localization
.	O

These	O
data	O
provide	O
evidence	O
that	O
adenosine	S-Drug_or_compound
could	O
modulate	S-Regulation
the	O
migration	S-Localization
of	O
colon	B-Cell
cancer	I-Cell
cells	E-Cell
by	O
an	O
HIF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1alpha	E-Gene_or_gene_product
/	O
VEGF	S-Gene_or_gene_product
/	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	E-Gene_or_gene_product
-	O
dependent	S-Positive_regulation
mechanism	S-Pathway
and	O
that	O
caffeine	S-Drug_or_compound
has	O
the	O
potential	O
to	O
inhibit	S-Negative_regulation
colon	B-Cell
cancer	I-Cell
cell	E-Cell
growth	S-Cell_proliferation
.	O

Angiogenesis	S-Blood_vessel_development
in	O
the	O
caprine	S-Organism
caruncles	S-Organism_subdivision
in	O
non	O
-	O
pregnant	O
and	O
pregnant	O
normal	O
and	O
swainsonine	S-Drug_or_compound
-	O
treated	S-Planned_process
does	S-Organism
.	O

Microvascular	O
corrosion	O
casts	O
of	O
caruncles	S-Organism_subdivision
from	O
non	O
-	O
pregnant	O
and	O
pregnant	O
doe	O
goats	S-Organism
at	O
4	O
,	O
7	O
,	O
10	O
,	O
13	O
,	O
16	O
,	O
and	O
18	O
weeks	O
were	O
examined	O
with	O
scanning	O
electron	O
microscopy	O
.	O

The	O
internal	O
convex	O
surface	O
of	O
the	O
caruncles	S-Organism_subdivision
of	O
non	O
-	O
pregnant	O
does	S-Organism
was	O
covered	O
with	O
capillary	B-Multi-tissue_structure
meshes	E-Multi-tissue_structure
of	O
regular	O
diameter	O
and	O
form	O
,	O
without	O
crypts	O
.	O

As	O
pregnancy	O
advanced	O
the	O
complexity	O
of	O
the	O
vasculature	S-Multi-tissue_structure
increased	O
:	O
at	O
4	O
weeks	O
the	O
surface	O
showed	O
a	O
pattern	O
of	O
ridges	O
separated	O
by	O
troughs	O
.	O

At	O
later	O
stages	O
,	O
branches	O
of	O
radial	B-Multi-tissue_structure
arteries	E-Multi-tissue_structure
penetrated	O
the	O
periphery	O
forming	O
an	O
extensive	O
mesh	O
of	O
capillaries	S-Tissue
on	O
the	O
concave	O
surface	O
.	O

Capillary	S-Tissue
diameters	B-Development
increased	E-Development
significantly	O
during	O
pregnancy	O
,	O
especially	O
after	O
4	O
weeks	O
,	O
when	O
large	O
flattened	O
sinusoids	O
formed	O
.	O

These	O
sinusoids	O
had	O
a	O
great	O
deal	O
of	O
surface	O
area	O
for	O
potential	O
contact	O
with	O
the	O
fetal	O
component	O
.	O

The	O
caprine	S-Organism
placenta	S-Organ
is	O
usually	O
considered	O
to	O
have	O
increased	O
interhemal	O
distance	O
compared	O
with	O
endotheliochorial	O
and	O
hemochorial	O
types	O
:	O
our	O
results	O
suggest	O
that	O
the	O
very	O
extensive	O
development	S-Development
of	O
sinusoids	S-Tissue
and	O
crypts	O
may	O
compensate	O
for	O
any	O
negative	O
consequences	O
of	O
the	O
placental	S-Organ
architecture	O
.	O

Placental	S-Organ
angiogenesis	S-Blood_vessel_development
,	O
which	O
is	O
physiologically	O
normal	O
,	O
may	O
serve	O
as	O
a	O
general	O
model	O
of	O
this	O
process	O
in	O
other	O
circumstances	O
,	O
such	O
as	O
tumor	S-Pathological_formation
.	O

The	O
effect	S-Regulation
of	O
swainsonine	S-Drug_or_compound
(	O
active	O
compound	O
of	O
locoweed	S-Organism
and	O
a	O
potential	O
anticancer	O
drug	O
)	O
on	O
vascular	S-Multi-tissue_structure
development	S-Development
showed	O
no	O
differences	O
in	O
sinusoidal	O
diameters	O
at	O
7	O
weeks	O
,	O
but	O
a	O
decrease	S-Negative_regulation
in	O
capillary	S-Tissue
density	O
was	O
noted	O
.	O

Swainsonine	S-Drug_or_compound
caused	O
a	O
great	O
distortion	O
to	O
the	O
vasculature	S-Multi-tissue_structure
at	O
18	O
weeks	O
.	O

The	O
effects	S-Regulation
of	O
this	O
compound	O
on	O
the	O
vascular	S-Multi-tissue_structure
development	S-Development
lend	O
credibility	O
to	O
its	O
potential	O
as	O
an	O
anticancer	O
agent	O
.	O

High	O
-	O
grade	O
clear	B-Pathological_formation
cell	I-Pathological_formation
renal	I-Pathological_formation
cell	I-Pathological_formation
carcinoma	E-Pathological_formation
has	O
a	O
higher	O
angiogenic	S-Blood_vessel_development
activity	O
than	O
low	O
-	O
grade	O
renal	B-Pathological_formation
cell	I-Pathological_formation
carcinoma	E-Pathological_formation
based	O
on	O
histomorphological	O
quantification	O
and	O
qRT	O
-	O
PCR	O
mRNA	O
expression	O
profile	O
.	O

Clear	B-Pathological_formation
cell	I-Pathological_formation
renal	I-Pathological_formation
cell	I-Pathological_formation
carcinoma	E-Pathological_formation
(	O
CC	B-Pathological_formation
-	I-Pathological_formation
RCC	E-Pathological_formation
)	O
is	O
a	O
highly	O
vascularised	O
tumour	S-Pathological_formation
and	O
is	O
therefore	O
an	O
attractive	O
disease	O
to	O
study	O
angiogenesis	S-Blood_vessel_development
and	O
to	O
test	O
novel	O
angiogenesis	S-Blood_vessel_development
inhibitors	O
in	O
early	O
clinical	O
development	O
.	O

Endothelial	B-Cell
cell	E-Cell
proliferation	S-Cell_proliferation
plays	B-Regulation
a	I-Regulation
pivotal	I-Regulation
role	E-Regulation
in	O
the	O
process	O
of	O
angiogenesis	S-Blood_vessel_development
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
angiogenesis	S-Blood_vessel_development
parameters	O
in	O
low	O
nuclear	O
grade	O
(	O
n	O
=	O
87	O
)	O
vs	O
high	O
nuclear	O
grade	O
CC	B-Pathological_formation
-	I-Pathological_formation
RCC	E-Pathological_formation
(	O
n	O
=	O
63	O
)	O
.	O

A	O
panel	O
of	O
antibodies	O
was	O
used	O
for	O
immunohistochemistry	O
:	O
CD34	S-Gene_or_gene_product
/	O
Ki	B-Gene_or_gene_product
-	I-Gene_or_gene_product
67	E-Gene_or_gene_product
,	O
carbonic	B-Gene_or_gene_product
anhydrase	I-Gene_or_gene_product
IX	E-Gene_or_gene_product
,	O
hypoxia	B-Gene_or_gene_product
-	I-Gene_or_gene_product
inducible	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
-	I-Gene_or_gene_product
1alpha	E-Gene_or_gene_product
(	O
HIF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1alpha	E-Gene_or_gene_product
)	O
and	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
(	O
VEGF	S-Gene_or_gene_product
)	O
.	O

Vessel	S-Multi-tissue_structure
density	O
(	O
MVD	O
-	O
microvessel	S-Tissue
density	O
)	O
,	O
endothelial	B-Cell
cell	E-Cell
proliferation	S-Cell_proliferation
fraction	O
(	O
ECP	O
%	O
)	O
and	O
tumour	B-Cell
cell	E-Cell
proliferation	S-Cell_proliferation
fraction	O
(	O
TCP	O
%	O
)	O
were	O
assessed	O
.	O

mRNA	O
expression	O
levels	O
of	O
angiogenesis	S-Blood_vessel_development
stimulators	O
and	O
inhibitors	O
were	O
determined	O
by	O
quantitative	O
RT	O
-	O
PCR	O
.	O

High	O
-	O
grade	O
CC	B-Pathological_formation
-	I-Pathological_formation
RCC	E-Pathological_formation
showed	O
a	O
higher	O
ECP	O
%	O
(	O
P	O
=	O
0	O
.	O
049	O
)	O
,	O
a	O
higher	O
TCP	O
%	O
(	O
P	O
=	O
0	O
.	O
009	O
)	O
,	O
a	O
higher	O
VEGF	S-Gene_or_gene_product
protein	O
expression	S-Gene_expression
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
a	O
lower	O
MVD	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
and	O
a	O
lower	O
HIF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1alpha	E-Gene_or_gene_product
protein	O
expression	S-Gene_expression
(	O
P	O
=	O
0	O
.	O
002	O
)	O
than	O
low	O
-	O
grade	O
CC	B-Pathological_formation
-	I-Pathological_formation
RCC	E-Pathological_formation
.	O

Growth	O
factor	O
mRNA	O
expression	O
analyses	O
revealed	O
a	O
higher	O
expression	S-Transcription
of	O
angiopoietin	B-Gene_or_gene_product
2	E-Gene_or_gene_product
in	O
low	O
-	O
grade	O
CC	B-Pathological_formation
-	I-Pathological_formation
RCC	E-Pathological_formation
.	O

Microvessel	S-Tissue
density	O
and	O
ECP	O
%	O
were	O
inversely	O
correlated	O
(	O
Rho	O
=	O
-	O
0	O
.	O
26	O
,	O
P	O
=	O
0	O
.	O
001	O
)	O
.	O

Because	O
of	O
the	O
imperfect	O
association	O
of	O
nuclear	O
grade	O
and	O
ECP	O
%	O
or	O
MVD	O
,	O
CC	B-Pathological_formation
-	I-Pathological_formation
RCC	E-Pathological_formation
was	O
also	O
grouped	O
based	O
on	O
low	O
/	O
high	O
MVD	O
and	O
ECP	O
%	O
.	O

This	O
analysis	O
revealed	O
a	O
higher	O
expression	S-Gene_expression
of	O
vessel	S-Multi-tissue_structure
maturation	S-Development
and	O
stabilisation	O
factors	O
(	O
placental	B-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
,	O
PDGFB1	S-Gene_or_gene_product
,	O
angiopoietin	B-Gene_or_gene_product
1	E-Gene_or_gene_product
)	O
in	O
CC	B-Pathological_formation
-	I-Pathological_formation
RCC	E-Pathological_formation
with	O
high	O
MVD	O
,	O
a	O
group	O
of	O
CC	B-Pathological_formation
-	I-Pathological_formation
RCC	E-Pathological_formation
highly	O
enriched	O
in	O
low	O
nuclear	O
grade	O
CC	B-Pathological_formation
-	I-Pathological_formation
RCC	E-Pathological_formation
,	O
with	O
low	O
ECP	O
%	O
.	O

Our	O
results	O
suggest	O
heterogeneity	O
in	O
angiogenic	S-Blood_vessel_development
activity	O
and	O
vessel	S-Multi-tissue_structure
maturation	S-Development
of	O
CC	B-Pathological_formation
-	I-Pathological_formation
RCC	E-Pathological_formation
,	O
to	O
a	O
large	O
extent	O
linked	O
to	O
nuclear	O
grade	O
,	O
and	O
,	O
with	O
probable	O
therapeutic	O
implications	O
.	O

Medical	O
therapy	O
for	O
intermittent	O
claudication	O
.	O

Medical	O
therapy	O
to	O
improve	O
symptoms	O
,	O
stabilise	O
the	O
underlying	O
vascular	O
disease	O
and	O
improve	O
lower	B-Organism_subdivision
limb	E-Organism_subdivision
outcomes	O
is	O
an	O
important	O
and	O
effective	O
adjunct	O
to	O
lifestyle	O
modification	O
and	O
surgical	O
or	O
endovascular	O
interventions	O
in	O
patients	S-Organism
with	O
IC	O
.	O

Randomised	O
placebo	O
controlled	O
trials	O
have	O
shown	O
that	O
the	O
phosphodiesterase	B-Gene_or_gene_product
III	E-Gene_or_gene_product
inhibitor	O
cilostazol	S-Drug_or_compound
100mg	O
bid	O
improves	O
pain	O
-	O
free	O
and	O
maximum	O
walking	O
distance	O
,	O
as	O
well	O
as	O
quality	O
of	O
life	O
,	O
in	O
a	O
range	O
of	O
patients	S-Organism
with	O
intermittent	O
claudication	O
in	O
whom	O
there	O
is	O
no	O
evidence	O
of	O
tissue	S-Tissue
necrosis	S-Death
or	O
rest	O
pain	O
.	O

This	O
review	O
summarises	O
the	O
evidence	O
from	O
8	O
pivotal	O
trials	O
of	O
cilostazol	S-Drug_or_compound
involving	O
over	O
2000	O
patients	S-Organism
with	O
intermittent	O
claudication	O
treated	S-Planned_process
for	O
up	O
to	O
6	O
months	O
.	O

There	O
is	O
comparatively	O
less	O
evidence	O
to	O
support	O
the	O
use	O
of	O
other	O
treatment	O
modalities	O
for	O
relief	O
of	O
symptoms	O
in	O
intermittent	O
claudication	O
,	O
but	O
there	O
is	O
considerable	O
interest	O
in	O
therapeutic	O
angiogenesis	S-Blood_vessel_development
to	O
promote	S-Positive_regulation
new	O
vessel	S-Multi-tissue_structure
formation	S-Development
and	O
enhance	S-Positive_regulation
collateralisation	S-Blood_vessel_development
of	O
the	O
lower	B-Organism_subdivision
limb	E-Organism_subdivision
using	O
recombinant	O
growth	O
factor	O
proteins	O
or	O
gene	O
transfer	O
strategies	O
.	O

The	O
rationale	O
for	O
therapeutic	O
angiogenesis	S-Blood_vessel_development
is	O
discussed	O
,	O
together	O
with	O
the	O
most	O
recent	O
results	O
from	O
randomised	B-Planned_process
trials	E-Planned_process
in	O
patients	S-Organism
with	O
peripheral	O
arterial	O
disease	O
.	O

The	O
contribution	O
of	O
Harold	O
F	O
.	O
Dvorak	O
to	O
the	O
study	O
of	O
tumor	S-Pathological_formation
angiogenesis	S-Blood_vessel_development
and	O
stroma	S-Tissue
generation	S-Development
mechanisms	O
.	O

In	O
1983	O
,	O
Harold	O
Dvorak	O
and	O
his	O
colleagues	O
were	O
the	O
first	O
to	O
show	O
that	O
tumor	B-Cell
cells	E-Cell
secreted	S-Localization
vascular	B-Gene_or_gene_product
permeability	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
(	O
VPF	S-Gene_or_gene_product
)	O
and	O
that	O
a	O
blocking	O
antibody	O
to	O
VPF	S-Gene_or_gene_product
could	O
prevent	S-Negative_regulation
the	O
edema	S-Pathological_formation
and	O
fluid	O
accumulation	O
that	O
is	O
characteristic	O
of	O
human	S-Organism
cancers	S-Pathological_formation
.	O

In	O
1986	O
,	O
Dvorak	O
went	O
on	O
to	O
demonstrate	O
that	O
VPF	S-Gene_or_gene_product
was	O
secreted	S-Localization
by	O
a	O
variety	O
of	O
human	S-Organism
tumor	B-Cell
cell	I-Cell
lines	E-Cell
and	O
proposed	O
that	O
VPF	S-Gene_or_gene_product
was	O
in	O
part	O
responsible	O
for	O
the	O
abnormal	O
vasculature	S-Multi-tissue_structure
seen	O
in	O
human	S-Organism
tumors	S-Pathological_formation
.	O

As	O
a	O
result	O
,	O
he	O
and	O
other	O
investigators	O
demonstrated	O
that	O
VPF	S-Gene_or_gene_product
was	O
capable	O
of	O
stimulating	S-Positive_regulation
endothelial	B-Cell
cell	E-Cell
growth	S-Cell_proliferation
and	O
angiogenesis	S-Blood_vessel_development
.	O

These	O
fundamental	O
discoveries	O
led	O
to	O
additional	O
research	O
conducted	O
by	O
Napoleone	O
Ferrara	O
and	O
his	O
laboratory	O
,	O
confirming	O
the	O
cloning	O
of	O
VPF	S-Gene_or_gene_product
and	O
renaming	O
the	O
protein	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
(	O
VEGF	S-Gene_or_gene_product
)	O
.	O

In	O
1986	O
,	O
Dvorak	O
proposed	O
that	O
by	O
secreting	S-Localization
VPF	S-Gene_or_gene_product
,	O
tumors	S-Pathological_formation
induce	S-Positive_regulation
angiogenesis	S-Blood_vessel_development
by	O
turning	O
on	O
the	O
wound	O
healing	O
response	O
.	O

He	O
noted	O
that	O
wounds	O
,	O
like	O
tumors	S-Pathological_formation
,	O
secrete	S-Localization
VPF	S-Gene_or_gene_product
,	O
causing	O
blood	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
to	O
leak	S-Localization
plasma	S-Organism_substance
fibrinogen	S-Gene_or_gene_product
,	O
which	O
stimulates	S-Positive_regulation
blood	B-Multi-tissue_structure
vessel	E-Multi-tissue_structure
growth	S-Growth
and	O
provides	O
a	O
matrix	O
on	O
which	O
they	O
can	O
spread	O
.	O

Unlike	O
wounds	O
,	O
however	O
,	O
that	O
turn	B-Negative_regulation
off	E-Negative_regulation
VPF	S-Gene_or_gene_product
production	S-Gene_expression
after	O
healing	O
,	O
tumors	S-Pathological_formation
did	O
not	O
turn	B-Negative_regulation
off	E-Negative_regulation
their	O
VPF	S-Gene_or_gene_product
production	S-Gene_expression
and	O
instead	O
continued	O
to	O
make	S-Gene_expression
large	O
amounts	O
of	O
VPF	S-Gene_or_gene_product
,	O
allowing	O
malignant	B-Cell
cells	E-Cell
to	O
continue	O
to	O
induce	S-Positive_regulation
new	O
blood	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
and	O
so	O
to	O
grow	S-Cell_proliferation
and	O
spread	S-Localization
.	O

Thus	O
,	O
tumors	S-Pathological_formation
behave	O
like	O
wounds	O
that	O
fail	O
to	O
heal	O
.	O

This	O
work	O
is	O
again	O
extremely	O
significant	O
for	O
patients	S-Organism
worldwide	O
,	O
as	O
Dvorak	O
'	O
s	O
scientific	O
research	O
is	O
leading	O
his	O
colleagues	O
all	O
over	O
the	O
world	O
to	O
examine	O
how	O
to	O
treat	S-Planned_process
a	O
tumor	S-Pathological_formation
through	O
its	O
blood	S-Organism_substance
supply	O
.	O

An	O
assay	O
to	O
measure	O
angiogenesis	S-Blood_vessel_development
in	O
human	S-Organism
fat	B-Tissue
tissue	E-Tissue
.	O

BACKGROUND	O
:	O
Inhibition	S-Negative_regulation
of	O
angiogenesis	S-Blood_vessel_development
reverses	O
rodent	O
obesity	O
.	O

A	O
validated	O
assay	O
in	O
human	S-Organism
fat	B-Tissue
tissue	E-Tissue
is	O
needed	O
to	O
study	O
the	O
role	S-Regulation
of	O
angiogenesis	S-Blood_vessel_development
in	O
human	S-Organism
obesity	O
.	O

METHODS	O
:	O
Human	S-Organism
fat	B-Tissue
tissue	E-Tissue
fragments	O
from	O
surgery	S-Planned_process
were	O
placed	S-Planned_process
in	O
96	O
-	O
well	O
plates	O
,	O
embedded	S-Planned_process
in	O
fibrin	S-Gene_or_gene_product
thrombin	S-Gene_or_gene_product
clot	S-Organism_substance
and	O
overlaid	S-Planned_process
with	O
cell	S-Cell
culture	S-Planned_process
media	O
containing	O
20	O
%	O
fetal	O
bovine	S-Organism
serum	S-Organism_substance
.	O

After	O
15	O
days	O
,	O
the	O
clots	S-Organism_substance
were	O
examined	O
by	O
histology	O
and	O
electron	O
microscopy	O
.	O

The	O
effect	O
of	O
taxol	S-Drug_or_compound
,	O
cobalt	B-Drug_or_compound
chloride	E-Drug_or_compound
and	O
a	O
heparin	B-Drug_or_compound
-	I-Drug_or_compound
steroid	E-Drug_or_compound
combination	O
was	O
tested	O
in	O
the	O
fat	B-Tissue
tissue	E-Tissue
assay	O
and	O
compared	O
to	O
the	O
validated	O
human	S-Organism
placental	B-Multi-tissue_structure
vein	E-Multi-tissue_structure
angiogenesis	S-Blood_vessel_development
model	O
(	O
HPVAM	O
)	O
.	O

RESULTS	O
:	O
Blood	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
initiated	S-Positive_regulation
growth	S-Growth
and	O
elongated	S-Growth
from	O
the	O
fat	B-Tissue
tissue	E-Tissue
fragments	O
over	O
15	O
days	O
.	O

Presence	O
of	O
blood	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
was	O
confirmed	O
with	O
histology	O
and	O
electron	O
microscopy	O
.	O

Taxol	S-Drug_or_compound
at	O
10	O
(	O
-	O
6	O
)	O
and	O
10	O
(	O
-	O
7	O
)	O
M	O
completely	O
inhibited	S-Negative_regulation
angiogenesis	S-Blood_vessel_development
,	O
while	O
Taxol	S-Drug_or_compound
10	O
(	O
-	O
8	O
)	O
and	O
10	O
(	O
-	O
9	O
)	O
M	O
and	O
the	O
heparin	B-Drug_or_compound
-	I-Drug_or_compound
steroid	E-Drug_or_compound
partially	O
inhibited	S-Negative_regulation
angiogenesis	S-Blood_vessel_development
.	O

The	O
response	O
to	O
taxol	S-Drug_or_compound
and	O
heparin	B-Drug_or_compound
-	I-Drug_or_compound
steroid	E-Drug_or_compound
was	O
similar	O
to	O
that	O
of	O
the	O
HPVAM	O
,	O
a	O
validated	O
angiogenesis	S-Blood_vessel_development
assay	O
.	O

Cobalt	B-Drug_or_compound
chloride	E-Drug_or_compound
,	O
a	O
stimulator	O
of	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
(	O
VEGF	S-Gene_or_gene_product
)	O
stimulated	S-Positive_regulation
angiogenesis	S-Blood_vessel_development
initiation	S-Positive_regulation
at	O
10	O
(	O
-	O
9	O
)	O
M	O
in	O
fat	B-Tissue
tissue	E-Tissue
and	O
the	O
HPVAM	O
,	O
but	O
at	O
10	O
(	O
-	O
10	O
)	O
M	O
blood	B-Multi-tissue_structure
vessel	E-Multi-tissue_structure
growth	S-Growth
was	O
stimulated	S-Positive_regulation
only	O
in	O
the	O
fat	S-Tissue
assay	O
.	O

CONCLUSION	O
:	O
This	O
angiogenesis	S-Blood_vessel_development
assay	O
based	O
on	O
human	S-Organism
fat	B-Tissue
tissue	E-Tissue
uses	O
three	O
-	O
dimensionally	O
intact	O
human	S-Organism
tissue	S-Tissue
.	O

The	O
vessels	S-Multi-tissue_structure
are	O
derived	O
from	O
quiescient	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
within	O
the	O
fat	S-Tissue
.	O

These	O
properties	O
allow	O
the	O
angiogenic	S-Blood_vessel_development
switch	O
to	O
be	O
evaluated	O
in	O
an	O
in	O
vitro	O
setting	O
.	O

The	O
angiogenic	S-Blood_vessel_development
response	O
of	O
fat	B-Tissue
tissue	E-Tissue
is	O
not	O
identical	O
to	O
placental	B-Tissue
tissue	E-Tissue
.	O

This	O
assay	O
allows	O
exploration	S-Positive_regulation
of	O
angiogenesis	S-Blood_vessel_development
in	O
fat	B-Tissue
tissue	E-Tissue
.	O

Hedgehog	S-Gene_or_gene_product
signaling	S-Pathway
in	O
the	O
murine	S-Organism
melanoma	S-Pathological_formation
microenvironment	O
.	O

The	O
Hedgehog	S-Gene_or_gene_product
intercellular	B-Pathway
signaling	I-Pathway
pathway	E-Pathway
regulates	O
cell	S-Cell
proliferation	S-Cell_proliferation
and	O
differentiation	S-Development
.	O

This	O
pathway	O
has	O
been	O
implicated	O
to	O
play	O
a	O
role	O
in	O
the	O
pathogenesis	O
of	O
cancer	O
and	O
in	O
embryonic	O
blood	B-Multi-tissue_structure
vessel	E-Multi-tissue_structure
development	S-Development
.	O

In	O
the	O
current	O
study	O
,	O
Hedgehog	S-Gene_or_gene_product
signaling	S-Pathway
in	O
tumor	S-Pathological_formation
related	O
vasculature	S-Multi-tissue_structure
and	O
microenvironment	O
was	O
examined	O
using	O
human	B-Cell
umbilical	I-Cell
vein	I-Cell
endothelial	I-Cell
cells	E-Cell
and	O
B16F0	S-Cell
(	O
murine	S-Organism
melanoma	S-Pathological_formation
)	O
tumors	S-Pathological_formation
models	O
.	O

Use	O
of	O
exogenous	O
Sonic	B-Gene_or_gene_product
hedgehog	E-Gene_or_gene_product
(	O
Shh	S-Gene_or_gene_product
)	O
peptide	O
significantly	O
increased	S-Positive_regulation
BrdU	S-Drug_or_compound
incorporation	S-Localization
in	O
endothelial	B-Cell
cells	E-Cell
in	O
vitro	O
by	O
a	O
factor	O
of	O
2	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O

The	O
Hedgehog	S-Gene_or_gene_product
pathway	S-Pathway
antagonist	O
cyclopamine	S-Drug_or_compound
effectively	O
reduced	S-Negative_regulation
Shh	S-Gene_or_gene_product
-	O
induced	S-Positive_regulation
proliferation	S-Cell_proliferation
to	O
control	O
levels	O
.	O

To	O
study	O
Hedgehog	S-Gene_or_gene_product
signaling	S-Pathway
in	O
vivo	O
a	O
hind	B-Pathological_formation
limb	I-Pathological_formation
tumor	E-Pathological_formation
model	O
with	O
the	O
B16F0	B-Cell
cell	I-Cell
line	E-Cell
was	O
used	O
.	O

Treatment	S-Planned_process
with	O
25	O
mg	O
/	O
kg	O
cyclopamine	S-Drug_or_compound
significantly	O
attenuated	S-Negative_regulation
BrdU	S-Drug_or_compound
incorporation	S-Localization
in	O
tumor	B-Cell
cells	E-Cell
threefold	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
in	O
tumor	S-Pathological_formation
related	O
endothelial	B-Cell
cells	E-Cell
threefold	O
(	O
P	O
=	O
0	O
.	O
004	O
)	O
,	O
and	O
delayed	S-Negative_regulation
tumor	S-Pathological_formation
growth	S-Growth
by	O
4	O
days	O
.	O

Immunohistochemistry	O
revealed	O
that	O
the	O
Hedgehog	S-Gene_or_gene_product
receptor	O
Patched	S-Gene_or_gene_product
was	O
localized	S-Localization
to	O
the	O
tumor	B-Pathological_formation
stroma	E-Pathological_formation
and	O
that	O
B16F0	B-Cell
cells	E-Cell
expressed	S-Gene_expression
Shh	S-Gene_or_gene_product
peptide	O
.	O

Furthermore	O
,	O
mouse	S-Organism
embryonic	B-Cell
fibroblasts	E-Cell
required	O
the	O
presence	O
of	O
B16F0	B-Cell
cells	E-Cell
to	O
express	S-Gene_expression
Patched	S-Gene_or_gene_product
in	O
a	O
co	O
-	O
culture	O
assay	O
system	O
.	O

These	O
studies	O
indicate	O
that	O
Shh	S-Gene_or_gene_product
peptide	O
produced	S-Gene_expression
by	O
melanoma	B-Cell
cells	E-Cell
induces	S-Positive_regulation
Patched	S-Gene_or_gene_product
expression	S-Gene_expression
in	O
fibroblasts	S-Cell
.	O

To	O
study	O
tumor	S-Pathological_formation
related	O
angiogenesis	S-Blood_vessel_development
a	O
vascular	O
window	O
model	O
was	O
used	O
to	O
monitor	O
tumor	S-Pathological_formation
vascularity	O
.	O

Treatment	S-Planned_process
with	O
cyclopamine	S-Drug_or_compound
significantly	O
attenuated	S-Negative_regulation
vascular	S-Multi-tissue_structure
formation	S-Development
by	O
a	O
factor	O
of	O
2	O
.	O
5	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
and	O
altered	S-Regulation
vascular	S-Multi-tissue_structure
morphology	O
.	O

Furthermore	O
,	O
cyclopamine	S-Drug_or_compound
reduced	O
tumor	B-Multi-tissue_structure
blood	I-Multi-tissue_structure
vessel	E-Multi-tissue_structure
permeability	O
to	O
FITC	S-Drug_or_compound
labeled	S-Planned_process
dextran	S-Drug_or_compound
while	O
having	O
no	O
effect	S-Regulation
on	O
normal	O
blood	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
.	O

These	O
studies	O
suggest	O
that	O
Hedgehog	S-Gene_or_gene_product
signaling	S-Pathway
regulates	S-Regulation
melanoma	S-Pathological_formation
related	O
vascular	S-Multi-tissue_structure
formation	S-Development
and	O
function	O
.	O

CX3CR1	S-Gene_or_gene_product
-	O
dependent	S-Positive_regulation
subretinal	B-Cell
microglia	I-Cell
cell	E-Cell
accumulation	S-Cell_proliferation
is	O
associated	S-Regulation
with	O
cardinal	O
features	O
of	O
age	O
-	O
related	O
macular	S-Tissue
degeneration	S-Breakdown
.	O

The	O
role	S-Regulation
of	O
retinal	O
microglial	B-Cell
cells	E-Cell
(	O
MCs	S-Cell
)	O
in	O
age	O
-	O
related	O
macular	S-Tissue
degeneration	S-Breakdown
(	O
AMD	O
)	O
is	O
unclear	O
.	O

Here	O
we	O
demonstrated	O
that	O
all	O
retinal	B-Cell
MCs	E-Cell
express	S-Gene_expression
CX3C	B-Gene_or_gene_product
chemokine	I-Gene_or_gene_product
receptor	I-Gene_or_gene_product
1	E-Gene_or_gene_product
(	O
CX3CR1	S-Gene_or_gene_product
)	O
and	O
that	O
homozygosity	O
for	O
the	O
CX3CR1	S-Gene_or_gene_product
M280	O
allele	O
,	O
which	O
is	O
associated	O
with	O
impaired	S-Negative_regulation
cell	S-Cell
migration	S-Localization
,	O
increases	O
the	O
risk	O
of	O
AMD	O
.	O

In	O
humans	S-Organism
with	O
AMD	O
,	O
MCs	S-Cell
accumulated	S-Cell_proliferation
in	O
the	O
subretinal	B-Immaterial_anatomical_entity
space	E-Immaterial_anatomical_entity
at	O
sites	O
of	O
retinal	S-Multi-tissue_structure
degeneration	S-Breakdown
and	O
choroidal	O
neovascularization	S-Blood_vessel_development
(	O
CNV	S-Blood_vessel_development
)	O
.	O

In	O
CX3CR1	S-Gene_or_gene_product
-	O
deficient	O
mice	S-Organism
,	O
MCs	S-Cell
accumulated	S-Cell_proliferation
subretinally	S-Immaterial_anatomical_entity
with	O
age	O
and	O
albino	O
background	O
and	O
after	O
laser	O
impact	O
preceding	O
retinal	S-Multi-tissue_structure
degeneration	S-Breakdown
.	O

Raising	O
the	O
albino	O
mice	S-Organism
in	O
the	O
dark	O
prevented	O
both	O
events	O
.	O

The	O
appearance	O
of	O
lipid	S-Drug_or_compound
-	O
bloated	O
subretinal	B-Cell
MCs	E-Cell
was	O
drusen	S-Pathological_formation
-	O
like	O
on	O
funduscopy	O
of	O
senescent	O
mice	S-Organism
,	O
and	O
CX3CR1	S-Gene_or_gene_product
-	O
dependent	S-Positive_regulation
MC	S-Cell
accumulation	S-Cell_proliferation
was	O
associated	S-Regulation
with	O
an	O
exacerbation	S-Positive_regulation
of	O
experimental	O
CNV	S-Blood_vessel_development
.	O

These	O
results	O
show	O
that	O
CX3CR1	S-Gene_or_gene_product
-	O
dependent	S-Positive_regulation
accumulation	S-Cell_proliferation
of	O
subretinal	B-Cell
MCs	E-Cell
evokes	O
cardinal	O
features	O
of	O
AMD	O
.	O

These	O
findings	O
reveal	O
what	O
we	O
believe	O
to	O
be	O
a	O
novel	O
pathogenic	O
process	O
with	O
important	O
implications	O
for	O
the	O
development	O
of	O
new	O
therapies	O
for	O
AMD	O
.	O

Ovarian	O
cancers	O
overexpress	S-Gene_expression
the	O
antimicrobial	O
protein	O
hCAP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
18	E-Gene_or_gene_product
and	O
its	O
derivative	O
LL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
37	E-Gene_or_gene_product
increases	S-Positive_regulation
ovarian	B-Cell
cancer	I-Cell
cell	E-Cell
proliferation	S-Cell_proliferation
and	O
invasion	S-Localization
.	O

The	O
role	S-Regulation
of	O
the	O
pro	O
-	O
inflammatory	O
peptide	O
,	O
LL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
37	E-Gene_or_gene_product
,	O
and	O
its	O
pro	O
-	O
form	O
,	O
human	B-Gene_or_gene_product
cationic	I-Gene_or_gene_product
antimicrobial	I-Gene_or_gene_product
protein	I-Gene_or_gene_product
18	E-Gene_or_gene_product
(	O
hCAP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
18	E-Gene_or_gene_product
)	O
,	O
in	O
cancer	S-Pathological_formation
development	S-Development
and	O
progression	S-Development
is	O
poorly	O
understood	O
.	O

In	O
damaged	S-Breakdown
and	O
inflamed	O
tissue	S-Tissue
,	O
LL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
37	E-Gene_or_gene_product
functions	O
as	O
a	O
chemoattractant	O
,	O
mitogen	O
and	O
pro	O
-	O
angiogenic	S-Blood_vessel_development
factor	O
suggesting	O
that	O
the	O
peptide	O
may	O
potentiate	O
tumor	S-Pathological_formation
progression	S-Development
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
characterize	O
the	O
distribution	O
of	O
hCAP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
18	E-Gene_or_gene_product
/	O
LL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
37	E-Gene_or_gene_product
in	O
normal	O
and	O
cancerous	O
ovarian	B-Tissue
tissue	E-Tissue
and	O
to	O
examine	O
the	O
effects	S-Regulation
of	O
LL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
37	E-Gene_or_gene_product
on	O
ovarian	B-Cell
cancer	I-Cell
cells	E-Cell
.	O

Expression	S-Gene_expression
of	O
hCAP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
18	E-Gene_or_gene_product
/	O
LL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
37	E-Gene_or_gene_product
was	O
localized	S-Localization
to	O
immune	S-Cell
and	O
granulosa	B-Cell
cells	E-Cell
of	O
normal	B-Tissue
ovarian	I-Tissue
tissue	E-Tissue
.	O

By	O
contrast	O
,	O
ovarian	B-Pathological_formation
tumors	E-Pathological_formation
displayed	O
significantly	O
higher	O
levels	O
of	O
hCAP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
18	E-Gene_or_gene_product
/	O
LL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
37	E-Gene_or_gene_product
where	O
expression	S-Gene_expression
was	O
observed	O
in	O
tumor	S-Cell
and	O
stromal	B-Cell
cells	E-Cell
.	O

Protein	O
expression	O
was	O
statistically	O
compared	O
to	O
the	O
degree	O
of	O
immune	B-Cell
cell	E-Cell
infiltration	S-Localization
and	O
microvessel	S-Tissue
density	O
in	O
epithelial	B-Pathological_formation
-	I-Pathological_formation
derived	I-Pathological_formation
ovarian	I-Pathological_formation
tumors	E-Pathological_formation
and	O
a	O
significant	O
correlation	O
was	O
observed	O
for	O
both	O
.	O

It	O
was	O
demonstrated	O
that	O
ovarian	B-Organism_substance
tumor	I-Organism_substance
tissue	I-Organism_substance
lysates	E-Organism_substance
and	O
ovarian	B-Cell
cancer	I-Cell
cell	I-Cell
lines	E-Cell
express	S-Gene_expression
hCAP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
18	E-Gene_or_gene_product
/	O
LL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
37	E-Gene_or_gene_product
.	O

Treatment	S-Planned_process
of	O
ovarian	B-Cell
cancer	I-Cell
cell	I-Cell
lines	E-Cell
with	O
recombinant	O
LL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
37	E-Gene_or_gene_product
stimulated	S-Positive_regulation
proliferation	S-Cell_proliferation
,	O
chemotaxis	S-Localization
,	O
invasion	S-Localization
and	O
matrix	B-Gene_or_gene_product
metalloproteinase	E-Gene_or_gene_product
expression	S-Gene_expression
.	O

These	O
data	O
demonstrate	O
for	O
the	O
first	O
time	O
that	O
hCAP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
18	E-Gene_or_gene_product
/	O
LL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
37	E-Gene_or_gene_product
is	O
significantly	O
overexpressed	S-Gene_expression
in	O
ovarian	B-Pathological_formation
tumors	E-Pathological_formation
and	O
suggest	O
LL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
37	E-Gene_or_gene_product
may	O
contribute	S-Regulation
to	O
ovarian	O
tumorigenesis	O
through	O
direct	O
stimulation	S-Positive_regulation
of	O
tumor	B-Cell
cells	E-Cell
,	O
initiation	S-Positive_regulation
of	O
angiogenesis	S-Blood_vessel_development
and	O
recruitment	S-Localization
of	O
immune	B-Cell
cells	E-Cell
.	O

These	O
data	O
provide	O
further	O
evidence	O
of	O
the	O
existing	O
relationship	O
between	O
pro	O
-	O
inflammatory	O
molecules	O
and	O
ovarian	B-Pathological_formation
cancer	E-Pathological_formation
progression	S-Development
.	O

Role	O
of	O
telomeres	O
in	O
vascular	O
senescence	O
.	O

Telomeres	O
are	O
DNA	O
regions	O
composed	O
of	O
TTAGGG	O
repeats	O
that	O
are	O
located	O
at	O
the	O
ends	O
of	O
chromosomes	S-Cellular_component
.	O

Specific	O
proteins	O
associate	O
with	O
the	O
telomeres	O
and	O
form	O
non	O
-	O
nucleosomal	O
DNA	O
-	O
protein	O
complexes	O
that	O
serve	O
as	O
protective	O
caps	O
for	O
the	O
chromosome	S-Cellular_component
ends	O
.	O

There	O
is	O
accumulating	O
evidence	O
that	O
progressive	O
telomere	O
shortening	O
is	O
closely	O
related	O
to	O
cardiovascular	O
disease	O
.	O

For	O
example	O
,	O
vascular	B-Cell
cell	E-Cell
senescence	O
has	O
been	O
reported	O
to	O
occur	O
in	O
human	S-Organism
atherosclerotic	B-Pathological_formation
lesions	E-Pathological_formation
and	O
this	O
change	O
is	O
associated	O
with	O
telomere	O
shortening	O
.	O

Impairment	O
of	O
telomere	O
integrity	O
causes	O
vascular	S-Multi-tissue_structure
dysfunction	S-Breakdown
,	O
which	O
is	O
prevented	S-Negative_regulation
by	O
the	O
activation	S-Positive_regulation
of	O
telomerase	S-Gene_or_gene_product
.	O

Mice	S-Organism
with	O
short	O
telomeres	O
develop	O
hypertension	O
and	O
exhibit	O
impaired	O
neovascularization	S-Blood_vessel_development
.	O

Short	O
telomeres	O
have	O
also	O
been	O
reported	O
in	O
the	O
leukocytes	S-Cell
of	O
patients	S-Organism
with	O
cardiovascular	O
disease	O
or	O
various	O
cardiovascular	O
risk	O
factors	O
.	O

Although	O
it	O
remains	O
unclear	O
whether	O
short	O
telomeres	O
directly	O
cause	O
cardiovascular	O
disease	O
,	O
manipulation	O
of	O
telomere	O
function	O
is	O
potentially	O
an	O
attractive	O
strategy	O
for	O
the	O
treatment	O
of	O
vascular	O
senescence	O
.	O

Ectopic	O
decorin	S-Gene_or_gene_product
expression	S-Gene_expression
up	B-Positive_regulation
-	I-Positive_regulation
regulates	E-Positive_regulation
VEGF	S-Gene_or_gene_product
expression	S-Gene_expression
in	O
mouse	S-Organism
cerebral	B-Cell
endothelial	I-Cell
cells	E-Cell
via	O
activation	S-Positive_regulation
of	O
the	O
transcription	O
factors	O
Sp1	S-Gene_or_gene_product
,	O
HIF1alpha	S-Gene_or_gene_product
,	O
and	O
Stat3	S-Gene_or_gene_product
.	O

We	O
demonstrate	O
that	O
a	O
proteoglycan	O
decorin	S-Gene_or_gene_product
(	O
DCN	S-Gene_or_gene_product
)	O
up	B-Positive_regulation
-	I-Positive_regulation
regulates	E-Positive_regulation
the	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
(	O
VEGF	S-Gene_or_gene_product
)	O
expression	S-Gene_expression
with	O
activation	S-Positive_regulation
of	O
VEGF	S-Gene_or_gene_product
regulating	S-Regulation
transcription	O
factors	O
Sp1	S-Gene_or_gene_product
,	O
hypoxia	B-Gene_or_gene_product
-	I-Gene_or_gene_product
inducible	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
1alpha	E-Gene_or_gene_product
(	O
HIF1alpha	S-Gene_or_gene_product
)	O
,	O
and	O
signal	B-Gene_or_gene_product
transducer	I-Gene_or_gene_product
and	I-Gene_or_gene_product
activator	I-Gene_or_gene_product
of	I-Gene_or_gene_product
transcription	I-Gene_or_gene_product
3	E-Gene_or_gene_product
(	O
Stat3	S-Gene_or_gene_product
)	O
via	O
epidermal	B-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
receptor	E-Gene_or_gene_product
(	O
EGFR	S-Gene_or_gene_product
)	O
,	O
mitogen	B-Gene_or_gene_product
-	I-Gene_or_gene_product
activated	I-Gene_or_gene_product
protein	I-Gene_or_gene_product
kinase	I-Gene_or_gene_product
extracellular	I-Gene_or_gene_product
signal	I-Gene_or_gene_product
-	I-Gene_or_gene_product
regulated	I-Gene_or_gene_product
kinase	I-Gene_or_gene_product
1	I-Gene_or_gene_product
/	I-Gene_or_gene_product
2	E-Gene_or_gene_product
(	O
ERK1	B-Gene_or_gene_product
/	I-Gene_or_gene_product
2	E-Gene_or_gene_product
)	O
,	O
and	O
protein	B-Gene_or_gene_product
kinase	I-Gene_or_gene_product
B	E-Gene_or_gene_product
(	O
AKT	S-Gene_or_gene_product
)	O
pathways	S-Pathway
in	O
DCN	S-Gene_or_gene_product
transfected	S-Planned_process
mouse	S-Organism
cerebral	B-Cell
endothelial	I-Cell
(	I-Cell
MCE	I-Cell
)	I-Cell
cells	E-Cell
.	O

Treatment	O
with	O
pharmacological	O
inhibitors	O
and	O
small	O
interfering	O
RNAs	O
reveal	O
that	O
induction	S-Positive_regulation
and	O
activation	S-Positive_regulation
of	O
Sp1	S-Gene_or_gene_product
,	O
HIF1alpha	S-Gene_or_gene_product
,	O
and	O
Stat3	S-Gene_or_gene_product
facilitate	O
their	O
nuclear	O
localization	S-Localization
and	O
binding	S-Binding
to	O
their	O
specific	O
motifs	O
of	O
the	O
VEGF	S-Gene_or_gene_product
promoter	S-DNA_domain_or_region
and	O
induce	S-Positive_regulation
VEGF	S-Gene_or_gene_product
expression	S-Gene_expression
via	O
two	O
independent	O
pathways	S-Pathway
,	O
DCN	S-Gene_or_gene_product
/	O
EGFR	S-Gene_or_gene_product
/	O
phosphoinositide	B-Gene_or_gene_product
-	I-Gene_or_gene_product
3	I-Gene_or_gene_product
kinase	E-Gene_or_gene_product
/	O
AKT	S-Gene_or_gene_product
and	O
DCN	S-Gene_or_gene_product
/	O
EGFR	S-Gene_or_gene_product
/	O
ERK1	B-Gene_or_gene_product
/	I-Gene_or_gene_product
2	E-Gene_or_gene_product
,	O
respectively	O
,	O
in	O
DCN	S-Gene_or_gene_product
synthesizing	S-Gene_expression
MCE	B-Cell
cells	E-Cell
.	O

The	O
cell	S-Cell
type	O
specific	O
glycosylation	O
protects	S-Negative_regulation
Sp1	S-Gene_or_gene_product
and	O
HIF1alpha	S-Gene_or_gene_product
from	O
proteosome	O
degradation	S-Catabolism
and	O
plays	O
an	O
important	O
and	O
novel	O
role	O
in	O
the	O
regulation	S-Regulation
of	O
VEGF	S-Gene_or_gene_product
in	O
DCN	S-Gene_or_gene_product
transfected	S-Planned_process
MCE	B-Cell
cells	E-Cell
.	O

Induction	S-Positive_regulation
of	O
gelatinases	O
(	O
matrix	B-Gene_or_gene_product
metalloproteinase	I-Gene_or_gene_product
2	E-Gene_or_gene_product
and	O
9	S-Gene_or_gene_product
)	O
,	O
the	O
serine	O
protease	O
tissue	B-Gene_or_gene_product
plasminogen	I-Gene_or_gene_product
activator	E-Gene_or_gene_product
and	O
plasmin	S-Gene_or_gene_product
by	O
DCN	S-Gene_or_gene_product
transfection	S-Planned_process
in	O
MCE	B-Cell
cells	E-Cell
leads	S-Positive_regulation
to	O
extracellular	O
proteolysis	O
and	O
to	O
release	S-Dissociation
of	O
matrix	O
-	O
bound	S-Binding
VEGF	S-Gene_or_gene_product
and	O
activation	S-Positive_regulation
of	O
angiogenesis	S-Blood_vessel_development
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
two	O
independent	O
downstream	O
signal	B-Pathway
pathways	E-Pathway
,	O
DCN	S-Gene_or_gene_product
/	O
EGFR	S-Gene_or_gene_product
/	O
ERK1	B-Gene_or_gene_product
/	I-Gene_or_gene_product
2	E-Gene_or_gene_product
and	O
DCN	S-Gene_or_gene_product
/	O
EGFR	S-Gene_or_gene_product
/	O
phosphoinositide	B-Gene_or_gene_product
-	I-Gene_or_gene_product
3	I-Gene_or_gene_product
kinase	E-Gene_or_gene_product
/	O
AKT	S-Gene_or_gene_product
,	O
mediate	S-Positive_regulation
up	B-Positive_regulation
-	I-Positive_regulation
regulation	E-Positive_regulation
and	O
activation	S-Positive_regulation
of	O
transcription	O
factors	O
of	O
VEGF	S-Gene_or_gene_product
such	O
as	O
HIF1alpha	S-Gene_or_gene_product
,	O
Stat3	S-Gene_or_gene_product
,	O
and	O
Sp1	S-Gene_or_gene_product
and	O
increase	S-Positive_regulation
VEGF	S-Gene_or_gene_product
transcription	S-Transcription
and	O
angiogenesis	S-Blood_vessel_development
in	O
MCE	B-Cell
cells	E-Cell
.	O

[	O
Clinical	O
significance	O
of	O
interleukin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
6	E-Gene_or_gene_product
(	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
6	E-Gene_or_gene_product
)	O
as	O
a	O
prognostic	O
factor	O
of	O
cancer	S-Pathological_formation
disease	O
]	O

Interleukin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
6	E-Gene_or_gene_product
(	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
6	E-Gene_or_gene_product
)	O
is	O
proinflammatory	O
cytokine	O
that	O
produces	O
multifunctional	O
effects	O
.	O

It	O
is	O
also	O
involved	O
in	O
the	O
regulation	O
of	O
immune	O
reactions	O
,	O
hematopoiesis	O
and	O
inflammatory	O
state	O
.	O

Interleukin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
6	E-Gene_or_gene_product
has	O
been	O
shown	O
to	O
be	O
associated	S-Regulation
with	O
tumor	S-Pathological_formation
progression	S-Development
including	O
inhibition	S-Negative_regulation
of	O
cancer	B-Cell
cells	E-Cell
apoptosis	S-Death
and	O
stimulation	S-Positive_regulation
of	O
angiogenesis	S-Blood_vessel_development
.	O

Anti	B-Gene_or_gene_product
-	I-Gene_or_gene_product
IL	I-Gene_or_gene_product
-	I-Gene_or_gene_product
6	E-Gene_or_gene_product
therapy	S-Planned_process
is	O
a	O
new	O
strategy	O
in	O
the	O
inflammatory	O
autoimmune	O
diseases	O
and	O
cancer	S-Pathological_formation
.	O

Clinical	O
studies	O
have	O
shown	O
elevated	S-Positive_regulation
serum	S-Organism_substance
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
6	E-Gene_or_gene_product
concentrations	O
in	O
patients	S-Organism
with	O
endometrial	B-Pathological_formation
cancer	E-Pathological_formation
,	O
non	B-Pathological_formation
-	I-Pathological_formation
small	I-Pathological_formation
cell	I-Pathological_formation
lung	I-Pathological_formation
carcinoma	E-Pathological_formation
,	O
colorectal	B-Pathological_formation
cancer	E-Pathological_formation
,	O
renal	B-Pathological_formation
cell	I-Pathological_formation
carcinoma	E-Pathological_formation
,	O
breast	S-Pathological_formation
and	O
ovarian	B-Pathological_formation
cancer	E-Pathological_formation
.	O

Serum	S-Organism_substance
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
6	E-Gene_or_gene_product
levels	O
correlate	O
with	O
tumor	S-Pathological_formation
stage	O
,	O
and	O
survival	S-Death
of	O
patients	S-Organism
.	O

In	O
this	O
article	O
we	O
have	O
focused	O
on	O
a	O
role	O
of	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
6	E-Gene_or_gene_product
as	O
a	O
prognostic	O
factor	O
in	O
several	O
malignancies	O
such	O
as	O
colorectal	B-Pathological_formation
cancer	E-Pathological_formation
,	O
breast	B-Pathological_formation
cancer	E-Pathological_formation
,	O
gastric	B-Pathological_formation
cancer	E-Pathological_formation
and	O
pancreatic	B-Pathological_formation
cancer	E-Pathological_formation
.	O

Tumor	S-Pathological_formation
microenvironment	O
,	O
a	O
dangerous	O
society	O
leading	O
to	O
cancer	S-Pathological_formation
metastasis	S-Localization
.	O

From	O
mechanisms	O
to	O
therapy	O
and	O
prevention	O
.	O

Cancer	S-Pathological_formation
is	O
no	O
longer	O
considered	O
by	O
scientists	O
just	O
a	O
jumble	O
of	O
mutated	O
cells	S-Cell
.	O

To	O
grow	S-Growth
,	O
invade	S-Localization
and	O
metastasize	S-Localization
,	O
a	O
treacherous	O
society	O
between	O
cancer	S-Pathological_formation
and	O
host	B-Cell
cells	E-Cell
must	O
be	O
formed	O
,	O
and	O
this	O
association	O
provides	O
novel	O
and	O
effective	O
clinical	O
targets	O
for	O
cancer	S-Pathological_formation
control	S-Regulation
and	O
prevention	S-Negative_regulation
.	O

This	O
collection	O
of	O
reviews	O
at	O
the	O
front	O
-	O
edge	O
of	O
scientific	O
knowledge	O
focuses	O
on	O
host	S-Cell
-	O
tumor	B-Cell
cell	E-Cell
interactions	S-Binding
,	O
the	O
disastrous	O
consequences	O
they	O
can	O
produce	O
and	O
approaches	O
the	O
ways	O
to	O
break	O
up	O
these	O
cellular	O
conspiracies	O
,	O
to	O
leave	O
the	O
tumor	B-Cell
cells	E-Cell
unattended	O
and	O
vulnerable	O
.	O

Effects	S-Regulation
of	O
spironolactone	S-Drug_or_compound
on	O
corneal	B-Multi-tissue_structure
allograft	E-Multi-tissue_structure
survival	S-Death
in	O
the	O
rat	S-Organism
.	O

PURPOSE	O
:	O
Spironolactone	S-Drug_or_compound
has	O
recently	O
been	O
shown	O
to	O
have	O
suppressive	O
effects	O
on	O
several	O
immunoactive	O
and	O
proinflammatory	O
cytokines	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effects	S-Regulation
of	O
spironolactone	S-Drug_or_compound
on	O
the	O
prevention	S-Negative_regulation
of	O
corneal	B-Multi-tissue_structure
allograft	E-Multi-tissue_structure
rejection	S-Death
in	O
a	O
MHC	B-Gene_or_gene_product
class	I-Gene_or_gene_product
I	E-Gene_or_gene_product
/	O
II	S-Gene_or_gene_product
mismatch	O
rat	S-Organism
corneal	S-Multi-tissue_structure
transplant	S-Planned_process
model	O
.	O

METHODS	O
:	O
Grafted	O
animals	O
for	O
corneal	S-Multi-tissue_structure
survival	S-Death
analysis	O
were	O
assigned	O
to	O
receive	O
either	O
spironolactone	S-Drug_or_compound
suspension	O
(	O
orally	O
,	O
100	O
mg	O
/	O
kg	O
/	O
day	O
,	O
n	O
=	O
7	O
)	O
,	O
phosphate	B-Drug_or_compound
-	I-Drug_or_compound
buffered	I-Drug_or_compound
saline	E-Drug_or_compound
(	O
PBS	S-Drug_or_compound
,	O
orally	O
,	O
same	O
volume	O
as	O
spironolactone	S-Drug_or_compound
,	O
n	O
=	O
9	O
)	O
or	O
remained	O
untreated	O
(	O
n	O
=	O
16	O
)	O
.	O

Additional	O
grafted	S-Planned_process
rats	S-Organism
treated	S-Planned_process
with	O
spironolactone	S-Drug_or_compound
(	O
n	O
=	O
6	O
)	O
or	O
PBS	S-Drug_or_compound
(	O
n	O
=	O
8	O
)	O
were	O
sacrificed	S-Planned_process
on	O
day	O
12	O
for	O
quantitative	O
RT	O
-	O
PCR	O
analysis	O
for	O
mechanistic	O
studies	O
.	O

RESULTS	O
:	O
Mean	O
(	O
+	O
/	O
-	O
SEM	O
)	O
graft	S-Multi-tissue_structure
survival	S-Death
was	O
significantly	O
prolonged	S-Positive_regulation
in	O
animals	O
receiving	S-Planned_process
spironolactone	S-Drug_or_compound
(	O
14	O
.	O
9	O
+	O
/	O
-	O
2	O
.	O
0	O
days	O
)	O
compared	O
with	O
both	O
PBS	S-Drug_or_compound
-	O
treated	S-Planned_process
(	O
12	O
.	O
3	O
+	O
/	O
-	O
1	O
.	O
2	O
days	O
,	O
p	O
=	O
0	O
.	O
007	O
)	O
and	O
untreated	S-Planned_process
controls	O
(	O
13	O
.	O
0	O
+	O
/	O
-	O
1	O
.	O
0	O
days	O
,	O
p	O
=	O
0	O
.	O
01	O
)	O
.	O

We	O
found	O
a	O
decrease	S-Negative_regulation
in	O
corneal	S-Multi-tissue_structure
neovascularization	S-Blood_vessel_development
in	O
spironolactone	S-Drug_or_compound
-	O
treated	S-Planned_process
rats	S-Organism
compared	O
with	O
the	O
PBS	S-Drug_or_compound
-	O
treated	S-Planned_process
group	O
,	O
although	O
the	O
difference	O
was	O
not	O
statistically	O
significant	O
.	O

Spironolactone	S-Drug_or_compound
affected	S-Regulation
both	O
systemic	O
(	O
down	B-Negative_regulation
-	I-Negative_regulation
regulation	E-Negative_regulation
of	O
CD25	B-Cell
+	I-Cell
cells	E-Cell
in	O
spleen	S-Organ
)	O
and	O
local	O
immune	O
response	O
(	O
up	B-Positive_regulation
-	I-Positive_regulation
regulation	E-Positive_regulation
of	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
10	E-Gene_or_gene_product
in	O
cornea	S-Multi-tissue_structure
)	O
.	O

CONCLUSION	O
:	O
We	O
present	O
initial	O
results	O
demonstrating	O
anti	O
-	O
inflammatory	O
effects	O
of	O
spironolactone	S-Drug_or_compound
.	O

[	O
Photodynamic	O
therapy	O
in	O
severe	O
chronic	O
central	O
serous	O
chorioretinopaty	O
]	O

OBJECTIVE	O
:	O
To	O
determine	O
the	O
efficacy	O
of	O
Photodynamic	O
Therapy	O
(	O
PDT	O
)	O
in	O
chronic	O
Central	O
Serous	O
Chorioretinopathy	O
(	O
CSC	O
)	O
.	O

METHODS	O
:	O
Patients	S-Organism
diagnosed	O
with	O
chronic	O
CSC	O
,	O
with	O
clinical	O
evidence	O
of	O
activity	O
and	O
treated	S-Planned_process
with	O
Photodynamic	O
Therapy	O
,	O
are	O
included	O
in	O
this	O
report	O
.	O

All	O
were	O
assessed	O
by	O
a	O
complete	O
ophthalmological	O
examination	O
,	O
including	O
assessment	O
of	O
the	O
best	O
corrected	O
visual	O
acuity	O
(	O
BCVA	O
)	O
using	O
an	O
ETDRS	O
chart	O
,	O
fluorescein	S-Drug_or_compound
and	O
indocyanine	S-Drug_or_compound
angiography	O
and	O
optical	O
coherence	O
tomography	O
(	O
OCT	O
)	O
.	O

The	O
main	O
objective	O
of	O
the	O
study	O
was	O
to	O
determine	O
the	O
mean	O
visual	O
acuity	O
change	O
.	O

RESULTS	O
:	O
11	O
eyes	S-Organ
of	O
11	O
patients	S-Organism
were	O
included	O
in	O
the	O
study	O
,	O
which	O
had	O
a	O
mean	O
follow	O
-	O
up	O
period	O
of	O
11	O
months	O
.	O

The	O
mean	O
BCVA	O
increased	O
from	O
20	O
/	O
76	O
to	O
20	O
/	O
64	O
.	O

35	O
%	O
of	O
eyes	S-Organ
improved	S-Positive_regulation
their	O
BCVA	O
by	O
2	O
lines	O
or	O
more	O
,	O
45	O
%	O
remained	O
stable	O
and	O
18	O
%	O
lost	O
2	O
lines	O
or	O
more	O
.	O

Choroidal	O
hyperpermeability	O
was	O
reduced	O
in	O
every	O
case	O
.	O

Neurosensorial	O
retinal	S-Multi-tissue_structure
detachment	O
decreased	O
in	O
80	O
%	O
of	O
cases	O
.	O

Only	O
one	O
eye	S-Organ
received	O
a	O
second	O
PDT	B-Planned_process
treatment	E-Planned_process
due	O
to	O
choroidal	O
neovascularization	S-Blood_vessel_development
.	O

An	O
increase	S-Positive_regulation
of	O
atrophy	O
over	O
the	O
Retinal	B-Tissue
Pigment	I-Tissue
Epithelium	E-Tissue
(	O
RPE	S-Tissue
)	O
was	O
observed	O
in	O
another	O
patient	S-Organism
.	O

CONCLUSIONS	O
:	O
PDT	O
can	O
reduce	O
the	O
clinical	O
signs	O
of	O
activity	O
,	O
such	O
as	O
choroidal	O
hyperpermeability	O
or	O
neurosensorial	O
retinal	S-Multi-tissue_structure
detachment	O
,	O
in	O
patients	S-Organism
affected	O
by	O
chronic	O
CSC	O
.	O

However	O
,	O
the	O
increase	O
in	O
visual	O
acuity	O
is	O
variable	O
,	O
probably	O
due	O
to	O
the	O
extent	O
of	O
RPE	O
damage	O
.	O

Angiopoietin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
prevents	S-Negative_regulation
VEGF	S-Gene_or_gene_product
-	O
induced	S-Positive_regulation
endothelial	S-Tissue
permeability	O
by	O
sequestering	S-Negative_regulation
Src	S-Gene_or_gene_product
through	O
mDia	S-Gene_or_gene_product
.	O

Vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
(	O
VEGF	S-Gene_or_gene_product
)	O
and	O
Angiopoietin	B-Gene_or_gene_product
1	E-Gene_or_gene_product
(	O
Ang1	S-Gene_or_gene_product
)	O
are	O
both	O
potent	O
proangiogenic	S-Blood_vessel_development
factors	O
,	O
but	O
,	O
whereas	O
VEGF	S-Gene_or_gene_product
causes	O
vascular	O
permeability	O
,	O
Ang1	S-Gene_or_gene_product
stabilizes	S-Regulation
blood	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
and	O
protects	S-Negative_regulation
them	O
from	O
VEGF	S-Gene_or_gene_product
-	O
induced	S-Positive_regulation
plasma	S-Organism_substance
leakage	S-Localization
.	O

The	O
antivascular	O
permeability	O
mechanisms	O
deployed	O
by	O
Ang1	S-Gene_or_gene_product
are	O
still	O
undefined	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
Ang1	S-Gene_or_gene_product
halts	S-Negative_regulation
the	O
ability	O
of	O
VEGF	S-Gene_or_gene_product
to	O
induce	S-Positive_regulation
the	O
phosphorylation	S-Phosphorylation
-	O
dependent	S-Positive_regulation
redistribution	S-Localization
of	O
the	O
adhesion	O
molecule	O
VE	B-Gene_or_gene_product
-	I-Gene_or_gene_product
cadherin	E-Gene_or_gene_product
,	O
thereby	O
rescuing	O
the	O
endothelial	S-Tissue
barrier	O
function	O
.	O

Ang1	S-Gene_or_gene_product
inhibits	S-Negative_regulation
the	O
activation	S-Positive_regulation
of	O
Src	S-Gene_or_gene_product
by	O
VEGF	S-Gene_or_gene_product
,	O
the	O
most	O
upstream	O
component	O
of	O
the	O
pathway	O
linking	O
VEGF	S-Gene_or_gene_product
receptors	O
to	O
VE	B-Gene_or_gene_product
-	I-Gene_or_gene_product
cadherin	E-Gene_or_gene_product
internalization	S-Localization
.	O

Indeed	O
,	O
Ang1	S-Gene_or_gene_product
promotes	S-Positive_regulation
the	O
activation	S-Positive_regulation
of	O
mDia	S-Gene_or_gene_product
through	O
RhoA	S-Gene_or_gene_product
,	O
resulting	S-Positive_regulation
in	O
the	O
association	S-Binding
of	O
mDia	S-Gene_or_gene_product
with	O
Src	S-Gene_or_gene_product
.	O

This	O
ultimately	O
deprives	O
VEGF	S-Gene_or_gene_product
receptors	O
of	O
an	O
essential	O
molecule	O
required	S-Positive_regulation
for	O
promoting	S-Positive_regulation
the	O
disruption	S-Negative_regulation
of	O
endothelial	S-Cell
cell	B-Binding
-	I-Binding
cell	I-Binding
contacts	E-Binding
and	O
paracellular	O
permeability	O
.	O

A	O
new	O
autosomal	O
dominant	O
vascular	O
retinopathy	O
syndrome	O
.	O

We	O
describe	O
a	O
new	O
syndrome	O
with	O
autosomal	O
dominant	O
transmission	O
whose	O
most	O
striking	O
feature	O
is	O
vascular	O
retinopathy	O
.	O

The	O
retinopathy	O
is	O
often	O
associated	O
with	O
migraine	O
,	O
Raynaud	O
'	O
s	O
phenomenon	O
and	O
mental	O
changes	O
,	O
mainly	O
forgetfulness	O
,	O
aggression	O
and	O
depression	O
.	O

To	O
define	O
this	O
syndrome	O
we	O
collected	O
medical	O
data	O
on	O
110	O
family	O
members	O
.	O

General	O
ophthalmological	O
examination	O
and	O
fluorescein	S-Drug_or_compound
angiography	S-Planned_process
were	O
performed	O
in	O
61	O
persons	S-Organism
.	O

The	O
retinopathy	O
,	O
as	O
diagnosed	O
in	O
22	O
persons	S-Organism
,	O
is	O
characterized	O
by	O
central	O
and	O
peripheral	O
microangiopathy	O
,	O
areas	O
of	O
capillary	S-Tissue
non	O
-	O
perfusion	O
,	O
haemorrhages	O
,	O
cotton	S-Organism
wool	O
spots	O
and	O
,	O
in	O
a	O
more	O
advanced	O
stage	O
,	O
occlusion	O
of	O
large	O
retinal	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
,	O
which	O
can	O
induce	S-Positive_regulation
a	O
neovascular	B-Blood_vessel_development
response	E-Blood_vessel_development
.	O

A	O
vascular	O
occlusive	O
disorder	O
may	O
be	O
the	O
common	O
aetiological	O
factor	O
of	O
the	O
various	O
manifestation	O
of	O
this	O
syndrome	O
.	O

Suppression	S-Negative_regulation
of	O
lung	B-Pathological_formation
tumor	E-Pathological_formation
growth	S-Growth
and	O
metastasis	S-Localization
in	O
mice	S-Organism
by	O
adeno	B-Organism
-	I-Organism
associated	I-Organism
virus	E-Organism
-	O
mediated	S-Positive_regulation
expression	S-Gene_expression
of	O
vasostatin	S-Gene_or_gene_product
.	O

PURPOSE	O
:	O
Angiogenesis	S-Blood_vessel_development
inhibitors	O
have	O
strong	O
therapeutic	O
potential	O
as	O
antitumor	S-Pathological_formation
agents	O
in	O
suppressing	S-Negative_regulation
tumor	S-Pathological_formation
growth	S-Growth
and	O
metastatic	B-Development
progression	E-Development
.	O

Vasostatin	S-Gene_or_gene_product
,	O
the	O
N	O
-	O
terminal	O
domain	O
of	O
calreticulin	S-Gene_or_gene_product
,	O
is	O
a	O
potent	O
angiogenesis	S-Blood_vessel_development
inhibitor	O
.	O

In	O
this	O
study	O
,	O
we	O
determined	O
the	O
effectiveness	S-Regulation
of	O
vasostatin	S-Gene_or_gene_product
delivered	S-Planned_process
by	O
recombinant	B-Organism
pseudotype	I-Organism
adeno	I-Organism
-	I-Organism
associated	I-Organism
virus	I-Organism
2	E-Organism
/	O
5	S-Organism
(	O
rAAV2	S-Organism
/	O
5	B-Organism
-	I-Organism
VAS	E-Organism
)	O
as	O
a	O
gene	B-Planned_process
therapy	E-Planned_process
approach	O
for	O
lung	B-Pathological_formation
cancer	E-Pathological_formation
treatment	O
.	O

EXPERIMENTAL	O
DESIGN	O
:	O
We	O
used	O
rAAV2	S-Organism
/	O
5	S-Organism
to	O
deliver	S-Planned_process
vasostatin	S-Gene_or_gene_product
intratumorally	S-Pathological_formation
or	O
systemically	O
in	O
different	O
mouse	S-Organism
lung	B-Pathological_formation
tumor	E-Pathological_formation
models	O
-	O
-	O
subcutaneous	O
,	O
orthotopic	O
xenograft	O
,	O
and	O
spontaneous	O
metastasis	O
lung	B-Pathological_formation
tumor	E-Pathological_formation
models	O
.	O

The	O
therapeutic	O
efficacy	O
of	O
rAAV2	S-Organism
/	O
5	B-Organism
-	I-Organism
VAS	E-Organism
was	O
determined	O
by	O
monitoring	O
tumor	S-Pathological_formation
volume	O
,	O
survival	O
rate	O
,	O
and	O
degree	O
of	O
neovascularization	S-Blood_vessel_development
after	O
treatment	O
in	O
these	O
models	O
.	O

RESULTS	O
:	O
Mice	S-Organism
bearing	O
subcutaneous	B-Pathological_formation
tumor	E-Pathological_formation
of	O
rAAV2	S-Organism
/	O
5	B-Organism
-	I-Organism
VAS	E-Organism
pretreated	S-Planned_process
Lewis	B-Cell
lung	I-Cell
carcinoma	I-Cell
cells	E-Cell
showed	O
>	O
50	O
%	O
reduction	S-Negative_regulation
in	O
primary	O
tumor	S-Pathological_formation
volume	O
and	O
reduced	S-Negative_regulation
spontaneous	O
pulmonary	S-Organ
metastases	S-Localization
.	O

The	O
tumor	B-Negative_regulation
-	I-Negative_regulation
suppressive	I-Negative_regulation
action	E-Negative_regulation
of	O
rAAV2	S-Organism
/	O
5	B-Organism
-	I-Organism
VAS	E-Organism
in	O
subcutaneous	O
human	S-Organism
lung	B-Pathological_formation
tumor	I-Pathological_formation
A549	I-Pathological_formation
xenograft	E-Pathological_formation
correlated	O
with	O
a	O
reduced	S-Negative_regulation
number	O
of	O
capillary	B-Tissue
vessels	E-Tissue
in	O
tumors	S-Pathological_formation
.	O

In	O
the	O
orthotopic	O
xenograft	O
model	O
,	O
rAAV2	S-Organism
/	O
5	B-Organism
-	I-Organism
VAS	E-Organism
suppressed	S-Negative_regulation
metastasis	S-Localization
of	O
A549	B-Pathological_formation
tumors	E-Pathological_formation
to	O
mediastinal	O
lymph	B-Multi-tissue_structure
nodes	E-Multi-tissue_structure
and	O
contralateral	O
lung	S-Organ
.	O

Furthermore	O
,	O
treatment	S-Planned_process
of	O
immunocompetent	O
mice	S-Organism
in	O
the	O
spontaneous	O
lung	B-Pathological_formation
metastases	E-Pathological_formation
model	O
with	O
rAAV2	S-Organism
/	O
5	B-Organism
-	I-Organism
VAS	E-Organism
after	O
primary	O
tumor	S-Pathological_formation
excision	S-Planned_process
prolonged	O
their	O
median	O
survival	O
from	O
21	O
to	O
51	O
.	O
5	O
days	O
.	O

CONCLUSION	O
:	O
Our	O
results	O
show	O
the	O
effectiveness	S-Negative_regulation
of	O
rAAV2	S-Organism
/	O
5	B-Organism
-	I-Organism
VAS	E-Organism
as	O
an	O
angiogenesis	S-Blood_vessel_development
inhibitor	O
in	O
suppressing	S-Negative_regulation
tumor	S-Pathological_formation
growth	S-Growth
during	O
different	O
stages	O
of	O
tumor	S-Pathological_formation
progression	S-Development
,	O
validating	O
the	O
application	O
of	O
rAAV2	S-Organism
/	O
5	B-Organism
-	I-Organism
VAS	E-Organism
gene	B-Planned_process
therapy	E-Planned_process
in	O
treatment	O
against	S-Negative_regulation
lung	B-Pathological_formation
cancer	E-Pathological_formation
.	O

Radiation	O
retinopathy	O
is	O
treatable	O
with	O
anti	B-Gene_or_gene_product
-	I-Gene_or_gene_product
vascular	I-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
bevacizumab	S-Drug_or_compound
(	O
Avastin	S-Drug_or_compound
)	O
.	O

PURPOSE	O
:	O
To	O
report	O
on	O
bevacizumab	S-Drug_or_compound
treatment	S-Planned_process
for	O
radiation	O
retinopathy	O
affecting	S-Regulation
the	O
macula	S-Tissue
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
Twenty	O
-	O
one	O
patients	S-Organism
with	O
radiation	O
retinopathy	O
(	O
edema	S-Pathological_formation
,	O
hemorrhages	O
,	O
capillary	S-Tissue
dropout	O
,	O
and	O
neovascularization	S-Blood_vessel_development
)	O
and	O
a	O
subjective	O
or	O
objective	O
loss	O
of	O
vision	O
were	O
treated	O
.	O

Treatment	O
involved	O
intravitreal	B-Planned_process
injection	E-Planned_process
of	O
bevacizumab	S-Drug_or_compound
(	O
1	O
.	O
25	O
mg	O
in	O
0	O
.	O
05	O
mL	O
)	O
every	O
6	O
-	O
12	O
weeks	O
.	O

Treatment	O
was	O
discontinued	O
at	O
patient	S-Organism
request	O
or	O
if	O
there	O
was	O
no	O
measurable	O
response	O
to	O
therapy	O
.	O

Main	O
outcome	O
measures	O
included	O
best	O
corrected	O
visual	O
acuity	O
,	O
ophthalmic	O
examination	O
,	O
retinal	O
photography	O
,	O
and	O
angiography	O
.	O

RESULTS	O
:	O
Bevacizumab	S-Drug_or_compound
treatment	S-Planned_process
was	O
followed	O
by	O
reductions	O
in	O
retinal	O
hemorrhage	O
,	O
exudation	O
,	O
and	O
edema	S-Pathological_formation
.	O

Visual	O
acuities	O
were	O
stable	O
or	O
improved	O
in	O
86	O
%	O
(	O
n	O
=	O
18	O
)	O
.	O

Three	O
patients	S-Organism
discontinued	O
therapy	O
.	O

Each	O
was	O
legally	O
blind	O
before	O
treatment	O
(	O
n	O
=	O
1	O
)	O
,	O
experienced	O
little	O
to	O
no	O
subjective	O
improvement	O
(	O
n	O
=	O
2	O
)	O
,	O
or	O
was	O
poorly	O
compliant	O
(	O
n	O
=	O
2	O
)	O
.	O

Three	O
patients	S-Organism
(	O
14	O
%	O
)	O
regained	O
2	O
or	O
more	O
lines	O
of	O
visual	O
acuity	O
.	O

No	O
ocular	O
or	O
systemic	O
bevacizumab	S-Drug_or_compound
-	O
related	O
side	O
effects	O
were	O
observed	O
.	O

CONCLUSIONS	O
:	O
Intravitreal	O
bevacizumab	S-Drug_or_compound
can	O
be	O
used	O
to	O
treat	O
radiation	O
retinopathy	O
.	O

In	O
most	O
cases	O
treatment	O
was	O
associated	O
with	O
decreased	O
vascular	S-Multi-tissue_structure
leakage	O
,	O
stabilization	O
,	O
or	O
improved	O
vision	O
.	O

An	O
anti	B-Gene_or_gene_product
-	I-Gene_or_gene_product
vascular	I-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
strategy	O
may	O
reduce	S-Negative_regulation
tissue	S-Tissue
damage	S-Breakdown
associated	O
with	O
radiation	O
vasculopathy	O
and	O
neuropathy	O
.	O

Mitogen	B-Gene_or_gene_product
-	I-Gene_or_gene_product
activated	I-Gene_or_gene_product
protein	I-Gene_or_gene_product
kinase	I-Gene_or_gene_product
kinase	E-Gene_or_gene_product
signaling	S-Pathway
promotes	S-Positive_regulation
growth	S-Growth
and	O
vascularization	S-Blood_vessel_development
of	O
fibrosarcoma	S-Pathological_formation
.	O

We	O
hypothesized	O
that	O
signaling	O
through	O
multiple	O
mitogen	B-Gene_or_gene_product
-	I-Gene_or_gene_product
activated	I-Gene_or_gene_product
protein	I-Gene_or_gene_product
kinase	I-Gene_or_gene_product
(	I-Gene_or_gene_product
MAPK	I-Gene_or_gene_product
)	I-Gene_or_gene_product
kinase	E-Gene_or_gene_product
(	O
MKK	S-Gene_or_gene_product
)	O
pathways	S-Pathway
is	O
essential	S-Positive_regulation
for	O
the	O
growth	S-Growth
and	O
vascularization	S-Blood_vessel_development
of	O
soft	B-Pathological_formation
-	I-Pathological_formation
tissue	I-Pathological_formation
sarcomas	E-Pathological_formation
,	O
which	O
are	O
malignant	O
tumors	S-Pathological_formation
derived	O
from	O
mesenchymal	B-Tissue
tissues	E-Tissue
.	O

We	O
tested	O
this	O
using	O
HT	B-Cell
-	I-Cell
1080	E-Cell
,	O
NCI	S-Cell
,	O
and	O
Shac	B-Cell
fibrosarcoma	I-Cell
-	I-Cell
derived	I-Cell
cell	I-Cell
lines	E-Cell
and	O
anthrax	S-Organism
lethal	B-Drug_or_compound
toxin	E-Drug_or_compound
(	O
LeTx	S-Drug_or_compound
)	O
,	O
a	O
bacterial	O
toxin	O
that	O
inactivates	S-Negative_regulation
MKKs	S-Gene_or_gene_product
.	O

Western	O
blots	O
confirmed	O
that	O
LeTx	S-Drug_or_compound
treatment	S-Planned_process
reduced	S-Negative_regulation
the	O
levels	O
of	O
phosphorylated	S-Phosphorylation
extracellular	B-Gene_or_gene_product
signal	I-Gene_or_gene_product
-	I-Gene_or_gene_product
regulated	I-Gene_or_gene_product
kinase	E-Gene_or_gene_product
and	O
p38	B-Gene_or_gene_product
MAPK	E-Gene_or_gene_product
in	O
vitro	O
.	O

Although	O
short	O
treatments	S-Planned_process
with	O
LeTx	S-Drug_or_compound
only	O
modestly	O
affected	S-Regulation
cell	S-Cell
proliferation	S-Cell_proliferation
,	O
sustained	O
treatment	O
markedly	O
reduced	O
cell	S-Cell
numbers	O
.	O

LeTx	S-Drug_or_compound
also	O
substantially	O
inhibited	S-Negative_regulation
the	O
extracellular	O
release	S-Localization
of	O
angioproliferative	S-Blood_vessel_development
factors	O
including	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
,	O
interleukin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	E-Gene_or_gene_product
,	O
and	O
basic	B-Gene_or_gene_product
fibroblast	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
.	O

Similar	O
results	O
were	O
obtained	O
with	O
cell	S-Cell
lines	O
derived	O
from	O
malignant	B-Pathological_formation
fibrous	I-Pathological_formation
histiocytomas	E-Pathological_formation
,	O
leiomyosarcomas	S-Pathological_formation
,	O
and	O
liposarcomas	S-Pathological_formation
.	O

In	O
vivo	O
,	O
LeTx	S-Drug_or_compound
decreased	S-Negative_regulation
MAPK	S-Gene_or_gene_product
activity	O
and	O
blocked	S-Negative_regulation
fibrosarcoma	S-Pathological_formation
growth	S-Growth
.	O

Growth	S-Growth
inhibition	S-Negative_regulation
correlated	O
with	O
decreased	O
cellular	S-Cell
proliferation	S-Cell_proliferation
and	O
extensive	O
necrosis	O
,	O
and	O
it	O
was	O
accompanied	O
by	O
a	O
decrease	S-Negative_regulation
in	O
tumor	S-Pathological_formation
mean	O
vessel	S-Multi-tissue_structure
density	O
as	O
well	O
as	O
a	O
reduction	S-Negative_regulation
in	O
serum	S-Organism_substance
expression	O
of	O
angioproliferative	S-Blood_vessel_development
cytokines	O
.	O

Vital	O
imaging	O
using	O
high	O
-	O
resolution	O
ultrasound	O
enhanced	O
with	O
contrast	O
microbubbles	O
revealed	O
that	O
the	O
effects	S-Regulation
of	O
LeTx	S-Drug_or_compound
on	O
tumor	S-Pathological_formation
perfusion	S-Development
were	O
remarkably	O
rapid	O
(	O
less	O
than	O
24	O
h	O
)	O
and	O
resulted	S-Positive_regulation
in	O
a	O
marked	O
reduction	S-Negative_regulation
of	O
perfusion	S-Development
within	O
the	O
tumor	S-Pathological_formation
but	O
not	O
in	O
nontumor	B-Tissue
tissues	E-Tissue
.	O

These	O
results	O
are	O
consistent	O
with	O
our	O
initial	O
hypothesis	O
and	O
lead	O
us	O
to	O
propose	O
that	O
MKK	S-Gene_or_gene_product
inhibition	S-Negative_regulation
by	O
LeTx	S-Drug_or_compound
is	O
a	O
broadly	O
effective	O
strategy	O
for	O
targeting	S-Regulation
neovascularization	S-Blood_vessel_development
in	O
fibrosarcomas	S-Pathological_formation
and	O
other	O
similar	O
proliferative	B-Pathological_formation
lesions	E-Pathological_formation
.	O

Functional	O
significance	O
of	O
VEGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
a	E-Gene_or_gene_product
in	O
human	S-Organism
ovarian	B-Pathological_formation
carcinoma	E-Pathological_formation
:	O
role	S-Regulation
in	O
vasculogenic	B-Blood_vessel_development
mimicry	E-Blood_vessel_development
.	O

Ovarian	B-Pathological_formation
cancer	E-Pathological_formation
is	O
a	O
silent	O
killer	O
,	O
and	O
shows	O
early	O
extensive	O
tumor	S-Pathological_formation
invasion	S-Localization
and	O
peritoneal	S-Multi-tissue_structure
metastasis	S-Localization
.	O

The	O
microcirculation	O
of	O
most	O
tumors	S-Pathological_formation
includes	O
cooperation	O
of	O
pre	O
-	O
existing	O
vessels	S-Multi-tissue_structure
,	O
intussusceptive	O
microvascular	S-Tissue
growth	S-Growth
,	O
postnatal	O
vasculogenesis	S-Blood_vessel_development
,	O
glomeruloid	O
angiogenesis	S-Blood_vessel_development
and	O
vasculogenic	B-Blood_vessel_development
mimicry	E-Blood_vessel_development
(	O
VM	S-Blood_vessel_development
)	O
.	O

VM	S-Blood_vessel_development
is	O
critical	O
for	O
a	O
tumor	S-Pathological_formation
blood	S-Organism_substance
supply	O
and	O
is	O
asscociated	O
with	O
aggressive	O
features	O
and	O
metastasis	O
.	O

Our	O
studies	O
highlight	O
the	O
plasticity	O
of	O
aggressive	O
human	S-Organism
ovarian	B-Cell
carcinoma	I-Cell
cells	E-Cell
and	O
call	O
into	O
question	O
the	O
underlying	O
significance	O
of	O
their	O
ability	O
to	O
form	O
VM	S-Blood_vessel_development
in	O
vitro	O
induced	S-Positive_regulation
by	O
VEGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
a	E-Gene_or_gene_product
.	O

These	O
studies	O
also	O
show	O
their	O
clinicalpathological	O
features	O
of	O
the	O
cancers	O
with	O
human	S-Organism
Paraffin	O
-	O
embedded	O
tumor	B-Tissue
tissue	I-Tissue
samples	E-Tissue
.	O

Results	O
show	O
that	O
the	O
process	O
:	O
VEGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
a	E-Gene_or_gene_product
-	O
-	O
greater	O
than	O
EphA2	S-Gene_or_gene_product
-	O
-	O
greater	O
than	O
MMPs	S-Gene_or_gene_product
-	O
-	O
greater	O
than	O
VM	S-Blood_vessel_development
is	O
the	O
main	O
pathway	S-Pathway
for	O
VM	B-Blood_vessel_development
formation	E-Blood_vessel_development
and	O
VEGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
a	E-Gene_or_gene_product
appears	O
to	O
play	B-Regulation
an	I-Regulation
important	I-Regulation
role	E-Regulation
in	O
the	O
formation	B-Blood_vessel_development
of	I-Blood_vessel_development
VM	E-Blood_vessel_development
based	O
on	O
our	O
in	O
vitro	O
assays	O
and	O
clinical	O
immunohistochemical	O
analyses	O
.	O

VM	S-Blood_vessel_development
-	O
targeting	S-Regulation
strategies	O
for	O
ovarian	B-Pathological_formation
cancer	E-Pathological_formation
include	O
anti	B-Gene_or_gene_product
-	I-Gene_or_gene_product
VEGF	I-Gene_or_gene_product
-	I-Gene_or_gene_product
a	E-Gene_or_gene_product
treatment	S-Planned_process
,	O
knocking	B-Planned_process
down	E-Planned_process
the	O
EphA2	S-Gene_or_gene_product
gene	O
and	O
using	S-Planned_process
antibodies	B-Gene_or_gene_product
against	I-Gene_or_gene_product
human	I-Gene_or_gene_product
MMPs	E-Gene_or_gene_product
if	O
the	O
tumor	S-Pathological_formation
is	O
VM	S-Blood_vessel_development
positive	O
.	O

This	O
strategy	O
may	O
be	O
of	O
significant	O
value	O
in	O
laying	O
the	O
foundation	O
for	O
a	O
more	O
explicit	O
anti	O
-	O
tumor	S-Pathological_formation
angiogenesis	S-Blood_vessel_development
therapy	S-Negative_regulation
.	O

A	O
novel	O
role	O
of	O
thrombospondin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
in	O
cervical	S-Multi-tissue_structure
carcinogenesis	O
:	O
inhibit	S-Negative_regulation
stroma	S-Tissue
reaction	O
by	O
inhibiting	S-Negative_regulation
activated	S-Positive_regulation
fibroblasts	S-Cell
from	O
invading	S-Localization
cancer	S-Pathological_formation
.	O

Thrombospondin	B-Gene_or_gene_product
(	I-Gene_or_gene_product
TSP	I-Gene_or_gene_product
)	I-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
,	O
a	O
potent	O
angiogenesis	S-Blood_vessel_development
inhibitor	O
,	O
has	O
been	O
shown	O
to	O
exert	O
different	O
biological	O
functions	O
on	O
various	O
cell	S-Cell
types	O
.	O

Here	O
,	O
we	O
investigate	O
the	O
role	S-Regulation
of	O
TSP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
in	O
tumor	S-Pathological_formation
-	O
stroma	S-Tissue
reaction	S-Binding
,	O
which	O
is	O
mainly	O
characterized	O
by	O
fibroblast	S-Cell
activation	S-Positive_regulation
to	O
create	O
a	O
permissive	O
microenvironment	O
for	O
tumor	S-Pathological_formation
progression	S-Development
.	O

Immunohistochemistry	O
examinations	O
in	O
the	O
human	S-Organism
surgical	O
specimens	O
have	O
shown	O
that	O
a	O
downregulation	S-Negative_regulation
of	O
TSP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
during	O
the	O
progression	O
of	O
cervical	S-Multi-tissue_structure
carcinogenesis	O
was	O
accompanied	O
by	O
an	O
emergence	O
in	O
the	O
upregulation	S-Positive_regulation
of	O
stroma	B-Gene_or_gene_product
markers	E-Gene_or_gene_product
,	O
alpha	B-Gene_or_gene_product
-	I-Gene_or_gene_product
smooth	I-Gene_or_gene_product
muscle	I-Gene_or_gene_product
actin	E-Gene_or_gene_product
(	O
alpha	B-Gene_or_gene_product
-	I-Gene_or_gene_product
SMA	E-Gene_or_gene_product
)	O
and	O
desmin	S-Gene_or_gene_product
.	O

Transfection	S-Planned_process
of	O
SiHa	B-Cell
cervical	I-Cell
cancer	I-Cell
cells	E-Cell
with	O
a	O
plasmid	O
expressing	S-Gene_expression
the	O
TSP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
protein	O
exhibited	O
antiangiogenic	S-Blood_vessel_development
activity	S-Negative_regulation
in	O
vitro	O
and	O
resulted	S-Positive_regulation
in	O
reduced	S-Negative_regulation
tumor	S-Pathological_formation
growth	S-Growth
in	O
severe	O
combined	O
immunodeficiency	O
(	O
SCID	O
)	O
mice	S-Organism
,	O
which	O
was	O
accompanied	O
by	O
a	O
decrease	S-Negative_regulation
in	O
tumor	S-Pathological_formation
vascularization	S-Blood_vessel_development
and	O
lower	O
expressions	S-Gene_expression
of	O
alpha	B-Gene_or_gene_product
-	I-Gene_or_gene_product
SMA	E-Gene_or_gene_product
and	O
desmin	S-Gene_or_gene_product
than	O
those	O
in	O
the	O
vector	O
controls	O
.	O

Transfection	S-Planned_process
with	O
TSP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
and	O
purified	O
TSP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
added	S-Planned_process
to	O
NIH3T3	B-Cell
cells	E-Cell
did	O
not	O
alter	S-Regulation
the	O
protein	O
levels	O
of	O
alpha	B-Gene_or_gene_product
-	I-Gene_or_gene_product
SMA	E-Gene_or_gene_product
and	O
desmin	S-Gene_or_gene_product
but	O
significantly	O
inhibited	S-Negative_regulation
matrix	B-Gene_or_gene_product
metalloprotease	I-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
activity	O
.	O

Transforming	B-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
-	I-Gene_or_gene_product
beta	E-Gene_or_gene_product
(	O
TGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
beta	E-Gene_or_gene_product
)	O
,	O
a	O
major	O
factor	O
in	O
the	O
activation	S-Positive_regulation
of	O
fibroblasts	S-Cell
,	O
increased	S-Positive_regulation
alpha	B-Gene_or_gene_product
-	I-Gene_or_gene_product
SMA	E-Gene_or_gene_product
and	O
desmin	S-Gene_or_gene_product
expression	S-Gene_expression
and	O
the	O
ability	O
of	O
cell	S-Cell
migration	S-Localization
and	O
invasion	S-Localization
in	O
NIH3T3	B-Cell
cells	E-Cell
.	O

The	O
increased	S-Positive_regulation
migration	S-Localization
ability	O
and	O
the	O
invasive	S-Localization
ability	O
into	O
tumor	S-Pathological_formation
cluster	O
of	O
TGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
beta	E-Gene_or_gene_product
-	O
treated	S-Planned_process
NIH3T3	B-Cell
cells	E-Cell
were	O
dose	O
dependently	O
inhibited	S-Negative_regulation
by	O
TSP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
.	O

In	O
contrast	O
,	O
ectopic	O
TSP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
expression	S-Gene_expression
in	O
SiHa	B-Cell
cells	E-Cell
has	O
little	O
effect	S-Regulation
on	O
the	O
invasive	S-Localization
ability	O
of	O
the	O
NIH3T3	B-Cell
cells	E-Cell
.	O

Together	O
,	O
our	O
findings	O
demonstrate	O
a	O
novel	O
role	S-Regulation
of	O
TSP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
to	O
inhibit	S-Negative_regulation
tumor	S-Pathological_formation
-	O
stroma	S-Tissue
reaction	S-Binding
that	O
could	O
be	O
attributed	O
to	O
the	O
blockage	S-Negative_regulation
of	O
activated	S-Positive_regulation
fibroblasts	S-Cell
from	O
invading	S-Localization
cancer	B-Cell
cells	E-Cell
.	O

Acute	O
ethanol	S-Drug_or_compound
exposure	S-Planned_process
disrupts	S-Negative_regulation
VEGF	B-Gene_or_gene_product
receptor	E-Gene_or_gene_product
cell	B-Pathway
signaling	E-Pathway
in	O
endothelial	B-Cell
cells	E-Cell
.	O

Physiological	O
angiogenesis	S-Blood_vessel_development
is	O
regulated	S-Regulation
by	O
various	O
factors	O
,	O
including	O
signaling	O
through	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
(	I-Gene_or_gene_product
VEGF	I-Gene_or_gene_product
)	I-Gene_or_gene_product
receptors	E-Gene_or_gene_product
.	O

We	O
previously	O
reported	O
that	O
a	O
single	O
dose	O
of	O
ethanol	S-Drug_or_compound
(	O
1	O
.	O
4	O
g	O
/	O
kg	O
)	O
,	O
yielding	O
a	O
blood	S-Organism_substance
alcohol	S-Drug_or_compound
concentration	O
of	O
100	O
mg	O
/	O
dl	O
,	O
significantly	O
impairs	S-Negative_regulation
angiogenesis	S-Blood_vessel_development
in	O
murine	S-Organism
wounds	S-Pathological_formation
,	O
despite	O
adequate	O
levels	O
of	O
VEGF	S-Gene_or_gene_product
,	O
suggesting	O
direct	O
effects	S-Regulation
of	O
ethanol	S-Drug_or_compound
on	O
endothelial	B-Cell
cell	E-Cell
signaling	S-Pathway
(	O
40	O
)	O
.	O

To	O
examine	O
the	O
mechanism	O
by	O
which	O
ethanol	S-Drug_or_compound
influences	S-Regulation
angiogenesis	S-Blood_vessel_development
in	O
wounds	S-Pathological_formation
,	O
we	O
employed	O
two	O
different	O
in	O
vitro	O
angiogenesis	S-Blood_vessel_development
assays	O
to	O
determine	O
whether	O
acute	O
ethanol	S-Drug_or_compound
exposure	S-Planned_process
(	O
100	O
mg	O
/	O
dl	O
)	O
would	O
have	O
long	O
-	O
lasting	O
effects	S-Regulation
on	O
VEGF	S-Gene_or_gene_product
-	O
induced	S-Positive_regulation
capillary	B-Multi-tissue_structure
network	E-Multi-tissue_structure
formation	S-Development
.	O

Ethanol	S-Drug_or_compound
exposure	S-Planned_process
resulted	S-Positive_regulation
in	O
reduced	S-Negative_regulation
VEGF	S-Gene_or_gene_product
-	O
induced	S-Positive_regulation
cord	S-Tissue
formation	S-Development
on	O
collagen	S-Gene_or_gene_product
and	O
reduced	S-Negative_regulation
capillary	B-Multi-tissue_structure
network	E-Multi-tissue_structure
structure	O
on	O
Matrigel	O
in	O
vitro	O
.	O

In	O
addition	O
,	O
ethanol	S-Drug_or_compound
exposure	S-Planned_process
decreased	S-Negative_regulation
expression	S-Gene_expression
of	O
endothelial	O
VEGF	B-Gene_or_gene_product
receptor	I-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
,	O
as	O
well	O
as	O
VEGF	B-Gene_or_gene_product
receptor	I-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
phosphorylation	S-Phosphorylation
in	O
vitro	O
.	O

Inhibition	S-Negative_regulation
of	O
ethanol	S-Drug_or_compound
metabolism	S-Metabolism
by	O
4	B-Drug_or_compound
-	I-Drug_or_compound
methylpyrazole	E-Drug_or_compound
partially	O
abrogated	S-Negative_regulation
the	O
effect	S-Regulation
of	O
ethanol	S-Drug_or_compound
on	O
endothelial	B-Tissue
cell	I-Tissue
cord	E-Tissue
formation	S-Development
.	O

However	O
,	O
mice	S-Organism
treated	S-Planned_process
with	O
t	B-Drug_or_compound
-	I-Drug_or_compound
butanol	E-Drug_or_compound
,	O
an	O
alcohol	S-Drug_or_compound
not	O
metabolized	S-Metabolism
by	O
alcohol	B-Gene_or_gene_product
dehydrogenase	E-Gene_or_gene_product
,	O
exhibited	O
no	O
change	O
in	O
wound	O
vascularity	O
.	O

These	O
results	O
suggest	O
that	O
products	O
of	O
ethanol	S-Drug_or_compound
metabolism	S-Metabolism
are	O
important	S-Regulation
factors	O
in	O
the	O
development	O
of	O
ethanol	S-Drug_or_compound
-	O
induced	S-Positive_regulation
changes	S-Regulation
in	O
endothelial	B-Cell
cell	E-Cell
responsiveness	S-Regulation
to	O
VEGF	S-Gene_or_gene_product
.	O

In	O
vivo	O
,	O
ethanol	S-Drug_or_compound
exposure	S-Planned_process
caused	O
both	O
decreased	S-Negative_regulation
angiogenesis	S-Blood_vessel_development
and	O
increased	O
hypoxia	O
in	O
wounds	S-Pathological_formation
.	O

Moreover	O
,	O
in	O
vitro	O
experiments	O
demonstrated	O
a	O
direct	O
effect	O
of	O
ethanol	S-Drug_or_compound
on	O
the	O
response	O
to	O
hypoxia	O
in	O
endothelial	B-Cell
cells	E-Cell
,	O
as	O
ethanol	S-Drug_or_compound
diminished	S-Negative_regulation
nuclear	O
hypoxia	B-Gene_or_gene_product
-	I-Gene_or_gene_product
inducible	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
-	I-Gene_or_gene_product
1alpha	E-Gene_or_gene_product
protein	O
levels	O
.	O

Together	O
,	O
the	O
data	O
establish	O
that	O
acute	O
ethanol	S-Drug_or_compound
exposure	S-Planned_process
significantly	O
impairs	S-Negative_regulation
angiogenesis	S-Blood_vessel_development
and	O
suggest	O
that	O
this	O
effect	O
is	O
mediated	S-Regulation
by	O
changes	S-Regulation
in	O
endothelial	B-Cell
cell	E-Cell
responsiveness	S-Regulation
to	O
both	O
VEGF	S-Gene_or_gene_product
and	O
hypoxia	O
.	O

Management	O
of	O
early	O
and	O
advanced	O
colorectal	B-Pathological_formation
cancer	E-Pathological_formation
:	O
therapeutic	O
issues	O
.	O

PURPOSE	O
:	O
The	O
staging	O
of	O
colorectal	B-Pathological_formation
cancer	E-Pathological_formation
,	O
therapeutic	O
decision	O
making	O
in	O
the	O
management	S-Regulation
of	O
early	O
and	O
advanced	O
colorectal	B-Pathological_formation
cancer	E-Pathological_formation
,	O
and	O
dilemmas	O
posed	O
by	O
drug	O
-	O
related	O
toxicity	O
are	O
discussed	O
.	O

SUMMARY	O
:	O
Staging	O
of	O
colorectal	B-Pathological_formation
cancer	E-Pathological_formation
occurs	O
after	O
surgery	O
and	O
is	O
based	O
on	O
the	O
extent	O
of	O
disease	O
invasiveness	O
and	O
dissemination	O
.	O

Surgery	O
is	O
the	O
primary	O
treatment	O
for	O
stage	O
I	O
disease	O
.	O

Adjuvant	O
chemotherapy	S-Planned_process
is	O
recommended	O
after	O
resection	O
in	O
selected	O
high	O
-	O
risk	O
patients	S-Organism
with	O
stage	O
II	O
disease	O
and	O
in	O
all	O
patients	S-Organism
with	O
stage	O
III	O
disease	O
.	O

Convenience	O
of	O
administration	O
,	O
tolerability	O
,	O
and	O
patient	S-Organism
factors	O
not	O
necessarily	O
age	O
may	O
be	O
considerations	O
in	O
decisions	O
about	O
adjuvant	O
therapy	O
after	O
resection	O
.	O

Treatment	S-Planned_process
of	O
stage	O
IV	O
colorectal	B-Pathological_formation
cancer	E-Pathological_formation
is	O
based	O
on	O
the	O
type	O
of	O
prior	O
therapy	O
and	O
patient	S-Organism
-	O
specific	O
factors	O
.	O

Recently	O
,	O
significant	O
improvements	O
in	O
survival	O
have	O
been	O
achieved	O
through	O
the	O
use	O
of	O
combination	O
chemotherapy	O
and	O
monoclonal	O
antibody	O
regimens	O
.	O

Bevacizumab	S-Drug_or_compound
in	O
combination	O
with	O
chemotherapy	S-Planned_process
is	O
first	O
-	O
line	O
therapy	O
for	O
stage	O
IV	O
disease	O
.	O

Age	O
alone	O
should	O
not	O
preclude	O
the	O
use	O
of	O
chemotherapy	S-Planned_process
in	O
stage	O
IV	O
colorectal	B-Pathological_formation
cancer	E-Pathological_formation
,	O
although	O
the	O
ability	O
to	O
tolerate	O
drug	O
-	O
related	O
toxicity	O
may	O
be	O
a	O
consideration	O
.	O

The	O
optimal	O
duration	O
of	O
chemotherapy	S-Planned_process
in	O
patients	S-Organism
with	O
early	O
and	O
metastatic	O
colorectal	B-Pathological_formation
cancer	E-Pathological_formation
is	O
unclear	O
.	O

CONCLUSION	O
:	O
The	O
optimal	O
approach	O
to	O
the	O
treatment	S-Planned_process
of	O
colorectal	B-Pathological_formation
cancer	E-Pathological_formation
depends	O
on	O
several	O
considerations	O
,	O
including	O
patient	S-Organism
-	O
specific	O
factors	O
.	O

Serum	S-Organism_substance
and	O
urine	S-Organism_substance
levels	O
of	O
interleukin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	E-Gene_or_gene_product
in	O
patients	S-Organism
with	O
non	B-Pathological_formation
-	I-Pathological_formation
Hodgkin	I-Pathological_formation
'	I-Pathological_formation
s	I-Pathological_formation
lymphoma	E-Pathological_formation
.	O

Angiogenesis	S-Blood_vessel_development
plays	B-Regulation
an	I-Regulation
important	I-Regulation
role	E-Regulation
in	O
many	O
types	O
of	O
cancer	S-Pathological_formation
.	O

Interleukin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	E-Gene_or_gene_product
(	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	E-Gene_or_gene_product
)	O
is	O
known	O
to	O
be	O
a	O
pro	O
-	O
inflammatory	O
and	O
pro	O
-	O
angiogenic	S-Blood_vessel_development
cytokine	O
,	O
and	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	E-Gene_or_gene_product
has	O
been	O
reported	O
to	O
be	O
associated	S-Regulation
with	O
tumor	S-Pathological_formation
progression	S-Development
,	O
prognosis	O
and	O
survival	O
in	O
several	O
types	O
of	O
cancers	S-Pathological_formation
.	O

However	O
,	O
the	O
role	S-Regulation
of	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	E-Gene_or_gene_product
in	O
non	B-Pathological_formation
-	I-Pathological_formation
Hodgkin	I-Pathological_formation
'	I-Pathological_formation
s	I-Pathological_formation
lymphoma	E-Pathological_formation
(	O
NHL	S-Pathological_formation
)	O
has	O
not	O
been	O
fully	O
determined	O
.	O

Here	O
,	O
we	O
evaluated	O
the	O
usefulness	O
of	O
measuring	O
serum	S-Organism_substance
and	O
urine	S-Organism_substance
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	E-Gene_or_gene_product
levels	O
in	O
patients	S-Organism
with	O
NHL	S-Pathological_formation
.	O

We	O
developed	O
reference	O
intervals	O
for	O
serum	S-Organism_substance
and	O
urine	S-Organism_substance
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	E-Gene_or_gene_product
level	O
in	O
131	O
control	O
individuals	O
.	O

We	O
measured	O
serum	S-Organism_substance
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	E-Gene_or_gene_product
and	O
urine	S-Organism_substance
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	E-Gene_or_gene_product
levels	O
in	O
patients	S-Organism
with	O
NHL	S-Pathological_formation
,	O
and	O
we	O
compared	O
the	O
concentrations	O
with	O
those	O
of	O
control	O
individuals	O
.	O

The	O
reference	O
intervals	O
for	O
serum	S-Organism_substance
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	E-Gene_or_gene_product
and	O
urine	S-Organism_substance
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	E-Gene_or_gene_product
corrected	O
by	O
creatinine	S-Drug_or_compound
(	O
Cr	S-Drug_or_compound
)	O
were	O
15	O
.	O
9	O
-	O
430	O
.	O
3	O
pg	O
/	O
mL	O
and	O
0	O
.	O
0	O
-	O
28	O
.	O
4	O
pg	O
/	O
mg	O
Cr	S-Drug_or_compound
,	O
respectively	O
.	O

The	O
concentrations	O
of	O
urine	S-Organism_substance
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	E-Gene_or_gene_product
/	O
Cr	S-Drug_or_compound
were	O
significantly	O
higher	O
in	O
patients	S-Organism
than	O
in	O
controls	O
(	O
48	O
.	O
9	O
+	O
/	O
-	O
194	O
.	O
4	O
vs	O
.	O
5	O
.	O
2	O
+	O
/	O
-	O
13	O
.	O
8	O
pg	O
/	O
mg	O
Cr	S-Drug_or_compound
,	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O

However	O
,	O
there	O
were	O
no	O
significant	O
differences	O
in	O
serum	S-Organism_substance
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	E-Gene_or_gene_product
concentrations	O
between	O
NHL	S-Pathological_formation
patients	S-Organism
and	O
controls	O
(	O
159	O
.	O
2	O
+	O
/	O
-	O
40	O
.	O
4	O
vs	O
.	O
99	O
.	O
6	O
+	O
/	O
-	O
107	O
.	O
1	O
pg	O
/	O
mL	O
;	O
P	O
=	O
0	O
.	O
099	O
)	O
.	O

Receiver	O
operating	O
characteristic	O
(	O
ROC	O
)	O
analysis	O
gave	O
0	O
.	O
83	O
and	O
0	O
.	O
43	O
ROC	O
area	O
values	O
for	O
urine	S-Organism_substance
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	E-Gene_or_gene_product
/	O
Cr	S-Drug_or_compound
and	O
serum	S-Organism_substance
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	E-Gene_or_gene_product
,	O
respectively	O
.	O

There	O
was	O
no	O
correlation	O
between	O
the	O
serum	S-Organism_substance
and	O
urine	S-Organism_substance
concentrations	O
of	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	E-Gene_or_gene_product
and	O
clinical	O
variables	O
,	O
the	O
only	O
exception	O
being	O
the	O
international	O
prognostic	O
index	O
(	O
IPI	O
)	O
,	O
which	O
showed	O
a	O
marginal	O
correlation	O
with	O
urine	S-Organism_substance
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	E-Gene_or_gene_product
/	O
Cr	S-Drug_or_compound
levels	O
(	O
P	O
=	O
0	O
.	O
07	O
)	O
.	O

This	O
study	O
indicated	O
that	O
urine	S-Organism_substance
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	E-Gene_or_gene_product
/	O
Cr	S-Drug_or_compound
levels	O
might	O
be	O
useful	O
as	O
a	O
diagnostic	O
marker	O
of	O
NHL	S-Pathological_formation
.	O

Adenomatoid	B-Pathological_formation
tumour	E-Pathological_formation
of	O
the	O
liver	S-Organ
.	O

An	O
unusual	O
primary	O
adenomatoid	B-Pathological_formation
tumour	E-Pathological_formation
arising	O
in	O
the	O
normal	O
liver	S-Organ
is	O
described	O
.	O

Hepatectomy	S-Planned_process
was	O
performed	O
,	O
and	O
the	O
patient	S-Organism
is	O
alive	O
and	O
free	O
of	O
disease	O
1	O
year	O
postsurgery	O
.	O

Grossly	O
,	O
the	O
tumour	S-Pathological_formation
showed	O
a	O
haemorrhagic	O
cut	O
surface	O
with	O
numerous	O
microcystic	B-Pathological_formation
structures	E-Pathological_formation
.	O

Histological	O
examination	O
revealed	O
cystic	O
or	O
angiomatoid	S-Blood_vessel_development
spaces	O
of	O
various	O
sizes	O
lined	O
by	O
cuboidal	O
,	O
low	O
-	O
columnar	O
,	O
or	O
flattened	S-Planned_process
epithelioid	B-Cell
cells	E-Cell
with	O
vacuolated	B-Cellular_component
cytoplasm	E-Cellular_component
and	O
round	O
to	O
oval	O
nuclei	S-Cellular_component
.	O

The	O
epithelioid	B-Cell
cells	E-Cell
were	O
entirely	O
supported	O
by	O
proliferated	S-Growth
capillaries	S-Tissue
and	O
arteries	S-Multi-tissue_structure
together	O
with	O
collagenous	B-Tissue
stroma	E-Tissue
.	O

Immunohistochemical	O
studies	O
showed	O
that	O
the	O
epithelioid	B-Cell
cells	E-Cell
were	O
strongly	O
positive	O
for	O
a	O
broad	O
spectrum	O
of	O
cytokeratins	S-Gene_or_gene_product
(	O
AE1	S-Gene_or_gene_product
/	O
AE3	S-Gene_or_gene_product
,	O
CAM5	B-Gene_or_gene_product
.	I-Gene_or_gene_product
2	E-Gene_or_gene_product
,	O
epithelial	B-Gene_or_gene_product
membrane	I-Gene_or_gene_product
antigen	E-Gene_or_gene_product
and	O
cytokeratin	B-Gene_or_gene_product
7	E-Gene_or_gene_product
)	O
and	O
mesothelial	S-Tissue
markers	O
(	O
calretinin	S-Gene_or_gene_product
,	O
Wilms	B-Gene_or_gene_product
'	I-Gene_or_gene_product
tumour	I-Gene_or_gene_product
1	E-Gene_or_gene_product
and	O
D2	B-Gene_or_gene_product
-	I-Gene_or_gene_product
40	E-Gene_or_gene_product
)	O
.	O

These	O
cells	S-Cell
were	O
negative	O
for	O
Hep	B-Gene_or_gene_product
par	I-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
,	O
carcinoembryonic	B-Gene_or_gene_product
antigen	E-Gene_or_gene_product
,	O
neural	B-Gene_or_gene_product
cell	I-Gene_or_gene_product
adhesion	I-Gene_or_gene_product
molecule	E-Gene_or_gene_product
,	O
CD34	S-Gene_or_gene_product
,	O
CD31	S-Gene_or_gene_product
and	O
HMB45	S-Gene_or_gene_product
.	O

Atypically	O
,	O
abundant	O
capillaries	S-Tissue
were	O
observed	O
;	O
however	O
,	O
the	O
cystic	S-Pathological_formation
proliferation	S-Cell_proliferation
of	O
epithelioid	B-Cell
cells	E-Cell
with	O
vacuoles	S-Cellular_component
and	O
immunohistochemical	O
profile	O
of	O
the	O
epithelioid	B-Tissue
element	E-Tissue
were	O
consistent	O
with	O
hepatic	B-Pathological_formation
adenomatoid	I-Pathological_formation
tumour	E-Pathological_formation
.	O

Research	O
advances	O
of	O
endostatin	S-Gene_or_gene_product
and	O
its	O
short	O
internal	O
fragments	O
.	O

Endostatin	S-Gene_or_gene_product
,	O
the	O
C	O
-	O
terminal	O
fragment	O
of	O
collagen	B-Gene_or_gene_product
XVIII	E-Gene_or_gene_product
,	O
is	O
a	O
potent	O
angiogenesis	S-Blood_vessel_development
inhibitor	O
.	O

At	O
present	O
,	O
there	O
are	O
a	O
large	O
number	O
of	O
research	O
papers	O
on	O
endostatin	S-Gene_or_gene_product
.	O

However	O
,	O
the	O
action	O
mechanism	O
of	O
endostatin	S-Gene_or_gene_product
is	O
still	O
a	O
matter	O
of	O
ongoing	O
discussion	O
.	O

The	O
objective	O
of	O
this	O
review	O
is	O
to	O
elucidate	O
its	O
origin	O
and	O
elementary	O
structure	O
,	O
and	O
to	O
discuss	O
its	O
structure	O
basis	O
of	O
activity	O
and	O
action	O
mechanisms	O
based	O
on	O
the	O
latest	O
research	O
.	O

Furthermore	O
,	O
some	O
published	O
studies	O
reporting	O
the	O
antiangiogenic	S-Blood_vessel_development
effects	S-Negative_regulation
of	O
endostatin	S-Gene_or_gene_product
-	O
derived	O
peptides	O
were	O
also	O
reviewed	O
.	O

It	O
is	O
proposed	O
that	O
the	O
amino	O
acid	O
sequence	O
of	O
endostatin	S-Gene_or_gene_product
contains	O
both	O
angiosuppressive	S-Blood_vessel_development
and	O
angiostimulatory	S-Blood_vessel_development
domains	O
.	O

Short	O
endostatin	S-Gene_or_gene_product
fragments	O
may	O
be	O
exploited	O
as	O
a	O
new	O
angiogenesis	S-Blood_vessel_development
inhibitor	O
for	O
therapeutic	O
applications	O
,	O
in	O
substitution	O
of	O
the	O
full	O
length	O
endostatin	S-Gene_or_gene_product
.	O

These	O
studies	O
on	O
endostatin	S-Gene_or_gene_product
fragments	O
also	O
shed	O
light	O
on	O
our	O
understanding	O
of	O
the	O
molecular	O
action	O
mechanisms	O
of	O
endostatin	S-Gene_or_gene_product
.	O

Microscopic	O
technique	O
for	O
the	O
detection	O
of	O
nitric	B-Drug_or_compound
oxide	E-Drug_or_compound
-	O
dependent	S-Positive_regulation
angiogenesis	S-Blood_vessel_development
in	O
an	O
animal	O
model	O
.	O

Nitric	B-Drug_or_compound
oxide	E-Drug_or_compound
(	O
NO	S-Drug_or_compound
)	O
plays	O
an	O
important	O
role	O
in	O
maintaining	O
vascular	O
homeostasis	O
.	O

The	O
importance	O
of	O
NO	S-Drug_or_compound
in	O
the	O
vasculature	S-Anatomical_system
is	O
demonstrated	O
by	O
several	O
experimental	O
conditions	O
,	O
such	O
as	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
(	O
VEGF	S-Gene_or_gene_product
)	O
-	O
induced	S-Positive_regulation
angiogenesis	S-Blood_vessel_development
.	O

Thus	O
,	O
the	O
NO	S-Drug_or_compound
metabolic	B-Pathway
pathway	E-Pathway
in	O
endothelial	B-Cell
cells	E-Cell
could	O
be	O
one	O
of	O
the	O
main	O
contributing	O
factors	O
for	O
angiogenesis	S-Blood_vessel_development
.	O

Although	O
several	O
methods	O
have	O
been	O
used	O
for	O
measuring	O
in	O
vitro	O
angiogenesis	S-Blood_vessel_development
,	O
a	O
proper	O
technique	O
has	O
not	O
been	O
developed	O
for	O
identifying	O
in	O
vivo	O
NO	S-Drug_or_compound
-	O
dependent	S-Positive_regulation
angiogenesis	S-Blood_vessel_development
.	O

This	O
chapter	O
provides	O
a	O
new	O
intravital	O
microscopic	O
method	O
for	O
detecting	O
and	O
measuring	O
NO	S-Drug_or_compound
-	O
dependent	S-Positive_regulation
angiogenesis	S-Blood_vessel_development
in	O
a	O
mouse	S-Organism
model	O
.	O

This	O
technique	O
showed	O
strong	O
abdominal	O
neovascularization	S-Blood_vessel_development
in	O
wild	O
-	O
type	O
mice	S-Organism
,	O
but	O
not	O
eNOS	B-Organism
knockout	I-Organism
mice	E-Organism
,	O
locally	O
injected	S-Planned_process
with	O
VEGF	S-Gene_or_gene_product
,	O
as	O
well	O
as	O
stimulation	S-Positive_regulation
of	O
angiogenesis	S-Blood_vessel_development
in	O
NO	S-Drug_or_compound
donor	O
-	O
injected	S-Planned_process
mice	S-Organism
.	O

This	O
technique	O
also	O
revealed	O
the	O
inhibitory	B-Negative_regulation
effect	E-Negative_regulation
of	O
the	O
NOS	S-Gene_or_gene_product
inhibitor	O
N	B-Drug_or_compound
(	I-Drug_or_compound
G	I-Drug_or_compound
)	I-Drug_or_compound
-	I-Drug_or_compound
iminoethyl	I-Drug_or_compound
-	I-Drug_or_compound
L	I-Drug_or_compound
-	I-Drug_or_compound
ornithine	E-Drug_or_compound
in	O
VEGF	S-Gene_or_gene_product
-	O
mediated	S-Positive_regulation
in	O
vivo	O
angiogenesis	S-Blood_vessel_development
.	O

This	O
chapter	O
describes	O
intravital	O
microscopy	O
as	O
a	O
new	O
imaging	O
technique	O
for	O
detecting	O
NO	S-Drug_or_compound
-	O
dependent	S-Positive_regulation
angiogenesis	S-Blood_vessel_development
in	O
an	O
animal	O
model	O
.	O

The	O
tyrosine	O
kinase	O
inhibitor	O
cediranib	S-Drug_or_compound
blocks	S-Negative_regulation
ligand	O
-	O
induced	S-Positive_regulation
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
receptor	I-Gene_or_gene_product
-	I-Gene_or_gene_product
3	E-Gene_or_gene_product
activity	O
and	O
lymphangiogenesis	O
.	O

Solid	B-Pathological_formation
tumors	E-Pathological_formation
express	O
a	O
range	O
of	O
factors	O
required	O
to	O
sustain	O
their	O
growth	O
and	O
promote	O
their	O
dissemination	O
.	O

Among	O
these	O
are	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
-	I-Gene_or_gene_product
A	E-Gene_or_gene_product
(	O
VEGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
A	E-Gene_or_gene_product
)	O
,	O
the	O
key	O
angiogenic	S-Blood_vessel_development
stimulant	O
,	O
and	O
VEGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
C	E-Gene_or_gene_product
,	O
a	O
primary	O
mediator	O
of	O
lymphangiogenesis	O
.	O

Small	O
molecule	O
tyrosine	B-Drug_or_compound
kinase	I-Drug_or_compound
inhibitors	E-Drug_or_compound
offer	O
the	O
potential	O
to	O
inhibit	O
more	O
than	O
one	O
kinase	O
and	O
impede	S-Negative_regulation
tumor	S-Pathological_formation
growth	S-Growth
by	O
multiple	O
mechanisms	O
.	O

However	O
,	O
their	O
potency	O
toward	O
individual	O
targets	O
can	O
vary	O
.	O

Cediranib	S-Drug_or_compound
(	O
RECENTIN	S-Drug_or_compound
;	O
AZD2171	S-Drug_or_compound
)	O
is	O
an	O
inhibitor	O
of	O
VEGF	S-Gene_or_gene_product
signaling	S-Pathway
that	O
has	O
been	O
shown	O
in	O
experimental	O
models	O
to	O
prevent	S-Negative_regulation
VEGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
A	E-Gene_or_gene_product
-	O
induced	S-Positive_regulation
angiogenesis	S-Blood_vessel_development
and	O
primary	O
tumor	S-Pathological_formation
growth	S-Growth
,	O
yet	O
the	O
effects	S-Regulation
of	O
cediranib	S-Drug_or_compound
on	O
VEGF	B-Gene_or_gene_product
receptor	I-Gene_or_gene_product
(	I-Gene_or_gene_product
VEGFR	I-Gene_or_gene_product
)	I-Gene_or_gene_product
-	I-Gene_or_gene_product
3	E-Gene_or_gene_product
-	O
mediated	S-Regulation
endothelial	B-Cell
cell	E-Cell
function	O
and	O
lymphangiogenesis	O
are	O
unknown	O
.	O

To	O
better	O
understand	O
the	O
activity	O
of	O
cediranib	S-Drug_or_compound
against	O
VEGFR	B-Gene_or_gene_product
-	I-Gene_or_gene_product
3	E-Gene_or_gene_product
and	O
its	O
associated	O
signaling	O
events	O
compared	O
with	O
its	O
activity	O
against	O
VEGFR	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
,	O
we	O
used	O
the	O
receptor	O
-	O
specific	O
ligands	O
VEGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
E	E-Gene_or_gene_product
and	O
VEGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
C156S	E-Gene_or_gene_product
.	O

In	O
human	S-Organism
endothelial	B-Cell
cells	E-Cell
,	O
cediranib	S-Drug_or_compound
inhibited	S-Negative_regulation
VEGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
E	E-Gene_or_gene_product
-	O
induced	S-Positive_regulation
phosphorylation	S-Phosphorylation
of	O
VEGFR	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
and	O
VEGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
C156S	E-Gene_or_gene_product
-	O
induced	S-Positive_regulation
phosphorylation	S-Phosphorylation
of	O
VEGFR	B-Gene_or_gene_product
-	I-Gene_or_gene_product
3	E-Gene_or_gene_product
at	O
concentrations	O
of	O
less	O
than	O
/	O
=	O
1nmol	O
/	O
L	O
and	O
inhibited	O
activation	O
of	O
downstream	O
signaling	O
molecules	O
.	O

Additionally	O
,	O
cediranib	S-Drug_or_compound
blocked	S-Negative_regulation
VEGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
C156S	E-Gene_or_gene_product
-	O
induced	S-Positive_regulation
and	O
VEGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
E	E-Gene_or_gene_product
-	O
induced	S-Positive_regulation
proliferation	S-Cell_proliferation
,	O
survival	S-Death
,	O
and	O
migration	S-Localization
of	O
lymphatic	S-Cell
and	O
blood	B-Cell
vascular	I-Cell
endothelial	I-Cell
cells	E-Cell
.	O

In	O
vivo	O
,	O
cediranib	S-Drug_or_compound
(	O
6	O
mg	O
/	O
kg	O
/	O
d	O
)	O
prevented	S-Negative_regulation
angiogenesis	S-Blood_vessel_development
and	O
lymphangiogenesis	O
induced	S-Positive_regulation
by	O
VEGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
E	E-Gene_or_gene_product
-	O
expressing	S-Gene_expression
and	O
VEGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
C156S	E-Gene_or_gene_product
-	O
expressing	S-Gene_expression
adenoviruses	S-Organism
,	O
respectively	O
.	O

Cediranib	S-Drug_or_compound
(	O
6	O
mg	O
/	O
kg	O
/	O
day	O
)	O
also	O
blocked	S-Negative_regulation
angiogenesis	S-Blood_vessel_development
and	O
lymphangiogenesis	O
induced	O
by	O
adenoviruses	S-Organism
expressing	S-Gene_expression
VEGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
A	E-Gene_or_gene_product
or	O
VEGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
C	E-Gene_or_gene_product
and	O
compromised	O
the	O
blood	S-Organism_substance
and	O
lymphatic	B-Multi-tissue_structure
vasculatures	E-Multi-tissue_structure
of	O
VEGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
C	E-Gene_or_gene_product
-	O
expressing	S-Gene_expression
tumors	S-Pathological_formation
.	O

Cediranib	S-Drug_or_compound
may	O
,	O
therefore	O
,	O
be	O
an	O
effective	O
means	O
of	O
preventing	S-Negative_regulation
tumor	S-Pathological_formation
progression	S-Development
,	O
not	O
only	O
by	O
inhibiting	S-Negative_regulation
VEGFR	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
activity	O
and	O
angiogenesis	S-Blood_vessel_development
,	O
but	O
also	O
by	O
concomitantly	O
inhibiting	S-Negative_regulation
VEGFR	B-Gene_or_gene_product
-	I-Gene_or_gene_product
3	E-Gene_or_gene_product
activity	O
and	O
lymphangiogenesis	O
.	O

Contemporary	O
perspectives	O
on	O
vital	O
pulp	S-Tissue
therapy	S-Planned_process
:	O
views	O
from	O
the	O
endodontists	O
and	O
pediatric	O
dentists	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
level	O
of	O
agreement	O
between	O
pediatric	O
dentists	O
and	O
endodontists	O
at	O
a	O
pulp	S-Tissue
therapy	S-Planned_process
symposium	O
conjointly	O
sponsored	O
by	O
the	O
American	O
Association	O
of	O
Endodontists	O
(	O
AAE	O
)	O
and	O
the	O
American	O
Academy	O
of	O
Pediatric	O
Dentistry	O
(	O
AAPD	O
)	O
on	O
November	O
2	O
-	O
3	O
,	O
2007	O
.	O

Presymposium	O
and	O
postsymposium	O
tests	O
were	O
administered	O
,	O
and	O
respondent	O
answers	O
were	O
compared	O
between	O
pediatric	O
dentists	O
and	O
endodontists	O
.	O

Opinions	O
on	O
3	O
areas	O
were	O
sought	O
:	O
pulp	S-Tissue
therapy	S-Planned_process
for	O
cariously	O
involved	O
primary	O
teeth	S-Organ
;	O
indirect	O
pulp	S-Tissue
treatment	S-Planned_process
(	O
IPT	O
)	O
for	O
cariously	O
involved	O
immature	O
permanent	O
teeth	S-Organ
;	O
and	O
innovative	O
treatment	O
options	O
including	O
pulpal	S-Tissue
revascularization	S-Blood_vessel_development
and	O
regeneration	S-Development
.	O

Results	O
were	O
analyzed	O
with	O
chi2	O
tests	O
.	O

Comparisons	O
of	O
presymposium	O
and	O
postsymposium	O
responses	O
and	O
between	O
the	O
2	O
groups	O
of	O
attendees	O
indicated	O
that	O
the	O
pediatric	O
dentistry	O
and	O
endodontic	O
communities	O
agree	O
that	O
formocresol	S-Drug_or_compound
will	O
be	O
replaced	O
as	O
a	O
primary	O
tooth	S-Organ
pulpotomy	O
agent	O
,	O
that	O
mineral	B-Drug_or_compound
trioxide	E-Drug_or_compound
is	O
the	O
first	O
choice	O
to	O
take	O
its	O
place	O
,	O
that	O
IPT	O
in	O
primary	O
teeth	S-Organ
holds	O
hope	O
as	O
a	O
replacement	O
for	O
pulpotomy	O
,	O
and	O
that	O
IPT	O
is	O
an	O
acceptable	O
pulp	S-Tissue
therapy	S-Planned_process
technique	O
for	O
cariously	O
involved	O
young	O
permanent	O
teeth	S-Organ
.	O

Both	O
groups	O
believe	O
that	O
pulp	S-Tissue
revascularization	S-Blood_vessel_development
and	O
regeneration	S-Development
will	O
be	O
viable	O
treatment	O
modalities	O
in	O
the	O
future	O
.	O

The	O
AAE	O
and	O
the	O
AAPD	O
are	O
positioned	O
to	O
begin	O
preparation	O
of	O
best	O
practice	O
guidelines	O
that	O
share	O
common	O
language	O
and	O
treatment	O
recommendations	O
for	O
pulp	S-Tissue
therapies	S-Planned_process
performed	O
by	O
both	O
specialties	O
.	O

Neurotrophin	B-Gene_or_gene_product
p75	I-Gene_or_gene_product
receptor	E-Gene_or_gene_product
(	O
p75NTR	S-Gene_or_gene_product
)	O
promotes	S-Positive_regulation
endothelial	B-Cell
cell	E-Cell
apoptosis	S-Death
and	O
inhibits	S-Negative_regulation
angiogenesis	S-Blood_vessel_development
:	O
implications	O
for	O
diabetes	O
-	O
induced	O
impaired	S-Negative_regulation
neovascularization	S-Blood_vessel_development
in	O
ischemic	O
limb	B-Organ
muscles	E-Organ
.	O

Diabetes	O
impairs	S-Negative_regulation
endothelial	S-Cell
function	O
and	O
reparative	O
neovascularization	S-Blood_vessel_development
.	O

The	O
p75	B-Gene_or_gene_product
receptor	I-Gene_or_gene_product
of	I-Gene_or_gene_product
neurotrophins	E-Gene_or_gene_product
(	O
p75	B-Gene_or_gene_product
(	I-Gene_or_gene_product
NTR	I-Gene_or_gene_product
)	E-Gene_or_gene_product
)	O
,	O
which	O
is	O
scarcely	O
present	O
in	O
healthy	O
endothelial	B-Cell
cells	E-Cell
(	O
ECs	S-Cell
)	O
,	O
becomes	O
strongly	O
expressed	S-Gene_expression
by	O
capillary	B-Cell
ECs	E-Cell
after	O
induction	O
of	O
peripheral	O
ischemia	O
in	O
type	O
-	O
1	O
diabetic	O
mice	S-Organism
.	O

Here	O
,	O
we	O
show	O
that	O
gene	O
transfer	O
-	O
induced	S-Positive_regulation
p75	B-Gene_or_gene_product
(	I-Gene_or_gene_product
NTR	I-Gene_or_gene_product
)	E-Gene_or_gene_product
expression	S-Gene_expression
impairs	S-Negative_regulation
the	O
survival	S-Death
,	O
proliferation	S-Cell_proliferation
,	O
migration	S-Localization
,	O
and	O
adhesion	S-Binding
capacities	O
of	O
cultured	S-Planned_process
ECs	S-Cell
and	O
endothelial	B-Cell
progenitor	I-Cell
cells	E-Cell
(	O
EPCs	S-Cell
)	O
and	O
inhibits	S-Negative_regulation
angiogenesis	S-Blood_vessel_development
in	O
vitro	O
.	O

Moreover	O
,	O
intramuscular	O
p75	B-Gene_or_gene_product
(	I-Gene_or_gene_product
NTR	I-Gene_or_gene_product
)	E-Gene_or_gene_product
gene	O
delivery	S-Localization
impairs	S-Negative_regulation
neovascularization	S-Blood_vessel_development
and	O
blood	S-Organism_substance
flow	O
recovery	O
in	O
a	O
mouse	S-Organism
model	O
of	O
limb	S-Organism_subdivision
ischemia	O
.	O

These	O
disturbed	O
functions	O
are	O
associated	O
with	O
suppression	O
of	O
signaling	O
mechanisms	O
implicated	O
in	O
EC	S-Cell
survival	S-Death
and	O
angiogenesis	S-Blood_vessel_development
.	O

In	O
fact	O
,	O
p75	B-Gene_or_gene_product
(	I-Gene_or_gene_product
NTR	I-Gene_or_gene_product
)	E-Gene_or_gene_product
depresses	S-Negative_regulation
the	O
VEGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
A	E-Gene_or_gene_product
/	O
Akt	S-Gene_or_gene_product
/	O
eNOS	S-Gene_or_gene_product
/	O
NO	S-Drug_or_compound
pathway	S-Pathway
and	O
additionally	O
reduces	S-Negative_regulation
the	O
mRNA	O
levels	O
of	O
ITGB1	S-Gene_or_gene_product
[	O
beta	B-Gene_or_gene_product
(	I-Gene_or_gene_product
1	I-Gene_or_gene_product
)	I-Gene_or_gene_product
integrin	E-Gene_or_gene_product
]	O
,	O
BIRC5	S-Gene_or_gene_product
(	O
survivin	S-Gene_or_gene_product
)	O
,	O
PTTG1	S-Gene_or_gene_product
(	O
securin	S-Gene_or_gene_product
)	O
and	O
VEZF1	S-Gene_or_gene_product
.	O

Diabetic	O
mice	S-Organism
,	O
which	O
typically	O
show	O
impaired	O
postischemic	O
muscular	O
neovascularization	S-Blood_vessel_development
and	O
blood	S-Organism_substance
perfusion	O
recovery	O
,	O
have	O
these	O
defects	O
corrected	O
by	O
intramuscular	O
gene	O
transfer	O
of	O
a	O
dominant	O
negative	O
mutant	O
form	O
of	O
p75	B-Gene_or_gene_product
(	I-Gene_or_gene_product
NTR	I-Gene_or_gene_product
)	E-Gene_or_gene_product
.	O

Collectively	O
,	O
our	O
data	O
newly	O
demonstrate	O
the	O
antiangiogenic	S-Blood_vessel_development
action	S-Negative_regulation
of	O
p75	B-Gene_or_gene_product
(	I-Gene_or_gene_product
NTR	I-Gene_or_gene_product
)	E-Gene_or_gene_product
and	O
open	O
new	O
avenues	O
for	O
the	O
therapeutic	O
use	O
of	O
p75	B-Gene_or_gene_product
(	I-Gene_or_gene_product
NTR	I-Gene_or_gene_product
)	E-Gene_or_gene_product
inhibition	S-Negative_regulation
to	O
combat	O
diabetes	O
-	O
induced	S-Positive_regulation
microvascular	S-Tissue
liabilities	O
.	O

Tumor	B-Cell
endothelial	I-Cell
cell	E-Cell
targeted	S-Planned_process
cyclic	B-Drug_or_compound
RGD	I-Drug_or_compound
-	I-Drug_or_compound
modified	I-Drug_or_compound
heparin	I-Drug_or_compound
derivative	E-Drug_or_compound
:	O
inhibition	S-Negative_regulation
of	O
angiogenesis	S-Blood_vessel_development
and	O
tumor	S-Pathological_formation
growth	S-Growth
.	O

PURPOSE	O
:	O
We	O
prepared	O
tumor	B-Tissue
endothelium	E-Tissue
targeted	S-Planned_process
cRGD	B-Drug_or_compound
-	I-Drug_or_compound
modified	I-Drug_or_compound
heparin	I-Drug_or_compound
derivative	E-Drug_or_compound
(	O
cRGD	B-Drug_or_compound
-	I-Drug_or_compound
HL	E-Drug_or_compound
)	O
by	O
coupling	O
heparin	B-Drug_or_compound
-	I-Drug_or_compound
lithocholic	I-Drug_or_compound
acid	E-Drug_or_compound
(	O
HL	S-Drug_or_compound
)	O
with	O
cRGDyK	S-Drug_or_compound
,	O
and	O
evaluated	O
inhibition	S-Negative_regulation
effects	O
of	O
cRGD	B-Drug_or_compound
-	I-Drug_or_compound
HL	E-Drug_or_compound
on	O
angiogenesis	S-Blood_vessel_development
and	O
tumor	S-Pathological_formation
growth	S-Growth
.	O

METHODS	O
:	O
To	O
evaluate	O
antiangiogenic	S-Blood_vessel_development
activity	S-Negative_regulation
of	O
cRGD	B-Drug_or_compound
-	I-Drug_or_compound
HL	E-Drug_or_compound
,	O
we	O
performed	O
tests	O
on	O
endothelial	B-Cell
cell	E-Cell
adhesion	S-Binding
and	O
migration	S-Localization
to	O
vitronectin	S-Gene_or_gene_product
,	O
tube	S-Tissue
formation	S-Development
,	O
binding	S-Binding
affinity	O
to	O
purified	O
alpha	B-Gene_or_gene_product
(	I-Gene_or_gene_product
v	I-Gene_or_gene_product
)	I-Gene_or_gene_product
beta	I-Gene_or_gene_product
(	I-Gene_or_gene_product
3	I-Gene_or_gene_product
)	I-Gene_or_gene_product
integrin	E-Gene_or_gene_product
,	O
and	O
in	O
vivo	O
Matrigel	O
plug	O
assay	O
.	O

The	O
antitumor	S-Pathological_formation
activity	S-Negative_regulation
of	O
cRGD	B-Drug_or_compound
-	I-Drug_or_compound
HL	E-Drug_or_compound
was	O
also	O
evaluated	O
by	O
monitoring	O
tumor	S-Pathological_formation
growth	S-Growth
and	O
microvessel	S-Tissue
formation	S-Development
in	O
squamous	B-Pathological_formation
cell	I-Pathological_formation
carcinoma	I-Pathological_formation
(	I-Pathological_formation
SCC7	I-Pathological_formation
)	I-Pathological_formation
tumor	E-Pathological_formation
.	O

RESULTS	O
:	O
The	O
cRGD	B-Drug_or_compound
-	I-Drug_or_compound
HL	E-Drug_or_compound
significantly	O
inhibited	S-Negative_regulation
adhesion	S-Binding
and	O
migration	S-Localization
of	O
endothelial	B-Cell
cells	E-Cell
to	O
vitronectin	S-Gene_or_gene_product
,	O
and	O
tubular	B-Tissue
structures	E-Tissue
of	O
endothelial	B-Cell
cells	E-Cell
.	O

Compared	O
to	O
cRGDyK	S-Drug_or_compound
and	O
HL	S-Drug_or_compound
,	O
cRGD	B-Drug_or_compound
-	I-Drug_or_compound
HL	E-Drug_or_compound
has	O
high	O
binding	S-Binding
affinity	O
to	O
purified	O
alpha	B-Gene_or_gene_product
(	I-Gene_or_gene_product
v	I-Gene_or_gene_product
)	I-Gene_or_gene_product
beta	I-Gene_or_gene_product
(	I-Gene_or_gene_product
3	I-Gene_or_gene_product
)	I-Gene_or_gene_product
integrin	E-Gene_or_gene_product
.	O

The	O
enhanced	S-Positive_regulation
antiangiogenic	S-Blood_vessel_development
effect	S-Negative_regulation
of	O
cRGD	B-Drug_or_compound
-	I-Drug_or_compound
HL	E-Drug_or_compound
was	O
confirmed	O
in	O
Matrigel	O
assay	O
by	O
showing	O
the	O
significant	O
inhibition	S-Negative_regulation
of	O
bFGF	S-Gene_or_gene_product
-	O
driven	S-Positive_regulation
angiogenesis	S-Blood_vessel_development
and	O
blood	B-Multi-tissue_structure
vessel	E-Multi-tissue_structure
formation	S-Development
.	O

It	O
was	O
thought	O
that	O
potent	O
antiangiogenic	S-Blood_vessel_development
effect	S-Negative_regulation
of	O
cRGD	B-Drug_or_compound
-	I-Drug_or_compound
HL	E-Drug_or_compound
was	O
probably	O
due	O
to	O
the	O
interference	S-Negative_regulation
of	O
alpha	B-Gene_or_gene_product
(	I-Gene_or_gene_product
v	I-Gene_or_gene_product
)	I-Gene_or_gene_product
beta	I-Gene_or_gene_product
(	I-Gene_or_gene_product
3	I-Gene_or_gene_product
)	E-Gene_or_gene_product
-	O
mediated	O
interaction	S-Binding
,	O
resulting	O
in	O
the	O
enhanced	S-Positive_regulation
antitumoral	O
activity	O
against	S-Negative_regulation
SCC7	B-Pathological_formation
tumor	E-Pathological_formation
.	O

CONCLUSION	O
:	O
These	O
results	O
demonstrated	O
that	O
cRGD	B-Drug_or_compound
-	I-Drug_or_compound
modified	I-Drug_or_compound
heparin	I-Drug_or_compound
derivative	E-Drug_or_compound
enhanced	S-Positive_regulation
anti	O
-	O
angiotherapeutic	S-Blood_vessel_development
effects	S-Negative_regulation
against	O
solid	B-Pathological_formation
tumor	E-Pathological_formation
,	O
and	O
therefore	O
,	O
it	O
could	O
be	O
applied	O
to	O
treat	S-Planned_process
various	O
cancers	S-Pathological_formation
and	O
angiogenic	S-Blood_vessel_development
diseases	O
as	O
a	O
potent	O
angiogenesis	S-Blood_vessel_development
inhibitor	O
.	O

The	O
role	S-Regulation
of	O
platelet	B-Gene_or_gene_product
-	I-Gene_or_gene_product
derived	I-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
cell	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
/	O
thymidine	B-Gene_or_gene_product
phosphorylase	E-Gene_or_gene_product
in	O
tumor	S-Pathological_formation
behavior	O
.	O

Platelet	B-Gene_or_gene_product
-	I-Gene_or_gene_product
derived	I-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
cell	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
-	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
(	O
PD	B-Gene_or_gene_product
-	I-Gene_or_gene_product
ECGF	E-Gene_or_gene_product
)	O
is	O
similar	O
to	O
the	O
pyrimidine	O
enzyme	O
thymidine	B-Gene_or_gene_product
phosphorylase	E-Gene_or_gene_product
(	O
TP	S-Gene_or_gene_product
)	O
.	O

A	O
high	O
TP	S-Gene_or_gene_product
expression	S-Gene_expression
at	O
tumor	S-Pathological_formation
sites	O
is	O
correlated	O
with	O
tumor	S-Pathological_formation
growth	S-Growth
,	O
induction	S-Positive_regulation
of	O
angiogenesis	S-Blood_vessel_development
,	O
and	O
metastasis	O
.	O

Therefore	O
,	O
high	O
TP	S-Gene_or_gene_product
is	O
most	O
likely	O
associated	O
with	O
a	O
poor	O
prognosis	O
.	O

TP	S-Gene_or_gene_product
is	O
not	O
only	O
expressed	S-Gene_expression
in	O
tumor	B-Cell
cells	E-Cell
but	O
also	O
in	O
tumor	B-Tissue
surrounding	I-Tissue
tissues	E-Tissue
,	O
such	O
as	O
tumor	B-Cell
infiltrating	I-Cell
macrophages	E-Cell
.	O

TP	S-Gene_or_gene_product
catalyzes	S-Regulation
the	O
conversion	O
of	O
thymidine	S-Drug_or_compound
to	O
thymine	S-Drug_or_compound
and	O
doxyribose	B-Drug_or_compound
-	I-Drug_or_compound
1	I-Drug_or_compound
-	I-Drug_or_compound
phosphate	E-Drug_or_compound
(	O
dR	B-Drug_or_compound
-	I-Drug_or_compound
1	I-Drug_or_compound
-	I-Drug_or_compound
P	E-Drug_or_compound
)	O
.	O

The	O
latter	O
in	O
its	O
parent	O
form	O
or	O
in	O
its	O
sugar	S-Drug_or_compound
form	O
,	O
deoxyribose	S-Drug_or_compound
(	O
dR	S-Drug_or_compound
)	O
may	O
play	B-Regulation
a	I-Regulation
role	E-Regulation
in	O
the	O
induction	S-Positive_regulation
of	O
angiogenesis	S-Blood_vessel_development
.	O

It	O
may	O
modulate	O
cellular	O
energy	O
metabolism	O
or	O
be	O
a	O
substrate	O
in	O
a	O
chemical	O
reaction	O
generating	O
reactive	B-Drug_or_compound
oxygen	I-Drug_or_compound
species	E-Drug_or_compound
.	O

L	B-Drug_or_compound
-	I-Drug_or_compound
deoxyribose	E-Drug_or_compound
(	O
L	B-Drug_or_compound
-	I-Drug_or_compound
dR	E-Drug_or_compound
)	O
and	O
thymidine	B-Drug_or_compound
phosphorylase	I-Drug_or_compound
inhibitor	E-Drug_or_compound
(	O
TPI	S-Drug_or_compound
)	O
can	O
reverse	O
these	O
effects	O
.	O

The	O
mechanism	O
of	O
TP	S-Gene_or_gene_product
induction	S-Positive_regulation
is	O
not	O
yet	O
completely	O
clear	O
,	O
but	O
TNF	S-Gene_or_gene_product
,	O
IL10	S-Gene_or_gene_product
and	O
other	O
cytokines	O
have	O
been	O
clearly	O
shown	O
to	O
induce	S-Positive_regulation
its	O
expression	S-Gene_expression
.	O

The	O
various	O
complex	O
interactions	O
of	O
TP	S-Gene_or_gene_product
give	O
it	O
an	O
essential	O
role	O
in	O
cellular	O
functioning	O
and	O
,	O
hence	O
,	O
it	O
is	O
an	O
ideal	O
target	O
in	O
cancer	O
therapy	O
.	O

[	O
Inhibitory	O
effect	O
of	O
adenovirus	S-Organism
-	O
mediated	S-Positive_regulation
endostatin	S-Gene_or_gene_product
gene	B-Planned_process
transfer	E-Planned_process
on	O
transplanted	S-Planned_process
lung	B-Pathological_formation
carcinoma	E-Pathological_formation
in	O
mice	S-Organism
]	O

OBJECTIVE	O
:	O
To	O
investigate	O
the	O
effect	S-Regulation
of	O
adenovirus	S-Organism
-	O
mediated	S-Positive_regulation
endostatin	S-Gene_or_gene_product
gene	B-Planned_process
transfer	E-Planned_process
on	O
transplanted	S-Planned_process
lung	B-Pathological_formation
cancer	E-Pathological_formation
in	O
mice	S-Organism
and	O
its	O
mechanism	O
of	O
action	O
.	O

METHODS	O
:	O
Transplant	S-Planned_process
tumor	S-Pathological_formation
model	O
was	O
induced	O
by	O
subcutaneous	B-Planned_process
inoculation	E-Planned_process
of	O
2	O
x	O
10	O
(	O
6	O
)	O
Lewis	B-Cell
lung	I-Cell
cancer	I-Cell
(	I-Cell
LLC	I-Cell
)	I-Cell
cells	E-Cell
into	O
the	O
back	O
of	O
C57BL	O
/	O
6	O
mice	S-Organism
.	O

The	O
mice	S-Organism
were	O
treated	O
by	O
intratumoral	B-Planned_process
injection	E-Planned_process
of	O
2	O
x	O
10	O
(	O
9	O
)	O
pfu	O
Ad	B-Gene_or_gene_product
-	I-Gene_or_gene_product
mEndostatin	E-Gene_or_gene_product
.	O

The	O
expression	S-Gene_expression
of	O
endostatin	S-Gene_or_gene_product
in	O
situ	O
and	O
its	O
maintaining	O
time	O
were	O
detected	O
by	O
immunohistochemistry	O
and	O
Western	O
Blot	O
,	O
respectively	O
.	O

The	O
endostatin	S-Gene_or_gene_product
level	O
in	O
serum	S-Organism_substance
was	O
determined	O
by	O
ELISA	O
.	O

The	O
inhibition	S-Negative_regulation
of	O
tumor	S-Pathological_formation
growth	S-Growth
and	O
changes	O
of	O
survival	O
were	O
recorded	O
and	O
the	O
microvessel	S-Tissue
density	O
(	O
MVD	O
)	O
was	O
determined	O
by	O
histochemical	O
stainingwith	O
CD31	S-Gene_or_gene_product
and	O
CD105	S-Gene_or_gene_product
antibodies	O
.	O

The	O
tumor	S-Pathological_formation
apoptosis	S-Death
was	O
observed	O
by	O
electron	O
microscopy	O
.	O

RESULTS	O
:	O
In	O
comparison	O
with	O
controls	O
,	O
intratumoral	B-Planned_process
injection	E-Planned_process
of	O
Ad	B-Gene_or_gene_product
-	I-Gene_or_gene_product
mEndostatin	E-Gene_or_gene_product
significantly	O
inhibited	S-Negative_regulation
the	O
tumor	S-Pathological_formation
growth	S-Growth
and	O
metastasis	S-Localization
,	O
and	O
prolonged	S-Positive_regulation
the	O
survival	S-Death
rate	O
of	O
mice	S-Organism
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

Strong	O
positive	O
expression	S-Gene_expression
of	O
mEndostatin	S-Gene_or_gene_product
was	O
seen	O
in	O
the	O
tumor	B-Tissue
tissue	E-Tissue
after	O
injection	S-Planned_process
of	O
Ad	B-Gene_or_gene_product
-	I-Gene_or_gene_product
mEndostatin	E-Gene_or_gene_product
,	O
immunhistochemically	O
ostained	O
by	O
mouse	S-Organism
endostatin	S-Gene_or_gene_product
monoclonal	O
antibody	O
,	O
while	O
the	O
control	O
groups	O
showed	O
only	O
very	O
low	O
expression	S-Gene_expression
or	O
absence	S-Gene_expression
.	O

Serum	O
endostatin	S-Gene_or_gene_product
concentration	O
was	O
1540	O
+	O
/	O
-	O
560	O
ng	O
/	O
ml	O
at	O
the	O
second	O
week	O
of	O
administration	S-Planned_process
,	O
the	O
expression	S-Gene_expression
of	O
endostatin	S-Gene_or_gene_product
diminished	S-Negative_regulation
a	O
month	O
later	O
.	O

The	O
microvessel	S-Tissue
density	O
(	O
MVD	O
)	O
)	O
decreased	S-Negative_regulation
from	O
42	O
.	O
4	O
+	O
/	O
-	O
4	O
.	O
8	O
to	O
10	O
.	O
5	O
+	O
/	O
-	O
3	O
.	O
2	O
per	O
x	O
200	O
magnificetion	O
microscopic	O
field	O
by	O
CD10	S-Gene_or_gene_product
staining	O
and	O
from	O
68	O
.	O
5	O
+	O
/	O
-	O
4	O
.	O
5	O
to	O
37	O
.	O
5	O
+	O
/	O
-	O
4	O
.	O
6	O
by	O
CD31	S-Gene_or_gene_product
staining	O
,	O
respectively	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

More	O
apoptotic	S-Death
tumor	B-Cell
cells	E-Cell
were	O
seen	O
under	O
the	O
transmission	O
electron	O
microscope	O
.	O

CONCLUSION	O
:	O
Endostatin	S-Gene_or_gene_product
gene	B-Planned_process
therapy	E-Planned_process
mediated	S-Positive_regulation
by	O
adenoviral	O
vector	O
efficiently	O
induces	S-Positive_regulation
expression	S-Gene_expression
of	O
endostatin	S-Gene_or_gene_product
in	O
vivo	O
,	O
and	O
inhibits	S-Negative_regulation
the	O
growth	S-Growth
and	O
metastasis	S-Localization
of	O
tumor	S-Pathological_formation
.	O

It	O
is	O
concluded	O
that	O
its	O
action	S-Regulation
is	O
targeted	O
to	O
tumor	B-Multi-tissue_structure
neovasculature	E-Multi-tissue_structure
and	O
the	O
mechanism	O
is	O
inhibition	S-Negative_regulation
of	O
tumor	S-Pathological_formation
angiogenesis	S-Blood_vessel_development
.	O

Allogeneic	O
injection	S-Planned_process
of	O
fetal	B-Cell
membrane	I-Cell
-	I-Cell
derived	I-Cell
mesenchymal	I-Cell
stem	I-Cell
cells	E-Cell
induces	S-Positive_regulation
therapeutic	O
angiogenesis	S-Blood_vessel_development
in	O
a	O
rat	S-Organism
model	O
of	O
hind	B-Organism_subdivision
limb	E-Organism_subdivision
ischemia	O
.	O

Bone	B-Cell
marrow	I-Cell
-	I-Cell
derived	I-Cell
mesenchymal	I-Cell
stem	I-Cell
cells	E-Cell
(	O
BM	B-Cell
-	I-Cell
MSC	E-Cell
)	O
have	O
been	O
demonstrated	O
to	O
be	O
an	O
attractive	O
therapeutic	O
cell	S-Cell
source	O
for	O
tissue	S-Tissue
regeneration	S-Development
and	O
repair	S-Development
.	O

However	O
,	O
it	O
remains	O
unknown	O
whether	O
or	O
not	O
allogeneic	O
transplantation	S-Planned_process
of	O
mesenchymal	B-Cell
stem	I-Cell
cells	E-Cell
(	O
MSC	S-Cell
)	O
derived	O
from	O
fetal	B-Multi-tissue_structure
membranes	E-Multi-tissue_structure
(	O
FM	S-Multi-tissue_structure
)	O
,	O
which	O
are	O
generally	O
discarded	O
as	O
medical	O
waste	O
after	O
delivery	O
,	O
has	O
therapeutic	O
potential	O
.	O

FM	B-Cell
-	I-Cell
MSC	E-Cell
were	O
obtained	S-Planned_process
from	O
Lewis	O
rats	S-Organism
and	O
had	O
surface	O
antigen	O
expression	O
and	O
multipotent	O
potential	O
partly	O
similar	O
to	O
those	O
of	O
BM	B-Cell
-	I-Cell
MSC	E-Cell
.	O

Compared	O
with	O
BM	B-Cell
-	I-Cell
MSC	E-Cell
,	O
FM	B-Cell
-	I-Cell
MSC	E-Cell
secreted	S-Localization
a	O
comparable	O
amount	O
of	O
hepatocyte	B-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
despite	O
a	O
small	O
amount	O
of	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
.	O

FM	B-Cell
-	I-Cell
MSC	E-Cell
and	O
BM	B-Cell
-	I-Cell
MSC	E-Cell
both	O
expressed	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
class	O
I	O
but	O
not	O
MHC	O
class	O
II	O
antigens	O
and	O
did	O
not	O
elicit	O
allogeneic	O
lymphocyte	S-Cell
proliferation	S-Cell_proliferation
in	O
mixed	O
lymphocyte	S-Cell
culture	O
.	O

FM	B-Cell
-	I-Cell
MSC	E-Cell
or	O
BM	B-Cell
-	I-Cell
MSC	E-Cell
obtained	S-Planned_process
from	O
Lewis	O
rats	S-Organism
were	O
injected	S-Planned_process
into	O
a	O
MHC	O
-	O
mismatched	O
August	O
-	O
Copenhagen	O
-	O
Irish	O
rat	S-Organism
model	O
of	O
hind	B-Organism_subdivision
limb	E-Organism_subdivision
ischemia	O
.	O

Three	O
weeks	O
after	O
injection	O
,	O
blood	S-Organism_substance
perfusion	O
and	O
capillary	S-Tissue
density	O
were	O
significantly	O
higher	O
in	O
the	O
FM	B-Cell
-	I-Cell
MSC	E-Cell
and	O
BM	B-Cell
-	I-Cell
MSC	E-Cell
groups	O
than	O
in	O
the	O
phosphate	B-Drug_or_compound
-	I-Drug_or_compound
buffered	I-Drug_or_compound
saline	E-Drug_or_compound
group	O
,	O
and	O
allogeneic	O
FM	B-Cell
-	I-Cell
MSC	E-Cell
and	O
BM	B-Cell
-	I-Cell
MSC	E-Cell
were	O
still	O
observed	S-Planned_process
.	O

In	O
nonischemic	O
hind	B-Tissue
limb	I-Tissue
tissues	E-Tissue
,	O
allogeneic	O
FM	B-Cell
-	I-Cell
MSC	E-Cell
and	O
BM	B-Cell
-	I-Cell
MSC	E-Cell
injection	S-Planned_process
were	O
associated	O
with	O
a	O
comparatively	O
small	O
amount	O
of	O
T	B-Cell
lymphocyte	E-Cell
infiltration	S-Localization
,	O
compared	O
with	O
the	O
injection	S-Planned_process
of	O
allogeneic	O
splenic	B-Cell
lymphocytes	E-Cell
.	O

In	O
conclusion	O
,	O
allogeneic	O
FM	B-Cell
-	I-Cell
MSC	E-Cell
injection	S-Planned_process
did	O
not	O
elicit	S-Positive_regulation
a	O
lymphocyte	S-Cell
proliferative	B-Cell_proliferation
response	E-Cell_proliferation
and	O
provided	O
significant	O
improvement	O
in	O
a	O
rat	S-Organism
model	O
of	O
hind	B-Organism_subdivision
limb	E-Organism_subdivision
ischemia	O
,	O
comparable	O
to	O
the	O
response	O
to	O
BM	B-Cell
-	I-Cell
MSC	E-Cell
.	O

Thus	O
,	O
allogeneic	O
injection	S-Planned_process
of	O
FM	B-Cell
-	I-Cell
MSC	E-Cell
may	O
be	O
a	O
new	O
therapeutic	O
strategy	O
for	O
the	O
treatment	O
of	O
severe	O
peripheral	O
vascular	O
disease	O
.	O

Disclosure	O
of	O
potential	O
conflicts	O
of	O
interest	O
is	O
found	O
at	O
the	O
end	O
of	O
this	O
article	O
.	O

Bevacizumab	S-Drug_or_compound
and	O
irinotecan	S-Drug_or_compound
therapy	S-Planned_process
in	O
glioblastoma	B-Pathological_formation
multiforme	E-Pathological_formation
:	O
a	O
series	O
of	O
13	O
cases	O
.	O

OBJECT	O
:	O
Endothelial	S-Cell
proliferation	S-Cell_proliferation
has	O
been	O
recognized	O
as	O
a	O
marker	O
of	O
high	O
-	O
grade	O
or	O
aggressive	O
glioma	S-Pathological_formation
.	O

Bevacizumab	S-Drug_or_compound
is	O
a	O
humanized	O
immunoglobulin	B-Gene_or_gene_product
G1	E-Gene_or_gene_product
monoclonal	O
antibody	O
to	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
that	O
has	O
been	O
shown	O
to	O
have	B-Regulation
activity	E-Regulation
in	O
malignant	O
gliomas	S-Pathological_formation
when	O
combined	O
with	O
irinotecan	S-Drug_or_compound
.	O

The	O
authors	O
report	O
on	O
a	O
case	O
series	O
of	O
13	O
patients	S-Organism
with	O
recurrent	O
heavily	O
pretreated	S-Planned_process
malignant	O
glioma	S-Pathological_formation
that	O
was	O
treated	S-Planned_process
with	O
the	O
combination	O
of	O
bevacizumab	S-Drug_or_compound
and	O
irinotecan	S-Drug_or_compound
.	O

METHODS	O
:	O
Standard	O
therapy	O
with	O
primary	O
resection	O
followed	O
by	O
adjuvant	O
chemotherapy	S-Planned_process
and	O
radiation	S-Planned_process
had	O
failed	O
in	O
all	O
patients	S-Organism
.	O

The	O
median	O
number	O
of	O
therapies	O
applied	O
,	O
including	O
initial	O
surgery	O
,	O
was	O
5	O
(	O
range	O
3	O
-	O
7	O
therapies	O
)	O
.	O

Nine	O
patients	S-Organism
were	O
started	S-Planned_process
on	O
bevacizumab	S-Drug_or_compound
at	O
a	O
dose	O
of	O
5	O
mg	O
/	O
m2	O
every	O
2	O
weeks	O
.	O

Four	O
patients	S-Organism
received	S-Planned_process
bevacizumab	S-Drug_or_compound
at	O
a	O
dose	O
of	O
10	O
mg	O
/	O
m2	O
;	O
irinotecan	S-Drug_or_compound
was	O
given	S-Planned_process
at	O
a	O
dose	O
of	O
125	O
mg	O
/	O
m2	O
every	O
week	O
for	O
3	O
weeks	O
.	O

RESULTS	O
:	O
Of	O
the	O
13	O
treated	S-Planned_process
patients	S-Organism
,	O
10	O
(	O
77	O
%	O
)	O
had	O
a	O
radiologically	O
demonstrated	O
partial	O
response	O
and	O
3	O
(	O
23	O
%	O
)	O
had	O
stable	O
disease	O
.	O

Six	O
patients	S-Organism
(	O
46	O
%	O
)	O
had	O
a	O
clinical	O
response	O
.	O

The	O
median	O
time	O
to	O
disease	O
progression	O
while	O
on	O
treatment	O
was	O
24	O
weeks	O
.	O

The	O
median	O
overall	O
survival	O
was	O
27	O
weeks	O
.	O

The	O
disease	O
progressed	O
in	O
8	O
patients	S-Organism
,	O
despite	O
an	O
initial	O
response	O
.	O

Five	O
patients	S-Organism
are	O
still	O
responding	O
to	O
therapy	O
.	O

Six	O
of	O
the	O
8	O
patients	S-Organism
whose	O
disease	O
progressed	O
have	O
died	S-Death
.	O

Bevacizumab	S-Drug_or_compound
was	O
discontinued	S-Planned_process
in	O
2	O
patients	S-Organism
because	O
of	O
nonfatal	O
intracranial	S-Immaterial_anatomical_entity
bleeding	O
.	O

CONCLUSIONS	O
:	O
The	O
combination	O
of	O
bevacizumab	S-Drug_or_compound
and	O
irinotecan	S-Drug_or_compound
is	O
safe	O
and	O
has	O
excellent	O
activity	O
even	O
in	O
this	O
relapsed	O
,	O
heavily	O
pretreated	S-Planned_process
population	O
of	O
patients	S-Organism
with	O
high	O
-	O
grade	O
malignant	O
glioma	S-Pathological_formation
,	O
most	O
of	O
whom	O
would	O
not	O
be	O
candidates	O
for	O
clinical	O
trials	O
.	O

Intracerebral	B-Planned_process
grafting	E-Planned_process
of	O
cultured	O
autologous	O
skin	B-Cell
fibroblasts	E-Cell
into	O
the	O
rat	S-Organism
striatum	S-Multi-tissue_structure
:	O
an	O
assessment	O
of	O
graft	S-Tissue
size	O
and	O
ultrastructure	O
.	O

To	O
identify	O
a	O
suitable	O
donor	O
cell	S-Cell
population	O
for	O
gene	O
therapy	O
applications	O
to	O
the	O
central	B-Anatomical_system
nervous	I-Anatomical_system
system	E-Anatomical_system
,	O
primary	O
fibroblasts	S-Cell
isolated	S-Planned_process
from	O
skin	B-Multi-tissue_structure
biopsies	E-Multi-tissue_structure
and	O
maintained	O
in	O
culture	O
are	O
employed	O
as	O
autologous	O
cells	S-Cell
for	O
intracerebral	B-Planned_process
grafting	E-Planned_process
within	O
the	O
adult	O
rat	S-Organism
striatum	S-Multi-tissue_structure
.	O

Results	O
from	O
the	O
present	O
investigation	O
reveal	O
that	O
cultured	S-Planned_process
primary	O
skin	B-Cell
fibroblasts	E-Cell
cease	O
to	O
proliferate	S-Cell_proliferation
once	O
they	O
reach	O
confluence	O
;	O
these	O
cells	S-Cell
are	O
thus	O
contact	S-Binding
inhibited	S-Negative_regulation
in	O
vitro	O
.	O

Following	O
implantation	S-Planned_process
within	O
the	O
striatum	S-Multi-tissue_structure
,	O
the	O
volume	O
of	O
the	O
primary	O
fibroblast	B-Tissue
grafts	E-Tissue
,	O
stained	O
immunohistochemically	O
for	O
fibronectin	S-Gene_or_gene_product
,	O
does	O
not	O
differ	O
significantly	O
at	O
3	O
and	O
8	O
weeks	O
.	O

The	O
graft	S-Tissue
size	O
is	O
dependent	O
on	O
the	O
density	O
of	O
the	O
cell	S-Cell
suspension	O
,	O
but	O
not	O
dependent	O
on	O
either	O
the	O
number	O
of	O
passages	S-Planned_process
the	O
cells	S-Cell
are	O
taken	O
through	O
in	O
culture	S-Planned_process
prior	O
to	O
grafting	S-Planned_process
or	O
on	O
the	O
postoperative	O
survival	O
period	O
.	O

Ultrastructural	O
evidence	O
reveals	O
that	O
at	O
8	O
weeks	O
the	O
grafts	S-Tissue
are	O
composed	O
primarily	O
of	O
collagen	S-Gene_or_gene_product
and	O
fibroblasts	S-Cell
with	O
rough	O
endoplasmic	B-Cellular_component
reticulum	E-Cellular_component
and	O
vesicles	S-Cellular_component
.	O

Reactive	O
astrocytic	B-Cellular_component
processes	E-Cellular_component
and	O
phagocytic	B-Cell
cells	E-Cell
are	O
also	O
present	O
in	O
the	O
grafts	S-Tissue
.	O

The	O
grafts	S-Tissue
are	O
extensively	O
vascularized	O
with	O
capillaries	S-Tissue
composed	O
of	O
nonfenestrated	O
endothelium	S-Tissue
;	O
intercellular	O
junctions	O
are	O
evident	O
at	O
sites	O
of	O
apposition	O
between	O
endothelial	B-Cell
cells	E-Cell
.	O

It	O
is	O
concluded	O
that	O
primary	O
skin	B-Cell
fibroblasts	E-Cell
are	O
able	O
to	O
survive	S-Death
for	O
at	O
least	O
8	O
weeks	O
following	O
intracerebral	O
implantation	O
and	O
continue	O
to	O
synthesize	S-Gene_expression
collagen	S-Gene_or_gene_product
and	O
fibronectin	S-Gene_or_gene_product
in	O
vivo	O
.	O

Also	O
,	O
the	O
grafts	S-Tissue
maintain	O
a	O
constant	O
volume	O
between	O
3	O
and	O
8	O
weeks	O
,	O
thereby	O
indicating	O
that	O
primary	O
skin	B-Cell
fibroblasts	E-Cell
do	O
not	O
produce	S-Development
tumors	S-Pathological_formation
.	O

Finally	O
,	O
dynamic	O
host	O
-	O
to	O
-	O
graft	S-Tissue
interactions	O
-	O
-	O
including	O
phagocytic	O
migration	O
,	O
astrocytic	O
hypertrophy	O
and	O
infiltration	O
within	O
the	O
grafts	S-Tissue
,	O
and	O
angiogenesis	S-Blood_vessel_development
-	O
-	O
are	O
features	O
that	O
constitute	O
the	O
structural	O
integration	O
of	O
primary	O
skin	B-Cell
fibroblasts	E-Cell
grafted	S-Planned_process
within	O
the	O
adult	O
rat	S-Organism
central	B-Anatomical_system
nervous	I-Anatomical_system
system	E-Anatomical_system
.	O

Endosialin	S-Gene_or_gene_product
/	O
TEM	B-Gene_or_gene_product
1	E-Gene_or_gene_product
/	O
CD248	S-Gene_or_gene_product
is	O
a	O
pericyte	S-Cell
marker	O
of	O
embryonic	O
and	O
tumor	S-Pathological_formation
neovascularization	S-Blood_vessel_development
.	O

The	O
formation	S-Development
of	O
functional	O
,	O
mature	O
blood	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
depends	S-Positive_regulation
on	O
the	O
interaction	S-Binding
between	O
endothelial	B-Cell
cells	E-Cell
and	O
pericytes	S-Cell
.	O

Commonality	O
exists	O
in	O
the	O
processes	O
involved	O
in	O
vasculature	S-Multi-tissue_structure
development	S-Development
between	O
tissues	S-Tissue
whether	O
healthy	O
or	O
diseased	O
.	O

Endosialin	S-Gene_or_gene_product
/	O
TEM	B-Gene_or_gene_product
1	E-Gene_or_gene_product
is	O
a	O
cell	B-Cellular_component
membrane	E-Cellular_component
protein	O
that	O
is	O
expressed	S-Gene_expression
in	O
blood	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
during	O
embryogenesis	O
and	O
tumorigenesis	O
but	O
not	O
in	O
normal	O
mature	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
.	O

Antibodies	O
developed	O
to	O
human	S-Organism
endosialin	S-Gene_or_gene_product
were	O
used	O
to	O
investigate	O
endosialin	S-Gene_or_gene_product
expression	S-Gene_expression
and	O
function	O
in	O
human	S-Organism
prenatal	B-Cell
brain	I-Cell
pericytes	E-Cell
and	O
pericytes	S-Cell
residing	O
in	O
tumors	S-Pathological_formation
.	O

Anti	B-Gene_or_gene_product
-	I-Gene_or_gene_product
endosialin	E-Gene_or_gene_product
was	O
capable	O
of	O
preventing	S-Negative_regulation
pericyte	B-Tissue
tube	E-Tissue
formation	S-Development
in	O
culture	O
and	O
inhibited	O
migration	O
.	O

Brain	B-Cell
pericytes	E-Cell
in	O
culture	O
had	O
higher	O
levels	O
of	O
endosialin	S-Gene_or_gene_product
/	O
TEM	B-Gene_or_gene_product
1	E-Gene_or_gene_product
than	O
TEMs	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
,	O
-	B-Gene_or_gene_product
3	E-Gene_or_gene_product
,	O
-	B-Gene_or_gene_product
4	E-Gene_or_gene_product
,	O
-	B-Gene_or_gene_product
5	E-Gene_or_gene_product
,	O
-	B-Gene_or_gene_product
7	E-Gene_or_gene_product
,	O
and	O
-	B-Gene_or_gene_product
8	E-Gene_or_gene_product
.	O

Immunocytochemistry	O
revealed	O
that	O
endosialin	S-Gene_or_gene_product
was	O
present	S-Localization
in	O
the	O
cytoplasmic	O
body	O
and	O
in	O
the	O
elongated	O
extensions	O
essential	O
to	O
pericyte	S-Cell
function	O
.	O

Transgenic	S-Planned_process
mice	S-Organism
engineered	O
to	O
express	S-Gene_expression
human	S-Organism
endosialin	S-Gene_or_gene_product
bred	O
on	O
an	O
immunocompromised	O
background	O
allowed	O
the	O
growth	S-Growth
of	O
human	S-Organism
tumor	B-Tissue
xenografts	E-Tissue
.	O

In	O
human	S-Organism
colon	B-Pathological_formation
carcinoma	I-Pathological_formation
Colo205	E-Pathological_formation
and	O
HT29	S-Pathological_formation
xenografts	O
grown	S-Growth
in	O
human	S-Organism
endosialin	S-Gene_or_gene_product
-	O
transgenic	S-Planned_process
mice	S-Organism
,	O
endosialin	S-Gene_or_gene_product
expression	S-Gene_expression
was	O
largely	O
confined	O
to	O
NG2	S-Gene_or_gene_product
-	O
expressing	S-Gene_expression
perivascular	B-Cell
cells	E-Cell
and	O
not	O
CD31	S-Gene_or_gene_product
-	O
positive	S-Gene_expression
endothelial	B-Cell
cells	E-Cell
.	O

Similar	O
methods	O
applied	O
to	O
human	S-Organism
ovarian	S-Pathological_formation
and	O
colon	B-Pathological_formation
tumors	E-Pathological_formation
confirmed	O
endosialin	S-Gene_or_gene_product
expression	S-Gene_expression
by	O
pericytes	S-Cell
.	O

The	O
data	O
indicate	O
that	O
endosialin	S-Gene_or_gene_product
is	O
strongly	O
expressed	S-Gene_expression
by	O
pericytes	S-Cell
during	O
periods	O
of	O
active	O
angiogenesis	S-Blood_vessel_development
during	O
embryonic	O
and	O
tumor	S-Pathological_formation
development	S-Development
.	O

Anti	B-Gene_or_gene_product
-	I-Gene_or_gene_product
endosialin	I-Gene_or_gene_product
antibodies	E-Gene_or_gene_product
may	O
have	O
value	O
in	O
identifying	O
vasculature	S-Multi-tissue_structure
in	O
malignant	B-Tissue
tissues	E-Tissue
.	O

With	O
the	O
appropriate	O
agent	O
,	O
targeting	S-Planned_process
endosialin	S-Gene_or_gene_product
may	O
interfere	S-Negative_regulation
with	O
blood	B-Multi-tissue_structure
vessel	E-Multi-tissue_structure
growth	S-Growth
during	O
tumor	S-Pathological_formation
development	S-Development
.	O

Efficient	O
inhibition	S-Negative_regulation
of	O
ovarian	B-Pathological_formation
cancer	E-Pathological_formation
growth	S-Growth
and	O
prolonged	O
survival	S-Death
by	O
transfection	S-Planned_process
with	O
a	O
novel	O
pro	O
-	O
apoptotic	O
gene	O
,	O
hPNAS	B-Gene_or_gene_product
-	I-Gene_or_gene_product
4	E-Gene_or_gene_product
,	O
in	O
a	O
mouse	S-Organism
model	O
.	O

In	O
vivo	O
and	O
in	O
vitro	O
results	O
.	O

OBJECTIVE	O
:	O
We	O
transfected	S-Planned_process
ovarian	B-Cell
cancer	I-Cell
cells	E-Cell
and	O
administered	S-Planned_process
recombinant	O
plasmid	O
encoding	O
hPNAS	B-Gene_or_gene_product
-	I-Gene_or_gene_product
4	E-Gene_or_gene_product
to	O
nude	B-Organism
mice	E-Organism
bearing	O
ovarian	B-Pathological_formation
cancer	E-Pathological_formation
,	O
aiming	O
to	O
evaluate	O
the	O
effect	S-Regulation
of	O
hPNAS	B-Gene_or_gene_product
-	I-Gene_or_gene_product
4	E-Gene_or_gene_product
against	O
ovarian	B-Pathological_formation
cancer	E-Pathological_formation
in	O
vitro	O
and	O
in	O
vivo	O
.	O

METHODS	O
:	O
Ovarian	B-Cell
cancer	I-Cell
SKOV3	I-Cell
cells	E-Cell
were	O
transfected	S-Planned_process
with	O
hPNAS	B-Gene_or_gene_product
-	I-Gene_or_gene_product
4	E-Gene_or_gene_product
-	O
plasmid	O
,	O
and	O
cell	S-Cell
proliferation	S-Cell_proliferation
was	O
evaluated	O
by	O
MTT	O
assay	O
;	O
apoptosis	S-Death
was	O
examined	O
by	O
DNA	O
ladder	O
,	O
Hoechst33258	O
staining	O
and	O
flow	O
-	O
cytometric	O
assays	O
.	O

Nude	B-Organism
mice	E-Organism
bearing	O
ovarian	B-Pathological_formation
cancers	E-Pathological_formation
were	O
treated	S-Planned_process
with	O
hPNAS	B-Gene_or_gene_product
-	I-Gene_or_gene_product
4	E-Gene_or_gene_product
-	O
p	O
/	O
liposome	S-Drug_or_compound
.	O

Tumor	S-Pathological_formation
growth	S-Growth
was	O
determined	O
and	O
survival	O
was	O
recorded	O
.	O

TUNEL	O
assay	O
and	O
microvessel	S-Tissue
density	O
was	O
assessed	O
to	O
evaluate	O
apoptosis	O
and	O
angiogenesis	S-Blood_vessel_development
.	O

RESULTS	O
:	O
Both	O
inhibition	S-Negative_regulation
of	O
proliferation	S-Cell_proliferation
(	O
p	O
<	O
0	O
.	O
05	O
)	O
and	O
induction	S-Positive_regulation
of	O
apoptosis	S-Death
(	O
p	O
<	O
0	O
.	O
05	O
)	O
were	O
observed	O
in	O
SKOV3	B-Cell
cells	E-Cell
transfected	S-Planned_process
with	O
hPNAS	B-Gene_or_gene_product
-	I-Gene_or_gene_product
4	E-Gene_or_gene_product
-	O
p	O
in	O
vitro	O
.	O

In	O
hPNAS	B-Gene_or_gene_product
-	I-Gene_or_gene_product
4	E-Gene_or_gene_product
-	O
p	O
-	O
treated	S-Planned_process
tumor	B-Cell
cells	E-Cell
in	O
vivo	O
,	O
tumor	S-Pathological_formation
growth	S-Growth
significantly	O
decreased	S-Negative_regulation
,	O
while	O
the	O
survival	S-Death
time	O
of	O
tumor	S-Pathological_formation
-	O
bearing	O
mice	S-Organism
was	O
prolonged	S-Positive_regulation
compared	O
with	O
control	O
groups	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Increased	S-Positive_regulation
apoptosis	S-Death
of	O
tumor	B-Cell
cells	E-Cell
and	O
decreased	S-Negative_regulation
angiogenesis	S-Blood_vessel_development
in	O
tumor	B-Tissue
tissue	E-Tissue
were	O
also	O
observed	O
.	O

CONCLUSIONS	O
:	O
Our	O
promising	O
results	O
on	O
the	O
potential	O
antitumor	S-Pathological_formation
effects	S-Negative_regulation
of	O
hPNAS	B-Gene_or_gene_product
-	I-Gene_or_gene_product
4	E-Gene_or_gene_product
on	O
ovarian	B-Pathological_formation
cancer	E-Pathological_formation
in	O
vitro	O
and	O
in	O
vivo	O
may	O
be	O
explained	O
,	O
in	O
part	O
,	O
by	O
the	O
induction	S-Positive_regulation
of	O
apoptosis	S-Death
and	O
inhibition	S-Negative_regulation
of	O
angiogenesis	S-Blood_vessel_development
.	O

Consequently	O
,	O
hPNAS	B-Gene_or_gene_product
-	I-Gene_or_gene_product
4	E-Gene_or_gene_product
has	O
potential	O
as	O
a	O
new	O
gene	B-Planned_process
therapy	E-Planned_process
for	O
human	S-Organism
ovarian	B-Pathological_formation
cancer	E-Pathological_formation
.	O

Diverse	O
cell	S-Cell
signaling	O
events	O
modulated	O
by	O
perlecan	S-Gene_or_gene_product
.	O

Perlecan	S-Gene_or_gene_product
is	O
a	O
ubiquitous	O
pericellular	O
proteoglycan	O
ideally	O
placed	O
to	O
mediate	O
cell	S-Cell
signaling	O
events	O
controlling	O
migration	O
,	O
proliferation	O
,	O
and	O
differentiation	O
.	O

Its	O
control	O
of	O
growth	O
factor	O
signaling	O
usually	O
involves	O
interactions	O
with	O
the	O
heparan	O
sulfate	O
chains	O
covalently	O
coupled	O
to	O
the	O
protein	O
core	O
'	O
s	O
N	O
-	O
terminus	O
.	O

However	O
,	O
this	O
modular	O
protein	O
core	O
also	O
binds	O
with	O
relatively	O
high	O
affinity	O
to	O
a	O
number	O
of	O
growth	O
factors	O
and	O
surface	O
receptors	O
,	O
thereby	O
stabilizing	O
cell	S-Cell
-	O
matrix	O
links	O
.	O

This	O
review	O
will	O
focus	O
on	O
perlecan	S-Gene_or_gene_product
-	O
growth	O
factor	O
interactions	S-Binding
and	O
describe	O
recent	O
advances	O
in	O
our	O
understanding	O
of	O
this	O
highly	O
conserved	O
proteoglycan	O
during	O
development	O
,	O
cancer	S-Pathological_formation
growth	S-Growth
,	O
and	O
angiogenesis	S-Blood_vessel_development
.	O

The	O
pro	O
-	O
angiogenic	S-Blood_vessel_development
capacities	O
of	O
perlecan	S-Gene_or_gene_product
that	O
involve	O
proliferative	O
and	O
migratory	O
signals	O
in	O
response	O
to	O
bound	S-Binding
growth	O
factors	O
will	O
be	O
explored	O
,	O
as	O
well	O
as	O
the	O
anti	O
-	O
angiogenic	S-Blood_vessel_development
signals	S-Negative_regulation
resulting	S-Positive_regulation
from	O
interactions	S-Binding
between	O
the	O
C	O
-	O
terminal	O
domain	O
known	O
as	O
endorepellin	S-Gene_or_gene_product
and	O
integrins	S-Gene_or_gene_product
that	O
control	S-Regulation
adhesion	S-Binding
of	O
cells	S-Cell
to	O
the	O
extracellular	B-Cellular_component
matrix	E-Cellular_component
.	O

These	O
two	O
somewhat	O
diametrically	O
opposed	O
roles	O
will	O
be	O
discussed	O
in	O
light	O
of	O
new	O
data	O
emerging	O
from	O
various	O
fields	O
which	O
converge	O
on	O
perlecan	S-Gene_or_gene_product
as	O
a	O
key	O
regulator	O
of	O
cell	S-Cell
growth	S-Cell_proliferation
and	O
angiogenesis	S-Blood_vessel_development
.	O

Angiogenesis	S-Blood_vessel_development
associated	O
with	O
visceral	S-Tissue
and	O
subcutaneous	B-Tissue
adipose	I-Tissue
tissue	E-Tissue
in	O
severe	O
human	S-Organism
obesity	O
.	O

OBJECTIVE	O
:	O
The	O
expansion	S-Development
of	O
adipose	B-Tissue
tissue	E-Tissue
is	O
linked	S-Regulation
to	O
the	O
development	S-Development
of	O
its	O
vasculature	S-Multi-tissue_structure
.	O

However	O
,	O
the	O
regulation	S-Regulation
of	O
adipose	B-Tissue
tissue	E-Tissue
angiogenesis	S-Blood_vessel_development
in	O
humans	S-Organism
has	O
not	O
been	O
extensively	O
studied	O
.	O

Our	O
aim	O
was	O
to	O
compare	O
the	O
angiogenesis	S-Blood_vessel_development
associated	O
with	O
subcutaneous	B-Tissue
adipose	I-Tissue
tissue	E-Tissue
(	O
SAT	S-Tissue
)	O
and	O
visceral	B-Tissue
adipose	I-Tissue
tissue	E-Tissue
(	O
VAT	S-Tissue
)	O
from	O
the	O
same	O
obese	O
patients	S-Organism
in	O
an	O
in	O
vivo	O
model	O
.	O

RESEARCH	O
DESIGN	O
AND	O
METHODS	O
:	O
Adipose	B-Tissue
tissue	I-Tissue
samples	E-Tissue
from	O
visceral	O
(	O
VAT	S-Tissue
)	O
and	O
subcutaneous	O
(	O
SAT	S-Tissue
)	O
sites	O
,	O
obtained	S-Planned_process
from	O
36	O
obese	O
patients	S-Organism
(	O
mean	O
BMI	O
46	O
.	O
5	O
kg	O
/	O
m	O
(	O
2	O
)	O
)	O
during	O
bariatric	O
surgery	O
,	O
were	O
layered	S-Planned_process
on	O
chick	S-Organism
chorioallantoic	B-Multi-tissue_structure
membrane	E-Multi-tissue_structure
(	O
CAM	S-Multi-tissue_structure
)	O
.	O

RESULTS	O
:	O
Both	O
SAT	S-Tissue
and	O
VAT	S-Tissue
expressed	O
angiogenic	S-Blood_vessel_development
factors	O
without	O
significant	O
difference	O
for	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
(	O
VEGF	S-Gene_or_gene_product
)	O
expression	S-Gene_expression
.	O

Adipose	B-Tissue
tissue	E-Tissue
layered	S-Planned_process
on	O
CAM	S-Multi-tissue_structure
stimulated	S-Positive_regulation
angiogenesis	S-Blood_vessel_development
.	O

Angiogenic	S-Blood_vessel_development
stimulation	S-Positive_regulation
was	O
macroscopically	O
detectable	O
,	O
with	O
engulfment	O
of	O
the	O
samples	O
,	O
in	O
39	O
%	O
and	O
was	O
evidenced	O
by	O
angiography	O
in	O
59	O
%	O
of	O
the	O
samples	O
.	O

A	O
connection	S-Binding
between	O
CAM	S-Multi-tissue_structure
and	O
adipose	B-Tissue
tissue	I-Tissue
vessels	E-Tissue
was	O
evidenced	O
by	O
immunohistochemistry	O
,	O
with	O
recruitment	S-Localization
of	O
both	O
avian	S-Organism
and	O
human	S-Organism
endothelial	B-Cell
cells	E-Cell
.	O

The	O
angiogenic	S-Blood_vessel_development
potency	O
of	O
adipose	B-Tissue
tissue	E-Tissue
was	O
not	O
related	O
to	O
its	O
localization	S-Localization
(	O
with	O
an	O
angiogenic	S-Blood_vessel_development
stimulation	S-Positive_regulation
in	O
60	O
%	O
of	O
SAT	B-Tissue
samples	E-Tissue
and	O
61	O
%	O
of	O
VAT	B-Tissue
samples	E-Tissue
)	O
or	O
to	O
adipocyte	S-Cell
size	O
or	O
inflammatory	O
infiltrate	O
assessed	O
in	O
adipose	B-Tissue
samples	E-Tissue
before	O
the	O
graft	S-Tissue
on	O
CAM	S-Multi-tissue_structure
.	O

Stimulation	S-Positive_regulation
of	O
angiogenesis	S-Blood_vessel_development
by	O
adipose	B-Tissue
tissue	E-Tissue
was	O
nearly	O
abolished	S-Negative_regulation
by	O
bevacizumab	S-Drug_or_compound
,	O
which	O
specifically	O
targets	S-Regulation
human	S-Organism
VEGF	S-Gene_or_gene_product
.	O

CONCLUSIONS	O
:	O
We	O
have	O
established	O
a	O
model	O
to	O
study	O
the	O
regulation	S-Regulation
of	O
angiogenesis	S-Blood_vessel_development
by	O
human	S-Organism
adipose	B-Tissue
tissue	E-Tissue
.	O

This	O
model	O
highlighted	O
the	O
role	S-Regulation
of	O
VEGF	S-Gene_or_gene_product
in	O
angiogenesis	S-Blood_vessel_development
in	O
both	O
SAT	S-Tissue
and	O
VAT	S-Tissue
.	O

The	O
in	O
vivo	O
properties	O
of	O
STX243	S-Drug_or_compound
:	O
a	O
potent	O
angiogenesis	S-Blood_vessel_development
inhibitor	O
in	O
breast	B-Pathological_formation
cancer	E-Pathological_formation
.	O

The	O
steroidal	O
-	O
based	O
drug	O
2	B-Drug_or_compound
-	I-Drug_or_compound
ethyloestradiol	I-Drug_or_compound
-	I-Drug_or_compound
3	I-Drug_or_compound
,	I-Drug_or_compound
17	I-Drug_or_compound
-	I-Drug_or_compound
O	I-Drug_or_compound
,	I-Drug_or_compound
O	I-Drug_or_compound
-	I-Drug_or_compound
bis	I-Drug_or_compound
-	I-Drug_or_compound
sulphamate	E-Drug_or_compound
(	O
STX243	S-Drug_or_compound
)	O
has	O
been	O
developed	O
as	O
a	O
potent	O
antiangiogenic	S-Blood_vessel_development
and	O
antitumour	O
compound	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
ascertain	O
whether	O
STX243	S-Drug_or_compound
is	O
more	O
active	O
in	O
vivo	O
than	O
the	O
clinically	O
relevant	O
drug	O
2	B-Drug_or_compound
-	I-Drug_or_compound
methoxyoestradiol	E-Drug_or_compound
(	O
2	B-Drug_or_compound
-	I-Drug_or_compound
MeOE2	E-Drug_or_compound
)	O
and	O
the	O
structurally	O
similar	O
compound	O
2	B-Drug_or_compound
-	I-Drug_or_compound
MeOE2	I-Drug_or_compound
-	I-Drug_or_compound
3	I-Drug_or_compound
,	I-Drug_or_compound
17	I-Drug_or_compound
-	I-Drug_or_compound
O	I-Drug_or_compound
,	I-Drug_or_compound
O	I-Drug_or_compound
-	I-Drug_or_compound
bis	I-Drug_or_compound
-	I-Drug_or_compound
sulphamate	E-Drug_or_compound
(	O
STX140	S-Drug_or_compound
)	O
.	O

The	O
tumour	S-Pathological_formation
growth	S-Growth
inhibition	S-Negative_regulation
efficacy	O
,	O
antiangiogenic	S-Blood_vessel_development
potential	S-Negative_regulation
and	O
pharmacokinetics	O
of	O
STX243	S-Drug_or_compound
were	O
examined	O
using	O
four	O
in	O
vivo	O
models	O
.	O

Both	O
STX243	S-Drug_or_compound
and	O
STX140	S-Drug_or_compound
were	O
capable	O
of	O
retarding	S-Negative_regulation
the	O
growth	S-Growth
of	O
MDA	B-Pathological_formation
-	I-Pathological_formation
MB	I-Pathological_formation
-	I-Pathological_formation
231	I-Pathological_formation
xenograft	I-Pathological_formation
tumours	E-Pathological_formation
(	O
72	O
and	O
63	O
%	O
,	O
respectively	O
)	O
,	O
whereas	O
no	O
inhibition	O
was	O
observed	O
for	O
animals	O
treated	S-Planned_process
with	O
2	B-Drug_or_compound
-	I-Drug_or_compound
MeOE2	E-Drug_or_compound
.	O

Further	O
tumour	S-Pathological_formation
inhibition	S-Negative_regulation
studies	O
showed	O
that	O
STX243	S-Drug_or_compound
was	O
also	O
active	B-Regulation
against	E-Regulation
MCF	B-Pathological_formation
-	I-Pathological_formation
7	I-Pathological_formation
paclitaxel	I-Pathological_formation
-	I-Pathological_formation
resistant	I-Pathological_formation
tumours	E-Pathological_formation
.	O

Using	O
a	O
Matrigel	O
plug	O
-	O
based	O
model	O
,	O
in	O
vivo	O
angiogenesis	S-Blood_vessel_development
was	O
restricted	S-Negative_regulation
with	O
STX243	S-Drug_or_compound
and	O
STX140	S-Drug_or_compound
(	O
50	O
and	O
72	O
%	O
,	O
respectively	O
,	O
using	O
a	O
10	O
mg	O
kg	O
(	O
-	O
1	O
)	O
oral	O
dose	O
)	O
,	O
thereby	O
showing	O
the	O
antiangiogenic	S-Blood_vessel_development
activity	S-Negative_regulation
of	O
both	O
compounds	O
.	O

The	O
pharmacokinetics	O
of	O
STX243	S-Drug_or_compound
were	O
examined	O
at	O
two	O
different	O
doses	O
using	O
adult	O
female	O
rats	S-Organism
.	O

The	O
compound	O
was	O
orally	O
bioavailable	O
(	O
31	O
%	O
after	O
a	O
single	O
10	O
mg	O
kg	O
(	O
-	O
1	O
)	O
dose	O
)	O
and	O
resistant	O
to	O
metabolism	O
.	O

These	O
results	O
show	O
that	O
STX243	S-Drug_or_compound
is	O
a	O
potent	O
in	O
vivo	O
drug	O
and	O
could	O
be	O
clinically	O
effective	O
at	O
treating	O
a	O
number	O
of	O
oncological	O
conditions	O
.	O

M	B-Gene_or_gene_product
-	I-Gene_or_gene_product
CSF	E-Gene_or_gene_product
signals	S-Regulation
through	O
the	O
MAPK	S-Gene_or_gene_product
/	O
ERK	S-Gene_or_gene_product
pathway	S-Pathway
via	O
Sp1	S-Gene_or_gene_product
to	O
induce	S-Positive_regulation
VEGF	S-Gene_or_gene_product
production	S-Gene_expression
and	O
induces	O
angiogenesis	S-Blood_vessel_development
in	O
vivo	O
.	O

BACKGROUND	O
:	O
M	B-Gene_or_gene_product
-	I-Gene_or_gene_product
CSF	E-Gene_or_gene_product
recruits	S-Regulation
mononuclear	B-Cell
phagocytes	E-Cell
which	O
regulate	S-Regulation
processes	O
such	O
as	O
angiogenesis	S-Blood_vessel_development
and	O
metastases	S-Localization
in	O
tumors	S-Pathological_formation
.	O

VEGF	S-Gene_or_gene_product
is	O
a	O
potent	O
activator	S-Positive_regulation
of	O
angiogenesis	S-Blood_vessel_development
as	O
it	O
promotes	S-Positive_regulation
endothelial	B-Cell
cell	E-Cell
proliferation	S-Cell_proliferation
and	O
new	O
blood	B-Multi-tissue_structure
vessel	E-Multi-tissue_structure
formation	S-Development
.	O

Previously	O
,	O
we	O
reported	O
that	O
in	O
vitro	O
M	B-Gene_or_gene_product
-	I-Gene_or_gene_product
CSF	E-Gene_or_gene_product
induces	S-Positive_regulation
the	O
expression	S-Gene_expression
of	O
biologically	O
-	O
active	O
VEGF	S-Gene_or_gene_product
from	O
human	S-Organism
monocytes	S-Cell
.	O

METHODOLOGY	O
AND	O
RESULTS	O
:	O
In	O
this	O
study	O
,	O
we	O
demonstrate	O
the	O
molecular	O
mechanism	O
of	O
M	B-Gene_or_gene_product
-	I-Gene_or_gene_product
CSF	E-Gene_or_gene_product
-	O
induced	S-Positive_regulation
VEGF	S-Gene_or_gene_product
production	S-Gene_expression
.	O

Using	O
a	O
construct	O
containing	O
the	O
VEGF	S-Gene_or_gene_product
promoter	S-DNA_domain_or_region
linked	S-Planned_process
to	O
a	O
luciferase	S-Gene_or_gene_product
reporter	O
,	O
we	O
found	O
that	O
a	O
mutation	O
reducing	S-Negative_regulation
HIF	S-Gene_or_gene_product
binding	S-Binding
to	O
the	O
VEGF	S-Gene_or_gene_product
promoter	S-DNA_domain_or_region
had	O
no	O
significant	O
effect	S-Regulation
on	O
luciferase	S-Gene_or_gene_product
production	S-Gene_expression
induced	S-Positive_regulation
by	O
M	B-Gene_or_gene_product
-	I-Gene_or_gene_product
CSF	E-Gene_or_gene_product
stimulation	S-Positive_regulation
.	O

Further	O
analysis	O
revealed	O
that	O
M	B-Gene_or_gene_product
-	I-Gene_or_gene_product
CSF	E-Gene_or_gene_product
induced	S-Positive_regulation
VEGF	S-Gene_or_gene_product
through	O
the	O
MAPK	S-Gene_or_gene_product
/	O
ERK	S-Gene_or_gene_product
signaling	B-Pathway
pathway	E-Pathway
via	O
the	O
transcription	O
factor	O
,	O
Sp1	S-Gene_or_gene_product
.	O

Thus	O
,	O
inhibition	S-Negative_regulation
of	O
either	O
ERK	S-Gene_or_gene_product
or	O
Sp1	S-Gene_or_gene_product
suppressed	S-Negative_regulation
M	B-Gene_or_gene_product
-	I-Gene_or_gene_product
CSF	E-Gene_or_gene_product
-	O
induced	S-Positive_regulation
VEGF	S-Gene_or_gene_product
at	O
the	O
mRNA	O
and	O
protein	O
level	O
.	O

M	B-Gene_or_gene_product
-	I-Gene_or_gene_product
CSF	E-Gene_or_gene_product
also	O
induced	S-Positive_regulation
the	O
nuclear	S-Cellular_component
localization	S-Localization
of	O
Sp1	S-Gene_or_gene_product
,	O
which	O
was	O
blocked	S-Negative_regulation
by	O
ERK	S-Gene_or_gene_product
inhibition	S-Negative_regulation
.	O

Finally	O
,	O
mutating	S-Planned_process
the	O
Sp1	S-Gene_or_gene_product
binding	B-DNA_domain_or_region
sites	E-DNA_domain_or_region
within	O
the	O
VEGF	S-Gene_or_gene_product
promoter	S-DNA_domain_or_region
or	O
inhibiting	S-Negative_regulation
ERK	S-Gene_or_gene_product
decreased	S-Negative_regulation
VEGF	S-Gene_or_gene_product
promoter	S-DNA_domain_or_region
activity	O
in	O
M	B-Gene_or_gene_product
-	I-Gene_or_gene_product
CSF	E-Gene_or_gene_product
-	O
treated	S-Planned_process
human	S-Organism
monocytes	S-Cell
.	O

To	O
evaluate	O
the	O
biological	O
significance	O
of	O
M	B-Gene_or_gene_product
-	I-Gene_or_gene_product
CSF	E-Gene_or_gene_product
induced	S-Positive_regulation
VEGF	S-Gene_or_gene_product
production	S-Gene_expression
,	O
we	O
used	O
an	O
in	O
vivo	O
angiogenesis	S-Blood_vessel_development
model	O
to	O
illustrate	O
the	O
ability	S-Regulation
of	O
M	B-Gene_or_gene_product
-	I-Gene_or_gene_product
CSF	E-Gene_or_gene_product
to	O
recruit	S-Localization
mononuclear	B-Cell
phagocytes	E-Cell
,	O
increase	S-Positive_regulation
VEGF	S-Gene_or_gene_product
levels	O
,	O
and	O
enhance	S-Positive_regulation
angiogenesis	S-Blood_vessel_development
.	O

Importantly	O
,	O
the	O
addition	O
of	O
a	O
neutralizing	O
VEGF	B-Gene_or_gene_product
antibody	E-Gene_or_gene_product
abolished	S-Negative_regulation
M	B-Gene_or_gene_product
-	I-Gene_or_gene_product
CSF	E-Gene_or_gene_product
-	O
induced	S-Positive_regulation
blood	B-Multi-tissue_structure
vessel	E-Multi-tissue_structure
formation	S-Development
.	O

CONCLUSION	O
:	O
These	O
data	O
delineate	O
an	O
ERK	S-Gene_or_gene_product
-	O
and	O
Sp1	S-Gene_or_gene_product
-	O
dependent	S-Positive_regulation
mechanism	O
of	O
M	B-Gene_or_gene_product
-	I-Gene_or_gene_product
CSF	E-Gene_or_gene_product
induced	S-Positive_regulation
VEGF	S-Gene_or_gene_product
production	S-Gene_expression
and	O
demonstrate	O
for	O
the	O
first	O
time	O
the	O
ability	O
of	O
M	B-Gene_or_gene_product
-	I-Gene_or_gene_product
CSF	E-Gene_or_gene_product
to	O
induce	S-Positive_regulation
angiogenesis	S-Blood_vessel_development
via	O
VEGF	S-Gene_or_gene_product
in	O
vivo	O
.	O

[	O
Retinochoroidopathy	O
after	O
intravitreal	O
anti	O
-	O
VEGF	S-Gene_or_gene_product
treatment	O
]	O

A	O
74	O
-	O
year	O
-	O
old	O
man	S-Organism
presented	O
with	O
persistent	O
metamorphopsias	O
of	O
the	O
right	O
eye	S-Organ
2	O
weeks	O
after	O
intravitreal	B-Planned_process
injection	E-Planned_process
of	O
bevacizumab	S-Drug_or_compound
to	O
treat	S-Planned_process
choroidal	O
neovascularization	S-Blood_vessel_development
due	B-Positive_regulation
to	E-Positive_regulation
exudative	O
age	O
-	O
related	O
macular	S-Tissue
degeneration	S-Breakdown
.	O

The	O
diagnosis	O
reached	O
was	O
retinochoroiditis	O
as	O
an	O
occult	O
manifestation	O
of	O
sarcoidosis	O
,	O
possibly	O
resulting	O
from	O
an	O
intravitreal	B-Planned_process
injection	E-Planned_process
of	O
bevacizumab	S-Drug_or_compound
.	O

The	O
patient	S-Organism
received	S-Planned_process
a	O
prescription	O
for	O
100	O
mg	O
Ultralan	S-Drug_or_compound
to	O
be	O
taken	O
daily	O
for	O
3	O
days	O
and	O
then	O
tapered	O
in	O
3	O
day	O
steps	O
.	O

During	O
the	O
further	O
course	O
no	O
deterioration	O
of	O
the	O
condition	O
was	O
observed	O
.	O

Silencing	O
of	O
directional	O
migration	S-Localization
in	O
roundabout4	B-Cell
knockdown	I-Cell
endothelial	I-Cell
cells	E-Cell
.	O

BACKGROUND	O
:	O
Roundabouts	S-Gene_or_gene_product
are	O
axon	O
guidance	O
molecules	O
that	O
have	O
recently	O
been	O
identified	O
to	O
play	B-Regulation
a	I-Regulation
role	E-Regulation
in	O
vascular	S-Multi-tissue_structure
guidance	S-Development
as	O
well	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
investigated	O
gene	O
knockdown	S-Planned_process
analysis	O
of	O
endothelial	O
Robos	S-Gene_or_gene_product
,	O
in	O
particular	O
roundabout	B-Gene_or_gene_product
4	E-Gene_or_gene_product
(	O
robo4	S-Gene_or_gene_product
)	O
,	O
the	O
predominant	O
Robo	S-Gene_or_gene_product
in	O
endothelial	B-Cell
cells	E-Cell
using	O
small	B-Planned_process
interfering	I-Planned_process
RNA	E-Planned_process
technology	O
in	O
vitro	O
.	O

RESULTS	O
:	O
Robo1	S-Cell
and	O
Robo4	B-Cell
knockdown	I-Cell
cells	E-Cell
display	O
distinct	O
activity	O
in	O
endothelial	B-Cell
cell	E-Cell
migration	S-Localization
assay	O
.	O

The	O
knockdown	S-Planned_process
of	O
robo4	S-Gene_or_gene_product
abrogated	S-Negative_regulation
the	O
chemotactic	O
response	S-Regulation
of	O
endothelial	B-Cell
cells	E-Cell
to	O
serum	S-Organism_substance
but	O
enhanced	S-Positive_regulation
a	O
chemokinetic	O
response	S-Regulation
to	O
Slit2	S-Gene_or_gene_product
,	O
while	O
robo1	B-Cell
knockdown	I-Cell
cells	E-Cell
do	O
not	O
display	O
chemotactic	O
response	S-Regulation
to	O
serum	S-Organism_substance
or	O
VEGF	S-Gene_or_gene_product
.	O

Robo4	B-Cell
knockdown	I-Cell
endothelial	I-Cell
cells	E-Cell
unexpectedly	O
show	O
up	B-Positive_regulation
regulation	E-Positive_regulation
of	O
Rho	B-Gene_or_gene_product
GTPases	E-Gene_or_gene_product
.	O

Zebrafish	S-Organism
Robo4	S-Gene_or_gene_product
rescues	S-Positive_regulation
both	O
Rho	B-Gene_or_gene_product
GTPase	E-Gene_or_gene_product
homeostasis	O
and	O
serum	S-Organism_substance
reduced	S-Negative_regulation
chemotaxis	S-Localization
in	O
robo4	B-Cell
knockdown	I-Cell
cells	E-Cell
.	O

Robo1	S-Gene_or_gene_product
and	O
Robo4	S-Gene_or_gene_product
interact	S-Binding
and	O
share	O
molecules	O
such	O
as	O
Slit2	S-Gene_or_gene_product
,	O
Mena	S-Gene_or_gene_product
and	O
Vilse	S-Gene_or_gene_product
,	O
a	O
Cdc42	B-Gene_or_gene_product
-	I-Gene_or_gene_product
GAP	E-Gene_or_gene_product
.	O

In	O
addition	O
,	O
this	O
study	O
mechanistically	O
implicates	O
IRSp53	S-Gene_or_gene_product
in	O
the	O
signaling	O
nexus	O
between	O
activated	S-Positive_regulation
Cdc42	S-Gene_or_gene_product
and	O
Mena	S-Gene_or_gene_product
,	O
both	O
of	O
which	O
have	O
previously	O
been	O
shown	O
to	O
be	O
involved	O
with	O
Robo4	S-Gene_or_gene_product
signaling	S-Pathway
in	O
endothelial	B-Cell
cells	E-Cell
.	O

CONCLUSION	O
:	O
This	O
study	O
identifies	O
specific	O
components	O
of	O
the	O
Robo	S-Gene_or_gene_product
signaling	B-Pathway
apparatus	E-Pathway
that	O
work	O
together	O
to	O
guide	O
directional	O
migration	S-Localization
of	O
endothelial	B-Cell
cells	E-Cell
.	O

A	O
novel	O
integrin	B-Gene_or_gene_product
alpha5beta1	E-Gene_or_gene_product
antagonistic	O
peptide	O
,	O
A5	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
,	O
screened	O
by	O
Protein	O
Chip	O
system	O
as	O
a	O
potent	O
angiogenesis	S-Blood_vessel_development
inhibitor	O
.	O

Integrin	B-Gene_or_gene_product
alpha5beta1	E-Gene_or_gene_product
immobilized	O
on	O
a	O
ProteoChip	O
was	O
used	O
to	O
screen	O
new	O
antagonistic	O
peptides	O
from	O
multiple	O
hexapeptide	O
sub	O
-	O
libraries	O
of	O
the	O
positional	O
scanning	O
synthetic	O
peptide	O
combinatorial	O
library	O
(	O
PS	O
-	O
SPCL	O
)	O
.	O

The	O
integrin	B-Gene_or_gene_product
alpha5beta1	E-Gene_or_gene_product
-	O
Fibronectin	S-Gene_or_gene_product
interaction	S-Binding
was	O
demonstrated	O
on	O
the	O
chip	O
.	O

A	O
novel	O
peptide	O
ligand	O
,	O
A5	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
(	O
VILVLF	S-Gene_or_gene_product
)	O
,	O
with	O
high	O
affinity	O
to	O
integrin	B-Gene_or_gene_product
alpha5beta1	E-Gene_or_gene_product
was	O
identified	O
from	O
the	O
hexapeptide	O
libraries	O
with	O
this	O
chip	O
-	O
based	O
screening	O
method	O
on	O
the	O
basis	O
of	O
a	O
competitive	O
inhibition	O
assay	O
.	O

A5	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
inhibits	S-Negative_regulation
the	O
integrin	S-Gene_or_gene_product
-	O
fibronectin	S-Gene_or_gene_product
interaction	S-Binding
in	O
a	O
dose	O
-	O
dependent	O
manner	O
(	O
IC	O
(	O
50	O
)	O
;	O
1	O
.	O
56	O
+	O
/	O
-	O
0	O
.	O
28	O
microM	O
.	O

In	O
addition	O
,	O
it	O
inhibits	S-Negative_regulation
human	B-Cell
umbilical	I-Cell
vein	I-Cell
endothelial	I-Cell
cell	E-Cell
proliferation	S-Cell_proliferation
,	O
migration	S-Localization
,	O
adhesion	S-Binding
,	O
tubular	B-Multi-tissue_structure
network	E-Multi-tissue_structure
formation	S-Development
,	O
and	O
bFGF	S-Gene_or_gene_product
-	O
induced	S-Positive_regulation
neovascularization	S-Blood_vessel_development
in	O
a	O
chick	S-Organism
chorioallantoic	B-Multi-tissue_structure
membrane	E-Multi-tissue_structure
.	O

These	O
results	O
suggest	O
that	O
A5	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
will	O
be	O
a	O
potent	O
inhibitor	O
of	O
neovascularization	S-Blood_vessel_development
.	O

Evaluation	O
of	O
electrical	O
stimulation	O
for	O
ischemic	O
wound	O
therapy	O
:	O
a	O
feasibility	O
study	O
using	O
the	O
lapine	O
wound	O
model	O
.	O

Chronic	O
wounds	O
are	O
a	O
major	O
secondary	O
complication	O
for	O
many	O
people	S-Organism
with	O
impaired	O
mobility	O
.	O

Electrical	O
stimulation	O
(	O
ES	O
)	O
has	O
been	O
recommended	O
as	O
a	O
adjunctive	O
therapy	O
,	O
however	O
optimal	O
treatment	O
paradigms	O
have	O
not	O
been	O
established	O
.	O

Our	O
group	O
seeks	O
to	O
determine	O
the	O
basic	O
mechanisms	O
underlying	O
ES	O
wound	O
therapy	O
,	O
an	O
area	O
where	O
understanding	O
is	O
currently	O
limited	O
.	O

A	O
feasibility	O
study	O
was	O
carried	O
out	O
to	O
develop	O
the	O
Ahn	O
/	O
Mustoe	O
lapine	O
wound	O
model	O
for	O
systematic	O
investigation	O
of	O
the	O
effects	O
of	O
electrical	O
stimulation	O
on	O
ischemic	O
wound	O
therapy	O
.	O

A	O
standardized	O
surgical	O
procedure	O
incorporated	O
a	O
hybrid	O
stimulation	O
system	O
comprising	O
an	O
implantable	O
mini	O
-	O
stimulator	O
and	O
surface	O
electrodes	O
,	O
with	O
creation	O
of	O
repeatable	O
ischemic	O
wounds	O
.	O

Twenty	O
mature	O
male	O
New	O
Zealand	O
white	O
rabbits	S-Organism
(	O
3	O
kg	O
weight	O
)	O
were	O
employed	O
to	O
evaluate	O
the	O
effects	O
of	O
two	O
empirically	O
selected	O
stimulation	O
paradigms	O
applied	O
continuously	O
for	O
7	O
-	O
21	O
days	O
,	O
using	O
each	O
animal	O
as	O
its	O
own	O
control	O
.	O

Outcomes	O
measures	O
included	O
transcutaneous	O
blood	S-Organism_substance
gas	O
levels	O
,	O
histology	O
,	O
total	O
RNA	O
content	O
and	O
analysis	O
of	O
alpha2	B-Gene_or_gene_product
(	I-Gene_or_gene_product
I	I-Gene_or_gene_product
)	I-Gene_or_gene_product
collagen	E-Gene_or_gene_product
(	O
COL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
I	E-Gene_or_gene_product
)	O
,	O
type	B-Gene_or_gene_product
IV	I-Gene_or_gene_product
collagen	E-Gene_or_gene_product
(	O
COL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
IV	E-Gene_or_gene_product
)	O
,	O
alpha1	B-Gene_or_gene_product
(	I-Gene_or_gene_product
V	I-Gene_or_gene_product
)	I-Gene_or_gene_product
collagen	E-Gene_or_gene_product
(	O
COL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
V	E-Gene_or_gene_product
)	O
,	O
and	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
(	O
VEGF	S-Gene_or_gene_product
)	O
expression	S-Gene_expression
using	O
real	O
-	O
time	O
quantitative	O
PCR	O
.	O

All	O
markers	O
for	O
stimulated	O
wounds	O
showed	O
increased	O
activity	O
relative	O
to	O
non	O
-	O
stimulated	O
control	O
wounds	O
between	O
7	O
and	O
14	O
days	O
following	O
injury	O
,	O
with	O
peak	O
activity	O
at	O
14	O
days	O
.	O

By	O
21	O
days	O
post	O
-	O
injury	O
,	O
all	O
activity	O
had	O
returned	O
to	O
near	O
baseline	O
level	O
.	O

VEGF	S-Gene_or_gene_product
and	O
COL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
IV	E-Gene_or_gene_product
levels	O
were	O
found	O
to	O
be	O
significantly	O
higher	O
for	O
pattern	O
A	O
(	O
110	O
mus	O
pulse	O
width	O
)	O
compared	O
to	O
pattern	O
B	O
(	O
5	O
mus	O
pulse	O
width	O
)	O
at	O
14	O
days	O
,	O
implying	O
that	O
pattern	O
A	O
may	O
be	O
more	O
effective	O
at	O
promoting	S-Positive_regulation
angiogenesis	S-Blood_vessel_development
.	O

All	O
wounds	O
were	O
fully	O
re	O
-	O
epithelialized	O
by	O
10	O
days	O
post	O
-	O
injury	O
.	O

Both	O
COL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
I	E-Gene_or_gene_product
and	O
COL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
V	E-Gene_or_gene_product
showed	O
statistically	O
significant	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
increased	O
activity	S-Positive_regulation
between	O
day	O
7	O
and	O
day	O
14	O
for	O
pattern	O
A	O
,	O
potentially	O
indicating	O
a	O
continued	O
effect	S-Regulation
on	O
matrix	S-Cellular_component
remodeling	S-Remodeling
.	O

The	O
early	O
closure	O
of	O
all	O
wounds	O
implies	O
that	O
the	O
rabbit	S-Organism
ear	S-Organ
model	O
may	O
not	O
be	O
valid	O
for	O
chronic	O
wound	O
studies	O
.	O

VEGF	S-Gene_or_gene_product
,	O
angiopoietin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
and	O
-	B-Gene_or_gene_product
2	E-Gene_or_gene_product
in	O
bronchial	O
asthma	O
:	O
new	O
molecular	O
targets	O
in	O
airway	O
angiogenesis	S-Blood_vessel_development
and	O
microvascular	S-Multi-tissue_structure
remodeling	S-Remodeling
.	O

Airway	O
angiogenesis	S-Blood_vessel_development
and	O
microvascular	S-Multi-tissue_structure
remodeling	S-Remodeling
are	O
known	O
features	O
of	O
bronchial	O
asthma	O
,	O
but	O
the	O
mechanisms	O
of	O
these	O
structural	O
alterations	O
are	O
just	O
beginning	O
to	O
be	O
elucidated	O
.	O

Vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
(	O
VEGF	S-Gene_or_gene_product
)	O
,	O
one	O
of	O
the	O
most	O
potent	O
angiogenic	S-Blood_vessel_development
factors	O
,	O
stimulates	S-Positive_regulation
endothelial	B-Cell
cell	E-Cell
proliferation	S-Cell_proliferation
and	O
induces	S-Positive_regulation
the	O
angiogenesis	S-Blood_vessel_development
.	O

Recently	O
,	O
considerable	O
attentions	O
have	O
been	O
devoted	O
to	O
the	O
physiological	O
roles	O
of	O
angiopoietin	B-Gene_or_gene_product
(	I-Gene_or_gene_product
Ang	I-Gene_or_gene_product
)	I-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
and	O
-	B-Gene_or_gene_product
2	E-Gene_or_gene_product
as	O
regulatory	O
factors	O
of	O
VEGF	S-Gene_or_gene_product
.	O

Ang	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
has	O
been	O
shown	O
to	O
induce	S-Positive_regulation
the	O
migration	S-Localization
and	O
sprouting	S-Development
of	O
endothelial	B-Cell
cells	E-Cell
,	O
and	O
coexpression	S-Gene_expression
of	O
Ang	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
and	O
VEGF	S-Gene_or_gene_product
enhanced	S-Positive_regulation
angiogenesis	S-Blood_vessel_development
.	O

In	O
the	O
presence	S-Localization
of	O
high	O
levels	O
of	O
VEGF	S-Gene_or_gene_product
,	O
Ang	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
also	O
promotes	S-Positive_regulation
rapid	O
increase	O
in	O
capillary	S-Tissue
diameter	O
,	O
remodeling	S-Remodeling
of	O
the	O
basal	B-Cellular_component
lamina	E-Cellular_component
,	O
proliferation	S-Cell_proliferation
and	O
migration	S-Localization
of	O
endothelial	B-Cell
cells	E-Cell
,	O
and	O
stimulates	S-Positive_regulation
sprouting	S-Development
of	O
new	O
blood	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
.	O

Thus	O
,	O
VEGF	S-Gene_or_gene_product
,	O
Ang	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
and	O
-	B-Gene_or_gene_product
2	E-Gene_or_gene_product
may	O
play	B-Regulation
complementary	I-Regulation
and	I-Regulation
coordinated	I-Regulation
roles	E-Regulation
in	O
airway	O
angiogenesis	S-Blood_vessel_development
and	O
microvascular	S-Multi-tissue_structure
remodeling	S-Remodeling
,	O
and	O
these	O
structural	O
changes	O
are	O
potentially	O
reversible	O
by	O
therapeutic	O
intervention	O
.	O

The	O
scope	O
of	O
the	O
present	O
review	O
is	O
to	O
discuss	O
from	O
a	O
clinical	O
point	O
of	O
view	O
the	O
potential	O
interactions	S-Binding
between	O
VEGF	S-Gene_or_gene_product
and	O
angiopoietins	S-Gene_or_gene_product
in	O
the	O
asthmatic	O
airways	O
,	O
and	O
focus	O
on	O
the	O
therapeutic	O
implications	O
targeting	O
for	O
these	O
angiogenic	S-Blood_vessel_development
factors	O
.	O

Recently	O
,	O
there	O
is	O
an	O
increasing	O
number	O
of	O
patents	O
which	O
have	O
been	O
focused	O
on	O
the	O
inhibitors	O
of	O
VEGF	S-Gene_or_gene_product
action	O
.	O

These	O
inhibitors	O
are	O
directed	O
towards	O
the	O
receptors	O
of	O
VEGF	S-Gene_or_gene_product
or	O
intracellular	O
substrates	O
for	O
the	O
receptors	O
.	O

We	O
will	O
also	O
discuss	O
several	O
patents	O
regarding	O
inhibitors	O
of	O
VEGF	S-Gene_or_gene_product
action	O
in	O
the	O
present	O
review	O
.	O

Effect	O
of	O
transplanted	S-Planned_process
mesenchymal	B-Cell
stem	I-Cell
cells	E-Cell
from	O
rats	S-Organism
of	O
different	O
ages	O
on	O
the	O
improvement	O
of	O
heart	S-Organ
function	O
after	O
acute	O
myocardial	O
infarction	O
.	O

BACKGROUND	O
:	O
Mesenchymal	B-Cell
stem	I-Cell
cells	E-Cell
(	O
MSCs	S-Cell
)	O
transplantation	S-Planned_process
is	O
of	O
therapeutic	O
potential	O
after	O
ischemic	O
injury	O
in	O
both	O
experimental	O
and	O
clinical	O
studies	O
.	O

Clinically	O
,	O
elderly	O
patients	S-Organism
are	O
more	O
vulnerable	O
to	O
acute	O
myocardial	O
infarction	O
(	O
AMI	O
)	O
.	O

But	O
little	O
is	O
known	O
about	O
the	O
characteristics	O
of	O
young	O
donor	O
-	O
derived	O
MSCs	S-Cell
transplanted	S-Planned_process
to	O
old	O
patients	S-Organism
with	O
AMI	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
effect	O
of	O
transplanted	S-Planned_process
MSCs	S-Cell
from	O
rats	S-Organism
of	O
different	O
ages	O
on	O
the	O
improvement	O
of	O
heart	S-Organ
function	O
after	O
AMI	O
.	O

METHODS	O
:	O
MSCs	S-Cell
from	O
Sprague	B-Organism
-	I-Organism
Dawley	I-Organism
(	I-Organism
SD	I-Organism
)	I-Organism
rats	E-Organism
were	O
isolated	S-Planned_process
and	O
cultured	S-Planned_process
in	O
vitro	O
.	O

The	O
apoptosis	S-Death
characteristics	O
of	O
MSCs	S-Cell
were	O
observed	O
under	O
conditions	O
of	O
ischemia	O
and	O
anoxia	O
.	O

SD	B-Organism
rats	E-Organism
underwent	O
MI	O
received	O
intramyocardial	O
injection	S-Planned_process
of	O
MSCs	S-Cell
from	O
young	O
donor	O
rats	S-Organism
(	O
n	O
=	O
8	O
)	O
,	O
old	O
donor	O
rats	S-Organism
(	O
n	O
=	O
8	O
)	O
,	O
respectively	O
.	O

AMI	O
control	O
group	O
received	O
equal	O
volume	O
physiological	O
saline	O
.	O

Immunofluorescence	O
was	O
used	O
to	O
observe	O
the	O
differentiation	S-Development
of	O
the	O
grafted	S-Planned_process
cells	S-Cell
into	O
cardiomyocytes	S-Cell
.	O

Four	O
weeks	O
after	O
cell	S-Cell
transplantation	S-Planned_process
,	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
immunohistochemistry	O
for	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
(	O
VEGF	S-Gene_or_gene_product
)	O
,	O
VIII	B-Gene_or_gene_product
-	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
immunohistochemistry	O
for	O
vessel	S-Multi-tissue_structure
density	O
,	O
TUNEL	O
,	O
caspase	B-Gene_or_gene_product
-	I-Gene_or_gene_product
3	E-Gene_or_gene_product
for	O
cardiomyocyte	S-Cell
apoptosis	S-Death
,	O
echocardiography	O
and	O
hemodynamic	O
detection	O
for	O
heart	S-Organ
function	O
were	O
performed	O
.	O

RESULTS	O
:	O
The	O
apoptosis	S-Death
rate	O
of	O
the	O
old	O
donor	O
-	O
derived	O
MSCs	S-Cell
group	O
was	O
significantly	O
higher	O
than	O
that	O
of	O
the	O
young	O
donor	O
-	O
derived	O
MSCs	S-Cell
group	O
under	O
conditions	O
of	O
ischemia	O
and	O
anoxia	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

Engrafted	S-Planned_process
MSCs	S-Cell
survived	S-Death
,	O
proliferated	S-Cell_proliferation
and	O
differentiated	S-Development
into	O
myocardium	B-Cell
-	I-Cell
like	I-Cell
cells	E-Cell
.	O

VEGF	S-Gene_or_gene_product
gene	O
expression	S-Gene_expression
and	O
capillary	S-Tissue
density	O
in	O
the	O
old	O
donor	O
-	O
derived	O
group	O
were	O
lower	O
than	O
those	O
in	O
the	O
young	O
donor	O
-	O
derived	O
group	O
but	O
higher	O
than	O
those	O
in	O
the	O
control	O
group	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

The	O
transplantation	S-Planned_process
of	O
old	O
donor	O
-	O
derived	O
MSCs	S-Cell
attenuated	S-Negative_regulation
apoptosis	S-Death
of	O
cardiomyocytes	S-Cell
in	O
the	O
peri	O
-	O
infarct	O
region	O
compared	O
with	O
the	O
control	O
group	O
and	O
the	O
effect	S-Regulation
was	O
elevated	S-Positive_regulation
in	O
young	O
donor	O
-	O
derived	O
MSCs	S-Cell
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

The	O
heart	S-Organ
functions	O
(	O
left	O
ventricle	S-Multi-tissue_structure
ejection	O
fraction	O
(	O
LVEF	O
)	O
,	O
left	O
ventricle	S-Multi-tissue_structure
fractional	O
shortening	O
(	O
LVFS	O
)	O
)	O
were	O
improved	O
more	O
significantly	O
in	O
the	O
old	O
donor	O
-	O
derived	O
MSCs	S-Cell
group	O
than	O
in	O
the	O
control	O
group	O
and	O
the	O
heart	S-Organ
function	O
in	O
the	O
young	O
donor	O
-	O
derived	O
MSCs	S-Cell
group	O
further	O
improved	S-Positive_regulation
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

CONCLUSIONS	O
:	O
Young	O
donor	O
-	O
derived	O
MSCs	S-Cell
can	O
improve	S-Positive_regulation
heart	S-Organ
function	O
significantly	O
through	O
angiogenesis	S-Blood_vessel_development
and	O
decreasing	S-Negative_regulation
cardiomyocyte	S-Cell
apoptosis	S-Death
when	O
transplanted	S-Planned_process
to	O
the	O
infarcted	O
area	O
.	O

Clinical	O
significance	O
of	O
chicken	B-Gene_or_gene_product
ovalbumin	I-Gene_or_gene_product
upstream	I-Gene_or_gene_product
promoter	I-Gene_or_gene_product
-	I-Gene_or_gene_product
transcription	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
II	E-Gene_or_gene_product
expression	S-Gene_expression
in	O
human	S-Organism
colorectal	B-Pathological_formation
cancer	E-Pathological_formation
.	O

Chicken	B-Gene_or_gene_product
ovalbumin	I-Gene_or_gene_product
upstream	I-Gene_or_gene_product
promoter	I-Gene_or_gene_product
-	I-Gene_or_gene_product
transcription	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
II	E-Gene_or_gene_product
(	O
COUP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
TFII	E-Gene_or_gene_product
)	O
plays	B-Regulation
an	I-Regulation
essential	I-Regulation
role	E-Regulation
in	O
angiogenesis	S-Blood_vessel_development
and	O
development	O
.	O

A	O
previous	O
study	O
showed	O
that	O
the	O
expression	S-Gene_expression
of	O
COUP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
TFII	E-Gene_or_gene_product
enhanced	S-Positive_regulation
invasiveness	S-Localization
of	O
human	S-Organism
lung	B-Cell
carcinoma	I-Cell
cells	E-Cell
.	O

However	O
,	O
no	O
published	O
data	O
are	O
available	O
concerning	O
the	O
biological	O
and	O
clinical	O
significance	O
of	O
COUP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
TFII	E-Gene_or_gene_product
expression	S-Gene_expression
in	O
colorectal	B-Pathological_formation
cancer	E-Pathological_formation
.	O

Thus	O
,	O
our	O
objective	O
was	O
to	O
explore	O
the	O
expression	S-Gene_expression
of	O
COUP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
TFII	E-Gene_or_gene_product
in	O
colorectal	B-Pathological_formation
cancer	E-Pathological_formation
as	O
well	O
as	O
its	O
association	O
with	O
clinicopathological	O
features	O
,	O
and	O
to	O
evaluate	O
the	O
role	S-Regulation
of	O
COUP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
TFII	E-Gene_or_gene_product
as	O
a	O
prognostic	O
indicator	O
in	O
colorectal	B-Pathological_formation
cancer	E-Pathological_formation
.	O

We	O
investigated	O
the	O
presence	S-Localization
of	O
COUP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
TFII	E-Gene_or_gene_product
in	O
human	S-Organism
colorectal	B-Tissue
cancer	I-Tissue
tissues	E-Tissue
and	O
adjacent	O
normal	B-Tissue
tissues	E-Tissue
from	O
95	O
primary	O
colorectal	B-Pathological_formation
cancer	E-Pathological_formation
patients	S-Organism
by	O
immunohistochemistry	O
.	O

The	O
correlation	O
between	O
the	O
expression	S-Gene_expression
of	O
COUP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
TFII	E-Gene_or_gene_product
and	O
clinicopathologic	O
features	O
was	O
investigated	O
.	O

The	O
3	O
-	O
year	O
disease	O
-	O
free	O
survival	O
(	O
DFS	O
)	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
of	O
patients	S-Organism
with	O
tumors	S-Pathological_formation
expressing	S-Gene_expression
different	O
levels	O
of	O
COUP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
TFII	E-Gene_or_gene_product
were	O
evaluated	O
by	O
the	O
Kaplan	O
-	O
Meier	O
method	O
.	O

No	O
significant	O
correlation	O
was	O
found	O
between	O
COUP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
TFII	E-Gene_or_gene_product
expression	S-Gene_expression
and	O
age	O
at	O
surgery	O
,	O
gender	O
,	O
histopathologic	O
differentiation	O
,	O
vessel	S-Multi-tissue_structure
invasion	S-Localization
,	O
carcinoembryonic	B-Gene_or_gene_product
antigen	E-Gene_or_gene_product
(	O
CEA	S-Gene_or_gene_product
)	O
,	O
or	O
nodal	O
involvement	O
.	O

However	O
,	O
survival	O
analysis	O
showed	O
that	O
the	O
COUP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
TFII	E-Gene_or_gene_product
-	O
positive	S-Gene_expression
group	O
had	O
a	O
significantly	O
better	O
OS	O
compared	O
to	O
COUP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
TFII	E-Gene_or_gene_product
-	O
negative	S-Gene_expression
group	O
(	O
80	O
.	O
4	O
%	O
vs	O
.	O
57	O
.	O
7	O
%	O
,	O
P	O
=	O
0	O
.	O
0491	O
)	O
.	O

Based	O
on	O
our	O
results	O
,	O
COUP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
TFII	E-Gene_or_gene_product
may	O
represent	O
a	O
biomarker	O
for	O
good	O
prognosis	O
in	O
colorectal	B-Pathological_formation
cancer	E-Pathological_formation
.	O

p53	S-Gene_or_gene_product
hot	O
-	O
spot	O
mutants	O
increase	S-Positive_regulation
tumor	S-Pathological_formation
vascularization	S-Blood_vessel_development
via	O
ROS	S-Drug_or_compound
-	O
mediated	S-Positive_regulation
activation	S-Positive_regulation
of	O
the	O
HIF1	S-Gene_or_gene_product
/	O
VEGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
A	E-Gene_or_gene_product
pathway	S-Pathway
.	O

The	O
function	O
of	O
p53	S-Gene_or_gene_product
tumor	S-Pathological_formation
suppressor	O
is	O
often	O
altered	O
in	O
various	O
human	S-Organism
tumors	S-Pathological_formation
predominantly	O
through	O
missense	O
-	O
mutations	O
resulting	O
in	O
accumulation	O
of	O
mutant	O
proteins	O
.	O

We	O
revealed	O
that	O
expression	S-Gene_expression
of	O
p53	S-Gene_or_gene_product
proteins	O
with	O
amino	O
-	O
acid	O
substitutions	O
at	O
codons	O
175	O
(	O
R175H	O
)	O
,	O
248	O
(	O
R248W	O
)	O
,	O
and	O
273	O
(	O
R273H	O
)	O
,	O
representing	O
the	O
hot	O
-	O
spots	O
of	O
mutations	O
in	O
various	O
human	S-Organism
tumors	S-Pathological_formation
,	O
increased	S-Positive_regulation
the	O
number	O
of	O
vessels	S-Multi-tissue_structure
in	O
HCT116	B-Pathological_formation
human	I-Pathological_formation
colon	I-Pathological_formation
carcinoma	I-Pathological_formation
xenografts	E-Pathological_formation
and	O
,	O
as	O
a	O
result	O
,	O
accelerated	S-Positive_regulation
their	O
growth	S-Growth
.	O

Stimulation	S-Positive_regulation
of	O
tumor	S-Pathological_formation
angiogenesis	S-Blood_vessel_development
was	O
connected	O
with	O
about	O
2	O
-	O
fold	O
increase	S-Positive_regulation
in	O
intracellular	O
level	O
of	O
reactive	B-Drug_or_compound
oxygen	I-Drug_or_compound
species	E-Drug_or_compound
(	O
ROS	S-Drug_or_compound
)	O
.	O

Antioxidant	O
N	B-Drug_or_compound
-	I-Drug_or_compound
acetyl	I-Drug_or_compound
-	I-Drug_or_compound
l	I-Drug_or_compound
-	I-Drug_or_compound
aspartate	E-Drug_or_compound
(	O
NAC	S-Drug_or_compound
)	O
decreased	S-Negative_regulation
vessels	S-Multi-tissue_structure
number	O
in	O
tumors	S-Pathological_formation
formed	S-Development
by	O
cells	S-Cell
with	O
inactivated	S-Negative_regulation
p53	S-Gene_or_gene_product
and	O
inhibited	S-Negative_regulation
their	O
growth	S-Growth
.	O

Effect	S-Regulation
of	O
ROS	S-Drug_or_compound
on	O
angiogenesis	S-Blood_vessel_development
in	O
tumors	S-Pathological_formation
expressing	S-Gene_expression
hot	O
-	O
spot	O
p53	S-Gene_or_gene_product
mutants	O
was	O
correlated	O
with	O
their	O
ability	O
to	O
increase	S-Positive_regulation
a	O
content	O
of	O
HIF1	S-Gene_or_gene_product
transcriptional	O
factor	O
responsible	S-Regulation
for	O
up	B-Positive_regulation
-	I-Positive_regulation
regulation	E-Positive_regulation
of	O
VEGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
A	E-Gene_or_gene_product
mRNAs	O
.	O

Estradiol	S-Drug_or_compound
increases	S-Positive_regulation
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	E-Gene_or_gene_product
secretion	S-Localization
of	O
normal	O
human	S-Organism
breast	B-Tissue
tissue	E-Tissue
and	O
breast	B-Pathological_formation
cancer	E-Pathological_formation
in	O
vivo	O
.	O

IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	E-Gene_or_gene_product
or	O
CXCL8	S-Gene_or_gene_product
has	O
been	O
associated	S-Regulation
with	O
tumor	S-Pathological_formation
angiogenesis	S-Blood_vessel_development
,	O
metastasis	S-Localization
,	O
and	O
poor	O
prognosis	O
in	O
breast	B-Pathological_formation
cancer	E-Pathological_formation
.	O

Estrogen	S-Drug_or_compound
is	O
crucial	S-Positive_regulation
in	O
breast	S-Organism_subdivision
carcinogenesis	O
and	O
tumor	S-Pathological_formation
progression	S-Development
.	O

Whether	O
sex	O
steroids	O
affect	S-Regulation
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	E-Gene_or_gene_product
secretion	S-Localization
of	O
normal	O
breast	B-Tissue
tissue	E-Tissue
or	O
breast	B-Pathological_formation
cancer	E-Pathological_formation
is	O
not	O
known	O
.	O

Several	O
cell	S-Cell
types	O
in	O
a	O
tissue	S-Tissue
secrete	S-Localization
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	E-Gene_or_gene_product
.	O

Hence	O
,	O
regulatory	S-Regulation
mechanisms	O
of	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	E-Gene_or_gene_product
need	O
to	O
be	O
investigated	O
in	O
whole	O
tissue	S-Tissue
.	O

We	O
used	O
microdialysis	O
to	O
sample	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	E-Gene_or_gene_product
in	O
normal	O
human	S-Organism
breast	B-Tissue
tissue	E-Tissue
in	O
situ	O
in	O
pre	O
-	O
and	O
postmenopausal	O
women	S-Organism
,	O
preoperatively	O
in	O
breast	B-Pathological_formation
cancers	E-Pathological_formation
of	O
women	S-Organism
,	O
and	O
in	O
experimental	B-Pathological_formation
breast	I-Pathological_formation
cancer	E-Pathological_formation
in	O
mice	S-Organism
.	O

We	O
found	O
a	O
significant	O
positive	O
correlation	O
between	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	E-Gene_or_gene_product
and	O
estradiol	S-Drug_or_compound
in	O
normal	O
breast	B-Tissue
tissue	E-Tissue
and	O
hormone	B-Pathological_formation
-	I-Pathological_formation
dependent	I-Pathological_formation
breast	I-Pathological_formation
cancer	E-Pathological_formation
in	O
vivo	O
.	O

Ex	O
vivo	O
,	O
estradiol	S-Drug_or_compound
exposure	S-Planned_process
increased	S-Positive_regulation
the	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	E-Gene_or_gene_product
secretion	S-Localization
of	O
normal	O
whole	O
breast	B-Tissue
tissue	E-Tissue
in	O
culture	S-Planned_process
.	O

In	O
experimental	O
breast	B-Pathological_formation
cancer	E-Pathological_formation
,	O
estradiol	S-Drug_or_compound
increased	S-Positive_regulation
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	E-Gene_or_gene_product
whereas	O
the	O
anti	O
-	O
estrogen	O
tamoxifen	S-Drug_or_compound
inhibited	S-Negative_regulation
the	O
secretion	S-Localization
of	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	E-Gene_or_gene_product
both	O
in	O
vitro	O
and	O
extracellularly	O
in	O
vivo	O
in	O
tumors	S-Pathological_formation
of	O
nude	B-Organism
mice	E-Organism
.	O

An	O
anti	B-Drug_or_compound
-	I-Drug_or_compound
IL	I-Drug_or_compound
-	I-Drug_or_compound
8	I-Drug_or_compound
Ab	E-Drug_or_compound
inhibited	S-Negative_regulation
endothelial	B-Cell
cell	E-Cell
proliferation	S-Cell_proliferation
induced	S-Positive_regulation
by	O
cancer	B-Cell
cell	E-Cell
produced	S-Gene_expression
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	E-Gene_or_gene_product
and	O
tumors	S-Pathological_formation
with	O
low	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	E-Gene_or_gene_product
levels	O
exhibited	O
decreased	S-Negative_regulation
angiogenesis	S-Blood_vessel_development
.	O

Our	O
results	O
strongly	O
suggest	O
that	O
estradiol	S-Drug_or_compound
has	O
a	O
critical	B-Regulation
role	E-Regulation
in	O
the	O
regulation	S-Regulation
of	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	E-Gene_or_gene_product
in	O
normal	O
human	S-Organism
breast	B-Tissue
tissue	E-Tissue
and	O
human	S-Organism
breast	B-Pathological_formation
cancer	E-Pathological_formation
.	O

IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
8	E-Gene_or_gene_product
may	O
present	O
a	O
novel	O
therapeutic	O
target	O
for	O
estrogen	S-Drug_or_compound
driven	S-Regulation
breast	S-Organism_subdivision
carcinogenesis	O
and	O
tumor	S-Pathological_formation
progression	S-Development
.	O

Involvement	O
of	O
PTEN	S-Gene_or_gene_product
promoter	S-DNA_domain_or_region
methylation	S-DNA_methylation
in	O
cerebral	B-Pathological_formation
cavernous	I-Pathological_formation
malformations	E-Pathological_formation
.	O

BACKGROUND	O
AND	O
PURPOSE	O
:	O
Cerebral	B-Pathological_formation
cavernous	I-Pathological_formation
malformations	E-Pathological_formation
(	O
CCMs	S-Pathological_formation
)	O
are	O
prevalent	O
cerebral	B-Pathological_formation
vascular	I-Pathological_formation
lesions	E-Pathological_formation
involving	O
aberrant	O
angiogenesis	S-Blood_vessel_development
.	O

However	O
,	O
the	O
underlying	O
mechanism	O
is	O
poorly	O
understood	O
.	O

Phosphatase	B-Gene_or_gene_product
and	I-Gene_or_gene_product
tension	I-Gene_or_gene_product
homolog	I-Gene_or_gene_product
deleted	I-Gene_or_gene_product
on	I-Gene_or_gene_product
chromosome	I-Gene_or_gene_product
10	E-Gene_or_gene_product
(	O
PTEN	S-Gene_or_gene_product
)	O
,	O
a	O
tumor	S-Pathological_formation
suppressor	O
,	O
is	O
frequently	O
deficient	S-Gene_expression
in	O
various	O
pathologies	O
due	O
to	O
mutation	O
or	O
epigenetic	O
alterations	O
.	O

PTEN	S-Gene_or_gene_product
promoter	S-DNA_domain_or_region
hypermethylation	S-DNA_methylation
is	O
a	O
major	O
epigenetic	O
silencing	O
mechanism	O
leading	S-Positive_regulation
to	O
activation	S-Positive_regulation
of	O
angiogenesis	S-Blood_vessel_development
in	O
tumors	S-Pathological_formation
.	O

The	O
present	O
study	O
aimed	O
to	O
investigate	O
whether	O
PTEN	S-Gene_or_gene_product
promoter	S-DNA_domain_or_region
methylation	S-DNA_methylation
was	O
involved	O
in	O
CCMs	S-Pathological_formation
.	O

METHODS	O
:	O
PTEN	S-Gene_or_gene_product
promoter	S-DNA_domain_or_region
methylation	S-DNA_methylation
was	O
detected	O
in	O
surgical	O
specimens	O
of	O
CCMs	S-Pathological_formation
(	O
n	O
=	O
69	O
)	O
by	O
methylation	O
-	O
specific	O
polymerase	O
chain	O
reaction	O
.	O

The	O
methylation	O
status	O
was	O
correlated	O
to	O
the	O
clinical	O
manifestations	O
and	O
to	O
PTEN	S-Gene_or_gene_product
expression	S-Gene_expression
,	O
which	O
was	O
analyzed	O
by	O
both	O
Western	O
blot	O
and	O
immunohistochemistry	O
.	O

To	O
investigate	O
the	O
endothelial	S-Cell
proliferation	S-Cell_proliferation
and	O
the	O
potential	O
signaling	O
pathways	O
affected	S-Regulation
by	O
PTEN	S-Gene_or_gene_product
methylation	S-DNA_methylation
,	O
proliferating	B-Gene_or_gene_product
cell	I-Gene_or_gene_product
nuclear	I-Gene_or_gene_product
antigen	E-Gene_or_gene_product
as	O
well	O
as	O
phosphor	B-Gene_or_gene_product
-	I-Gene_or_gene_product
Akt	E-Gene_or_gene_product
and	O
phosphor	B-Gene_or_gene_product
-	I-Gene_or_gene_product
Erk1	I-Gene_or_gene_product
,	I-Gene_or_gene_product
2	E-Gene_or_gene_product
were	O
detected	O
by	O
immunofluorescence	O
and	O
Western	O
blot	O
,	O
respectively	O
,	O
in	O
CCM	S-Pathological_formation
specimens	O
.	O

RESULTS	O
:	O
Methylation	O
-	O
specific	O
polymerase	O
chain	O
reaction	O
revealed	O
PTEN	S-Gene_or_gene_product
promoter	S-DNA_domain_or_region
methylation	S-DNA_methylation
in	O
15	O
.	O
9	O
%	O
CCMs	S-Pathological_formation
.	O

Strikingly	O
,	O
5	O
of	O
6	O
familial	O
CCMs	S-Pathological_formation
showed	O
PTEN	S-Gene_or_gene_product
promoter	S-DNA_domain_or_region
methylation	S-DNA_methylation
(	O
83	O
.	O
3	O
%	O
)	O
,	O
which	O
was	O
significantly	O
higher	O
than	O
in	O
sporadic	O
cases	O
(	O
9	O
.	O
4	O
%	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

In	O
addition	O
,	O
PTEN	S-Gene_or_gene_product
promoter	S-DNA_domain_or_region
methylation	S-DNA_methylation
appeared	O
more	O
frequently	O
in	O
multiple	O
CCMs	S-Pathological_formation
,	O
including	O
familial	O
cases	O
(	O
46	O
.	O
7	O
%	O
)	O
,	O
than	O
that	O
in	O
single	O
-	O
lesioned	O
CCMs	S-Pathological_formation
(	O
11	O
.	O
8	O
%	O
;	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Immunostaining	O
and	O
Western	O
blot	O
revealed	O
a	O
more	O
significant	O
PTEN	S-Gene_or_gene_product
downregulation	S-Negative_regulation
in	O
PTEN	S-Gene_or_gene_product
-	O
methylated	S-DNA_methylation
CCMs	S-Pathological_formation
in	O
comparison	O
to	O
PTEN	S-Gene_or_gene_product
-	O
unmethylated	S-DNA_methylation
CCMs	S-Pathological_formation
.	O

Reduced	S-Negative_regulation
PTEN	S-Gene_or_gene_product
expression	S-Gene_expression
was	O
inversely	O
correlated	O
to	O
the	O
expression	S-Gene_expression
of	O
proliferating	B-Gene_or_gene_product
cell	I-Gene_or_gene_product
nuclear	I-Gene_or_gene_product
antigen	E-Gene_or_gene_product
and	O
to	O
the	O
activation	S-Positive_regulation
of	O
Erk1	S-Gene_or_gene_product
,	O
2	S-Gene_or_gene_product
,	O
but	O
not	O
of	O
Akt	S-Gene_or_gene_product
.	O

CONCLUSIONS	O
:	O
We	O
reported	O
here	O
for	O
the	O
first	O
time	O
the	O
involvement	O
of	O
PTEN	S-Gene_or_gene_product
promoter	S-DNA_domain_or_region
methylation	S-DNA_methylation
in	O
CCMs	S-Pathological_formation
,	O
particularly	O
in	O
familial	O
CCMs	S-Pathological_formation
,	O
suggesting	O
this	O
epigenetic	O
alteration	O
as	O
a	O
potential	O
pathomechanism	O
of	O
CCMs	S-Pathological_formation
.	O

The	O
identification	O
of	O
Erk1	S-Gene_or_gene_product
,	O
2	S-Gene_or_gene_product
as	O
triggered	O
signaling	O
in	O
the	O
lesions	S-Pathological_formation
may	O
be	O
valuable	O
for	O
the	O
development	O
of	O
effective	O
therapy	O
for	O
this	O
disease	O
.	O

Grape	B-Organism_substance
seed	I-Organism_substance
extract	E-Organism_substance
inhibits	S-Negative_regulation
angiogenesis	S-Blood_vessel_development
via	O
suppression	S-Negative_regulation
of	O
the	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
receptor	E-Gene_or_gene_product
signaling	B-Pathway
pathway	E-Pathway
.	O

Blockade	S-Negative_regulation
of	O
angiogenesis	S-Blood_vessel_development
is	O
an	O
important	O
approach	O
for	O
cancer	S-Pathological_formation
treatment	S-Planned_process
and	O
prevention	S-Negative_regulation
.	O

Vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
(	O
VEGF	S-Gene_or_gene_product
)	O
is	O
one	O
of	O
the	O
most	O
critical	O
factors	O
that	O
induce	S-Positive_regulation
angiogenesis	S-Blood_vessel_development
and	O
has	O
thus	O
become	O
an	O
attractive	O
target	O
for	O
antiangiogenesis	S-Blood_vessel_development
treatment	S-Negative_regulation
.	O

However	O
,	O
most	O
current	O
anti	O
-	O
VEGF	S-Gene_or_gene_product
agents	O
often	O
cause	O
some	O
side	O
effects	O
when	O
given	O
chronically	O
.	O

Identification	O
of	O
naturally	O
occurring	O
VEGF	S-Gene_or_gene_product
inhibitors	O
derived	O
from	O
diet	O
would	O
be	O
one	O
alternative	O
approach	O
with	O
an	O
advantage	O
of	O
known	O
safety	O
.	O

Grape	B-Organism_substance
seed	I-Organism_substance
extract	E-Organism_substance
(	O
GSE	S-Organism_substance
)	O
,	O
a	O
widely	O
used	O
dietary	O
supplement	O
,	O
is	O
known	O
to	O
have	O
antitumor	S-Pathological_formation
activity	S-Negative_regulation
.	O

In	O
this	O
study	O
,	O
we	O
have	O
explored	O
the	O
activity	O
of	O
GSE	S-Organism_substance
on	O
VEGF	B-Gene_or_gene_product
receptor	E-Gene_or_gene_product
and	O
angiogenesis	S-Blood_vessel_development
.	O

We	O
found	O
that	O
GSE	S-Organism_substance
could	O
directly	O
inhibit	S-Negative_regulation
the	O
kinase	O
activity	O
of	O
purified	O
VEGF	B-Gene_or_gene_product
receptor	I-Gene_or_gene_product
2	E-Gene_or_gene_product
,	O
a	O
novel	O
activity	O
of	O
GSE	S-Organism_substance
that	O
has	O
not	O
been	O
characterized	O
.	O

GSE	S-Organism_substance
could	O
also	O
inhibit	S-Negative_regulation
the	O
VEGF	B-Gene_or_gene_product
receptor	E-Gene_or_gene_product
/	O
mitogen	B-Gene_or_gene_product
-	I-Gene_or_gene_product
activated	I-Gene_or_gene_product
protein	I-Gene_or_gene_product
kinase	E-Gene_or_gene_product
-	O
mediated	S-Positive_regulation
signaling	B-Pathway
pathway	E-Pathway
in	O
endothelial	B-Cell
cells	E-Cell
.	O

As	O
a	O
result	O
,	O
GSE	S-Organism_substance
could	O
inhibit	S-Negative_regulation
VEGF	S-Gene_or_gene_product
-	O
induced	S-Positive_regulation
endothelial	B-Cell
cell	E-Cell
proliferation	S-Cell_proliferation
and	O
migration	S-Localization
as	O
well	O
as	O
sprout	S-Tissue
formation	S-Development
from	O
aorta	B-Multi-tissue_structure
ring	E-Multi-tissue_structure
.	O

In	O
vivo	O
assay	O
further	O
showed	O
that	O
GSE	S-Organism_substance
could	O
inhibit	S-Negative_regulation
tumor	S-Pathological_formation
growth	S-Growth
and	O
tumor	S-Pathological_formation
angiogenesis	S-Blood_vessel_development
of	O
MDA	B-Cell
-	I-Cell
MB	I-Cell
-	I-Cell
231	I-Cell
breast	I-Cell
cancer	I-Cell
cells	E-Cell
in	O
mice	S-Organism
.	O

Consistent	O
with	O
the	O
in	O
vitro	O
data	O
,	O
GSE	S-Organism_substance
treatment	S-Planned_process
of	O
tumor	S-Pathological_formation
-	O
bearing	O
mice	S-Organism
led	S-Positive_regulation
to	O
concomitant	O
reduction	S-Negative_regulation
of	O
blood	B-Multi-tissue_structure
vessel	E-Multi-tissue_structure
density	O
and	O
phosphorylation	S-Phosphorylation
of	O
mitogen	B-Gene_or_gene_product
-	I-Gene_or_gene_product
activated	I-Gene_or_gene_product
protein	I-Gene_or_gene_product
kinase	E-Gene_or_gene_product
.	O

Depletion	S-Negative_regulation
of	O
polyphenol	S-Drug_or_compound
with	O
polyvinylpyrrolidone	S-Drug_or_compound
abolished	S-Negative_regulation
the	O
antiangiogenic	S-Blood_vessel_development
activity	S-Negative_regulation
of	O
GSE	S-Organism_substance
,	O
suggesting	O
a	O
water	O
-	O
soluble	O
fraction	O
of	O
polyphenol	S-Drug_or_compound
in	O
GSE	S-Organism_substance
is	O
responsible	S-Positive_regulation
for	O
the	O
antiangiogenic	S-Blood_vessel_development
activity	S-Negative_regulation
.	O

Taken	O
together	O
,	O
this	O
study	O
indicates	O
that	O
GSE	S-Organism_substance
is	O
a	O
well	O
-	O
tolerated	O
and	O
inexpensive	O
natural	O
VEGF	S-Gene_or_gene_product
inhibitor	O
and	O
could	O
potentially	O
be	O
useful	O
in	O
cancer	S-Pathological_formation
prevention	S-Negative_regulation
or	O
treatment	S-Planned_process
.	O

Effect	S-Regulation
of	O
estrogen	S-Drug_or_compound
and	O
progesterone	S-Drug_or_compound
on	O
macrophage	S-Cell
activation	S-Positive_regulation
during	O
wound	O
healing	O
.	O

Age	O
-	O
related	O
impaired	O
wound	O
healing	O
leads	O
to	O
substantial	O
morbidity	O
and	O
mortality	O
along	O
with	O
a	O
large	O
financial	O
burden	O
to	O
health	O
services	O
.	O

There	O
is	O
accumulating	O
evidence	O
that	O
the	O
tissue	S-Tissue
damage	S-Breakdown
associated	O
with	O
chronic	O
wounds	O
is	O
initiated	S-Positive_regulation
and	O
propagated	O
by	O
an	O
inappropriately	O
excessive	O
inflammatory	O
response	O
.	O

Research	O
on	O
age	O
-	O
related	O
impaired	O
wound	O
healing	O
suggests	O
that	O
the	O
decline	O
in	O
sex	B-Drug_or_compound
steroid	I-Drug_or_compound
hormones	E-Drug_or_compound
with	O
age	O
may	O
have	O
a	O
substantial	O
influence	O
on	O
the	O
inflammatory	O
response	O
in	O
vivo	O
.	O

Topical	O
and	O
systemic	O
estrogen	S-Drug_or_compound
treatments	S-Planned_process
have	O
shown	O
an	O
increased	O
rate	O
of	O
healing	O
by	O
reducing	O
inflammation	O
,	O
however	O
the	O
underlying	O
mechanisms	O
are	O
little	O
understood	O
.	O

In	O
vitro	O
studies	O
also	O
suggest	O
progesterone	S-Drug_or_compound
may	O
play	O
a	O
role	O
in	O
modulating	O
inflammation	O
.	O

Macrophages	S-Cell
are	O
essential	O
mediators	O
of	O
inflammation	O
and	O
wound	O
healing	O
.	O

Macrophages	S-Cell
can	O
be	O
activated	S-Positive_regulation
in	O
a	O
classical	O
or	O
alternative	O
manner	O
in	O
parallel	O
with	O
the	O
T	B-Cell
(	I-Cell
H	I-Cell
)	I-Cell
1	E-Cell
/	O
T	B-Cell
(	I-Cell
H	I-Cell
)	I-Cell
2	E-Cell
dichotomy	O
,	O
respectively	O
.	O

Using	O
a	O
murine	S-Organism
incisional	O
wound	O
healing	O
model	O
this	O
study	O
was	O
carried	O
out	O
to	O
investigate	O
the	B-Regulation
roles	I-Regulation
of	E-Regulation
estrogen	S-Drug_or_compound
and	O
progesterone	S-Drug_or_compound
on	O
macrophage	S-Cell
activation	S-Positive_regulation
during	O
the	O
wound	O
healing	O
response	O
.	O

Our	O
findings	O
suggest	O
with	O
a	O
reduction	S-Negative_regulation
of	O
steroid	B-Drug_or_compound
hormones	E-Drug_or_compound
following	O
ovariectomy	O
,	O
alternatively	O
activated	S-Positive_regulation
macrophage	S-Cell
markers	O
(	O
Fizz1	S-Gene_or_gene_product
and	O
Ym1	S-Gene_or_gene_product
)	O
were	O
reduced	S-Negative_regulation
,	O
with	O
this	O
effect	O
being	O
reversed	S-Negative_regulation
with	O
the	O
administration	S-Planned_process
of	O
estrogen	S-Drug_or_compound
or	O
progesterone	S-Drug_or_compound
;	O
suggesting	O
that	O
with	O
the	O
reduction	S-Negative_regulation
of	O
steroid	B-Drug_or_compound
hormones	E-Drug_or_compound
macrophages	S-Cell
are	O
activated	S-Positive_regulation
in	O
a	O
classical	O
manner	O
,	O
promoting	O
inflammation	O
,	O
whereas	O
estrogen	S-Drug_or_compound
or	O
progesterone	S-Drug_or_compound
are	O
contributing	S-Regulation
toward	O
macrophage	S-Cell
activation	S-Positive_regulation
in	O
an	O
alternative	O
manner	O
,	O
driving	S-Positive_regulation
wound	S-Pathological_formation
repair	O
,	O
angiogenesis	S-Blood_vessel_development
,	O
and	O
remodeling	O
.	O

Effect	S-Gene_or_gene_product
of	O
platelet	B-Organism_substance
-	I-Organism_substance
rich	I-Organism_substance
plasma	E-Organism_substance
and	O
fibrin	S-Gene_or_gene_product
glue	O
on	O
healing	O
of	O
critical	O
-	O
size	O
calvarial	B-Organ
bone	E-Organ
defects	O
.	O

Despite	O
the	O
insufficient	O
number	O
of	O
experimental	O
studies	O
,	O
platelet	B-Organism_substance
-	I-Organism_substance
rich	I-Organism_substance
plasma	E-Organism_substance
(	O
PRP	S-Organism_substance
)	O
including	O
high	O
amounts	O
of	O
growth	O
factors	O
is	O
introduced	O
to	O
clinical	O
use	O
rapidly	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
effects	S-Regulation
of	O
PRP	S-Organism_substance
and	O
platelet	B-Organism_substance
-	I-Organism_substance
poor	I-Organism_substance
plasma	E-Organism_substance
(	O
PPP	S-Organism_substance
)	O
on	O
healing	O
of	O
critical	O
-	O
size	O
bone	S-Organ
defects	O
.	O
Bilateral	O
full	O
-	O
thickness	O
,	O
critical	O
-	O
size	O
bone	S-Organ
defects	O
were	O
created	O
in	O
the	O
parietal	B-Organ
bones	E-Organ
of	O
32	O
rabbits	S-Organism
,	O
which	O
had	O
been	O
studied	O
in	O
4	O
groups	O
.	O

Saline	S-Drug_or_compound
,	O
thrombin	S-Gene_or_gene_product
solution	O
,	O
PPP	S-Organism_substance
,	O
and	O
PRP	S-Organism_substance
were	O
applied	S-Planned_process
to	O
the	O
created	O
defects	O
before	O
closure	O
.	O

Radiologic	O
defect	O
area	O
measurement	O
results	O
at	O
0	O
,	O
4	O
,	O
and	O
16	O
weeks	O
were	O
compared	O
between	O
the	O
groups	O
.	O

In	O
addition	O
,	O
densities	O
of	O
the	O
newly	O
formed	S-Development
bones	S-Organ
at	O
16th	O
week	O
were	O
studied	O
.	O

Histologic	O
parameters	O
(	O
primary	O
and	O
secondary	O
bone	B-Tissue
trabecula	E-Tissue
,	O
neovascularization	S-Blood_vessel_development
,	O
and	O
bone	B-Multi-tissue_structure
marrow	E-Multi-tissue_structure
and	O
connective	B-Tissue
tissue	E-Tissue
formation	S-Development
)	O
were	O
compared	O
between	O
4	O
-	O
and	O
16	O
-	O
week	O
groups	O
.	O
More	O
rapid	O
decrease	O
in	O
defect	O
size	O
was	O
observed	O
in	O
groups	O
3	O
and	O
4	O
than	O
in	O
groups	O
1	O
and	O
2	O
,	O
both	O
in	O
the	O
4th	O
and	O
16th	O
weeks	O
.	O

Newly	O
formed	S-Development
bone	S-Organ
densities	O
were	O
also	O
found	O
to	O
be	O
higher	O
in	O
these	O
2	O
groups	O
.	O

New	O
bone	S-Organ
formation	S-Development
was	O
detected	O
to	O
be	O
more	O
rapid	O
considering	O
histologic	O
parameters	O
,	O
in	O
groups	O
3	O
and	O
4	O
at	O
4th	O
and	O
16th	O
weeks	O
.	O
Study	O
demonstrates	O
that	O
PRP	S-Organism_substance
and	O
PPP	S-Organism_substance
might	O
have	O
favorable	O
effects	S-Regulation
on	O
bone	S-Organ
healing	O
.	O

Although	O
we	O
cannot	O
reveal	O
any	O
statistical	O
difference	O
between	O
these	O
2	O
substances	O
considering	O
osteoinductive	O
potential	O
,	O
PRP	S-Organism_substance
group	O
has	O
demonstrated	O
superior	O
results	O
compared	O
with	O
fibrin	S-Gene_or_gene_product
glue	O
group	O
.	O

Higher	O
platelet	S-Cell
concentrations	O
may	O
expose	O
beneficial	O
effects	O
of	O
PRP	S-Organism_substance
.	O

Host	O
-	O
derived	O
angiopoietin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
affects	S-Regulation
early	O
stages	O
of	O
tumor	S-Pathological_formation
development	S-Development
and	O
vessel	S-Multi-tissue_structure
maturation	S-Development
but	O
is	O
dispensable	S-Regulation
for	O
later	O
stages	O
of	O
tumor	S-Pathological_formation
growth	S-Growth
.	O

The	O
angiopoietin	S-Gene_or_gene_product
/	O
Tie2	S-Gene_or_gene_product
system	S-Pathway
has	O
been	O
identified	O
as	O
the	O
second	O
vascular	S-Multi-tissue_structure
-	O
specific	O
receptor	O
tyrosine	O
kinase	O
system	O
controlling	S-Regulation
vessel	S-Multi-tissue_structure
assembly	S-Development
,	O
maturation	S-Development
,	O
and	O
quiescence	S-Development
.	O

Angiopoietin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
(	O
Ang	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
)	O
is	O
prominently	O
up	B-Positive_regulation
-	I-Positive_regulation
regulated	E-Positive_regulation
in	O
the	O
host	O
-	O
derived	O
vasculature	S-Multi-tissue_structure
of	O
most	O
tumors	S-Pathological_formation
,	O
making	O
it	O
an	O
attractive	O
candidate	O
for	O
antiangiogenic	S-Blood_vessel_development
intervention	S-Negative_regulation
.	O

Yet	O
,	O
the	O
net	O
outcome	O
of	O
Ang	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
functions	O
on	O
tumor	S-Pathological_formation
angiogenesis	S-Blood_vessel_development
is	O
believed	O
to	O
be	O
contextual	O
depending	S-Regulation
on	O
the	O
local	O
cytokine	O
milieu	O
.	O

Correspondingly	O
,	O
Ang	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
manipulatory	O
therapies	O
have	O
been	O
shown	O
to	O
exert	O
protumorigenic	O
as	O
well	O
as	O
antitumorigenic	O
effects	O
.	O

To	O
clarify	O
the	O
role	S-Regulation
of	O
Ang	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
for	O
angiogenesis	S-Blood_vessel_development
and	O
tumor	S-Pathological_formation
growth	S-Growth
in	O
a	O
definite	O
genetic	O
experimental	O
setting	O
,	O
the	O
present	O
study	O
was	O
aimed	O
at	O
comparatively	O
studying	O
the	O
growth	S-Growth
of	O
different	O
tumors	S-Pathological_formation
in	O
wild	O
-	O
type	O
and	O
Ang	B-Organism
-	I-Organism
2	I-Organism
-	I-Organism
deficient	I-Organism
mice	E-Organism
.	O

Lewis	B-Pathological_formation
lung	I-Pathological_formation
carcinomas	E-Pathological_formation
,	O
MT	B-Pathological_formation
-	I-Pathological_formation
ret	I-Pathological_formation
melanomas	E-Pathological_formation
,	O
and	O
B16F10	B-Pathological_formation
melanomas	E-Pathological_formation
all	O
grew	S-Growth
slower	O
in	O
Ang	B-Organism
-	I-Organism
2	I-Organism
-	I-Organism
deficient	I-Organism
mice	E-Organism
.	O

Yet	O
,	O
tumor	S-Pathological_formation
growth	S-Growth
in	O
wild	O
-	O
type	O
and	O
Ang	B-Organism
-	I-Organism
2	I-Organism
-	I-Organism
deficient	I-Organism
mice	E-Organism
dissociated	O
during	O
early	O
stages	O
of	O
tumor	S-Pathological_formation
development	S-Development
,	O
whereas	O
tumor	S-Pathological_formation
growth	S-Growth
rates	O
during	O
later	O
stages	O
of	O
primary	O
tumor	S-Pathological_formation
progression	S-Development
were	O
similar	O
.	O

Analysis	O
of	O
the	O
intratumoral	B-Multi-tissue_structure
vascular	I-Multi-tissue_structure
architecture	E-Multi-tissue_structure
revealed	O
no	O
major	O
differences	O
in	O
microvessel	S-Tissue
density	O
and	O
perfusion	S-Localization
characteristics	O
.	O

However	O
,	O
diameters	O
of	O
intratumoral	B-Tissue
microvessels	E-Tissue
were	O
smaller	O
in	O
tumors	S-Pathological_formation
grown	S-Growth
in	O
Ang	B-Organism
-	I-Organism
2	I-Organism
-	I-Organism
deficient	I-Organism
mice	E-Organism
,	O
and	O
the	O
vasculature	S-Multi-tissue_structure
had	O
an	O
altered	O
pattern	O
of	O
pericyte	S-Cell
recruitment	S-Localization
and	O
maturation	S-Development
.	O

Ang	B-Tissue
-	I-Tissue
2	I-Tissue
-	I-Tissue
deficient	I-Tissue
tumor	I-Tissue
vessels	E-Tissue
had	O
higher	O
pericyte	S-Cell
coverage	O
indices	O
.	O

Recruited	S-Localization
pericytes	S-Cell
were	O
desmin	S-Gene_or_gene_product
and	O
NG2	S-Gene_or_gene_product
positive	O
and	O
predominately	O
alpha	B-Gene_or_gene_product
-	I-Gene_or_gene_product
smooth	I-Gene_or_gene_product
muscle	I-Gene_or_gene_product
actin	E-Gene_or_gene_product
negative	O
,	O
indicative	O
of	O
a	O
more	O
mature	O
pericyte	S-Cell
phenotype	O
.	O

Collectively	O
,	O
the	O
experiments	O
define	O
the	O
role	S-Regulation
of	O
Ang	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
during	O
tumor	S-Pathological_formation
angiogenesis	S-Blood_vessel_development
and	O
establish	O
a	O
better	O
rationale	O
for	O
combination	O
therapies	O
involving	O
Ang	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
manipulatory	O
therapies	O
.	O

Short	B-Gene_or_gene_product
pigment	I-Gene_or_gene_product
epithelial	I-Gene_or_gene_product
-	I-Gene_or_gene_product
derived	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
-	I-Gene_or_gene_product
derived	I-Gene_or_gene_product
peptide	E-Gene_or_gene_product
inhibits	S-Negative_regulation
angiogenesis	S-Blood_vessel_development
and	O
tumor	S-Pathological_formation
growth	S-Growth
.	O

PURPOSE	O
:	O
Pigment	B-Gene_or_gene_product
epithelial	I-Gene_or_gene_product
-	I-Gene_or_gene_product
derived	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
(	O
PEDF	S-Gene_or_gene_product
)	O
is	O
a	O
potent	O
angiogenesis	S-Blood_vessel_development
inhibitor	O
with	O
multiple	O
other	O
functions	O
,	O
some	O
of	O
which	O
enhance	S-Positive_regulation
tumor	S-Pathological_formation
growth	S-Growth
.	O

Our	O
previous	O
studies	O
mapped	O
PEDF	S-Gene_or_gene_product
antiangiogenic	S-Blood_vessel_development
and	O
prosurvival	O
activities	S-Negative_regulation
to	O
distinct	O
epitopes	O
.	O

This	O
study	O
was	O
aimed	O
to	O
determine	O
the	O
minimal	O
fragment	O
of	O
PEDF	S-Gene_or_gene_product
,	O
which	O
maintains	O
antiangiogenic	S-Blood_vessel_development
and	O
antitumor	S-Pathological_formation
efficacy	S-Negative_regulation
.	O

EXPERIMENTAL	O
DESIGN	O
:	O
We	O
analyzed	O
antigenicity	O
,	O
hydrophilicity	O
,	O
and	O
charge	O
distribution	O
of	O
the	O
angioinhibitory	S-Blood_vessel_development
epitope	O
(	O
the	O
34	O
-	O
mer	O
)	O
and	O
designed	O
three	O
peptides	O
covering	O
its	O
COOH	O
terminus	O
,	O
P14	S-Gene_or_gene_product
,	O
P18	S-Gene_or_gene_product
,	O
and	O
P23	S-Gene_or_gene_product
.	O

We	O
analyzed	O
their	O
ability	O
to	O
block	S-Negative_regulation
endothelial	B-Cell
cell	E-Cell
chemotaxis	S-Localization
and	O
induce	S-Positive_regulation
apoptosis	S-Death
in	O
vitro	O
and	O
their	O
antiangiogenic	S-Blood_vessel_development
activity	S-Negative_regulation
in	O
vivo	O
.	O

The	O
selected	O
peptide	O
was	O
tested	O
for	O
the	O
antitumor	S-Pathological_formation
activity	S-Negative_regulation
against	O
mildly	O
aggressive	O
xenografted	S-Planned_process
prostate	B-Pathological_formation
carcinoma	E-Pathological_formation
and	O
highly	O
aggressive	O
renal	B-Pathological_formation
cell	I-Pathological_formation
carcinoma	E-Pathological_formation
.	O

To	O
verify	O
that	O
P18	S-Gene_or_gene_product
acts	O
in	O
the	O
same	O
manner	O
as	O
PEDF	S-Gene_or_gene_product
,	O
we	O
used	O
immunohistochemistry	O
to	O
measure	O
PEDF	B-Gene_or_gene_product
targets	E-Gene_or_gene_product
,	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
receptor	I-Gene_or_gene_product
2	E-Gene_or_gene_product
,	O
and	O
CD95	B-Gene_or_gene_product
ligand	E-Gene_or_gene_product
expression	S-Gene_expression
in	O
P18	S-Gene_or_gene_product
-	O
treated	S-Planned_process
vasculature	S-Multi-tissue_structure
.	O

RESULTS	O
:	O
P14	S-Gene_or_gene_product
and	O
P18	S-Gene_or_gene_product
blocked	S-Negative_regulation
endothelial	B-Cell
cell	E-Cell
chemotaxis	S-Localization
;	O
P18	S-Gene_or_gene_product
and	O
P23	S-Gene_or_gene_product
induced	S-Positive_regulation
apoptosis	S-Death
.	O

P18	S-Gene_or_gene_product
showed	O
the	O
highest	O
IC50	O
and	O
blocked	S-Negative_regulation
angiogenesis	S-Blood_vessel_development
in	O
vivo	O
:	O
P23	S-Gene_or_gene_product
was	O
inactive	S-Negative_regulation
and	O
P14	S-Gene_or_gene_product
was	O
proangiogenic	S-Blood_vessel_development
.	O

P18	S-Gene_or_gene_product
increased	S-Positive_regulation
the	O
production	S-Gene_expression
of	O
CD95	B-Gene_or_gene_product
ligand	E-Gene_or_gene_product
and	O
reduced	S-Negative_regulation
the	O
expression	S-Gene_expression
of	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
receptor	I-Gene_or_gene_product
2	E-Gene_or_gene_product
by	O
the	O
endothelial	B-Cell
cells	E-Cell
in	O
vivo	O
.	O

In	O
tumor	S-Pathological_formation
studies	O
,	O
P18	S-Gene_or_gene_product
was	O
more	O
effective	O
in	O
blocking	S-Negative_regulation
the	O
angiogenesis	S-Blood_vessel_development
and	O
growth	S-Growth
of	O
the	O
prostate	B-Pathological_formation
cancer	E-Pathological_formation
than	O
parental	B-Gene_or_gene_product
34	I-Gene_or_gene_product
-	I-Gene_or_gene_product
mer	E-Gene_or_gene_product
;	O
in	O
the	O
renal	B-Pathological_formation
cell	I-Pathological_formation
carcinoma	E-Pathological_formation
,	O
P18	S-Gene_or_gene_product
strongly	O
decreased	S-Negative_regulation
angiogenesis	S-Blood_vessel_development
and	O
halted	S-Negative_regulation
the	O
progression	S-Positive_regulation
of	O
established	O
tumors	S-Pathological_formation
.	O

CONCLUSIONS	O
:	O
P18	S-Gene_or_gene_product
is	O
a	O
novel	O
and	O
potent	O
antiangiogenic	S-Blood_vessel_development
biotherapeutic	O
agent	O
that	O
has	O
potential	O
to	O
be	O
developed	O
for	O
the	O
treatment	S-Planned_process
of	O
prostate	S-Pathological_formation
and	O
renal	B-Pathological_formation
cancer	E-Pathological_formation
.	O

Aflibercept	S-Drug_or_compound
(	O
AVE0005	S-Drug_or_compound
)	O
:	O
an	O
alternative	O
strategy	O
for	O
inhibiting	S-Negative_regulation
tumour	S-Pathological_formation
angiogenesis	S-Blood_vessel_development
by	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factors	E-Gene_or_gene_product
.	O

BACKGROUND	O
:	O
Aberrant	S-Regulation
angiogenesis	S-Blood_vessel_development
is	O
a	O
landmark	O
feature	O
in	O
cancer	S-Pathological_formation
,	O
which	O
is	O
important	O
for	O
proliferation	O
,	O
growth	O
and	O
metastasis	O
,	O
and	O
is	O
mediated	S-Regulation
by	O
various	O
pro	O
-	O
angiogenic	S-Blood_vessel_development
factors	O
.	O

The	O
VEGF	S-Gene_or_gene_product
pathway	S-Pathway
is	O
one	O
of	O
the	O
most	O
important	O
and	O
best	O
-	O
studied	O
angiogenic	S-Blood_vessel_development
pathways	O
.	O

Inhibition	S-Negative_regulation
of	O
this	O
pathway	O
may	O
provide	O
clinical	O
benefits	O
to	O
cancer	S-Pathological_formation
patients	S-Organism
.	O

OBJECTIVES	O
:	O
Strategies	O
to	O
inhibit	S-Negative_regulation
the	O
VEGF	S-Gene_or_gene_product
pathway	S-Pathway
,	O
including	O
antibodies	B-Gene_or_gene_product
to	I-Gene_or_gene_product
VEGF	E-Gene_or_gene_product
,	O
antibodies	B-Gene_or_gene_product
to	I-Gene_or_gene_product
the	I-Gene_or_gene_product
extracellular	I-Gene_or_gene_product
domain	I-Gene_or_gene_product
of	I-Gene_or_gene_product
VEGFR	I-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
or	O
VEGFR	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
,	O
decoy	O
receptors	O
for	O
VEGF	S-Gene_or_gene_product
and	O
tyrosine	B-Drug_or_compound
kinase	I-Drug_or_compound
inhibitors	E-Drug_or_compound
of	O
VEGFRs	S-Gene_or_gene_product
,	O
are	O
summarized	O
.	O

METHODS	O
:	O
This	O
review	O
outlines	O
and	O
compares	O
the	O
latest	O
development	O
of	O
these	O
strategies	O
,	O
with	O
emphasis	O
on	O
aflibercept	S-Drug_or_compound
,	O
a	O
novel	O
decoy	O
fusion	O
protein	O
of	O
domain	O
2	O
of	O
VEGFR	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
and	O
domain	O
3	O
of	O
VEGFR	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
with	O
the	O
Fc	B-Protein_domain_or_region
fragment	E-Protein_domain_or_region
of	O
IgG1	S-Gene_or_gene_product
.	O

RESULTS	O
:	O
Aflibercept	S-Drug_or_compound
was	O
shown	O
to	O
have	O
early	O
clinical	O
activity	O
.	O

Multiple	O
studies	O
are	O
ongoing	O
to	O
determine	O
the	O
clinical	O
benefits	O
of	O
aflibercept	S-Drug_or_compound
in	O
cancer	S-Pathological_formation
patients	S-Organism
.	O

The	O
effect	S-Regulation
of	O
perfluorocarbon	S-Drug_or_compound
-	O
based	O
artificial	O
oxygen	S-Drug_or_compound
carriers	O
on	O
tissue	B-Multi-tissue_structure
-	I-Multi-tissue_structure
engineered	I-Multi-tissue_structure
trachea	E-Multi-tissue_structure
.	O

The	O
biological	O
effect	S-Regulation
of	O
the	O
perfluorocarbon	S-Drug_or_compound
-	O
based	O
artificial	O
oxygen	S-Drug_or_compound
carrier	O
(	O
Oxygent	S-Drug_or_compound
)	O
was	O
investigated	O
in	O
tissue	B-Multi-tissue_structure
-	I-Multi-tissue_structure
engineered	I-Multi-tissue_structure
trachea	E-Multi-tissue_structure
(	O
TET	S-Multi-tissue_structure
)	O
construction	O
.	O

Media	O
supplemented	O
with	O
and	O
without	O
10	O
%	O
Oxygent	S-Drug_or_compound
were	O
compared	O
in	O
all	O
assessments	O
.	O

Partial	O
tissue	S-Tissue
oxygen	S-Drug_or_compound
tension	O
(	O
PtO	O
(	O
2	O
)	O
)	O
was	O
measured	O
with	O
polarographic	O
microprobes	O
;	O
epithelial	O
metabolism	O
was	O
monitored	O
by	O
microdialysis	O
inside	O
the	O
TET	B-Tissue
epithelium	E-Tissue
perfused	O
with	O
the	O
medium	O
underneath	O
.	O

Chondrocyte	S-Cell
-	O
DegraPol	O
constructs	O
were	O
cultured	O
for	O
1	O
month	O
with	O
the	O
medium	O
before	O
glycosaminoglycan	S-Drug_or_compound
assessment	O
and	O
histology	O
.	O

Tissue	S-Tissue
reaction	O
of	O
TET	B-Tissue
epithelial	I-Tissue
scaffolds	E-Tissue
immersed	O
with	O
the	O
medium	O
was	O
evaluated	O
on	O
the	O
chick	S-Organism
embryo	B-Multi-tissue_structure
chorioallantoic	I-Multi-tissue_structure
membrane	E-Multi-tissue_structure
.	O

Oxygent	S-Drug_or_compound
perfusion	O
medium	O
increased	O
the	O
TET	B-Tissue
epithelial	E-Tissue
PtO	O
(	O
2	O
)	O
(	O
51	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
3	O
mm	O
Hg	O
vs	O
.	O
33	O
.	O
4	O
+	O
/	O
-	O
0	O
.	O
3	O
mm	O
Hg	O
at	O
200	O
microm	O
thickness	O
;	O
12	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
1	O
mm	O
Hg	O
vs	O
.	O
3	O
.	O
1	O
+	O
/	O
-	O
0	O
.	O
1	O
mm	O
Hg	O
at	O
400	O
microm	O
thickness	O
,	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
and	O
decreased	O
the	O
lactate	S-Drug_or_compound
concentration	O
(	O
0	O
.	O
63	O
+	O
/	O
-	O
0	O
.	O
08	O
vs	O
.	O
0	O
.	O
80	O
+	O
/	O
-	O
0	O
.	O
06	O
mmol	O
/	O
L	O
,	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
,	O
lactate	S-Drug_or_compound
/	O
pyruvate	S-Drug_or_compound
(	O
1	O
.	O
87	O
+	O
/	O
-	O
0	O
.	O
26	O
vs	O
.	O
3	O
.	O
36	O
+	O
/	O
-	O
10	O
.	O
13	O
,	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
,	O
and	O
lactate	S-Drug_or_compound
/	O
glucose	S-Drug_or_compound
ratios	O
(	O
0	O
.	O
10	O
+	O
/	O
-	O
0	O
.	O
00	O
vs	O
.	O
0	O
.	O
29	O
+	O
/	O
-	O
0	O
.	O
14	O
,	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

Chondrocyte	S-Cell
-	O
DegraPol	O
in	O
Oxygent	S-Drug_or_compound
group	O
presented	O
lower	O
glycosaminoglycan	S-Drug_or_compound
value	O
(	O
0	O
.	O
03	O
+	O
/	O
-	O
0	O
.	O
00	O
vs	O
.	O
0	O
.	O
13	O
+	O
/	O
-	O
0	O
.	O
00	O
,	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
;	O
histology	O
slides	O
showed	O
poor	O
acid	O
mucopolysaccharides	S-Drug_or_compound
formation	S-Synthesis
.	O

Orthogonal	O
polarization	O
spectral	O
imaging	O
showed	O
no	O
difference	O
in	O
functional	O
capillary	S-Tissue
density	O
between	O
the	O
scaffolds	O
cultured	S-Planned_process
on	O
chorioallantoic	B-Multi-tissue_structure
membranes	E-Multi-tissue_structure
.	O

The	O
foreign	O
body	O
reaction	O
was	O
similar	O
in	O
both	O
groups	O
.	O

We	O
conclude	O
that	O
Oxygent	S-Drug_or_compound
increases	S-Positive_regulation
TET	B-Tissue
epithelial	E-Tissue
PtO	O
(	O
2	O
)	O
,	O
improves	O
epithelial	O
metabolism	O
,	O
does	O
not	O
impair	S-Negative_regulation
angiogenesis	S-Blood_vessel_development
,	O
and	O
tends	O
to	O
slow	S-Negative_regulation
cartilage	B-Tissue
tissue	E-Tissue
formation	S-Development
.	O

Distinct	O
role	O
of	O
PLCbeta3	S-Gene_or_gene_product
in	O
VEGF	S-Gene_or_gene_product
-	O
mediated	S-Regulation
directional	O
migration	O
and	O
vascular	S-Multi-tissue_structure
sprouting	S-Development
.	O

Endothelial	B-Cell
cell	E-Cell
proliferation	S-Cell_proliferation
and	O
migration	S-Localization
is	O
essential	S-Positive_regulation
to	O
angiogenesis	S-Blood_vessel_development
.	O

Typically	O
,	O
proliferation	S-Cell_proliferation
and	O
chemotaxis	S-Localization
of	O
endothelial	B-Cell
cells	E-Cell
is	O
driven	S-Regulation
by	O
growth	O
factors	O
such	O
as	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
(	O
VEGF	S-Gene_or_gene_product
)	O
and	O
basic	B-Gene_or_gene_product
fibroblast	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
(	O
bFGF	S-Gene_or_gene_product
)	O
.	O

VEGF	S-Gene_or_gene_product
activates	S-Positive_regulation
phospholipases	S-Gene_or_gene_product
(	O
PLCs	S-Gene_or_gene_product
)	O
-	O
specifically	O
PLCgamma1	S-Gene_or_gene_product
-	O
that	O
are	O
important	S-Positive_regulation
for	O
tubulogenesis	S-Blood_vessel_development
,	O
differentiation	O
and	O
DNA	O
synthesis	O
.	O

However	O
,	O
we	O
show	O
here	O
that	O
VEGF	S-Gene_or_gene_product
,	O
specifically	O
through	O
VEGFR2	S-Gene_or_gene_product
,	O
induces	S-Positive_regulation
phosphorylation	S-Phosphorylation
of	O
two	B-Protein_domain_or_region
serine	I-Protein_domain_or_region
residues	E-Protein_domain_or_region
on	O
PLCbeta3	S-Gene_or_gene_product
,	O
and	O
this	O
was	O
confirmed	O
in	O
an	O
ex	O
vivo	O
embryoid	O
body	O
model	O
.	O

Knockdown	S-Planned_process
of	O
PLCbeta3	S-Gene_or_gene_product
in	O
HUVEC	B-Cell
cells	E-Cell
affects	S-Regulation
IP3	S-Gene_or_gene_product
production	S-Gene_expression
,	O
actin	S-Gene_or_gene_product
reorganization	S-Regulation
,	O
migration	S-Localization
and	O
proliferation	S-Cell_proliferation
;	O
whereas	O
migration	S-Localization
is	O
inhibited	S-Negative_regulation
,	O
proliferation	S-Cell_proliferation
is	O
enhanced	S-Positive_regulation
.	O

Our	O
data	O
suggest	O
that	O
enhanced	O
proliferation	O
is	O
precipitated	O
by	O
an	O
accelerated	O
cell	S-Cell
cycle	O
,	O
and	O
decreased	O
migration	O
by	O
an	O
inability	O
to	O
activate	S-Positive_regulation
CDC42	S-Gene_or_gene_product
.	O

Given	O
that	O
PLCbeta3	S-Gene_or_gene_product
is	O
typically	O
known	O
as	O
an	O
effector	O
of	O
heterotrimeric	B-Gene_or_gene_product
G	I-Gene_or_gene_product
-	I-Gene_or_gene_product
proteins	E-Gene_or_gene_product
,	O
our	O
data	O
demonstrate	O
a	O
unique	O
crosstalk	O
between	O
the	O
G	B-Gene_or_gene_product
-	I-Gene_or_gene_product
protein	E-Gene_or_gene_product
and	O
receptor	O
tyrosine	O
kinase	O
(	O
RTK	O
)	O
axes	O
and	O
reveal	O
a	O
novel	O
molecular	O
mechanism	O
of	O
VEGF	S-Gene_or_gene_product
signaling	S-Pathway
and	O
,	O
thus	O
,	O
angiogenesis	S-Blood_vessel_development
.	O

The	O
semaphorin	B-Gene_or_gene_product
7A	E-Gene_or_gene_product
receptor	O
Plexin	B-Gene_or_gene_product
C1	E-Gene_or_gene_product
is	O
lost	O
during	O
melanoma	S-Pathological_formation
metastasis	S-Localization
.	O

The	O
transformation	S-Development
of	O
normal	O
melanocytes	S-Cell
,	O
or	O
melanocyte	B-Cell
stem	I-Cell
cells	E-Cell
,	O
to	O
melanoma	S-Pathological_formation
,	O
is	O
a	O
complex	O
process	O
involving	O
multiple	O
mechanisms	O
.	O

Loss	O
of	O
tumor	S-Pathological_formation
suppressor	O
proteins	O
,	O
which	O
function	O
as	O
brakes	S-Negative_regulation
on	O
cell	S-Cell
growth	S-Cell_proliferation
,	O
migration	S-Localization
,	O
or	O
cell	S-Cell
survival	S-Death
,	O
was	O
recognized	O
early	O
on	O
as	O
an	O
important	O
mechanism	O
for	O
initiation	O
and	O
progression	O
of	O
melanoma	S-Pathological_formation
.	O

Semaphorins	S-Gene_or_gene_product
and	O
their	O
cognate	O
receptors	O
,	O
Plexins	S-Gene_or_gene_product
and	O
neuropilins	S-Gene_or_gene_product
,	O
are	O
involved	O
in	O
neuronal	O
pathfinding	O
,	O
immune	O
function	O
,	O
and	O
tumor	S-Pathological_formation
progression	S-Development
through	S-Positive_regulation
effects	S-Regulation
on	O
blood	B-Multi-tissue_structure
vessel	E-Multi-tissue_structure
growth	S-Growth
and	O
cell	S-Cell
migration	S-Localization
.	O

Semaphorin	B-Gene_or_gene_product
7A	E-Gene_or_gene_product
(	O
Sema7A	S-Gene_or_gene_product
)	O
is	O
a	O
membrane	S-Cellular_component
-	O
linked	S-Binding
semaphorin	S-Gene_or_gene_product
that	O
is	O
expressed	S-Gene_expression
by	O
human	S-Organism
keratinocytes	S-Cell
,	O
and	O
we	O
have	O
shown	O
that	O
Sema7A	S-Gene_or_gene_product
binds	S-Binding
to	O
human	S-Organism
melanocytes	S-Cell
through	O
beta1	B-Gene_or_gene_product
-	I-Gene_or_gene_product
integrins	E-Gene_or_gene_product
and	O
the	O
Plexin	B-Gene_or_gene_product
C1	E-Gene_or_gene_product
receptor	O
.	O

Functional	O
studies	O
showed	O
that	O
Sema7A	S-Gene_or_gene_product
stimulates	S-Positive_regulation
cytoskeletal	S-Cellular_component
reorganization	S-Regulation
in	O
human	S-Organism
melanocytes	S-Cell
,	O
resulting	S-Positive_regulation
in	O
adhesion	S-Binding
and	O
dendrite	B-Development
formation	E-Development
.	O

Downstream	O
targets	S-Regulation
of	O
Plexin	B-Gene_or_gene_product
C1	E-Gene_or_gene_product
signaling	S-Pathway
in	O
human	S-Organism
melanocytes	S-Cell
include	O
cofilin	S-Gene_or_gene_product
and	O
LIM	B-Gene_or_gene_product
kinase	I-Gene_or_gene_product
II	E-Gene_or_gene_product
,	O
both	O
of	O
which	O
are	O
critical	O
mediators	O
of	O
cell	S-Cell
adhesion	S-Binding
and	O
migration	S-Localization
.	O

In	O
this	O
report	O
,	O
we	O
analyzed	O
the	O
expression	S-Gene_expression
of	O
Plexin	B-Gene_or_gene_product
C1	E-Gene_or_gene_product
using	O
immunohistochemistry	O
on	O
sections	O
of	O
primary	O
and	O
matched	O
metastatic	O
lesions	S-Pathological_formation
from	O
19	O
subjects	O
and	O
in	O
a	O
large	O
melanoma	B-Pathological_formation
tumor	E-Pathological_formation
microarray	O
.	O

Our	O
data	O
show	O
a	O
significant	O
loss	O
of	O
Plexin	B-Gene_or_gene_product
C1	E-Gene_or_gene_product
in	O
metastatic	B-Pathological_formation
melanoma	E-Pathological_formation
compared	O
with	O
primary	B-Pathological_formation
melanoma	E-Pathological_formation
,	O
suggesting	O
the	O
possibility	O
that	O
the	O
Plexin	B-Gene_or_gene_product
C1	E-Gene_or_gene_product
receptor	O
is	O
a	O
tumor	S-Pathological_formation
suppressor	O
protein	O
for	O
melanoma	S-Pathological_formation
.	O

Role	S-Regulation
of	O
the	O
interferon	S-Gene_or_gene_product
-	O
inducible	S-Positive_regulation
IFI16	S-Gene_or_gene_product
gene	O
in	O
the	O
induction	S-Positive_regulation
of	O
ICAM	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
by	O
TNF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
alpha	E-Gene_or_gene_product
.	O

The	O
Interferon	S-Gene_or_gene_product
-	O
inducible	S-Positive_regulation
gene	O
IFI16	S-Gene_or_gene_product
,	O
a	O
member	O
of	O
the	O
HIN200	S-Gene_or_gene_product
family	O
,	O
is	O
activated	S-Positive_regulation
by	O
oxidative	O
stress	O
and	O
cell	S-Cell
density	O
,	O
in	O
addition	O
to	O
Interferons	S-Gene_or_gene_product
,	O
and	O
it	O
is	O
implicated	O
in	O
the	O
regulation	S-Regulation
of	O
endothelial	B-Cell
cell	E-Cell
proliferation	S-Cell_proliferation
and	O
vessel	S-Multi-tissue_structure
formation	S-Development
in	O
vitro	O
.	O

We	O
have	O
previously	O
shown	O
that	O
IFI16	S-Gene_or_gene_product
is	O
required	O
for	O
proinflammatory	O
gene	O
stimulation	O
by	O
IFN	B-Gene_or_gene_product
-	I-Gene_or_gene_product
gamma	E-Gene_or_gene_product
through	O
the	O
NF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
kappaB	E-Gene_or_gene_product
complex	O
.	O

To	O
examine	O
whether	O
IFI16	S-Gene_or_gene_product
induction	S-Positive_regulation
might	O
be	O
extended	S-Positive_regulation
to	O
other	O
proinflammatory	O
cytokines	O
such	O
as	O
tumor	B-Gene_or_gene_product
necrosis	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
(	I-Gene_or_gene_product
TNF	I-Gene_or_gene_product
)	I-Gene_or_gene_product
-	I-Gene_or_gene_product
alpha	E-Gene_or_gene_product
,	O
we	O
used	O
the	O
strategy	O
of	O
the	O
RNA	O
interference	O
to	O
knock	B-Planned_process
down	E-Planned_process
IFI16	S-Gene_or_gene_product
expression	S-Gene_expression
,	O
and	O
analyze	O
the	O
capability	O
of	O
TNF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
alpha	E-Gene_or_gene_product
to	O
stimulate	S-Positive_regulation
intercellular	B-Gene_or_gene_product
adhesion	I-Gene_or_gene_product
molecule	I-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
(	O
ICAM	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
or	O
CD54	S-Gene_or_gene_product
)	O
expression	S-Gene_expression
in	O
the	O
absence	O
of	O
functional	O
IFI16	S-Gene_or_gene_product
.	O

Our	O
studies	O
demonstrate	O
that	O
IFI16	S-Gene_or_gene_product
mediates	S-Regulation
ICAM	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
stimulation	S-Positive_regulation
by	O
TNF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
alpha	E-Gene_or_gene_product
through	O
the	O
NF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
kappaB	E-Gene_or_gene_product
pathway	S-Pathway
,	O
thus	O
reinforcing	O
the	O
role	O
of	O
the	O
IFI16	S-Gene_or_gene_product
molecule	O
in	O
the	O
inflammation	O
process	O
.	O

Antivascular	S-Multi-tissue_structure
actions	S-Negative_regulation
of	O
microtubule	B-Drug_or_compound
-	I-Drug_or_compound
binding	I-Drug_or_compound
drugs	E-Drug_or_compound
.	O

Microtubule	B-Drug_or_compound
-	I-Drug_or_compound
binding	I-Drug_or_compound
drugs	E-Drug_or_compound
(	O
MBD	S-Drug_or_compound
)	O
are	O
widely	O
used	O
in	O
cancer	S-Pathological_formation
chemotherapy	S-Planned_process
and	O
also	O
have	O
clinically	O
relevant	O
antiangiogenic	S-Blood_vessel_development
and	O
vascular	S-Multi-tissue_structure
-	O
disrupting	S-Breakdown
properties	S-Negative_regulation
.	O

These	O
antivascular	S-Multi-tissue_structure
actions	S-Negative_regulation
are	O
due	O
in	O
part	O
to	O
direct	O
effects	S-Regulation
on	O
endothelial	B-Cell
cells	E-Cell
,	O
and	O
all	O
MBDs	S-Drug_or_compound
(	O
both	O
microtubule	S-Cellular_component
-	O
stabilizing	O
and	O
microtubule	S-Cellular_component
-	O
destabilizing	O
)	O
inhibit	S-Negative_regulation
endothelial	B-Cell
cell	E-Cell
proliferation	S-Cell_proliferation
,	O
migration	S-Localization
,	O
and	O
tube	S-Tissue
formation	S-Development
in	O
vitro	O
,	O
actions	O
that	O
are	O
thought	O
to	O
correspond	O
to	O
therapeutic	O
antiangiogenic	S-Blood_vessel_development
actions	S-Planned_process
.	O

In	O
addition	O
,	O
the	O
microtubule	B-Drug_or_compound
-	I-Drug_or_compound
destabilizing	I-Drug_or_compound
agents	E-Drug_or_compound
cause	S-Regulation
prominent	O
changes	S-Regulation
in	O
endothelial	B-Cell
cell	E-Cell
morphology	O
,	O
an	O
action	O
associated	S-Regulation
with	O
rapid	O
vascular	S-Multi-tissue_structure
collapse	S-Breakdown
in	O
vivo	O
.	O

The	O
effects	S-Regulation
on	O
endothelial	B-Cell
cells	E-Cell
occur	O
in	O
vitro	O
at	O
low	O
drug	O
concentrations	O
,	O
which	O
do	O
not	O
affect	S-Regulation
microtubule	S-Cellular_component
gross	O
morphology	O
,	O
do	O
not	O
cause	S-Regulation
microtubule	S-Cellular_component
bundling	S-Development
or	O
microtubule	S-Cellular_component
loss	S-Breakdown
and	O
do	O
not	O
induce	O
cell	S-Cell
cycle	O
arrest	O
,	O
apoptosis	S-Death
,	O
or	O
cell	S-Cell
death	S-Death
.	O

Rather	O
,	O
it	O
has	O
been	O
hypothesized	O
that	O
,	O
at	O
low	O
concentrations	O
,	O
MBDs	S-Drug_or_compound
produce	O
more	O
subtle	O
effects	S-Regulation
on	O
microtubule	S-Cellular_component
dynamics	O
,	O
block	O
critical	O
cell	S-Cell
signaling	O
pathways	O
,	O
and	O
prevent	S-Negative_regulation
the	O
microtubules	S-Cellular_component
from	O
properly	O
interacting	S-Binding
with	O
transient	O
subcellular	B-Cellular_component
assemblies	E-Cellular_component
(	O
focal	B-Cellular_component
adhesions	E-Cellular_component
and	O
adherens	B-Cellular_component
junctions	E-Cellular_component
)	O
whose	O
subsequent	O
stabilization	S-Breakdown
and	O
/	O
or	O
maturation	S-Development
are	O
required	S-Positive_regulation
for	O
cell	S-Cell
motility	S-Localization
and	O
cell	S-Cell
-	O
cell	S-Cell
interactions	S-Binding
.	O

This	O
review	O
will	O
focus	O
on	O
recent	O
studies	O
to	O
define	O
the	O
molecular	O
mechanisms	O
for	O
the	O
antivascular	S-Multi-tissue_structure
actions	S-Negative_regulation
of	O
the	O
MBDs	S-Drug_or_compound
,	O
information	O
that	O
could	O
be	O
useful	O
in	O
the	O
identification	O
or	O
design	O
of	O
agents	O
whose	O
actions	O
more	O
selectively	O
target	S-Regulation
the	O
tumor	B-Multi-tissue_structure
vasculature	E-Multi-tissue_structure
.	O

Neurovascular	O
effects	O
of	O
CD47	S-Gene_or_gene_product
signaling	S-Pathway
:	O
promotion	S-Positive_regulation
of	O
cell	S-Cell
death	S-Death
,	O
inflammation	O
,	O
and	O
suppression	S-Negative_regulation
of	O
angiogenesis	S-Blood_vessel_development
in	O
brain	B-Cell
endothelial	I-Cell
cells	E-Cell
in	O
vitro	O
.	O

The	O
concept	O
of	O
the	O
neurovascular	O
unit	O
emphasizes	O
that	O
common	O
signals	O
and	O
substrates	O
underlie	O
the	O
physiology	O
and	O
pathophysiology	O
of	O
neuronal	S-Multi-tissue_structure
and	O
endothelial	B-Multi-tissue_structure
compartments	E-Multi-tissue_structure
in	O
brain	S-Organ
.	O

Recent	O
data	O
suggest	O
that	O
activation	S-Positive_regulation
of	O
the	O
integrin	S-Gene_or_gene_product
-	O
associated	S-Binding
protein	O
CD47	S-Gene_or_gene_product
promotes	S-Positive_regulation
neuronal	B-Cell
cell	E-Cell
death	S-Death
.	O

Is	O
it	O
possible	O
that	O
CD47	S-Gene_or_gene_product
may	O
also	O
negatively	B-Negative_regulation
affect	E-Negative_regulation
cerebral	B-Cell
endothelial	I-Cell
cells	E-Cell
?	O

Exposure	S-Planned_process
of	O
wild	O
-	O
type	O
primary	O
mouse	S-Organism
cerebral	B-Cell
endothelial	I-Cell
cells	E-Cell
to	O
the	O
CD47	S-Gene_or_gene_product
ligand	O
thrombospondin	B-Gene_or_gene_product
1	E-Gene_or_gene_product
(	O
TSP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
)	O
induced	S-Positive_regulation
an	O
increasing	O
amount	O
of	O
cell	S-Cell
death	S-Death
,	O
whereas	O
cytotoxicity	O
was	O
significantly	O
decreased	O
in	O
cerebral	B-Cell
endothelial	I-Cell
cells	E-Cell
derived	O
from	O
CD47	B-Organism
knockout	I-Organism
mice	E-Organism
.	O

The	O
specific	O
CD47	S-Gene_or_gene_product
-	O
activating	S-Positive_regulation
peptide	O
,	O
4N1K	S-Gene_or_gene_product
,	O
similarly	O
induced	S-Positive_regulation
cell	B-Death
death	E-Death
in	O
human	S-Organism
brain	B-Cell
microvascular	I-Cell
endothelial	I-Cell
cells	E-Cell
.	O

Promotion	O
of	O
inflammation	O
was	O
also	O
involved	O
because	O
lower	O
TSP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
was	O
able	O
to	O
up	B-Positive_regulation
-	I-Positive_regulation
regulate	E-Positive_regulation
the	O
adhesion	O
molecules	O
intercellular	B-Gene_or_gene_product
adhesion	I-Gene_or_gene_product
molecule	I-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
and	O
vascular	B-Gene_or_gene_product
cell	I-Gene_or_gene_product
adhesion	I-Gene_or_gene_product
molecule	I-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
.	O

Finally	O
,	O
CD47	S-Gene_or_gene_product
signaling	S-Pathway
may	O
suppress	S-Negative_regulation
angiogenesis	S-Blood_vessel_development
because	O
4N1K	S-Gene_or_gene_product
significantly	O
inhibited	S-Negative_regulation
endothelial	B-Cell
cell	E-Cell
migration	S-Localization
and	O
tube	S-Tissue
formation	S-Development
in	O
vitro	O
.	O

We	O
conclude	O
that	O
CD47	S-Gene_or_gene_product
signaling	S-Pathway
can	O
negatively	B-Negative_regulation
affect	E-Negative_regulation
the	O
viability	O
and	O
function	O
of	O
cerebral	B-Cell
endothelial	I-Cell
cells	E-Cell
,	O
further	O
supporting	O
the	O
notion	O
that	O
CD47	S-Gene_or_gene_product
may	O
be	O
a	O
potential	O
neurovascular	O
target	O
for	O
stroke	O
and	O
brain	S-Organ
injury	S-Breakdown
.	O

Characterization	O
of	O
the	O
metabolic	O
changes	O
underlying	O
growth	O
factor	O
angiogenic	S-Blood_vessel_development
activation	S-Positive_regulation
:	O
identification	O
of	O
new	O
potential	O
therapeutic	O
targets	O
.	O

Angiogenesis	S-Blood_vessel_development
is	O
a	O
fundamental	O
process	O
to	O
normal	O
and	O
abnormal	O
tissue	S-Tissue
growth	S-Growth
and	O
repair	S-Development
,	O
which	O
consists	O
of	O
recruiting	S-Localization
endothelial	B-Cell
cells	E-Cell
toward	O
an	O
angiogenic	S-Blood_vessel_development
stimulus	O
.	O

The	O
cells	S-Cell
subsequently	O
proliferate	S-Cell_proliferation
and	O
differentiate	S-Development
to	O
form	S-Development
endothelial	B-Tissue
tubes	E-Tissue
and	O
capillary	B-Tissue
-	I-Tissue
like	I-Tissue
structures	E-Tissue
.	O

Little	O
is	O
known	O
about	O
the	O
metabolic	O
adaptation	O
of	O
endothelial	B-Cell
cells	E-Cell
through	O
such	O
a	O
transformation	S-Development
.	O

We	O
studied	O
the	O
metabolic	O
changes	S-Regulation
of	O
endothelial	B-Cell
cell	E-Cell
activation	S-Positive_regulation
by	O
growth	O
factors	O
using	O
human	B-Cell
umbilical	I-Cell
vein	I-Cell
endothelial	I-Cell
cells	E-Cell
(	O
HUVECs	S-Cell
)	O
,	O
[	B-Drug_or_compound
1	I-Drug_or_compound
,	I-Drug_or_compound
2	I-Drug_or_compound
-	I-Drug_or_compound
(	I-Drug_or_compound
13	I-Drug_or_compound
)	I-Drug_or_compound
C	I-Drug_or_compound
(	I-Drug_or_compound
2	I-Drug_or_compound
)	I-Drug_or_compound
]	I-Drug_or_compound
-	I-Drug_or_compound
glucose	E-Drug_or_compound
and	O
mass	O
isotopomer	O
distribution	O
analysis	O
.	O

The	O
metabolism	S-Metabolism
of	O
[	B-Drug_or_compound
1	I-Drug_or_compound
,	I-Drug_or_compound
2	I-Drug_or_compound
-	I-Drug_or_compound
(	I-Drug_or_compound
13	I-Drug_or_compound
)	I-Drug_or_compound
C	I-Drug_or_compound
(	I-Drug_or_compound
2	I-Drug_or_compound
)	I-Drug_or_compound
]	I-Drug_or_compound
-	I-Drug_or_compound
glucose	E-Drug_or_compound
by	O
HUVEC	S-Cell
allows	O
us	O
to	O
trace	O
many	O
of	O
the	O
main	O
glucose	S-Drug_or_compound
metabolic	B-Pathway
pathways	E-Pathway
,	O
including	O
glycogen	S-Drug_or_compound
synthesis	S-Synthesis
,	O
the	O
pentose	S-Drug_or_compound
cycle	S-Pathway
and	O
the	O
glycolytic	B-Pathway
pathways	E-Pathway
.	O

So	O
we	O
established	O
that	O
these	O
pathways	O
were	O
crucial	O
to	O
endothelial	B-Cell
cell	E-Cell
proliferation	S-Cell_proliferation
under	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
(	O
VEGF	S-Gene_or_gene_product
)	O
and	O
fibroblast	B-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
(	O
FGF	S-Gene_or_gene_product
)	O
stimulation	S-Positive_regulation
.	O

A	O
specific	O
VEGF	B-Gene_or_gene_product
receptor	I-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
inhibitor	O
demonstrated	O
the	O
importance	O
of	O
glycogen	S-Drug_or_compound
metabolism	S-Metabolism
and	O
pentose	S-Drug_or_compound
cycle	B-Pathway
pathway	E-Pathway
.	O

Furthermore	O
,	O
we	O
showed	O
that	O
glycogen	S-Drug_or_compound
was	O
depleted	S-Catabolism
in	O
a	O
low	O
glucose	S-Drug_or_compound
medium	O
,	O
but	O
conserved	O
under	O
hypoxic	O
conditions	O
.	O

Finally	O
,	O
we	O
demonstrated	O
that	O
direct	O
inhibition	O
of	O
key	O
enzymes	O
to	O
glycogen	S-Drug_or_compound
metabolism	S-Metabolism
and	O
pentose	S-Drug_or_compound
phosphate	B-Pathway
pathways	E-Pathway
reduced	S-Negative_regulation
HUVEC	S-Cell
viability	O
and	O
migration	S-Localization
.	O

In	O
this	O
regard	O
,	O
inhibitors	O
of	O
these	O
pathways	O
have	O
been	O
shown	O
to	O
be	O
effective	O
antitumoral	O
agents	O
.	O

To	O
sum	O
up	O
,	O
our	O
data	O
suggest	O
that	O
the	O
inhibition	O
of	O
metabolic	O
pathways	O
offers	O
a	O
novel	O
and	O
powerful	O
therapeutic	O
approach	O
,	O
which	O
simultaneously	O
inhibits	S-Negative_regulation
tumor	B-Cell
cell	E-Cell
proliferation	S-Cell_proliferation
and	O
tumor	S-Pathological_formation
-	O
induced	S-Positive_regulation
angiogenesis	S-Blood_vessel_development
.	O

Rab	B-Gene_or_gene_product
GTPase	E-Gene_or_gene_product
regulation	S-Regulation
of	O
VEGFR2	S-Gene_or_gene_product
trafficking	S-Localization
and	O
signaling	O
in	O
endothelial	B-Cell
cells	E-Cell
.	O

OBJECTIVE	O
:	O
Vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
receptor	I-Gene_or_gene_product
2	E-Gene_or_gene_product
(	O
VEGFR2	S-Gene_or_gene_product
)	O
is	O
a	O
receptor	O
tyrosine	O
kinase	O
that	O
regulates	S-Regulation
vascular	S-Multi-tissue_structure
physiology	O
.	O

However	O
,	O
mechanism	O
(	O
s	O
)	O
by	O
which	O
VEGFR2	S-Gene_or_gene_product
signaling	S-Pathway
and	O
trafficking	S-Localization
is	O
coordinated	O
are	O
not	O
clear	O
.	O

Here	O
,	O
we	O
have	O
tested	O
endocytic	O
Rab	B-Gene_or_gene_product
GTPases	E-Gene_or_gene_product
for	O
regulation	S-Regulation
of	O
VEGFR2	S-Gene_or_gene_product
trafficking	S-Localization
and	O
signaling	S-Pathway
linked	S-Regulation
to	O
endothelial	B-Cell
cell	E-Cell
migration	S-Localization
.	O

METHODS	O
AND	O
RESULTS	O
:	O
Quiescent	O
VEGFR2	S-Gene_or_gene_product
displays	O
endosomal	O
localization	S-Localization
and	O
colocalization	S-Localization
with	O
the	O
Rab5a	B-Gene_or_gene_product
GTPase	E-Gene_or_gene_product
,	O
an	O
early	O
endosome	O
fusion	O
regulator	O
.	O

Expression	S-Gene_expression
of	O
GTP	S-Drug_or_compound
or	O
GDP	S-Drug_or_compound
-	O
bound	S-Binding
Rab5a	S-Gene_or_gene_product
mutants	O
block	S-Negative_regulation
activated	S-Positive_regulation
VEGFR2	S-Gene_or_gene_product
trafficking	S-Localization
and	O
degradation	S-Catabolism
.	O

Manipulation	S-Regulation
of	O
Rab7a	B-Gene_or_gene_product
GTPase	E-Gene_or_gene_product
activity	O
associated	O
with	O
late	O
endosomes	O
using	O
overexpression	S-Gene_expression
of	O
wild	O
-	O
type	O
or	O
mutant	O
proteins	O
blocks	S-Negative_regulation
activated	S-Positive_regulation
VEGFR2	S-Gene_or_gene_product
trafficking	S-Localization
and	O
degradation	S-Catabolism
.	O

Depletion	S-Negative_regulation
of	O
Rab7a	S-Gene_or_gene_product
decreased	S-Negative_regulation
VEGFR2	S-Gene_or_gene_product
Y1175	S-Protein_domain_or_region
phosphorylation	S-Phosphorylation
but	O
increased	S-Positive_regulation
p42	B-Gene_or_gene_product
/	I-Gene_or_gene_product
44	E-Gene_or_gene_product
(	O
pERK1	B-Gene_or_gene_product
/	I-Gene_or_gene_product
2	E-Gene_or_gene_product
)	O
MAPK	S-Gene_or_gene_product
phosphorylation	S-Phosphorylation
.	O

Endothelial	B-Cell
cell	E-Cell
migration	S-Localization
was	O
increased	S-Positive_regulation
by	O
Rab5a	S-Gene_or_gene_product
depletion	S-Negative_regulation
but	O
decreased	S-Negative_regulation
by	O
Rab7a	S-Gene_or_gene_product
depletion	S-Negative_regulation
.	O

CONCLUSIONS	O
:	O
Rab5a	S-Gene_or_gene_product
and	O
Rab7a	S-Gene_or_gene_product
regulate	S-Regulation
VEGFR2	S-Gene_or_gene_product
trafficking	S-Localization
toward	O
early	O
and	O
late	O
endosomes	O
.	O

Our	O
data	O
suggest	O
that	O
VEGFR2	S-Gene_or_gene_product
-	O
mediated	S-Regulation
regulation	S-Regulation
of	O
endothelial	S-Cell
function	O
is	O
dependent	S-Positive_regulation
on	O
different	O
but	O
specific	O
Rab	S-Gene_or_gene_product
-	O
mediated	S-Regulation
GTP	S-Drug_or_compound
hydrolysis	S-Catabolism
activity	O
required	O
for	O
endosomal	O
trafficking	O
.	O

AngiomiRs	S-Gene_or_gene_product
-	O
-	O
key	O
regulators	O
of	O
angiogenesis	S-Blood_vessel_development
.	O

The	O
formation	S-Development
of	O
new	O
blood	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
through	O
the	O
process	O
of	O
angiogenesis	S-Blood_vessel_development
is	O
critical	S-Positive_regulation
in	O
vascular	S-Multi-tissue_structure
development	S-Development
and	O
homeostasis	O
.	O

Aberrant	S-Regulation
angiogenesis	S-Blood_vessel_development
leads	S-Positive_regulation
to	O
a	O
variety	O
of	O
diseases	O
,	O
such	O
as	O
ischemia	O
and	O
cancer	S-Pathological_formation
.	O

Recent	O
studies	O
have	O
revealed	O
important	O
roles	O
for	O
miRNAs	O
in	O
regulating	S-Regulation
endothelial	B-Cell
cell	E-Cell
(	O
EC	S-Cell
)	O
function	O
,	O
especially	O
angiogenesis	S-Blood_vessel_development
.	O

Mice	S-Organism
with	O
EC	S-Cell
-	O
specific	O
deletion	S-Negative_regulation
of	O
Dicer	S-Gene_or_gene_product
,	O
a	O
key	O
enzyme	O
for	O
generating	O
miRNAs	O
,	O
display	O
defective	O
postnatal	O
angiogenesis	S-Blood_vessel_development
.	O

Specific	O
miRNAs	O
(	O
angiomiRs	S-Gene_or_gene_product
)	O
have	O
recently	O
been	O
shown	O
to	O
regulate	S-Regulation
angiogenesis	S-Blood_vessel_development
in	O
vivo	O
.	O

miRNA	B-Gene_or_gene_product
-	I-Gene_or_gene_product
126	E-Gene_or_gene_product
,	O
an	O
EC	S-Cell
-	O
restricted	O
miRNA	O
,	O
regulates	S-Regulation
vascular	S-Multi-tissue_structure
integrity	O
and	O
developmental	O
angiogenesis	S-Blood_vessel_development
.	O

miR	B-Gene_or_gene_product
-	I-Gene_or_gene_product
378	E-Gene_or_gene_product
,	O
miR	B-Gene_or_gene_product
-	I-Gene_or_gene_product
296	E-Gene_or_gene_product
,	O
and	O
the	O
miR	B-Gene_or_gene_product
-	I-Gene_or_gene_product
17	I-Gene_or_gene_product
-	E-Gene_or_gene_product
92	S-Gene_or_gene_product
cluster	O
contribute	S-Regulation
to	O
tumor	S-Pathological_formation
angiogenesis	S-Blood_vessel_development
.	O

Manipulating	O
angiomiRs	S-Gene_or_gene_product
in	O
the	O
settings	O
of	O
pathological	O
vascularization	S-Blood_vessel_development
represents	O
a	O
new	O
therapeutic	O
approach	O
.	O

Cisplatin	S-Drug_or_compound
reduces	S-Negative_regulation
endothelial	B-Cell
cell	E-Cell
migration	S-Localization
via	O
regulation	S-Regulation
of	O
type	B-Gene_or_gene_product
2	I-Gene_or_gene_product
-	I-Gene_or_gene_product
matrix	I-Gene_or_gene_product
metalloproteinase	E-Gene_or_gene_product
activity	O
.	O

AIMS	O
:	O
In	O
this	O
study	O
we	O
investigated	O
the	O
effect	S-Regulation
of	O
cisplatin	S-Drug_or_compound
on	O
endothelial	B-Cell
cell	E-Cell
migration	S-Localization
,	O
an	O
essential	S-Positive_regulation
process	O
for	O
vascular	S-Multi-tissue_structure
remodeling	S-Remodeling
and	O
regeneration	S-Development
in	O
several	O
physiological	O
and	O
pathological	O
situations	O
.	O

MATERIAL	O
AND	O
METHODS	O
:	O
Human	B-Cell
umbilical	I-Cell
vein	I-Cell
endothelial	I-Cell
cells	E-Cell
(	O
HUVEC	S-Cell
)	O
were	O
treated	S-Planned_process
with	O
cisplatin	S-Drug_or_compound
and	O
endothelial	B-Cell
cell	E-Cell
migration	S-Localization
analyzed	O
by	O
fluorescence	O
and	O
scratch	O
-	O
wound	O
migration	O
assay	O
.	O

MMP2	S-Gene_or_gene_product
and	O
MMP9	S-Gene_or_gene_product
activity	O
were	O
determined	O
by	O
zymographic	O
assay	O
,	O
and	O
MAPK	S-Gene_or_gene_product
activation	S-Positive_regulation
by	O
Western	O
blotting	O
analysis	O
.	O

RESULTS	O
:	O
We	O
demonstrated	O
that	O
cisplatin	S-Drug_or_compound
provoked	S-Positive_regulation
a	O
time	O
-	O
and	O
dose	O
-	O
dependent	O
decrease	S-Negative_regulation
of	O
HUVEC	S-Cell
migration	S-Localization
;	O
this	O
effect	O
was	O
clearly	O
independent	O
from	O
its	O
well	O
known	O
cytotoxic	O
activity	O
.	O

In	O
addition	O
,	O
cisplatin	S-Drug_or_compound
markedly	O
reduced	S-Negative_regulation
MMP2	S-Gene_or_gene_product
activity	O
in	O
both	O
conditioned	O
media	O
and	O
cell	B-Organism_substance
lysates	E-Organism_substance
,	O
increased	S-Positive_regulation
p38	B-Gene_or_gene_product
MAPK	E-Gene_or_gene_product
and	O
JNK	S-Gene_or_gene_product
phosphorylation	S-Phosphorylation
,	O
but	O
did	O
not	O
affect	S-Regulation
ERK	S-Gene_or_gene_product
phosphorylation	S-Phosphorylation
.	O

Endothelial	B-Cell
cell	E-Cell
migration	S-Localization
was	O
attenuated	S-Negative_regulation
by	O
treatment	S-Planned_process
of	O
cells	S-Cell
with	O
GM6001	S-Drug_or_compound
,	O
a	O
non	O
-	O
specific	O
inhibitor	O
of	O
MMPs	S-Gene_or_gene_product
,	O
or	O
by	O
a	O
selective	B-Gene_or_gene_product
anti	I-Gene_or_gene_product
-	I-Gene_or_gene_product
MMP2	I-Gene_or_gene_product
antibody	E-Gene_or_gene_product
.	O

However	O
,	O
treatment	S-Planned_process
of	O
cells	O
with	O
SB202190	S-Drug_or_compound
or	O
SP600125	S-Drug_or_compound
,	O
inhibitors	O
of	O
p38	B-Gene_or_gene_product
MAPK	E-Gene_or_gene_product
and	O
JNK	S-Gene_or_gene_product
respectively	O
,	O
did	O
not	O
affect	S-Regulation
HUVEC	S-Cell
migration	S-Localization
.	O

CONCLUSION	O
:	O
These	O
results	O
suggested	O
that	O
cisplatin	S-Drug_or_compound
induced	S-Positive_regulation
a	O
reduction	S-Negative_regulation
of	O
endothelial	B-Cell
cell	E-Cell
migration	S-Localization
through	O
an	O
inhibition	S-Negative_regulation
of	O
MMP2	S-Gene_or_gene_product
activity	O
by	O
downstream	O
signal	O
transduction	O
pathways	O
independent	S-Regulation
of	O
JNK	S-Gene_or_gene_product
and	O
p38	B-Gene_or_gene_product
MAPK	E-Gene_or_gene_product
activation	S-Positive_regulation
.	O

Promoting	S-Positive_regulation
angiogenesis	S-Blood_vessel_development
via	O
manipulation	S-Regulation
of	O
VEGF	S-Gene_or_gene_product
responsiveness	O
with	O
notch	B-Pathway
signaling	E-Pathway
.	O

Promoting	S-Positive_regulation
angiogenesis	S-Blood_vessel_development
via	O
delivery	S-Localization
of	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
(	O
VEGF	S-Gene_or_gene_product
)	O
and	O
other	O
angiogenic	S-Blood_vessel_development
factors	O
is	O
both	O
a	O
potential	O
therapy	O
for	O
cardiovascular	S-Anatomical_system
diseases	O
and	O
a	O
critical	O
aspect	O
for	O
tissue	S-Tissue
regeneration	S-Development
.	O

The	O
recent	O
demonstration	O
that	O
VEGF	S-Gene_or_gene_product
signaling	S-Pathway
is	O
modulated	S-Regulation
by	O
the	O
Notch	B-Pathway
signaling	I-Pathway
pathway	E-Pathway
,	O
however	O
,	O
suggests	O
that	O
inhibiting	S-Negative_regulation
Notch	B-Pathway
signaling	E-Pathway
may	O
enhance	S-Positive_regulation
regional	O
neovascularization	S-Blood_vessel_development
,	O
by	O
altering	O
the	O
responsiveness	S-Regulation
of	O
local	O
endothelial	B-Cell
cells	E-Cell
to	O
angiogenic	S-Blood_vessel_development
stimuli	O
.	O

We	O
tested	O
this	O
possibility	O
with	O
in	O
vitro	O
assays	O
using	O
human	S-Organism
endothelial	B-Cell
cells	E-Cell
,	O
as	O
well	O
as	O
in	O
a	O
rodent	O
hindlimb	S-Organism_subdivision
ischemia	O
model	O
.	O

Treatment	S-Planned_process
of	O
cultured	S-Planned_process
human	S-Organism
endothelial	B-Cell
cells	E-Cell
with	O
DAPT	S-Drug_or_compound
,	O
a	O
gamma	B-Gene_or_gene_product
secretase	E-Gene_or_gene_product
inhibitor	O
,	O
increased	S-Positive_regulation
cell	S-Cell
migration	S-Localization
and	O
sprout	S-Tissue
formation	S-Development
in	O
response	O
to	O
VEGF	S-Gene_or_gene_product
stimulation	S-Positive_regulation
with	O
a	O
biphasic	O
dependence	O
on	O
DAPT	S-Drug_or_compound
concentration	O
.	O

Further	O
,	O
delivery	O
of	O
an	O
appropriate	O
combination	O
of	O
DAPT	S-Drug_or_compound
and	O
VEGF	S-Gene_or_gene_product
from	O
an	O
injectable	O
alginate	O
hydrogel	O
system	O
into	O
ischemic	O
hindlimbs	S-Organism_subdivision
led	O
to	O
a	O
faster	O
recovery	O
of	O
blood	S-Organism_substance
flow	O
than	O
VEGF	S-Gene_or_gene_product
or	O
DAPT	S-Drug_or_compound
alone	O
;	O
perfusion	O
levels	O
reached	O
80	O
%	O
of	O
the	O
normal	O
level	O
by	O
week	O
4	O
with	O
combined	O
DAPT	S-Drug_or_compound
and	O
VEGF	S-Gene_or_gene_product
delivery	S-Localization
.	O

Direct	O
intramuscular	O
or	O
intraperitoneal	O
injection	S-Planned_process
of	O
DAPT	S-Drug_or_compound
did	O
not	O
result	O
in	O
the	O
same	O
level	O
of	O
improvement	O
,	O
suggesting	O
that	O
appropriate	O
presentation	O
of	O
DAPT	S-Drug_or_compound
(	O
gel	O
delivery	O
)	O
is	O
important	O
for	O
its	O
activity	O
.	O

DAPT	S-Drug_or_compound
delivery	S-Localization
from	O
the	O
hydrogels	O
also	O
did	O
not	O
lead	O
to	O
any	O
adverse	O
side	O
effects	O
,	O
in	O
contrast	O
to	O
systemic	O
introduction	S-Positive_regulation
of	O
DAPT	S-Drug_or_compound
.	O

Altogether	O
,	O
these	O
results	O
suggest	O
a	O
new	O
approach	O
to	O
promote	S-Positive_regulation
angiogenesis	S-Blood_vessel_development
by	O
controlling	S-Regulation
Notch	B-Pathway
signaling	E-Pathway
,	O
and	O
may	O
provide	O
new	O
options	O
to	O
treat	S-Planned_process
patients	S-Organism
with	O
diseases	O
that	O
diminish	S-Negative_regulation
angiogenic	S-Blood_vessel_development
responsiveness	O
.	O

[	O
Activation	S-Positive_regulation
of	O
sterol	B-Gene_or_gene_product
regulatory	I-Gene_or_gene_product
element	I-Gene_or_gene_product
binding	I-Gene_or_gene_product
protein	E-Gene_or_gene_product
and	O
its	O
involvement	S-Regulation
in	O
endothelial	B-Cell
cell	E-Cell
migration	S-Localization
]	O

OBJECTIVE	O
:	O
To	O
study	O
the	O
activation	S-Positive_regulation
of	O
sterol	B-Gene_or_gene_product
regulatory	I-Gene_or_gene_product
element	I-Gene_or_gene_product
binding	I-Gene_or_gene_product
protein	E-Gene_or_gene_product
(	O
SREBP	S-Gene_or_gene_product
)	O
and	O
its	O
critical	B-Regulation
role	E-Regulation
in	O
endothelial	B-Cell
cell	E-Cell
migration	S-Localization
.	O

METHODS	O
:	O
Bovine	S-Organism
aortic	B-Cell
endothelial	I-Cell
cells	E-Cell
(	O
ECs	S-Cell
)	O
were	O
cultured	S-Planned_process
.	O

The	O
expression	S-Gene_expression
of	O
SREBP	S-Gene_or_gene_product
and	O
Cdc42	S-Gene_or_gene_product
were	O
determined	O
by	O
Western	O
blot	O
and	O
quantitative	O
real	O
-	O
time	O
PCR	O
.	O

Moreover	O
,	O
outward	O
growth	O
migration	O
model	O
and	O
transwell	O
chamber	O
assay	O
were	O
used	O
to	O
detect	O
ECs	S-Cell
migration	S-Localization
.	O

RESULTS	O
:	O
(	O
1	O
)	O
SREBP	S-Gene_or_gene_product
was	O
activated	S-Positive_regulation
during	O
ECs	S-Cell
migration	S-Localization
.	O

Western	O
blot	O
analysis	O
demonstrated	O
increased	S-Positive_regulation
active	O
form	O
SREBP	S-Gene_or_gene_product
in	O
migrating	S-Localization
as	O
compared	O
to	O
non	B-Localization
-	I-Localization
migrating	E-Localization
ECs	S-Cell
population	O
.	O

SREBP	S-Gene_or_gene_product
activation	S-Positive_regulation
decreased	S-Negative_regulation
as	O
ECs	S-Cell
migration	S-Localization
slowed	S-Negative_regulation
;	O
(	O
2	O
)	O
Coincidental	O
with	O
SREBP	S-Gene_or_gene_product
activation	S-Positive_regulation
,	O
mRNA	B-Transcription
expression	E-Transcription
of	O
its	O
target	O
genes	O
such	O
as	O
low	B-Gene_or_gene_product
density	I-Gene_or_gene_product
lipoprotein	I-Gene_or_gene_product
receptor	E-Gene_or_gene_product
,	O
HMG	B-Gene_or_gene_product
-	I-Gene_or_gene_product
CoA	I-Gene_or_gene_product
reductase	E-Gene_or_gene_product
,	O
and	O
fatty	B-Gene_or_gene_product
acid	I-Gene_or_gene_product
synthase	E-Gene_or_gene_product
also	O
increased	S-Positive_regulation
in	O
migrating	S-Localization
ECs	S-Cell
population	O
as	O
detected	O
by	O
real	O
-	O
time	O
PCR	O
;	O
(	O
3	O
)	O
Migration	S-Localization
induced	S-Positive_regulation
SREBP	S-Gene_or_gene_product
activation	S-Positive_regulation
in	O
ECs	S-Cell
was	O
inhibited	S-Negative_regulation
by	O
SREBP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
acting	I-Gene_or_gene_product
protein	E-Gene_or_gene_product
RNAi	O
and	O
pharmacologically	O
by	O
25	B-Drug_or_compound
-	I-Drug_or_compound
hydroxycholesterol	E-Drug_or_compound
;	O
(	O
4	O
)	O
Inhibition	S-Negative_regulation
of	O
SREBP	S-Gene_or_gene_product
led	S-Positive_regulation
to	O
decreased	S-Negative_regulation
ECs	S-Cell
migration	S-Localization
in	O
various	O
models	O
;	O
(	O
5	O
)	O
Cells	S-Cell
genetically	O
deficient	S-Gene_expression
in	O
SREBP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
acting	I-Gene_or_gene_product
protein	E-Gene_or_gene_product
,	O
S1P	S-Gene_or_gene_product
,	O
or	O
S2P	S-Gene_or_gene_product
,	O
phenotypically	O
exhibited	O
impaired	O
migration	O
;	O
(	O
6	O
)	O
SREBP	S-Gene_or_gene_product
inhibition	S-Negative_regulation
in	O
ECs	S-Cell
suppressed	S-Negative_regulation
the	O
activity	O
of	O
small	O
GTPase	O
Cdc42	S-Gene_or_gene_product
,	O
a	O
key	O
molecule	O
for	O
ECs	S-Cell
motility	S-Localization
.	O

CONCLUSIONS	O
:	O
SREBP	S-Gene_or_gene_product
is	O
activated	S-Positive_regulation
during	O
and	O
plays	B-Regulation
a	I-Regulation
critical	I-Regulation
role	E-Regulation
in	O
ECs	S-Cell
migration	S-Localization
.	O

Targeting	S-Planned_process
SREBP	S-Gene_or_gene_product
could	O
become	O
a	O
novel	O
approach	O
in	O
fighting	O
diseases	O
involving	O
abnormal	O
ECs	S-Cell
migration	S-Localization
.	O

Fibroblast	B-Cell
growth	I-Cell
factor	I-Cell
receptor	I-Cell
2	I-Cell
-	I-Cell
positive	I-Cell
fibroblasts	E-Cell
provide	O
a	O
suitable	O
microenvironment	O
for	O
tumor	S-Pathological_formation
development	S-Development
and	O
progression	S-Development
in	O
esophageal	B-Pathological_formation
carcinoma	E-Pathological_formation
.	O

PURPOSE	O
:	O
Tumor	B-Cell
fibroblasts	E-Cell
(	O
TF	S-Cell
)	O
have	O
been	O
suggested	O
to	O
play	B-Regulation
an	I-Regulation
essential	I-Regulation
role	E-Regulation
in	O
the	O
complex	O
process	O
of	O
tumor	S-Pathological_formation
-	O
stroma	S-Tissue
interactions	S-Binding
and	O
tumorigenesis	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
specific	O
role	O
of	O
TF	S-Cell
in	O
the	O
esophageal	B-Pathological_formation
cancer	E-Pathological_formation
microenvironment	O
.	O

EXPERIMENTAL	O
DESIGN	O
:	O
An	O
Affymetrix	O
expression	O
microarray	O
was	O
used	O
to	O
compare	O
gene	O
expression	O
profiles	O
between	O
six	O
pairs	O
of	O
TFs	S-Cell
and	O
normal	O
fibroblasts	S-Cell
from	O
esophageal	B-Pathological_formation
squamous	I-Pathological_formation
cell	I-Pathological_formation
carcinoma	E-Pathological_formation
(	O
ESCC	S-Pathological_formation
)	O
.	O

Differentially	O
expressed	O
genes	O
were	O
identified	O
,	O
and	O
a	O
subset	O
was	O
evaluated	O
by	O
quantitative	O
real	O
-	O
time	O
PCR	O
and	O
immunohistochemistry	O
.	O

RESULTS	O
:	O
About	O
43	O
%	O
(	O
126	O
of	O
292	O
)	O
of	O
known	O
deregulated	O
genes	O
in	O
TFs	S-Cell
were	O
associated	O
with	O
cell	S-Cell
proliferation	S-Cell_proliferation
,	O
extracellular	B-Cellular_component
matrix	E-Cellular_component
remodeling	S-Remodeling
,	O
and	O
immune	O
response	O
.	O

Up	B-Positive_regulation
-	I-Positive_regulation
regulation	E-Positive_regulation
of	O
fibroblast	B-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
receptor	I-Gene_or_gene_product
2	E-Gene_or_gene_product
(	O
FGFR2	S-Gene_or_gene_product
)	O
,	O
which	O
showed	O
the	O
most	O
significant	O
change	O
,	O
was	O
detected	O
in	O
all	O
six	O
tested	O
TFs	S-Cell
compared	O
with	O
their	O
paired	O
normal	O
fibroblasts	S-Cell
.	O

A	O
further	O
study	O
found	O
that	O
FGFR2	B-Cell
-	I-Cell
positive	I-Cell
fibroblasts	E-Cell
were	O
only	O
observed	O
inside	O
the	O
tumor	B-Tissue
tissues	E-Tissue
and	O
not	O
in	O
tumor	B-Tissue
-	I-Tissue
surrounding	I-Tissue
stromal	I-Tissue
tissues	E-Tissue
,	O
suggesting	O
that	O
FGFR2	S-Gene_or_gene_product
could	O
be	O
used	O
as	O
a	O
TF	S-Cell
-	O
specific	O
marker	O
in	O
ESCC	S-Pathological_formation
.	O

Moreover	O
,	O
the	O
conditioned	O
medium	O
from	O
TFs	S-Cell
was	O
found	O
to	O
be	O
able	O
to	O
promote	O
ESCC	B-Cell
tumor	I-Cell
cell	E-Cell
growth	S-Cell_proliferation
,	O
migration	S-Localization
,	O
and	O
invasion	S-Localization
in	O
vitro	O
.	O

CONCLUSIONS	O
:	O
Our	O
study	O
provides	O
new	O
candidate	O
genes	O
for	O
the	O
esophageal	B-Pathological_formation
cancer	E-Pathological_formation
microenvironment	O
.	O

Based	O
on	O
our	O
results	O
,	O
we	O
hypothesize	O
that	O
FGFR2	B-Cell
(	I-Cell
+	I-Cell
)	I-Cell
-	I-Cell
TFs	E-Cell
might	O
provide	O
cancer	B-Cell
cells	E-Cell
with	O
a	O
suitable	O
microenvironment	O
via	O
secretion	O
of	O
proteins	O
that	O
could	O
promote	O
cancer	O
development	O
and	O
progression	O
through	O
stimulation	S-Positive_regulation
of	O
cancer	B-Cell
cell	E-Cell
proliferation	S-Cell_proliferation
,	O
induction	S-Positive_regulation
of	O
angiogenesis	S-Blood_vessel_development
,	O
inhibition	S-Negative_regulation
of	O
cell	S-Cell
adhesion	S-Binding
,	O
enhancement	S-Positive_regulation
of	O
cell	S-Cell
mobility	S-Localization
,	O
and	O
promotion	S-Positive_regulation
of	O
the	O
epithelial	S-Cell
-	O
mesenchymal	S-Cell
transition	S-Development
.	O

[	O
Role	O
of	O
the	O
tumor	S-Pathological_formation
suppressor	O
ARF	S-Gene_or_gene_product
in	O
oncogenesis	O
]	O

The	O
paper	O
reviews	O
the	O
data	O
available	O
in	O
the	O
literature	O
on	O
a	O
role	O
of	O
the	O
tumor	S-Pathological_formation
suppressor	O
ARF	S-Gene_or_gene_product
in	O
oncogenesis	O
and	O
considers	O
the	O
structure	O
of	O
a	O
gene	O
encoding	O
ARF	S-Gene_or_gene_product
protein	O
.	O

The	O
p53	S-Gene_or_gene_product
-	O
dependent	S-Positive_regulation
and	O
p	B-Gene_or_gene_product
-	I-Gene_or_gene_product
53	E-Gene_or_gene_product
-	O
independent	S-Regulation
functions	O
of	O
this	O
protein	O
are	O
under	O
many	O
studies	O
.	O

There	O
is	O
evidence	O
for	O
the	O
implication	S-Regulation
of	O
ARF	S-Gene_or_gene_product
in	O
angiogenesis	S-Blood_vessel_development
.	O

There	O
is	O
more	O
and	O
more	O
information	O
on	O
the	O
role	O
of	O
ARF	S-Gene_or_gene_product
in	O
the	O
regulation	S-Regulation
of	O
a	O
cell	S-Cell
cycle	O
,	O
apoptosis	S-Death
,	O
and	O
autophagy	O
.	O

The	O
importance	O
of	O
this	O
tumor	S-Pathological_formation
suppressor	O
in	O
the	O
mechanisms	O
of	O
carcinogenesis	O
is	O
beyond	O
question	O
as	O
the	O
inactivation	S-Negative_regulation
of	O
ARF	S-Gene_or_gene_product
suppressor	O
activity	O
leads	S-Positive_regulation
to	O
the	O
rapid	O
growth	S-Growth
of	O
neoplasia	S-Pathological_formation
.	O

However	O
,	O
the	O
exact	O
mechanisms	O
of	O
ARF	S-Gene_or_gene_product
action	O
yet	O
remain	O
unclear	O
and	O
require	O
further	O
studies	O
by	O
different	O
specialists	O
at	O
both	O
the	O
molecular	O
genetic	O
and	O
other	O
levels	O
of	O
investigation	O
.	O

Impact	O
of	O
tumor	B-Cell
cell	E-Cell
VEGF	S-Gene_or_gene_product
expression	S-Gene_expression
on	O
the	O
in	O
vivo	O
efficacy	O
of	O
vandetanib	S-Drug_or_compound
(	O
ZACTIMA	S-Drug_or_compound
;	O
ZD6474	S-Drug_or_compound
)	O
.	O

VEGF	S-Gene_or_gene_product
is	O
the	O
key	O
player	O
in	O
tumor	S-Pathological_formation
angiogenesis	S-Blood_vessel_development
.	O

In	O
the	O
current	O
study	O
,	O
the	O
impact	O
of	O
VEGF	S-Gene_or_gene_product
expression	S-Gene_expression
on	O
the	O
response	S-Regulation
of	O
tumors	S-Pathological_formation
to	O
the	O
VEGFR2	S-Gene_or_gene_product
associated	S-Binding
tyrosine	O
kinase	O
inhibitor	O
vandetanib	S-Drug_or_compound
was	O
evaluated	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Human	S-Organism
colon	B-Pathological_formation
carcinoma	E-Pathological_formation
(	O
HT29	S-Cell
)	O
and	O
murine	S-Organism
squamous	B-Pathological_formation
carcinoma	E-Pathological_formation
(	O
SCCVII	S-Cell
)	O
clonal	O
cell	B-Cell
lines	E-Cell
expressing	S-Gene_expression
varying	O
levels	O
of	O
VEGF	S-Gene_or_gene_product
were	O
established	O
and	O
their	O
response	S-Regulation
to	O
vandetanib	S-Drug_or_compound
was	O
assessed	O
in	O
tissue	S-Tissue
culture	O
and	O
as	O
solid	B-Pathological_formation
tumors	E-Pathological_formation
.	O

RESULTS	O
:	O
Vandetanib	S-Drug_or_compound
treatment	S-Planned_process
had	O
no	O
effect	S-Regulation
on	O
tumor	B-Cell
cell	E-Cell
clonogenic	O
cell	S-Cell
survival	S-Death
in	O
vitro	O
but	O
doses	O
>	O
or	O
=	O
10	O
nM	O
significantly	O
reduced	S-Negative_regulation
endothelial	B-Cell
cell	E-Cell
migration	S-Localization
.	O

In	O
vivo	O
,	O
tumors	S-Pathological_formation
derived	O
from	O
cell	B-Cell
clones	E-Cell
expressing	S-Gene_expression
high	O
levels	O
of	O
VEGF	S-Gene_or_gene_product
displayed	O
significantly	O
enhanced	S-Positive_regulation
angiogenesis	S-Blood_vessel_development
and	O
more	O
aggressive	O
growth	S-Growth
.	O

An	O
intradermal	S-Multi-tissue_structure
angiogenesis	S-Blood_vessel_development
assay	O
was	O
used	O
to	O
demonstrate	O
that	O
a	O
4	O
-	O
day	O
treatment	S-Planned_process
with	O
vandetanib	S-Drug_or_compound
(	O
50	O
mg	O
/	O
kg	O
/	O
day	O
)	O
was	O
able	O
to	O
significantly	O
inhibit	S-Negative_regulation
blood	B-Multi-tissue_structure
vessel	E-Multi-tissue_structure
growth	S-Growth
induced	S-Positive_regulation
by	O
both	O
parental	O
and	O
high	O
VEGF	S-Gene_or_gene_product
-	O
expressing	S-Gene_expression
tumor	B-Cell
cell	E-Cell
clones	O
.	O

In	O
the	O
HT29	B-Pathological_formation
tumor	E-Pathological_formation
model	O
,	O
treatment	S-Planned_process
response	S-Regulation
to	O
vandetanib	S-Drug_or_compound
(	O
50	O
mg	O
/	O
kg	O
/	O
day	O
,	O
Monday	O
-	O
Friday	O
for	O
2	O
weeks	O
)	O
was	O
greatest	O
in	O
xenografts	O
derived	O
from	O
the	O
highest	O
VEGF	S-Gene_or_gene_product
-	O
expressing	S-Gene_expression
cell	B-Cell
clones	E-Cell
.	O

A	O
similar	O
trend	O
was	O
noted	O
in	O
the	O
SCCVII	B-Pathological_formation
tumor	E-Pathological_formation
model	O
.	O

The	O
present	O
findings	O
indicate	O
that	O
vandetanib	S-Drug_or_compound
therapy	S-Planned_process
effectively	O
counteracted	S-Negative_regulation
the	O
aggressive	O
feature	O
of	O
tumor	S-Pathological_formation
growth	S-Growth
resulting	O
from	O
VEGF	S-Gene_or_gene_product
over	B-Gene_expression
-	I-Gene_expression
expressing	E-Gene_expression
tumor	B-Cell
cells	E-Cell
and	O
suggest	O
that	O
such	O
tumors	S-Pathological_formation
may	O
be	O
particularly	O
well	O
suited	O
for	O
anti	O
-	O
VEGF	S-Gene_or_gene_product
interventions	S-Negative_regulation
.	O

The	O
modulation	S-Regulation
of	O
platelet	S-Cell
and	O
endothelial	B-Cell
cell	E-Cell
adhesion	S-Binding
to	O
vascular	B-Multi-tissue_structure
graft	E-Multi-tissue_structure
materials	O
by	O
perlecan	S-Gene_or_gene_product
.	O

Controlled	S-Regulation
neo	B-Blood_vessel_development
-	I-Blood_vessel_development
endothelialisation	E-Blood_vessel_development
is	O
critical	O
to	O
the	O
patency	O
of	O
small	O
diameter	O
vascular	B-Multi-tissue_structure
grafts	E-Multi-tissue_structure
.	O

Endothelialisation	S-Blood_vessel_development
and	O
platelet	S-Cell
adhesion	S-Binding
to	O
purified	O
endothelial	B-Cell
cell	E-Cell
-	O
derived	O
perlecan	S-Gene_or_gene_product
,	O
the	O
major	O
heparan	B-Gene_or_gene_product
sulfate	I-Gene_or_gene_product
(	I-Gene_or_gene_product
HS	I-Gene_or_gene_product
)	I-Gene_or_gene_product
proteoglycan	E-Gene_or_gene_product
in	O
basement	B-Cellular_component
membranes	E-Cellular_component
,	O
were	O
investigated	O
using	O
in	O
vivo	O
and	O
in	O
vitro	O
assays	O
.	O

Expanded	O
polytetrafluoroethylene	S-Drug_or_compound
(	O
ePTFE	S-Drug_or_compound
)	O
vascular	B-Multi-tissue_structure
grafts	E-Multi-tissue_structure
were	O
coated	S-Planned_process
with	O
perlecan	S-Gene_or_gene_product
and	O
tested	O
in	O
an	O
ovine	O
carotid	O
interposition	O
model	O
for	O
a	O
period	O
of	O
6	O
weeks	O
and	O
assessed	O
using	O
light	O
and	O
scanning	O
microscopy	O
.	O

Enhanced	S-Positive_regulation
endothelial	B-Cell
cell	E-Cell
growth	S-Cell_proliferation
and	O
reduced	S-Negative_regulation
platelet	S-Cell
adhesion	S-Binding
were	O
observed	O
on	O
the	O
perlecan	S-Gene_or_gene_product
coated	S-Planned_process
grafts	S-Multi-tissue_structure
when	O
compared	O
to	O
uncoated	S-Planned_process
controls	O
implanted	S-Planned_process
in	O
the	O
same	O
sheep	S-Organism
(	O
n	O
=	O
5	O
)	O
.	O

Perlecan	S-Gene_or_gene_product
was	O
also	O
found	O
to	O
stimulate	S-Positive_regulation
endothelial	B-Cell
cell	E-Cell
proliferation	S-Cell_proliferation
in	O
vitro	O
over	O
a	O
period	O
of	O
6	O
days	O
in	O
the	O
presence	S-Localization
of	O
plasma	S-Organism_substance
proteins	O
and	O
fibroblastic	B-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
2	E-Gene_or_gene_product
(	O
FGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
)	O
,	O
however	O
in	O
the	O
absence	S-Localization
of	O
FGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
endothelial	B-Cell
cell	E-Cell
growth	S-Cell_proliferation
could	O
not	O
be	O
maintained	O
during	O
this	O
period	O
.	O

Perlecan	S-Gene_or_gene_product
was	O
found	O
to	O
be	O
anti	B-Binding
-	I-Binding
adhesive	E-Binding
for	O
platelets	S-Cell
,	O
however	O
after	O
removal	O
of	O
the	O
HS	O
chains	O
attached	O
to	O
perlecan	S-Gene_or_gene_product
,	O
platelet	S-Cell
adhesion	S-Binding
and	O
aggregation	S-Binding
were	O
supported	O
.	O

These	O
results	O
suggest	O
a	O
role	O
for	O
HS	B-Protein_domain_or_region
chains	E-Protein_domain_or_region
of	O
perlecan	S-Gene_or_gene_product
in	O
improving	O
graft	S-Multi-tissue_structure
patency	O
by	O
selectively	O
promoting	S-Positive_regulation
endothelial	B-Cell
cell	E-Cell
proliferation	S-Cell_proliferation
while	O
modulating	S-Regulation
platelet	S-Cell
adhesion	S-Binding
.	O

Mechanical	O
regulation	S-Regulation
of	O
the	O
proangiogenic	S-Blood_vessel_development
factor	O
CCN1	S-Gene_or_gene_product
/	O
CYR61	S-Gene_or_gene_product
gene	O
requires	S-Positive_regulation
the	O
combined	O
activities	O
of	O
MRTF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
A	E-Gene_or_gene_product
and	O
CREB	B-Gene_or_gene_product
-	I-Gene_or_gene_product
binding	I-Gene_or_gene_product
protein	I-Gene_or_gene_product
histone	I-Gene_or_gene_product
acetyltransferase	E-Gene_or_gene_product
.	O

Smooth	B-Tissue
muscle	I-Tissue
-	I-Tissue
rich	I-Tissue
tissues	E-Tissue
respond	S-Regulation
to	O
mechanical	O
overload	O
by	O
an	O
adaptive	O
hypertrophic	O
growth	O
combined	O
with	O
activation	S-Positive_regulation
of	O
angiogenesis	S-Blood_vessel_development
,	O
which	O
potentiates	O
their	O
mechanical	O
overload	O
-	O
bearing	O
capabilities	O
.	O

Neovascularization	S-Blood_vessel_development
is	O
associated	O
with	O
mechanical	O
strain	O
-	O
dependent	O
induction	S-Positive_regulation
of	O
angiogenic	S-Blood_vessel_development
factors	O
such	O
as	O
CCN1	S-Gene_or_gene_product
,	O
an	O
immediate	O
-	O
early	O
gene	O
-	O
encoded	O
matricellular	O
molecule	O
critical	S-Positive_regulation
for	O
vascular	S-Multi-tissue_structure
development	S-Development
and	O
repair	S-Development
.	O

Here	O
we	O
have	O
demonstrated	O
that	O
mechanical	O
strain	O
-	O
dependent	O
induction	S-Positive_regulation
of	O
the	O
CCN1	S-Gene_or_gene_product
gene	O
involves	O
signaling	O
cascades	O
through	O
RhoA	S-Gene_or_gene_product
-	O
mediated	S-Regulation
actin	S-Gene_or_gene_product
remodeling	O
and	O
the	O
p38	B-Gene_or_gene_product
stress	I-Gene_or_gene_product
-	I-Gene_or_gene_product
activated	I-Gene_or_gene_product
protein	I-Gene_or_gene_product
kinase	E-Gene_or_gene_product
(	O
SAPK	S-Gene_or_gene_product
)	O
.	O

Actin	S-Gene_or_gene_product
signaling	S-Pathway
controls	S-Regulation
serum	B-Gene_or_gene_product
response	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
(	O
SRF	S-Gene_or_gene_product
)	O
activity	O
via	S-Positive_regulation
SRF	S-Gene_or_gene_product
interaction	S-Binding
with	O
the	O
myocardin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
related	I-Gene_or_gene_product
transcriptional	I-Gene_or_gene_product
activator	I-Gene_or_gene_product
(	I-Gene_or_gene_product
MRTF	I-Gene_or_gene_product
)	I-Gene_or_gene_product
-	I-Gene_or_gene_product
A	E-Gene_or_gene_product
and	O
tethering	O
to	O
a	O
single	O
CArG	O
box	O
sequence	O
within	O
the	O
CCN1	S-Gene_or_gene_product
promoter	S-DNA_domain_or_region
.	O

Such	O
activity	O
was	O
abolished	O
in	O
mechanically	O
stimulated	S-Positive_regulation
mouse	S-Organism
MRTF	B-Cell
-	I-Cell
A	I-Cell
(	I-Cell
-	I-Cell
/	I-Cell
-	I-Cell
)	I-Cell
cells	E-Cell
or	O
upon	O
inhibition	S-Negative_regulation
of	O
CREB	B-Gene_or_gene_product
-	I-Gene_or_gene_product
binding	I-Gene_or_gene_product
protein	I-Gene_or_gene_product
(	I-Gene_or_gene_product
CBP	I-Gene_or_gene_product
)	I-Gene_or_gene_product
histone	I-Gene_or_gene_product
acetyltransferase	I-Gene_or_gene_product
(	I-Gene_or_gene_product
HAT	I-Gene_or_gene_product
)	E-Gene_or_gene_product
either	O
pharmacologically	O
or	O
by	O
siRNAs	O
.	O

Mechanical	O
strain	O
induced	S-Positive_regulation
CBP	S-Gene_or_gene_product
-	O
mediated	S-Positive_regulation
acetylation	S-Acetylation
of	O
histones	B-Gene_or_gene_product
3	E-Gene_or_gene_product
and	O
4	S-Gene_or_gene_product
at	O
the	O
SRF	S-Gene_or_gene_product
-	O
binding	O
site	O
and	O
within	O
the	O
CCN1	S-Gene_or_gene_product
gene	O
coding	O
region	O
.	O

Inhibition	S-Negative_regulation
of	O
p38	B-Gene_or_gene_product
SAPK	E-Gene_or_gene_product
reduced	S-Negative_regulation
CBP	B-Gene_or_gene_product
HAT	E-Gene_or_gene_product
activity	O
and	O
its	O
recruitment	S-Binding
to	O
the	O
SRF	S-Gene_or_gene_product
.	O
MRTF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
A	E-Gene_or_gene_product
complex	O
,	O
whereas	O
enforced	O
induction	S-Positive_regulation
of	O
p38	S-Gene_or_gene_product
by	O
upstream	O
activators	O
(	O
e	O
.	O
g	O
.	O
MKK3	S-Gene_or_gene_product
and	O
MKK6	S-Gene_or_gene_product
)	O
enhanced	S-Positive_regulation
both	O
CBP	B-Gene_or_gene_product
HAT	E-Gene_or_gene_product
and	O
CCN1	S-Gene_or_gene_product
promoter	S-DNA_domain_or_region
activities	O
.	O

Similarly	O
,	O
mechanical	O
overload	O
-	O
induced	S-Positive_regulation
CCN1	S-Gene_or_gene_product
gene	O
expression	S-Gene_expression
in	O
vivo	O
was	O
associated	S-Regulation
with	O
nuclear	O
localization	S-Localization
of	O
MRTF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
A	E-Gene_or_gene_product
and	O
enrichment	O
of	O
the	O
CCN1	S-Gene_or_gene_product
promoter	O
with	O
both	O
MRTF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
A	E-Gene_or_gene_product
and	O
acetylated	S-Acetylation
histone	B-Gene_or_gene_product
H3	E-Gene_or_gene_product
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
signal	O
-	O
controlled	S-Regulation
activation	S-Positive_regulation
of	O
SRF	S-Gene_or_gene_product
,	O
MRTF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
A	E-Gene_or_gene_product
,	O
and	O
CBP	S-Gene_or_gene_product
provides	O
a	O
novel	O
connection	O
between	O
mechanical	O
stimuli	O
and	O
angiogenic	S-Blood_vessel_development
gene	O
expression	O
.	O

Tumour	S-Pathological_formation
angiogenesis	S-Blood_vessel_development
:	O
its	O
mechanism	O
and	O
therapeutic	O
implications	O
in	O
malignant	O
gliomas	S-Pathological_formation
.	O

Angiogenesis	S-Blood_vessel_development
is	O
a	O
key	O
event	O
in	O
the	O
progression	S-Development
of	O
malignant	O
gliomas	S-Pathological_formation
.	O

The	O
presence	O
of	O
microvascular	S-Tissue
proliferation	S-Development
leads	O
to	O
the	O
histological	O
diagnosis	O
of	O
glioblastoma	B-Pathological_formation
multiforme	E-Pathological_formation
.	O

Tumour	S-Pathological_formation
angiogenesis	S-Blood_vessel_development
involves	S-Regulation
multiple	O
cellular	O
processes	O
including	O
endothelial	B-Cell
cell	E-Cell
proliferation	S-Cell_proliferation
,	O
migration	S-Localization
,	O
reorganisation	S-Remodeling
of	O
extracellular	B-Cellular_component
matrix	E-Cellular_component
and	O
tube	S-Tissue
formation	S-Development
.	O

These	O
processes	O
are	O
regulated	O
by	O
numerous	O
pro	O
-	O
angiogenic	S-Blood_vessel_development
and	O
anti	O
-	O
angiogenic	S-Blood_vessel_development
growth	O
factors	O
.	O

Angiogenesis	S-Blood_vessel_development
inhibitors	O
have	O
been	O
developed	O
to	O
interrupt	O
the	O
angiogenic	S-Blood_vessel_development
process	O
at	O
the	O
growth	O
factor	O
,	O
receptor	O
tyrosine	O
kinase	O
and	O
intracellular	O
kinase	O
levels	O
.	O

Other	O
anti	O
-	O
angiogenic	S-Blood_vessel_development
therapies	S-Negative_regulation
alter	O
the	O
immune	O
response	O
and	O
endogeneous	O
angiogenesis	S-Blood_vessel_development
inhibitor	O
levels	O
.	O

Most	O
anti	O
-	O
angiogenic	S-Blood_vessel_development
therapies	S-Negative_regulation
for	O
malignant	O
gliomas	S-Pathological_formation
are	O
in	O
Phase	O
I	O
/	O
II	O
trials	O
and	O
only	O
modest	O
efficacies	O
are	O
reported	O
for	O
monotherapies	O
.	O

The	O
greatest	O
potential	O
for	O
angiogenesis	S-Blood_vessel_development
inhibitors	O
may	O
lie	O
in	O
their	O
ability	O
to	O
combine	O
safely	O
with	O
chemotherapy	O
and	O
radiotherapy	O
.	O

Regulation	S-Regulation
of	O
thrombospondin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
by	O
natural	O
and	O
synthetic	O
progestins	S-Drug_or_compound
in	O
human	S-Organism
breast	B-Cell
cancer	I-Cell
cells	E-Cell
.	O

Our	O
recent	O
studies	O
show	O
that	O
progestins	S-Drug_or_compound
induce	S-Positive_regulation
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
(	O
VEGF	S-Gene_or_gene_product
)	O
in	O
breast	B-Cell
cancer	I-Cell
cells	E-Cell
that	O
express	S-Gene_expression
mutant	O
p53	S-Gene_or_gene_product
protein	O
.	O

Here	O
,	O
we	O
show	O
that	O
natural	O
and	O
synthetic	O
progestins	S-Drug_or_compound
also	O
induce	S-Positive_regulation
thrombospondin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
(	O
TSP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
)	O
mRNA	O
and	O
protein	O
in	O
T47	B-Cell
-	I-Cell
D	E-Cell
and	O
BT	B-Cell
-	I-Cell
474	I-Cell
breast	I-Cell
cancer	I-Cell
cells	E-Cell
.	O

Antiprogestin	B-Drug_or_compound
RU	I-Drug_or_compound
-	I-Drug_or_compound
486	E-Drug_or_compound
inhibits	S-Negative_regulation
the	O
induction	S-Positive_regulation
of	O
VEGF	S-Gene_or_gene_product
and	O
TSP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
by	O
progestins	S-Drug_or_compound
,	O
suggesting	O
that	O
this	O
effect	O
of	O
progestin	S-Drug_or_compound
is	O
mediated	S-Regulation
by	O
the	O
progesterone	B-Gene_or_gene_product
receptor	E-Gene_or_gene_product
(	O
PR	S-Gene_or_gene_product
)	O
.	O

Actinomycin	B-Drug_or_compound
-	I-Drug_or_compound
D	E-Drug_or_compound
,	O
but	O
not	O
puromycin	S-Drug_or_compound
,	O
also	O
blocks	S-Negative_regulation
progestin	S-Drug_or_compound
-	O
dependent	S-Positive_regulation
induction	S-Positive_regulation
of	O
TSP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
.	O

A	O
putative	O
progestin	S-Drug_or_compound
-	O
response	O
element	O
was	O
identified	O
in	O
the	O
human	S-Organism
TSP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
promoter	O
,	O
which	O
is	O
consistent	O
with	O
the	O
hypothesis	O
that	O
a	O
progestin	S-Drug_or_compound
-	O
PR	S-Gene_or_gene_product
complex	O
might	O
directly	O
regulate	S-Regulation
transcription	S-Transcription
of	O
the	O
TSP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
gene	O
in	O
human	S-Organism
cells	S-Cell
.	O

Conditioned	O
medium	O
from	O
progestin	S-Drug_or_compound
-	O
treated	S-Planned_process
breast	B-Cell
cancer	I-Cell
cells	E-Cell
stimulates	S-Positive_regulation
endothelial	B-Cell
cell	E-Cell
proliferation	S-Cell_proliferation
in	O
the	O
absence	O
though	O
not	O
in	O
the	O
presence	O
of	O
antibody	B-Gene_or_gene_product
to	I-Gene_or_gene_product
TSP	I-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
,	O
indicating	O
that	O
TSP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
secreted	S-Localization
by	O
breast	B-Cell
cancer	I-Cell
cells	E-Cell
could	O
be	O
pro	O
-	O
angiogenic	S-Blood_vessel_development
.	O

Since	O
tumor	B-Cell
cell	E-Cell
-	O
derived	O
TSP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
has	O
the	O
potential	O
to	O
promote	S-Positive_regulation
angiogenesis	S-Blood_vessel_development
in	O
the	O
tumor	S-Pathological_formation
microenvironment	O
,	O
it	O
could	O
be	O
a	O
potential	O
target	O
for	O
breast	B-Pathological_formation
cancer	E-Pathological_formation
therapy	S-Planned_process
.	O

Angiogenesis	S-Blood_vessel_development
in	O
platelet	B-Organism
endothelial	I-Organism
cell	I-Organism
adhesion	I-Organism
molecule	I-Organism
-	I-Organism
1	I-Organism
-	I-Organism
null	I-Organism
mice	E-Organism
.	O

Platelet	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
cell	I-Gene_or_gene_product
adhesion	I-Gene_or_gene_product
molecule	I-Gene_or_gene_product
(	I-Gene_or_gene_product
PECAM	I-Gene_or_gene_product
)	I-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
has	O
been	O
previously	O
implicated	O
in	O
endothelial	B-Cell
cell	E-Cell
migration	S-Localization
;	O
additionally	O
,	O
anti	B-Gene_or_gene_product
-	I-Gene_or_gene_product
PECAM	I-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
antibodies	E-Gene_or_gene_product
have	O
been	O
shown	O
to	O
inhibit	S-Negative_regulation
in	O
vivo	O
angiogenesis	S-Blood_vessel_development
.	O

Studies	O
were	O
therefore	O
performed	O
with	O
PECAM	B-Organism
-	I-Organism
1	I-Organism
-	I-Organism
null	I-Organism
mice	E-Organism
to	O
further	O
define	O
the	O
involvement	S-Regulation
of	O
PECAM	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
in	O
blood	B-Multi-tissue_structure
vessel	E-Multi-tissue_structure
formation	S-Development
.	O

Vascularization	S-Blood_vessel_development
of	O
subcutaneous	O
Matrigel	O
implants	O
as	O
well	O
as	O
tumor	S-Pathological_formation
angiogenesis	S-Blood_vessel_development
were	O
both	O
inhibited	S-Negative_regulation
in	O
PECAM	B-Organism
-	I-Organism
1	I-Organism
-	I-Organism
null	I-Organism
mice	E-Organism
.	O

Reciprocal	O
bone	B-Multi-tissue_structure
marrow	E-Multi-tissue_structure
transplants	S-Planned_process
that	O
involved	O
both	O
wild	O
-	O
type	O
and	O
PECAM	B-Organism
-	I-Organism
1	I-Organism
-	I-Organism
deficient	I-Organism
mice	E-Organism
revealed	O
that	O
the	O
impaired	S-Negative_regulation
angiogenic	S-Blood_vessel_development
response	O
resulted	O
from	O
a	O
loss	S-Localization
of	O
endothelial	S-Cell
,	O
but	O
not	O
leukocyte	S-Cell
,	O
PECAM	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
.	O

In	O
vitro	O
wound	O
migration	O
and	O
single	O
-	O
cell	S-Cell
motility	S-Localization
by	O
PECAM	B-Cell
-	I-Cell
1	I-Cell
-	I-Cell
null	I-Cell
endothelial	I-Cell
cells	E-Cell
were	O
also	O
compromised	O
.	O

In	O
addition	O
,	O
filopodia	S-Cellular_component
formation	S-Development
,	O
a	O
feature	O
of	O
motile	O
cells	S-Cell
,	O
was	O
inhibited	S-Negative_regulation
in	O
PECAM	B-Cell
-	I-Cell
1	I-Cell
-	I-Cell
null	I-Cell
endothelial	I-Cell
cells	E-Cell
as	O
well	O
as	O
in	O
human	S-Organism
endothelial	B-Cell
cells	E-Cell
treated	S-Planned_process
with	O
either	O
anti	B-Gene_or_gene_product
-	I-Gene_or_gene_product
PECAM	I-Gene_or_gene_product
-	I-Gene_or_gene_product
1	I-Gene_or_gene_product
antibody	E-Gene_or_gene_product
or	O
PECAM	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
siRNA	O
.	O

Furthermore	O
,	O
the	O
expression	S-Gene_expression
of	O
PECAM	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
promoted	S-Positive_regulation
filopodia	S-Cellular_component
formation	S-Development
and	O
increased	S-Positive_regulation
the	O
protein	O
expression	S-Gene_expression
levels	O
of	O
Cdc42	S-Gene_or_gene_product
,	O
a	O
Rho	S-Gene_or_gene_product
GTPase	O
that	O
is	O
known	O
to	O
promote	S-Positive_regulation
the	O
formation	S-Development
of	O
filopodia	S-Cellular_component
.	O

In	O
the	O
developing	S-Development
retinal	B-Multi-tissue_structure
vasculature	E-Multi-tissue_structure
,	O
numerous	O
,	O
long	B-Cellular_component
filamentous	I-Cellular_component
filopodia	E-Cellular_component
,	O
emanating	O
from	O
endothelial	B-Cell
cells	E-Cell
at	O
the	O
tips	O
of	O
angiogenic	S-Blood_vessel_development
sprouts	S-Tissue
,	O
were	O
observed	O
in	O
wild	O
-	O
type	O
animals	O
,	O
but	O
to	O
a	O
lesser	O
extent	O
in	O
the	O
PECAM	B-Organism
-	I-Organism
1	I-Organism
-	I-Organism
null	I-Organism
mice	E-Organism
.	O

Together	O
,	O
these	O
data	O
further	O
establish	O
the	O
involvement	S-Regulation
of	O
endothelial	O
PECAM	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
in	O
angiogenesis	S-Blood_vessel_development
and	O
suggest	O
that	O
,	O
in	O
vivo	O
,	O
PECAM	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
may	O
stimulate	S-Positive_regulation
endothelial	B-Cell
cell	E-Cell
motility	S-Localization
by	O
promoting	S-Positive_regulation
the	O
formation	S-Development
of	O
filopodia	S-Cellular_component
.	O

c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
Ski	E-Gene_or_gene_product
overexpression	S-Gene_expression
promotes	S-Positive_regulation
tumor	S-Pathological_formation
growth	S-Growth
and	O
angiogenesis	S-Blood_vessel_development
through	O
inhibition	S-Negative_regulation
of	O
transforming	B-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
-	I-Gene_or_gene_product
beta	E-Gene_or_gene_product
signaling	S-Pathway
in	O
diffuse	O
-	O
type	O
gastric	B-Pathological_formation
carcinoma	E-Pathological_formation
.	O

c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
Ski	E-Gene_or_gene_product
,	O
originally	O
identified	O
as	O
a	O
proto	O
-	O
oncogene	O
product	O
,	O
is	O
an	O
important	O
negative	O
regulator	O
of	O
transforming	B-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
(	I-Gene_or_gene_product
TGF	I-Gene_or_gene_product
)	I-Gene_or_gene_product
-	I-Gene_or_gene_product
beta	E-Gene_or_gene_product
family	O
signaling	S-Pathway
through	O
interaction	S-Binding
with	O
Smad2	S-Gene_or_gene_product
,	O
Smad3	S-Gene_or_gene_product
,	O
and	O
Smad4	S-Gene_or_gene_product
.	O

High	O
expression	S-Gene_expression
of	O
c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
Ski	E-Gene_or_gene_product
has	O
been	O
found	O
in	O
some	O
cancers	S-Pathological_formation
,	O
including	O
gastric	B-Pathological_formation
cancer	E-Pathological_formation
.	O

We	O
previously	O
showed	O
that	O
disruption	S-Negative_regulation
of	O
TGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
beta	E-Gene_or_gene_product
signaling	S-Pathway
by	O
dominant	O
-	O
negative	O
TGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
beta	I-Gene_or_gene_product
type	I-Gene_or_gene_product
II	I-Gene_or_gene_product
receptor	E-Gene_or_gene_product
in	O
a	O
diffuse	O
-	O
type	O
gastric	B-Pathological_formation
carcinoma	E-Pathological_formation
model	O
accelerated	S-Positive_regulation
tumor	S-Pathological_formation
growth	S-Growth
through	O
induction	S-Positive_regulation
of	O
tumor	S-Pathological_formation
angiogenesis	S-Blood_vessel_development
by	O
decreased	S-Negative_regulation
expression	S-Gene_expression
of	O
the	O
anti	O
-	O
angiogenic	S-Blood_vessel_development
factor	O
thrombospondin	B-Gene_or_gene_product
(	I-Gene_or_gene_product
TSP	I-Gene_or_gene_product
)	I-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
.	O

Here	O
,	O
we	O
examined	O
the	O
function	O
of	O
c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
Ski	E-Gene_or_gene_product
in	O
human	S-Organism
diffuse	O
-	O
type	O
gastric	B-Pathological_formation
carcinoma	E-Pathological_formation
OCUM	B-Cell
-	I-Cell
2MLN	I-Cell
cells	E-Cell
.	O

Overexpression	S-Gene_expression
of	O
c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
Ski	E-Gene_or_gene_product
inhibited	S-Negative_regulation
TGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
beta	E-Gene_or_gene_product
signaling	S-Pathway
in	O
OCUM	B-Cell
-	I-Cell
2MLN	I-Cell
cells	E-Cell
.	O

Interestingly	O
,	O
c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
Ski	E-Gene_or_gene_product
overexpression	S-Gene_expression
resulted	O
in	O
extensive	O
acceleration	O
of	O
the	O
growth	S-Growth
of	O
subcutaneous	O
xenografts	S-Pathological_formation
in	O
BALB	B-Organism
/	I-Organism
c	I-Organism
nu	I-Organism
/	I-Organism
nu	I-Organism
female	I-Organism
mice	E-Organism
(	O
6	O
weeks	O
of	O
age	O
)	O
.	O

Similar	O
to	O
tumors	S-Pathological_formation
expressing	S-Gene_expression
dominant	O
-	O
negative	O
TGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
beta	I-Gene_or_gene_product
type	I-Gene_or_gene_product
II	I-Gene_or_gene_product
receptor	E-Gene_or_gene_product
,	O
histochemical	O
studies	O
revealed	O
less	O
fibrosis	O
and	O
increased	S-Positive_regulation
angiogenesis	S-Blood_vessel_development
in	O
xenografted	O
tumors	S-Pathological_formation
expressing	S-Gene_expression
c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
Ski	E-Gene_or_gene_product
compared	O
to	O
control	O
tumors	S-Pathological_formation
.	O

Induction	S-Positive_regulation
of	O
TSP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
mRNA	O
by	O
TGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
beta	E-Gene_or_gene_product
was	O
attenuated	S-Negative_regulation
by	O
c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
Ski	E-Gene_or_gene_product
in	O
vitro	O
,	O
and	O
expression	S-Transcription
of	O
TSP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
mRNA	O
was	O
decreased	S-Negative_regulation
in	O
tumors	S-Pathological_formation
expressing	S-Gene_expression
c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
Ski	E-Gene_or_gene_product
in	O
vivo	O
.	O

These	O
findings	O
suggest	O
that	O
c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
Ski	E-Gene_or_gene_product
overexpression	S-Gene_expression
promotes	S-Positive_regulation
the	O
growth	S-Growth
of	O
diffuse	O
-	O
type	O
gastric	B-Pathological_formation
carcinoma	E-Pathological_formation
through	O
induction	S-Positive_regulation
of	O
angiogenesis	S-Blood_vessel_development
.	O

MEK5	S-Gene_or_gene_product
/	O
ERK5	S-Gene_or_gene_product
signaling	S-Pathway
modulates	S-Regulation
endothelial	B-Cell
cell	E-Cell
migration	S-Localization
and	O
focal	B-Cellular_component
contact	E-Cellular_component
turnover	O
.	O

The	O
formation	S-Development
of	O
new	O
blood	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
from	O
pre	O
-	O
existing	O
ones	O
requires	S-Positive_regulation
highly	O
coordinated	O
restructuring	S-Remodeling
of	O
endothelial	B-Cell
cells	E-Cell
(	O
EC	S-Cell
)	O
and	O
the	O
surrounding	O
extracellular	B-Cellular_component
matrix	E-Cellular_component
.	O

Directed	O
EC	S-Cell
migration	S-Localization
is	O
a	O
central	O
step	O
in	O
this	O
process	O
and	O
depends	O
on	O
cellular	O
signaling	O
cascades	O
that	O
initiate	O
and	O
control	O
the	O
structural	O
rearrangements	O
.	O

On	O
the	O
basis	O
of	O
earlier	O
findings	O
that	O
ERK5	S-Gene_or_gene_product
deficiency	S-Gene_expression
in	O
mouse	S-Organism
EC	S-Cell
results	S-Positive_regulation
in	O
massive	O
defects	S-Negative_regulation
in	O
vessel	B-Multi-tissue_structure
architecture	E-Multi-tissue_structure
,	O
we	O
focused	O
on	O
the	O
impact	S-Regulation
of	O
the	O
MEK5	S-Gene_or_gene_product
/	O
ERK5	S-Gene_or_gene_product
signaling	B-Pathway
pathway	E-Pathway
on	O
EC	S-Cell
migration	S-Localization
.	O

Using	O
a	O
retroviral	O
gene	O
transfer	O
approach	O
,	O
we	O
found	O
that	O
constitutive	O
activation	S-Positive_regulation
of	O
MEK5	S-Gene_or_gene_product
/	O
ERK5	S-Gene_or_gene_product
signaling	S-Pathway
strongly	O
inhibits	S-Negative_regulation
EC	S-Cell
migration	S-Localization
and	O
results	O
in	O
massive	O
morphological	O
changes	O
.	O

The	O
area	O
covered	O
by	O
spread	S-Localization
EC	S-Cell
was	O
dramatically	O
enlarged	O
,	O
accompanied	O
by	O
an	O
increase	O
in	O
focal	B-Cellular_component
contacts	E-Cellular_component
and	O
altered	O
organization	S-Remodeling
of	O
actin	S-Gene_or_gene_product
filaments	S-Cellular_component
.	O

Consequently	O
,	O
cells	S-Cell
were	O
more	O
rigid	O
and	O
show	O
reduced	S-Negative_regulation
motility	S-Localization
.	O

This	O
phenotype	O
was	O
most	O
likely	O
based	O
on	O
decreased	O
focal	B-Cellular_component
contact	E-Cellular_component
turnover	O
caused	O
by	O
reduced	S-Negative_regulation
expression	S-Gene_expression
of	O
p130Cas	S-Gene_or_gene_product
,	O
a	O
key	O
player	O
in	O
directed	O
cell	S-Cell
migration	S-Localization
.	O

We	O
demonstrate	O
for	O
the	O
first	O
time	O
that	O
ERK5	S-Gene_or_gene_product
signaling	S-Pathway
not	O
only	O
is	O
involved	S-Regulation
in	O
EC	S-Cell
survival	S-Death
and	O
stress	O
response	O
but	O
also	O
controls	S-Regulation
migration	S-Localization
and	O
morphology	O
of	O
EC	S-Cell
.	O

The	O
Down	B-Gene_or_gene_product
syndrome	I-Gene_or_gene_product
critical	I-Gene_or_gene_product
region	I-Gene_or_gene_product
gene	I-Gene_or_gene_product
1	E-Gene_or_gene_product
short	O
variant	O
promoters	O
direct	O
vascular	B-Multi-tissue_structure
bed	E-Multi-tissue_structure
-	O
specific	O
gene	O
expression	O
during	O
inflammation	O
in	O
mice	S-Organism
.	O

Down	B-Gene_or_gene_product
syndrome	I-Gene_or_gene_product
critical	I-Gene_or_gene_product
region	I-Gene_or_gene_product
gene	I-Gene_or_gene_product
1	E-Gene_or_gene_product
(	O
DSCR	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
)	O
short	O
variant	O
(	O
DSCR	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1s	E-Gene_or_gene_product
)	O
is	O
an	O
inhibitor	O
of	O
calcineurin	S-Gene_or_gene_product
/	O
NFAT	S-Gene_or_gene_product
signaling	S-Pathway
encoded	O
by	O
exons	O
4	O
-	O
7	O
of	O
DSCR1	S-Gene_or_gene_product
.	O

We	O
previously	O
reported	O
that	O
VEGF	S-Gene_or_gene_product
induces	S-Positive_regulation
DSCR	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1s	E-Gene_or_gene_product
expression	S-Gene_expression
in	O
endothelial	B-Cell
cells	E-Cell
,	O
which	O
in	O
turn	O
negatively	O
feeds	O
back	O
to	O
attenuate	S-Negative_regulation
endothelial	B-Cell
cell	E-Cell
activation	S-Positive_regulation
.	O

Here	O
,	O
in	O
order	O
to	O
characterize	O
the	O
role	O
of	O
the	O
promoter	O
that	O
drives	O
DSCR	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1s	E-Gene_or_gene_product
expression	S-Gene_expression
in	O
mediating	O
inducible	O
expression	O
in	O
vivo	O
and	O
to	O
determine	O
the	O
functional	O
relevance	O
of	O
DSCR	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1s	E-Gene_or_gene_product
in	O
inflammation	O
,	O
we	O
targeted	S-Planned_process
a	O
DNA	O
construct	O
containing	O
1	O
.	O
7	O
kb	O
of	O
the	O
human	S-Organism
DSCR1s	S-Gene_or_gene_product
promoter	O
coupled	S-Planned_process
to	O
the	O
lacZ	S-Gene_or_gene_product
reporter	O
to	O
the	O
hypoxanthine	B-Gene_or_gene_product
guanine	I-Gene_or_gene_product
phosphoribosyl	I-Gene_or_gene_product
transferase	E-Gene_or_gene_product
(	O
Hprt	S-Gene_or_gene_product
)	O
locus	O
of	O
mice	S-Organism
.	O

We	O
determined	O
that	O
lacZ	S-Gene_or_gene_product
was	O
uniformly	O
expressed	S-Gene_expression
in	O
the	O
endothelium	S-Tissue
of	O
transgenic	B-Developing_anatomical_structure
embryos	E-Developing_anatomical_structure
but	O
was	O
markedly	O
downregulated	S-Negative_regulation
postnatally	O
.	O

Systemic	O
administration	S-Planned_process
of	O
VEGF	S-Gene_or_gene_product
or	O
LPS	S-Drug_or_compound
in	O
adult	O
mice	S-Organism
resulted	S-Positive_regulation
in	O
cyclosporine	B-Drug_or_compound
A	E-Drug_or_compound
-	O
sensitive	S-Regulation
reactivation	S-Positive_regulation
of	O
the	O
DSCR1s	S-Gene_or_gene_product
promoter	S-DNA_domain_or_region
and	O
endogenous	O
gene	O
expression	O
in	O
a	O
subset	O
of	O
organs	S-Organ
,	O
including	O
the	O
heart	S-Organ
and	O
brain	S-Organ
.	O

The	O
DSCR1s	S-Gene_or_gene_product
promoter	S-DNA_domain_or_region
was	O
similarly	O
induced	S-Positive_regulation
in	O
the	O
endothelium	S-Tissue
of	O
tumor	S-Pathological_formation
xenografts	O
.	O

In	O
a	O
mouse	S-Organism
model	O
of	O
endotoxemia	O
,	O
DSCR	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1s	E-Gene_or_gene_product
-	O
deficient	S-Gene_expression
mice	S-Organism
demonstrated	O
increased	O
sepsis	O
mortality	O
,	O
whereas	O
adenovirus	S-Organism
-	O
mediated	S-Positive_regulation
DSCR	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1s	E-Gene_or_gene_product
overexpression	S-Gene_expression
protected	O
against	O
LPS	S-Drug_or_compound
-	O
induced	O
lethality	O
.	O

Collectively	O
,	O
these	O
data	O
suggest	O
that	O
the	O
DSCR1s	S-Gene_or_gene_product
promoter	S-DNA_domain_or_region
directs	O
vascular	B-Multi-tissue_structure
bed	E-Multi-tissue_structure
-	O
specific	O
expression	S-Gene_expression
in	O
activated	S-Positive_regulation
endothelium	S-Tissue
and	O
that	O
DSCR	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1s	E-Gene_or_gene_product
serves	O
to	O
dampen	O
the	O
host	O
response	O
to	O
infection	O
.	O

EPOX	S-Drug_or_compound
inhibits	S-Negative_regulation
angiogenesis	S-Blood_vessel_development
by	O
degradation	S-Catabolism
of	O
Mcl	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
through	S-Positive_regulation
ERK	S-Gene_or_gene_product
inactivation	S-Negative_regulation
.	O

PURPOSE	O
:	O
Antiangiogenic	S-Blood_vessel_development
therapy	S-Negative_regulation
is	O
considered	O
as	O
an	O
effective	O
strategy	O
for	O
controlling	S-Regulation
the	O
growth	S-Growth
and	O
metastasis	S-Localization
of	O
tumors	S-Pathological_formation
.	O

Among	O
a	O
myriad	O
of	O
biological	O
activities	O
described	O
for	O
xanthone	B-Drug_or_compound
derivatives	E-Drug_or_compound
,	O
the	O
anticancer	S-Pathological_formation
activity	S-Negative_regulation
is	O
quite	O
remarkable	O
,	O
but	O
the	O
molecular	O
mechanism	O
is	O
not	O
clearly	O
resolved	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
antiangiogenic	S-Blood_vessel_development
mechanism	S-Negative_regulation
of	O
3	B-Drug_or_compound
,	I-Drug_or_compound
6	I-Drug_or_compound
-	I-Drug_or_compound
di	I-Drug_or_compound
(	I-Drug_or_compound
2	I-Drug_or_compound
,	I-Drug_or_compound
3	I-Drug_or_compound
-	I-Drug_or_compound
epoxypropoxy	I-Drug_or_compound
)	I-Drug_or_compound
xanthone	E-Drug_or_compound
(	O
EPOX	S-Drug_or_compound
)	O
,	O
a	O
novel	O
Mcl	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
targeting	S-Regulation
drug	O
.	O

EXPERIMENTAL	O
DESIGN	O
:	O
To	O
evaluate	O
the	O
antiangiogenic	S-Blood_vessel_development
activity	S-Negative_regulation
of	O
EPOX	S-Drug_or_compound
,	O
we	O
did	O
cell	S-Cell
viability	O
,	O
cell	S-Cell
cycle	O
,	O
tube	S-Tissue
formation	S-Development
assay	O
in	O
vitro	O
,	O
and	O
Matrigel	O
plug	O
assay	O
in	O
vivo	O
.	O

To	O
evaluate	O
the	O
effect	S-Regulation
of	O
EPOX	S-Drug_or_compound
on	O
the	O
endothelial	B-Pathway
signaling	I-Pathway
pathway	E-Pathway
,	O
we	O
did	O
immunoblotting	O
,	O
immunoprecipitation	O
,	O
and	O
immunofluorescence	O
analysis	O
.	O

Intracellular	O
glutathione	S-Drug_or_compound
levels	O
were	O
determined	O
with	O
the	O
use	O
of	O
monochlorobimane	S-Drug_or_compound
,	O
a	O
glutathione	S-Drug_or_compound
-	O
specific	O
probe	O
.	O

RESULTS	O
:	O
EPOX	S-Drug_or_compound
induced	S-Positive_regulation
endothelial	B-Cell
cell	E-Cell
apoptosis	S-Death
in	O
association	S-Regulation
with	O
proteasome	O
-	O
dependent	S-Positive_regulation
Mcl	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
degradation	S-Catabolism
.	O

Down	B-Negative_regulation
-	I-Negative_regulation
regulation	E-Negative_regulation
of	O
Mcl	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
resulted	S-Positive_regulation
in	O
an	O
increase	S-Positive_regulation
in	O
Mcl	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
-	O
free	S-Regulation
Bim	S-Gene_or_gene_product
,	O
activation	S-Positive_regulation
of	O
Bax	S-Gene_or_gene_product
,	O
and	O
then	O
signaling	O
of	O
mitochondria	O
-	O
mediated	O
apoptosis	O
.	O

Additionally	O
,	O
glutathione	S-Drug_or_compound
depletion	S-Negative_regulation
and	O
extracellular	B-Gene_or_gene_product
signal	I-Gene_or_gene_product
-	I-Gene_or_gene_product
regulated	I-Gene_or_gene_product
kinase	E-Gene_or_gene_product
(	O
ERK	S-Gene_or_gene_product
)	O
inactivation	S-Negative_regulation
was	O
observed	O
in	O
EPOX	S-Drug_or_compound
-	O
treated	S-Planned_process
cells	S-Cell
.	O

Glutathione	S-Drug_or_compound
supplementation	S-Planned_process
reversed	S-Negative_regulation
the	O
inhibitory	B-Negative_regulation
effects	E-Negative_regulation
of	O
EPOX	S-Drug_or_compound
on	O
ERK	S-Gene_or_gene_product
,	O
which	O
increases	S-Positive_regulation
the	O
phosphorylation	S-Phosphorylation
of	O
Mcl	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
at	O
T	B-Protein_domain_or_region
(	I-Protein_domain_or_region
163	E-Protein_domain_or_region
.	O
)	O
Overexpression	S-Gene_expression
of	O
mitogen	B-Gene_or_gene_product
-	I-Gene_or_gene_product
activated	I-Gene_or_gene_product
protein	I-Gene_or_gene_product
/	I-Gene_or_gene_product
ERK	I-Gene_or_gene_product
kinase	E-Gene_or_gene_product
(	O
MEK	S-Gene_or_gene_product
)	O
partially	O
reversed	S-Negative_regulation
the	O
effect	S-Regulation
of	O
EPOX	S-Drug_or_compound
on	O
Mcl	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
dephosphorylation	S-Dephosphorylation
,	O
ubiquitination	S-Ubiquitination
,	O
and	O
degradation	S-Catabolism
,	O
further	O
implicating	O
ERK	S-Gene_or_gene_product
in	O
the	O
regulation	S-Regulation
of	O
Mcl	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
stability	O
.	O

CONCLUSIONS	O
:	O
This	O
study	O
provides	O
evidence	O
that	O
EPOX	S-Drug_or_compound
induces	S-Positive_regulation
glutathione	S-Drug_or_compound
depletion	S-Negative_regulation
,	O
ERK	S-Gene_or_gene_product
inactivation	S-Negative_regulation
,	O
and	O
Mcl	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
degradation	S-Catabolism
on	O
endothelial	B-Cell
cells	E-Cell
,	O
which	O
leads	S-Positive_regulation
to	O
inhibition	S-Negative_regulation
of	O
angiogenesis	S-Blood_vessel_development
.	O

Our	O
results	O
suggest	O
that	O
EPOX	S-Drug_or_compound
is	O
a	O
novel	O
antiangiogenic	S-Blood_vessel_development
agent	O
,	O
making	O
it	O
a	O
promising	O
lead	O
compound	O
for	O
further	O
development	O
in	O
the	O
treatment	O
of	O
angiogenesis	S-Blood_vessel_development
-	O
related	O
pathologies	O
.	O

Angiogenesis	S-Blood_vessel_development
-	O
a	O
novel	O
therapeutic	O
approach	O
for	O
ischemic	O
heart	S-Organ
disease	O
.	O

Angiogenesis	S-Blood_vessel_development
is	O
the	O
biologic	O
process	O
of	O
forming	S-Development
new	O
blood	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
.	O

Undoubtedly	O
,	O
blood	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
growth	S-Growth
regulation	S-Regulation
is	O
a	O
vital	O
aspect	O
in	O
health	O
and	O
disease	O
.	O

Under	O
physiological	O
conditions	O
,	O
angiogenesis	S-Blood_vessel_development
is	O
regulated	S-Regulation
by	O
local	O
balance	O
between	O
endogenous	O
stimulators	O
and	O
inhibitors	O
of	O
this	O
process	O
.	O

In	O
many	O
diseases	O
state	O
body	O
loses	O
control	S-Regulation
over	O
angiogenesis	S-Blood_vessel_development
.	O

Angiogenesis	S-Blood_vessel_development
-	O
dependent	O
diseases	O
result	O
when	O
new	O
blood	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
either	O
grow	S-Growth
excessively	O
or	O
insufficiently	O
.	O

Insufficient	O
angiogenesis	S-Blood_vessel_development
occurs	O
in	O
diseases	O
such	O
as	O
coronary	B-Multi-tissue_structure
artery	E-Multi-tissue_structure
disease	O
,	O
stroke	O
and	O
chronic	O
wounds	O
.	O

Myocardial	O
ischemia	O
both	O
acute	O
and	O
chronic	O
has	O
been	O
clearly	O
shown	O
to	O
stimulate	S-Positive_regulation
angiogenesis	S-Blood_vessel_development
in	O
many	O
experimental	O
models	O
.	O

Therapeutic	O
angiogenesis	S-Blood_vessel_development
is	O
the	O
biological	O
agents	O
or	O
bioactive	O
material	O
to	O
stimulate	S-Positive_regulation
the	O
growth	S-Growth
of	O
new	O
blood	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
.	O

Traditional	O
coronary	O
revascularization	S-Blood_vessel_development
therapies	O
such	O
as	O
coronary	O
angioplasty	O
or	O
bypass	O
graft	O
surgery	O
,	O
act	O
by	O
restoring	S-Regulation
blood	S-Organism_substance
flow	O
through	O
the	O
preexisting	S-Localization
coronary	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
.	O

One	O
limitation	O
of	O
these	O
approaches	O
,	O
however	O
,	O
may	O
be	O
the	O
failure	O
to	O
normalize	O
myocardial	O
perfusion	O
,	O
due	O
to	O
the	O
concomitant	O
presence	O
or	O
small	O
of	O
resistance	O
vessel	S-Multi-tissue_structure
disease	O
.	O

In	O
contrast	O
,	O
therapeutic	O
angiogenesis	S-Blood_vessel_development
is	O
based	O
on	O
the	O
concept	O
that	O
coronary	B-Multi-tissue_structure
collateral	E-Multi-tissue_structure
development	S-Development
may	O
be	O
stimulated	S-Positive_regulation
by	O
pharmacological	O
or	O
molecular	O
means	O
and	O
can	O
limit	O
myocardial	O
ischemia	O
.	O

Studies	O
,	O
both	O
in	O
human	S-Organism
and	O
animal	O
models	O
support	O
the	O
notion	O
that	O
,	O
various	O
angiogenic	S-Blood_vessel_development
growth	O
factors	O
and	O
progenitor	B-Cell
cells	E-Cell
can	O
enhance	S-Positive_regulation
new	O
blood	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
.	O

Vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
(	O
VEGF	S-Gene_or_gene_product
)	O
,	O
fibroblast	B-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
(	O
FGF	S-Gene_or_gene_product
)	O
,	O
recombinant	O
proteins	O
and	O
bone	B-Cell
marrow	I-Cell
stem	I-Cell
cells	E-Cell
are	O
currently	O
used	O
therapeutic	O
stimulators	O
for	O
angiogenesis	S-Blood_vessel_development
.	O

As	O
coronary	B-Multi-tissue_structure
artery	E-Multi-tissue_structure
disease	O
is	O
the	O
major	O
cause	O
of	O
death	O
in	O
the	O
developed	O
societies	O
and	O
also	O
an	O
emerging	O
health	O
problem	O
in	O
developing	O
countries	O
like	O
Bangladesh	O
therapeutic	O
angiogenesis	S-Blood_vessel_development
may	O
provide	O
hope	O
as	O
a	O
new	O
treatment	O
modality	O
for	O
ischemic	O
heart	S-Organ
disease	O
with	O
or	O
in	O
place	O
of	O
current	O
therapies	O
.	O

Nicked	B-Gene_or_gene_product
{	I-Gene_or_gene_product
beta	I-Gene_or_gene_product
}	I-Gene_or_gene_product
2	I-Gene_or_gene_product
-	I-Gene_or_gene_product
glycoprotein	I-Gene_or_gene_product
I	E-Gene_or_gene_product
binds	S-Binding
angiostatin	B-Gene_or_gene_product
4	I-Gene_or_gene_product
.	I-Gene_or_gene_product
5	E-Gene_or_gene_product
(	O
plasminogen	B-Protein_domain_or_region
kringle	I-Protein_domain_or_region
1	E-Protein_domain_or_region
-	O
5	S-Protein_domain_or_region
)	O
and	O
attenuates	S-Negative_regulation
its	O
antiangiogenic	S-Blood_vessel_development
property	S-Negative_regulation
.	O

Angiostatin	S-Gene_or_gene_product
was	O
first	O
discovered	O
as	O
a	O
plasminogen	B-Gene_or_gene_product
fragment	E-Gene_or_gene_product
with	O
antitumor	S-Pathological_formation
/	O
antiangiogenic	S-Blood_vessel_development
property	S-Negative_regulation
.	O

One	O
of	O
the	O
angiostatin	S-Gene_or_gene_product
isoforms	O
,	O
that	O
is	O
,	O
angiostatin	B-Gene_or_gene_product
4	I-Gene_or_gene_product
.	I-Gene_or_gene_product
5	E-Gene_or_gene_product
(	O
AS4	B-Gene_or_gene_product
.	I-Gene_or_gene_product
5	E-Gene_or_gene_product
)	O
,	O
consisting	O
of	O
plasminogen	B-Protein_domain_or_region
kringle	I-Protein_domain_or_region
1	E-Protein_domain_or_region
to	O
4	S-Protein_domain_or_region
and	O
a	O
most	O
part	O
of	O
kringle	B-Protein_domain_or_region
5	E-Protein_domain_or_region
,	O
is	O
produced	O
by	O
autoproteolysis	S-Protein_processing
and	O
present	O
in	O
human	S-Organism
plasma	S-Organism_substance
.	O

beta2	B-Gene_or_gene_product
-	I-Gene_or_gene_product
glycoprotein	I-Gene_or_gene_product
I	E-Gene_or_gene_product
(	O
beta2GPI	S-Gene_or_gene_product
)	O
is	O
proteolytically	O
cleaved	S-Protein_processing
by	O
plasmin	S-Gene_or_gene_product
in	O
its	O
domain	B-Protein_domain_or_region
V	E-Protein_domain_or_region
(	O
nicked	B-Gene_or_gene_product
beta2GPI	E-Gene_or_gene_product
)	O
,	O
resulting	S-Positive_regulation
in	O
binding	S-Binding
to	O
plasminogen	S-Gene_or_gene_product
.	O

Antiangiogenic	S-Blood_vessel_development
properties	S-Negative_regulation
have	O
been	O
recently	O
reported	O
in	O
nicked	B-Gene_or_gene_product
beta2GPI	E-Gene_or_gene_product
as	O
well	O
as	O
in	O
intact	O
beta2GPI	S-Gene_or_gene_product
at	O
higher	O
concentrations	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
found	O
significant	O
binding	S-Binding
of	O
nicked	B-Gene_or_gene_product
beta2GPI	E-Gene_or_gene_product
to	O
AS4	B-Gene_or_gene_product
.	I-Gene_or_gene_product
5	E-Gene_or_gene_product
(	O
K	O
(	O
D	O
)	O
=	O
3	O
.	O
27	O
x	O
10	O
(	O
6	O
)	O
M	O
(	O
-	O
1	O
)	O
)	O
.	O

Via	O
this	O
binding	S-Binding
,	O
nicked	B-Gene_or_gene_product
beta2GPI	E-Gene_or_gene_product
attenuates	S-Negative_regulation
the	O
antiangiogenic	S-Blood_vessel_development
functions	S-Negative_regulation
of	O
AS4	B-Gene_or_gene_product
.	I-Gene_or_gene_product
5	E-Gene_or_gene_product
in	O
the	O
proliferation	S-Cell_proliferation
of	O
arterial	S-Cell
/	O
venous	B-Cell
endothelial	I-Cell
cells	E-Cell
,	O
in	O
the	O
extracellular	B-Cellular_component
matrix	E-Cellular_component
invasion	S-Localization
and	O
the	O
tube	S-Tissue
formation	S-Development
of	O
venous	B-Cell
endothelial	I-Cell
cells	E-Cell
,	O
and	O
in	O
vivo	O
angiogenesis	S-Blood_vessel_development
.	O

In	O
contrast	O
,	O
intact	O
beta2GPI	S-Gene_or_gene_product
does	O
not	O
bind	S-Binding
to	O
AS4	B-Gene_or_gene_product
.	I-Gene_or_gene_product
5	E-Gene_or_gene_product
or	O
inhibit	S-Negative_regulation
its	O
antiangiogenic	S-Blood_vessel_development
activity	S-Negative_regulation
.	O

Thus	O
,	O
nicked	B-Gene_or_gene_product
beta2GPI	E-Gene_or_gene_product
exerts	O
dual	O
effects	O
on	O
angiogenesis	S-Blood_vessel_development
,	O
that	O
is	O
,	O
nicked	B-Gene_or_gene_product
beta2GPI	E-Gene_or_gene_product
promotes	S-Positive_regulation
angiogenesis	S-Blood_vessel_development
in	O
the	O
presence	O
of	O
AS4	B-Gene_or_gene_product
.	I-Gene_or_gene_product
5	E-Gene_or_gene_product
,	O
whereas	O
nicked	B-Gene_or_gene_product
beta2GPI	E-Gene_or_gene_product
inhibits	S-Negative_regulation
angiogenesis	S-Blood_vessel_development
at	O
concentrations	O
high	O
enough	O
to	O
neutralize	O
AS4	B-Gene_or_gene_product
.	I-Gene_or_gene_product
5	E-Gene_or_gene_product
.	O

Our	O
data	O
suggest	O
that	O
plasmin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
nicked	I-Gene_or_gene_product
beta2GPI	E-Gene_or_gene_product
promotes	S-Regulation
angiogenesis	S-Blood_vessel_development
by	O
interacting	S-Binding
with	O
plasmin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
generated	I-Gene_or_gene_product
AS4	I-Gene_or_gene_product
.	I-Gene_or_gene_product
5	E-Gene_or_gene_product
in	O
sites	O
of	O
increased	O
fibrinolysis	O
such	O
as	O
thrombus	S-Pathological_formation
.	O

Use	O
of	O
uteroglobin	S-Gene_or_gene_product
for	O
the	O
engineering	O
of	O
polyvalent	O
,	O
polyspecific	O
fusion	O
proteins	O
.	O

We	O
report	O
a	O
novel	O
strategy	O
to	O
engineer	O
and	O
express	O
stable	O
and	O
soluble	O
human	S-Organism
recombinant	O
polyvalent	O
/	O
polyspecific	O
fusion	O
proteins	O
.	O

The	O
procedure	O
is	O
based	O
on	O
the	O
use	O
of	O
a	O
central	O
skeleton	O
of	O
uteroglobin	S-Gene_or_gene_product
,	O
a	O
small	O
and	O
very	O
soluble	O
covalently	O
linked	O
homodimeric	O
protein	O
that	O
is	O
very	O
resistant	O
to	O
proteolytic	O
enzymes	O
and	O
to	O
pH	O
variations	O
.	O

Using	O
a	O
human	S-Organism
recombinant	O
antibody	O
(	O
scFv	O
)	O
specific	O
for	O
the	O
angiogenesis	S-Blood_vessel_development
marker	O
domain	O
B	O
of	O
fibronectin	S-Gene_or_gene_product
,	O
interleukin	B-Gene_or_gene_product
2	E-Gene_or_gene_product
,	O
and	O
an	O
scFv	O
able	O
to	O
neutralize	S-Negative_regulation
tumor	B-Gene_or_gene_product
necrosis	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
-	I-Gene_or_gene_product
alpha	E-Gene_or_gene_product
,	O
we	O
expressed	O
various	O
biologically	O
active	O
uteroglobin	S-Gene_or_gene_product
fusion	O
proteins	O
.	O

The	O
results	O
demonstrate	O
the	O
possibility	O
to	O
generate	O
monospecific	O
divalent	O
and	O
tetravalent	O
antibodies	O
,	O
immunocytokines	O
,	O
and	O
dual	O
specificity	O
tetravalent	O
antibodies	O
.	O

Furthermore	O
,	O
compared	O
with	O
similar	O
fusion	O
proteins	O
in	O
which	O
uteroglobin	S-Gene_or_gene_product
was	O
not	O
used	O
,	O
the	O
use	O
of	O
uteroglobin	S-Gene_or_gene_product
improved	O
properties	O
of	O
solubility	O
and	O
stability	O
.	O

Indeed	O
,	O
in	O
the	O
reported	O
cases	O
it	O
was	O
possible	O
to	O
vacuum	O
dry	O
and	O
reconstitute	O
the	O
proteins	O
without	O
any	O
aggregation	O
or	O
loss	O
in	O
protein	O
and	O
biological	O
activity	O
.	O

Targeting	O
angiogenesis	S-Blood_vessel_development
:	O
progress	O
with	O
anti	O
-	O
VEGF	S-Gene_or_gene_product
treatment	O
with	O
large	O
molecules	O
.	O

Angiogenesis	S-Blood_vessel_development
-	O
-	O
one	O
of	O
the	O
hallmarks	O
of	O
cancer	O
-	O
-	O
has	O
emerged	O
as	O
a	O
valid	O
therapeutic	O
target	O
in	O
oncology	O
.	O

The	O
VEGF	S-Gene_or_gene_product
system	S-Pathway
represents	O
a	O
key	O
mediator	O
of	O
tumor	S-Pathological_formation
-	O
initiated	S-Positive_regulation
angiogenesis	S-Blood_vessel_development
and	O
the	O
first	O
target	O
of	O
antiangiogenesis	S-Blood_vessel_development
agents	O
introduced	O
in	O
clinical	O
practice	O
.	O

Although	O
anti	B-Gene_or_gene_product
-	I-Gene_or_gene_product
VEGF	E-Gene_or_gene_product
therapies	S-Planned_process
have	O
clearly	O
demonstrated	O
antitumor	S-Pathological_formation
efficacy	S-Negative_regulation
in	O
various	O
malignancies	O
,	O
especially	O
when	O
combined	O
with	O
conventional	O
cytotoxic	O
chemotherapy	O
,	O
their	O
mechanism	O
of	O
action	O
is	O
not	O
fully	O
understood	O
.	O

This	O
Review	O
will	O
discuss	O
the	O
rationale	O
for	O
using	O
antiangiogenic	S-Blood_vessel_development
compounds	O
and	O
will	O
focus	O
on	O
large	O
molecules	O
,	O
such	O
as	O
antibodies	O
,	O
that	O
target	O
the	O
VEGF	S-Gene_or_gene_product
system	S-Pathway
.	O

Clinical	O
data	O
on	O
bevacizumab	S-Drug_or_compound
is	O
discussed	O
in	O
detail	O
.	O

Predictive	O
markers	O
for	O
anti	O
-	O
VEGF	S-Gene_or_gene_product
agents	O
have	O
not	O
yet	O
been	O
identified	O
and	O
questions	O
regarding	O
the	O
usefulness	O
of	O
bevacizumab	S-Drug_or_compound
in	O
the	O
adjuvant	O
setting	O
as	O
well	O
as	O
its	O
continued	O
use	O
beyond	O
progression	O
remain	O
unanswered	O
,	O
in	O
spite	O
of	O
negative	O
data	O
on	O
bevacizumab	S-Drug_or_compound
in	O
treating	S-Planned_process
patients	S-Organism
with	O
adjuvant	O
colon	B-Pathological_formation
cancer	E-Pathological_formation
.	O

Nonetheless	O
,	O
anti	O
-	O
VEGF	S-Gene_or_gene_product
therapy	O
has	O
enhanced	O
the	O
arsenal	O
of	O
anticancer	O
therapies	O
and	O
has	O
provided	O
new	O
insights	O
into	O
the	O
biology	O
of	O
malignancy	O
.	O

[	O
An	O
experimental	O
study	O
on	O
angiogenesis	S-Blood_vessel_development
of	O
non	O
-	O
vascularized	S-Blood_vessel_development
autogenous	B-Multi-tissue_structure
bone	I-Multi-tissue_structure
graft	E-Multi-tissue_structure
with	O
vascular	B-Multi-tissue_structure
bundle	E-Multi-tissue_structure
implantation	S-Planned_process
]	O

OBJECTIVE	O
:	O
To	O
investigate	O
the	O
effect	S-Regulation
of	O
vascular	B-Multi-tissue_structure
bundle	E-Multi-tissue_structure
implantation	S-Planned_process
in	O
autogenous	B-Multi-tissue_structure
bone	I-Multi-tissue_structure
graft	E-Multi-tissue_structure
on	O
angiogenesis	S-Blood_vessel_development
.	O

METHODS	O
:	O
Thirty	O
-	O
six	O
New	B-Organism
Zealand	I-Organism
white	I-Organism
rabbits	E-Organism
were	O
evaluated	O
in	O
this	O
study	O
.	O

A	O
portion	O
of	O
bilateral	B-Organ
radial	I-Organ
bones	E-Organ
of	O
a	O
rabbit	S-Organism
were	O
removed	S-Planned_process
as	O
free	O
bone	B-Multi-tissue_structure
grafts	E-Multi-tissue_structure
,	O
whose	O
periostea	S-Tissue
were	O
peeled	B-Planned_process
off	E-Planned_process
.	O

In	O
test	O
group	O
,	O
the	O
external	B-Multi-tissue_structure
maxillary	I-Multi-tissue_structure
artery	I-Multi-tissue_structure
bundle	E-Multi-tissue_structure
was	O
passed	O
through	O
the	O
marrow	B-Immaterial_anatomical_entity
cavity	E-Immaterial_anatomical_entity
of	O
the	O
bone	S-Organ
.	O

In	O
control	O
group	O
,	O
there	O
was	O
no	O
vascular	B-Multi-tissue_structure
bundle	E-Multi-tissue_structure
implantation	S-Planned_process
.	O

Each	O
bone	S-Organ
was	O
placed	S-Planned_process
in	O
masseter	B-Organ
muscle	E-Organ
separately	O
.	O

The	O
rabbits	S-Organism
were	O
sacrificed	S-Planned_process
and	O
the	O
specimens	O
were	O
procured	O
at	O
3	O
days	O
,	O
1	O
,	O
2	O
,	O
3	O
,	O
4	O
and	O
6	O
weeks	O
after	O
surgery	O
for	O
histological	O
observation	O
,	O
Chinese	O
ink	O
perfusion	O
and	O
CD34	S-Gene_or_gene_product
immunohistochemistry	O
.	O

Microvessel	S-Tissue
density	O
(	O
MVD	O
)	O
was	O
assessed	O
in	O
order	O
to	O
evaluate	O
angiogenesis	S-Blood_vessel_development
of	O
autogenous	B-Multi-tissue_structure
bone	I-Multi-tissue_structure
grafts	E-Multi-tissue_structure
.	O

RESULTS	O
:	O
The	O
bone	B-Multi-tissue_structure
grafts	E-Multi-tissue_structure
were	O
found	O
revascularization	S-Blood_vessel_development
in	O
3	O
days	O
after	O
surgery	O
in	O
the	O
test	O
group	O
,	O
whereas	O
at	O
2	O
weeks	O
in	O
the	O
control	O
group	O
.	O

In	O
3	O
days	O
,	O
1	O
week	O
,	O
2	O
weeks	O
,	O
3	O
weeks	O
and	O
4	O
weeks	O
after	O
surgery	O
,	O
the	O
MVD	O
of	O
test	O
group	O
was	O
significantly	O
higher	O
than	O
that	O
of	O
control	O
group	O
.	O

In	O
4	O
weeks	O
after	O
surgery	O
,	O
angiogenesis	S-Blood_vessel_development
of	O
test	O
group	O
reached	O
to	O
peak	O
.	O

CONCLUSION	O
:	O
Vascular	B-Multi-tissue_structure
bundle	E-Multi-tissue_structure
implantation	S-Planned_process
improved	S-Positive_regulation
angiogenesis	S-Blood_vessel_development
in	O
non	O
-	O
vascularized	S-Blood_vessel_development
autogenous	B-Multi-tissue_structure
bone	I-Multi-tissue_structure
graft	E-Multi-tissue_structure
in	O
this	O
study	O
.	O

[	O
Ambiguity	O
role	O
of	O
neutrophils	S-Cell
in	O
oncogenesis	O
]	O

The	O
review	O
is	O
focused	O
on	O
the	O
participation	O
of	O
polymorphonuclear	B-Cell
granulocytes	E-Cell
(	O
neutrophils	S-Cell
)	O
in	O
development	S-Development
and	O
spreading	S-Localization
of	O
a	O
tumor	S-Pathological_formation
.	O

We	O
consider	O
both	O
the	O
well	O
known	O
functions	O
of	O
neutrophils	S-Cell
(	O
degranulation	O
,	O
production	S-Synthesis
of	O
reactive	B-Drug_or_compound
oxygen	I-Drug_or_compound
species	E-Drug_or_compound
(	O
ROS	S-Drug_or_compound
)	O
)	O
and	O
the	O
recently	O
shown	O
one	O
(	O
presentation	O
of	O
an	O
antigene	O
)	O
.	O

The	O
special	O
attention	O
is	O
focused	O
on	O
the	O
ambiguity	O
of	O
the	O
neutrophil	S-Cell
role	O
in	O
oncogenesis	O
.	O

The	O
dominant	O
view	O
is	O
that	O
neutrophils	S-Cell
display	O
exclusively	O
antitumor	S-Pathological_formation
properties	S-Negative_regulation
.	O

The	O
update	O
information	O
testifies	O
about	O
protumoral	O
activity	O
of	O
neutrophils	S-Cell
:	O
they	O
migrate	S-Localization
to	O
a	O
tumor	S-Pathological_formation
and	O
promote	S-Positive_regulation
angiogenesis	S-Blood_vessel_development
and	O
metastasis	S-Localization
at	O
late	O
stages	O
of	O
the	O
tumor	S-Pathological_formation
.	O

It	O
is	O
interesting	O
that	O
certain	O
components	O
of	O
neutrophil	S-Cell
cytotoxic	O
arsenal	O
(	O
ROS	S-Drug_or_compound
,	O
cytokines	O
,	O
specific	O
enzymes	O
)	O
participate	O
both	O
in	O
antitumoral	O
defenses	O
of	O
an	O
organism	O
and	O
protumoral	O
activity	O
.	O

Endothelial	B-Cell
cell	E-Cell
migration	S-Localization
and	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
expression	S-Gene_expression
are	O
the	O
result	O
of	O
loss	O
of	O
breast	B-Tissue
tissue	E-Tissue
polarity	O
.	O

Recruiting	S-Localization
a	O
new	O
blood	S-Organism_substance
supply	O
is	O
a	O
rate	O
-	O
limiting	O
step	O
in	O
tumor	S-Pathological_formation
progression	S-Development
.	O

In	O
a	O
three	O
-	O
dimensional	O
model	O
of	O
breast	S-Organism_subdivision
carcinogenesis	O
,	O
disorganized	O
,	O
proliferative	O
transformed	S-Development
breast	B-Cell
epithelial	I-Cell
cells	E-Cell
express	O
significantly	O
higher	O
expression	O
of	O
angiogenic	O
genes	O
compared	O
with	O
their	O
polarized	O
,	O
growth	O
-	O
arrested	O
nonmalignant	O
counterparts	O
.	O

Elevated	S-Positive_regulation
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
(	O
VEGF	S-Gene_or_gene_product
)	O
secretion	S-Localization
by	O
malignant	B-Cell
cells	E-Cell
enhanced	S-Positive_regulation
recruitment	S-Localization
of	O
endothelial	B-Cell
cells	E-Cell
(	O
EC	S-Cell
)	O
in	O
heterotypic	O
cocultures	O
.	O

Significantly	O
,	O
phenotypic	B-Development
reversion	E-Development
of	O
malignant	B-Cell
cells	E-Cell
via	O
reexpression	S-Gene_expression
of	O
HoxD10	S-Gene_or_gene_product
,	O
which	O
is	O
lost	O
in	O
malignant	O
progression	O
,	O
significantly	O
attenuated	S-Negative_regulation
VEGF	S-Gene_or_gene_product
expression	S-Gene_expression
in	O
a	O
hypoxia	B-Gene_or_gene_product
-	I-Gene_or_gene_product
inducible	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
1alpha	E-Gene_or_gene_product
-	O
independent	S-Regulation
fashion	O
and	O
reduced	S-Negative_regulation
EC	S-Cell
migration	S-Localization
.	O

This	O
was	O
due	O
primarily	O
to	O
restoring	O
polarity	O
:	O
forced	S-Positive_regulation
proliferation	S-Cell_proliferation
of	O
polarized	O
,	O
nonmalignant	B-Cell
cells	E-Cell
did	O
not	O
induce	S-Positive_regulation
VEGF	S-Gene_or_gene_product
expression	S-Gene_expression
and	O
EC	S-Cell
recruitment	S-Localization
,	O
whereas	O
disrupting	O
the	O
architecture	O
of	O
growth	O
-	O
arrested	O
,	O
reverted	O
cells	S-Cell
did	O
.	O

These	O
data	O
show	O
that	O
disrupting	S-Negative_regulation
cytostructure	S-Cellular_component
activates	S-Positive_regulation
the	O
angiogenic	S-Blood_vessel_development
switch	O
even	O
in	O
the	O
absence	O
of	O
proliferation	O
and	O
/	O
or	O
hypoxia	O
and	O
restoring	O
organization	O
of	O
malignant	O
clusters	O
reduces	S-Negative_regulation
VEGF	S-Gene_or_gene_product
expression	S-Gene_expression
and	O
EC	S-Cell
activation	S-Positive_regulation
to	O
levels	O
found	O
in	O
quiescent	O
nonmalignant	O
epithelium	S-Tissue
.	O

These	O
data	O
confirm	O
the	O
importance	O
of	O
tissue	S-Tissue
architecture	O
and	O
polarity	O
in	O
malignant	S-Pathological_formation
progression	S-Development
.	O

Metronomic	O
5	B-Drug_or_compound
-	I-Drug_or_compound
fluorouracil	E-Drug_or_compound
,	O
oxaliplatin	S-Drug_or_compound
and	O
irinotecan	S-Drug_or_compound
in	O
colorectal	B-Pathological_formation
cancer	E-Pathological_formation
.	O

Metronomic	O
chemotherapy	O
(	O
the	O
frequent	O
,	O
long	O
term	O
,	O
low	O
dose	O
administration	O
of	O
chemotherapeutic	O
drugs	O
)	O
is	O
a	O
promising	O
therapy	O
because	O
it	O
enhances	S-Positive_regulation
the	O
anti	O
-	O
endothelial	S-Tissue
activity	S-Negative_regulation
of	O
conventional	O
chemotherapeutics	O
,	O
but	O
with	O
lower	O
or	O
no	O
toxic	O
effects	O
compared	O
to	O
maximum	O
tolerated	O
dose	O
administration	O
.	O

The	O
aims	O
of	O
the	O
present	O
study	O
were	O
to	O
compare	O
,	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
the	O
antiangiogenic	S-Blood_vessel_development
and	O
antitumor	S-Pathological_formation
activities	S-Negative_regulation
of	O
metronomic	O
irinotecan	S-Drug_or_compound
(	O
CPT	B-Drug_or_compound
-	I-Drug_or_compound
11	E-Drug_or_compound
)	O
,	O
oxaliplatin	S-Drug_or_compound
(	O
L	B-Drug_or_compound
-	I-Drug_or_compound
OHP	E-Drug_or_compound
)	O
and	O
5	B-Drug_or_compound
-	I-Drug_or_compound
fluorouracil	E-Drug_or_compound
(	O
5	B-Drug_or_compound
-	I-Drug_or_compound
FU	E-Drug_or_compound
)	O
in	O
colorectal	B-Pathological_formation
cancer	E-Pathological_formation
and	O
to	O
investigate	O
the	O
metronomic	O
combination	O
of	O
these	O
drugs	O
.	O

In	O
vitro	O
cell	S-Cell
proliferation	S-Cell_proliferation
,	O
combination	O
studies	O
and	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
(	O
VEGF	S-Gene_or_gene_product
)	O
secretion	S-Localization
analyses	O
were	O
performed	O
on	O
endothelial	B-Cell
(	I-Cell
HMVEC	I-Cell
-	I-Cell
d	I-Cell
)	E-Cell
and	O
colorectal	B-Cell
cancer	I-Cell
(	I-Cell
HT	I-Cell
-	I-Cell
29	I-Cell
)	I-Cell
cells	E-Cell
exposed	S-Planned_process
for	O
144	O
h	O
to	O
metronomic	O
concentrations	O
of	O
SN	B-Drug_or_compound
-	I-Drug_or_compound
38	E-Drug_or_compound
,	O
the	O
active	O
metabolite	O
of	O
CPT	B-Drug_or_compound
-	I-Drug_or_compound
11	E-Drug_or_compound
,	O
L	B-Drug_or_compound
-	I-Drug_or_compound
OHP	E-Drug_or_compound
and	O
5	B-Drug_or_compound
-	I-Drug_or_compound
FU	E-Drug_or_compound
.	O

HT	B-Cell
-	I-Cell
29	E-Cell
human	S-Organism
colorectal	B-Pathological_formation
cancer	I-Pathological_formation
xenograft	I-Pathological_formation
model	E-Pathological_formation
was	O
used	O
and	O
tumour	S-Pathological_formation
growth	S-Growth
,	O
microvessel	S-Tissue
density	O
and	O
VEGF	S-Gene_or_gene_product
quantification	O
were	O
performed	O
in	O
tumours	S-Pathological_formation
after	O
the	O
administration	O
of	O
metronomic	O
CPT	B-Drug_or_compound
-	I-Drug_or_compound
11	E-Drug_or_compound
,	O
L	B-Drug_or_compound
-	I-Drug_or_compound
OHP	E-Drug_or_compound
,	O
5	B-Drug_or_compound
-	I-Drug_or_compound
FU	E-Drug_or_compound
and	O
their	O
simultaneous	O
combination	O
.	O

Low	O
concentrations	O
of	O
SN	B-Drug_or_compound
-	I-Drug_or_compound
38	E-Drug_or_compound
,	O
but	O
not	O
5	B-Drug_or_compound
-	I-Drug_or_compound
FU	E-Drug_or_compound
and	O
L	B-Drug_or_compound
-	I-Drug_or_compound
OHP	E-Drug_or_compound
,	O
preferentially	O
inhibited	S-Negative_regulation
endothelial	B-Cell
cell	E-Cell
proliferation	S-Cell_proliferation
.	O

Simultaneous	O
and	O
continuous	O
exposure	S-Planned_process
of	O
HT	B-Cell
-	I-Cell
29	E-Cell
and	O
HMVEC	B-Cell
-	I-Cell
d	I-Cell
cells	E-Cell
to	O
low	O
concentrations	O
SN	B-Drug_or_compound
-	I-Drug_or_compound
38	E-Drug_or_compound
+	O
L	B-Drug_or_compound
-	I-Drug_or_compound
OHP	E-Drug_or_compound
+	O
5	B-Drug_or_compound
-	I-Drug_or_compound
FU	E-Drug_or_compound
for	O
144	O
h	O
showed	O
a	O
strong	O
antagonism	O
and	O
an	O
unfavorable	O
dose	O
-	O
reduction	O
index	O
.	O

Moreover	O
,	O
the	O
ternary	O
combination	O
resulted	O
in	O
a	O
significant	O
increase	S-Positive_regulation
of	O
VEGF	S-Gene_or_gene_product
secretion	S-Localization
in	O
HT	B-Cell
-	I-Cell
29	I-Cell
cancer	I-Cell
cells	E-Cell
.	O

In	O
a	O
xenograft	O
model	O
metronomic	O
CPT	B-Drug_or_compound
-	I-Drug_or_compound
11	E-Drug_or_compound
,	O
but	O
not	O
5	B-Drug_or_compound
-	I-Drug_or_compound
FU	E-Drug_or_compound
and	O
L	B-Drug_or_compound
-	I-Drug_or_compound
OHP	E-Drug_or_compound
,	O
significantly	O
inhibits	S-Negative_regulation
HT	O
-	O
29	O
tumor	B-Growth
growth	E-Growth
and	O
microvessel	S-Tissue
density	O
in	O
the	O
absence	O
of	O
toxicity	O
.	O

On	O
the	O
contrary	O
,	O
metronomic	O
5	B-Drug_or_compound
-	I-Drug_or_compound
FU	E-Drug_or_compound
+	O
L	B-Drug_or_compound
-	I-Drug_or_compound
OHP	E-Drug_or_compound
+	O
CPT	B-Drug_or_compound
-	I-Drug_or_compound
11	E-Drug_or_compound
therapy	S-Planned_process
did	O
not	O
affect	S-Regulation
the	O
microvascular	S-Tissue
count	O
.	O

The	O
metronomic	O
concept	O
might	O
not	O
universally	O
apply	O
to	O
every	O
cytotoxic	O
drug	O
in	O
colorectal	B-Pathological_formation
cancer	E-Pathological_formation
and	O
metronomic	O
combination	O
regimens	O
should	O
be	O
used	O
with	O
caution	O
.	O

A	O
key	O
role	O
for	O
the	O
integrin	B-Gene_or_gene_product
alpha2beta1	E-Gene_or_gene_product
in	O
experimental	O
and	O
developmental	O
angiogenesis	S-Blood_vessel_development
.	O

The	O
alpha2beta1	B-Gene_or_gene_product
integrin	I-Gene_or_gene_product
receptor	E-Gene_or_gene_product
plays	B-Regulation
a	I-Regulation
key	I-Regulation
role	E-Regulation
in	O
angiogenesis	S-Blood_vessel_development
.	O

Here	O
we	O
investigated	O
the	O
effects	O
of	O
small	O
molecule	O
inhibitors	O
(	O
SMIs	O
)	O
designed	O
to	O
disrupt	O
integrin	B-Gene_or_gene_product
alpha2	E-Gene_or_gene_product
I	O
or	O
beta1	S-Gene_or_gene_product
I	O
-	O
like	O
domain	O
function	O
on	O
angiogenesis	S-Blood_vessel_development
.	O

In	O
unchallenged	S-Planned_process
endothelial	B-Cell
cells	E-Cell
,	O
fibrillar	B-Gene_or_gene_product
collagen	E-Gene_or_gene_product
induced	S-Positive_regulation
robust	O
capillary	S-Tissue
morphogenesis	S-Development
.	O

In	O
contrast	O
,	O
tube	S-Tissue
formation	S-Development
was	O
significantly	O
reduced	S-Negative_regulation
by	O
SMI496	S-Drug_or_compound
,	O
a	O
beta1	S-Gene_or_gene_product
I	O
-	O
like	O
domain	O
inhibitor	O
and	O
by	O
function	O
-	O
blocking	O
anti	B-Drug_or_compound
-	I-Drug_or_compound
alpha2beta1	E-Drug_or_compound
but	O
not	O
-	B-Drug_or_compound
alpha1beta1	I-Drug_or_compound
antibodies	E-Drug_or_compound
.	O

Endothelial	B-Cell
cells	E-Cell
bound	S-Binding
fluorescein	O
-	O
labeled	S-Planned_process
collagen	B-Gene_or_gene_product
I	I-Gene_or_gene_product
fibrils	E-Gene_or_gene_product
,	O
an	O
interaction	O
specifically	O
inhibited	S-Negative_regulation
by	O
SMI496	S-Drug_or_compound
.	O

Moreover	O
,	O
SMI496	S-Drug_or_compound
caused	S-Positive_regulation
cell	S-Cell
retraction	O
and	O
cytoskeletal	B-Death
collapse	E-Death
of	O
endothelial	B-Cell
cells	E-Cell
as	O
well	O
as	O
delayed	S-Negative_regulation
endothelial	B-Cell
cell	E-Cell
wound	O
healing	O
.	O

SMI	O
activities	O
were	O
examined	O
in	O
vivo	O
by	O
supplementing	O
the	O
growth	O
medium	O
of	O
zebrafish	S-Organism
embryos	S-Developing_anatomical_structure
expressing	S-Gene_expression
green	B-Gene_or_gene_product
fluorescent	I-Gene_or_gene_product
protein	E-Gene_or_gene_product
under	O
the	O
control	S-Regulation
of	O
the	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
receptor	I-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
promoter	S-DNA_domain_or_region
.	O

SMI496	S-Drug_or_compound
,	O
but	O
not	O
a	O
control	O
compound	O
,	O
interfered	S-Negative_regulation
with	O
angiogenesis	S-Blood_vessel_development
in	O
vivo	O
by	O
reversibly	O
inhibiting	S-Negative_regulation
sprouting	S-Development
from	O
the	O
axial	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
.	O

We	O
further	O
characterized	O
zebrafish	S-Organism
alpha2	B-Gene_or_gene_product
integrin	E-Gene_or_gene_product
and	O
discovered	O
that	O
this	O
integrin	S-Gene_or_gene_product
is	O
highly	O
conserved	O
,	O
especially	O
the	O
I	O
domain	O
.	O

Notably	O
,	O
a	O
similar	O
vascular	O
phenotype	O
was	O
induced	O
by	O
morpholino	O
-	O
mediated	O
knockdown	S-Planned_process
of	O
the	O
integrin	B-Gene_or_gene_product
alpha2	E-Gene_or_gene_product
subunit	O
.	O

By	O
live	O
videomicroscopy	O
,	O
we	O
confirmed	O
that	O
the	O
vessels	S-Multi-tissue_structure
were	O
largely	O
nonfunctional	O
in	O
the	O
absence	O
of	O
alpha2beta1	B-Gene_or_gene_product
integrin	E-Gene_or_gene_product
.	O

Collectively	O
,	O
our	O
results	O
provide	O
strong	O
biochemical	O
and	O
genetic	O
evidence	O
of	O
a	O
central	B-Regulation
role	E-Regulation
for	O
alpha2beta1	B-Gene_or_gene_product
integrin	E-Gene_or_gene_product
in	O
experimental	O
and	O
developmental	O
angiogenesis	S-Blood_vessel_development
.	O

Dopamine	S-Drug_or_compound
regulates	S-Regulation
phosphorylation	S-Phosphorylation
of	O
VEGF	B-Gene_or_gene_product
receptor	I-Gene_or_gene_product
2	E-Gene_or_gene_product
by	O
engaging	S-Regulation
Src	B-Gene_or_gene_product
-	I-Gene_or_gene_product
homology	I-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
-	I-Gene_or_gene_product
domain	I-Gene_or_gene_product
-	I-Gene_or_gene_product
containing	I-Gene_or_gene_product
protein	I-Gene_or_gene_product
tyrosine	I-Gene_or_gene_product
phosphatase	I-Gene_or_gene_product
2	E-Gene_or_gene_product
.	O

Vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
(	O
VEGF	S-Gene_or_gene_product
)	O
-	O
induced	O
receptor	O
phosphorylation	O
is	O
the	O
crucial	O
step	O
for	O
initiating	O
downstream	O
signaling	O
pathways	O
that	O
lead	S-Positive_regulation
to	O
angiogenesis	S-Blood_vessel_development
or	O
related	O
pathophysiological	O
outcomes	O
.	O

Our	O
previous	O
studies	O
have	O
shown	O
that	O
the	O
neurotransmitter	O
dopamine	S-Drug_or_compound
could	O
inhibit	S-Negative_regulation
VEGF	S-Gene_or_gene_product
-	O
induced	S-Positive_regulation
phosphorylation	S-Phosphorylation
of	O
VEGF	B-Gene_or_gene_product
receptor	I-Gene_or_gene_product
2	E-Gene_or_gene_product
(	O
VEGFR	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
)	O
,	O
endothelial	B-Cell
cell	E-Cell
proliferation	S-Cell_proliferation
,	O
migration	S-Localization
,	O
microvascular	S-Tissue
permeability	O
,	O
and	O
thus	O
,	O
angiogenesis	S-Blood_vessel_development
.	O

In	O
this	O
study	O
,	O
we	O
address	O
the	O
mechanism	O
by	O
which	O
VEGFR	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
phosphorylation	S-Phosphorylation
is	O
regulated	S-Regulation
by	O
dopamine	S-Drug_or_compound
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
D2	B-Gene_or_gene_product
dopamine	I-Gene_or_gene_product
receptor	E-Gene_or_gene_product
(	O
D2DR	S-Gene_or_gene_product
)	O
colocalizes	S-Localization
with	O
VEGFR	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
at	O
the	O
cell	B-Cellular_component
surface	E-Cellular_component
.	O

Dopamine	S-Drug_or_compound
pretreatment	S-Planned_process
increases	S-Positive_regulation
the	O
translocation	S-Localization
and	O
colocalization	S-Localization
of	O
Src	B-Gene_or_gene_product
-	I-Gene_or_gene_product
homology	I-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
-	I-Gene_or_gene_product
domain	I-Gene_or_gene_product
-	I-Gene_or_gene_product
containing	I-Gene_or_gene_product
protein	I-Gene_or_gene_product
tyrosine	I-Gene_or_gene_product
phosphatase	E-Gene_or_gene_product
(	O
SHP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
)	O
with	O
D2DR	S-Gene_or_gene_product
at	O
the	O
cell	B-Cellular_component
surface	E-Cellular_component
.	O

Dopamine	S-Drug_or_compound
administration	S-Planned_process
leads	S-Positive_regulation
to	O
increased	S-Positive_regulation
VEGF	S-Gene_or_gene_product
-	O
induced	S-Positive_regulation
phosphorylation	S-Phosphorylation
of	O
SHP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
and	O
this	O
increased	S-Positive_regulation
phosphorylation	S-Phosphorylation
parallels	O
the	O
increased	S-Positive_regulation
phosphatase	O
activity	O
of	O
SHP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
.	O

Active	O
SHP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
then	O
dephosphorylates	S-Dephosphorylation
VEGFR	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
at	O
Y951	S-Protein_domain_or_region
,	O
Y996	S-Protein_domain_or_region
and	O
Y1059	S-Protein_domain_or_region
,	O
but	O
not	O
Y1175	S-Protein_domain_or_region
.	O

We	O
also	O
observe	O
that	O
SHP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
knockdown	S-Planned_process
impairs	S-Negative_regulation
the	O
dopamine	S-Drug_or_compound
-	O
regulated	O
inhibition	S-Negative_regulation
of	O
VEGF	S-Gene_or_gene_product
-	O
induced	S-Positive_regulation
phosphorylation	S-Phosphorylation
of	O
VEGFR	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
and	O
,	O
subsequently	O
,	O
Src	S-Gene_or_gene_product
phosphorylation	S-Phosphorylation
and	O
migration	S-Localization
.	O

Our	O
data	O
establish	O
a	O
novel	O
role	S-Regulation
for	O
SHP	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	I-Gene_or_gene_product
phosphatase	E-Gene_or_gene_product
in	O
the	O
dopamine	S-Drug_or_compound
-	O
mediated	O
regulation	S-Regulation
of	O
VEGFR	B-Gene_or_gene_product
-	I-Gene_or_gene_product
2	E-Gene_or_gene_product
phosphorylation	S-Phosphorylation
.	O

Glioma	B-Cell
tumor	I-Cell
stem	I-Cell
-	I-Cell
like	I-Cell
cells	E-Cell
promote	S-Positive_regulation
tumor	S-Pathological_formation
angiogenesis	S-Blood_vessel_development
and	O
vasculogenesis	S-Blood_vessel_development
via	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
and	O
stromal	B-Gene_or_gene_product
-	I-Gene_or_gene_product
derived	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
1	E-Gene_or_gene_product
.	O

Cancer	B-Cell
stem	I-Cell
cells	E-Cell
(	O
CSC	S-Cell
)	O
are	O
predicted	O
to	O
be	O
critical	O
drivers	O
of	O
tumor	S-Pathological_formation
progression	S-Development
due	O
to	O
their	O
self	O
-	O
renewal	O
capacity	O
and	O
limitless	O
proliferative	S-Cell_proliferation
potential	O
.	O

An	O
emerging	O
area	O
of	O
research	O
suggests	O
that	O
CSC	S-Cell
may	O
also	O
support	S-Positive_regulation
tumor	S-Pathological_formation
progression	S-Development
by	O
promoting	S-Positive_regulation
tumor	S-Pathological_formation
angiogenesis	S-Blood_vessel_development
.	O

To	O
investigate	O
how	O
CSC	S-Cell
contribute	S-Regulation
to	O
tumor	S-Pathological_formation
vascular	S-Multi-tissue_structure
development	S-Development
,	O
we	O
used	O
an	O
approach	O
comparing	O
tumor	S-Pathological_formation
xenografts	O
of	O
the	O
C6	B-Cell
glioma	I-Cell
cell	I-Cell
line	E-Cell
containing	O
either	O
a	O
low	O
or	O
a	O
high	O
fraction	O
of	O
CSC	S-Cell
.	O

Compared	O
with	O
CSC	B-Pathological_formation
-	I-Pathological_formation
low	I-Pathological_formation
tumors	E-Pathological_formation
,	O
CSC	B-Pathological_formation
-	I-Pathological_formation
high	I-Pathological_formation
tumors	E-Pathological_formation
exhibited	O
increased	S-Positive_regulation
microvessel	S-Tissue
density	O
and	O
blood	S-Organism_substance
perfusion	O
and	O
induced	S-Positive_regulation
increased	O
mobilization	S-Localization
and	O
tumor	S-Pathological_formation
recruitment	S-Localization
of	O
bone	B-Multi-tissue_structure
marrow	E-Multi-tissue_structure
-	O
derived	O
endothelial	B-Cell
progenitor	I-Cell
cells	E-Cell
(	O
EPC	S-Cell
)	O
.	O

CSC	B-Cell
-	I-Cell
high	I-Cell
C6	I-Cell
cell	I-Cell
cultures	E-Cell
also	O
induced	S-Positive_regulation
higher	O
levels	O
of	O
endothelial	B-Cell
cell	E-Cell
proliferation	S-Cell_proliferation
and	O
tubule	S-Tissue
organization	S-Development
in	O
vitro	O
compared	O
with	O
CSC	B-Cell
-	I-Cell
low	I-Cell
cultures	E-Cell
.	O

CSC	B-Cell
-	I-Cell
high	I-Cell
cultures	E-Cell
and	O
tumors	S-Pathological_formation
expressed	S-Gene_expression
increased	S-Positive_regulation
levels	O
of	O
the	O
proangiogenic	S-Blood_vessel_development
factors	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
and	O
stromal	B-Gene_or_gene_product
-	I-Gene_or_gene_product
derived	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
1	E-Gene_or_gene_product
,	O
and	O
when	O
signaling	O
by	O
either	O
factor	O
was	O
blocked	S-Negative_regulation
,	O
all	O
aspects	O
of	O
angiogenesis	S-Blood_vessel_development
observed	O
in	O
CSC	B-Cell
-	I-Cell
high	I-Cell
cultures	E-Cell
and	O
tumors	S-Pathological_formation
,	O
including	O
microvessel	S-Tissue
density	O
,	O
perfusion	O
,	O
EPC	S-Cell
mobilization	B-Localization
/	I-Localization
recruitment	E-Localization
,	O
and	O
stimulation	S-Positive_regulation
of	O
endothelial	B-Cell
cell	E-Cell
activity	O
,	O
were	O
reduced	S-Negative_regulation
to	O
levels	O
comparable	O
with	O
those	O
observed	O
in	O
CSC	B-Cell
-	I-Cell
low	I-Cell
cultures	E-Cell
/	O
tumors	S-Pathological_formation
.	O

These	O
results	O
suggest	O
that	O
CSC	S-Cell
contribute	S-Regulation
to	O
tumor	S-Pathological_formation
angiogenesis	S-Blood_vessel_development
by	O
promoting	S-Positive_regulation
both	O
local	O
endothelial	B-Cell
cell	E-Cell
activity	O
and	O
systemic	O
angiogenic	S-Blood_vessel_development
processes	O
involving	O
bone	B-Multi-tissue_structure
marrow	E-Multi-tissue_structure
-	O
derived	O
EPC	S-Cell
in	O
a	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
-	O
dependent	S-Positive_regulation
and	O
stromal	B-Gene_or_gene_product
-	I-Gene_or_gene_product
derived	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
1	E-Gene_or_gene_product
-	O
dependent	S-Positive_regulation
manner	O
.	O

Islet	B-Tissue
endothelial	E-Tissue
activation	S-Positive_regulation
and	O
oxidative	O
stress	O
gene	O
expression	O
is	O
reduced	S-Negative_regulation
by	O
IL	B-Drug_or_compound
-	I-Drug_or_compound
1Ra	E-Drug_or_compound
treatment	S-Planned_process
in	O
the	O
type	O
2	O
diabetic	O
GK	B-Organism
rat	E-Organism
.	O

BACKGROUND	O
:	O
Inflammation	O
followed	O
by	O
fibrosis	O
is	O
a	O
component	O
of	O
islet	S-Multi-tissue_structure
dysfunction	S-Breakdown
in	O
both	O
rodent	O
and	O
human	S-Organism
type	O
2	O
diabetes	O
.	O

Because	O
islet	S-Multi-tissue_structure
inflammation	O
may	O
originate	O
from	O
endothelial	B-Cell
cells	E-Cell
,	O
we	O
assessed	O
the	O
expression	O
of	O
selected	O
genes	O
involved	O
in	O
endothelial	B-Cell
cell	E-Cell
activation	S-Positive_regulation
in	O
islets	S-Multi-tissue_structure
from	O
a	O
spontaneous	O
model	O
of	O
type	O
2	O
diabetes	O
,	O
the	O
Goto	B-Organism
-	I-Organism
Kakizaki	I-Organism
(	I-Organism
GK	I-Organism
)	I-Organism
rat	E-Organism
.	O

We	O
also	O
examined	O
islet	B-Tissue
endotheliuml	E-Tissue
/	O
oxidative	O
stress	O
(	O
OS	O
)	O
/	O
inflammation	O
-	O
related	O
gene	O
expression	O
,	O
islet	S-Multi-tissue_structure
vascularization	S-Blood_vessel_development
and	O
fibrosis	O
after	O
treatment	S-Planned_process
with	O
the	O
interleukin	B-Drug_or_compound
-	I-Drug_or_compound
1	I-Drug_or_compound
(	I-Drug_or_compound
IL	I-Drug_or_compound
-	I-Drug_or_compound
1	I-Drug_or_compound
)	I-Drug_or_compound
receptor	I-Drug_or_compound
antagonist	E-Drug_or_compound
(	O
IL	B-Drug_or_compound
-	I-Drug_or_compound
1Ra	E-Drug_or_compound
)	O
.	O

METHODOLOGY	O
/	O
PRINCIPAL	O
FINDINGS	O
:	O
Gene	O
expression	O
was	O
analyzed	O
by	O
quantitative	O
RT	O
-	O
PCR	O
on	O
islets	S-Multi-tissue_structure
isolated	S-Planned_process
from	O
10	O
-	O
week	O
-	O
old	O
diabetic	O
GK	S-Organism
and	O
control	O
Wistar	B-Organism
rats	E-Organism
.	O

Furthermore	O
,	O
GK	B-Organism
rats	E-Organism
were	O
treated	S-Planned_process
s	O
.	O
c	O
twice	O
daily	O
with	O
IL	B-Drug_or_compound
-	I-Drug_or_compound
1Ra	E-Drug_or_compound
(	O
Kineret	S-Drug_or_compound
,	O
Amgen	O
,	O
100	O
mg	O
/	O
kg	O
/	O
day	O
)	O
or	O
saline	S-Drug_or_compound
,	O
from	O
4	O
weeks	O
of	O
age	O
onwards	O
(	O
onset	O
of	O
diabetes	O
)	O
.	O

Four	O
weeks	O
later	O
,	O
islet	S-Multi-tissue_structure
gene	O
analysis	O
and	O
pancreas	S-Organ
immunochemistry	O
were	O
performed	O
.	O

Thirty	O
-	O
two	O
genes	O
were	O
selected	O
encoding	O
molecules	O
involved	O
in	O
endothelial	B-Cell
cell	E-Cell
activation	S-Positive_regulation
,	O
particularly	O
fibrinolysis	O
,	O
vascular	O
tone	O
,	O
OS	O
,	O
angiogenesis	S-Blood_vessel_development
and	O
also	O
inflammation	O
.	O

All	O
genes	O
except	O
those	O
encoding	O
angiotensinogen	S-Gene_or_gene_product
and	O
epoxide	B-Gene_or_gene_product
hydrolase	E-Gene_or_gene_product
(	O
that	O
were	O
decreased	S-Negative_regulation
)	O
,	O
and	O
12	B-Gene_or_gene_product
-	I-Gene_or_gene_product
lipoxygenase	E-Gene_or_gene_product
and	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
(	O
that	O
showed	B-Regulation
no	I-Regulation
change	E-Regulation
)	O
,	O
were	O
significantly	O
up	B-Positive_regulation
-	I-Positive_regulation
regulated	E-Positive_regulation
in	O
GK	S-Organism
islets	S-Multi-tissue_structure
.	O

After	O
IL	B-Drug_or_compound
-	I-Drug_or_compound
1Ra	E-Drug_or_compound
treatment	S-Planned_process
of	O
GK	B-Organism
rats	E-Organism
in	O
vivo	O
,	O
most	O
selected	O
genes	O
implied	O
in	O
endothelium	S-Tissue
/	O
OS	O
/	O
immune	B-Cell
cells	E-Cell
/	O
fibrosis	O
were	O
significantly	O
down	O
-	O
regulated	O
.	O

IL	B-Drug_or_compound
-	I-Drug_or_compound
1Ra	E-Drug_or_compound
also	O
improved	S-Positive_regulation
islet	S-Multi-tissue_structure
vascularization	S-Blood_vessel_development
,	O
reduced	O
fibrosis	O
and	O
ameliorated	O
glycemia	O
.	O

CONCLUSIONS	O
/	O
SIGNIFICANCE	O
:	O
GK	B-Organism
rat	E-Organism
islets	S-Multi-tissue_structure
have	O
increased	O
mRNA	O
expression	O
of	O
markers	O
of	O
early	O
islet	B-Cell
endothelial	I-Cell
cell	E-Cell
activation	S-Positive_regulation
,	O
possibly	O
triggered	O
by	O
several	O
metabolic	O
factors	O
,	O
and	O
also	O
some	O
defense	O
mechanisms	O
.	O

The	O
beneficial	B-Positive_regulation
effect	E-Positive_regulation
of	O
IL	B-Drug_or_compound
-	I-Drug_or_compound
1Ra	E-Drug_or_compound
on	O
most	O
islet	B-Cell
endothelial	E-Cell
/	O
OS	O
/	O
immune	B-Cell
cells	E-Cell
/	O
fibrosis	O
parameters	O
analyzed	O
highlights	O
a	O
major	O
endothelial	O
-	O
related	O
role	S-Regulation
for	O
IL	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
in	O
GK	S-Organism
islet	S-Multi-tissue_structure
alterations	S-Development
.	O

Thus	O
,	O
metabolically	O
-	O
altered	S-Regulation
islet	B-Tissue
endothelium	E-Tissue
might	O
affect	S-Regulation
the	O
beta	B-Cell
-	I-Cell
cell	E-Cell
microenvironment	O
and	O
contribute	O
to	O
progressive	O
type	O
2	O
diabetic	O
beta	B-Cell
-	I-Cell
cell	E-Cell
dysfunction	O
in	O
GK	B-Organism
rats	E-Organism
.	O

Counteracting	O
islet	B-Cell
endothelial	I-Cell
cell	E-Cell
inflammation	O
might	O
be	O
one	O
way	O
to	O
ameliorate	O
/	O
prevent	O
beta	B-Cell
-	I-Cell
cell	E-Cell
dysfunction	O
in	O
type	O
2	O
diabetes	O
.	O

AVE8062	S-Drug_or_compound
:	O
a	O
new	O
combretastatin	S-Drug_or_compound
derivative	O
vascular	S-Multi-tissue_structure
disrupting	S-Breakdown
agent	O
.	O

Angiogenesis	S-Blood_vessel_development
has	B-Regulation
an	I-Regulation
essential	I-Regulation
role	E-Regulation
in	O
promoting	S-Positive_regulation
and	O
supporting	S-Positive_regulation
tumor	S-Pathological_formation
growth	S-Growth
and	O
it	O
is	O
an	O
important	O
therapeutic	O
target	O
.	O

The	O
tumor	B-Multi-tissue_structure
vascular	I-Multi-tissue_structure
network	E-Multi-tissue_structure
is	O
the	O
result	O
of	O
pro	O
-	O
angiogenic	S-Blood_vessel_development
and	O
inhibitory	O
factors	O
as	O
well	O
as	O
of	O
the	O
interaction	S-Binding
between	O
endothelial	B-Cell
cells	E-Cell
and	O
extracellular	B-Cellular_component
matrix	E-Cellular_component
.	O

Different	O
antiangiogenic	S-Blood_vessel_development
therapeutics	O
have	O
been	O
developed	O
to	O
improve	S-Positive_regulation
tumor	S-Pathological_formation
control	S-Regulation
through	O
vascular	B-Drug_or_compound
-	I-Drug_or_compound
targeting	I-Drug_or_compound
agents	E-Drug_or_compound
(	O
VTA	S-Drug_or_compound
)	O
.	O

VTAs	S-Drug_or_compound
can	O
be	O
divided	O
into	O
two	O
groups	O
:	O
antiangiogenic	B-Drug_or_compound
agents	E-Drug_or_compound
and	O
vascular	B-Drug_or_compound
-	I-Drug_or_compound
disrupting	I-Drug_or_compound
agents	E-Drug_or_compound
(	O
VDAs	S-Drug_or_compound
)	O
.	O

VTAs	S-Drug_or_compound
inhibit	O
specific	O
factors	O
required	O
to	O
induce	O
and	O
direct	O
the	O
angiogenic	S-Blood_vessel_development
process	O
,	O
with	O
major	O
activity	O
against	O
small	O
tumor	B-Pathological_formation
masses	E-Pathological_formation
and	O
at	O
the	O
tumor	B-Tissue
periphery	E-Tissue
,	O
encompassing	O
monoclonal	O
antibodies	O
and	O
small	O
molecules	O
inhibitors	O
of	O
the	O
tyrosine	O
kinase	O
domain	O
of	O
the	O
VEGF	B-Gene_or_gene_product
receptor	E-Gene_or_gene_product
.	O

VDAs	S-Drug_or_compound
specifically	O
target	S-Regulation
and	O
destroy	S-Negative_regulation
well	O
-	O
established	S-Development
tumor	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
with	O
ischemia	O
and	O
destruction	S-Breakdown
of	O
large	O
masses	S-Pathological_formation
with	O
central	O
hemorrhagic	O
necrosis	S-Death
and	O
survival	S-Death
of	O
a	O
thin	O
peripheral	B-Pathological_formation
tumor	I-Pathological_formation
layer	E-Pathological_formation
.	O

VDAs	S-Drug_or_compound
can	O
be	O
divided	O
into	O
biologics	O
,	O
such	O
as	O
ligand	O
-	O
based	O
,	O
and	O
small	O
-	O
molecule	O
agents	O
;	O
this	O
second	O
group	O
includes	O
small	B-Drug_or_compound
-	I-Drug_or_compound
molecule	I-Drug_or_compound
VDAs	E-Drug_or_compound
like	O
flavonoids	S-Drug_or_compound
,	O
such	O
as	O
5	B-Drug_or_compound
,	I-Drug_or_compound
6	I-Drug_or_compound
-	I-Drug_or_compound
dimethylxanthenone	I-Drug_or_compound
-	I-Drug_or_compound
4	I-Drug_or_compound
-	I-Drug_or_compound
acetic	I-Drug_or_compound
acid	E-Drug_or_compound
(	O
DMXAA	S-Drug_or_compound
)	O
,	O
and	O
microtubule	B-Drug_or_compound
-	I-Drug_or_compound
destabilizing	I-Drug_or_compound
agents	E-Drug_or_compound
.	O

In	O
this	O
review	O
we	O
will	O
discuss	O
the	O
mechanism	O
of	O
action	O
,	O
as	O
well	O
as	O
the	O
preclinical	O
and	O
clinical	O
results	O
,	O
of	O
one	O
of	O
the	O
most	O
promising	O
antitubulin	B-Drug_or_compound
agents	E-Drug_or_compound
:	O
the	O
combretastatin	B-Drug_or_compound
A4	I-Drug_or_compound
-	I-Drug_or_compound
phosphate	I-Drug_or_compound
derivative	E-Drug_or_compound
,	O
AVE8062A	S-Drug_or_compound
.	O

Targeting	O
TNF	S-Gene_or_gene_product
for	O
Treatment	S-Planned_process
of	O
Cancer	S-Pathological_formation
and	O
Autoimmunity	O
.	O

Tumor	B-Gene_or_gene_product
necrosis	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
-	I-Gene_or_gene_product
alpha	E-Gene_or_gene_product
(	O
TNF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
alpha	E-Gene_or_gene_product
)	O
was	O
first	O
isolated	O
two	O
decades	O
ago	O
as	O
a	O
macrophageproduced	O
protein	O
that	O
can	O
effectively	O
kill	S-Death
tumor	B-Cell
cells	E-Cell
.	O

TNF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
alpha	E-Gene_or_gene_product
is	O
also	O
an	O
essential	O
component	O
of	O
the	O
immune	O
system	O
and	O
is	O
required	O
for	O
hematopoiesis	O
,	O
for	O
protection	O
from	O
bacterial	O
infection	O
and	O
for	O
immune	B-Cell
cell	E-Cell
-	O
mediated	O
cytotoxicity	O
.	O

Extensive	O
research	O
,	O
however	O
,	O
has	O
revealed	O
that	O
TNF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
alpha	E-Gene_or_gene_product
is	O
one	O
of	O
the	O
major	B-Regulation
players	E-Regulation
in	O
tumor	S-Pathological_formation
initiation	S-Positive_regulation
,	O
proliferation	S-Growth
,	O
invasion	S-Localization
,	O
angiogenesis	S-Blood_vessel_development
and	O
metastasis	S-Localization
.	O

The	O
proinflammatory	O
activities	O
link	O
TNF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
alpha	E-Gene_or_gene_product
with	O
a	O
wide	O
variety	O
of	O
autoimmune	O
diseases	O
,	O
including	O
psoriasis	O
,	O
inflammatory	O
bowel	S-Organ
disease	O
,	O
rheumatoid	O
arthritis	O
,	O
systemic	O
sclerosis	O
,	O
systemic	O
lupus	O
erythematosus	O
,	O
multiple	O
sclerosis	O
,	O
diabetes	O
and	O
ankylosing	O
spondylitis	O
.	O

Systemic	O
inhibitors	O
of	O
TNF	S-Gene_or_gene_product
such	O
as	O
etanercept	S-Drug_or_compound
(	O
Enbrel	S-Drug_or_compound
)	O
(	O
a	O
soluble	O
TNF	S-Gene_or_gene_product
receptor	O
)	O
and	O
infliximab	S-Drug_or_compound
(	O
Remicade	S-Drug_or_compound
)	O
and	O
adalimumab	S-Drug_or_compound
(	O
Humira	S-Drug_or_compound
)	O
(	O
anti	B-Gene_or_gene_product
-	I-Gene_or_gene_product
TNF	I-Gene_or_gene_product
antibodies	E-Gene_or_gene_product
)	O
have	O
been	O
approved	O
for	O
the	O
treatment	S-Planned_process
inflammatory	O
bowel	S-Organ
disease	O
,	O
psoriasis	O
and	O
rheumatoid	O
arthritis	O
.	O

These	O
drugs	O
,	O
however	O
,	O
exhibit	O
severe	O
side	O
effects	O
and	O
are	O
expensive	O
.	O

Hence	O
orally	O
active	O
blockers	O
of	O
TNF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
alpha	E-Gene_or_gene_product
that	O
are	O
safe	O
,	O
efficacious	O
and	O
inexpensive	O
are	O
urgently	O
needed	O
.	O

Numerous	O
products	O
from	O
fruits	O
,	O
vegetable	O
and	O
traditional	O
medicinal	O
plants	O
have	O
been	O
described	O
which	O
can	O
suppress	S-Negative_regulation
TNF	S-Gene_or_gene_product
expression	S-Gene_expression
and	O
TNF	S-Gene_or_gene_product
signaling	S-Pathway
but	O
their	O
clinical	O
potential	O
is	O
yet	O
uncertain	O
.	O

[	O
Prognostic	O
significance	O
of	O
cellular	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
(	O
VEGF	S-Gene_or_gene_product
)	O
expression	S-Gene_expression
in	O
the	O
course	O
of	O
chronic	O
myeloid	O
leukaemia	O
]	O

INTRODUCTION	O
:	O
Increased	S-Positive_regulation
angiogenesis	S-Blood_vessel_development
in	O
bone	B-Multi-tissue_structure
marrow	E-Multi-tissue_structure
is	O
one	O
of	O
the	O
characteristics	O
of	O
chronic	O
myeloid	O
leukaemia	O
(	O
CML	O
)	O
,	O
a	O
clonal	O
myeloproliferative	O
disorder	O
that	O
expresses	O
a	O
chimeric	O
bcr	S-Gene_or_gene_product
/	O
abl	S-Gene_or_gene_product
protein	O
.	O

Vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
(	O
VEGF	S-Gene_or_gene_product
)	O
is	O
one	O
of	O
the	O
most	O
potent	O
and	O
a	O
specific	O
regulator	S-Regulation
of	O
angiogenesis	S-Blood_vessel_development
which	O
principally	O
targets	O
endothelial	B-Cell
cells	E-Cell
and	O
regulates	S-Regulation
several	O
of	O
their	O
functions	O
,	O
including	O
mitogenesis	O
,	O
permeability	O
and	O
migration	O
.	O

The	O
impact	O
of	O
elevated	S-Positive_regulation
VEGF	S-Gene_or_gene_product
expression	S-Gene_expression
on	O
the	O
course	O
of	O
chronic	O
myeloid	O
leukaemia	O
is	O
unknown	O
.	O

OBJECTIVE	O
:	O
The	O
aim	O
of	O
this	O
study	O
was	O
the	O
follow	O
-	O
up	O
of	O
VEGF	S-Gene_or_gene_product
expression	S-Gene_expression
during	O
the	O
course	O
of	O
CML	O
.	O

METHODS	O
:	O
We	O
studied	O
VEGF	S-Gene_or_gene_product
expression	S-Gene_expression
of	O
85	O
CML	O
patients	S-Organism
(	O
median	O
age	O
50	O
years	O
,	O
range	O
16	O
-	O
75	O
years	O
)	O
.	O

At	O
the	O
commencement	O
of	O
the	O
study	O
,	O
29	O
patients	S-Organism
were	O
in	O
chronic	O
phase	O
(	O
CP	O
)	O
,	O
25	O
in	O
an	O
accelerated	O
phase	O
(	O
AP	O
)	O
,	O
and	O
31	O
in	O
the	O
blast	O
crisis	O
(	O
BC	O
)	O
.	O

The	O
temporal	O
expression	S-Gene_expression
(	O
percentage	O
positivity	O
per	O
1000	O
analysed	O
cells	S-Cell
)	O
VEGF	S-Gene_or_gene_product
proteins	O
over	O
the	O
course	O
of	O
CML	O
were	O
studied	O
using	O
the	O
immunohistochemical	O
technique	O
utilizing	O
relevant	O
monoclonal	O
antibodies	O
.	O

It	O
was	O
correlated	O
with	O
the	O
laboratory	O
(	O
Hb	S-Gene_or_gene_product
,	O
WBC	S-Cell
and	O
platelet	S-Cell
counts	O
,	O
and	O
the	O
percentage	O
of	O
blasts	O
)	O
and	O
clinical	O
parameters	O
(	O
organomegaly	O
,	O
duration	O
of	O
CP	O
,	O
AP	O
,	O
and	O
BC	O
)	O
of	O
disease	O
progression	O
.	O

RESULTS	O
:	O
The	O
expression	S-Gene_expression
ofVEGF	S-Gene_or_gene_product
protein	O
was	O
most	O
pronounced	O
in	O
AP	O
(	O
ANOVA	O
,	O
p	O
=	O
0	O
.	O
033	O
)	O
.	O

The	O
level	O
of	O
VEGF	S-Gene_or_gene_product
expression	S-Gene_expression
correlated	O
inversely	O
with	O
the	O
degree	O
of	O
splenomegaly	O
(	O
Pearson	O
,	O
r	O
=	O
-	O
0	O
.	O
400	O
,	O
p	O
=	O
0	O
.	O
011	O
)	O
.	O

High	O
expression	S-Gene_expression
of	O
VEGF	S-Gene_or_gene_product
correlated	O
with	O
a	O
shorter	O
overall	O
survival	O
(	O
log	O
rank	O
,	O
p	O
=	O
0	O
.	O
042	O
)	O
.	O

CONCLUSION	O
:	O
Immunohistochemically	O
confirmed	O
significance	O
of	O
the	O
expression	S-Gene_expression
of	O
VEGF	S-Gene_or_gene_product
in	O
dependence	O
of	O
the	O
CML	O
stage	O
could	O
be	O
of	O
clinical	O
importance	O
in	O
deciding	O
on	O
the	O
timing	O
therapy	O
.	O

These	O
data	O
suggest	O
that	O
VEGF	S-Gene_or_gene_product
plays	O
a	O
role	O
in	O
the	O
biology	O
of	O
CML	O
and	O
that	O
VEGF	S-Gene_or_gene_product
inhibitors	O
should	O
be	O
investigated	O
in	O
CML	O
.	O

Inducible	B-Gene_or_gene_product
nitric	I-Gene_or_gene_product
oxide	I-Gene_or_gene_product
synthase	E-Gene_or_gene_product
modulates	S-Regulation
angiogenesis	S-Blood_vessel_development
in	O
ischemic	O
hindlimb	S-Organism_subdivision
of	O
rat	S-Organism
.	O

BACKGROUND	O
:	O
Angiogenesis	S-Blood_vessel_development
plays	B-Regulation
an	I-Regulation
important	I-Regulation
role	E-Regulation
in	O
maintaining	S-Regulation
adequate	O
oxygen	S-Drug_or_compound
delivery	S-Localization
,	O
and	O
nitric	B-Drug_or_compound
oxide	E-Drug_or_compound
(	O
NO	S-Drug_or_compound
)	O
is	O
a	O
potential	O
regulator	O
of	O
angiogenesis	S-Blood_vessel_development
.	O

NO	S-Drug_or_compound
is	O
synthesized	S-Synthesis
through	O
three	O
isoforms	O
of	O
NO	B-Gene_or_gene_product
synthase	E-Gene_or_gene_product
(	O
NOS	S-Gene_or_gene_product
)	O
.	O

It	O
is	O
hypothesized	O
that	O
the	O
NO	S-Drug_or_compound
derived	O
from	O
inducible	B-Gene_or_gene_product
NOS	E-Gene_or_gene_product
(	O
iNOS	S-Gene_or_gene_product
)	O
may	O
promote	S-Positive_regulation
survival	S-Death
of	O
ischemic	B-Tissue
tissue	E-Tissue
through	O
angiogenesis	S-Blood_vessel_development
.	O

To	O
test	O
this	O
hypothesis	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
iNOS	S-Gene_or_gene_product
deficiency	O
(	O
by	O
L	B-Drug_or_compound
-	I-Drug_or_compound
NIL	E-Drug_or_compound
)	O
on	O
angiogenesis	S-Blood_vessel_development
in	O
a	O
hindlimb	S-Organism_subdivision
ischemia	O
model	O
.	O

METHODS	O
:	O
Thirty	O
-	O
two	O
male	O
wistar	B-Organism
rats	E-Organism
randomly	O
divided	O
into	O
four	O
groups	O
.	O

In	O
groups	O
1	O
&	O
2	O
,	O
hindlimb	S-Organism_subdivision
ischemia	O
was	O
induced	O
by	O
ligation	S-Planned_process
of	O
femoral	B-Multi-tissue_structure
artery	E-Multi-tissue_structure
and	O
they	O
received	S-Planned_process
L	B-Drug_or_compound
-	I-Drug_or_compound
NIL	E-Drug_or_compound
and	O
saline	S-Drug_or_compound
respectively	O
.	O

The	O
animals	O
in	O
groups	O
3	O
and	O
4	O
also	O
received	S-Planned_process
L	B-Drug_or_compound
-	I-Drug_or_compound
NIL	E-Drug_or_compound
and	O
saline	S-Drug_or_compound
respectively	O
without	O
surgical	O
procedure	O
.	O

After	O
21	O
days	O
,	O
the	O
serum	S-Organism_substance
concentration	O
of	O
nitrite	S-Drug_or_compound
,	O
capillary	S-Tissue
density	O
and	O
expression	S-Gene_expression
of	O
HIF1alpha	S-Gene_or_gene_product
were	O
determined	O
.	O

RESULTS	O
:	O
Serum	S-Organism_substance
nitrite	S-Drug_or_compound
levels	O
were	O
significantly	O
lower	O
in	O
L	B-Drug_or_compound
-	I-Drug_or_compound
NIL	E-Drug_or_compound
groups	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
capillary	S-Tissue
density	O
in	O
group	O
1	O
(	O
ischemia	O
+	O
L	B-Drug_or_compound
-	I-Drug_or_compound
NIL	E-Drug_or_compound
)	O
was	O
significantly	O
different	O
from	O
group	O
2	O
(	O
ischemia	O
+	O
saline	S-Drug_or_compound
)	O
;	O
group	O
1	O
:	O
360	O
.	O
33	O
+	O
/	O
-	O
77	O
.	O
02	O
,	O
group	O
2	O
:	O
549	O
+	O
/	O
-	O
81	O
.	O
85	O
/	O
mm2	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O
In	O
addition	O
,	O
expression	S-Gene_expression
of	O
HIF1alpha	S-Gene_or_gene_product
was	O
significantly	O
increased	S-Positive_regulation
in	O
ischemic	O
groups	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

CONCLUSION	O
:	O
Selective	O
inhibition	S-Negative_regulation
of	O
iNOS	S-Gene_or_gene_product
by	O
L	B-Drug_or_compound
-	I-Drug_or_compound
NIL	E-Drug_or_compound
inhibits	S-Negative_regulation
angiogenesis	S-Blood_vessel_development
in	O
a	O
hindlimb	S-Organism_subdivision
ischemic	O
rat	S-Organism
model	O
.	O

In	O
addition	O
,	O
ischemia	O
induces	S-Positive_regulation
expression	S-Gene_expression
of	O
HIF1alpha	S-Gene_or_gene_product
in	O
hypoxic	B-Tissue
tissue	E-Tissue
.	O

Tumor	S-Pathological_formation
Angiogenesis	S-Blood_vessel_development
:	O
Initiation	O
and	O
Targeting	O
-	O
Therapeutic	B-Planned_process
Targeting	E-Planned_process
of	O
an	O
FGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
Binding	I-Gene_or_gene_product
Protein	E-Gene_or_gene_product
,	O
an	O
Angiogenic	S-Blood_vessel_development
Switch	O
Molecule	O
,	O
and	O
Indicator	O
of	O
Early	O
Stages	O
of	O
Gastrointestinal	B-Pathological_formation
Adenocarcinomas	E-Pathological_formation
-	O
.	O

Tumor	S-Pathological_formation
angiogenesis	S-Blood_vessel_development
has	O
been	O
related	O
to	O
the	O
initiation	S-Positive_regulation
as	O
well	O
as	O
progression	S-Positive_regulation
toward	O
more	O
aggressive	O
behavior	O
of	O
human	S-Organism
tumors	S-Pathological_formation
.	O

In	O
particular	O
,	O
the	O
activity	O
of	O
angiogenic	S-Blood_vessel_development
factors	O
is	O
crucial	O
for	O
tumor	S-Pathological_formation
progression	S-Development
.	O

We	O
previously	O
characterized	O
a	O
secreted	S-Localization
fibroblast	B-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	I-Gene_or_gene_product
-	I-Gene_or_gene_product
binding	I-Gene_or_gene_product
protein	E-Gene_or_gene_product
(	O
FGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
BP	E-Gene_or_gene_product
)	O
as	O
a	O
chaperone	O
molecule	O
,	O
which	O
binds	O
to	O
various	S-Binding
FGFs	S-Gene_or_gene_product
,	O
enhances	O
FGF	S-Gene_or_gene_product
-	O
mediated	O
biochemical	O
and	O
biologic	O
events	O
and	O
importantly	O
is	O
a	O
crucial	S-Positive_regulation
rate	O
-	O
limiting	O
factor	O
for	O
tumor	S-Pathological_formation
-	O
dependent	S-Positive_regulation
angiogenesis	S-Blood_vessel_development
.	O

We	O
generated	S-Planned_process
monoclonal	B-Gene_or_gene_product
antibodies	I-Gene_or_gene_product
that	I-Gene_or_gene_product
target	I-Gene_or_gene_product
FGF	I-Gene_or_gene_product
-	I-Gene_or_gene_product
BP	I-Gene_or_gene_product
protein	E-Gene_or_gene_product
and	O
used	O
them	O
as	O
a	O
tool	O
to	O
evaluate	O
frequency	O
and	O
pattern	O
of	O
FGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
BP	E-Gene_or_gene_product
expression	S-Gene_expression
during	O
the	O
malignant	O
progression	S-Development
of	O
pancreas	S-Pathological_formation
and	O
colorectal	B-Pathological_formation
carcinoma	E-Pathological_formation
in	O
archival	O
tissue	B-Tissue
samples	E-Tissue
.	O

We	O
found	O
that	O
FGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
BP	E-Gene_or_gene_product
is	O
dramatically	O
upregulated	S-Positive_regulation
during	O
the	O
initiation	S-Development
of	O
colorectal	S-Pathological_formation
and	O
pancreatic	B-Pathological_formation
adenocarcinoma	E-Pathological_formation
.	O

Crucial	O
genetic	O
events	O
underlying	O
the	O
initiation	S-Development
and	O
progression	S-Development
of	O
colorectal	S-Pathological_formation
and	O
pancreatic	B-Pathological_formation
adenocarcinoma	E-Pathological_formation
with	O
a	O
particular	O
focus	O
on	O
the	O
modulation	S-Regulation
of	O
angiogenesis	S-Blood_vessel_development
and	O
antiangiogenic	S-Blood_vessel_development
therapies	S-Planned_process
are	O
discussed	O
.	O

We	O
propose	O
that	O
the	O
upregulation	S-Positive_regulation
of	O
the	O
secreted	S-Localization
FGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
BP	E-Gene_or_gene_product
protein	O
during	O
early	O
phases	O
of	O
pancreas	S-Pathological_formation
and	O
colon	B-Pathological_formation
cancer	E-Pathological_formation
could	O
make	O
this	O
protein	O
a	O
possible	O
serum	S-Organism_substance
marker	O
indicating	O
the	O
presence	O
of	O
high	B-Pathological_formation
-	I-Pathological_formation
risk	I-Pathological_formation
premalignant	I-Pathological_formation
lesions	E-Pathological_formation
.	O

Furthermore	O
,	O
the	O
biological	O
activity	O
of	O
FGF	B-Gene_or_gene_product
-	I-Gene_or_gene_product
BP	E-Gene_or_gene_product
is	O
neutralized	O
by	O
monoclonal	O
antibodies	O
suggesting	O
the	O
potential	O
for	O
antibody	O
-	O
based	O
therapeutic	O
targeting	O
.	O

Expression	S-Gene_expression
of	O
basic	B-Gene_or_gene_product
fibroblast	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
in	O
normal	O
human	S-Organism
tissues	S-Tissue
.	O

The	O
distribution	S-Localization
of	O
basic	B-Gene_or_gene_product
fibroblast	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
(	O
bFGF	S-Gene_or_gene_product
)	O
was	O
studied	O
immunohistochemically	O
in	O
fresh	O
frozen	O
sections	O
of	O
normal	O
human	S-Organism
tissues	S-Tissue
.	O

Immunodetection	S-Planned_process
was	O
performed	O
with	O
a	O
specific	O
anti	B-Gene_or_gene_product
-	I-Gene_or_gene_product
bFGF	I-Gene_or_gene_product
mouse	I-Gene_or_gene_product
monoclonal	I-Gene_or_gene_product
antibody	E-Gene_or_gene_product
that	O
was	O
found	O
to	O
react	O
with	O
recombinant	O
human	S-Organism
bFGF	S-Gene_or_gene_product
in	O
Western	O
blot	O
analysis	O
,	O
and	O
to	O
specifically	O
neutralize	S-Negative_regulation
the	O
mitogenic	O
activity	O
of	O
bFGF	S-Gene_or_gene_product
on	O
bovine	S-Organism
vascular	B-Cell
endothelial	I-Cell
cells	E-Cell
.	O

Expression	S-Gene_expression
of	O
bFGF	S-Gene_or_gene_product
on	O
normal	O
human	S-Organism
tissues	S-Tissue
was	O
ubiquitously	B-Localization
detected	E-Localization
in	O
the	O
basement	B-Cellular_component
membranes	E-Cellular_component
of	O
all	O
size	O
blood	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
,	O
but	O
was	O
not	O
found	O
in	O
epidermal	S-Cellular_component
or	O
epithelial	B-Cellular_component
basement	I-Cellular_component
membranes	E-Cellular_component
of	O
a	O
variety	O
of	O
tissues	S-Tissue
tested	O
.	O

Intensity	O
and	O
patterns	O
of	O
localization	S-Localization
in	O
blood	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
was	O
consistent	O
in	O
various	O
tissues	S-Tissue
,	O
but	O
varied	O
among	O
different	O
regions	O
of	O
the	O
vascular	B-Multi-tissue_structure
bed	E-Multi-tissue_structure
.	O

Whereas	O
homogeneous	O
and	O
intense	O
immunoreactivity	O
were	O
observed	O
in	O
large	O
and	O
intermediate	O
size	O
blood	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
,	O
heterogeneity	O
of	O
expression	S-Gene_expression
was	O
found	O
in	O
capillaries	S-Tissue
.	O

The	O
most	O
intense	O
immunoreactivity	O
was	O
observed	O
in	O
branching	S-Development
capillaries	S-Tissue
.	O

Endothelial	B-Cell
cell	E-Cell
staining	O
was	O
heterogeneous	O
and	O
varied	O
in	O
different	O
regions	O
.	O

Strong	O
staining	O
for	O
bFGF	S-Gene_or_gene_product
was	O
also	O
found	S-Localization
in	O
cardiac	B-Cell
muscle	I-Cell
fibers	E-Cell
,	O
smooth	B-Cell
muscle	I-Cell
cells	E-Cell
of	O
mid	O
-	O
size	O
blood	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
,	O
the	O
gut	S-Multi-tissue_structure
and	O
the	O
myometrium	S-Multi-tissue_structure
,	O
in	O
central	B-Cell
nervous	I-Cell
system	I-Cell
neurons	E-Cell
and	O
cerebellar	B-Cell
Purkinje	I-Cell
cells	E-Cell
,	O
and	O
on	O
epithelial	B-Cell
cells	E-Cell
of	O
the	O
bronchi	S-Multi-tissue_structure
,	O
colon	S-Multi-tissue_structure
,	O
endometrium	S-Multi-tissue_structure
,	O
and	O
sweat	B-Multi-tissue_structure
gland	I-Multi-tissue_structure
ducts	E-Multi-tissue_structure
of	O
the	O
skin	S-Organ
.	O

The	O
presence	S-Localization
of	O
bFGF	S-Gene_or_gene_product
in	O
the	O
extracellular	B-Immaterial_anatomical_entity
compartment	E-Immaterial_anatomical_entity
of	O
a	O
diverse	O
variety	O
of	O
organs	S-Organ
may	O
play	B-Regulation
a	I-Regulation
role	E-Regulation
in	O
angiogenesis	S-Blood_vessel_development
.	O

However	O
,	O
the	O
function	O
of	O
bFGF	S-Gene_or_gene_product
in	O
parenchymal	B-Cell
cells	E-Cell
remains	O
to	O
be	O
determined	O
.	O

Retinal	S-Multi-tissue_structure
revascularisation	S-Blood_vessel_development
in	O
diabetic	O
retinopathy	O
.	O

The	O
case	O
history	O
of	O
a	O
33	O
-	O
year	O
-	O
old	O
diabetic	O
patient	S-Organism
who	O
has	O
had	O
diabetes	O
for	O
24	O
years	O
is	O
presented	O
.	O

When	O
first	O
seen	O
in	O
1975	O
he	O
had	O
bilateral	O
proliferative	O
retinopathy	O
with	O
new	O
vessels	S-Multi-tissue_structure
in	O
the	O
retinal	B-Tissue
periphery	E-Tissue
.	O

He	O
had	O
large	O
areas	O
of	O
capillary	S-Tissue
non	O
-	O
perfusion	O
lateral	O
to	O
the	O
macula	S-Tissue
in	O
the	O
right	O
eye	S-Organ
associated	O
with	O
the	O
new	O
vessels	S-Multi-tissue_structure
.	O

Nine	O
years	O
later	O
,	O
after	O
extensive	O
repeated	O
photocoagulation	O
,	O
revascularisation	S-Blood_vessel_development
of	O
large	O
areas	O
previously	O
not	O
perfused	O
were	O
seen	O
.	O

The	O
vessels	S-Multi-tissue_structure
are	O
in	O
the	O
plane	O
of	O
the	O
retina	S-Multi-tissue_structure
and	O
do	O
not	O
have	O
the	O
appearance	S-Development
of	O
new	O
vessels	S-Multi-tissue_structure
.	O

Experimental	O
drug	O
therapy	O
of	O
peritumoral	B-Pathological_formation
brain	I-Pathological_formation
edema	E-Pathological_formation
.	O

Four	O
drugs	O
with	O
potential	O
anti	O
-	O
peritumoral	B-Pathological_formation
brain	I-Pathological_formation
edema	E-Pathological_formation
activity	S-Negative_regulation
were	O
studied	O
using	O
the	O
VX2	B-Pathological_formation
rabbit	I-Pathological_formation
brain	I-Pathological_formation
tumor	E-Pathological_formation
model	O
.	O

Meclofenamate	S-Drug_or_compound
and	O
indomethacin	S-Drug_or_compound
were	O
tested	O
in	O
an	O
attempt	O
to	O
confirm	O
recent	O
reports	O
of	O
anti	O
-	O
edema	S-Pathological_formation
activity	S-Negative_regulation
in	O
non	B-Drug_or_compound
steroidal	I-Drug_or_compound
anti	I-Drug_or_compound
-	I-Drug_or_compound
inflammatory	I-Drug_or_compound
drugs	E-Drug_or_compound
(	O
NSAID	B-Drug_or_compound
'	I-Drug_or_compound
s	E-Drug_or_compound
)	O
.	O

The	O
'	O
angiostatic	O
'	O
steroids	O
17	B-Drug_or_compound
hydroxyprogesterone	E-Drug_or_compound
and	O
epicortisol	S-Drug_or_compound
were	O
tested	O
because	O
of	O
their	O
lack	O
of	O
glucocorticoid	S-Drug_or_compound
and	O
mineralocorticoid	S-Drug_or_compound
effects	O
and	O
their	O
structural	O
similarity	O
to	O
glucocorticoids	S-Drug_or_compound
.	O

The	O
protein	O
and	O
water	O
component	O
of	O
brain	B-Pathological_formation
edema	E-Pathological_formation
were	O
indirectly	O
quantitated	O
.	O

None	O
of	O
the	O
test	O
drugs	O
demonstrated	O
significant	O
anti	O
-	O
edema	S-Pathological_formation
activity	S-Negative_regulation
.	O

This	O
work	O
does	O
not	O
confirm	O
reports	O
that	O
NSAID	S-Drug_or_compound
'	O
s	O
have	O
anti	O
-	O
edema	S-Pathological_formation
activity	S-Negative_regulation
and	O
suggests	O
that	O
there	O
may	O
be	O
no	O
correlation	O
between	O
'	O
angiostatic	O
'	O
and	O
anti	O
-	O
edema	S-Pathological_formation
activity	S-Negative_regulation
in	O
certain	O
steroid	B-Drug_or_compound
compounds	E-Drug_or_compound
.	O

[	O
Intraepithelial	B-Pathological_formation
neoplasm	E-Pathological_formation
of	O
the	O
uterine	B-Multi-tissue_structure
cervix	E-Multi-tissue_structure
and	O
angiogenesis	S-Blood_vessel_development
:	O
morphologic	O
study	O
]	O

Thirty	O
uterine	B-Multi-tissue_structure
cervix	E-Multi-tissue_structure
specimens	O
sampled	O
following	O
conization	S-Planned_process
or	O
total	O
hysterectomy	S-Planned_process
were	O
studied	O
using	O
histology	O
,	O
histoenzymology	O
(	O
vessel	S-Multi-tissue_structure
phosphatase	O
alkaline	O
activity	O
)	O
,	O
and	O
immunohistochemistry	O
(	O
demonstration	O
of	O
laminin	S-Gene_or_gene_product
and	O
type	B-Gene_or_gene_product
IV	I-Gene_or_gene_product
collagen	E-Gene_or_gene_product
in	O
epithelium	S-Tissue
and	O
vessel	B-Cellular_component
basement	I-Cellular_component
membranes	E-Cellular_component
)	O
.	O

Pathologic	O
conditions	O
included	O
dystrophia	O
,	O
moderate	O
dysplasia	O
,	O
severe	O
dysplasia	O
,	O
and	O
intraepithelial	O
carcinoma	S-Pathological_formation
.	O

Results	O
were	O
compared	O
to	O
findings	O
in	O
a	O
control	O
group	O
.	O

We	O
found	O
that	O
the	O
severity	O
of	O
vascular	S-Multi-tissue_structure
abnormalities	O
correlated	O
positively	O
with	O
the	O
severity	O
of	O
histologic	O
epithelial	B-Pathological_formation
lesions	E-Pathological_formation
;	O
this	O
finding	O
is	O
consistent	O
with	O
colposcopic	O
results	O
.	O

Anarchic	O
angiogenesis	S-Blood_vessel_development
with	O
large	O
,	O
moniliform	O
,	O
tortuous	O
vessels	S-Multi-tissue_structure
was	O
seen	O
in	O
severe	O
dysplasias	O
and	O
carcinomas	S-Pathological_formation
.	O

The	O
vascular	S-Multi-tissue_structure
anomalies	O
seem	O
to	O
precede	O
the	O
development	O
of	O
histologic	B-Pathological_formation
lesions	E-Pathological_formation
in	O
some	O
instances	O
.	O

Histogenesis	S-Development
of	O
the	O
abnormal	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
may	O
involve	O
production	O
of	O
an	O
angiogenic	S-Blood_vessel_development
factor	O
by	O
the	O
cancerized	B-Tissue
epithelia	E-Tissue
.	O

Conjunctival	S-Multi-tissue_structure
hypoxia	O
in	O
diabetes	O
mellitus	O
.	O

A	O
frequently	O
cited	O
theory	O
for	O
the	O
pathogenesis	O
of	O
neovascularization	S-Blood_vessel_development
in	O
diabetic	O
retinopathy	O
is	O
that	O
retinal	S-Multi-tissue_structure
hypoxia	O
and	O
/	O
or	O
ischemia	O
release	O
a	O
factor	O
which	O
stimulates	S-Positive_regulation
neovascularization	S-Blood_vessel_development
.	O

To	O
the	O
authors	O
'	O
knowledge	O
,	O
there	O
is	O
no	O
direct	O
in	O
vivo	O
evidence	O
in	O
the	O
human	S-Organism
proving	O
this	O
theory	O
.	O

One	O
hundred	O
and	O
twenty	O
-	O
two	O
diabetic	O
subjects	O
were	O
studied	O
to	O
see	O
whether	O
worsening	O
retinopathy	O
was	O
associated	O
with	O
changes	S-Regulation
in	O
conjunctival	S-Multi-tissue_structure
oxygen	S-Drug_or_compound
tension	O
(	O
pO2	O
)	O
.	O

Diabetics	O
without	O
retinopathy	O
had	O
a	O
conjunctival	S-Multi-tissue_structure
pO2	O
which	O
was	O
similar	O
to	O
an	O
age	O
-	O
matched	O
normal	O
population	O
.	O

Diabetics	O
with	O
only	O
background	O
retinopathy	O
had	O
a	O
significantly	O
lower	O
conjunctival	S-Multi-tissue_structure
pO2	O
than	O
those	O
without	O
retinopathy	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

Diabetics	O
with	O
proliferative	O
retinopathy	O
showed	O
a	O
conjunctival	S-Multi-tissue_structure
pO2	O
that	O
was	O
significantly	O
lower	O
than	O
either	O
of	O
the	O
first	O
two	O
groups	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

The	O
lowest	O
value	O
of	O
all	O
was	O
found	O
in	O
patients	S-Organism
with	O
rubeosis	O
iridis	O
.	O

Duration	O
of	O
diabetes	O
alone	O
did	O
not	O
correlate	O
significantly	O
to	O
conjunctival	S-Multi-tissue_structure
pO2	O
.	O

These	O
findings	O
support	O
the	O
hypoxic	O
theory	O
of	O
diabetic	O
neovascular	S-Blood_vessel_development
retinopathy	O
.	O

New	O
functions	O
of	O
epidermal	B-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
:	O
stimulation	S-Positive_regulation
of	O
capillary	B-Cell
endothelial	I-Cell
cell	E-Cell
migration	S-Localization
and	O
matrix	S-Cellular_component
dependent	S-Positive_regulation
proliferation	S-Cell_proliferation
.	O

The	O
proliferative	S-Cell_proliferation
response	S-Regulation
of	O
bovine	S-Organism
retinal	B-Cell
capillary	I-Cell
endothelial	I-Cell
cells	E-Cell
to	O
EGF	S-Gene_or_gene_product
is	O
dependent	S-Positive_regulation
upon	O
attaching	S-Binding
the	O
cells	S-Cell
to	O
a	O
matrix	S-Cellular_component
of	O
fibronectin	S-Gene_or_gene_product
.	O

Bovine	S-Organism
capillary	B-Cell
endothelial	I-Cell
cells	E-Cell
are	O
also	O
stimulated	S-Positive_regulation
to	O
actively	O
migrate	S-Localization
when	O
exposed	S-Planned_process
to	O
EGF	S-Gene_or_gene_product
in	O
vitro	O
.	O

These	O
activities	O
provide	O
an	O
explanation	O
for	O
the	O
angiogenic	S-Blood_vessel_development
properties	O
of	O
EGF	S-Gene_or_gene_product
in	O
vivo	O
.	O

Capillary	B-Cell
cell	E-Cell
migration	S-Localization
and	O
proliferation	S-Cell_proliferation
are	O
proposed	O
as	O
sensitive	O
quantifiable	O
bioassays	O
to	O
explore	O
the	O
functional	O
domains	O
of	O
the	O
EGF	S-Gene_or_gene_product
molecule	O
.	O

Studies	O
on	O
the	O
inactivation	S-Negative_regulation
of	O
these	O
properties	O
of	O
EGF	S-Gene_or_gene_product
by	O
specific	O
cleavage	S-Catabolism
of	O
the	O
molecule	O
with	O
CNBr	S-Drug_or_compound
or	O
proteases	O
suggest	O
that	O
an	O
intact	O
loop	O
composed	O
in	O
part	O
by	O
amino	O
acid	O
residues	O
20	O
to	O
31	O
is	O
essential	O
for	O
at	O
least	O
some	O
functions	O
.	O

Low	O
-	O
level	O
X	O
-	O
radiation	O
effects	S-Regulation
on	O
functional	O
vascular	S-Multi-tissue_structure
changes	S-Regulation
in	O
Syrian	B-Organism
hamster	E-Organism
cheek	B-Tissue
pouch	I-Tissue
epithelium	E-Tissue
during	O
hydrocarbon	O
carcinogenesis	O
.	O

Effects	S-Regulation
of	O
repeated	O
low	O
-	O
level	O
X	O
radiation	O
on	O
functional	O
microvascular	S-Tissue
changes	S-Regulation
in	O
hamster	S-Organism
cheek	B-Tissue
pouch	I-Tissue
epithelium	E-Tissue
during	O
and	O
following	O
carcinogenesis	O
by	O
7	B-Drug_or_compound
,	I-Drug_or_compound
12	I-Drug_or_compound
-	I-Drug_or_compound
dimethylbenz	I-Drug_or_compound
[	I-Drug_or_compound
a	I-Drug_or_compound
]	I-Drug_or_compound
anthracene	E-Drug_or_compound
(	O
DMBA	S-Drug_or_compound
)	O
were	O
studied	O
.	O

Prior	O
studies	O
showed	O
enhancement	O
of	O
such	O
carcinogenesis	O
by	O
repeated	O
20	O
rad	O
head	S-Organism_subdivision
and	O
neck	S-Organism_subdivision
X	B-Planned_process
-	I-Planned_process
radiation	I-Planned_process
exposures	E-Planned_process
,	O
and	O
it	O
was	O
proposed	O
that	O
one	O
possible	O
mechanism	O
was	O
radiogenic	O
alteration	S-Regulation
of	O
the	O
functional	O
microvasculature	S-Multi-tissue_structure
in	O
a	O
manner	O
which	O
favored	S-Positive_regulation
subsequent	O
tumor	S-Pathological_formation
development	S-Development
.	O

Hamsters	S-Organism
were	O
treated	S-Planned_process
with	O
either	O
radiation	O
,	O
DMBA	S-Drug_or_compound
,	O
radiation	O
+	O
DMBA	S-Drug_or_compound
,	O
or	O
no	O
treatment	S-Planned_process
.	O

Animals	O
were	O
sacrificed	O
at	O
3	O
-	O
week	O
intervals	O
from	O
0	O
to	O
39	O
weeks	O
after	O
treatments	O
began	O
.	O

Pouch	B-Multi-tissue_structure
vascular	E-Multi-tissue_structure
volume	O
and	O
permeability	O
changes	O
were	O
studied	O
by	O
fractional	O
distributions	O
of	O
radiotracers	O
and	O
were	O
analyzed	O
by	O
a	O
variety	O
of	O
statistical	O
methods	O
which	O
explored	O
the	O
vascular	O
parameters	O
,	O
treatment	O
types	O
,	O
elapsed	O
time	O
,	O
presence	O
of	O
the	O
carcinogen	O
,	O
and	O
histopathologic	O
changes	O
.	O

All	O
treatments	O
resulted	O
in	O
significant	O
changes	S-Regulation
in	O
vascular	S-Multi-tissue_structure
volume	O
with	O
time	O
,	O
while	O
only	O
DMBA	S-Drug_or_compound
treatments	O
alone	O
resulted	O
in	O
significant	O
changes	S-Regulation
in	O
vascular	S-Multi-tissue_structure
permeability	O
with	O
time	O
.	O

Prior	O
to	O
the	O
appearances	O
of	O
frank	O
neoplasms	S-Pathological_formation
,	O
volumetric	O
changes	S-Regulation
in	O
DMBA	S-Drug_or_compound
only	O
and	O
radiation	O
only	O
groups	O
were	O
similar	O
,	O
while	O
volume	O
changes	S-Regulation
in	O
DMBA	S-Drug_or_compound
+	O
radiation	O
groups	O
increased	S-Positive_regulation
slowly	O
to	O
a	O
peak	O
later	O
than	O
in	O
other	O
groups	O
and	O
then	O
declined	O
steadily	O
to	O
levels	O
similar	O
to	O
the	O
radiation	O
only	O
group	O
.	O

As	O
in	O
prior	O
studies	O
,	O
there	O
were	O
significant	O
vascular	S-Multi-tissue_structure
volume	O
differences	O
between	O
DMBA	S-Drug_or_compound
and	O
DMBA	S-Drug_or_compound
+	O
radiation	O
groups	O
of	O
tumor	S-Pathological_formation
-	O
bearing	O
cheek	B-Organism_subdivision
pouches	E-Organism_subdivision
.	O

DMBA	S-Drug_or_compound
maxima	O
were	O
significantly	O
higher	O
than	O
those	O
of	O
DMBA	S-Drug_or_compound
+	O
radiation	O
.	O

Radiation	O
significantly	O
affected	S-Regulation
DMBA	S-Drug_or_compound
-	O
associated	S-Regulation
vascular	S-Multi-tissue_structure
volume	O
and	O
permeability	O
changes	O
during	O
carcinogenesis	O
.	O

Several	O
possible	O
explanations	O
for	O
the	O
relationship	O
of	O
these	O
changes	O
to	O
the	O
enhancement	S-Positive_regulation
of	O
DMBA	S-Drug_or_compound
carcinogenesis	O
include	O
:	O
radiation	O
blocking	O
normal	O
capillary	S-Tissue
proliferative	S-Growth
and	O
/	O
or	O
dilatory	O
responses	O
to	O
inflammation	O
secondary	O
to	O
neoplastic	O
changes	O
;	O
radiation	O
-	O
induced	O
focal	O
increases	O
in	O
the	O
pericapillary	B-Tissue
connective	I-Tissue
tissue	E-Tissue
histohematic	O
barrier	O
,	O
stimulating	S-Positive_regulation
angiogenesis	S-Blood_vessel_development
but	O
reducing	O
nutrient	O
diffusion	O
;	O
radiation	O
exposures	O
sensitizing	O
vascular	B-Tissue
endothelium	E-Tissue
to	O
subsequent	O
angiogenic	S-Blood_vessel_development
stimulation	S-Positive_regulation
from	O
premalignant	B-Tissue
tissues	E-Tissue
;	O
DMBA	S-Drug_or_compound
vascular	O
and	O
epithelial	O
effects	O
partially	O
or	O
completely	O
blocking	S-Negative_regulation
radiation	O
effects	S-Regulation
on	O
epithelial	S-Cell
and	O
/	O
or	O
endothelial	B-Cell
cells	E-Cell
;	O
and	O
radiation	O
damage	S-Breakdown
to	O
vessel	B-Multi-tissue_structure
walls	E-Multi-tissue_structure
partially	O
or	O
fully	O
inhibiting	O
normal	O
physiologic	O
mechanisms	O
of	O
repairing	O
DMBA	S-Drug_or_compound
damage	S-Breakdown
to	O
the	O
vessels	S-Multi-tissue_structure
.	O

Mast	B-Cell
cells	E-Cell
and	O
tumors	S-Pathological_formation
.	O

The	O
specific	O
enhancement	S-Positive_regulation
of	O
tumor	S-Pathological_formation
proliferation	S-Growth
in	O
vitro	O
.	O

Mast	B-Cell
cells	E-Cell
were	O
found	O
to	O
be	O
unique	O
among	O
the	O
peritoneal	B-Cell
leukocytes	E-Cell
by	O
virtue	O
of	O
their	O
capacity	O
to	O
enhance	S-Positive_regulation
profoundly	O
the	O
proliferation	S-Growth
of	O
a	O
variety	O
of	O
tumors	S-Pathological_formation
in	O
vitro	O
.	O

This	O
phenomenon	O
occurs	O
at	O
mast	B-Cell
cell	E-Cell
/	O
tumor	S-Pathological_formation
ratios	O
which	O
reflect	O
the	O
stoichiometry	O
of	O
host	B-Cell
cell	E-Cell
/	O
tumor	S-Pathological_formation
relationships	O
in	O
vivo	O
.	O

The	O
growth	O
factor	O
was	O
found	O
to	O
reside	O
in	O
mast	B-Cell
cell	E-Cell
granules	S-Organism_substance
and	O
was	O
identified	O
as	O
heparin	S-Drug_or_compound
by	O
sequential	O
purification	O
and	O
enzymatic	O
degradation	O
.	O

This	O
cellular	O
interaction	O
was	O
tumor	S-Pathological_formation
-	O
specific	O
,	O
although	O
isolated	O
granules	S-Organism_substance
could	O
enhance	S-Positive_regulation
fibroblast	S-Cell
proliferation	S-Cell_proliferation
.	O

The	O
findings	O
are	O
discussed	O
in	O
relation	O
to	O
previous	O
morphologic	O
studies	O
,	O
reports	O
of	O
in	O
vitro	O
mast	B-Cell
-	I-Cell
cell	E-Cell
-	O
mediated	S-Regulation
tumor	S-Pathological_formation
cytotoxicity	O
,	O
and	O
the	O
role	S-Regulation
of	O
mast	B-Cell
cells	E-Cell
in	O
angiogenesis	S-Blood_vessel_development
and	O
connective	B-Tissue
tissue	E-Tissue
proliferation	S-Growth
.	O

Scanning	O
electron	O
microscopy	O
of	O
vascular	O
casts	O
in	O
experimental	O
ocular	O
vasoproliferation	S-Blood_vessel_development
.	O

Scanning	O
electron	O
microscopy	O
of	O
vascular	O
casts	O
was	O
used	O
to	O
investigate	O
three	O
experimental	O
models	O
of	O
neovascularization	S-Blood_vessel_development
.	O

In	O
each	O
experimental	O
situation	O
,	O
the	O
casts	O
provided	O
a	O
valuable	O
three	O
dimensional	O
representation	O
of	O
the	O
newly	O
formed	S-Development
blood	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
and	O
permitted	O
subclassification	O
of	O
the	O
vessels	S-Multi-tissue_structure
within	O
normal	O
and	O
proliferating	S-Growth
vascular	B-Multi-tissue_structure
networks	E-Multi-tissue_structure
.	O

They	O
defined	O
also	O
the	O
predominant	O
origin	O
of	O
new	O
vessels	S-Multi-tissue_structure
from	O
venules	S-Multi-tissue_structure
and	O
capillaries	S-Tissue
,	O
and	O
enabled	O
the	O
evolution	S-Development
of	O
proliferating	S-Growth
vessels	S-Multi-tissue_structure
into	O
arterioles	S-Multi-tissue_structure
and	O
venules	S-Multi-tissue_structure
to	O
be	O
documented	O
.	O

Although	O
vascular	S-Multi-tissue_structure
casts	O
must	O
be	O
interpreted	O
with	O
caution	O
in	O
light	O
of	O
the	O
possibility	O
of	O
incomplete	O
filling	O
and	O
other	O
artifacts	O
,	O
they	O
are	O
a	O
valuable	O
tool	O
in	O
the	O
study	O
of	O
ocular	S-Organ
vasoproliferation	S-Blood_vessel_development
.	O

Angiogenesis	S-Blood_vessel_development
:	O
initiation	S-Positive_regulation
and	O
control	S-Regulation
.	O

From	O
in	O
vivo	O
experiments	O
using	O
new	O
methods	O
such	O
as	O
the	O
rabbit	S-Organism
cornea	S-Multi-tissue_structure
,	O
it	O
is	O
now	O
becoming	O
clear	O
that	O
the	O
growth	S-Growth
of	O
a	O
capillary	S-Tissue
involves	S-Regulation
an	O
ordered	O
sequence	O
of	O
events	O
that	O
includes	O
lysis	S-Breakdown
of	O
the	O
basement	B-Cellular_component
membrane	E-Cellular_component
of	O
a	O
parent	O
venule	S-Multi-tissue_structure
,	O
directional	O
migration	S-Localization
of	O
capillary	B-Cell
endothelial	I-Cell
cells	E-Cell
toward	O
the	O
angiogenic	S-Blood_vessel_development
stimulus	O
,	O
lumen	S-Immaterial_anatomical_entity
formation	S-Development
,	O
development	S-Development
of	O
branches	S-Tissue
,	O
and	O
anastomosis	S-Development
of	O
the	O
tip	O
of	O
one	O
tube	S-Tissue
with	O
another	O
to	O
form	O
a	O
loop	O
.	O

It	O
is	O
also	O
clear	O
that	O
diffusible	O
angiogenic	S-Blood_vessel_development
stimuli	O
can	O
be	O
released	O
not	O
only	O
from	O
most	O
solid	B-Pathological_formation
tumors	E-Pathological_formation
,	O
but	O
also	O
from	O
at	O
least	O
three	O
non	B-Cell
-	I-Cell
neoplastic	I-Cell
cells	E-Cell
.	O

These	O
include	O
activated	S-Positive_regulation
macrophages	S-Cell
,	O
sensitized	O
lymphocytes	S-Cell
,	O
and	O
adipocytes	S-Cell
.	O

Other	O
normal	B-Tissue
tissues	E-Tissue
can	O
also	O
stimulate	S-Positive_regulation
angiogenesis	S-Blood_vessel_development
,	O
but	O
the	O
type	O
of	O
cell	S-Cell
giving	O
rise	O
to	O
the	O
angiogenic	S-Blood_vessel_development
stimulus	O
is	O
unknown	O
,	O
and	O
the	O
period	O
of	O
angiogenic	S-Blood_vessel_development
stimulation	S-Positive_regulation
is	O
brief	O
.	O

With	O
the	O
recent	O
ability	O
to	O
clone	S-Planned_process
capillary	B-Cell
endothelial	I-Cell
cells	E-Cell
and	O
to	O
carry	O
them	O
in	O
long	O
-	O
term	O
culture	S-Planned_process
,	O
it	O
has	O
been	O
possible	O
to	O
further	O
delineate	O
the	O
mechanism	O
of	O
capillary	S-Tissue
growth	S-Growth
.	O

In	O
vitro	O
studies	O
have	O
shown	O
that	O
the	O
mast	B-Cell
cell	E-Cell
seems	O
to	O
behave	O
as	O
a	O
helper	B-Cell
cell	E-Cell
for	O
capillary	B-Cell
endothelial	I-Cell
cells	E-Cell
,	O
in	O
some	O
way	O
speeding	B-Positive_regulation
up	E-Positive_regulation
their	O
rate	O
of	O
directional	O
migration	S-Localization
.	O

At	O
this	O
writing	O
,	O
heparin	S-Drug_or_compound
appears	O
to	O
be	O
the	O
principal	O
mast	B-Cell
cell	E-Cell
factor	O
responsible	O
for	O
this	O
effect	S-Regulation
on	O
capillary	B-Cell
endothelial	I-Cell
cells	E-Cell
.	O

One	O
theoretical	O
possibility	O
is	O
that	O
mast	B-Cell
cells	E-Cell
may	O
prepare	S-Development
the	O
matrix	S-Cellular_component
,	O
perhaps	O
by	O
slow	O
release	S-Localization
of	O
heparin	S-Drug_or_compound
,	O
so	O
that	O
capillary	B-Tissue
sprouts	E-Tissue
can	O
more	O
easily	O
move	S-Localization
through	O
it	O
toward	O
their	O
angiogenic	S-Blood_vessel_development
target	O
.	O

While	O
the	O
study	O
of	O
angiogenesis	S-Blood_vessel_development
as	O
a	O
phenomenon	O
is	O
still	O
in	O
an	O
early	O
phase	O
,	O
it	O
has	O
become	O
possible	O
,	O
by	O
using	O
a	O
combination	O
of	O
in	O
vitro	O
and	O
in	O
vivo	O
techniques	O
,	O
to	O
more	O
thoroughly	O
understand	O
the	O
initiation	S-Positive_regulation
and	O
control	S-Regulation
of	O
capillary	S-Tissue
growth	S-Growth
.	O

Protection	O
from	O
experimental	O
ocular	O
herpetic	O
keratitis	O
by	O
a	O
heat	O
-	O
killed	O
virus	O
vaccine	O
.	O

New	B-Organism
Zealand	I-Organism
white	I-Organism
rabbits	E-Organism
were	O
given	O
limbal	O
inoculations	S-Planned_process
of	O
a	O
heat	O
-	O
killed	O
suspension	O
of	O
herpes	B-Organism
simplex	I-Organism
virus	E-Organism
(	O
HSV	S-Organism
)	O
in	O
a	O
lysate	O
of	O
human	S-Organism
embryonic	B-Cell
kidney	I-Cell
cells	E-Cell
.	O

At	O
intervals	O
of	O
four	O
to	O
14	O
days	O
,	O
the	O
animals	O
were	O
challenged	O
by	O
intrastromal	O
inoculation	S-Planned_process
with	O
10	O
,	O
000	O
plaque	O
-	O
forming	O
units	O
of	O
viable	O
HSV	S-Organism
.	O

Epithelial	S-Tissue
keratitis	O
,	O
disciform	B-Pathological_formation
edema	E-Pathological_formation
,	O
and	O
necrotizing	O
keratitis	O
with	O
neovascularization	S-Blood_vessel_development
of	O
the	O
cornea	S-Multi-tissue_structure
developed	S-Development
in	O
control	O
animals	O
.	O

Epithelial	S-Tissue
keratitis	O
and	O
corneal	B-Pathological_formation
edema	E-Pathological_formation
also	O
developed	S-Development
in	O
the	O
immunized	O
animals	O
during	O
the	O
first	O
week	O
after	O
virus	O
challenge	O
,	O
but	O
these	O
symptoms	O
rapidly	O
resolved	O
during	O
the	O
following	O
weeks	O
.	O

The	O
absence	O
of	O
iritis	O
,	O
neovascularization	S-Blood_vessel_development
,	O
and	O
necrotizing	O
keratitis	O
in	O
the	O
corneas	S-Multi-tissue_structure
of	O
the	O
immunized	O
animals	O
was	O
particularly	O
striking	O
.	O

Subretinal	O
neovascularization	S-Blood_vessel_development
following	O
rubella	O
retinopathy	O
.	O

A	O
17	O
-	O
year	O
-	O
old	O
girl	S-Organism
and	O
an	O
11	O
-	O
year	O
-	O
old	O
girl	S-Organism
with	O
rubella	O
retinopathy	O
had	O
decreased	O
vision	O
in	O
one	O
eye	S-Organ
secondary	O
to	O
subretinal	O
neovascularization	S-Blood_vessel_development
and	O
hemorrhage	O
.	O

In	O
both	O
cases	O
a	O
disciform	O
scar	S-Pathological_formation
with	O
permanent	O
decrease	O
in	O
central	O
vision	O
resulted	O
.	O

Mast	B-Cell
cell	E-Cell
heparin	S-Drug_or_compound
stimulates	S-Positive_regulation
migration	S-Localization
of	O
capillary	B-Cell
endothelial	I-Cell
cells	E-Cell
in	O
vitro	O
.	O

Migration	S-Localization
of	O
capillary	B-Cell
endothelial	I-Cell
cells	E-Cell
is	O
an	O
important	O
component	O
of	O
angiogenesis	S-Blood_vessel_development
in	O
vivo	O
.	O

Increased	S-Positive_regulation
numbers	O
of	O
mast	B-Cell
cells	E-Cell
have	O
been	O
associated	S-Regulation
with	O
several	O
types	O
of	O
angiogenesis	S-Blood_vessel_development
.	O

We	O
have	O
used	O
a	O
quantitative	O
assay	O
in	O
vitro	O
to	O
demonstrate	O
that	O
mast	B-Cell
cells	E-Cell
release	O
a	O
factor	O
that	O
significantly	O
increases	S-Positive_regulation
bovine	S-Organism
capillary	B-Cell
endothelial	I-Cell
cell	E-Cell
migration	S-Localization
.	O

The	O
factor	O
is	O
present	O
in	O
medium	O
conditioned	O
by	O
mast	B-Cell
cells	E-Cell
as	O
well	O
as	O
lysates	O
of	O
mast	B-Cell
cells	E-Cell
.	O

The	O
stimulatory	B-Positive_regulation
effect	E-Positive_regulation
of	O
mast	B-Cell
cells	E-Cell
on	O
migration	S-Localization
is	O
specific	O
for	O
capillary	B-Cell
endothelial	I-Cell
cells	E-Cell
.	O

Furthermore	O
,	O
mast	B-Cell
cells	E-Cell
have	O
no	O
mitogenic	B-Regulation
activity	E-Regulation
for	O
capillary	B-Cell
endothelial	I-Cell
cells	E-Cell
.	O

Of	O
all	O
the	O
secretory	O
products	O
of	O
mast	B-Cell
cells	E-Cell
tested	O
,	O
only	O
heparin	S-Drug_or_compound
stimulated	S-Positive_regulation
capillary	B-Cell
endothelial	I-Cell
cell	E-Cell
migration	S-Localization
in	O
vitro	O
.	O

Heparin	S-Drug_or_compound
preparations	O
from	O
a	O
variety	O
of	O
sources	O
stimulated	S-Positive_regulation
capillary	B-Cell
endothelial	I-Cell
cell	E-Cell
migration	S-Localization
to	O
the	O
same	O
degree	O
but	O
did	O
not	O
stimulate	S-Positive_regulation
migration	S-Localization
of	O
several	O
other	O
cell	S-Cell
types	O
.	O

The	O
migration	O
activity	O
of	O
heparin	S-Drug_or_compound
and	O
mast	B-Cell
cell	E-Cell
conditioned	O
medium	O
was	O
blocked	S-Negative_regulation
by	O
specific	O
antagonists	O
of	O
heparin	S-Drug_or_compound
(	O
protamine	S-Gene_or_gene_product
and	O
heparinase	S-Gene_or_gene_product
)	O
,	O
but	O
not	O
by	O
chondroitinase	B-Gene_or_gene_product
ABC	E-Gene_or_gene_product
.	O

The	O
migration	O
activity	O
of	O
mast	B-Cell
cell	E-Cell
conditioned	O
medium	O
was	O
resistant	O
to	O
heat	O
(	O
100	O
degrees	O
C	O
)	O
and	O
incubation	O
with	O
proteolytic	O
enzymes	O
.	O

These	O
results	O
suggest	O
that	O
the	O
role	S-Regulation
of	O
mast	B-Cell
cells	E-Cell
in	O
angiogenesis	S-Blood_vessel_development
may	O
be	O
to	O
enhance	S-Positive_regulation
migration	S-Localization
of	O
the	O
endothelial	B-Cell
cells	E-Cell
of	O
growing	S-Growth
capillaries	S-Tissue
.	O

Molecular	O
mediators	O
of	O
interactions	S-Binding
with	O
extracellular	B-Cellular_component
matrix	I-Cellular_component
components	E-Cellular_component
in	O
metastasis	O
and	O
angiogenesis	S-Blood_vessel_development
.	O

Metastasis	O
and	O
tumor	S-Pathological_formation
angiogenesis	S-Blood_vessel_development
are	O
invasive	O
phenomena	O
and	O
share	O
many	O
common	O
properties	O
at	O
the	O
physiological	O
level	O
and	O
some	O
similarities	O
at	O
the	O
molecular	O
level	O
.	O

Each	O
consists	O
of	O
repetitive	O
cycles	O
of	O
interaction	S-Binding
with	O
adjacent	O
extracellular	B-Cellular_component
matrix	I-Cellular_component
components	E-Cellular_component
by	O
mediating	S-Regulation
cellular	S-Cell
adhesion	S-Binding
,	O
matrix	B-Breakdown
dissolution	E-Breakdown
,	O
and	O
cellular	S-Cell
motility	S-Localization
to	O
achieve	O
metastasis	S-Localization
of	O
cancer	B-Cell
cells	E-Cell
or	O
neovascularization	S-Blood_vessel_development
of	O
tumors	S-Pathological_formation
.	O

Molecular	O
factors	O
which	O
implement	O
this	O
triad	O
of	O
events	O
are	O
reviewed	O
,	O
as	O
are	O
several	O
signal	O
transduction	O
components	O
which	O
may	O
regulate	O
them	O
.	O

Some	O
potentially	O
promising	O
prognostic	O
,	O
diagnostic	O
,	O
and	O
therapeutic	O
modalities	O
for	O
tumor	S-Pathological_formation
angiogenesis	S-Blood_vessel_development
and	O
metastatic	O
disease	O
are	O
also	O
discussed	O
.	O

VEGF165	S-Gene_or_gene_product
expressed	S-Gene_expression
by	O
a	O
replication	O
-	O
deficient	O
recombinant	O
adenovirus	S-Organism
vector	O
induces	S-Positive_regulation
angiogenesis	S-Blood_vessel_development
in	O
vivo	O
.	O

To	O
evaluate	O
the	O
concept	O
that	O
localized	O
delivery	O
of	O
angiogenic	S-Blood_vessel_development
factors	O
via	O
virus	O
-	O
mediated	O
gene	O
transfer	O
may	O
be	O
useful	O
in	O
the	O
treatment	O
of	O
ischemic	O
disorders	O
,	O
the	O
replication	O
-	O
deficient	O
adenovirus	S-Organism
(	O
Ad	S-Organism
)	O
vector	O
AdCMV	B-Organism
.	I-Organism
VEGF165	E-Organism
(	O
where	O
CMV	S-Organism
is	O
cytomegalovirus	S-Organism
and	O
VEGF	S-Gene_or_gene_product
is	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
)	O
containing	O
the	O
cDNA	O
for	O
human	S-Organism
VEGF165	S-Gene_or_gene_product
,	O
a	O
secreted	O
endothelial	B-Cell
cell	E-Cell
-	O
specific	O
angiogenic	S-Blood_vessel_development
growth	O
factor	O
,	O
was	O
constructed	O
.	O

Human	B-Cell
umbilical	I-Cell
vein	I-Cell
endothelial	I-Cell
cells	E-Cell
(	O
HUVECs	S-Cell
)	O
and	O
rat	B-Cell
aorta	I-Cell
smooth	I-Cell
muscle	I-Cell
cells	E-Cell
(	O
RASMCs	S-Cell
)	O
infected	S-Planned_process
with	O
AdCMV	B-Organism
.	I-Organism
VEGF165	E-Organism
(	O
5	O
and	O
20	O
plaque	O
-	O
forming	O
units	O
[	O
pfu	O
]	O
per	O
cell	S-Cell
)	O
demonstrated	O
VEGF	S-Gene_or_gene_product
mRNA	O
expression	S-Transcription
and	O
protein	O
secretion	S-Localization
into	O
the	O
supernatant	O
.	O

Furthermore	O
,	O
the	O
conditioned	O
medium	O
from	O
these	O
cells	S-Cell
enhanced	S-Positive_regulation
vascular	S-Multi-tissue_structure
permeability	O
in	O
vivo	O
.	O

In	O
contrast	O
,	O
neither	O
VEGF	S-Gene_or_gene_product
mRNA	O
nor	O
secreted	S-Localization
protein	O
was	O
found	O
in	O
uninfected	S-Planned_process
HUVECs	S-Cell
or	O
RASMCs	S-Cell
or	O
in	O
cells	S-Cell
infected	S-Planned_process
with	O
the	O
control	O
vector	O
AdCMV	B-Organism
.	I-Organism
beta	I-Organism
gal	E-Organism
(	O
where	O
beta	B-Gene_or_gene_product
gal	E-Gene_or_gene_product
is	O
beta	B-Gene_or_gene_product
-	I-Gene_or_gene_product
galactosidase	E-Gene_or_gene_product
)	O
.	O

Assessment	O
of	O
starved	O
HUVECs	S-Cell
at	O
14	O
days	O
demonstrated	O
sixfold	O
more	O
cells	S-Cell
for	O
AdCMV	B-Organism
.	I-Organism
VEGF165	E-Organism
-	O
infected	S-Planned_process
HUVECs	S-Cell
(	O
20	O
pfu	O
per	O
cell	S-Cell
)	O
than	O
for	O
either	O
infected	S-Planned_process
or	O
uninfected	S-Planned_process
control	O
cells	S-Cell
.	O

RASMC	S-Cell
proliferation	S-Cell_proliferation
was	O
unaffected	S-Regulation
by	O
infection	S-Planned_process
with	O
AdCMV	B-Organism
.	I-Organism
VEGF165	E-Organism
.	O

When	O
plated	S-Planned_process
in	O
2	O
%	O
serum	O
on	O
dishes	O
precoated	O
with	O
reconstituted	O
basement	B-Cellular_component
membrane	E-Cellular_component
(	O
Matrigel	O
)	O
,	O
HUVECs	S-Cell
infected	S-Planned_process
with	O
AdCMV	B-Organism
.	I-Organism
VEGF165	E-Organism
(	O
20	O
pfu	O
per	O
cell	S-Cell
)	O
differentiated	S-Development
into	O
capillary	B-Tissue
-	I-Tissue
like	I-Tissue
structures	E-Tissue
.	O

Under	O
similar	O
conditions	O
,	O
both	O
uninfected	S-Planned_process
HUVECs	S-Cell
and	O
HUVECs	S-Cell
infected	S-Planned_process
with	O
AdCMV	B-Organism
.	I-Organism
beta	I-Organism
gal	E-Organism
did	O
not	O
differentiate	S-Development
.	O

To	O
evaluate	O
the	O
ability	O
of	O
AdCMV	B-Organism
.	I-Organism
VEGF165	E-Organism
to	O
function	O
in	O
vivo	O
,	O
either	O
AdCMV	B-Organism
.	I-Organism
VEGF165	E-Organism
or	O
AdCMV	B-Organism
.	I-Organism
beta	I-Organism
gal	E-Organism
(	O
2	O
x	O
10	O
(	O
10	O
)	O
pfu	O
)	O
was	O
resuspended	S-Planned_process
in	O
0	O
.	O
5	O
mL	O
Matrigel	O
and	O
injected	S-Planned_process
subcutaneously	O
into	O
mice	S-Organism
.	O

Immunohistochemical	B-Planned_process
staining	E-Planned_process
demonstrated	O
VEGF	S-Gene_or_gene_product
in	O
the	O
tissues	S-Tissue
surrounding	O
the	O
Matrigel	O
plugs	O
containing	O
AdCMV	B-Organism
.	I-Organism
VEGF165	E-Organism
up	O
to	O
3	O
weeks	O
after	O
injection	S-Planned_process
,	O
whereas	O
no	O
VEGF	S-Gene_or_gene_product
was	O
found	O
in	O
the	O
control	O
plugs	O
with	O
AdCMV	B-Organism
.	I-Organism
beta	I-Organism
gal	E-Organism
.	O

Two	O
weeks	O
after	O
injection	O
,	O
there	O
was	O
histological	O
evidence	O
of	O
neovascularization	S-Blood_vessel_development
in	O
the	O
tissues	S-Tissue
surrounding	O
the	O
Matrigel	O
containing	O
AdCMV	B-Organism
.	I-Organism
VEGF165	E-Organism
,	O
whereas	O
no	O
significant	O
angiogenesis	S-Blood_vessel_development
was	O
observed	O
in	O
response	S-Regulation
to	O
AdCMV	B-Organism
.	I-Organism
beta	I-Organism
gal	E-Organism
.	O

Furthermore	O
,	O
the	O
Matrigel	O
plugs	O
with	O
AdCMV	B-Organism
.	I-Organism
VEGF165	E-Organism
demonstrated	O
hemoglobin	S-Gene_or_gene_product
content	O
fourfold	O
higher	O
than	O
the	O
plugs	O
with	O
AdCMV	B-Organism
.	I-Organism
beta	I-Organism
gal	E-Organism
.	O

Together	O
,	O
these	O
in	O
vitro	O
and	O
in	O
vivo	O
studies	O
are	O
consistent	O
with	O
the	O
concept	O
that	O
Ad	S-Organism
vectors	O
may	O
provide	O
a	O
useful	O
strategy	O
for	O
efficient	O
local	O
delivery	O
of	O
VEGF165	S-Gene_or_gene_product
in	O
the	O
treatment	O
of	O
ischemic	O
diseases	O
.	O

Heparin	S-Drug_or_compound
-	O
steroid	S-Drug_or_compound
conjugates	O
:	O
new	O
angiogenesis	S-Blood_vessel_development
inhibitors	O
with	O
antitumor	S-Pathological_formation
activity	S-Negative_regulation
in	O
mice	S-Organism
.	O

Inhibitors	O
of	O
angiogenesis	S-Blood_vessel_development
hold	O
potential	O
in	O
the	O
treatment	S-Planned_process
of	O
cancer	S-Pathological_formation
and	O
other	O
diseases	O
where	O
the	O
disease	O
is	O
caused	O
or	O
maintained	O
by	O
the	O
inappropriate	O
growth	S-Growth
of	O
blood	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
.	O

In	O
the	O
present	O
study	O
,	O
a	O
novel	O
inhibitor	O
of	O
angiogenesis	S-Blood_vessel_development
was	O
synthesized	O
by	O
covalently	O
linking	O
a	O
nonanticoagulating	O
derivative	O
of	O
heparin	S-Drug_or_compound
,	O
heparin	B-Drug_or_compound
adipic	I-Drug_or_compound
hydrazide	E-Drug_or_compound
(	O
HAH	S-Drug_or_compound
)	O
,	O
by	O
an	O
acid	O
-	O
labile	O
bond	O
to	O
the	O
antiangiogenic	S-Blood_vessel_development
steroid	S-Drug_or_compound
,	O
cortisol	S-Drug_or_compound
.	O

The	O
rationale	O
was	O
that	O
the	O
heparin	S-Drug_or_compound
derivative	O
,	O
which	O
binds	S-Binding
to	O
sulfated	O
polyanion	O
receptors	O
on	O
endothelial	B-Cell
cells	E-Cell
,	O
should	O
concentrate	O
the	O
steroid	S-Drug_or_compound
on	O
the	O
surface	O
of	O
vascular	B-Cell
endothelial	I-Cell
cells	E-Cell
.	O

Endocytosis	O
of	O
the	O
conjugate	O
and	O
decomposition	O
of	O
the	O
acid	O
-	O
labile	O
linkage	O
inside	O
lysosomes	O
and	O
other	O
acidic	O
intracellular	O
compartments	O
should	O
then	O
lead	O
to	O
release	S-Localization
of	O
the	O
cortisol	S-Drug_or_compound
and	O
expression	O
of	O
its	O
antiproliferative	O
activity	O
.	O

Analysis	O
of	O
the	O
stability	O
of	O
HAH	B-Drug_or_compound
-	I-Drug_or_compound
cortisol	E-Drug_or_compound
showed	O
that	O
it	O
was	O
stable	O
at	O
pH	O
7	O
.	O
4	O
and	O
broke	B-Catabolism
down	E-Catabolism
rapidly	O
(	O
t1	O
/	O
2	O
15	O
min	O
)	O
at	O
pH	O
4	O
.	O
8	O
at	O
37	O
degrees	O
C	O
.	O

Treatment	S-Planned_process
of	O
murine	S-Organism
pulmonary	B-Cell
capillary	I-Cell
endothelial	I-Cell
cells	E-Cell
with	O
HAH	B-Drug_or_compound
-	I-Drug_or_compound
cortisol	E-Drug_or_compound
at	O
10	O
(	O
-	O
5	O
)	O
M	O
(	O
with	O
respect	O
to	O
cortisol	S-Drug_or_compound
)	O
suppressed	O
their	O
DNA	O
synthesis	O
by	O
50	O
%	O
and	O
inhibited	S-Negative_regulation
their	O
migration	S-Localization
into	O
wounded	O
areas	O
of	O
confluent	O
monolayers	O
.	O

HAH	B-Drug_or_compound
-	I-Drug_or_compound
cortisol	E-Drug_or_compound
at	O
10	O
(	O
-	O
4	O
)	O
M	O
(	O
with	O
respect	O
to	O
cortisol	S-Drug_or_compound
)	O
did	O
not	O
suppress	O
the	O
DNA	O
synthesis	O
of	O
Lewis	B-Cell
lung	I-Cell
carcinoma	I-Cell
cells	E-Cell
.	O

Daily	O
i	O
.	O
p	O
.	O
injections	S-Planned_process
of	O
HAH	B-Drug_or_compound
-	I-Drug_or_compound
cortisol	E-Drug_or_compound
into	O
mice	S-Organism
bearing	O
s	O
.	O
c	O
.	O
sponge	O
implants	O
retarded	S-Negative_regulation
vascularization	S-Blood_vessel_development
of	O
the	O
sponge	O
,	O
and	O
injections	O
directly	O
into	O
the	O
sponge	O
abolished	S-Negative_regulation
vascularization	S-Blood_vessel_development
for	O
as	O
long	O
as	O
the	O
injections	O
were	O
continued	O
.	O

Daily	O
i	O
.	O
v	O
.	O
injections	S-Planned_process
of	O
HAH	B-Drug_or_compound
-	I-Drug_or_compound
cortisol	E-Drug_or_compound
at	O
doses	O
causing	O
no	O
apparent	O
toxicity	O
retarded	S-Negative_regulation
the	O
growth	S-Growth
of	O
solid	O
s	O
.	O
c	O
.	O

Lewis	B-Pathological_formation
lung	I-Pathological_formation
carcinomas	E-Pathological_formation
in	O
mice	S-Organism
by	O
up	O
to	O
65	O
%	O
.	O

In	O
all	O
of	O
these	O
assays	O
,	O
equivalent	O
treatments	S-Planned_process
with	O
a	O
mixture	O
of	O
the	O
HAH	S-Drug_or_compound
plus	O
cortisol	S-Drug_or_compound
was	O
significantly	O
less	O
effective	O
.	O

The	O
antiproliferative	S-Cell_proliferation
effect	S-Negative_regulation
of	O
HAH	B-Drug_or_compound
-	I-Drug_or_compound
cortisol	E-Drug_or_compound
on	O
endothelial	B-Cell
cells	E-Cell
appeared	O
independent	O
of	O
the	O
glucocorticoid	S-Drug_or_compound
activity	O
of	O
the	O
steroid	S-Drug_or_compound
since	O
HAH	S-Drug_or_compound
conjugated	S-Planned_process
to	O
5	B-Drug_or_compound
beta	I-Drug_or_compound
-	I-Drug_or_compound
pregnane	I-Drug_or_compound
-	I-Drug_or_compound
3	I-Drug_or_compound
alpha	I-Drug_or_compound
,	I-Drug_or_compound
17	I-Drug_or_compound
alpha	I-Drug_or_compound
,	I-Drug_or_compound
21	I-Drug_or_compound
-	I-Drug_or_compound
triol	I-Drug_or_compound
-	I-Drug_or_compound
20	I-Drug_or_compound
-	I-Drug_or_compound
one	E-Drug_or_compound
,	O
a	O
steroid	S-Drug_or_compound
lacking	O
glucocorticoid	S-Drug_or_compound
or	O
mineralocorticoid	S-Drug_or_compound
activity	O
,	O
was	O
even	O
more	O
effective	O
at	O
inhibiting	O
DNA	O
synthesis	O
by	O
murine	S-Organism
pulmonary	B-Cell
capillary	I-Cell
endothelial	I-Cell
cells	E-Cell
than	O
was	O
HAH	B-Drug_or_compound
-	I-Drug_or_compound
cortisol	E-Drug_or_compound
.	O

In	O
conclusion	O
,	O
HAH	B-Drug_or_compound
-	I-Drug_or_compound
cortisol	E-Drug_or_compound
represents	O
the	O
prototype	O
of	O
a	O
new	O
class	O
of	O
angiogenesis	S-Blood_vessel_development
inhibitors	O
for	O
the	O
treatment	S-Planned_process
of	O
cancer	S-Pathological_formation
and	O
other	O
angiogenic	S-Blood_vessel_development
diseases	O
.	O

Effects	S-Regulation
of	O
doxycycline	S-Drug_or_compound
on	O
in	O
vitro	O
growth	S-Cell_proliferation
,	O
migration	S-Localization
,	O
and	O
gelatinase	O
activity	O
of	O
breast	B-Cell
carcinoma	I-Cell
cells	E-Cell
.	O

Metastatic	O
disease	O
is	O
one	O
of	O
the	O
major	O
causes	O
of	O
death	S-Death
from	O
cancer	S-Pathological_formation
in	O
human	S-Organism
beings	O
.	O

Several	O
enzyme	O
systems	O
have	O
been	O
implicated	O
in	O
the	O
metastatic	O
process	O
,	O
but	O
the	O
metalloproteinases	S-Gene_or_gene_product
(	O
MPs	S-Gene_or_gene_product
)	O
appear	O
to	O
be	O
the	O
major	O
group	O
involved	O
in	O
most	O
instances	O
of	O
neoplastic	O
invasion	O
.	O

Increased	S-Positive_regulation
MP	S-Gene_or_gene_product
activity	O
has	O
been	O
correlated	O
with	O
the	O
metastatic	O
potential	O
of	O
many	O
cancers	S-Pathological_formation
,	O
including	O
breast	B-Pathological_formation
cancer	E-Pathological_formation
.	O

MPs	S-Gene_or_gene_product
also	O
play	B-Regulation
a	I-Regulation
role	E-Regulation
in	O
tumor	S-Pathological_formation
angiogenesis	S-Blood_vessel_development
.	O

Tetracyclines	S-Drug_or_compound
are	O
antimicrobial	O
agents	O
that	O
can	O
suppress	S-Negative_regulation
MP	S-Gene_or_gene_product
activity	O
in	O
a	O
variety	O
of	O
tissues	S-Tissue
,	O
including	O
gingiva	S-Multi-tissue_structure
,	O
bone	S-Tissue
,	O
and	O
cartilage	S-Tissue
.	O

Several	O
reports	O
have	O
indicated	O
that	O
tetracyclines	S-Drug_or_compound
can	O
suppress	S-Negative_regulation
tumor	S-Pathological_formation
MPs	S-Gene_or_gene_product
as	O
well	O
.	O

A	O
synthetic	O
tetracycline	S-Drug_or_compound
,	O
doxycycline	S-Drug_or_compound
,	O
inhibits	S-Negative_regulation
migration	S-Localization
of	O
human	S-Organism
MDA	B-Cell
-	I-Cell
MB	I-Cell
-	I-Cell
435	I-Cell
breast	I-Cell
adenocarcinoma	I-Cell
cells	E-Cell
through	O
a	O
reconstituted	S-Remodeling
basement	B-Cellular_component
membrane	E-Cellular_component
(	O
Matrigel	O
)	O
,	O
an	O
assay	O
used	O
as	O
an	O
in	O
vitro	O
surrogate	O
for	O
the	O
in	O
vivo	O
process	O
of	O
tumor	S-Pathological_formation
invasion	S-Localization
through	O
basement	B-Cellular_component
membranes	E-Cellular_component
.	O

Additionally	O
,	O
doxycycline	S-Drug_or_compound
diminishes	S-Negative_regulation
the	O
proliferation	S-Cell_proliferation
of	O
this	O
breast	B-Cell
cancer	I-Cell
cell	I-Cell
line	E-Cell
and	O
also	O
decreases	O
its	O
gelatinolytic	O
activity	O
,	O
as	O
determined	O
by	O
gel	O
zymography	O
.	O

High	O
density	O
of	O
somatostatin	B-Gene_or_gene_product
receptors	E-Gene_or_gene_product
in	O
veins	S-Multi-tissue_structure
surrounding	O
human	S-Organism
cancer	B-Tissue
tissue	E-Tissue
:	O
role	S-Regulation
in	O
tumor	S-Pathological_formation
-	O
host	O
interaction	S-Binding
?	O

Somatostatin	B-Gene_or_gene_product
receptors	E-Gene_or_gene_product
were	O
detected	S-Localization
in	O
peritumoral	O
veins	S-Multi-tissue_structure
of	O
various	O
human	S-Organism
cancer	B-Tissue
tissue	E-Tissue
specimens	O
.	O

Vascular	S-Tissue
and	O
neoplastic	B-Tissue
tissue	E-Tissue
from	O
14	O
colonic	B-Pathological_formation
adenocarcinomas	E-Pathological_formation
,	O
13	O
carcinoids	S-Pathological_formation
,	O
6	O
renal	B-Pathological_formation
-	I-Pathological_formation
cell	I-Pathological_formation
carcinomas	E-Pathological_formation
and	O
7	O
malignant	B-Pathological_formation
lymphomas	E-Pathological_formation
were	O
analyzed	O
for	O
somatostatin	B-Gene_or_gene_product
receptors	E-Gene_or_gene_product
by	O
use	O
of	O
quantitative	O
receptor	O
autoradiography	O
.	O

In	O
colonic	B-Pathological_formation
carcinoma	E-Pathological_formation
specimens	O
,	O
the	O
peritumoral	O
vessels	S-Multi-tissue_structure
expressed	S-Gene_expression
a	O
high	O
density	O
of	O
somatostatin	B-Gene_or_gene_product
receptors	E-Gene_or_gene_product
,	O
whereas	O
the	O
neoplastic	B-Tissue
tissue	E-Tissue
itself	O
was	O
receptor	O
-	O
negative	S-Gene_expression
in	O
many	O
cases	O
.	O

In	O
contrast	O
,	O
the	O
incidence	O
and	O
density	O
of	O
somatostatin	B-Gene_or_gene_product
receptors	E-Gene_or_gene_product
in	O
peritumoral	O
vessels	S-Multi-tissue_structure
was	O
low	O
in	O
well	O
-	O
differentiated	S-Development
gastrointestinal	S-Pathological_formation
and	O
bronchial	B-Pathological_formation
carcinoids	E-Pathological_formation
,	O
in	O
contrast	O
to	O
the	O
high	O
density	O
of	O
such	O
receptors	O
in	O
the	O
carcinoid	B-Tissue
tumor	I-Tissue
tissue	E-Tissue
.	O

Autochthonous	O
vessels	S-Multi-tissue_structure
surrounding	O
other	O
tumors	S-Pathological_formation
such	O
as	O
renal	B-Pathological_formation
-	I-Pathological_formation
cell	I-Pathological_formation
carcinomas	E-Pathological_formation
or	O
malignant	B-Pathological_formation
lymphomas	E-Pathological_formation
also	O
frequently	O
expressed	S-Gene_expression
somatostatin	B-Gene_or_gene_product
receptors	E-Gene_or_gene_product
.	O

In	O
all	O
cases	O
,	O
the	O
somatostatin	B-Gene_or_gene_product
receptors	E-Gene_or_gene_product
were	O
localized	S-Localization
in	O
veins	S-Multi-tissue_structure
,	O
particularly	O
in	O
the	O
smooth	B-Cell
-	I-Cell
muscle	I-Cell
cell	E-Cell
layer	O
.	O

They	O
exhibited	O
specific	O
and	O
high	O
-	O
affinity	O
binding	S-Binding
of	O
somatostatin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
14	E-Gene_or_gene_product
,	O
somatostatin	B-Gene_or_gene_product
-	I-Gene_or_gene_product
28	E-Gene_or_gene_product
and	O
octreotide	S-Drug_or_compound
,	O
suggesting	O
a	O
preferential	O
expression	S-Gene_expression
of	O
the	O
SSTR2	B-Gene_or_gene_product
receptor	E-Gene_or_gene_product
subtype	O
.	O

Since	O
the	O
vessels	S-Multi-tissue_structure
of	O
normal	O
non	O
-	O
neoplastic	O
human	S-Organism
tissues	S-Tissue
,	O
e	O
.	O
g	O
.	O
of	O
intestine	S-Organ
or	O
lymphatic	B-Organ
organs	E-Organ
,	O
have	O
few	O
somatostatin	B-Gene_or_gene_product
receptors	E-Gene_or_gene_product
,	O
the	O
increased	S-Positive_regulation
somatostatin	B-Gene_or_gene_product
receptor	E-Gene_or_gene_product
expression	S-Gene_expression
in	O
peritumoral	O
vessels	S-Multi-tissue_structure
observed	O
in	O
this	O
study	O
may	O
be	O
linked	O
to	O
the	O
neoplastic	O
process	O
itself	O
.	O

The	O
results	O
suggest	O
that	O
somatostatin	S-Gene_or_gene_product
and	O
somatostatin	B-Gene_or_gene_product
receptors	E-Gene_or_gene_product
may	O
play	B-Regulation
a	I-Regulation
regulatory	I-Regulation
role	E-Regulation
for	O
hemodynamic	O
tumor	S-Pathological_formation
-	O
host	O
interactions	S-Binding
,	O
possibly	O
involving	S-Regulation
tumor	B-Tissue
stroma	E-Tissue
generation	S-Development
,	O
tumor	S-Pathological_formation
environment	O
,	O
angiogenesis	S-Blood_vessel_development
and	O
,	O
particularly	O
,	O
vascular	O
drainage	O
of	O
poorly	O
differentiated	S-Development
neoplasms	S-Pathological_formation
.	O

[	O
Treatment	S-Planned_process
of	O
the	O
diabetic	O
foot	S-Organism_subdivision
by	O
hyperbaric	B-Drug_or_compound
oxygen	E-Drug_or_compound
]	O

Diabetic	O
foot	S-Organism_subdivision
wounds	O
are	O
consequences	O
of	O
the	O
neuropathy	O
and	O
the	O
small	O
and	O
large	O
vessel	S-Multi-tissue_structure
disease	O
that	O
complicate	O
diabetes	O
.	O

At	O
the	O
cellular	O
level	O
,	O
the	O
result	O
is	O
hypoxia	O
which	O
impairs	O
wound	O
healing	O
.	O

Hyperbaric	O
oxygenation	O
(	O
HBO	O
)	O
may	O
be	O
a	O
useful	O
adjuvant	O
to	O
wound	O
care	O
.	O

It	O
leads	O
to	O
enhanced	O
oxygenation	O
of	O
the	O
affected	S-Regulation
tissues	S-Tissue
,	O
has	O
an	O
antiseptic	O
effect	O
,	O
reduces	S-Negative_regulation
edema	S-Pathological_formation
,	O
and	O
accelerates	S-Positive_regulation
collagen	S-Gene_or_gene_product
production	S-Gene_expression
and	O
angiogenesis	S-Blood_vessel_development
,	O
thus	O
enhancing	S-Positive_regulation
tissue	S-Tissue
repair	S-Development
.	O

14	O
diabetics	O
with	O
chronic	O
nonhealing	O
wounds	O
which	O
did	O
not	O
respond	O
to	O
treatment	O
for	O
at	O
least	O
3	O
months	O
were	O
treated	O
by	O
HBO	O
.	O

All	O
had	O
palpable	O
pedal	O
pulses	O
.	O

Transcutaneous	O
measurements	O
of	O
tissue	S-Tissue
pO2	O
showed	O
elevation	O
from	O
20	O
+	O
/	O
-	O
10	O
mm	O
Hg	O
during	O
air	O
breathing	O
to	O
643	O
+	O
/	O
-	O
242	O
mm	O
Hg	O
while	O
breathing	O
pure	O
oxygen	S-Drug_or_compound
at	O
2	O
.	O
5	O
ATA	O
.	O

They	O
were	O
treated	O
with	O
HBO	O
in	O
56	O
+	O
/	O
-	O
10	O
consecutive	O
HBO	O
sessions	O
.	O

In	O
11	O
there	O
was	O
complete	O
wound	O
healing	O
,	O
while	O
in	O
1	O
there	O
was	O
partial	O
response	O
,	O
in	O
1	O
minimal	O
response	O
,	O
and	O
in	O
1	O
a	O
transient	O
response	O
.	O

HBO	O
is	O
useful	O
in	O
chronic	O
nonhealing	O
wounds	O
of	O
the	O
diabetic	O
foot	S-Organism_subdivision
and	O
of	O
the	O
diabetic	O
foot	S-Organism_subdivision
with	O
impending	O
amputation	S-Planned_process
.	O

It	O
is	O
a	O
safe	O
mode	O
of	O
therapy	O
,	O
but	O
further	O
studies	O
are	O
required	O
to	O
establish	O
its	O
efficacy	O
and	O
to	O
ascertain	O
which	O
diabetic	O
patients	S-Organism
and	O
wounds	O
will	O
benefit	O
the	O
most	O
from	O
it	O
.	O

Immune	O
consequences	O
of	O
burn	O
injury	O
.	O

The	O
purpose	O
of	O
the	O
immune	O
system	O
is	O
to	O
protect	O
cells	S-Cell
from	O
invasion	O
by	O
microorganisms	O
.	O

The	O
body	O
has	O
three	O
equally	O
important	O
interactive	O
immune	O
defense	O
systems	O
,	O
all	O
of	O
which	O
are	O
profoundly	O
disrupted	O
with	O
major	O
burn	O
injury	O
.	O

The	O
immune	O
response	O
to	O
burn	O
injury	O
is	O
immediate	O
,	O
prolonged	O
,	O
and	O
severe	O
.	O

The	O
end	O
result	O
in	O
individuals	O
surviving	O
burn	O
shock	O
is	O
immunosuppression	O
,	O
with	O
increased	O
susceptibility	O
to	O
potentially	O
fatal	O
systemic	O
burn	O
wound	O
or	O
pulmonary	O
sepsis	O
.	O

Nursing	O
actions	O
to	O
support	O
the	O
humoral	O
and	O
cell	S-Cell
-	O
mediated	O
immune	O
system	O
of	O
the	O
burned	O
patient	S-Organism
include	O
providing	O
nutritional	O
support	O
to	O
maintain	O
serum	S-Organism_substance
protein	O
levels	O
at	O
optimal	O
levels	O
;	O
measures	O
to	O
decrease	S-Negative_regulation
edema	S-Pathological_formation
and	O
promote	S-Positive_regulation
angiogenesis	S-Blood_vessel_development
in	O
areas	O
of	O
partial	O
-	O
thickness	O
injury	O
;	O
meticulous	O
treatment	O
of	O
the	O
wound	O
to	O
prevent	O
infection	O
and	O
promote	O
healing	O
;	O
monitoring	O
of	O
antibiotic	O
use	O
;	O
conservative	O
use	O
of	O
invasive	O
techniques	O
,	O
including	O
intubation	O
and	O
vascular	O
access	O
devices	O
;	O
maintenance	O
of	O
fluid	O
and	O
electrolyte	O
balance	O
and	O
body	O
temperature	O
;	O
and	O
energy	O
conservation	O
measures	O
.	O

Autocrine	O
angiogenic	S-Blood_vessel_development
vascular	O
prosthesis	O
with	O
bone	B-Multi-tissue_structure
marrow	E-Multi-tissue_structure
transplantation	S-Planned_process
.	O

Synthetic	O
vascular	O
prostheses	O
are	O
foreign	O
bodies	O
,	O
so	O
that	O
blood	S-Organism_substance
coagulation	O
can	O
occur	O
on	O
their	O
luminal	O
surfaces	O
,	O
causing	O
graft	O
occlusion	O
very	O
frequently	O
in	O
prostheses	O
of	O
small	O
diameter	O
.	O

A	O
vascular	O
prosthesis	O
needs	O
angiogenesis	S-Blood_vessel_development
for	O
endothelialization	S-Blood_vessel_development
of	O
the	O
luminal	O
surface	O
,	O
as	O
endothelial	B-Cell
cells	E-Cell
have	O
natural	O
and	O
permanent	O
antithrombogenic	O
properties	O
.	O

To	O
induce	S-Positive_regulation
capillary	S-Tissue
growth	S-Growth
into	O
the	O
graft	O
,	O
we	O
developed	O
a	O
method	O
of	O
transplanting	S-Planned_process
bone	B-Cell
marrow	I-Cell
cells	E-Cell
,	O
which	O
are	O
primitive	O
,	O
strong	O
enough	O
to	O
survive	O
,	O
and	O
create	S-Development
blood	B-Cell
cells	E-Cell
,	O
resulting	S-Positive_regulation
in	O
the	O
inducement	S-Positive_regulation
of	O
capillary	S-Tissue
growth	S-Growth
.	O

In	O
an	O
animal	O
experiment	O
,	O
marrow	B-Cell
cells	E-Cell
were	O
infiltrated	S-Localization
into	O
the	O
walls	O
of	O
long	O
-	O
fibril	O
expanded	O
polytetrafluoroethylene	O
(	O
ePTFE	O
)	O
vascular	O
grafts	O
.	O

The	O
grafts	O
were	O
implanted	S-Planned_process
in	O
the	O
abdominal	B-Multi-tissue_structure
aortic	E-Multi-tissue_structure
position	O
of	O
24	O
dogs	S-Organism
autologously	O
.	O

Marrow	B-Cell
cells	E-Cell
survived	S-Death
and	O
continued	O
exogenous	O
hemopoiesis	O
for	O
up	O
to	O
six	O
months	O
and	O
were	O
immunohistochemically	O
reactive	O
to	O
basic	B-Gene_or_gene_product
fibroblast	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
(	O
bFGF	S-Gene_or_gene_product
)	O
.	O

All	O
the	O
grafts	O
older	O
than	O
three	O
weeks	O
had	O
complete	O
endothelialization	S-Blood_vessel_development
and	O
maintained	O
their	O
patency	O
.	O

Twenty	O
grafts	O
without	O
bone	B-Multi-tissue_structure
marrow	E-Multi-tissue_structure
were	O
implanted	O
as	O
controls	O
.	O

Endothelialization	S-Blood_vessel_development
was	O
present	O
at	O
anastomotic	O
sites	O
,	O
but	O
other	O
areas	O
were	O
covered	O
with	O
fresh	O
thrombi	O
.	O

Four	O
out	O
of	O
seven	O
control	O
grafts	O
were	O
patent	O
with	O
endothelial	B-Cell
cell	E-Cell
lining	O
at	O
six	O
months	O
,	O
but	O
three	O
were	O
occluded	O
and	O
one	O
of	O
the	O
four	O
grafts	O
was	O
still	O
covered	O
with	O
a	O
thrombus	S-Pathological_formation
layer	O
.	O

Bone	B-Multi-tissue_structure
marrow	E-Multi-tissue_structure
with	O
its	O
unique	O
native	O
properties	O
produced	O
autocrine	O
angiogenicity	S-Blood_vessel_development
in	O
the	O
graft	O
.	O

The	O
effects	S-Regulation
of	O
radiation	O
on	O
neovascularization	S-Blood_vessel_development
in	O
a	O
rat	S-Organism
model	O
.	O

It	O
is	O
thought	O
that	O
radiation	O
treatment	O
inhibits	S-Negative_regulation
neovascularization	S-Blood_vessel_development
of	O
recipient	O
and	O
/	O
or	O
graft	B-Tissue
tissues	E-Tissue
,	O
and	O
this	O
may	O
account	O
in	O
part	O
for	O
abnormalities	O
in	O
wound	O
healing	O
associated	O
with	O
radiation	O
therapy	O
.	O

We	O
have	O
examined	O
this	O
hypothesis	O
using	O
a	O
model	O
that	O
measures	O
the	O
neovascularization	S-Blood_vessel_development
of	O
an	O
implanted	O
foreign	O
material	O
.	O

Expanded	O
polytetrafluoroethylene	S-Drug_or_compound
(	O
PTFE	S-Drug_or_compound
)	O
sheets	O
were	O
implanted	S-Planned_process
adjacent	O
to	O
both	O
superficial	O
epigastric	B-Multi-tissue_structure
vascular	I-Multi-tissue_structure
pedicles	E-Multi-tissue_structure
of	O
63	O
rats	S-Organism
distributed	O
into	O
7	O
groups	O
(	O
n	O
=	O
7	O
)	O
that	O
differed	O
with	O
respect	O
to	O
dose	O
and	O
timing	O
of	O
irradiation	O
.	O

Zero	O
to	O
10	O
daily	O
fractions	O
of	O
electron	O
-	O
beam	O
radiation	O
(	O
300	O
cGy	O
each	O
)	O
were	O
delivered	O
to	O
the	O
implant	O
in	O
the	O
right	B-Organism_subdivision
groin	E-Organism_subdivision
,	O
while	O
the	O
implant	O
in	O
the	O
left	B-Organism_subdivision
groin	E-Organism_subdivision
served	O
as	O
a	O
nonirradiated	O
internal	O
control	O
.	O

Unirradiated	O
animals	O
showed	O
equal	O
neovascularization	S-Blood_vessel_development
of	O
both	O
implants	O
.	O

Rats	S-Organism
that	O
were	O
irradiated	S-Planned_process
twice	O
(	O
single	O
fractions	O
at	O
0	O
and	O
24	O
hours	O
after	O
implantation	O
)	O
did	O
not	O
show	O
a	O
significant	O
decrease	S-Negative_regulation
in	O
the	O
neovascularization	S-Blood_vessel_development
of	O
the	O
irradiated	O
implant	O
compared	O
with	O
the	O
contralateral	O
control	O
implant	O
.	O

In	O
contrast	O
,	O
the	O
implants	O
that	O
were	O
irradiated	O
three	O
times	O
(	O
single	O
fractions	O
at	O
0	O
,	O
24	O
,	O
and	O
48	O
hours	O
after	O
implantation	O
)	O
demonstrated	O
significantly	O
diminished	S-Negative_regulation
(	O
greater	O
than	O
25	O
percent	O
,	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
neovascularization	S-Blood_vessel_development
beyond	O
day	O
7	O
,	O
whereas	O
implants	O
irradiated	O
only	O
at	O
48	O
hours	O
after	O
implantation	O
did	O
not	O
.	O

Interestingly	O
,	O
neovascularization	S-Blood_vessel_development
of	O
the	O
implants	O
irradiated	O
with	O
10	O
fractions	O
(	O
3000	O
cGy	O
)	O
was	O
not	O
significantly	O
decreased	S-Negative_regulation
compared	O
with	O
irradiation	O
with	O
three	O
fractions	O
(	O
900	O
cGy	O
)	O
.	O

Irradiation	O
delivered	O
before	O
implantation	O
(	O
900	O
cGy	O
)	O
inhibited	S-Negative_regulation
neovascularization	S-Blood_vessel_development
significantly	O
less	O
than	O
the	O
same	O
dose	O
administered	O
after	O
implantation	O
.	O

The	O
results	O
of	O
this	O
study	O
suggest	O
that	O
a	O
subclinical	O
cumulative	O
dose	O
of	O
900	O
cGy	O
is	O
the	O
threshold	O
for	O
impaired	S-Negative_regulation
tissue	S-Tissue
revascularization	S-Blood_vessel_development
provided	O
that	O
treatment	O
is	O
delivered	O
immediately	O
after	O
implantation	O
over	O
a	O
48	O
-	O
hour	O
interval	O
.	O

Stimulation	S-Positive_regulation
of	O
endothelial	B-Cell
cell	E-Cell
migration	S-Localization
by	O
vascular	B-Gene_or_gene_product
permeability	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
/	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
through	O
cooperative	O
mechanisms	O
involving	O
the	O
alphavbeta3	B-Gene_or_gene_product
integrin	E-Gene_or_gene_product
,	O
osteopontin	S-Gene_or_gene_product
,	O
and	O
thrombin	S-Gene_or_gene_product
.	O

We	O
have	O
identified	O
several	O
mechanisms	O
by	O
which	O
the	O
angiogenic	S-Blood_vessel_development
cytokine	O
vascular	B-Gene_or_gene_product
permeability	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
/	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
(	O
VPF	S-Gene_or_gene_product
/	O
VEGF	S-Gene_or_gene_product
)	O
likely	O
regulates	S-Regulation
endothelial	B-Cell
cells	E-Cell
(	O
EC	S-Cell
)	O
migration	S-Localization
.	O

VPF	S-Gene_or_gene_product
/	O
VEGF	S-Gene_or_gene_product
induced	S-Positive_regulation
dermal	O
microvascular	B-Cell
EC	E-Cell
expression	S-Transcription
of	O
mRNAs	O
encoding	O
the	O
alphav	S-Gene_or_gene_product
and	O
beta3	B-Gene_or_gene_product
integrin	I-Gene_or_gene_product
subunits	E-Gene_or_gene_product
resulting	O
in	O
increased	S-Positive_regulation
levels	O
of	O
the	O
alphavbeta3	S-Gene_or_gene_product
heterodimer	O
at	O
the	O
cell	B-Cellular_component
surface	E-Cellular_component
,	O
and	O
VPF	S-Gene_or_gene_product
/	O
VEGF	S-Gene_or_gene_product
also	O
induced	S-Positive_regulation
mRNA	O
encoding	O
osteopontin	S-Gene_or_gene_product
(	O
OPN	S-Gene_or_gene_product
)	O
,	O
an	O
alphavbeta3	S-Gene_or_gene_product
ligand	O
.	O

OPN	S-Gene_or_gene_product
promoted	S-Positive_regulation
EC	S-Cell
migration	S-Localization
in	O
vitro	O
;	O
and	O
VPF	S-Gene_or_gene_product
/	O
VEGF	S-Gene_or_gene_product
induction	S-Positive_regulation
of	O
alphavbeta3	S-Gene_or_gene_product
was	O
accompanied	O
by	O
increased	S-Positive_regulation
EC	S-Cell
migration	S-Localization
toward	O
OPN	S-Gene_or_gene_product
.	O

Because	O
thrombin	S-Gene_or_gene_product
cleavage	S-Catabolism
of	O
OPN	S-Gene_or_gene_product
results	O
in	O
substantial	O
enhancement	S-Positive_regulation
of	O
OPN	S-Gene_or_gene_product
'	O
s	O
adhesive	O
properties	O
,	O
and	O
because	O
VPF	S-Gene_or_gene_product
/	O
VEGF	S-Gene_or_gene_product
promotes	S-Positive_regulation
increased	S-Positive_regulation
microvascular	S-Tissue
permeability	O
leading	O
to	O
activation	S-Positive_regulation
of	O
the	O
extrinsic	B-Pathway
coagulation	I-Pathway
pathway	E-Pathway
,	O
we	O
also	O
investigated	O
whether	O
VPF	S-Gene_or_gene_product
/	O
VEGF	S-Gene_or_gene_product
facilitates	S-Regulation
thrombin	S-Gene_or_gene_product
cleavage	S-Catabolism
of	O
OPN	S-Gene_or_gene_product
in	O
vivo	O
.	O

Consistent	O
with	O
this	O
hypothesis	O
,	O
co	B-Planned_process
-	I-Planned_process
injection	E-Planned_process
of	O
VPF	S-Gene_or_gene_product
/	O
VEGF	S-Gene_or_gene_product
together	O
with	O
OPN	S-Gene_or_gene_product
resulted	O
in	O
rapid	O
cleavage	S-Catabolism
of	O
OPN	S-Gene_or_gene_product
by	O
endogenous	O
thrombin	S-Gene_or_gene_product
.	O

Furthermore	O
,	O
in	O
comparison	O
with	O
native	O
OPN	S-Gene_or_gene_product
,	O
thrombin	S-Gene_or_gene_product
-	O
cleaved	S-Catabolism
OPN	S-Gene_or_gene_product
stimulated	S-Positive_regulation
a	O
greater	O
rate	O
of	O
EC	S-Cell
migration	S-Localization
in	O
vitro	O
,	O
which	O
was	O
additive	O
to	O
the	O
increased	O
migration	O
associated	O
with	O
induction	S-Positive_regulation
of	O
alpha	B-Gene_or_gene_product
v	I-Gene_or_gene_product
beta	I-Gene_or_gene_product
3	E-Gene_or_gene_product
.	O

Thus	O
,	O
these	O
data	O
demonstrate	O
cooperative	O
mechanisms	O
for	O
VPF	S-Gene_or_gene_product
/	O
VEGF	S-Gene_or_gene_product
regulation	S-Regulation
of	O
EC	S-Cell
migration	S-Localization
involving	O
the	O
alphavbeta3	B-Gene_or_gene_product
integrin	E-Gene_or_gene_product
,	O
the	O
alphavbeta3	S-Gene_or_gene_product
ligand	O
OPN	S-Gene_or_gene_product
,	O
and	O
thrombin	S-Gene_or_gene_product
cleavage	S-Catabolism
of	O
OPN	S-Gene_or_gene_product
.	O

These	O
findings	O
also	O
illustrate	O
an	O
operational	O
link	O
between	O
VPF	S-Gene_or_gene_product
/	O
VEGF	S-Gene_or_gene_product
induction	O
of	O
EC	S-Cell
gene	O
expression	O
and	O
VPF	S-Gene_or_gene_product
/	O
VEGF	S-Gene_or_gene_product
enhancement	S-Positive_regulation
of	O
microvascular	S-Tissue
permeability	O
,	O
suggesting	O
that	O
these	O
distinct	O
biological	O
activities	O
may	O
act	O
accordingly	O
to	O
stimulate	S-Positive_regulation
EC	S-Cell
migration	S-Localization
during	O
angiogenesis	S-Blood_vessel_development
.	O

Prognostic	O
value	O
of	O
angiogenesis	S-Blood_vessel_development
in	O
operable	O
non	B-Pathological_formation
-	I-Pathological_formation
small	I-Pathological_formation
cell	I-Pathological_formation
lung	I-Pathological_formation
cancer	E-Pathological_formation
.	O

Tumour	S-Pathological_formation
angiogenesis	S-Blood_vessel_development
is	O
an	O
important	O
factor	O
for	O
tumour	S-Pathological_formation
growth	S-Growth
and	O
metastasis	S-Localization
.	O

Although	O
some	O
recent	O
reports	O
suggest	O
that	O
microvessel	S-Tissue
counts	O
in	O
non	B-Pathological_formation
-	I-Pathological_formation
small	I-Pathological_formation
cell	I-Pathological_formation
lung	I-Pathological_formation
cancer	E-Pathological_formation
are	O
related	O
to	O
a	O
poor	O
disease	O
outcome	O
,	O
the	O
results	O
were	O
not	O
conclusive	O
and	O
were	O
not	O
compared	O
with	O
other	O
molecular	O
prognostic	O
markers	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
vascular	O
grade	O
was	O
assessed	O
in	O
107	O
(	O
T1	O
,	O
2	O
-	O
N0	O
,	O
1	O
)	O
operable	O
non	B-Pathological_formation
-	I-Pathological_formation
small	I-Pathological_formation
cell	I-Pathological_formation
lung	I-Pathological_formation
carcinomas	E-Pathological_formation
,	O
using	O
the	O
JC70	O
monoclonal	O
antibody	O
to	O
CD31	S-Gene_or_gene_product
.	O

Three	O
vascular	O
grades	O
were	O
defined	O
with	O
appraisal	O
by	O
eye	S-Organ
and	O
by	O
Chalkley	O
counting	O
:	O
high	O
(	O
Chalkley	O
score	O
7	O
-	O
12	O
)	O
,	O
medium	O
(	O
5	O
-	O
6	O
)	O
,	O
and	O
low	O
(	O
2	O
-	O
4	O
)	O
.	O

There	O
was	O
a	O
significant	O
correlation	O
between	O
eye	S-Organ
appraisal	O
and	O
Chalkley	O
counting	O
(	O
P	O
less	O
than	O
0	O
.	O
0001	O
)	O
.	O

Vascular	O
grade	O
was	O
not	O
related	O
to	O
histology	O
,	O
grade	O
,	O
proliferation	O
index	O
(	O
Ki67	S-Gene_or_gene_product
)	O
,	O
or	O
EGFR	S-Gene_or_gene_product
or	O
p53	S-Gene_or_gene_product
expression	S-Gene_expression
.	O

Tumours	S-Pathological_formation
from	O
younger	O
patients	S-Organism
had	O
a	O
higher	O
grade	O
of	O
angiogenesis	S-Blood_vessel_development
(	O
P	O
=	O
0	O
.	O
05	O
)	O
.	O

Apart	O
from	O
the	O
vascular	O
grade	O
,	O
none	O
of	O
the	O
other	O
factors	O
examined	O
was	O
statistically	O
related	O
to	O
lymph	B-Multi-tissue_structure
node	E-Multi-tissue_structure
metastasis	O
(	O
P	O
less	O
than	O
0	O
.	O
0001	O
)	O
.	O

A	O
univariate	O
analysis	O
of	O
survival	O
showed	O
that	O
vascular	O
grade	O
was	O
the	O
most	O
significant	O
prognostic	O
factor	O
(	O
P	O
=	O
0	O
.	O
0004	O
)	O
,	O
followed	O
by	O
N	O
-	O
stage	O
(	O
P	O
=	O
0	O
.	O
001	O
)	O
.	O

In	O
a	O
multivariate	O
analysis	O
,	O
N	O
-	O
stage	O
and	O
vascular	O
grade	O
were	O
not	O
found	O
to	O
be	O
independent	O
prognostic	O
factors	O
,	O
since	O
they	O
were	O
strongly	O
related	O
to	O
each	O
other	O
.	O

Excluding	O
N	O
-	O
stage	O
,	O
vascular	O
grade	O
was	O
the	O
only	O
independent	O
prognostic	O
factor	O
(	O
P	O
=	O
0	O
.	O
007	O
)	O
.	O

Kaplan	O
-	O
Meier	O
survival	O
curves	O
showed	O
a	O
statistically	O
significant	O
worse	O
prognosis	O
for	O
patients	S-Organism
with	O
high	O
vascular	O
grade	O
,	O
but	O
no	O
difference	O
was	O
observed	O
between	O
low	O
and	O
medium	O
vascular	O
grade	O
.	O

These	O
data	O
suggest	O
that	O
angiogenesis	S-Blood_vessel_development
in	O
operable	O
non	B-Pathological_formation
-	I-Pathological_formation
small	I-Pathological_formation
cell	I-Pathological_formation
lung	I-Pathological_formation
cancer	E-Pathological_formation
is	O
a	O
major	O
prognostic	O
factor	O
for	O
survival	O
and	O
,	O
among	O
the	O
parameters	O
tested	O
,	O
is	O
the	O
only	O
factor	O
related	O
to	O
cancer	B-Cell
cell	E-Cell
migration	S-Localization
to	O
lymph	B-Multi-tissue_structure
nodes	E-Multi-tissue_structure
.	O

The	O
integration	O
of	O
vascular	O
grading	O
in	O
clinical	O
trials	O
on	O
adjuvant	O
chemotherapy	S-Planned_process
and	O
/	O
or	O
radiotherapy	S-Planned_process
could	O
substantially	O
contribute	O
in	O
defining	O
groups	O
of	O
operable	O
patients	S-Organism
who	O
might	O
benefit	O
from	O
cytotoxic	O
treatment	O
.	O

Gene	O
transfer	O
of	O
naked	O
DNA	O
encoding	O
for	O
three	O
isoforms	O
of	O
vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
stimulates	S-Positive_regulation
collateral	S-Multi-tissue_structure
development	S-Development
in	O
vivo	O
.	O

Vascular	B-Gene_or_gene_product
endothelial	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
(	O
VEGF	S-Gene_or_gene_product
)	O
is	O
a	O
naturally	O
secreted	S-Localization
endothelial	B-Cell
cell	E-Cell
-	O
specific	O
mitogen	O
.	O

We	O
investigated	O
the	O
hypothesis	O
that	O
naked	O
DNA	O
encoding	O
for	O
VEGF	S-Gene_or_gene_product
could	O
be	O
used	O
in	O
a	O
strategy	O
of	O
arterial	B-Planned_process
gene	I-Planned_process
therapy	E-Planned_process
to	O
stimulate	S-Positive_regulation
collateral	B-Multi-tissue_structure
artery	E-Multi-tissue_structure
development	S-Development
.	O

Plasmid	O
DNA	O
encoding	O
each	O
of	O
the	O
three	O
principal	O
human	S-Organism
VEGF	S-Gene_or_gene_product
isoforms	O
(	O
phVEGF121	S-Gene_or_gene_product
,	O
phVEGF165	S-Gene_or_gene_product
,	O
or	O
phVEGF189	S-Gene_or_gene_product
)	O
was	O
applied	O
to	O
the	O
hydrogel	O
polymer	O
coating	O
of	O
an	O
angioplasty	O
balloon	O
and	O
delivered	O
percutaneously	O
to	O
one	O
iliac	B-Multi-tissue_structure
artery	E-Multi-tissue_structure
of	O
rabbits	S-Organism
with	O
operatively	O
induced	O
hindlimb	S-Organism_subdivision
ischemia	O
.	O

Compared	O
with	O
control	O
animals	O
transfected	S-Planned_process
with	O
LacZ	S-Gene_or_gene_product
,	O
site	B-Planned_process
-	I-Planned_process
specific	I-Planned_process
transfection	E-Planned_process
of	O
phVEGF	S-Gene_or_gene_product
resulted	S-Positive_regulation
in	O
augmented	O
collateral	B-Multi-tissue_structure
vessel	E-Multi-tissue_structure
development	S-Development
documented	O
by	O
serial	O
angiography	O
,	O
and	O
improvement	O
in	O
calf	S-Organism
blood	S-Organism_substance
pressure	O
ratio	O
(	O
ischemic	S-Organism_subdivision
to	O
normal	B-Organism_subdivision
limb	E-Organism_subdivision
)	O
,	O
resting	O
and	O
maximum	O
blood	S-Organism_substance
flow	O
,	O
and	O
capillary	S-Tissue
to	O
myocyte	S-Cell
ratio	O
.	O

Similar	O
results	O
were	O
obtained	O
with	O
phVEGF121	S-Gene_or_gene_product
,	O
phVEGF165	S-Gene_or_gene_product
,	O
and	O
phVEGF189	S-Gene_or_gene_product
,	O
which	O
suggests	O
that	O
these	O
isoforms	O
are	O
biologically	O
equivalent	O
with	O
respect	O
to	O
in	O
vivo	O
angiogenesis	S-Blood_vessel_development
.	O

The	O
fact	O
that	O
viral	O
or	O
other	O
adjunctive	O
vectors	O
were	O
not	O
required	O
further	O
suggests	O
that	O
secreted	O
gene	O
products	O
may	O
have	O
potential	O
therapeutic	O
utility	O
even	O
when	O
the	O
number	O
of	O
successfully	O
transfected	O
cells	S-Cell
remains	O
low	O
.	O

Arterial	O
gene	O
transfer	O
of	O
naked	O
DNA	O
encoding	O
for	O
a	O
secreted	O
angiogenic	S-Blood_vessel_development
cytokine	O
,	O
thus	O
,	O
represents	O
a	O
potential	O
alternative	O
to	O
recombinant	O
protein	O
administration	O
for	O
stimulating	S-Positive_regulation
collateral	B-Multi-tissue_structure
vessel	E-Multi-tissue_structure
development	S-Development
.	O

Integrin	B-Gene_or_gene_product
alphavbeta3	E-Gene_or_gene_product
requirement	O
for	O
sustained	O
mitogen	B-Gene_or_gene_product
-	I-Gene_or_gene_product
activated	I-Gene_or_gene_product
protein	I-Gene_or_gene_product
kinase	E-Gene_or_gene_product
activity	O
during	O
angiogenesis	S-Blood_vessel_development
.	O

Angiogenesis	S-Blood_vessel_development
depends	S-Positive_regulation
on	O
growth	O
factors	O
and	O
vascular	B-Cell
cell	E-Cell
adhesion	S-Binding
events	O
.	O

Integrins	S-Gene_or_gene_product
and	O
growth	O
factors	O
are	O
capable	O
of	O
activating	S-Positive_regulation
the	O
ras	S-Gene_or_gene_product
/	O
MAP	B-Gene_or_gene_product
kinase	E-Gene_or_gene_product
pathway	S-Pathway
in	O
vitro	O
,	O
yet	O
how	O
these	O
signals	O
influence	S-Regulation
endothelial	B-Cell
cells	E-Cell
during	O
angiogenesis	S-Blood_vessel_development
is	O
unknown	O
.	O

Upon	O
initiation	S-Positive_regulation
of	O
angiogenesis	S-Blood_vessel_development
with	O
basic	B-Gene_or_gene_product
fibroblast	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
(	O
bFGF	S-Gene_or_gene_product
)	O
on	O
the	O
chick	S-Organism
chorioallantoic	B-Multi-tissue_structure
membrane	E-Multi-tissue_structure
(	O
CAM	S-Multi-tissue_structure
)	O
,	O
endothelial	B-Cell
cell	E-Cell
mitogen	B-Gene_or_gene_product
-	I-Gene_or_gene_product
activated	I-Gene_or_gene_product
protein	I-Gene_or_gene_product
(	I-Gene_or_gene_product
MAP	I-Gene_or_gene_product
)	I-Gene_or_gene_product
kinase	E-Gene_or_gene_product
(	O
ERK	S-Gene_or_gene_product
)	O
activity	O
was	O
detected	O
as	O
early	O
as	O
5	O
min	O
yet	O
was	O
sustained	O
for	O
at	O
least	O
20	O
h	O
.	O

The	O
initial	O
wave	O
of	O
ERK	S-Gene_or_gene_product
activity	O
(	O
5	O
-	O
120	O
min	O
)	O
was	O
refractory	S-Regulation
to	O
integrin	B-Drug_or_compound
antagonists	E-Drug_or_compound
,	O
whereas	O
the	O
sustained	O
activity	O
(	O
4	O
-	O
20	O
h	O
)	O
depended	S-Positive_regulation
on	O
integrin	B-Gene_or_gene_product
alphavbeta3	E-Gene_or_gene_product
,	O
but	O
not	O
beta1	B-Gene_or_gene_product
integrins	E-Gene_or_gene_product
.	O

Inhibition	S-Negative_regulation
of	O
MAP	B-Gene_or_gene_product
kinase	I-Gene_or_gene_product
kinase	E-Gene_or_gene_product
(	O
MEK	S-Gene_or_gene_product
)	O
during	O
this	O
sustained	O
alphavbeta3	S-Gene_or_gene_product
-	O
dependent	S-Positive_regulation
ERK	S-Gene_or_gene_product
signal	O
blocked	S-Negative_regulation
the	O
formation	S-Development
of	O
new	O
blood	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
while	O
not	O
influencing	S-Regulation
preexisting	O
blood	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
on	O
the	O
CAM	S-Multi-tissue_structure
.	O

Inhibition	S-Negative_regulation
of	O
MEK	S-Gene_or_gene_product
also	O
blocked	O
growth	O
factor	O
induced	S-Positive_regulation
migration	S-Localization
but	O
not	O
adhesion	S-Binding
of	O
endothelial	B-Cell
cells	E-Cell
in	O
vitro	O
.	O

Therefore	O
,	O
angiogenesis	S-Blood_vessel_development
depends	S-Positive_regulation
on	O
sustained	O
ERK	S-Gene_or_gene_product
activity	O
regulated	S-Regulation
by	O
the	O
ligation	O
state	O
of	O
both	O
a	O
growth	O
factor	O
receptor	O
and	O
integrin	B-Gene_or_gene_product
alphavbeta3	E-Gene_or_gene_product
.	O

Basic	B-Gene_or_gene_product
fibroblast	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
:	O
a	O
missing	O
link	O
between	O
collagen	B-Gene_or_gene_product
VII	E-Gene_or_gene_product
,	O
increased	S-Positive_regulation
collagenase	S-Gene_or_gene_product
,	O
and	O
squamous	B-Pathological_formation
cell	I-Pathological_formation
carcinoma	E-Pathological_formation
in	O
recessive	O
dystrophic	O
epidermolysis	O
bullosa	O
.	O

BACKGROUND	O
:	O
Patients	S-Organism
with	O
recessive	O
dystrophic	O
epidermolysis	O
bullosa	O
(	O
RDEB	O
)	O
have	O
deficiencies	S-Gene_expression
of	O
collagen	B-Gene_or_gene_product
type	I-Gene_or_gene_product
VII	E-Gene_or_gene_product
and	O
have	O
elevated	S-Positive_regulation
levels	O
of	O
fibroblast	B-Gene_or_gene_product
collagenase	E-Gene_or_gene_product
,	O
and	O
a	O
greatly	O
increased	O
risk	O
of	O
cutaneous	B-Pathological_formation
squamous	I-Pathological_formation
cell	I-Pathological_formation
carcinoma	E-Pathological_formation
.	O

Patients	S-Organism
with	O
other	O
genetic	O
blistering	O
disorders	O
do	O
not	O
have	O
elevated	S-Positive_regulation
collagenase	S-Gene_or_gene_product
or	O
an	O
increased	O
risk	O
of	O
squamous	B-Pathological_formation
cell	I-Pathological_formation
carcinoma	E-Pathological_formation
,	O
despite	O
chronic	O
wounding	O
.	O

The	O
connection	O
between	O
collagen	B-Gene_or_gene_product
type	I-Gene_or_gene_product
VII	E-Gene_or_gene_product
deficiency	O
,	O
increased	S-Positive_regulation
collagenase	S-Gene_or_gene_product
,	O
and	O
squamous	B-Pathological_formation
cell	I-Pathological_formation
carcinoma	E-Pathological_formation
is	O
not	O
understood	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Urine	S-Organism_substance
from	O
81	O
patients	S-Organism
with	O
RDEB	O
(	O
39	O
patients	S-Organism
)	O
,	O
junctional	O
epidermolysis	O
bullosa	O
(	O
JEB	O
;	O
12	O
patients	S-Organism
)	O
,	O
and	O
epidermolysis	O
bullosa	O
simplex	O
(	O
EBS	O
;	O
30	O
patients	S-Organism
)	O
,	O
as	O
well	O
as	O
unaffected	O
family	O
members	O
of	O
RDEB	O
patients	S-Organism
(	O
33	O
patients	S-Organism
)	O
,	O
was	O
tested	O
for	O
the	O
presence	S-Localization
of	O
basic	B-Gene_or_gene_product
fibroblast	I-Gene_or_gene_product
growth	I-Gene_or_gene_product
factor	E-Gene_or_gene_product
(	O
bFGF	S-Gene_or_gene_product
)	O
using	O
a	O
sensitive	O
radioimmunoassay	O
.	O

These	O
patients	S-Organism
included	O
many	O
who	O
were	O
enrolled	O
in	O
the	O
Epidermolysis	O
Bullosa	O
Registry	O
and	O
others	O
who	O
were	O
referred	O
by	O
their	O
physicians	O
.	O

RESULTS	O
:	O
Fifty	O
-	O
one	O
percent	O
of	O
patients	S-Organism
with	O
RDEB	O
had	O
elevated	S-Positive_regulation
levels	O
(	O
greater	O
than	O
5000	O
pg	O
/	O
g	O
)	O
of	O
urinary	S-Organism_substance
bFGF	S-Gene_or_gene_product
.	O

In	O
contrast	O
,	O
none	O
of	O
the	O
patients	S-Organism
with	O
JEB	O
had	O
elevated	S-Positive_regulation
levels	O
of	O
bFGF	S-Gene_or_gene_product
.	O

Twenty	O
-	O
one	O
percent	O
of	O
clinically	O
unaffected	O
family	O
members	O
had	O
elevated	S-Positive_regulation
levels	O
of	O
bFGF	S-Gene_or_gene_product
,	O
and	O
13	O
%	O
of	O
patients	S-Organism
with	O
EBS	O
had	O
elevated	S-Positive_regulation
levels	O
of	O
bFGF	S-Gene_or_gene_product
.	O

The	O
frequency	O
of	O
elevated	S-Positive_regulation
bFGF	S-Gene_or_gene_product
values	O
among	O
all	O
groups	O
was	O
statistically	O
significant	O
(	O
p	O
=	O
0	O
.	O
002	O
)	O
,	O
and	O
the	O
levels	O
of	O
bFGF	S-Gene_or_gene_product
in	O
RDEB	O
patients	S-Organism
were	O
significantly	O
elevated	S-Positive_regulation
compared	O
with	O
those	O
of	O
other	O
groups	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

CONCLUSIONS	O
:	O
We	O
have	O
found	O
that	O
patients	S-Organism
with	O
RDEB	O
have	O
elevated	S-Positive_regulation
levels	O
of	O
bFGF	S-Gene_or_gene_product
,	O
which	O
may	O
contribute	O
to	O
increased	S-Positive_regulation
fibroblast	B-Gene_or_gene_product
collagenase	E-Gene_or_gene_product
and	O
the	O
development	S-Development
of	O
squamous	B-Pathological_formation
cell	I-Pathological_formation
carcinoma	E-Pathological_formation
.	O

These	O
results	O
suggest	O
a	O
novel	O
treatment	O
for	O
RDEB	O
,	O
namely	O
,	O
angiogenesis	S-Blood_vessel_development
inhibitors	O
,	O
which	O
may	O
antagonize	B-Negative_regulation
the	I-Negative_regulation
effects	E-Negative_regulation
of	O
bFGF	S-Gene_or_gene_product
in	O
this	O
disorder	O
.	O

There	O
are	O
currently	O
no	O
other	O
means	O
of	O
treatment	O
for	O
this	O
disorder	O
,	O
which	O
has	O
a	O
high	O
morbidity	O
and	O
mortality	O
rate	O
.	O

Induction	S-Positive_regulation
of	O
Ets	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
in	O
endothelial	B-Cell
cells	E-Cell
during	O
reendothelialization	S-Blood_vessel_development
after	O
denuding	O
injury	O
.	O

Ets	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
,	O
a	O
transcription	O
factor	O
,	O
is	O
induced	S-Positive_regulation
in	O
endothelial	B-Cell
cells	E-Cell
(	O
ECs	S-Cell
)	O
during	O
angiogenesis	S-Blood_vessel_development
.	O

Here	O
,	O
we	O
investigated	O
the	O
expression	S-Gene_expression
of	O
Ets	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
during	O
reendothelialization	S-Blood_vessel_development
.	O

When	O
a	O
confluent	O
monolayer	O
of	O
human	B-Cell
umbilical	I-Cell
vein	I-Cell
endothelial	I-Cell
cell	I-Cell
line	E-Cell
,	O
ECV304	S-Cell
,	O
was	O
denuded	S-Planned_process
,	O
ECV304	S-Cell
at	O
the	O
wound	O
edge	O
expressed	S-Gene_expression
Ets	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
.	O

An	O
immunohistochemical	O
analysis	O
revealed	O
that	O
Ets	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
accumulated	S-Positive_regulation
in	O
migrating	B-Cell
cells	E-Cell
at	O
the	O
wound	O
edge	O
and	O
returned	O
to	O
basal	O
level	O
when	O
reendothelialization	S-Blood_vessel_development
was	O
accomplished	O
.	O

This	O
induction	S-Positive_regulation
of	O
Ets	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
could	O
be	O
reproduced	S-Positive_regulation
in	O
in	O
vivo	O
denudation	S-Planned_process
of	O
rat	S-Organism
aortic	B-Tissue
endothelium	E-Tissue
by	O
a	O
balloon	O
catheter	O
.	O

The	O
induction	S-Positive_regulation
of	O
Ets	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
in	O
ECs	S-Cell
after	O
denudation	S-Planned_process
was	O
regulated	S-Regulation
transcriptionally	O
,	O
and	O
humeral	B-Gene_or_gene_product
factors	E-Gene_or_gene_product
released	S-Localization
from	O
injured	O
ECs	S-Cell
might	O
not	O
be	O
responsible	O
.	O

Mitogen	B-Gene_or_gene_product
-	I-Gene_or_gene_product
activated	I-Gene_or_gene_product
protein	I-Gene_or_gene_product
kinase	E-Gene_or_gene_product
(	O
MAPK	S-Gene_or_gene_product
)	O
activities	O
were	O
investigated	O
to	O
explore	O
the	O
mechanism	O
of	O
this	O
induction	S-Positive_regulation
.	O

Although	O
extracellular	B-Gene_or_gene_product
signal	I-Gene_or_gene_product
-	I-Gene_or_gene_product
regulated	I-Gene_or_gene_product
protein	I-Gene_or_gene_product
kinase	I-Gene_or_gene_product
1	E-Gene_or_gene_product
/	O
2	S-Gene_or_gene_product
(	O
ERK1	S-Gene_or_gene_product
/	O
2	S-Gene_or_gene_product
)	O
,	O
c	B-Gene_or_gene_product
-	I-Gene_or_gene_product
Jun	I-Gene_or_gene_product
N	I-Gene_or_gene_product
-	I-Gene_or_gene_product
terminal	I-Gene_or_gene_product
kinase	I-Gene_or_gene_product
1	E-Gene_or_gene_product
(	O
JNK1	S-Gene_or_gene_product
)	O
,	O
and	O
p38	S-Gene_or_gene_product
were	O
activated	S-Positive_regulation
after	O
denudation	O
,	O
the	O
activation	S-Positive_regulation
of	O
ERK1	S-Gene_or_gene_product
and	O
p38	S-Gene_or_gene_product
was	O
more	O
rapid	O
and	O
prominent	O
.	O

PD98059	S-Drug_or_compound
,	O
a	O
specific	O
MAPK	B-Gene_or_gene_product
/	I-Gene_or_gene_product
ERK	I-Gene_or_gene_product
kinase	I-Gene_or_gene_product
(	I-Gene_or_gene_product
MEK	I-Gene_or_gene_product
)	I-Gene_or_gene_product
1	E-Gene_or_gene_product
inhibitor	O
,	O
did	O
not	O
affect	S-Regulation
the	O
induction	S-Positive_regulation
of	O
ets	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
mRNA	O
,	O
whereas	O
SB203580	S-Drug_or_compound
,	O
a	O
specific	O
p38	S-Gene_or_gene_product
inhibitor	O
,	O
almost	O
completely	O
abrogated	S-Negative_regulation
its	O
induction	S-Positive_regulation
.	O

These	O
results	O
indicate	O
that	O
Ets	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
is	O
induced	S-Positive_regulation
in	O
ECs	S-Cell
after	O
denudation	S-Planned_process
through	O
activation	S-Positive_regulation
of	O
p38	S-Gene_or_gene_product
.	O

This	O
induction	S-Positive_regulation
of	O
Ets	B-Gene_or_gene_product
-	I-Gene_or_gene_product
1	E-Gene_or_gene_product
may	O
be	O
relevant	O
for	O
reendothelialization	S-Blood_vessel_development
by	O
regulating	O
the	O
expression	O
of	O
certain	O
genes	O
.	O

The	O
myoadipose	B-Multi-tissue_structure
flap	E-Multi-tissue_structure
:	O
a	O
new	O
composite	O
.	O

A	O
prefabricated	S-Planned_process
composite	B-Multi-tissue_structure
fat	I-Multi-tissue_structure
flap	E-Multi-tissue_structure
consisting	O
of	O
muscle	S-Tissue
woven	S-Planned_process
into	O
an	O
anatomically	O
distinct	O
fat	B-Tissue
pad	E-Tissue
was	O
studied	O
in	O
a	O
rabbit	S-Organism
model	O
.	O

In	O
17	O
rabbits	S-Organism
,	O
a	O
2	O
-	O
cm	O
strip	S-Multi-tissue_structure
of	O
latissimus	B-Organ
dorsi	E-Organ
was	O
woven	S-Planned_process
into	O
the	O
parascapular	B-Tissue
fat	I-Tissue
pad	E-Tissue
on	O
one	O
side	O
,	O
with	O
the	O
contralateral	B-Tissue
fat	I-Tissue
pad	E-Tissue
serving	O
as	O
a	O
control	O
.	O

At	O
3	O
weeks	O
,	O
the	O
endogenous	O
blood	S-Organism_substance
supply	O
of	O
both	O
the	O
control	O
and	O
the	O
experimental	O
fat	B-Tissue
pads	E-Tissue
was	O
isolated	O
and	O
ligated	O
,	O
and	O
the	O
composite	B-Multi-tissue_structure
fat	I-Multi-tissue_structure
/	I-Multi-tissue_structure
muscle	I-Multi-tissue_structure
flap	E-Multi-tissue_structure
was	O
transferred	S-Planned_process
to	O
the	O
chest	B-Organism_subdivision
wall	E-Organism_subdivision
.	O

At	O
6	O
weeks	O
,	O
animals	O
were	O
killed	O
,	O
and	O
flaps	S-Multi-tissue_structure
were	O
analyzed	O
for	O
length	O
,	O
width	O
,	O
and	O
weight	O
;	O
perfused	S-Planned_process
with	O
fluorescein	S-Drug_or_compound
or	O
lead	B-Drug_or_compound
oxide	E-Drug_or_compound
;	O
and	O
examined	O
histologically	O
.	O

Significant	O
differences	O
were	O
found	O
between	O
the	O
control	O
and	O
experimental	O
fat	B-Tissue
pads	E-Tissue
with	O
regard	O
to	O
weight	O
and	O
length	O
.	O

Experimental	O
flaps	S-Multi-tissue_structure
were	O
found	O
to	O
be	O
perfused	S-Planned_process
fully	O
with	O
fluorescein	S-Drug_or_compound
and	O
lead	B-Drug_or_compound
oxide	E-Drug_or_compound
;	O
control	O
fat	B-Tissue
pads	E-Tissue
were	O
found	O
not	O
to	O
be	O
perfused	S-Planned_process
.	O

The	O
lead	B-Drug_or_compound
oxide	E-Drug_or_compound
group	O
revealed	O
extensive	O
growth	S-Growth
of	O
blood	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
from	O
the	O
latissimus	B-Multi-tissue_structure
graft	E-Multi-tissue_structure
into	O
the	O
experimental	O
fat	B-Tissue
pad	E-Tissue
.	O

No	O
vessels	S-Multi-tissue_structure
were	O
visualized	O
in	O
the	O
controls	O
.	O

Finally	O
,	O
sections	O
of	O
the	O
control	O
and	O
experimental	O
flaps	S-Multi-tissue_structure
were	O
analyzed	O
histologically	O
.	O

A	O
preponderance	O
of	O
viable	O
fat	S-Tissue
,	O
with	O
evidence	O
of	O
neovascularization	S-Blood_vessel_development
,	O
was	O
found	O
in	O
experimental	O
flaps	S-Multi-tissue_structure
,	O
compared	O
with	O
the	O
necrotic	O
fat	S-Tissue
that	O
characterized	O
the	O
controls	O
.	O

We	O
conclude	O
that	O
prefabrication	S-Planned_process
of	O
a	O
fat	B-Multi-tissue_structure
flap	E-Multi-tissue_structure
is	O
possible	O
and	O
may	O
have	O
extensive	O
application	O
in	O
various	O
areas	O
of	O
plastic	O
surgery	O
.	O

Store	O
-	O
operated	O
calcium	S-Drug_or_compound
entry	S-Localization
promotes	S-Positive_regulation
shape	B-Development
change	E-Development
in	O
pulmonary	B-Cell
endothelial	I-Cell
cells	E-Cell
expressing	S-Gene_expression
Trp1	S-Gene_or_gene_product
.	O

Activation	S-Positive_regulation
of	O
Ca2	B-Drug_or_compound
+	E-Drug_or_compound
entry	S-Localization
is	O
known	O
to	O
produce	S-Regulation
endothelial	B-Cell
cell	E-Cell
shape	B-Development
change	E-Development
,	O
leading	O
to	O
increased	O
permeability	O
,	O
leukocyte	S-Cell
migration	S-Localization
,	O
and	O
initiation	S-Positive_regulation
of	O
angiogenesis	S-Blood_vessel_development
in	O
conduit	B-Cell
-	I-Cell
vessel	I-Cell
endothelial	I-Cell
cells	E-Cell
.	O

The	O
mode	O
of	O
Ca2	B-Drug_or_compound
+	E-Drug_or_compound
entry	S-Localization
regulating	O
cell	S-Cell
shape	O
is	O
unknown	O
.	O

We	O
hypothesized	O
that	O
activation	O
of	O
store	O
-	O
operated	O
Ca2	B-Drug_or_compound
+	E-Drug_or_compound
channels	O
(	O
SOCs	O
)	O
is	O
sufficient	O
to	O
promote	O
cell	S-Cell
shape	B-Development
change	E-Development
necessary	O
for	O
these	O
processes	O
.	O

SOC	O
activation	O
in	O
rat	S-Organism
pulmonary	B-Cell
arterial	I-Cell
endothelial	I-Cell
cells	E-Cell
increased	S-Positive_regulation
free	O
cytosolic	S-Organism_substance
Ca2	B-Drug_or_compound
+	E-Drug_or_compound
that	O
was	O
dependent	S-Positive_regulation
on	O
a	O
membrane	S-Cellular_component
current	O
having	O
a	O
net	O
inward	O
component	O
of	O
5	O
.	O
45	O
+	O
/	O
-	O
0	O
.	O
90	O
pA	O
/	O
pF	O
at	O
-	O
80	O
mV	O
.	O

Changes	S-Development
in	O
endothelial	B-Cell
cell	E-Cell
shape	O
accompanied	O
SOC	O
activation	O
and	O
were	O
dependent	S-Positive_regulation
on	O
Ca2	B-Drug_or_compound
+	E-Drug_or_compound
entry	S-Localization
-	O
induced	S-Positive_regulation
reconfiguration	S-Regulation
of	O
peripheral	B-Gene_or_gene_product
(	I-Gene_or_gene_product
cortical	I-Gene_or_gene_product
)	I-Gene_or_gene_product
filamentous	I-Gene_or_gene_product
actin	E-Gene_or_gene_product
(	O
F	B-Gene_or_gene_product
-	I-Gene_or_gene_product
actin	E-Gene_or_gene_product
)	O
.	O

Because	O
the	O
identity	O
of	O
pulmonary	O
endothelial	O
SOCs	O
is	O
unknown	O
,	O
but	O
mammalian	O
homologues	O
of	O
the	O
Drosophila	B-Organism
melanogaster	E-Organism
transient	B-Gene_or_gene_product
receptor	I-Gene_or_gene_product
potential	E-Gene_or_gene_product
(	O
trp	S-Gene_or_gene_product
)	O
gene	O
have	O
been	O
proposed	O
to	O
form	O
Ca2	B-Drug_or_compound
+	E-Drug_or_compound
entry	S-Localization
channels	O
in	O
nonexcitable	O
cells	S-Cell
,	O
we	O
performed	O
RT	O
-	O
PCR	O
using	O
Trp	S-Gene_or_gene_product
oligonucleotide	O
primers	O
in	O
both	O
rat	S-Organism
and	O
human	S-Organism
pulmonary	B-Cell
arterial	I-Cell
endothelial	I-Cell
cells	E-Cell
.	O

Both	O
cell	S-Cell
types	O
were	O
found	O
to	O
express	S-Gene_expression
Trp1	S-Gene_or_gene_product
,	O
but	O
neither	O
expressed	S-Gene_expression
Trp3	S-Gene_or_gene_product
nor	O
Trp6	S-Gene_or_gene_product
.	O

Our	O
study	O
indicates	O
that	O
1	O
)	O
Ca2	B-Drug_or_compound
+	E-Drug_or_compound
entry	S-Localization
in	O
pulmonary	B-Cell
endothelial	I-Cell
cells	E-Cell
through	O
SOCs	O
produces	S-Regulation
cell	S-Cell
shape	B-Development
change	E-Development
that	O
is	O
dependent	O
on	O
site	O
-	O
specific	O
rearrangement	O
of	O
the	O
microfilamentous	O
cytoskeleton	O
and	O
2	O
)	O
Trp1	S-Gene_or_gene_product
may	O
be	O
a	O
component	O
of	O
pulmonary	O
endothelial	O
SOCs	O
.	O

Effect	O
of	O
U	B-Gene_or_gene_product
-	I-Gene_or_gene_product
995	E-Gene_or_gene_product
,	O
a	O
potent	O
shark	S-Organism
cartilage	S-Tissue
-	O
derived	O
angiogenesis	S-Blood_vessel_development
inhibitor	O
,	O
on	O
anti	O
-	O
angiogenesis	S-Blood_vessel_development
and	O
anti	O
-	O
tumor	S-Pathological_formation
activities	S-Negative_regulation
.	O

BACKGROUND	O
:	O
A	O
potent	O
angiogenesis	S-Blood_vessel_development
inhibitor	O
,	O
U	B-Gene_or_gene_product
-	I-Gene_or_gene_product
995	E-Gene_or_gene_product
,	O
has	O
been	O
purified	S-Planned_process
from	O
the	O
cartilage	S-Tissue
of	O
the	O
blue	B-Organism
shark	E-Organism
(	O
Prionace	B-Organism
glauca	E-Organism
)	O
.	O

U	B-Gene_or_gene_product
-	I-Gene_or_gene_product
995	E-Gene_or_gene_product
is	O
composed	O
of	O
two	O
single	O
peptides	O
with	O
molecular	O
mass	O
of	O
10	O
and	O
14	O
kDa	O
,	O
respectively	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
U	B-Gene_or_gene_product
-	I-Gene_or_gene_product
995	E-Gene_or_gene_product
was	O
designed	O
to	O
study	O
human	B-Cell
umbilical	I-Cell
vein	I-Cell
endothelial	I-Cell
cell	E-Cell
(	O
HUVEC	S-Cell
)	O
migration	S-Localization
and	O
proliferation	S-Cell_proliferation
in	O
vitro	O
and	O
angiogenesis	S-Blood_vessel_development
induced	S-Positive_regulation
by	O
TNF	B-Gene_or_gene_product
alpha	E-Gene_or_gene_product
in	O
chicken	S-Organism
chorioallantoic	B-Multi-tissue_structure
membrane	E-Multi-tissue_structure
(	O
CAM	S-Multi-tissue_structure
)	O
.	O

Furthermore	O
,	O
we	O
determined	O
the	O
ability	O
of	O
U	B-Gene_or_gene_product
-	I-Gene_or_gene_product
995	E-Gene_or_gene_product
to	O
inhibiting	S-Negative_regulation
tumor	B-Cell
cell	E-Cell
growth	S-Cell_proliferation
and	O
metastasis	S-Localization
.	O

RESULTS	O
:	O
U	B-Gene_or_gene_product
-	I-Gene_or_gene_product
995	E-Gene_or_gene_product
(	O
15	O
and	O
30	O
micrograms	O
/	O
ml	O
)	O
markedly	O
inhibited	S-Negative_regulation
HUVEC	S-Cell
migration	S-Localization
and	O
,	O
at	O
15	O
-	O
50	O
micrograms	O
/	O
ml	O
produced	O
a	O
dose	O
-	O
dependent	O
decline	O
in	O
[	O
3H	O
]	O
-	O
thymidine	S-Drug_or_compound
incorporation	O
.	O

30	O
and	O
50	O
micrograms	O
/	O
ml	O
of	O
U	B-Gene_or_gene_product
-	I-Gene_or_gene_product
995	E-Gene_or_gene_product
,	O
when	O
added	S-Planned_process
to	O
TNF	B-Gene_or_gene_product
alpha	E-Gene_or_gene_product
-	O
induced	S-Positive_regulation
angiogenesis	S-Blood_vessel_development
caused	S-Positive_regulation
discontinuous	O
and	O
disrupted	S-Breakdown
blood	B-Multi-tissue_structure
vessels	E-Multi-tissue_structure
.	O

Moreover	O
,	O
U	B-Gene_or_gene_product
-	I-Gene_or_gene_product
995	E-Gene_or_gene_product
(	O
30	O
micrograms	O
/	O
ml	O
)	O
markedly	O
prevented	S-Negative_regulation
collagenase	S-Gene_or_gene_product
-	O
induced	S-Positive_regulation
collagenolysis	S-Blood_vessel_development
.	O

In	O
addition	O
,	O
when	O
200	O
micrograms	O
U	B-Gene_or_gene_product
-	I-Gene_or_gene_product
995	E-Gene_or_gene_product
was	O
injected	S-Planned_process
i	O
.	O
p	O
.	O
into	O
mice	S-Organism
it	O
suppressed	S-Negative_regulation
sarcoma	B-Cell
-	I-Cell
180	I-Cell
cell	E-Cell
growth	S-Cell_proliferation
and	O
B16	B-Cell
-	I-Cell
F10	I-Cell
mouse	I-Cell
melanoma	I-Cell
cell	E-Cell
metastasis	S-Localization
in	O
vivo	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
suggest	O
that	O
the	O
anti	O
-	O
angiogenic	S-Blood_vessel_development
effects	S-Negative_regulation
of	O
U	B-Gene_or_gene_product
-	I-Gene_or_gene_product
995	E-Gene_or_gene_product
may	O
be	O
be	O
due	S-Positive_regulation
to	O
interference	S-Negative_regulation
with	O
the	O
proliferation	S-Cell_proliferation
and	O
migration	S-Localization
of	O
HUVECs	S-Cell
as	O
well	O
as	O
inhibition	S-Negative_regulation
of	O
collagenolysis	S-Pathway
,	O
thereby	O
leading	O
to	O
inhibition	S-Negative_regulation
of	O
both	O
angiogenesis	S-Blood_vessel_development
and	O
tumor	B-Cell
cell	E-Cell
growth	S-Cell_proliferation
.	O
